<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37607944</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Aug</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A ferroptosis-targeting ceria anchored halloysite as orally drug delivery system for radiation colitis therapy.</ArticleTitle>
        <Pagination>
          <StartPage>5083</StartPage>
          <MedlinePgn>5083</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">5083</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-40794-w</ELocationID>
        <Abstract>
          <AbstractText>Radiation colitis is the leading cause of diarrhea and hematochezia in pelvic radiotherapy patients. This work advances the pathogenesis of radiation colitis from the perspective of ferroptosis. An oral Pickering emulsion is stabilized with halloysite clay nanotubes to alleviate radiation colitis by inhibiting ferroptosis. Ceria nanozyme grown in situ on nanotubes can scavenge reactive oxygen species, and deferiprone was loaded into the lumen of nanotubes to relieve iron stress. These two strategies effectively inhibit lipid peroxidation and rescue ferroptosis in the intestinal microenvironment. The clay nanotubes play a critical role as either a medicine to alleviate colitis, a nanocarrier that targets the inflamed colon by electrostatic adsorption, or an interfacial stabilizer for emulsions. This ferroptosis-based strategy was effective in vitro and in vivo, providing a prospective candidate for radiotherapy protection via rational regulation of specific oxidative stress.</AbstractText>
          <CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Feng</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering, College of Chemistry and Materials Science, Jinan University, 511443, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Luo</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Engineering Research Center of Chinese Medicine &amp; Disease Susceptibility, Jinan University, 510632, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, 510632, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, 510632, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zichun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Engineering Research Center of Chinese Medicine &amp; Disease Susceptibility, Jinan University, 510632, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, 510632, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, 510632, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Xinjuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yiting</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Rong-Rong</ForeName>
            <Initials>RR</Initials>
            <Identifier Source="ORCID">0000-0001-5505-5672</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Engineering Research Center of Chinese Medicine &amp; Disease Susceptibility, Jinan University, 510632, Guangzhou, China. rongronghe@jnu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, 510632, Guangzhou, China. rongronghe@jnu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, 510632, Guangzhou, China. rongronghe@jnu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Mingxian</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-5466-3024</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering, College of Chemistry and Materials Science, Jinan University, 511443, Guangzhou, China. liumx@jnu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>52073121</GrantID>
            <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
          </Grant>
          <Grant>
            <GrantID>82125038</GrantID>
            <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
          </Grant>
          <Grant>
            <GrantID>2021B1515120023</GrantID>
            <Agency>Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>08</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>T1FAD4SS2M</RegistryNumber>
          <NameOfSubstance UI="D000077215">Clay</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077215" MajorTopicYN="N">Clay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005756" MajorTopicYN="Y">Gastritis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2023</Year>
          <Month>8</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>8</Month>
          <Day>23</Day>
          <Hour>0</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>23</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37607944</ArticleId>
        <ArticleId IdType="pmc">PMC10444825</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-023-40794-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-023-40794-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hauer-Jensen M, Denham JW, Andreyev HJN. Radiation enteropathy-pathogenesis, treatment and prevention. Nat. Rev. Gastroenterol. Hepatol. 2014;11:470&#x2013;479. doi: 10.1038/nrgastro.2014.46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2014.46</ArticleId>
            <ArticleId IdType="pmc">PMC4346191</ArticleId>
            <ArticleId IdType="pubmed">24686268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumagai T, Rahman F, Smith AM. The microbiome and radiation induced-bowel injury: evidence for potential mechanistic role in disease pathogenesis. Nutrients. 2018;10:1405. doi: 10.3390/nu10101405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu10101405</ArticleId>
            <ArticleId IdType="pmc">PMC6213333</ArticleId>
            <ArticleId IdType="pubmed">30279338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei G, et al. Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell. 2021;12:836&#x2013;857. doi: 10.1007/s13238-021-00841-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-021-00841-y</ArticleId>
            <ArticleId IdType="pmc">PMC8563889</ArticleId>
            <ArticleId IdType="pubmed">33891303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401&#x2013;2421. doi: 10.1016/j.cell.2022.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2022.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC9273022</ArticleId>
            <ArticleId IdType="pubmed">35803244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji Q, et al. ACSL4 is essential for radiation-induced intestinal injury by initiating ferroptosis. Cell Death Discov. 2022;8:1&#x2013;9. doi: 10.1038/s41420-022-01127-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41420-022-01127-w</ArticleId>
            <ArticleId IdType="pmc">PMC9307849</ArticleId>
            <ArticleId IdType="pubmed">35869042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo X, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28:1971&#x2013;1989. doi: 10.1038/s41418-020-00719-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-020-00719-2</ArticleId>
            <ArticleId IdType="pmc">PMC8185102</ArticleId>
            <ArticleId IdType="pubmed">33432112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, et al. Interaction between macrophages and ferroptosis. Cell Death Discov. 2022;13:355. doi: 10.1038/s41419-022-04775-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-022-04775-z</ArticleId>
            <ArticleId IdType="pmc">PMC9013379</ArticleId>
            <ArticleId IdType="pubmed">35429990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagliuca F, Luches P, Valeri S. Interfacial interaction between cerium oxide and silicon surfaces. Surf. Sci. 2013;607:164&#x2013;169. doi: 10.1016/j.susc.2012.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.susc.2012.09.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L, et al. Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. Sci. Adv. 2020;6:eaay9751. doi: 10.1126/sciadv.aay9751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aay9751</ArticleId>
            <ArticleId IdType="pmc">PMC7080448</ArticleId>
            <ArticleId IdType="pubmed">32206718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han SI, et al. Epitaxially strained CeO2/Mn3O4 nanocrystals as an enhanced antioxidant for radioprotection. Adv. Mater. 2020;32:2001566. doi: 10.1002/adma.202001566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.202001566</ArticleId>
            <ArticleId IdType="pubmed">32520432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S, et al. An orally administered CeO2@montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy. Adv. Funct. Mater. 2020;30:2004692. doi: 10.1002/adfm.202004692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adfm.202004692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang SF, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci. Transl. Med. 2015;7:300ra128. doi: 10.1126/scitranslmed.aaa5657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaa5657</ArticleId>
            <ArticleId IdType="pmc">PMC4825054</ArticleId>
            <ArticleId IdType="pubmed">26268315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Z, et al. Investigation of natural minerals for ulcerative colitis therapy. Appl. Clay Sci. 2020;186:105436. doi: 10.1016/j.clay.2020.105436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clay.2020.105436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Y, et al. Systematic studies on blood coagulation mechanisms of halloysite nanotubes-coated PET dressing as superior topical hemostatic agent. Chem. Eng. J. 2022;428:132049. doi: 10.1016/j.cej.2021.132049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cej.2021.132049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu XD, et al. Molecular-level understanding of metal ion retention in clay-rich materials. Nat. Rev. Earth Environ. 2022;3:461&#x2013;476. doi: 10.1038/s43017-022-00301-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43017-022-00301-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lvov YM, DeVilliers MM, Fakhrullin RF. The application of halloysite tubule nanoclay in drug delivery. Expert Opin. Drug Deliv. 2016;13:977&#x2013;986. doi: 10.1517/17425247.2016.1169271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425247.2016.1169271</ArticleId>
            <ArticleId IdType="pubmed">27027933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian S, Geng H, Tan XD. Cell death of intestinal epithelial cells in intestinal diseases. Acta Physiol. 2020;72:308&#x2013;324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755516</ArticleId>
            <ArticleId IdType="pubmed">32572429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han C, et al. Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nat. Immunol. 2020;21:546&#x2013;554. doi: 10.1038/s41590-020-0641-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-020-0641-5</ArticleId>
            <ArticleId IdType="pubmed">32231300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyurina YY, et al. Oxidative lipidomics of gamma-radiation-induced lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Radiat. Res. 2011;175:610&#x2013;621. doi: 10.1667/RR2297.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1667/RR2297.1</ArticleId>
            <ArticleId IdType="pmc">PMC3321728</ArticleId>
            <ArticleId IdType="pubmed">21338246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recknagel R. Free radical damage and lipid peroxidation. Hepatotoxicology. 1991;401:436.</Citation>
        </Reference>
        <Reference>
          <Citation>Lei G, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30:146&#x2013;162. doi: 10.1038/s41422-019-0263-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-019-0263-3</ArticleId>
            <ArticleId IdType="pmc">PMC7015061</ArticleId>
            <ArticleId IdType="pubmed">31949285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci. 2016;41:274&#x2013;286. doi: 10.1016/j.tibs.2015.11.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2015.11.012</ArticleId>
            <ArticleId IdType="pmc">PMC4783254</ArticleId>
            <ArticleId IdType="pubmed">26725301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riahi Y, Cohen G, Shamni O, Sasson S. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am. J. Physiol. Endocrinol. 2010;299:E879&#x2013;E886. doi: 10.1152/ajpendo.00508.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00508.2010</ArticleId>
            <ArticleId IdType="pubmed">20858748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye LF, et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem. Biol. 2020;15:469&#x2013;484. doi: 10.1021/acschembio.9b00939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.9b00939</ArticleId>
            <ArticleId IdType="pmc">PMC7180072</ArticleId>
            <ArticleId IdType="pubmed">31899616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kroemer G. Ferroptosis. Curr. Biol. 2020;30:R1292&#x2013;R1297. doi: 10.1016/j.cub.2020.09.068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2020.09.068</ArticleId>
            <ArticleId IdType="pubmed">33142092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McClements DJ, Xiao H. Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and nutraceuticals. Food Funct. 2014;5:1320&#x2013;1333. doi: 10.1039/C4FO00100A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C4FO00100A</ArticleId>
            <ArticleId IdType="pubmed">24760211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. Cell Res. 2018;28:9&#x2013;21. doi: 10.1038/cr.2017.133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2017.133</ArticleId>
            <ArticleId IdType="pmc">PMC5752838</ArticleId>
            <ArticleId IdType="pubmed">29076500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananthanarayanan, A., Goswami, M. &amp; Kothiyal, G. in Materials Under Extreme Conditions (Eds Tyagi, A. K. &amp; Banerjee, S.) 195&#x2013;233 (Elsevier, 2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Aneggi E, et al. Shape-dependent activity of ceria in soot combustion. ACS Catal. 2014;4:172&#x2013;181. doi: 10.1021/cs400850r.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cs400850r</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soh M, et al. Ceria-zirconia nanoparticles as an enhanced multi-antioxidant for sepsis treatment. Angew. Chem. 2017;56:11399&#x2013;11403. doi: 10.1002/anie.201704904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201704904</ArticleId>
            <ArticleId IdType="pubmed">28643857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu, K., Sun, L. D. &amp; Yan, C. H. Recent progress in well-controlled synthesis of ceria-based nanocatalysts towards enhanced catalytic performance. Adv. Energy Mater. 6, 1600501 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Wittmann C, et al. Hydrogen peroxide in inflammation: messenger, guide, and assassin. Adv. Hematol. 2012;2012:541471. doi: 10.1155/2012/541471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/541471</ArticleId>
            <ArticleId IdType="pmc">PMC3378963</ArticleId>
            <ArticleId IdType="pubmed">22737171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang GN, et al. Bioactive nanoenzyme reverses oxidative damage and endoplasmic reticulum stress in neurons under ischemic stroke. ACS Nano. 2022;16:431&#x2013;452. doi: 10.1021/acsnano.1c07205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.1c07205</ArticleId>
            <ArticleId IdType="pubmed">34958560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lvov Y, Wang WC, Zhang LQ, Fakhrullin R. Halloysite clay nanotubes for loading and sustained release of functional compounds. Adv. Mater. 2016;28:1227&#x2013;1250. doi: 10.1002/adma.201502341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201502341</ArticleId>
            <ArticleId IdType="pubmed">26438998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veerabadran NG, Price RR, Lvov YM. Clay nanotubes for encapsulation and sustained release of drugs. Nano. 2007;2:115&#x2013;120. doi: 10.1142/S1793292007000441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1142/S1793292007000441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lisuzzo L, et al. Pickering emulsions based on wax and halloysite nanotubes: an ecofriendly protocol for the treatment of archeological woods. ACS Appl. Mater. Interfaces. 2021;13:1651&#x2013;1661. doi: 10.1021/acsami.0c20443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.0c20443</ArticleId>
            <ArticleId IdType="pmc">PMC8021222</ArticleId>
            <ArticleId IdType="pubmed">33379868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamp F, et al. Rapid flip-flop of oleic acid across the plasma membrane of adipocytes. J. Biol. Chem. 2003;278:7988&#x2013;7995. doi: 10.1074/jbc.M206648200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M206648200</ArticleId>
            <ArticleId IdType="pubmed">12499383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol. Sci. 2017;38:489&#x2013;498. doi: 10.1016/j.tips.2017.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2017.02.005</ArticleId>
            <ArticleId IdType="pubmed">28363764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang H, et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J. Gastroenterol. Hepatol. 2018;33:878&#x2013;886. doi: 10.1111/jgh.14021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jgh.14021</ArticleId>
            <ArticleId IdType="pubmed">29047150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monajemi H, et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology. 1996;110:733&#x2013;739. doi: 10.1053/gast.1996.v110.pm8608882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/gast.1996.v110.pm8608882</ArticleId>
            <ArticleId IdType="pubmed">8608882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang SF, et al. Heparin&#x2010;coated albumin nanoparticles for drug combination in targeting inflamed intestine. Adv. Healthc. Mater. 2020;9:2000536. doi: 10.1002/adhm.202000536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adhm.202000536</ArticleId>
            <ArticleId IdType="pmc">PMC7482138</ArticleId>
            <ArticleId IdType="pubmed">32597571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Min JX, Wang FD. Ferroptosis: an emerging player in immune cells. Sci. Bull. 2021;66:2257&#x2013;2260. doi: 10.1016/j.scib.2021.02.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.scib.2021.02.026</ArticleId>
            <ArticleId IdType="pubmed">36654451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoyanovsky DA, et al. Iron catalysis of lipid peroxidation in ferroptosis: regulated enzymatic or random free radical reaction? Free Radic. Biol. Med. 2019;133:153&#x2013;161. doi: 10.1016/j.freeradbiomed.2018.09.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.09.008</ArticleId>
            <ArticleId IdType="pmc">PMC6555767</ArticleId>
            <ArticleId IdType="pubmed">30217775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tevlin R, Longaker MT, Wan DC. Deferoxamine to minimize fibrosis during radiation therapy. Adv. Wound Care. 2022;11:548&#x2013;559. doi: 10.1089/wound.2021.0021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/wound.2021.0021</ArticleId>
            <ArticleId IdType="pmc">PMC9347384</ArticleId>
            <ArticleId IdType="pubmed">34074152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mericli AF, et al. Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated tram flap model. Plast. Reconst. 2015;135:124e&#x2013;134e. doi: 10.1097/PRS.0000000000000844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PRS.0000000000000844</ArticleId>
            <ArticleId IdType="pubmed">25539319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Momeni A, et al. Clinical use of deferoxamine in distraction osteogenesis of irradiated bone. J. Craniofac. Surg. 2016;27:880&#x2013;882. doi: 10.1097/SCS.0000000000002633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SCS.0000000000002633</ArticleId>
            <ArticleId IdType="pmc">PMC4902756</ArticleId>
            <ArticleId IdType="pubmed">27171947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S, Neal CJ, Ortiz J, Seal S. Engineered nanoceria cytoprotection in vivo: mitigation of reactive oxygen species and double-stranded DNA breakage due to radiation exposure. Nanoscale. 2018;10:21069&#x2013;21075. doi: 10.1039/C8NR04640A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8NR04640A</ArticleId>
            <ArticleId IdType="pubmed">30226515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nukala U, et al. Antioxidant tocols as radiation countermeasures (challenges to be addressed to use tocols as radiation countermeasures in humans) Antioxidants. 2018;7:33. doi: 10.3390/antiox7020033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/antiox7020033</ArticleId>
            <ArticleId IdType="pmc">PMC5836023</ArticleId>
            <ArticleId IdType="pubmed">29473853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown, K. R. &amp; Rzucidlo, E. Acute and Chronic Radiation Injury. Vol. 53 (Elsevier, 2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20843630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do NL, Nagle D, Poylin VY. Radiation proctitis: current strategies in management. Gastroenterol. Res. Pract. 2011;2011:917941. doi: 10.1155/2011/917941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2011/917941</ArticleId>
            <ArticleId IdType="pmc">PMC3226317</ArticleId>
            <ArticleId IdType="pubmed">22144997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan S, et al. An unconventional treatment modality for persistent hematochezia in the setting of radiation proctitis. Am. J. Gastroenterol. 2021;116:S969. doi: 10.14309/01.ajg.0000782616.65316.e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/01.ajg.0000782616.65316.e2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong D, et al. Orally deliverable strategy based on microalgal biomass for intestinal disease treatment. Sci. Adv. 2021;7:eabi9265. doi: 10.1126/sciadv.abi9265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abi9265</ArticleId>
            <ArticleId IdType="pmc">PMC8612690</ArticleId>
            <ArticleId IdType="pubmed">34818040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Indaram AV, Visvalingam V, Locke M, Bank S. Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am. J. Gastroenterol. 2000;95:1221&#x2013;1225. doi: 10.1111/j.1572-0241.2000.02013.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2000.02013.x</ArticleId>
            <ArticleId IdType="pubmed">10811331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang EJ, et al. Activation of proinflammatory signaling by 4-hydroxynonenal-Src adducts in aged kidneys. Oncotarget. 2016;7:50864&#x2013;50874. doi: 10.18632/oncotarget.10854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10854</ArticleId>
            <ArticleId IdType="pmc">PMC5239442</ArticleId>
            <ArticleId IdType="pubmed">27472463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galea I, et al. Iron deposition in the brain after aneurysmal subarachnoid hemorrhage. Stroke. 2022;53:1633&#x2013;1642. doi: 10.1161/STROKEAHA.121.036645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.121.036645</ArticleId>
            <ArticleId IdType="pubmed">35196874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood. 2020;136:726&#x2013;739. doi: 10.1182/blood.2019002907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2019002907</ArticleId>
            <ArticleId IdType="pmc">PMC7414596</ArticleId>
            <ArticleId IdType="pubmed">32374849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, et al. Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. Cell Discov. 2022;8:1&#x2013;17. doi: 10.1038/s41421-022-00390-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41421-022-00390-6</ArticleId>
            <ArticleId IdType="pmc">PMC9065108</ArticleId>
            <ArticleId IdType="pubmed">35504898</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37505141</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>102</Volume>
            <Issue>30</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Jul</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of ferroptosis - related proteins and histone deacetylases1 on neoadjuvant chemotherapy in breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>e34444</StartPage>
          <MedlinePgn>e34444</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e34444</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000034444</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis may improve the efficacy of tumor treatment, according to recent evidences. This study is to explore value of histone deacetylases 1 (HDAC1), ATP binding cassette subfamily B member 1 and ferroptosis-related proteins as potential predictive biomarkers. Eighty-two women who received neoadjuvant chemotherapy (NAC) confirmed breast cancer was included. Immunohistochemistry staining of HDAC1, ATP binding cassette subfamily B member 1 and ferroptosis-related proteins was performed in core needle biopsy and tumor resection tissue. Univariate and multivariate logistic regression were conducted to explore the potential biomarkers for breast cancer undergoing NAC. There was a weak positive correlation of HDAC1 level before and after NAC with imaging outcome (R = 0.390, P &lt; .001). The expression of HDAC1 and glutathione peroxidase 4 before NAC was an independent predictor of imaging efficacy (OR = 7.633, CI 1.831-31.821, P &lt; .001; OR = 0.700, CI 0.505-0.971, P &lt; .05, respectively). HDAC1 and Glutathione peroxidase 4 may act as a new predictive biomarker for NAC in breast cancer. And personalized treatment can be provided based on them.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0009-0007-7548-6147</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Fujian Medical University, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiaohan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, South Branch of Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yiming</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Jiaqin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xiaoxia</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006657">Histones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>11</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>13</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>10</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37505141</ArticleId>
        <ArticleId IdType="pmc">PMC10378733</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000034444</ArticleId>
        <ArticleId IdType="pii">00005792-202307280-00024</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Montemurro F, Nuzzolese I, Ponzone R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother. 2020;21:1071&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32237920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korde LA, Somerfield MR, Carey LA, et al. . Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485&#x2013;505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8274745</ArticleId>
            <ArticleId IdType="pubmed">33507815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019;16:93&#x2013;103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6635916</ArticleId>
            <ArticleId IdType="pubmed">30556752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An J, Peng C, Tang H, et al. . New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. Int J Mol Sci . 2021;22:9644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8431789</ArticleId>
            <ArticleId IdType="pubmed">34502549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary LN. Early stage triple negative breast cancer: management and future directions. Semin Oncol. 2020;47:201&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7446736</ArticleId>
            <ArticleId IdType="pubmed">32507668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engle K, Kumar G. Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update. Eur J Med Chem. 2022;239:114542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35751979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. . Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Qiu X, Yan Y, et al. . Evaluation of ferroptosis-related gene AKR1C1 as a novel biomarker associated with the immune microenvironment and prognosis in breast cancer. Int J General Med. 2021;14:6189&#x2013;200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8487294</ArticleId>
            <ArticleId IdType="pubmed">34611432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui S, Xu S, Pang D. Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor progression. Pharmacol Ther. 2022;232:107992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34606782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy L, Sandhu JK, Harper ME, et al. . Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10:1429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7600400</ArticleId>
            <ArticleId IdType="pubmed">33050144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sha R, Xu Y, Yuan C, et al. . Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine. 2021;71:103560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8417304</ArticleId>
            <ArticleId IdType="pubmed">34482070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf IM, Fan Z, Rauh M, et al. . Histone deacetylases inhibition by SAHA/vorinostat normalizes the glioma microenvironment via xCT equilibration. Sci Rep. 2014;4:6226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4165982</ArticleId>
            <ArticleId IdType="pubmed">25228443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou HH, Chen X, Cai LY, et al. . Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front Oncol. 2019;9:1398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6930896</ArticleId>
            <ArticleId IdType="pubmed">31921655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolff AC, Hammond ME, Hicks DG, et al. . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997&#x2013;4013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24101045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nielsen TO, Leung SCY, Rimm DL, et al. . Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113:808&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8487652</ArticleId>
            <ArticleId IdType="pubmed">33369635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curigliano G, Burstein HJ, E PW, et al. . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Annal Oncol. 2019;30:1181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6637369</ArticleId>
            <ArticleId IdType="pubmed">30624592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F, Zhao Y, Wei L, et al. . Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018;19:695&#x2013;705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6067871</ArticleId>
            <ArticleId IdType="pubmed">29621426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu H, Ye D, Ren M, et al. . Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends Mol Med. 2021;27:856&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34312075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun LL, Linghu DL, Hung MC. Ferroptosis: a promising target for cancer immunotherapy. Am J Cancer Res. 2021;11:5856&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8727800</ArticleId>
            <ArticleId IdType="pubmed">35018229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv C, Qu H, Zhu W, et al. . Low-dose paclitaxel inhibits tumor cell growth by regulating glutaminolysis in colorectal carcinoma cells. Front Pharmacol. 2017;8:244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5415623</ArticleId>
            <ArticleId IdType="pubmed">28522974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Battaglia AM, Chirillo R, Aversa I, et al. . Ferroptosis and cancer: mitochondria meet the &#x201c;iron maiden&#x201d; cell death. Cells. 2020;9:1505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7349567</ArticleId>
            <ArticleId IdType="pubmed">32575749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Wang X, Liu Z, et al. . Role of GPX4-mediated ferroptosis in the sensitivity of triple negative breast cancer cells to gefitinib. Front Oncol. 2020;10:597434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7785974</ArticleId>
            <ArticleId IdType="pubmed">33425751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira T, Hermann E, Lin D, et al. . HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells. Redox Biol. 2021;47:102149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8487084</ArticleId>
            <ArticleId IdType="pubmed">34600336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan F, Liu P, Bao R, et al. . A Dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy. Cancer Res. 2021;81:6233&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34711611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunmeir R, Lagger S, Seiser C. Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation. Int J Dev Biol. 2009;53:275&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19412887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338:17&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15050820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damaskos C, Garmpis N, Valsami S, et al. . Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res. 2017;37:35&#x2013;46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28011471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai H, Li H, Avraham S, et al. . Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer. 2003;107:353&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14506733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Liu X, Li L, et al. . SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation. EMBO J. 2021;40:e107974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8488578</ArticleId>
            <ArticleId IdType="pubmed">34459501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modi A, Roy D, Sharma S, et al. . ABC transporters in breast cancer: their roles in multidrug resistance and beyond. J Drug Target. 2022;30:927&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35758271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge C, Cao B, Feng D, et al. . The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells. Sci Rep. 2017;7:3791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5476638</ArticleId>
            <ArticleId IdType="pubmed">28630426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Chi CH, Zhang Y, et al. . Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells. Oncol Lett. 2019;18:63&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6540461</ArticleId>
            <ArticleId IdType="pubmed">31289473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto K, Watanabe M, Boku S, et al. . xCT inhibition increases sensitivity to vorinostat in a ROS-dependent manner. Cancers (Basel). 2020;12:827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7226257</ArticleId>
            <ArticleId IdType="pubmed">32235498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni X, Li L, Pan G. HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review). Oncol Lett. 2015;9:515&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4301560</ArticleId>
            <ArticleId IdType="pubmed">25624882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Q, Cheng K, Wang X, et al. . Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer. Int J Clin Exp Path. 2020;13:563&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7137008</ArticleId>
            <ArticleId IdType="pubmed">32269697</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37462439</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2040-3372</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>30</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Aug</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nanoscale</Title>
          <ISOAbbreviation>Nanoscale</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An ultrasmall PVP-Fe-Cu-Ni-S nano-agent for synergistic cancer therapy through triggering ferroptosis and autophagy.</ArticleTitle>
        <Pagination>
          <StartPage>12598</StartPage>
          <EndPage>12611</EndPage>
          <MedlinePgn>12598-12611</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d3nr02708b</ELocationID>
        <Abstract>
          <AbstractText>Photothermal therapy (PTT) is an emerging field where photothermal agents could convert visible or near-infrared (NIR) radiation into heat to kill tumor cells. However, the low photothermal conversion efficiency of photothermal agents and their limited antitumor activities hinder the development of these agents into monotherapies for cancer. Herein, we have fabricated an ultrasmall polyvinylpyrrolidone (PVP)-Fe-Cu-Ni-S (PVP-NP) nano-agent via a simple hot injection method with excellent photothermal conversion efficiency (96%). Photothermal therapy with this nano-agent effectively inhibits tumor growth without apparent toxic side-effects. Mechanistically, our results demonstrated that, after NIR irradiation, PVP-NPs can induce ROS/singlet oxygen generation, decrease the mitochondrial membrane potential, release extracellular Fe[2+], and consume glutathione, triggering autophagy and ferroptosis of cancer cells. Moreover, PVP-NPs exhibit excellent contrast enhancement according to magnetic resonance imaging (MRI) analysis. In summary, PVP-NPs have a high photothermal conversion efficiency and can be applied for MRI-guided synergistic photothermal/photodynamic/chemodynamic cancer therapy, resolving the bottleneck of existing phototherapeutic agents.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Rongjun</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Medicine (IMM), Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Shuxiang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Cardiovascular Key Lab of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China. xuyang2020@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Binjiang Research Institute of Zhejiang University, Hangzhou, Zhejiang 310052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Miaomiao</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-2477-9066</Identifier>
            <AffiliationInfo>
              <Affiliation>Precision Research Center for Refractory Diseases in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. miaomiaoyuan2023@shsmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518033, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Lihao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Precision Research Center for Refractory Diseases in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. miaomiaoyuan2023@shsmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Luoyijun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518033, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Yingying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518033, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Cardiovascular Key Lab of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China. xuyang2020@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Binjiang Research Institute of Zhejiang University, Hangzhou, Zhejiang 310052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Xuemei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>International Peace Maternity and Child Health Hospital of China Welfare Institution, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China. fxmzj2004@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>08</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nanoscale</MedlineTA>
        <NlmUniqueID>101525249</NlmUniqueID>
        <ISSNLinking>2040-3364</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>FZ989GH94E</RegistryNumber>
          <NameOfSubstance UI="D011205">Povidone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011205" MajorTopicYN="N">Povidone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068936" MajorTopicYN="N">Theranostic Nanomedicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>8</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>13</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>9</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37462439</ArticleId>
        <ArticleId IdType="doi">10.1039/d3nr02708b</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37306000</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2055-6764</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Jul</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nanoscale horizons</Title>
          <ISOAbbreviation>Nanoscale Horiz</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Engineering magnetotactic bacteria MVs to synergize chemotherapy, ferroptosis and immunotherapy for augmented antitumor therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1062</StartPage>
          <EndPage>1072</EndPage>
          <MedlinePgn>1062-1072</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d3nh00061c</ELocationID>
        <Abstract>
          <AbstractText>One main obstacle to targeted cancer therapies is the immunosuppressive tumor microenvironment, which can facilitate tumor growth and induce resistance to antitumor treatments. Recent studies have indicated that treatment combined with immunotherapy often yields a better prognosis than monotherapy. Bacterial membrane vesicles (MVs), nanostructures released from the membrane of bacteria, can be used as natural nanocarriers for drug delivery and stimulate an immune response because of their immunogenicity. Inspired by the development of synergistic therapeutic strategies, we herein propose a novel nanovaccine-based platform to achieve chemotherapy, ferroptosis therapy, and immunotherapy simultaneously. By simply culturing magnetotactic bacteria in the medium with doxorubicin (DOX) and then extracting specialized MVs (BMVs), BMV@DOX, which are membrane vesicles containing iron ions and DOX, were obtained. We confirmed that in BMV@DOX, the BMV component can stimulate the innate immune system, DOX acts as the chemotherapeutic agent and iron ions will induce ferroptosis. Furthermore, BMV@DOX vesicles modified with DSPE-PEG-cRGD peptides (T-BMV@DOX) have minimized systemic toxicity and increased tumor-specificity. We demonstrated that the smart MVs-based nanovaccine system not only showed superior performance in the treatment of 4T1 breast cancer but also effectively restrained the growth of drug-resistant MCF-7/ADR tumors in mice. Moreover, the nanovaccine could abrogate in vivo lung metastasis of tumor cells in a 4T1-Luc cell induced-lung breast cancer metastasis model. Collectively, the MVs-based nanoplatform offers an alternative promise for surmounting the limitations of monotherapy and may deserve further study for application in synergistic cancer therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Gexuan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Theoretical and Computational Nanoscience, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Center for Excellence in Nanoscience, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, National Center for Nanoscience and Technology, Beijing 100190, China. xiangzhichu2021@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Zhichu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Theoretical and Computational Nanoscience, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Center for Excellence in Nanoscience, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, National Center for Nanoscience and Technology, Beijing 100190, China. xiangzhichu2021@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Qiaojun</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0002-2856-3281</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Theoretical and Computational Nanoscience, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Center for Excellence in Nanoscience, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, National Center for Nanoscience and Technology, Beijing 100190, China. xiangzhichu2021@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sino-Danish Center for Education and Research, Beijing 101408, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nanoscale Horiz</MedlineTA>
        <NlmUniqueID>101712576</NlmUniqueID>
        <ISSNLinking>2055-6756</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37306000</ArticleId>
        <ArticleId IdType="doi">10.1039/d3nh00061c</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="2">37245288</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2213-2317</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>63</Volume>
            <PubDate>
              <Year>2023</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Redox biology</Title>
          <ISOAbbreviation>Redox Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>SARS-CoV-2 ORF3a sensitizes cells to ferroptosis via Keap1-NRF2 axis.</ArticleTitle>
        <Pagination>
          <StartPage>102752</StartPage>
          <MedlinePgn>102752</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">102752</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redox.2023.102752</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2213-2317(23)00153-2</ELocationID>
        <Abstract>
          <AbstractText>Viral infection-induced cell death has long been considered as a double-edged sword in the inhibition or exacerbation of viral infections. Patients with severe Coronavirus Disease 2019 (COVID-19) are characterized by multiple organ dysfunction syndrome and cytokine storm, which may result from SARS-CoV-2-induced cell death. Previous studies have observed enhanced ROS level and signs of ferroptosis in SARS-CoV-2 infected cells or specimens of patients with COVID-19, but the exact mechanism is not clear yet. Here, we find SARS-CoV-2 ORF3a sensitizes cells to ferroptosis via Keap1-NRF2 axis. SARS-CoV-2 ORF3a promotes the degradation of NRF2 through recruiting Keap1, thereby attenuating cellular resistance to oxidative stress and facilitated cells to ferroptotic cell death. Our study uncovers that SARS-CoV-2 ORF3a functions as a positive regulator of ferroptosis, which might explain SARS-CoV-2-induced damage in multiple organs in COVID-19 patients and imply the potential of ferroptosis inhibition in COVID-19 treatment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Lihong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China; Guangzhou Laboratory, Bio-island, Guangzhou, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Sidi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Guangzhou Laboratory, Bio-island, Guangzhou, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Birong</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China; Guangzhou Laboratory, Bio-island, Guangzhou, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Central Hospital of Panyu District, Guangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jiacheng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Guangzhou Laboratory, Bio-island, Guangzhou, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Liu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Siyao</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xue</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Liping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chunmei</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ke</LastName>
            <ForeName>Changwen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Xiaofang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Deyin</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Guangzhou Laboratory, Bio-island, Guangzhou, Guangdong, PR China. Electronic address: guodeyin@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Tropical Disease Control, Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China; Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China. Electronic address: pengh37@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>05</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Redox Biol</MedlineTA>
        <NlmUniqueID>101605639</NlmUniqueID>
        <ISSNLinking>2213-2317</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C431364">KEAP1 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Keap1</Keyword>
        <Keyword MajorTopicYN="N">NRF2</Keyword>
        <Keyword MajorTopicYN="N">ORF3a</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest As the authors of this article, we accept the explanations and conditions listed below:</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>19</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>18</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37245288</ArticleId>
        <ArticleId IdType="pmc">PMC10202901</ArticleId>
        <ArticleId IdType="doi">10.1016/j.redox.2023.102752</ArticleId>
        <ArticleId IdType="pii">S2213-2317(23)00153-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wu F., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265&#x2013;269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094943</ArticleId>
            <ArticleId IdType="pubmed">32015508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7095418</ArticleId>
            <ArticleId IdType="pubmed">32015507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu N., et al. A novel coronavirus from patients with pneumonia in China. N. Engl. J. Med. 2019;382:727&#x2013;733. 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7092803</ArticleId>
            <ArticleId IdType="pubmed">31978945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nalbandian A., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8893149</ArticleId>
            <ArticleId IdType="pubmed">33753937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danthi P. Viruses and the diversity of cell death. Annu Rev Virol. 2016;3:533&#x2013;553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27501259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo J.A., Urcuqui-Inchima S. Mechanisms of monocyte cell death triggered by dengue virus infection. Apoptosis. 2018;23:576&#x2013;586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30267240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabiljo J., Laengle J., Bergmann M. From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. Cell Death Dis. 2020;6:48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7288254</ArticleId>
            <ArticleId IdType="pubmed">32542113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jorgensen I., Rayamajhi M., Miao E.A. Programmed cell death as a defence against infection. Nat. Rev. Immunol. 2017;17:151&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5328506</ArticleId>
            <ArticleId IdType="pubmed">28138137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashida H., et al. Cell death and infection: a double-edged sword for host and pathogen survival. J. Cell Biol. 2011;195:931&#x2013;942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241725</ArticleId>
            <ArticleId IdType="pubmed">22123830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naidoo J., et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol. 2017;35:709&#x2013;717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5559901</ArticleId>
            <ArticleId IdType="pubmed">27646942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Legrand A.J., Konstantinou M., Goode E.F., Meier P. The diversification of cell death and immunity: memento mori. Mol. Cell. 2019;76:232&#x2013;242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31586546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J&#xe9;r&#xf4;me Hadjadj N.Y. Laura Barnabei, Aur&#xe9;lien Corneau, etal, Impaired type I interferon activity and inflammatoryresponses in severe COVID-19 patient. Science (New York, N.Y.) 2020;369:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7402632</ArticleId>
            <ArticleId IdType="pubmed">32661059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fox S.E., et al. Unexpected features of cardiac pathology in COVID-19 infection. Circulation. 2020;142:1123&#x2013;1125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32689809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S., et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7406259</ArticleId>
            <ArticleId IdType="pubmed">32427582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andre S., et al. Cell Death Differentiation; 2022. T Cell Apoptosis Characterizes Severe Covid-19 Disease.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8782710</ArticleId>
            <ArticleId IdType="pubmed">35066575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6997353</ArticleId>
            <ArticleId IdType="pubmed">32015325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Sanchez D., et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid&#x2013;induced AKI. J. Am. Soc. Nephrol. 2017;28:218&#x2013;229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5198282</ArticleId>
            <ArticleId IdType="pubmed">27352622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E.H., Wong S.-W., Martinez J. Programmed Necrosis and Disease:We interrupt your regular programming to bring you necroinflammation. Cell Death Differ. 2019;26:25&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6294794</ArticleId>
            <ArticleId IdType="pubmed">30349078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proneth B., Conrad M. Ferroptosis and necroinflammation, a yet poorly explored link. Cell Death Differ. 2019;26:14&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6294786</ArticleId>
            <ArticleId IdType="pubmed">30082768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopes-Pacheco M., et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front. Physiol. 2021;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7876335</ArticleId>
            <ArticleId IdType="pubmed">33584343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y., et al. SARS-CoV-2 infection induces ferroptosis of sinoatrial node pacemaker cells. Circ. Res. 2022;130:963&#x2013;977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8963443</ArticleId>
            <ArticleId IdType="pubmed">35255712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Xu Y., Zhang K., Shen L., Deng M. Ferroptosis in COVID-19-related liver injury: a potential mechanism and therapeutic target. Front. Cell. Infect. Microbiol. 2022;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9363633</ArticleId>
            <ArticleId IdType="pubmed">35967872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fratta Pasini A.M., Stranieri C., Girelli D., Busti F., Cominacini L. Is ferroptosis a Key component of the process leading to multiorgan damage in COVID-19? Antioxidants. 2021;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8615234</ArticleId>
            <ArticleId IdType="pubmed">34829548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., et al. SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis. Food Chem. Toxicol. 2021;153</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8139185</ArticleId>
            <ArticleId IdType="pubmed">34023458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs W., et al. ESC Heart Fail; 2020. Fatal Lymphocytic Cardiac Damage in Coronavirus Disease 2019 (COVID-19): Autopsy Reveals a Ferroptosis Signature.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7607145</ArticleId>
            <ArticleId IdType="pubmed">32959998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K S., Perez-Bermejo Juan A., Rockwood Sarah J., et al. SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. Sci. Transl. Med. 2021;13 eabf7872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8128284</ArticleId>
            <ArticleId IdType="pubmed">33723017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellmann-Weiler R., et al. Prevalence and predictive value of anemia and dysregulated iron homeostasis in patients with COVID-19 infection. J. Clin. Med. 2020;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7464087</ArticleId>
            <ArticleId IdType="pubmed">32751400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang P., Fang L., Zhang H., Xia S., Xiao S. Functions of coronavirus accessory proteins: overview of the state of the art. Viruses. 2021;13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8231932</ArticleId>
            <ArticleId IdType="pubmed">34199223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco-Melo D., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036&#x2013;1045.e1039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7227586</ArticleId>
            <ArticleId IdType="pubmed">32416070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redondo N., Zald&#xed;var-L&#xf3;pez S., Garrido J.J., Montoya M. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. Front. Immunol. 2021;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8293742</ArticleId>
            <ArticleId IdType="pubmed">34305949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., Stockwell B.R. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165&#x2013;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X., Long D. Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Front. Neurosci. 2020;14:267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7186402</ArticleId>
            <ArticleId IdType="pubmed">32372896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007;47:89&#x2013;116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olagnier D., et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat. Commun. 2020;11:4938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7532469</ArticleId>
            <ArticleId IdType="pubmed">33009401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes J.D., Dinkova-Kostova A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014;39:199&#x2013;218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24647116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, Md. 2016;63:173&#x2013;184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta P., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7270045</ArticleId>
            <ArticleId IdType="pubmed">32192578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jose R.J., Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir. Med. 2020;8:e46&#x2013;e47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7185942</ArticleId>
            <ArticleId IdType="pubmed">32353251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fajgenbaum D.C., June C.H., Storm Cytokine. N. Engl. J. Med. 2020;383:2255&#x2013;2273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7727315</ArticleId>
            <ArticleId IdType="pubmed">33264547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D., Comish P., Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7244094</ArticleId>
            <ArticleId IdType="pubmed">32442210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koupenova M., et al. SARS-CoV-2 initiates programmed cell death in platelets. Circ. Res. 2021;129:631&#x2013;646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8409903</ArticleId>
            <ArticleId IdType="pubmed">34293929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Issa E., Merhi G., Panossian B., Salloum T., Tokajian S. SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis. mSystems. 2020;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7205519</ArticleId>
            <ArticleId IdType="pubmed">32371472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvas J.A., et al. Contribution of SARS-CoV-2 accessory proteins to viral pathogenicity in K18 human ACE2 transgenic mice. J. Virol. 2021;95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8354228</ArticleId>
            <ArticleId IdType="pubmed">34133899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue Y., et al. SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death. Cell Death Dis. 2018;9:904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6125346</ArticleId>
            <ArticleId IdType="pubmed">30185776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren Y., et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell. Mol. Immunol. 2020;17:881&#x2013;883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7301057</ArticleId>
            <ArticleId IdType="pubmed">32555321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olagnier D., et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat. Commun. 2020;11:4938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7532469</ArticleId>
            <ArticleId IdType="pubmed">33009401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846&#x2013;848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7080116</ArticleId>
            <ArticleId IdType="pubmed">32125452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu C., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern. Med. 2020;180:934&#x2013;943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7070509</ArticleId>
            <ArticleId IdType="pubmed">32167524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drakesmith H., Prentice A. Viral infection and iron metabolism. Nat. Rev. Microbiol. 2008;6:541&#x2013;552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18552864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLaughlin K.-M., et al. COVID-19-Related coagulopathy-is transferrin a missing link? Diagnostics. 2020;10:539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7459734</ArticleId>
            <ArticleId IdType="pubmed">32751741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes B.J., et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J. Exp. Med. 2020;217</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7161085</ArticleId>
            <ArticleId IdType="pubmed">32302401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D., et al. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress. Dev. Cell. 2021;56:3250&#x2013;3263 e3255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8502680</ArticleId>
            <ArticleId IdType="pubmed">34706264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y., et al. The emerging role of ferroptosis in inflammation. Biomed. Pharmacother. 2020;127</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32234642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C H.-J., Kunga Yu-An, Lib Mei-Ling, Gonga Yu-Nong, et al. Acyl-coenzyme A synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis. mBio. 2022;13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8764547</ArticleId>
            <ArticleId IdType="pubmed">35038927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuadrado A., et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 2019;18:295&#x2013;317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30610225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013;53:401&#x2013;426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4680839</ArticleId>
            <ArticleId IdType="pubmed">23294312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ordonez A.A., et al. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Communications Biology. 2022;5:242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8933402</ArticleId>
            <ArticleId IdType="pubmed">35304580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulte B., et al. Andrographolide derivatives target the KEAP1/NRF2 Axis and possess potent anti-SARS-CoV-2 activity. ChemMedChem. 2022;17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9015489</ArticleId>
            <ArticleId IdType="pubmed">35099120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Q., et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct. Targeted Ther. 2021;6:212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8164054</ArticleId>
            <ArticleId IdType="pubmed">34052830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan Y.X., et al. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. J. Virol. 2007;81:6346&#x2013;6355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1900074</ArticleId>
            <ArticleId IdType="pubmed">17428862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhixin Liu e. Ubiquitination of SARS-CoV-2 ORF7a prevents cell death induced by recruiting BclXL to activate ER stress. American society for microbiology. 2022;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9769937</ArticleId>
            <ArticleId IdType="pubmed">36326498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma K., et al. SARS-CoV 9b protein diffuses into nucleus, undergoes active Crm1 mediated nucleocytoplasmic export and triggers apoptosis when retained in the nucleus. PLoS One. 2011;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103500</ArticleId>
            <ArticleId IdType="pubmed">21637748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivasan K., Pandey A.K., Livingston A., Venkatesh S. Roles of host mitochondria in the development of COVID-19 pathology: could mitochondria be a potential therapeutic target? Mol Biomed. 2021;2:38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8608434</ArticleId>
            <ArticleId IdType="pubmed">34841263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faizan M.I., et al. NSP4 and ORF9b of SARS-CoV-2 induce pro-inflammatory mitochondrial DNA release in inner membrane-derived vesicles. Cells. 2022;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9561960</ArticleId>
            <ArticleId IdType="pubmed">36230930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West A.P., Shadel G.S. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat. Rev. Immunol. 2017;17:363&#x2013;375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7289178</ArticleId>
            <ArticleId IdType="pubmed">28393922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riley J.S., Tait S.W. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 2020;21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7132203</ArticleId>
            <ArticleId IdType="pubmed">32202065</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37220842</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-1597</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <PubDate>
              <Year>2023</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Photodiagnosis and photodynamic therapy</Title>
          <ISOAbbreviation>Photodiagnosis Photodyn Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>5-ALA-PDT induced ferroptosis in keloid fibroblasts via ROS, accompanied by downregulation of xCT, GPX4.</ArticleTitle>
        <Pagination>
          <StartPage>103612</StartPage>
          <MedlinePgn>103612</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pdpdt.2023.103612</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1572-1000(23)00339-3</ELocationID>
        <Abstract>
          <AbstractText>Keloids display many cancerous properties, including uncontrolled and invasive growth, high rates of recurrence as well as similar bioenergetics. 5-aminolevulinic acid-based photodynamic therapy (5-ALA-PDT) is an effective treatment that performs cytotoxic effects by producing reactive oxygen species (ROS), which is linked to lipid peroxidation and ferroptosis. Herein, we explored underlying mechanisms of 5-ALA-PDT against keloids. We identified that 5-ALA-PDT led to elevated levels of ROS and lipid peroxidation in keloid fibroblasts, accompanied by downregulation of xCT and GPX4, which are associated with anti-oxidation effects and ferroptosis inhibition. These results may indicate that 5-ALA-PDT treatment increases ROS while inhibiting xCT and GPX4, thus promoting lipid peroxidation to induce ferroptosis in keloid fibroblasts.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jiheng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Lulu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xinying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Xiaoxiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Bioengineering College of Chongqing University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Guihong</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Yumeng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Zhengwei</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Junbo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing, China. Electronic address: zhangjunbo0924@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yuangang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing, China. Electronic address: skin515@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>05</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Photodiagnosis Photodyn Ther</MedlineTA>
        <NlmUniqueID>101226123</NlmUniqueID>
        <ISSNLinking>1572-1000</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>88755TAZ87</RegistryNumber>
          <NameOfSubstance UI="D000622">Aminolevulinic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000622" MajorTopicYN="N">Aminolevulinic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007627" MajorTopicYN="Y">Keloid</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Fibroblast</Keyword>
        <Keyword MajorTopicYN="N">Keloids</Keyword>
        <Keyword MajorTopicYN="N">PDT</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors report no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>1</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>19</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37220842</ArticleId>
        <ArticleId IdType="doi">10.1016/j.pdpdt.2023.103612</ArticleId>
        <ArticleId IdType="pii">S1572-1000(23)00339-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37178565</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>05</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>05</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-7103</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>645</Volume>
            <PubDate>
              <Year>2023</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of colloid and interface science</Title>
          <ISOAbbreviation>J Colloid Interface Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Engineering nanoenzymes integrating Iron-based metal organic frameworks with Pt nanoparticles for enhanced Photodynamic-Ferroptosis therapy.</ArticleTitle>
        <Pagination>
          <StartPage>882</StartPage>
          <EndPage>894</EndPage>
          <MedlinePgn>882-894</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcis.2023.05.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0021-9797(23)00787-7</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT), as a promising strategy in cancer treatment that utilizes photosensitizers (PSs) to produce reactive oxygen species, has been widely used for eliminating cancer cells under specific wavelength light irradiation. However, the low aqueous solubility of PSs and special tumor microenvironments (TME), such as high glutathione (GSH) and tumor hypoxia remain challenges towards PDT for hypoxic tumor treatment. To address these problems, we constructed a novel nanoenzyme for enhanced PDT-ferroptosis therapy by integrating small Pt nanoparticles (Pt NPs) and near-infrared photosensitizer CyI into iron-based metal organic frameworks (MOFs). In addition, hyaluronic acid was adhered to the surface of the nanoenzymes to enhance the targeting ability. In this design, MOFs act not only as a delivery vector for PSs, but also a ferroptosis inducer. Pt NPs stabilized by MOFs were functioned as an oxygen (O2) generator by catalyzing hydrogen peroxide into O2 to relieve tumor hypoxia and increase singlet oxygen generation. In vitro and in vivo results demonstrated that under laser irradiation, this nanoenzyme could effectively relive the tumor hypoxia and decrease the level of GSH, resulting in enhanced PDT-ferroptosis therapy against hypoxic tumor. The proposed nanoenzymes represent an important advance in altering TME for improved clinical PDT-ferroptosis therapy, as well as their potential as effective theranostic agents for hypoxic tumors.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Yuyun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Hongli</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Bohan</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yifan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Bai</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Guanghe</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China. Electronic address: sunyong@qdu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China. Electronic address: caojie0829@qdu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>05</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Colloid Interface Sci</MedlineTA>
        <NlmUniqueID>0043125</NlmUniqueID>
        <ISSNLinking>0021-9797</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000073396">Metal-Organic Frameworks</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073396" MajorTopicYN="Y">Metal-Organic Frameworks</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis therapy</Keyword>
        <Keyword MajorTopicYN="N">Hypoxic tumor</Keyword>
        <Keyword MajorTopicYN="N">Iron-based MOFs</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">Pt nanoparticles</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>18</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37178565</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jcis.2023.05.003</ArticleId>
        <ArticleId IdType="pii">S0021-9797(23)00787-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37144959</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1936-086X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>May</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS nano</Title>
          <ISOAbbreviation>ACS Nano</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficient NIR-II Type-I AIE Photosensitizer for Mitochondria-Targeted Photodynamic Therapy through Synergistic Apoptosis-Ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>9110</StartPage>
          <EndPage>9125</EndPage>
          <MedlinePgn>9110-9125</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsnano.2c12319</ELocationID>
        <Abstract>
          <AbstractText>Hypoxia, the hallmark of malignant tumors, has been recognized as a major obstacle for photodynamic therapy (PDT). Precisely targeting cancer cells in intricate biological scenarios by a hypoxia-resistant photosensitizer (PS) is the cornerstone to conquer the inevitable tumor recurrence and metastasis. Herein, we describe an organic NIR-II PS (TPEQM-DMA) possessing potent type-I phototherapeutic efficacy to overcome the intrinsic pitfalls of PDT in combating hypoxic tumors. TPEQM-DMA exhibited prominent NIR-II emission (&gt;1000 nm) with an aggregation-induced emission feature and efficiently produced superoxide anion and hydroxyl radical in the aggregate state under white light irradiation exclusively through a low-O2-dependent type-I photochemical process. The suitable cationic nature assisted TPEQM-DMA to accumulate in cancerous mitochondria. Meanwhile, the PDT of TPEQM-DMA impaired the cellular redox homeostasis, led to the mitochondrial dysfunction, and raised the level of lethal peroxidized lipids, which induced cellular apoptosis and ferroptosis. This synergistic cell death modality enabled TPEQM-DMA to suppress the growth of cancer cells, multicellular tumor spheroids, and tumors. To improve the pharmacological properties of TPEQM-DMA, TPEQM-DMA nanoparticles were prepared by encapsulation of polymer. In vivo experiments proved the appealing NIR-II fluorescence imaging-guided PDT effect of TPEQM-DMA nanoparticles for tumors.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhuang</LastName>
            <ForeName>Jiabao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Applied Surface and Colloid Chemistry of MOE, Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry &amp; Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Applied Surface and Colloid Chemistry of MOE, Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry &amp; Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Applied Surface and Colloid Chemistry of MOE, Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry &amp; Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Keyi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Applied Surface and Colloid Chemistry of MOE, Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry &amp; Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Nan</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-1091-0086</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Applied Surface and Colloid Chemistry of MOE, Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry &amp; Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-7347-5865</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Applied Surface and Colloid Chemistry of MOE, Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry &amp; Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Ben Zhong</ForeName>
            <Initials>BZ</Initials>
            <Identifier Source="ORCID">0000-0002-0293-964X</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>05</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Nano</MedlineTA>
        <NlmUniqueID>101313589</NlmUniqueID>
        <ISSNLinking>1936-0851</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">aggregation-induced emission</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">mitochondria targeting</Keyword>
        <Keyword MajorTopicYN="N">near-infrared II</Keyword>
        <Keyword MajorTopicYN="N">type-I photosensitizer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>12</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>9</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37144959</ArticleId>
        <ArticleId IdType="doi">10.1021/acsnano.2c12319</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37070469</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2192-2659</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>21</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advanced healthcare materials</Title>
          <ISOAbbreviation>Adv Healthc Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Single Component Organic Photosensitizer with NIR-I Emission Realizing Type-I Photodynamic and GSH-Depletion Caused Ferroptosis Synergistic Theranostics.</ArticleTitle>
        <Pagination>
          <StartPage>e2300134</StartPage>
          <MedlinePgn>e2300134</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/adhm.202300134</ELocationID>
        <Abstract>
          <AbstractText>Phototheranostic agents have thrived as prominent tools for tumor luminescence imaging and therapies. Herein, a series of organic photosensitizers (PSs) with donor-acceptors (D-A) are elaborately designed and synthesized. In particular, PPR-2CN exhibits stable near infrared-I (NIR-I) emission, excellent free radicals generation and phototoxicity. Experimental analysis and calculations imply that a small singlet-triplet energy gap (ES1-T1) and large spin-orbit coupling (SOC) constant boost the intersystem crossing (ISC), leading to type-I photodynamic therapy (PDT). Additionally, the specific glutamate (Glu) and glutathione (GSH) consumption abilities of PPR-2CN inhibit the intracellular biosynthesis of GSH, resulting in redox dyshomeostasis and GSH-depletion causing ferroptosis. This work first realizes that single component organic PS could be simultaneously used as a type-I photodynamic agent and metal-free ferroptosis inducer for NIR-I imaging-guided multimodal synergistic therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2023 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Laiping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Mingda</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Botong</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Minmin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Mengpei</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Liyun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lian</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Materials Science and Engineering, National Institute for Advanced Materials, Tianjin Key Laboratory of Metal and Molecule-Based Material Chemistry, Nankai University, Tongyan Road 38, Tianjin, 300350, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Keke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Shouhua</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6888-068X</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Jilin Provincial International Cooperation Key Laboratory of Advanced Inorganic Solid Functional Materials, College of Chemistry, Jilin University, Qianjin Street 2699, Changchun, 130012, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>91959201</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <Agency>Funding Program Project of Interdisciplinary Research Team</Agency>
          </Grant>
          <Grant>
            <GrantID>419021420365</GrantID>
            <Agency>Jilin University</Agency>
          </Grant>
          <Grant>
            <GrantID>20210509035RQ</GrantID>
            <Agency>Jilin Province Science and Technology Development Plan</Agency>
          </Grant>
          <Grant>
            <GrantID>2022GBJS04</GrantID>
            <Agency>"Medicine + X" cross innovation team of Bethune Medical Department of Jilin University</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>05</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Adv Healthc Mater</MedlineTA>
        <NlmUniqueID>101581613</NlmUniqueID>
        <ISSNLinking>2192-2640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">molecular engineering</Keyword>
        <Keyword MajorTopicYN="N">phototheranostics integration</Keyword>
        <Keyword MajorTopicYN="N">type-I photodynamics</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37070469</ArticleId>
        <ArticleId IdType="doi">10.1002/adhm.202300134</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>a) J. Celli, B. Spring, I. Rizvi, C. Evans, K. Samkoe, S. Verma, B. Pogue, T. Hasan, Chem. Rev. 2010, 110, 2795;</Citation>
        </Reference>
        <Reference>
          <Citation>b) S. Liu, G. Feng, B. Z. Tang, B. Liu, Chem. Sci. 2021,12, 6488;</Citation>
        </Reference>
        <Reference>
          <Citation>c) S. Zhang, J. Wang, Z. Kong, X. Sun, Z. He, B. Sun, C. Luo, J. Sun, Biomaterials 2022, 282, 121433;</Citation>
        </Reference>
        <Reference>
          <Citation>d) Y. Wan, L.-H. Fu, C. Li, J. Lin, P. Huang, Adv. Mater. 2021, 33, 2103978.</Citation>
        </Reference>
        <Reference>
          <Citation>a) K.-X. Teng, W.-K. Chen, L.-Y. Niu, W.-H. Fang, G. Cui, Q.-Z. Yang, Angew. Chem., Int. Ed. 2021, 60, 19912;</Citation>
        </Reference>
        <Reference>
          <Citation>b) G. Yang, J.-S. Ni, Y. Li, M. Zha, Y. Tu, K. Li, Angew. Chem., Int. Ed. 2021, 60, 5386;</Citation>
        </Reference>
        <Reference>
          <Citation>c) J. Li, Z. Zhuang, Z. Zhao, B. Z. Tang, VIEW 2022, 3, 20200121.</Citation>
        </Reference>
        <Reference>
          <Citation>a) X. Zhao, Q. Yao, S. Long, W. Chi, Y. Yang, D. Tan, X. Liu, H. Huang, W. Sun, J. Du, J. Fan, X. Peng, J. Am. Chem. Soc. 2021, 143, 12345;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Y. Wang, S. Xu, L. Shi, C. Teh, G. Qi, B. Liu, Angew. Chem., Int. Ed. 2021, 60, 14945;</Citation>
        </Reference>
        <Reference>
          <Citation>c) J. Zou, L. Li, J. Zhu, X. Li, Z. Yang, W. Huang, X. Chen, Adv. Mater. 2021, 33, 2103627.</Citation>
        </Reference>
        <Reference>
          <Citation>a) S. Wang, Y. Fan, D. Li, C. Sun, Z. Lei, L. Lu, T. Wang, F. Zhang, Nat. Commun. 2019, 10, 1058;</Citation>
        </Reference>
        <Reference>
          <Citation>b) X. Li, S. Lee, J. Yoon, Chem. Soc. Rev. 2018, 47, 1174;</Citation>
        </Reference>
        <Reference>
          <Citation>c) S. Singh, A. Aggarwal, N. V. S. D. K. Bhupathiraju, G. Arianna, K. Tiwari, C. M. Drain, Chem. Rev. 2015, 115, 10261;</Citation>
        </Reference>
        <Reference>
          <Citation>d) J. Zhao, K. Xu, W. Yang, Z. Wang, F. Zhong, Chem. Soc. Rev. 2015, 44, 8904.</Citation>
        </Reference>
        <Reference>
          <Citation>a) Z. Zhang, M. Kang, H. Tan, N. Song, M. Li, P. Xiao, D. Yan, L. Zhang, D. Wang, B. Z. Tang, Chem. Soc. Rev. 2022, 51, 1983;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Z. Zhao, W. He, B. Z. Tang, Acc. Mater. Res. 2021, 2, 1251;</Citation>
        </Reference>
        <Reference>
          <Citation>c) H. Li, H. Kim, J. Han, V.-N. Nguyen, X. Peng, J. Yoon, Aggregate 2021, 2, e51.</Citation>
        </Reference>
        <Reference>
          <Citation>a) D. Li, X. Chen, D. Wang, H. Wu, H. Wen, L. Wang, Q. Jin, D. Wang, J. Ji, B. Z. Tang, Biomaterials 2022, 283, 121476;</Citation>
        </Reference>
        <Reference>
          <Citation>b) S. Gao, S. Yu, Y. Zhang, A. Wu, S. Zhang, G. Wei, H. Wang, Z. Xiao, W. Lu, Adv. Funct. Mater. 2021, 31, 2008356.</Citation>
        </Reference>
        <Reference>
          <Citation>a) D. Mao, F. Hu, Z. Yi, Kenry, S. Xu, S. Yan, Z. Luo, W. Wu, Z. Wang, D. Kong, X. Liu, B. Liu, Sci. Adv. 2020, 6, eabb2712;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Y. Wan, G. Lu, W.-C. Wei, Y.-H. Huang, S. Li, J.-X. Chen, X. Cui, Y.-F. Xiao, X. Li, Y. Liu, X.-M. Meng, P. Wang, H.-Y. Xie, J. Zhang, K.-T. Wong, C.-S. Lee, ACS Nano 2020, 14, 9917.</Citation>
        </Reference>
        <Reference>
          <Citation>a) D. Yan, W. Xie, J. Zhang, L. Wang, D. Wang, B. Z. Tang, Angew. Chem., Int. Ed. 2021, 60, 26769;</Citation>
        </Reference>
        <Reference>
          <Citation>b) S. Wang, H. Chen, J. Liu, C. Chen, B. Liu, Adv. Funct. Mater. 2020, 30, 2002546.</Citation>
        </Reference>
        <Reference>
          <Citation>a) G. Yuan, C. Lv, J. Liang, X. Zhong, Y. Li, J. He, A. Zhao, L. Li, Y. Shao, X. Zhang, S. Wang, Y. Cheng, H. He, Adv. Funct. Mater. 2021, 31, 2104026;</Citation>
        </Reference>
        <Reference>
          <Citation>b) C. Chen, X. Ni, S. Jia, Y. Liang, X. Wu, D. Kong, D. Ding, Adv. Mater. 2019, 31, 1904914.</Citation>
        </Reference>
        <Reference>
          <Citation>a) B. Hao, J. Wang, C. Wang, K. Xue, M. Xiao, S. Lv, C. Zhu, Chem. Sci. 2022, 13, 4139;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Z. Wang, L. Huang, Y. Yan, A. M. El-Zohry, A. Toffoletti, J. Zhao, A. Barbon, B. Dick, O. F. Mohammed, G. Han, Angew. Chem., Int. Ed. 2020, 59, 16114.</Citation>
        </Reference>
        <Reference>
          <Citation>a) V.-N. Nguyen, Y. Yan, J. Zhao, J. Yoon, Acc. Chem. Res. 2021, 54, 207;</Citation>
        </Reference>
        <Reference>
          <Citation>b) B. Ran, Z. Wang, W. Cai, L. Ran, W. Xia, W. Liu, X. Peng, J. Am. Chem. Soc. 2021, 143, 17891;</Citation>
        </Reference>
        <Reference>
          <Citation>c) K. Wen, H. Tan, Q. Peng, H. Chen, H. Ma, L. Wang, A. Peng, Q. Shi, X. Cai, H. Huang, Adv. Mater. 2022, 34, 2108146.</Citation>
        </Reference>
        <Reference>
          <Citation>a) H. Tsujimoto, D.-G. Ha, G. Markopoulos, H. S. Chae, M. A. Baldo, T. M. Swager, J. Am. Chem. Soc. 2017, 139, 4894;</Citation>
        </Reference>
        <Reference>
          <Citation>b) M. Kang, C. Zhou, S. Wu, B. Yu, Z. Zhang, N. Song, M. M. S. Lee, W. Xu, F. Xu, D. Wang, L. Wang, B. Z. Tang, J. Am. Chem. Soc. 2019, 141, 16781.</Citation>
        </Reference>
        <Reference>
          <Citation>a) L.-A. Ortiz-Rodr&#xed;guez, S.-J. Hoehn, A. Loredo, L. Wang, H. Xiao, C.-E. Crespo-Hernandez, J. Am. Chem. Soc. 2021, 143, 2676;</Citation>
        </Reference>
        <Reference>
          <Citation>b) S. Monro, K. Colon, H. Yin, J. R. P. Konda, 3rd, S. Gujar, R. Thummel, L. Lilge, C. Cameron, S. McFarland, Chem. Rev. 2019, 119, 797;</Citation>
        </Reference>
        <Reference>
          <Citation>c) K.-M. Farrell, M.-M. Brister, M. Pittelkow, T. I. S&#xf8;lling, C.-E. Crespo-Hernandez, J. Am. Chem. Soc. 2018, 140, 11214.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Zheng, M. Conrad, Cell Metab. 2020, 32, 920.</Citation>
        </Reference>
        <Reference>
          <Citation>a) X. Meng, D. Li, L. Chen, H. He, Q. Wang, C. Hong, J. He, X. Gao, Y. Yang, B. Jiang, G. Nie, X. Yan, L. Gao, K. Fan, ACS Nano 2021, 15, 5735;</Citation>
        </Reference>
        <Reference>
          <Citation>b) J. Chen, Z. Jiang, W. Xu, T. Sun, X. Zhuang, J. Ding, X. Chen, Nano Lett. 2020, 20, 6191.</Citation>
        </Reference>
        <Reference>
          <Citation>a) Z. Zhou, H. Liang, R. Yang, Y. Yang, J. Dong, Y. Di, M. Sun, Angew. Chem., Int. Ed. 2022, 61, e202202843;</Citation>
        </Reference>
        <Reference>
          <Citation>b) C. Ou, W. Na, W. Ge, H. Huang, F. Gao, L. Zhong, Y. Zhao, X. Dong, Angew. Chem., Int. Ed. 2021, 60, 8157.</Citation>
        </Reference>
        <Reference>
          <Citation>a) R. Yue, C. Zhang, L. Xu, Y. Wang, G. Guan, L. Lei, X. Zhang, G. Song, Chem 2022, 8, 1956;</Citation>
        </Reference>
        <Reference>
          <Citation>b) B. Ding, P. Zheng, F. Jiang, Y. Zhao, M. Wang, M. Chang, P. Ma, J. Lin, Angew. Chem., Int. Ed. 2020, 59, 16381.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Meng, J. Deng, F. Liu, T. Guo, M. Liu, P. Dai, A. Fan, Z. Wang, Y. Zhao, Nano Lett. 2019, 19, 7866.</Citation>
        </Reference>
        <Reference>
          <Citation>a) M. Badgley, D. Kremer, H. Maurer, K. DelGiorno, H. J. Lee, V. Purohit, I. Sagalovskiy, A. Ma, J. Kapilian, C. Firla, A. Decker, S. Sastra, C. Palermo, L. Andrade, P. Sajjakulnukit, L. Zhang, Z. Tolstyka, T. Hirschhorn, C. Lamb, T. Liu, W. Gu, E. Seeley, E. Stone, G. Georgiou, C. Lyssiotis, K. Olive, Science 2020, 368, 85;</Citation>
        </Reference>
        <Reference>
          <Citation>b) B. Altman, Z. Stine, C. Dang, Nat. Rev. Cancer 2016, 16, 619.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Li, J. Liu, Y. Hong, R. Lin, Z. Liu, M. Chen, J.-W.-Y. Lam, G.-H. Ning, X. Zheng, A. Qin, B. Z. Tang, Angew. Chem., Int. Ed. 2022, 134, e202202005.</Citation>
        </Reference>
        <Reference>
          <Citation>a) O. Rusin, N. Luce, R. Agbaria, J. Escobedo, S. Jiang, I. Warner, F. Dawan, K. Lian, R. Strongin, J. Am. Chem. Soc. 2004, 126, 438;</Citation>
        </Reference>
        <Reference>
          <Citation>b) L. Niu, Y. Chen, H. Zheng, L. Wu, C. Tung, Q. Z. Yang, Chem. Soc. Rev. 2015, 44, 6143.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Yu, S. Wu, L. Zhang, S. Xu, C. Dai, S. Gan, G. Xie, G. Feng, B. Z. Tang, Biomaterials 2022, 280, 121255.</Citation>
        </Reference>
        <Reference>
          <Citation>S. Liu, C. Chen, Y. Li, H. Zhang, J. Liu, R. Wang, S.-T.-H. Wong, J.-W.-Y. Lam, D. Ding, B. Z. Tang, Adv. Funct. Mater. 2020, 30, 1908125.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Mei, N.-L. Leung, R.-T.-K. Kwok, J.-W.-Y. Lam, B. Z. Tang, Chem. Rev. 2015, 115, 11718.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Cai, B. Gao, X.-L. Li, Y. Cao, S.-J. Su, Adv. Funct. Mater. 2016, 26, 8042.</Citation>
        </Reference>
        <Reference>
          <Citation>S. Liu, H. Zhang, Y. Li, J. Liu, L. Du, M. Chen, R.-T.-K. Kwok, J.-W.-Y. Lam, D. Phillips, B. Z. Tang, Angew. Chem., Int. Ed. 2018, 57, 15189.</Citation>
        </Reference>
        <Reference>
          <Citation>L. G, Z. L, G. B, Nat. Rev. Cancer 2022, 22, 381.</Citation>
        </Reference>
        <Reference>
          <Citation>T. Yoshimura, O. Howard, T. Ito, M. Kuwabara, A. Matsukawa, K. Chen, Y. Liu, M. Liu, J. Oppenheim, J. Wang, PLoS One 2013, 8, e58791.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37060026</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2662-7671</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Apr</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC complementary medicine and therapies</Title>
          <ISOAbbreviation>BMC Complement Med Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prevotella histicola suppresses ferroptosis to mitigate ethanol-induced gastric mucosal lesions in mice.</ArticleTitle>
        <Pagination>
          <StartPage>118</StartPage>
          <MedlinePgn>118</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">118</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12906-023-03946-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ethanol-induced gastric mucosal lesions (EGML) is one of the most common digestive disorders for which current therapies have limited outcomes in clinical practice. Prevotella histicola (P. histicola) has shown probiotic efficacy against arthritis, multiple sclerosis and oestrogen deficiency-induced depression in mice; however, its role in EGML remains unclear in spite of its extensive colonisation of the stomach. Ferroptosis, which is characterised by lipid peroxidation, may be involved in EGML. Herein, we aimed to investigate the effects and underlying mechanism of action of P. histicola on EGML in the ferroptosis-dependent pathway.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">P. histicola was intragastrically administered for a week, and deferoxamine (DFO), a ferroptosis inhibitor, was intraperitoneally injected prior to oral ethanol administration. The gastric mucosal lesions and ferroptosis were assessed via histopathological examinations, quantitative real-time PCR, Western blot, immunohistochemistry and immunofluorescence.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">P. histicola was originally found to attenuate EGML by reducing histopathological changes and lipid reactive oxygen species (ROS) accumulation. The pro-ferroptotic genes of Transferrin Receptor (TFR1), Solute Carrier Family 39 Member 14 (SLC39A14), Haem Oxygenase-1 (HMOX-1), Acyl-CoA Synthetase Long-chain Family Member 4 (ACSL4), Cyclooxygenase 2 (COX-2) and mitochondrial Voltage-dependent Anion Channels (VDACs) were up-regulated; the anti-ferroptotic System Xc-/Glutathione Peroxidase 4 (GPX4) axis was inhibited after ethanol administration. However, the changes of histopathology and ferroptosis-related parameters induced by ethanol were reversed by DFO. Furthermore, P. histicola treatment significantly downregulated the expression of ACSL4, HMOX-1 and COX-2, as well as TFR1 and SLC39A14, on mRNA or the protein level, while activating the System Xc-/GPX4 axis.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found that P. histicola reduces ferroptosis to attenuate EGML by inhibiting the ACSL4- and VDAC-dependent pro-ferroptotic pathways and activating the anti-ferroptotic System Xc-/GPX4 axis.</AbstractText>
          <CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Sisi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wu</LastName>
            <ForeName>Du</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Wuyunshan Hospital Hangzhou Health Promotion Institution, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Fangquan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hongxia</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xinyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Hongbing</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Qingqing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hemodialysis, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Keke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China. jinkeke@wmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Fangyan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China. fangyan_wang@wmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Complement Med Ther</MedlineTA>
        <NlmUniqueID>101761232</NlmUniqueID>
        <ISSNLinking>2662-7671</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 1.14.99.1</RegistryNumber>
          <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3K9958V90M</RegistryNumber>
          <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C500556">SLC39A14 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Organism" UI="C000643281">Prevotella histicola</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027682" MajorTopicYN="Y">Cation Transport Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ACSL4</Keyword>
        <Keyword MajorTopicYN="N">Ethanol</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Gastric mucosal lesions</Keyword>
        <Keyword MajorTopicYN="N">Prevotella histicola</Keyword>
        <Keyword MajorTopicYN="N">System Xc-/GPX4 axis</Keyword>
        <Keyword MajorTopicYN="N">VDAC</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>23</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37060026</ArticleId>
        <ArticleId IdType="pmc">PMC10103513</ArticleId>
        <ArticleId IdType="doi">10.1186/s12906-023-03946-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12906-023-03946-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Muller DC, Duff EM, Stern KL. Timeline: 200 years of the New England Journal of Medicine. N Engl J Med. 2012;366(1):e3. doi: 10.1056/NEJMp1114819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp1114819</ArticleId>
            <ArticleId IdType="pubmed">22216863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adefisayo MA, et al. Gastro-protective effect of methanol extract of Vernonia amygdalina (del.) Leaf on aspirin-induced gastric ulcer in Wistar rats. Toxicol Rep. 2017;4:625&#x2013;33. doi: 10.1016/j.toxrep.2017.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxrep.2017.11.004</ArticleId>
            <ArticleId IdType="pmc">PMC5897319</ArticleId>
            <ArticleId IdType="pubmed">29657922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu T, et al. Prophylactic effect of Lactobacillus fermentum TKSN02 on gastric Injury Induced by Hydrochloric Acid/Ethanol in mice through its antioxidant capacity. Front Nutr. 2022;9:840566. doi: 10.3389/fnut.2022.840566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnut.2022.840566</ArticleId>
            <ArticleId IdType="pmc">PMC8921696</ArticleId>
            <ArticleId IdType="pubmed">35299759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomi A, et al. Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. J Dairy Sci. 2013;96(2):832&#x2013;7. doi: 10.3168/jds.2012-5950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3168/jds.2012-5950</ArticleId>
            <ArticleId IdType="pubmed">23200466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005;96(2):94&#x2013;102. doi: 10.1111/j.1742-7843.2005.pto960202.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-7843.2005.pto960202.x</ArticleId>
            <ArticleId IdType="pubmed">15679471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13(4):251&#x2013;6. doi: 10.1136/gut.13.4.251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.13.4.251</ArticleId>
            <ArticleId IdType="pmc">PMC1412163</ArticleId>
            <ArticleId IdType="pubmed">4556018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nardone G, Compare D. The human gastric microbiota: is it time to rethink the pathogenesis of stomach diseases? United Eur Gastroenterol J. 2015;3(3):255&#x2013;60. doi: 10.1177/2050640614566846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2050640614566846</ArticleId>
            <ArticleId IdType="pmc">PMC4480535</ArticleId>
            <ArticleId IdType="pubmed">26137299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangalam A, et al. Human gut-derived commensal Bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 2017;20(6):1269&#x2013;77. doi: 10.1016/j.celrep.2017.07.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.07.031</ArticleId>
            <ArticleId IdType="pmc">PMC5763484</ArticleId>
            <ArticleId IdType="pubmed">28793252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, et al. Chemical characterization and gastroprotective effect of an isolated polysaccharide fraction from Bletilla striata against ethanol-induced acute gastric ulcer. Food Chem Toxicol. 2019;131:110539. doi: 10.1016/j.fct.2019.05.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2019.05.047</ArticleId>
            <ArticleId IdType="pubmed">31158404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng H, et al. Evaluation of protective effects of costunolide and dehydrocostuslactone on ethanol-induced gastric ulcer in mice based on multi-pathway regulation. Chem Biol Interact. 2016;250:68&#x2013;77. doi: 10.1016/j.cbi.2016.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2016.03.003</ArticleId>
            <ArticleId IdType="pubmed">26970604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, et al. Tochu (Eucommia ulmoides) leaf extract prevents ammonia and vitamin C deficiency induced gastric mucosal injury. Life Sci. 2003;73(25):3245&#x2013;56. doi: 10.1016/j.lfs.2003.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2003.06.011</ArticleId>
            <ArticleId IdType="pubmed">14561529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaarin K, et al. Effect of palm vitamin E on the healing of ethanol-induced gastric injury in rats. Int J Food Sci Nutr. 2000;51(Suppl):31&#x2013;41. doi: 10.1080/096374800111113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/096374800111113</ArticleId>
            <ArticleId IdType="pubmed">11271855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solmaz A, et al. Protective and therapeutic effects of resveratrol on acetic acid-induced gastric ulcer. Free Radic Res. 2009;43(6):594&#x2013;603. doi: 10.1080/10715760902977424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10715760902977424</ArticleId>
            <ArticleId IdType="pubmed">19479585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med. 2019;33:130&#x2013;43. doi: 10.1016/j.freeradbiomed.2018.09.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.09.043</ArticleId>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32(6):920&#x2013;37. doi: 10.1016/j.cmet.2020.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2020.10.011</ArticleId>
            <ArticleId IdType="pubmed">33217331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26(11):2284&#x2013;99. doi: 10.1038/s41418-019-0299-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0299-4</ArticleId>
            <ArticleId IdType="pmc">PMC6889315</ArticleId>
            <ArticleId IdType="pubmed">30737476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayr L, et al. Dietary lipids fuel GPX4-restricted enteritis resembling Crohn&#x2019;s disease. Nat Commun. 2020;11(1):1775. doi: 10.1038/s41467-020-15646-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-15646-6</ArticleId>
            <ArticleId IdType="pmc">PMC7156516</ArticleId>
            <ArticleId IdType="pubmed">32286299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 2020;30(10):3411&#x2013;23. doi: 10.1016/j.celrep.2020.02.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.02.049</ArticleId>
            <ArticleId IdType="pmc">PMC7172030</ArticleId>
            <ArticleId IdType="pubmed">32160546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenkitkasemwong S, et al. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc Natl Acad Sci U S A. 2018;115(8):E1769&#x2013;78. doi: 10.1073/pnas.1720739115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1720739115</ArticleId>
            <ArticleId IdType="pmc">PMC5828629</ArticleId>
            <ArticleId IdType="pubmed">29437953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, et al. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338&#x2013;43. doi: 10.1016/j.bbrc.2016.08.124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.08.124</ArticleId>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grevengoed TJ, Klett EL, Coleman RA. Acyl-CoA metabolism and partitioning. Annu Rev Nutr. 2014;34:1&#x2013;30. doi: 10.1146/annurev-nutr-071813-105541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-nutr-071813-105541</ArticleId>
            <ArticleId IdType="pmc">PMC5881898</ArticleId>
            <ArticleId IdType="pubmed">24819326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. JCI Insight. 2017;2(7):e90777. doi: 10.1172/jci.insight.90777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.90777</ArticleId>
            <ArticleId IdType="pmc">PMC5374066</ArticleId>
            <ArticleId IdType="pubmed">28405617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1&#x2013;2):317&#x2013;31. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeHart DN, et al. Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol. 2018;148:155&#x2013;62. doi: 10.1016/j.bcp.2017.12.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2017.12.022</ArticleId>
            <ArticleId IdType="pmc">PMC5909406</ArticleId>
            <ArticleId IdType="pubmed">29289511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Jiang X. Gu. Emerging mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol. 2020;30(6):478&#x2013;90. doi: 10.1016/j.tcb.2020.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2020.02.009</ArticleId>
            <ArticleId IdType="pmc">PMC7230071</ArticleId>
            <ArticleId IdType="pubmed">32413317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo M, et al. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99(3):464&#x2013;72. doi: 10.1038/sj.bjc.6604485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604485</ArticleId>
            <ArticleId IdType="pmc">PMC2527809</ArticleId>
            <ArticleId IdType="pubmed">18648370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XY, et al. Gastroprotective activity of polysaccharide from Hericium erinaceus against ethanol-induced gastric mucosal lesion and pylorus ligation-induced gastric ulcer, and its antioxidant activities. Carbohydr Polym. 2018;186:100&#x2013;9. doi: 10.1016/j.carbpol.2018.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.carbpol.2018.01.004</ArticleId>
            <ArticleId IdType="pubmed">29455967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaccob AA. Protective effect of N-acetylcysteine against ethanol-induced gastric ulcer: a pharmacological assessment in mice. J Intercult Ethnopharmacol. 2015;4(2):90&#x2013;5. doi: 10.5455/jice.20150212103327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5455/jice.20150212103327</ArticleId>
            <ArticleId IdType="pmc">PMC4566772</ArticleId>
            <ArticleId IdType="pubmed">26401392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CL, et al. Reduced expression of the ferroptosis inhibitor glutathione peroxidase-4 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurochem. 2019;148(3):426&#x2013;39. doi: 10.1111/jnc.14604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.14604</ArticleId>
            <ArticleId IdType="pmc">PMC6347488</ArticleId>
            <ArticleId IdType="pubmed">30289974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell GR, et al. Mitochondrial changes within axons in multiple sclerosis: an update. Curr Opin Neurol. 2012;25(3):221&#x2013;30. doi: 10.1097/WCO.0b013e3283533a25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e3283533a25</ArticleId>
            <ArticleId IdType="pubmed">22543429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, et al. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052&#x2013;9. doi: 10.7150/thno.54113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.54113</ArticleId>
            <ArticleId IdType="pmc">PMC7847684</ArticleId>
            <ArticleId IdType="pubmed">33537073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessova IG, Cederbaum AI. Mitochondrial alterations in livers of Sod1-/- mice fed alcohol. Free Radic Biol Med. 2007;42(10):1470&#x2013;80. doi: 10.1016/j.freeradbiomed.2007.01.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2007.01.044</ArticleId>
            <ArticleId IdType="pmc">PMC1924491</ArticleId>
            <ArticleId IdType="pubmed">17448893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahi SK, et al. Prevotella histicola, A Human Gut Commensal, is as potent as COPAXONE(R) in an animal model of multiple sclerosis. Front Immunol. 2019;10:462. doi: 10.3389/fimmu.2019.00462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00462</ArticleId>
            <ArticleId IdType="pmc">PMC6448018</ArticleId>
            <ArticleId IdType="pubmed">30984162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marietta EV, et al. Suppression of inflammatory arthritis by human gut-derived Prevotella histicola in Humanized mice. Arthritis Rheumatol. 2016;68(12):2878&#x2013;88. doi: 10.1002/art.39785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39785</ArticleId>
            <ArticleId IdType="pmc">PMC5125894</ArticleId>
            <ArticleId IdType="pubmed">27337150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang F, et al. Prevotella histicola Mitigated Estrogen Deficiency-Induced Depression via Gut Microbiota-Dependent modulation of inflammation in Ovariectomized mice. Front Nutr. 2021;8:805465. doi: 10.3389/fnut.2021.805465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnut.2021.805465</ArticleId>
            <ArticleId IdType="pmc">PMC8826649</ArticleId>
            <ArticleId IdType="pubmed">35155523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira RM, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226&#x2013;36. doi: 10.1136/gutjnl-2017-314205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2017-314205</ArticleId>
            <ArticleId IdType="pmc">PMC5868293</ArticleId>
            <ArticleId IdType="pubmed">29102920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis. 1999;179(6):1523&#x2013;30. doi: 10.1086/314785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/314785</ArticleId>
            <ArticleId IdType="pubmed">10228075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osaki T, et al. Comparative analysis of gastric bacterial microbiota in mongolian gerbils after long-term infection with Helicobacter pylori. Microb Pathog. 2012;53(1):12&#x2013;8. doi: 10.1016/j.micpath.2012.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micpath.2012.03.008</ArticleId>
            <ArticleId IdType="pubmed">22783557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahi SK, et al. Human commensal Prevotella histicola ameliorates Disease as effectively as Interferon-Beta in the experimental autoimmune encephalomyelitis. Front Immunol. 2020;11:578648. doi: 10.3389/fimmu.2020.578648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.578648</ArticleId>
            <ArticleId IdType="pmc">PMC7759500</ArticleId>
            <ArticleId IdType="pubmed">33362764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, et al. Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis. Bioengineered. 2021;12(2):10924&#x2013;34. doi: 10.1080/21655979.2021.1995994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21655979.2021.1995994</ArticleId>
            <ArticleId IdType="pmc">PMC8809912</ArticleId>
            <ArticleId IdType="pubmed">34699317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu FF, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res. 2004;64(3):962&#x2013;8. doi: 10.1158/0008-5472.CAN-03-2272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2272</ArticleId>
            <ArticleId IdType="pubmed">14871826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balakrishnan B, et al. Prevotella histicola protects from arthritis by expansion of Allobaculum and Augmenting Butyrate production in Humanized mice. Front Immunol. 2021;12:609644. doi: 10.3389/fimmu.2021.609644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.609644</ArticleId>
            <ArticleId IdType="pmc">PMC8130672</ArticleId>
            <ArticleId IdType="pubmed">34017324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, et al. Short chain fatty acid acetate protects against Ethanol-Induced Acute gastric mucosal lesion in mice. Biol Pharm Bull. 2017;40(9):1439&#x2013;46. doi: 10.1248/bpb.b17-00240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1248/bpb.b17-00240</ArticleId>
            <ArticleId IdType="pubmed">28867726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang FY, et al. Potential protective effects of Clostridium butyricum on experimental gastric ulcers in mice. World J Gastroenterol. 2015;21(27):8340&#x2013;51. doi: 10.3748/wjg.v21.i27.8340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v21.i27.8340</ArticleId>
            <ArticleId IdType="pmc">PMC4507103</ArticleId>
            <ArticleId IdType="pubmed">26217085</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37023938</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>04</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>561</Volume>
            <PubDate>
              <Year>2023</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis: Promising approach for cancer and cancer immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>216152</StartPage>
          <MedlinePgn>216152</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2023.216152</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(23)00103-9</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is the cell death induced by ferrous ions and lipid peroxidation accumulation in tumor cells. Targeting ferroptosis, which is regulated by various metabolic and immune elements, might become a novel strategy for anti-tumor therapy. In this review, we will focus on the mechanism of ferroptosis and its interaction with cancer and tumor immune microenvironment, especially for the relationship between immune cells and ferroptosis. Also, we will discuss the latest preclinical progress of the collaboration between the ferroptosis-targeted drugs and immunotherapy, and the best potential conditions for their combined use. It will present a future insight on the possible value of ferroptosis in cancer immunotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Shuyue</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Xin-Yuan</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China; MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, Guangdong, China; Advanced Nuclear Energy and Nuclear Technology Research Center, Advanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong, China. Electronic address: xyguan@hku.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2023</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2023</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>19</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37023938</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2023.216152</ArticleId>
        <ArticleId IdType="pii">S0304-3835(23)00103-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36960609</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2055-6764</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>May</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nanoscale horizons</Title>
          <ISOAbbreviation>Nanoscale Horiz</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Carbonic anhydrase IX-targeted nanovesicles potentiated ferroptosis by remodeling the intracellular environment for synergetic cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>783</StartPage>
          <EndPage>793</EndPage>
          <MedlinePgn>783-793</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d2nh00494a</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is one critical kind of regulated cell death for tumor suppression, yet it still presents challenges of low efficiency due to the intracellular alkaline pH and aberrant redox status. Herein, we reported a carbonic anhydrase IX (CA IX)-targeted nanovesicle (PAHC NV) to potentiate ferroptosis by remodeling the intracellular environment. CA IX inhibitor 4-(2-aminoethyl) benzene sulfonamide (AEBS) was anchored onto nanovesicles loaded with hemoglobin (Hb) and chlorin e6 (Ce6). Upon reaching tumor regions, PAHC could be internalized by cancer cells specifically by means of CA IX targeting and intervention. Afterwards, the binding of AEBS could elicit intracellular acidification and alter redox homeostasis to boost the lipid peroxidation (LPO) level, thus aggravating the ferroptosis process. Meanwhile, Hb served as an iron reservoir that could efficiently evoke ferroptosis and release O2 to ameliorate tumor hypoxia. With the help of self-supplied O2, Ce6 produced a plethora of [1]O2 for enhanced photodynamic therapy, which in turn favored LPO accumulation to synergize ferroptosis. This study presents a promising paradigm for designing nanomedicines to heighten ferroptosis-based synergetic therapeutics through remodeling the intracellular environment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Nian</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. liangxj@nanoctr.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. liangxj@nanoctr.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zuo</LastName>
            <ForeName>Wenbao</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. liangxj@nanoctr.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Weibin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Xiamen University, Xiamen 361102, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Shan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Key Laboratory of Respiratory Diseases, Department of Basic Medicine, Xiamen Medical College, Xiamen 361023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Yinshu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Key Laboratory of Respiratory Diseases, Department of Basic Medicine, Xiamen Medical College, Xiamen 361023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Xing-Jie</ForeName>
            <Initials>XJ</Initials>
            <Identifier Source="ORCID">0000-0002-4793-1705</Identifier>
            <AffiliationInfo>
              <Affiliation>Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. liangxj@nanoctr.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Xuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. liangxj@nanoctr.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huo</LastName>
            <ForeName>Shuaidong</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-3590-044X</Identifier>
            <AffiliationInfo>
              <Affiliation>Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. liangxj@nanoctr.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>05</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nanoscale Horiz</MedlineTA>
        <NlmUniqueID>101712576</NlmUniqueID>
        <ISSNLinking>2055-6756</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 4.2.1.1</RegistryNumber>
          <NameOfSubstance UI="D000071231">Carbonic Anhydrase IX</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000071231" MajorTopicYN="N">Carbonic Anhydrase IX</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>3</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36960609</ArticleId>
        <ArticleId IdType="doi">10.1039/d2nh00494a</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36693788</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1613-6829</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Small (Weinheim an der Bergstrasse, Germany)</Title>
          <ISOAbbreviation>Small</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondria-Targeted Nanosystem with Reactive Oxygen Species-Controlled Release of CO to Enhance Photodynamic Therapy of PCN-224 by Sensitizing Ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>e2206124</StartPage>
          <MedlinePgn>e2206124</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/smll.202206124</ELocationID>
        <Abstract>
          <AbstractText>The apoptosis-resistant mechanism of photodynamic therapy (PDT) usually results in limited therapeutic efficacy. The development of new strategies for sensitizing targeted ferroptosis that bypass apoptosis resistance is of great significance to improve the antitumor efficacy of PDT. In this study, a novel amphiphilic copolymer whose main chain contains reactive oxygen species (ROS)-responsive groups and the end of side chains contains triphenylphosphine is synthesized, to encapsulate porphyrinic metal-organic framework PCN-224 via self-assembly which are hydrothermally synthesized by coordination of zirconium (IV) with tetra-kis(4-caboxyphenyl) porphyrin, and loaded carbon monoxide releasing molecule 401 (CORM-401) by their hollow structures (PCN-CORM), and finally, surface-coated with hyaluronic acid. The nanosystem can sequentially localize to mitochondria which is an important target to induce apoptosis and ferroptosis in cancer cells. Upon excitation with near-infrared light, PCN-224 is activated to produce amounts of ROS, and simultaneously triggers the rapid intracellular release of CO. More importantly, the released CO can sensitize ferroptosis and promote apoptosis to significantly enhance the antitumor efficacy of PCN-224 both in vitro and in vivo. These results illustrate that the mitochondria-targeted drug delivery system combined PDT with CO leads to an effective antitumor efficacy, which maybe a promising way to enhance the treatment efficiency of PDT.</AbstractText>
          <CopyrightInformation>&#xa9; 2023 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Futing</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Wenjie</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Qiying</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chunping</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Chong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Xinghua</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-3800-2322</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-7626-0026</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Radiation Chemistry and Functional Materials, Hubei University of Science and Technology, Xianning, 437100, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-1800-0466</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, School of Chemistry and Chemical Engineering &amp; College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Small</MedlineTA>
        <NlmUniqueID>101235338</NlmUniqueID>
        <ISSNLinking>1613-6810</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antitumor</Keyword>
        <Keyword MajorTopicYN="N">carbon monoxide (CO)</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">mitochondria-targeted</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy (PDT)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>22</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36693788</ArticleId>
        <ArticleId IdType="doi">10.1002/smll.202206124</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>M. Lan, S. Zhao, W. Liu, C. S. Lee, W. Zhang, P. Wang, Adv. Healthcare Mater. 2019, 8, 1900132.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Li, A. Wang, L. Zhao, Q. Dong, M. Wang, H. Xu, X. Yan, S. Bai, ACS Appl. Mater. Interfaces 2018, 10, 28420.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Yang, Y. W. Yang, Small 2020, 16, 1906846.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Tang, G. Ding, J. Niu, W. Zhang, G. Tang, Y. Liang, C. Fan, H. Dong, J. Yang, J. Li, Y. Cao, Chem. Eng. J. 2019, 359, 225.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Park, Q. Jiang, D. Feng, L. Mao, H. C. Zhou, J. Am. Chem. Soc. 2016, 138, 3518.</Citation>
        </Reference>
        <Reference>
          <Citation>K. Kim, S. Lee, E. Jin, L. Palanikumar, J. H. Lee, J. C. Kim, J. S. Nam, B. Jana, T. H. Kwon, S. K. Kwak, W. Choe, J. H. Ryu, ACS Appl. Mater. Interfaces 2019, 11, 27512.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Qiu, M. Liang, Y. Gao, X. Yang, X. Zhang, X. Zhang, P. Xue, Y. Kang, Z. Xu, Theranostics 2021, 11, 9652.</Citation>
        </Reference>
        <Reference>
          <Citation>N. Zheng, X. Luo, Z. Zhang, A. Wang, W. Song, ACS Appl. Mater. Interfaces 2021, 13, 27513.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. L. Yang, K. Lin, L. Yang, Pharmaceutics 2021, 13, 1951.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Z. Jing, S. J. Li, Z. J. Sun, J. Mater. Chem. B 2021, 9, 8541.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Fang, J. Cheng, Z. Shen, T. You, S. Ding, J. Hu, Macromol. Rapid Commun. 2022, 43, 2100814.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Liu, Y. Peng, L. Lu, S. Peng, T. Chen, M. Zhan, J Nanobiotechnology 2021, 19, 443.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Motterlini, L. E. Otterbein, Nat. Rev. Drug Discovery 2010, 9, 728.</Citation>
        </Reference>
        <Reference>
          <Citation>S. H. Heinemann, T. Hoshi, M. Westerhausen, A. Schiller, Chem. Commun. 2014, 50, 3644.</Citation>
        </Reference>
        <Reference>
          <Citation>A. B. Stein, Y. Guo, W. Tan, W. J. Wu, X. Zhu, Q. Li, C. Luo, B. Dawn, T. R. Johnson, R. Motterlini, R. Bolli, J. Mol. Cell. Cardiol. 2005, 38, 127.</Citation>
        </Reference>
        <Reference>
          <Citation>A. Nakao, A. M. Choi, N. Murase, J. Cell. Mol. Med. 2006, 10, 650.</Citation>
        </Reference>
        <Reference>
          <Citation>T. Takagi, Y. Naito, Y. Higashimura, K. Uchiyama, T. Okayama, K. Mizushima, K. Katada, K. Kamada, T. Ishikawa, Y. Itoh, Nitric Oxide 2021, 107, 19.</Citation>
        </Reference>
        <Reference>
          <Citation>D. W. Zheng, B. Li, C. X. Li, L. Xu, J. X. Fan, Q. Lei, X. Z. Zhang, Adv. Mater. 2017, 29, 1703822.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Yao, P. Yang, Z. Jin, Q. Jiang, R. Guo, R. Xie, Q. He, W. Yang, Biomaterials 2019, 197, 268.</Citation>
        </Reference>
        <Reference>
          <Citation>C. C. Romao, W. A. Blattler, J. D. Seixas, G. J. Bernardes, Chem. Soc. Rev. 2012, 41, 3571.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Jin, Y. Wen, L. Xiong, T. Yang, P. Zhao, L. Tan, T. Wang, Z. Qian, B. L. Su, Q. He, Chem. Commun. 2017, 53, 5557.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Jin, P. Zhao, J. Zhang, T. Yang, G. Zhou, D. Zhang, T. Wang, Q. He, Chemistry 2018, 24, 11667.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Wu, X. Cai, H. Zhu, J. Li, D. Shi, D. Su, D. Yue, Z. Gu, Adv. Funct. Mater. 2018, 28, 1804324.</Citation>
        </Reference>
        <Reference>
          <Citation>S. H. Crook, B. E. Mann, A. J. Meijer, H. Adams, P. Sawle, D. Scapens, R. Motterlini, Dalton Trans. 2011, 40, 4230.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Ji, K. Damera, Y. Zheng, B. Yu, L. E. Otterbein, B. Wang, J. Pharm. Sci. 2016, 105, 406.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. H. Lee, H. I. Park, W. S. Chang, J. S. Choi, Int. J. Biol. Macromol. 2021, 167, 35.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Zhou, H. Yu, L. J. Zhang, B. Wu, C. X. Wang, Q. Wang, K. Deng, R. X. Zhuo, S. W. Huang, Nanoscale 2017, 9, 17044.</Citation>
        </Reference>
        <Reference>
          <Citation>N. Peng, H. Yu, W. Yu, M. Yang, H. Chen, T. Zou, K. Deng, S. Huang, Y. Liu, Acta Biomater. 2020, 105, 223.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Liu, C. Hu, Y. Yang, J. Zhang, H. Gao, Acta Pharm. Sin. B 2019, 9, 410.</Citation>
        </Reference>
        <Reference>
          <Citation>D. Wu, Y. Fan, H. Yan, D. Li, Z. Zhao, X. Chen, X. Yang, X. Liu, Chem. Eng. J. 2021, 404, 126481.</Citation>
        </Reference>
        <Reference>
          <Citation>T. A. Mishchenko, I. V. Balalaeva, M. V. Vedunova, D. V. Krysko, Trends Cancer 2021, 7, 484.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Wang, Y. Fan, Y. Tan, X. Zhao, Y. Zhang, C. Cheng, M. Yang, ACS Appl. Mater. Interfaces 2018, 10, 36615.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36653312</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2192-2659</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advanced healthcare materials</Title>
          <ISOAbbreviation>Adv Healthc Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>e2202663</StartPage>
          <MedlinePgn>e2202663</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/adhm.202202663</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis, characterized by the accumulation of reactive oxygen species and lipid peroxides, has emerged as an attractive strategy to reverse drug resistance. Of particular interest is the ferroptosis-apoptosis combination therapy for cancer treatment. Herein, a nanoplatform is reported for effective co-delivery of the anticancer drug sorafenib (S) and the ferroptosis inducer hemin (H), toward synergistic ferroptosis-apoptosis therapy of advanced hepatocellular carcinoma (HCC) as a proof-of-concept study. Liposome is an excellent delivery system; however, it is not sufficiently responsive to the acidic tumor microenvironment (TME) for tumor-targeted drug delivery. The pH-sensitive vesicles are therefore developed (SH-AD-L) by incorporating amphiphilic dendrimers (AD) into liposomes for controlled and pH-stimulated release of sorafenib and hemin in the acidic TME, thanks to the protonation of numerous amine functionalities in AD. Importantly, SH-AD-L not only blocked glutathione synthesis to disrupt the antioxidant system, but also increased intracellular Fe[2+] and OH concentrations to amplify oxidative stress, both of which contribute to enhanced ferroptosis. Remarkably, high levels of OH also augmented sorafenib-mediated apoptosis in tumor cells. This study demonstrates the efficacy of ferroptosis-apoptosis combination therapy, as well as the promise of the AD-doped TME-responsive vesicles for drug delivery in combination therapy to treat advanced HCC.</AbstractText>
          <CopyrightInformation>&#xa9; 2023 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yanhong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Health Sciences, University of Macau, Taipa, Macau, 999078, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, 519000, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Health Sciences, University of Macau, Taipa, Macau, 999078, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Leo Tsz On</ForeName>
            <Initials>LTO</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Health Sciences, University of Macau, Taipa, Macau, 999078, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MOE Frontiers Science Centre for Precision Oncology, University of Macau, Taipa, Macau, 999078, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Aix Marseille Universit, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellise Ligue Contre le Cancer, Marseille, 13288, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Ligong</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-1405-0052</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, 519000, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, 519000, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xuanjun</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-6452-1778</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Health Sciences, University of Macau, Taipa, Macau, 999078, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MOE Frontiers Science Centre for Precision Oncology, University of Macau, Taipa, Macau, 999078, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Adv Healthc Mater</MedlineTA>
        <NlmUniqueID>101581613</NlmUniqueID>
        <ISSNLinking>2192-2640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050091">Dendrimers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>743LRP9S7N</RegistryNumber>
          <NameOfSubstance UI="D006427">Hemin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050091" MajorTopicYN="Y">Dendrimers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006427" MajorTopicYN="N">Hemin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">advanced hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">amphiphilic dendrimers</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">liposomal vesicles</Keyword>
        <Keyword MajorTopicYN="N">synergistic therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>22</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36653312</ArticleId>
        <ArticleId IdType="doi">10.1002/adhm.202202663</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>B. A. Carneiro, W. S. El-Deiry, Nat. Rev. Clin. Oncol. 2020, 17, 395.</Citation>
        </Reference>
        <Reference>
          <Citation>a) L. Gao, Z. X. Wu, Y. G. Assaraf, Z. S. Chen, L. Wang, Drug Resistance Updates 2021, 57, 100770;</Citation>
        </Reference>
        <Reference>
          <Citation>b) A. Valente, A. Podolski-Renic, I. Poetsch, N. Filipovic, O. Lopez, I. Turel, P. Heffeter, Drug Resistance Updates 2021, 58, 100778.</Citation>
        </Reference>
        <Reference>
          <Citation>a) G. Lei, C. Mao, Y. Yan, L. Zhuang, B. Gan, Protein Cell 2021, 12, 836;</Citation>
        </Reference>
        <Reference>
          <Citation>b) X. Chen, J. Li, R. Kang, D. J. Klionsky, D. Tang, Autophagy 2021, 17, 2054.</Citation>
        </Reference>
        <Reference>
          <Citation>a) C. Zhang, X. Liu, S. Jin, Y. Chen, R. Guo, Mol. Cancer 2022, 21, 47;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Q. Zeng, X. Ma, Y. Song, Q. Chen, Q. Jiao, L. Zhou, Theranostics 2022, 12, 817.</Citation>
        </Reference>
        <Reference>
          <Citation>a) L. Zhou, W. Feng, L. Chen, H. Huang, S. Huang, Q. Chen, X. Zhang, Y. Chen, Nano Today 2022, 46, 101623;</Citation>
        </Reference>
        <Reference>
          <Citation>b) L. Liang, L. Wen, Y. Weng, J. Song, H. Li, Y. Zhang, X. He, W. Zhao, M. Zhan, Y. Li, L. Lu, Y. Xin, C. Lu, Chem. Eng. J. 2021, 425, 131451.</Citation>
        </Reference>
        <Reference>
          <Citation>a) P. Koppula, L. Zhuang, B. Gan, Protein Cell 2020, 12, 599;</Citation>
        </Reference>
        <Reference>
          <Citation>b) B. Gan, Signal Transduction Targeted Ther. 2022, 7, 128;</Citation>
        </Reference>
        <Reference>
          <Citation>c) L. Zhou, W. Feng, Y. Mao, Y. Chen, X. Zhang, Bioact. Mater. 2023, 24, 26.</Citation>
        </Reference>
        <Reference>
          <Citation>H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Ca-Cancer J. Clin. 2021, 71, 209.</Citation>
        </Reference>
        <Reference>
          <Citation>a) S. Qin, F. Bi, S. Gu, Y. Bai, Z. Chen, Z. Wang, J. Ying, Y. Lu, Z. Meng, H. Pan, P. Yang, H. Zhang, X. Chen, A. Xu, C. Cui, B. Zhu, J. Wu, X. Xin, J. Wang, J. Shan, J. Chen, Z. Zheng, L. Xu, X. Wen, Z. You, Z. Ren, X. Liu, M. Qiu, L. Wu, F. Chen, J. Clin. Oncol. 2021, 39, 3002;</Citation>
        </Reference>
        <Reference>
          <Citation>b) T. Yau, J.-W. Park, R. S. Finn, A.-L. Cheng, P. Mathurin, J. Edeline, M. Kudo, J. J. Harding, P. Merle, O. Rosmorduc, L. Wyrwicz, E. Schott, S. P. Choo, R. K. Kelley, W. Sieghart, E. Assenat, R. Zaucha, J. Furuse, G. K. Abou-Alfa, A. B. El-Khoueiry, I. Melero, D. Begic, G. Chen, J. Neely, T. Wisniewski, M. Tschaika, B. Sangro, Lancet Oncol. 2022, 23, 77.</Citation>
        </Reference>
        <Reference>
          <Citation>a) J. Chen, X. Li, C. Ge, J. Min, F. Wang, Cell Death Differ. 2022, 29, 467;</Citation>
        </Reference>
        <Reference>
          <Citation>b) X. Hu, Y. He, Z. Han, W. Liu, D. Liu, X. Zhang, L. Chen, L. Qi, L. Chen, Y. Luo, Q. Li, P. Chen, Q. Wu, X. Zhu, H. Guo, Cell Death Dis. 2022, 13, 1010.</Citation>
        </Reference>
        <Reference>
          <Citation>J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, A. C. de Oliveira, A. Santoro, J. L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T. F. Greten, P. R. Galle, J. F. Seitz, I. Borbath, D. H&#xe4;ussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, N. Engl. J. Med. 2008, 359, 378.</Citation>
        </Reference>
        <Reference>
          <Citation>a) J. Feng, P. Lu, G. Zhu, S. C. Hooi, Y. Wu, X. Huang, H. Dai, P. Chen, Z. Li, W. Su, C. Han, X. Ye, T. Peng, J. Zhou, G. Lu, Acta Pharmacol. Sin. 2021, 42, 160;</Citation>
        </Reference>
        <Reference>
          <Citation>b) L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, S. Yang, Signal Transduction Targeted Ther. 2021, 6, 201.</Citation>
        </Reference>
        <Reference>
          <Citation>a) A. Ajoolabady, D. Tang, G. Kroemer, J. Ren, Br. J. Cancer 2022, https://doi.org/10.1038/s41416-022-01998-x;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Z. Li, H. Dai, X. Huang, J. Feng, J. Deng, Z. Wang, X. Yang, Y. Liu, Y. Wu, P. Chen, H. Shi, J. Wang, J. Zhou, G. Lu, Acta Pharmacol. Sin. 2021, 42, 301.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Louandre, Z. Ezzoukhry, C. Godin, J.-C. Barbare, J.-C. Maziere, B. Chauffert, A. Galmiche, Int. J. Cancer 2013, 133, 1732.</Citation>
        </Reference>
        <Reference>
          <Citation>a) X. Sun, X. Niu, R. Chen, W. He, D. Chen, R. Kang, D. Tang, Hepatology 2016, 64, 488;</Citation>
        </Reference>
        <Reference>
          <Citation>b) X. Sun, Z. Ou, R. Chen, X. Niu, D. Chen, R. Kang, D. Tang, Hepatology 2016, 63, 173.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Sun, C. Zhou, Y. Zhao, X. Zhang, W. Chen, Q. Zhou, B. Hu, D. Gao, L. Raatz, Z. Wang, P. J. Nelson, Y. Jiang, N. Ren, C. J. Bruns, H. Zhou, Redox Biol. 2021, 41, 101942.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Chen, F. Chen, L. Zhang, Z. Yang, T. Deng, Y. Zhao, T. Zheng, X. Gan, H. Zhong, Y. Geng, X. Fu, Y. Wang, C. Yu, ACS Appl. Mater. Interfaces 2021, 13, 27856.</Citation>
        </Reference>
        <Reference>
          <Citation>a) B. Hassannia, B. Wiernicki, I. Ingold, F. Qu, S. Van Herck, Y. Y. Tyurina, H. Bay&#x131;r, B. A. Abhari, J. P. F. Angeli, S. M. Choi, E. Meul, K. Heyninck, K. Declerck, C. S. Chirumamilla, M. Lahtela-Kakkonen, G. Van Camp, D. V. Krysko, P. G. Ekert, S. Fulda, B. G. De Geest, M. Conrad, V. E. Kagan, W. Vanden Berghe, P. Vandenabeele, T. Vanden Berghe, J. Clin. Invest. 2018, 128, 3341;</Citation>
        </Reference>
        <Reference>
          <Citation>b) X. Fang, H. Wang, D. Han, E. Xie, X. Yang, J. Wei, S. Gu, F. Gao, N. Zhu, X. Yin, Q. Cheng, P. Zhang, W. Dai, J. Chen, F. Yang, H.-T. Yang, A. Linkermann, W. Gu, J. Min, F. Wang, Proc. Natl. Acad. Sci. 2019, 116, 2672.</Citation>
        </Reference>
        <Reference>
          <Citation>a) S. K. NaveenKumar, B. N. SharathBabu, M. Hemshekhar, K. Kemparaju, K. S. Girish, G. Mugesh, ACS Chem. Biol. 2018, 13, 1996;</Citation>
        </Reference>
        <Reference>
          <Citation>b) B. Hassannia, P. Vandenabeele, T. V. Berghe, Cancer Cell 2019, 35, 830;</Citation>
        </Reference>
        <Reference>
          <Citation>c) K. Li, K. Xu, Y. He, L. Lu, Y. Mao, P. Gao, G. Liu, J. Wu, Y. Zhang, Y. Xiang, Z. Luo, K. Cai, Small 2021, 17, 2102046.</Citation>
        </Reference>
        <Reference>
          <Citation>a) T. Liu, W. Liu, M. Zhang, W. Yu, F. Gao, C. Li, S.-B. Wang, J. Feng, X.-Z. Zhang, ACS Nano 2018, 12, 12181;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Z.-H. Li, Y. Chen, X. Zeng, X.-Z. Zhang, Nano Today 2021, 38, 101150.</Citation>
        </Reference>
        <Reference>
          <Citation>H. Li, M. Huang, Z. Wei, J. He, Y. Ma, C. Lu, A. Jin, Z. Wang, L. Wen, Front Bioeng Biotechnol 2022, 10, 1032571.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Zheng, X. Li, C. Dong, L. Ding, H. Huang, T. Zhang, Y. Chen, R. Wu, Adv Funct Mater. 2021, 32, 2107529.</Citation>
        </Reference>
        <Reference>
          <Citation>a) X. Liu, J. Zhou, T. Yu, C. Chen, Q. Cheng, K. Sengupta, Y. Huang, H. Li, C. Liu, Y. Wang, P. Posocco, M. Wang, Q. Cui, S. Giorgio, M. Fermeglia, F. Qu, S. Pricl, Y. Shi, Z. Liang, P. Rocchi, J. J. Rossi, L. Peng, Angew. Chem. Int. Ed. Engl. 2014, 53, 11822;</Citation>
        </Reference>
        <Reference>
          <Citation>b) S. S. Hinman, C. J. Ruiz, Y. Cao, M. C. Ma, J. Tang, E. Laurini, P. Posocco, S. Giorgio, S. Pricl, L. Peng, Q. Cheng, ACS Appl. Mater. Interfaces 2017, 9, 1029;</Citation>
        </Reference>
        <Reference>
          <Citation>c) T. Wei, C. Chen, J. Liu, C. Liu, P. Posocco, X. Liu, Q. Cheng, S. Huo, Z. Liang, M. Fermeglia, S. Pricl, X.-J. Liang, P. Rocchi, L. Peng, Proc. Natl. Acad. Sci. 2015, 112, 2978.</Citation>
        </Reference>
        <Reference>
          <Citation>a) T. Yu, X. Liu, A. L. Bolcato-Bellemin, Y. Wang, C. Liu, P. Erbacher, F. Qu, P. Rocchi, J.-P. Behr, L. Peng, Angew. Chem. Int. Ed. Engl. 2012, 51, 8478;</Citation>
        </Reference>
        <Reference>
          <Citation>b) D. Dhumal, W. Lan, L. Ding, Y. Jiang, Z. Lyu, E. Laurini, D. Marson, A. Tintaru, N. Dusetti, S. Giorgio, J. L. Iovanna, S. Pricl, L. Peng, Nano Res. 2020, 14, 2247;</Citation>
        </Reference>
        <Reference>
          <Citation>c) J. Liu, C. Chen, T. Wei, O. Gayet, C. Loncle, L. Borge, N. Dusetti, X. Ma, D. Marson, E. Laurini, S. Pricl, Z. Gu, J. Iovanna, L. Peng, X.-J. Liang, Exploration 2021, 1, 21.</Citation>
        </Reference>
        <Reference>
          <Citation>a) S. Xu, S. Ling, Q. Shan, Q. Ye, Q. Zhan, G. Jiang, J. Zhuo, B. Pan, X. Wen, T. Feng, H. Lu, X. Wei, H. Xie, S. Zheng, J. Xiang, Y. Shen, X. Xu, Adv. Sci. 2021, 8, 2003042;</Citation>
        </Reference>
        <Reference>
          <Citation>b) T.-C. Chou, Cancer Res. 2010, 70, 440.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Chen, A. Ellert-Miklaszewska, S. Garofalo, A. K. Dey, J. Tang, Y. Jiang, F. Clement, P. N. Marche, X. Liu, B. Kaminska, A. Santoni, C. Limatola, J. J. Rossi, J. Zhou, L. Peng, Nat. Protoc. 2021, 16, 327.</Citation>
        </Reference>
        <Reference>
          <Citation>S. Gao, H. Lin, H. Zhang, H. Yao, Y. Chen, J. Shi, Adv. Sci. 2019, 6, 1801733.</Citation>
        </Reference>
        <Reference>
          <Citation>F. Wu, Y. Du, J. Yang, B. Shao, Z. Mi, Y. Yao, Y. Cui, F. He, Y. Zhang, P. Yang, ACS Nano 2022, 16, 3647.</Citation>
        </Reference>
        <Reference>
          <Citation>K. Ajeeshkumar, P. A. Aneesh, N. Raju, M. Suseela, C. N. Ravishankar, S. Benjakul, Compr. Rev. Food Sci. Food Saf. 2021, 20, 1280.</Citation>
        </Reference>
        <Reference>
          <Citation>D. E. Large, R. G. Abdelmessih, E. A. Fink, D. T. Auguste, Adv. Drug Delivery Rev. 2021, 176, 113851.</Citation>
        </Reference>
        <Reference>
          <Citation>M. Yang, Y. Su, Z. Wang, D. Du, S. Wei, Z. Liao, Q. Zhang, L. Zhao, X. Zhang, L. Han, J. Jiang, M. Zhan, L. Sun, S. Yuan, Z. Zhou, Biochem. Pharmacol. 2021, 190, 114641.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36607799</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>324</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Heart and circulatory physiology</Title>
          <ISOAbbreviation>Am J Physiol Heart Circ Physiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Iron chelation therapy to prevent poststroke cognitive impairments: role of diabetes and sex.</ArticleTitle>
        <Pagination>
          <StartPage>H210</StartPage>
          <EndPage>H211</EndPage>
          <MedlinePgn>H210-H211</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00004.2023</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sakamuri</LastName>
            <ForeName>Siva S V P</ForeName>
            <Initials>SSVP</Initials>
            <Identifier Source="ORCID">0000-0003-3569-9985</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sure</LastName>
            <ForeName>Venkata N</ForeName>
            <Initials>VN</Initials>
            <Identifier Source="ORCID">0000-0002-3657-962X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Katakam</LastName>
            <ForeName>Prasad V G</ForeName>
            <Initials>PVG</Initials>
            <Identifier Source="ORCID">0000-0002-4708-9140</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neuroscience Program, Tulane Brain Institute, Tulane University, New Orleans, Louisiana.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Neuroscience Research Center, Tulane University, New Orleans, Louisiana.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>01</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
        <NlmUniqueID>100901228</NlmUniqueID>
        <ISSNLinking>0363-6135</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>J06Y7MXW4D</RegistryNumber>
          <NameOfSubstance UI="D003676">Deferoxamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Am J Physiol Heart Circ Physiol. 2023 Feb 1;324(2):H212-H225</RefSource>
          <PMID Version="1">36563009</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015913" MajorTopicYN="N">Chelation Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003676" MajorTopicYN="N">Deferoxamine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003921" MajorTopicYN="Y">Diabetes Mellitus, Experimental</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cognitive</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">microglia</Keyword>
        <Keyword MajorTopicYN="N">microvascular</Keyword>
        <Keyword MajorTopicYN="N">neurovascular</Keyword>
      </KeywordList>
      <CoiStatement>No conflicts of interest, financial or otherwise, are declared by the authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2024</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>12</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36607799</ArticleId>
        <ArticleId IdType="pmc">PMC9870570</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpheart.00004.2023</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Maida CD, Daidone M, Pacinella G, Norrito RL, Pinto A, Tuttolomondo A. Diabetes and ischemic stroke: an old and new relationship an overview of the close interaction between these diseases. Int J Mol Sci 23: 2397, 2022. doi:10.3390/ijms23042397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms23042397</ArticleId>
            <ArticleId IdType="pmc">PMC8877605</ArticleId>
            <ArticleId IdType="pubmed">35216512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spronk E, Sykes G, Falcione S, Munsterman D, Joy T, Kamtchum-Tatuene J, Jickling GC. Hemorrhagic transformation in ischemic stroke and the role of inflammation. Front Neurol 12: 661955, 2021. doi:10.3389/fneur.2021.661955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.661955</ArticleId>
            <ArticleId IdType="pmc">PMC8160112</ArticleId>
            <ArticleId IdType="pubmed">34054705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang XL, Ding SY, Du XZ, Wang JH, Li XL. Ferroptosis-a novel mechanism with multifaceted actions on stroke. Front Neurol 13: 881809, 2022. doi:10.3389/fneur.2022.881809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2022.881809</ArticleId>
            <ArticleId IdType="pmc">PMC9035991</ArticleId>
            <ArticleId IdType="pubmed">35481263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149: 1060&#x2013;1072, 2012. doi:10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdul Y, Li W, Ward R, Abdelsaid M, Hafez S, Dong G, Jamil S, Wolf V, Johnson MH, Fagan SC, Ergul A. Deferoxamine treatment prevents post-stroke vasoregression and neurovascular unit remodeling leading to improved functional outcomes in type 2 male diabetic rats: role of endothelial ferroptosis. Transl Stroke Res 12: 615&#x2013;630, 2021. doi:10.1007/s12975-020-00844-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12975-020-00844-7</ArticleId>
            <ArticleId IdType="pmc">PMC7917163</ArticleId>
            <ArticleId IdType="pubmed">32875455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Valenzuela JP, Ward R, Abdelbary M, Dong G, Fagan SC, Ergul A. Post-stroke neovascularization and functional outcomes differ in diabetes depending on severity of injury and sex: Potential link to hemorrhagic transformation. Exp Neurol 311: 106&#x2013;114, 2019. doi:10.1016/j.expneurol.2018.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2018.09.013</ArticleId>
            <ArticleId IdType="pmc">PMC6585988</ArticleId>
            <ArticleId IdType="pubmed">30243988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bushnell CD, Chaturvedi S, Gage KR, Herson PS, Hurn PD, Jim&#xe9;nez MC, Kittner SJ, Madsen TE, McCullough LD, McDermott M, Reeves MJ, Rundek T. Sex differences in stroke: challenges and opportunities. J Cereb Blood Flow Metab 38: 2179&#x2013;2191, 2018. doi:10.1177/0271678X18793324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0271678X18793324</ArticleId>
            <ArticleId IdType="pmc">PMC6282222</ArticleId>
            <ArticleId IdType="pubmed">30114967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee A, McCullough LD. Sex-specific immune responses in stroke. Stroke 53: 1449&#x2013;1459, 2022. doi:10.1161/STROKEAHA.122.036945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.122.036945</ArticleId>
            <ArticleId IdType="pmc">PMC9668253</ArticleId>
            <ArticleId IdType="pubmed">35468002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Ward R, Valenzuela JP, Dong G, Fagan SC, Ergul A. Diabetes worsens functional outcomes in young female rats: comparison of stroke models, tissue plasminogen activator effects, and sexes. Transl Stroke Res 8: 429&#x2013;439, 2017. doi:10.1007/s12975-017-0525-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12975-017-0525-7</ArticleId>
            <ArticleId IdType="pmc">PMC5581299</ArticleId>
            <ArticleId IdType="pubmed">28247188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Abdul Y, Chandran R, Jamil S, Ward RA, Abdelsaid M, Dong G, Fagan SC, Ergul A. Deferoxamine prevents post-stroke memory impairment in female diabetic rats: potential links to hemorrhagic transformation and ferroptosis. Am J Physiol Heart Circ Physiol 324: TBA, 2023. doi:10.1152/ajpheart.00490.2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpheart.00490.2022</ArticleId>
            <ArticleId IdType="pmc">PMC9870589</ArticleId>
            <ArticleId IdType="pubmed">36563009</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">36375351</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2120</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>130</Volume>
            <PubDate>
              <Year>2023</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioorganic chemistry</Title>
          <ISOAbbreviation>Bioorg Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondria-targeted pentacyclic triterpenoid carbon dots for selective cancer cell destruction via inducing autophagy, apoptosis, as well as ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>106259</StartPage>
          <MedlinePgn>106259</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioorg.2022.106259</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0045-2068(22)00665-4</ELocationID>
        <Abstract>
          <AbstractText>Natural products have been an important database for anti-cancer drug development. However, low water solubility and poor biocompatibility limit the efficacy of natural products. Carbon dots (CDs), as an emerging 0D material, have unique properties in bioimaging, water solubility and biocompatibility. Here, we prepared three pentacyclic triterpenoids (PTs) included glycyrrhetinic acid (GA), ursolic acid (UA) and oleanolic acid (OA), which have anticancer activity but poor water solubility, as raw materials into CDs to improve disadvantages. Our data indicated that the active surface groups of all three CDs were largely preserved and were able to excite green fluorescence. Their carboxyl edges not only exhibited excellent water solubility, but also specifically targeted tumor cell mitochondria due to high sensitivity to ROS-induced damage and high internal oxidative stress. In cancer cells, the PT-CDs induced cell death through three pathways (apoptosis, ferroptosis, and autophagy), which is essentially the same way their raw materials induce death, but the effect was much stronger than raw materials. Notably, functionalized PT-CDs also exhibited extremely low toxicity. In summary, PT-CDs not only have improved water solubility and biocompatibility, but also retain the structure of their raw materials well and exert better efficacy, which provides new ideas for the development of anti-cancer natural product drugs.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Luyao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Haixia</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wenzhe</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Xiaoying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xinyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xia</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China. Electronic address: lixia2008@tju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Lanping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>National Resource Center for Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, PR China. Electronic address: glp01@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Luqi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>National Resource Center for Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, PR China. Electronic address: huangluqi01@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Wenyuan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China. Electronic address: pharmgao@tju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Bioorg Chem</MedlineTA>
        <NlmUniqueID>1303703</NlmUniqueID>
        <ISSNLinking>0045-2068</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7440-44-0</RegistryNumber>
          <NameOfSubstance UI="D002244">Carbon</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>059QF0KO0R</RegistryNumber>
          <NameOfSubstance UI="D014867">Water</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002244" MajorTopicYN="N">Carbon</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014315" MajorTopicYN="Y">Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045663" MajorTopicYN="Y">Quantum Dots</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Carbon dots</Keyword>
        <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Pentacyclic triterpenes</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>18</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36375351</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioorg.2022.106259</ArticleId>
        <ArticleId IdType="pii">S0045-2068(22)00665-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36228518</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-5905</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>290</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomaterials</Title>
          <ISOAbbreviation>Biomaterials</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxygen-boosted biomimetic nanoplatform for synergetic phototherapy/ferroptosis activation and reversal of immune-suppressed tumor microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>121832</StartPage>
          <MedlinePgn>121832</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biomaterials.2022.121832</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0142-9612(22)00472-0</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) induces apoptosis of cancer cells by generating cytotoxic reactive oxygen species, the therapeutic effect of which, however, is impeded by intrinsic/inducible apoptosis-resistant mechanisms in cancer cells and hypoxia of tumor microenvironment (TME); also, PDT-induced anti-tumor immunity activation is insufficient. To deal with these obstacles, a novel biomimetic nanoplatform is fabricated for the precise delivery of photosensitizer chlorin e6 (Ce6), hemin and PEP20 (CD47 inhibitory peptide), integrating oxygen-boosted PDT, ferroptosis activation and CD47-SIRP blockade. Hemin's catalase-mimetic activity alleviates TME hypoxia and enhances PDT. The nanoplatform activates ferroptosis via both classical (down-regulating glutathione peroxidase 4 pathway) and non-classical (inducing Fe[2+] overload) modes. Besides the role of hemin in consuming glutathione and up-regulating heme oxygenase-1 expression, interestingly, we observe that Ce6 enhance ferroptosis activation via both classical and non-classical modes. The anti-cancer immunity is reinforced by combining PEP20-mediated CD47-SIRP blockade and PDT-mediated T cell activation, efficiently suppressing primary tumor growth and metastasis. PEP20 has been revealed for the first time to sensitize ferroptosis by down-regulating system Xc[-]. This work sheds new light on the mechanisms of PDT-ferroptosis activation interplay and bridges immunotherapy and ferroptosis activation, laying the theoretical foundation for novel combinational modes of cancer treatment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhijing</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>He</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Xiyou</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Shangui</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Jianbo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xiaoye</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China. Electronic address: yangxiaoye@sdu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhai</LastName>
            <ForeName>Guangxi</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China. Electronic address: professorgxzhai@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>09</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biomaterials</MedlineTA>
        <NlmUniqueID>8100316</NlmUniqueID>
        <ISSNLinking>0142-9612</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051928">CD47 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>743LRP9S7N</RegistryNumber>
          <NameOfSubstance UI="D006427">Hemin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051928" MajorTopicYN="N">CD47 Antigen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006427" MajorTopicYN="N">Hemin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="Y">Chlorophyllides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="Y">Porphyrins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD47-SIRP&#x3b1; blockade</Keyword>
        <Keyword MajorTopicYN="N">Chlorin e6 (Ce6)</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Hemin</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic therapy (PDT)</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>18</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36228518</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biomaterials.2022.121832</ArticleId>
        <ArticleId IdType="pii">S0142-9612(22)00472-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36210735</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-4095</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>51</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advanced materials (Deerfield Beach, Fla.)</Title>
          <ISOAbbreviation>Adv Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferritin-Hijacking Nanoparticles Spatiotemporally Directing Endogenous Ferroptosis for Synergistic Anticancer Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>e2207174</StartPage>
          <MedlinePgn>e2207174</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/adma.202207174</ELocationID>
        <Abstract>
          <AbstractText>Existing ferroptosis as an iron-dependent form of regulated cell death primarily relies on importing exogenous iron. However, the excessive employment of toxic materials may cause potential adverse effects on human health. Herein, a ferritin-hijacking nanoparticle (Ce6-PEG-HKN15) is fabricated, by conjugating the ferritin-homing peptide HKN15 with the photosensitizer chlorin e6 (Ce6) for endogenous ferroptosis without introducing Fenton-reactive metals. Once internalized, the designed Ce6-PEG-HKN15 NPs can specifically accumulate around ferritin. With laser irradiation, the activated Ce6 in nanoparticles potently generates reactive oxygen species (ROS) surrounding ferritin. Abundant ROS not only helps to destroy the iron storage protein and activate endogenous ferroptosis but also directly kill tumor cells. In turn, the released iron partially interacts with intracellular excess H2 O2 to produce O2 , thereby enhancing photodynamic therapy and further amplifying oxidative stress. Overall, this work highlights the possibility of endogenous ferroptosis via spatiotemporally destroying ferritin, offering a paradigm for synergistic ferroptosis-photodynamic antitumor therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Luwen</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>You</LastName>
            <ForeName>Yuchan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Minxia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Yanling</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jucong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Jiahao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xinyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xiaoling</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Yongzhong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-2137-4517</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Jiansong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Lishui Hospital of Zhejiang University, Lishui, 323000, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2018YFE0126900</GrantID>
            <Agency>Nation Key Research and Development projects intergovernment cooperation in science and technology of China</Agency>
          </Grant>
          <Grant>
            <GrantID>LD21H300002</GrantID>
            <Agency>Zhejiang Provincial Natural Science Foundation</Agency>
          </Grant>
          <Grant>
            <GrantID>ZJU20220210</GrantID>
            <Agency>Center for Experimental Animals, Zhejiang University, Hangzhou, China</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Adv Mater</MedlineTA>
        <NlmUniqueID>9885358</NlmUniqueID>
        <ISSNLinking>0935-9648</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="Y">Porphyrins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">endogenous ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">ferritin</Keyword>
        <Keyword MajorTopicYN="N">nanosystems</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">synergistic therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>3</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36210735</ArticleId>
        <ArticleId IdType="doi">10.1002/adma.202207174</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>B. R. Stockwell, Free Radical Biol. Med. 2018, 120, S7.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Chen, R. Kang, G. Kroemer, D. L. Tang, Nat. Rev. Clin. Oncol. 2021, 18, 280.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Zhou, S. Fan, L. Feng, X. Huang, X. Chen, Adv. Mater. 2021, 33, 2104223.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Jia, Y. Guo, F. G. Wu, Small 2022, 18, 2103868.</Citation>
        </Reference>
        <Reference>
          <Citation>D. S. Li, Y. S. Li, Signal Transduction Targeted Ther. 2020, 5, 108.</Citation>
        </Reference>
        <Reference>
          <Citation>S. Wang, Z. Wang, G. Yu, Z. Zhou, O. Jacobson, Y. Liu, Y. Ma, F. Zhang, Z. Y. Chen, X. Chen, Adv. Sci. 2019, 6, 1801986.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Shen, T. Liu, Y. Li, J. Lau, Z. Yang, W. Fan, Z. Zhou, C. Shi, C. Ke, V. I. Bregadze, S. K. Mandal, Y. Liu, Z. Li, T. Xue, G. Zhu, J. Munasinghe, G. Niu, A. Wu, X. Chen, ACS Nano 2018, 12, 11355.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Chen, Y. Wang, H. Niu, Y. Wang, A. Wu, C. Shu, Y. Zhu, Y. Bian, K. Lin, ACS Appl. Mater. Interfaces 2021, 13, 45201.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Shen, J. Song, B. C. Yung, Z. Zhou, A. Wu, X. Chen, Adv. Mater. 2018, 30, 1704007.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Lin, S. Wang, H. Deng, W. Yang, L. Rao, R. Tian, Y. Liu, G. Yu, Z. Zhou, J. Song, H. H. Yang, Z. Y. Chen, X. Chen, J. Am. Chem. Soc. 2020, 142, 15320.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Zhang, W. B. Bu, D. L. Ni, S. J. Zhang, Q. Li, Z. W. Yao, J. W. Zhang, H. L. Yao, Z. Wang, J. L. Shi, Angew. Chem., Int. Ed. 2016, 55, 2101.</Citation>
        </Reference>
        <Reference>
          <Citation>K. Salnikow, Semin. Cancer Biol. 2021, 76, 189.</Citation>
        </Reference>
        <Reference>
          <Citation>S. V. Torti, F. M. Torti, Mol. Aspects Med. 2020, 75, 100860.</Citation>
        </Reference>
        <Reference>
          <Citation>S. V. Torti, F. M. Torti, Nat. Nanotechnol. 2019, 14, 499.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Luo, H. Wang, W. Tian, J. Zeng, Y. Huang, H. Luo, Am. J. Cancer Res. 2021, 11, 5508.</Citation>
        </Reference>
        <Reference>
          <Citation>D. M. Marcus, N. Zinberg, Arch. Biochem. Biophys. 1974, 162, 493.</Citation>
        </Reference>
        <Reference>
          <Citation>R. E. Weinstein, B. H. Bond, B. K. Silberberg, C. B. Vaughn, P. Subbaiah, D. R. Pieper, Breast Cancer Res. 1989, 14, 349.</Citation>
        </Reference>
        <Reference>
          <Citation>A. A. Alkhateeb, B. Han, J. R. Connor, Breast Cancer Res. 2013, 137, 733.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. L. Zhang, M. Guo, Y. J. Li, M. Shen, D. S. Kong, J. J. Shao, H. Ding, S. Z. Tan, A. P. Chen, F. Zhang, S. Z. Zheng, Autophagy 2020, 16, 1482.</Citation>
        </Reference>
        <Reference>
          <Citation>M. Plays, S. Muller, R. Rodriguez, Metallomics 2021, 13, mfab021.</Citation>
        </Reference>
        <Reference>
          <Citation>N. Jian, M. Dowle, R. D. Horniblow, C. Tselepis, R. E. Palmer, Nanotechnology 2016, 27, 175701.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Hou, Y. C. Xie, X. X. Song, X. F. Sun, M. T. Lotze, H. J. Zeh, R. Kang, D. L. Tang, Autophagy 2016, 12, 1425.</Citation>
        </Reference>
        <Reference>
          <Citation>N. Li, W. Wang, H. Zhou, Q. Q. Wu, M. X. Duan, C. Liu, H. M. Wu, W. Deng, D. F. Shen, Q. Z. Tang, Free Radical Biol. Med. 2020, 160, 303.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Tesfay, A. J. Huhn, H. Hatcher, F. M. Torti, S. V. Torti, PLoS One 2012, 7, e40030.</Citation>
        </Reference>
        <Reference>
          <Citation>L. G. Coffman, D. Parsonage, R. D'Agostino, F. M. Torti, S. V. Torti, Proc. Natl. Acad. Sci. USA 2009, 106, 570.</Citation>
        </Reference>
        <Reference>
          <Citation>A. J. Huhn, D. Parsonage, D. A. Horita, F. M. Torti, S. V. Torti, T. Hollis, Protein Sci. 2014, 23, 1013.</Citation>
        </Reference>
        <Reference>
          <Citation>B. Ezraty, A. Gennaris, F. Barras, J. F. Collet, Nat. Rev. Microbiol. 2017, 15, 385.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Xiong, J. Huang, S. Wang, Q. Yuan, D. Yang, Z. Zheng, Y. Wu, C. Wu, Y. Gao, L. Zou, G. Hu, Arch. Toxicol. 2022, 96, 767.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Liu, M. M. Zhang, Q. Zhang, W. Jiang, Sci. Total Environ. 2020, 734, 139229.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Li, J. F. Lovell, J. Yoon, X. Chen, Nat. Rev. Clin. Oncol. 2020, 17, 657.</Citation>
        </Reference>
        <Reference>
          <Citation>F. Zeng, L. Tang, Q. Zhang, C. Shi, Z. Huang, S. Nijiati, X. Chen, Z. Zhou, Angew. Chem., Int. Ed. 2022, 61, 202112925.</Citation>
        </Reference>
        <Reference>
          <Citation>L. H. Fu, Y. L. Wan, C. Qi, J. He, C. Y. Li, C. Yang, H. Xu, J. Lin, P. Huang, Adv. Mater. 2021, 33, 2006892.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. X. Yang, S. Y. Zuo, L. X. Li, X. Kuang, J. B. Li, B. J. Sun, S. J. Wang, Z. G. He, J. Sun, Asian J. Pharm. Sci. 2021, 16, 784.</Citation>
        </Reference>
        <Reference>
          <Citation>T. Zhu, L. Shi, C. Yu, Y. Dong, F. Qiu, L. Shen, Q. Qian, G. Zhou, X. Zhu, Theranostics 2019, 9, 3293.</Citation>
        </Reference>
        <Reference>
          <Citation>T. A. Mishchenko, I. V. Balalaeva, M. V. Vedunova, D. V. Krysko, Trends Cancer 2021, 7, 484.</Citation>
        </Reference>
        <Reference>
          <Citation>G. Lei, L. Zhuang, B. Y. Gan, Nat. Rev. Cancer 2022, 22, 381.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Y. Wang, M. Wu, X. L. Zhang, F. D. Li, Y. Y. Zeng, X. Y. Lin, X. L. Liu, J. F. Liu, J. Nanobiotechnol. 2021, 19, 204.</Citation>
        </Reference>
        <Reference>
          <Citation>Q. F. Chen, X. B. Ma, L. Xie, W. J. Chen, Z. G. Xu, E. Q. Song, X. K. Zhu, Y. Song, Nanoscale 2021, 13, 4855.</Citation>
        </Reference>
        <Reference>
          <Citation>G. B. Yang, S. Z. F. Phua, W. Q. Lim, R. Zhang, L. Z. Feng, G. F. Liu, H. W. Wu, A. K. Bindra, D. Jana, Z. Liu, Y. L. Zhao, Adv. Mater. 2019, 31, 1901513.</Citation>
        </Reference>
        <Reference>
          <Citation>F. Li, B. C. Bae, K. Na, Bioconjugate Chem. 2010, 21, 1312.</Citation>
        </Reference>
        <Reference>
          <Citation>X. R. Sun, Y. L. Hong, Y. B. Gong, S. S. Zheng, D. H. Xie, Int. J. Mol. Sci. 2021, 22, 7023.</Citation>
        </Reference>
        <Reference>
          <Citation>A. Mohanty, K. Mithra, S. S. Jena, R. K. Behera, Biomacromolecules 2021, 22, 1389.</Citation>
        </Reference>
        <Reference>
          <Citation>F. M. Torti, S. V. Torti, Blood 2002, 99, 3505.</Citation>
        </Reference>
        <Reference>
          <Citation>D. M. Marcus, N. Zinberg, J. Natl. Cancer Inst. 1975, 55, 791.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Kirkali, A. A. Esen, G. Kirkali, G. Guner, Eur. Urol. 1995, 28, 131.</Citation>
        </Reference>
        <Reference>
          <Citation>A. Subtil, A. Hemar, A. Dautryvarsat, J. Cell Sci. 1994, 107, 3461.</Citation>
        </Reference>
        <Reference>
          <Citation>J. E. Schnitzer, P. Oh, E. Pinney, J. Allard, J. Cell Biol. 1994, 127, 1217.</Citation>
        </Reference>
        <Reference>
          <Citation>M. Koivusalo, C. Welch, H. Hayashi, C. C. Scott, M. Kim, T. Alexander, N. Touret, K. M. Hahn, S. Grinstein, J. Cell Biol. 2010, 189, 385.</Citation>
        </Reference>
        <Reference>
          <Citation>N. Imre, A. Hetenyi, E. Szabo, B. Bodnar, A. Szkalisity, I. Grof, A. Bocsik, M. A. Deli, P. Horvath, A. Czibula, E. Monostori, T. A. Martinek, Adv. Sci. 2020, 7, 1902621.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Pelkmans, J. Kartenbeck, A. Helenius, Nat. Cell Biol. 2001, 3, 473.</Citation>
        </Reference>
        <Reference>
          <Citation>G. Zanninelli, O. Loreal, P. Brissot, A. M. Konijn, I. N. Slotki, R. C. Hider, Z. I. Cabantchik, J. Hepatol. 2002, 36, 39.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. J. He, X. Y. Liu, L. Xing, X. Wan, X. Chang, H. L. Jiang, Biomaterials 2020, 241, 119911.</Citation>
        </Reference>
        <Reference>
          <Citation>R. B. Li, L. M. Guiney, C. H. Chang, N. D. Mansukhani, Z. X. Ji, X. Wang, Y. P. Liao, W. Jiang, B. B. Sun, M. C. Hersam, A. E. Nel, T. Xia, ACS Nano 2018, 12, 1390.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36109814</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-3155</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of nanobiotechnology</Title>
          <ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hemin-incorporating DNA nanozyme enabling catalytic oxygenation and GSH depletion for enhanced photodynamic therapy and synergistic tumor ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>410</StartPage>
          <MedlinePgn>410</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">410</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-022-01617-0</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) has emerged as a promising tumor treatment method via light-triggered generation of reactive oxygen species (ROS) to kill tumor cells. However, the efficacy of PDT is usually restricted by several biological limitations, including hypoxia, excess glutathione (GSH) neutralization, as well as tumor resistance. To tackle these issues, herein we developed a new kind of DNA nanozyme to realize enhanced PDT and synergistic tumor ferroptosis. The DNA nanozyme was constructed via rolling circle amplification, which contained repeat AS1411 G quadruplex (G4) units to form multiple G4/hemin DNAzymes with catalase-mimic activity. Both hemin, an iron-containing porphyrin cofactor, and chlorine e6 (Ce6), a photosensitizer, were facilely inserted into G4 structure with high efficiency, achieving in-situ catalytic oxygenation and photodynamic ROS production. Compared to other self-oxygen-supplying tools, such DNA nanozyme is advantageous for high biological stability and compatibility. Moreover, the nanostructure could achieve tumor cells targeting internalization and intranuclear transport of Ce6 by virtue of specific nucleolin binding of AS1411. The nanozyme could catalyze the decomposition of intracellular H2O2 into oxygen for hypoxia relief as evidenced by the suppression of hypoxia-inducible factor-1 (HIF-1), and moreover, GSH depletion and cell ferroptosis were also achieved for synergistic tumor therapy. Upon intravenous injection, the nanostructure could effectively accumulate into tumor, and impose multi-modal tumor therapy with excellent biocompatibility. Therefore, by integrating the capabilities of O2 generation and GSH depletion, such DNA nanozyme is a promising nanoplatform for tumor PDT/ferroptosis combination therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Xiaoxiong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Geriatric Disorders, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, The Second People's Hospital of Huaihua City, Huaihua, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuchen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Yichun People's Hospital, Yichun, Jiangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Junyu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China. ndzhlyy1062@ncu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhou</LastName>
            <ForeName>Wenhu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, Hunan, China. zhouwenhuyaoji@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. zhouwenhuyaoji@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2022JJ40830</GrantID>
            <Agency>Natural Science Foundation General Program of Hunan Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>09</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Nanobiotechnology</MedlineTA>
        <NlmUniqueID>101152208</NlmUniqueID>
        <ISSNLinking>1477-3155</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D021881">DNA, Catalytic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>743LRP9S7N</RegistryNumber>
          <NameOfSubstance UI="D006427">Hemin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.6</RegistryNumber>
          <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>J Nanobiotechnology. 2022 Dec 2;20(1):508</RefSource>
          <PMID Version="1">36457096</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002374" MajorTopicYN="N">Catalase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021881" MajorTopicYN="Y">DNA, Catalytic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006427" MajorTopicYN="N">Hemin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="Y">Porphyrins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aptamer</Keyword>
        <Keyword MajorTopicYN="N">Catalysis</Keyword>
        <Keyword MajorTopicYN="N">DNAzyme</Keyword>
        <Keyword MajorTopicYN="N">Nanomedicine</Keyword>
        <Keyword MajorTopicYN="N">Phototherapy</Keyword>
        <Keyword MajorTopicYN="N">Targeting</Keyword>
        <Keyword MajorTopicYN="N">Tumor hypoxia</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>23</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36109814</ArticleId>
        <ArticleId IdType="pmc">PMC9479271</ArticleId>
        <ArticleId IdType="doi">10.1186/s12951-022-01617-0</ArticleId>
        <ArticleId IdType="pii">10.1186/s12951-022-01617-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Teo RD, Hwang JY, Termini J, Gross Z, Gray HB. Fighting cancer with corroles. Chem Rev. 2017;117:2711&#x2013;2729. doi: 10.1021/acs.chemrev.6b00400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.chemrev.6b00400</ArticleId>
            <ArticleId IdType="pmc">PMC6357784</ArticleId>
            <ArticleId IdType="pubmed">27759377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Xie X, Shi XY, Peng Y, Ding JS, Zhou WH. Oxygen-self-supplying and HIF-1 alpha-inhibiting core-shell nanosystem for hypoxia-resistant photodynamic therapy. ACS Appl Mater Interfaces. 2019;11:48261&#x2013;48270. doi: 10.1021/acsami.9b18112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.9b18112</ArticleId>
            <ArticleId IdType="pubmed">31763809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Lee S, Yoon J. Supramolecular photosensitizers rejuvenate photodynamic therapy. Chem Soc Rev. 2018;47:1174&#x2013;1188. doi: 10.1039/C7CS00594F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C7CS00594F</ArticleId>
            <ArticleId IdType="pubmed">29334090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monro S, Col&#xf3;n KL, Yin H, Roque J, Konda P, Gujar S, et al. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433. Chem Rev. 2019;119:797&#x2013;828. doi: 10.1021/acs.chemrev.8b00211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.chemrev.8b00211</ArticleId>
            <ArticleId IdType="pmc">PMC6453754</ArticleId>
            <ArticleId IdType="pubmed">30295467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6:535&#x2013;545. doi: 10.1038/nrc1894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1894</ArticleId>
            <ArticleId IdType="pmc">PMC2933780</ArticleId>
            <ArticleId IdType="pubmed">16794636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsaab HO, Alghamdi MS, Alotaibi AS, Alzhrani R, Alwuthaynani F, Althobaiti YS, et al. Progress in clinical trials of photodynamic therapy for solid tumors and the role of nanomedicine. Cancers (Basel) 2020;12:20. doi: 10.3390/cancers12102793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12102793</ArticleId>
            <ArticleId IdType="pmc">PMC7601252</ArticleId>
            <ArticleId IdType="pubmed">33003374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430&#x2013;439. doi: 10.1038/nrc3726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3726</ArticleId>
            <ArticleId IdType="pmc">PMC4283800</ArticleId>
            <ArticleId IdType="pubmed">24827502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan YT, Zhou TJ, Cui PF, He YJ, Chang X, Xing L, et al. Modulation of intracellular oxygen pressure by dual-drug nanoparticles to enhance photodynamic therapy. Adv Funct Mater. 2019;29:78. doi: 10.1002/adfm.201807104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adfm.201807104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X, Deng J, Liu F, Guo T, Liu M, Dai P, et al. Triggered all-active metal organic framework: ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett. 2019;19:7866&#x2013;7876. doi: 10.1021/acs.nanolett.9b02904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.9b02904</ArticleId>
            <ArticleId IdType="pubmed">31594301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Zhao SJ, Wu JS, Yu L, Singh N, Yang K, et al. Photodynamic therapy for hypoxic tumors: advances and perspectives. Coord Chem Rev. 2021;438:8. doi: 10.1016/j.ccr.2021.213888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2021.213888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang N, Xiao WY, Song XJ, Wang WJ, Dong XC. Recent advances in tumor microenvironment hydrogen peroxide-responsive materials for cancer photodynamic therapy. Nano-Micro Letters. 2020;12:8. doi: 10.1007/s40820-019-0352-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40820-019-0352-3</ArticleId>
            <ArticleId IdType="pmc">PMC7770924</ArticleId>
            <ArticleId IdType="pubmed">34138092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang W, Delahunty IM, Xie J. Oxygenating the way for enhanced chemophototherapy. Theranostics. 2018;8:3870&#x2013;3871. doi: 10.7150/thno.27810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.27810</ArticleId>
            <ArticleId IdType="pmc">PMC6071522</ArticleId>
            <ArticleId IdType="pubmed">30083265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei FM, Rees TW, Liao XX, Ji LN, Chao H. Oxygen self-sufficient photodynamic therapy. Coord Chem Rev. 2021;432:8. doi: 10.1016/j.ccr.2020.213714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2020.213714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi XD, Yang WT, Ma Q, Lu Y, Xu Y, Bian KX, et al. Hemoglobin-mediated biomimetic synthesis of paramagnetic O-2-evolving theranostic nanoprobes for MR imaging-guided enhanced photodynamic therapy of tumor. Theranostics. 2020;10:11607&#x2013;11621. doi: 10.7150/thno.46228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.46228</ArticleId>
            <ArticleId IdType="pmc">PMC7545996</ArticleId>
            <ArticleId IdType="pubmed">33052236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu DR, Zhong L, Wang MY, Li HH, Qu Y, Liu QY, et al. Perfluorocarbon-loaded and redox-activatable photosensitizing agent with oxygen supply for enhancement of fluorescence/photoacoustic imaging guided tumor photodynamic therapy. Adv Funct Mater. 2019;29:12.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu P, Xie X, Shi X, Peng Y, Ding J, Zhou W. Oxygen-self-supplying and hif-1&#x3b1;-inhibiting core-shell nanosystem for hypoxia-resistant photodynamic therapy. ACS Appl Mater Interfaces. 2019;11:48261&#x2013;48270. doi: 10.1021/acsami.9b18112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.9b18112</ArticleId>
            <ArticleId IdType="pubmed">31763809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H, Jiang Q, Luo KY, Zhu CP, Xie MM, Wang SG, et al. Synthesis of iridium-based nanocomposite with catalase activity for cancer phototherapy. J Nanobiotechnol. 2021;19:34. doi: 10.1186/s12951-021-00778-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12951-021-00778-8</ArticleId>
            <ArticleId IdType="pmc">PMC8265148</ArticleId>
            <ArticleId IdType="pubmed">34233696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Wang FM, Liu CQ, Wang ZZ, Kang LH, Huang YY, et al. Nanozyme decorated metal-organic frameworks for enhanced photodynamic therapy. ACS Nano. 2018;12:651&#x2013;661. doi: 10.1021/acsnano.7b07746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.7b07746</ArticleId>
            <ArticleId IdType="pubmed">29290107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu XL, Ni KY, Zhao ZH, Li MY, Huo LL, Zeng J, et al. Surface engineered iron oxide nanozyme for synergistic chemodynamic/ photodynamic therapy with glutathione depletion and hypoxia relief. Chem Eng J. 2022;440:99. doi: 10.1016/j.cej.2022.135957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cej.2022.135957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng LL, Liu B, Xie R, Wang DD, Qian C, Zhou WQ, et al. An Ultrasmall SnFe2O4 nanozyme with endogenous oxygen generation and glutathione depletion for synergistic cancer therapy. Adv Funct Mater. 2021;31:66.</Citation>
        </Reference>
        <Reference>
          <Citation>Meng YC, Chen Y, Zhu JJ, Qi Y, Ding JS, Zhou WH. Polarity control of DNA adsorption enabling the surface functionalization of CuO nanozymes for targeted tumor therapy. Mater Horiz. 2021;8:972&#x2013;986. doi: 10.1039/D0MH01372B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0MH01372B</ArticleId>
            <ArticleId IdType="pubmed">34821328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun WD, Xu YY, Yao Y, Yue J, Wu Z, Li HC, et al. Self-oxygenation mesoporous MnO2 nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy. J Nanobiotechnol. 2022;20:9. doi: 10.1186/s12951-021-01205-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12951-021-01205-8</ArticleId>
            <ArticleId IdType="pmc">PMC8858544</ArticleId>
            <ArticleId IdType="pubmed">35183183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Peng Y, Ding JS, Zhou WH. Fenton metal nanomedicines for imaging-guided combinatorial chemodynamic therapy against cancer. Asian J Pharm Sci. 2022;17:177&#x2013;192. doi: 10.1016/j.ajps.2021.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajps.2021.10.003</ArticleId>
            <ArticleId IdType="pmc">PMC9091802</ArticleId>
            <ArticleId IdType="pubmed">35582641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Shi XY, Zhong SH, Peng Y, Qi Y, Ding JS, et al. Metal-phenolic networks for cancer theranostics. Biomater Sci. 2021;9:2825&#x2013;2849. doi: 10.1039/D0BM02064H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0BM02064H</ArticleId>
            <ArticleId IdType="pubmed">33688863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou WH, Liu JW. Multi-metal-dependent nucleic acid enzymes. Metallomics. 2018;10:30&#x2013;48. doi: 10.1039/C7MT00268H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C7MT00268H</ArticleId>
            <ArticleId IdType="pubmed">29094140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou WH, Ding JS, Liu JW. Theranostic DNAzymes. Theranostics. 2017;7:1010&#x2013;1025. doi: 10.7150/thno.17736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.17736</ArticleId>
            <ArticleId IdType="pmc">PMC5381262</ArticleId>
            <ArticleId IdType="pubmed">28382172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou WH, Saran R, Liu JW. Metal Sensing by DNA. Chem Rev. 2017;117:8272&#x2013;8325. doi: 10.1021/acs.chemrev.7b00063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.chemrev.7b00063</ArticleId>
            <ArticleId IdType="pubmed">28598605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang PJJ, Liu J. In vitro Selection of Chemically Modified DNAzymes. Chemistry Open. 2020;9:1046&#x2013;1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7570446</ArticleId>
            <ArticleId IdType="pubmed">33101831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliouat H, Peng Y, Waseem Z, Wang SF, Zhou WH. Pure DNA scaffolded drug delivery systems for cancer therapy. Biomaterials. 2022;285:9. doi: 10.1016/j.biomaterials.2022.121532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2022.121532</ArticleId>
            <ArticleId IdType="pubmed">35487068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Shi XY, Peng Y, Hu JM, Ding JS, Zhou WH. Anti-PD-L1 DNAzyme Loaded Photothermal Mn2+/Fe3+ Hybrid Metal-Phenolic Networks for Cyclically Amplified Tumor Ferroptosis-Immunotherapy. Adv Healthc Mater. 2022;11:677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34841741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi Y, Xie X, Peng Y, Liu P, Ding JS, Zhou WH. DNAzyme-adsorbed polydopamine@MnO2 core-shell nanocomposites for enhanced photothermal therapy via the self-activated suppression of heat shock protein 70. Nanoscale. 2021;13:5125&#x2013;5135. doi: 10.1039/D0NR08845E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0NR08845E</ArticleId>
            <ArticleId IdType="pubmed">33651054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Liu XJ, Cheng Y, Zhong SH, Shi XY, Wang SF, et al. Core-Shell Nanosystems for Self-Activated Drug-Gene Combinations against Triple-Negative Breast Cancer. ACS Appl Mater Interfaces. 2020;12:53654&#x2013;53664. doi: 10.1021/acsami.0c15089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.0c15089</ArticleId>
            <ArticleId IdType="pubmed">33205940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie YB, Li D, Peng Y, Wang SF, Hu S, Liu M, et al. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self -activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm. 2020;585:78. doi: 10.1016/j.ijpharm.2020.119513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2020.119513</ArticleId>
            <ArticleId IdType="pubmed">32526334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Peng Y, Nie YB, Liu P, Hu S, Ding JS, et al. Co-delivery of doxorubicin and DNAzyme using ZnO@polydopamine core-shell nanocomposites for chemo/gene/photothermal therapy. Acta Biomater. 2020;110:242&#x2013;253. doi: 10.1016/j.actbio.2020.04.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actbio.2020.04.041</ArticleId>
            <ArticleId IdType="pubmed">32438113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang XJ, Fang CL, Mei HC, Chang TJ, Cao ZH, Shangguan DH. Characterization of G-Quadruplex/Hemin Peroxidase: Substrate Specificity and Inactivation Kinetics. Chem-Eur J. 2011;17:14475&#x2013;14484. doi: 10.1002/chem.201101941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/chem.201101941</ArticleId>
            <ArticleId IdType="pubmed">22106035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Zhu WJ, Feng LZ, Chao Y, Yi X, Dong ZL, et al. G-quadruplex-based nanoscale coordination polymers to modulate tumor hypoxia and achieve nuclear-targeted drug delivery for enhanced photodynamic therapy. Nano Lett. 2018;18:6867&#x2013;6875. doi: 10.1021/acs.nanolett.8b02732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.8b02732</ArticleId>
            <ArticleId IdType="pubmed">30303384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo LN, Chen Y, Wang T, Yuan Y, Yang YH, Luo XL, et al. Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy. J Control Release. 2021;330:119&#x2013;131. doi: 10.1016/j.jconrel.2020.10.069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2020.10.069</ArticleId>
            <ArticleId IdType="pubmed">33333119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng YC, Liu P, Zhou WH, Ding JS, Liu JW. Bioorthogonal DNA adsorption on polydopamine nanoparticles mediated by metal coordination for highly robust sensing in serum and living cells. ACS Nano. 2018;12:9070&#x2013;9080. doi: 10.1021/acsnano.8b03019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b03019</ArticleId>
            <ArticleId IdType="pubmed">30130385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouyang Q, Liu K, Zhu QB, Deng HY, Le Y, Ouyang W, et al. Brain-Penetration and Neuron-Targeting DNA Nanoflowers Co-Delivering miR-124 and Rutin for Synergistic Therapy of Alzheimer's Disease. Small. 2022;18:210784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35182016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang KX, Liu JJ, Song QL, Wang DY, Shi JJ, Zhang HY, et al. Multifunctional DNA Nanoflowers for autophagy inhibition and enhanced antitumor chemotherapy. Chem J Chin Univ-Chin. 2020;41:1461&#x2013;1469.</Citation>
        </Reference>
        <Reference>
          <Citation>Jin Y, Li ZH, Liu HF, Chen SZ, Wang F, Wang L, et al. Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy. Npg Asia Materials. 2017;9:365. doi: 10.1038/am.2017.34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/am.2017.34</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou WH, Zhou YB, Wu JP, Liu ZB, Zhao HZ, Liu JW, et al. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. J Drug Target. 2014;22:57&#x2013;66. doi: 10.3109/1061186X.2013.839683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/1061186X.2013.839683</ArticleId>
            <ArticleId IdType="pubmed">24156476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SF, Zhao CT, Liu P, Wang Z, Ding JS, Zhou WH. Facile construction of dual-targeting delivery system by using lipid capped polymer nanoparticles for anti-glioma therapy. RSC Adv. 2018;8:444&#x2013;453. doi: 10.1039/C7RA12376K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C7RA12376K</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding YX, Xu YJ, Yang WZ, Niu P, Li X, Chen YD, et al. Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy. Nano Today. 2020;35:100970. doi: 10.1016/j.nantod.2020.100970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nantod.2020.100970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon LCH, Methot SP, Morabi-Pazooki W, Pio F, Bennet AJ, Sen D. Guanine-Rich RNAs and DNAs that bind heme robustly catalyze oxygen transfer reactions. J Am Chem Soc. 2011;133:1877&#x2013;1884. doi: 10.1021/ja108571a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja108571a</ArticleId>
            <ArticleId IdType="pubmed">21265562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu JQ, Jiang RD, He HL, Ma CB, Tang ZW. Recent advances on G-quadruplex for biosensing, bioimaging and cancer therapy. Trac-Trends In Analytical Chemistry. 2021;139:11657. doi: 10.1016/j.trac.2021.116257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trac.2021.116257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu R, Shen LL, Chai ZH, Jing C, Zhang YF, An YL, et al. Hemin-block copolymer micelle as an artificial peroxidase and its applications in chromogenic detection and biocatalysis. ACS Appl Mater Interfaces. 2014;6:19207&#x2013;19216. doi: 10.1021/am505232h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/am505232h</ArticleId>
            <ArticleId IdType="pubmed">25286878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber GF. Metabolism in cancer metastasis. Int J Cancer. 2016;138:2061&#x2013;2066. doi: 10.1002/ijc.29839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29839</ArticleId>
            <ArticleId IdType="pubmed">26355498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou WH, Chen QY, Huang PJJ, Ding JS, Liu JW. DNAzyme hybridization, cleavage, degradation, and sensing in undiluted human blood serum. Anal Chem. 2015;87:4001&#x2013;4007. doi: 10.1021/acs.analchem.5b00220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.analchem.5b00220</ArticleId>
            <ArticleId IdType="pubmed">25757186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Zhu G, Mei L, Wu C, Qiu L, Cui C, et al. Self-assembled DNA immunonanoflowers as multivalent CpG nanoagents. ACS Appl Mater Interfaces. 2015;7:24069&#x2013;24074. doi: 10.1021/acsami.5b06987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.5b06987</ArticleId>
            <ArticleId IdType="pmc">PMC4898273</ArticleId>
            <ArticleId IdType="pubmed">26440045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu G, Hu R, Zhao Z, Chen Z, Zhang X, Tan W. Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. J Am Chem Soc. 2013;135:16438&#x2013;16445. doi: 10.1021/ja406115e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja406115e</ArticleId>
            <ArticleId IdType="pmc">PMC3855874</ArticleId>
            <ArticleId IdType="pubmed">24164620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazdian-Robati R, Bayat P, Oroojalian F, Zargari M, Ramezani M, Taghdisi SM, et al. Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol. 2020;155:1420&#x2013;1431. doi: 10.1016/j.ijbiomac.2019.11.118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2019.11.118</ArticleId>
            <ArticleId IdType="pubmed">31734366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Guo L, Wang Z, Liu P, Liu X, Ding J, et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization. Biomaterials. 2021;264:120390. doi: 10.1016/j.biomaterials.2020.120390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2020.120390</ArticleId>
            <ArticleId IdType="pubmed">32980634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Yang C, Mao J, Li H, Ding J, Zhou W. Spermine modified polymeric micelles with pH-sensitive drug release for targeted and enhanced antitumor therapy. RSC Adv. 2019;9:11026&#x2013;11037. doi: 10.1039/C9RA00834A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9RA00834A</ArticleId>
            <ArticleId IdType="pmc">PMC9063029</ArticleId>
            <ArticleId IdType="pubmed">35520220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Xie X, Liu M, Hu S, Ding JS, Zhou WH. A smart MnO2-doped graphene oxide nanosheet for enhanced chemo-photodynamic combinatorial therapy via simultaneous oxygenation and glutathione depletion. Acta Pharm Sin B. 2021;11:823&#x2013;834. doi: 10.1016/j.apsb.2020.07.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apsb.2020.07.021</ArticleId>
            <ArticleId IdType="pmc">PMC7982425</ArticleId>
            <ArticleId IdType="pubmed">33777684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Zhou YB, Shi XY, Yuan Y, Peng Y, Hua SR, et al. A cyclic nano-reactor achieving enhanced photodynamic tumor therapy by reversing multiple resistances. J Nanobiotechnol. 2021;19:8. doi: 10.1186/s12951-020-00738-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12951-020-00738-8</ArticleId>
            <ArticleId IdType="pmc">PMC8139056</ArticleId>
            <ArticleId IdType="pubmed">34020663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xuan W, Xia Y, Li T, Wang L, Liu Y, Tan W. Molecular self-assembly of bioorthogonal aptamer-prodrug conjugate micelles for hydrogen peroxide and ph-independent cancer chemodynamic therapy. J Am Chem Soc. 2020;142:937&#x2013;944. doi: 10.1021/jacs.9b10755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.9b10755</ArticleId>
            <ArticleId IdType="pubmed">31858794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngo W, Ahmed S, Blackadar C, Bussin B, Ji Q, Mladjenovic SM, et al. Why nanoparticles prefer liver macrophage cell uptake in vivo. Adv Drug Del Rev. 2022;185:114238. doi: 10.1016/j.addr.2022.114238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2022.114238</ArticleId>
            <ArticleId IdType="pubmed">35367524</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36055597</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4995</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>350</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of controlled release : official journal of the Controlled Release Society</Title>
          <ISOAbbreviation>J Control Release</ISOAbbreviation>
        </Journal>
        <ArticleTitle>pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors.</ArticleTitle>
        <Pagination>
          <StartPage>525</StartPage>
          <EndPage>537</EndPage>
          <MedlinePgn>525-537</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2022.08.050</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0168-3659(22)00557-0</ELocationID>
        <Abstract>
          <AbstractText>To overcome drug resistance and improve precision theranostics for hepatocellular carcinoma (HCC), a nanoplatform with an "off/on" function for multimodality imaging (near-infrared-II (NIR-II) fluorescence imaging, magnetic resonance imaging (MRI), and photoacoustic imaging) and synergistic therapy (photodynamic therapy and ferroptosis) activated by an acidic pH in the tumor microenvironment is proposed. Although many photosensitizers with photodynamic effects have been reported, very few of them have outstanding photodynamic effect and high stability with response to endogenous stimuli capable of NIR-II imaging. Herein, a new amphiphilic photosensitizer SR780 derived from croconaine dye, was developed with satisfactory photodynamic effects and pH-responsive NIR-II imaging. Interestingly, it was deactivated by coordination with Fe[3+] (SR780@Fe) and activated during their release under mild acidic condition. Ferroptosis can generate hydroxyl free radical and lipid peroxide, which aggravate the oxidative stress of tumor cells and mediate their death while depleting glutathione (GSH) to enhance photodynamic effect. In situ pH-activatable theranostic nanoplatform, SR780@Fe-PAE-GP, was thus developed by loading SR780@Fe with pH-responsive polymers, modified by a glypican-3 (GPC-3) receptor-targeting peptide. The synergistic antitumor effects were confirmed both in vitro and in vivo, and the tumor inhibition rate of the SR780@Fe-PAE-GP + L treatment group reached 98%.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China; Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan Hospital, Southern Medical University, Dongguan 523018, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China; Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan Hospital, Southern Medical University, Dongguan 523018, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ling</LastName>
            <ForeName>Mingjian</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Chenhong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Jingyue</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Jiangsu Key Laboratory of Molecular and Functional Imaging, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Meiyan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Xuzi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Longguang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>International Institutes of Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China. Electronic address: tanglongguang@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Zhiqiang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China; Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan Hospital, Southern Medical University, Dongguan 523018, China. Electronic address: yuzq@smu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Zhenwei</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China. Electronic address: pzhenw@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>09</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>J Control Release</MedlineTA>
        <NlmUniqueID>8607908</NlmUniqueID>
        <ISSNLinking>0168-3659</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053673">Glypicans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008054">Lipid Peroxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053673" MajorTopicYN="N">Glypicans</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008054" MajorTopicYN="N">Lipid Peroxides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068936" MajorTopicYN="N">Theranostic Nanomedicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Multimodality imaging</Keyword>
        <Keyword MajorTopicYN="N">NIR-II imaging</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">pH-activatable</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest All authors declare no competing financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>19</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36055597</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jconrel.2022.08.050</ArticleId>
        <ArticleId IdType="pii">S0168-3659(22)00557-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35953837</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-3155</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Aug</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of nanobiotechnology</Title>
          <ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation.</ArticleTitle>
        <Pagination>
          <StartPage>373</StartPage>
          <MedlinePgn>373</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">373</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-022-01575-7</ELocationID>
        <Abstract>
          <AbstractText>The escape of bladder cancer from immunosurveillance causes monotherapy to exhibit poor efficacy; therefore, designing a multifunctional nanoparticle that boosts programmed cell death and immunoactivation has potential as a treatment strategy. Herein, we developed a facile one-pot coprecipitation reaction to fabricate cluster-structured nanoparticles (CNPs) assembled from Fe3O4 and iron chlorophyll (Chl/Fe) photosensitizers. This nanoassembled CNP, as a multifunctional theranostic agent, could perform red-NIR fluorescence and change the redox balance by the photoinduction of reactive oxygen species (ROS) and attenuate iron-mediated lipid peroxidation by the induction of a Fenton-like reaction. The intravesical instillation of Fe3O4@Chl/Fe CNPs modified with 4-carboxyphenylboronic acid (CPBA) may target the BC wall through glycoproteins in the BC cavity, allowing local killing of cancer cells by photodynamic therapy (PDT)-induced singlet oxygen and causing chemodynamic therapy (CDT)-mediated ferroptosis. An interesting possibility is reprogramming of the tumor microenvironment from immunosuppressive to immunostimulatory after PDT-CDT treatment, which was demonstrated by the reduction of PD-L1 (lower "off" signal to the effector immune cells), IDO-1, TGF-, and M2-like macrophages and the induction of CD8[+] T cells on BC sections. Moreover, the intravesical instillation of Fe3O4@Chl/Fe CNPs may enhance the large-area distribution on the BC wall, improving antitumor efficacy and increasing survival rates from 0 to 91.7%. Our theranostic CNPs not only demonstrated combined PDT-CDT-induced cytotoxicity, ROS production, and ferroptosis to facilitate treatment efficacy but also opened up new horizons for eliminating the immunosuppressive effect by simultaneous PDT-CDT.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chin</LastName>
            <ForeName>Yu-Cheng</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Li-Xing</ForeName>
            <Initials>LX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Fei-Ting</ForeName>
            <Initials>FT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Science and Technology, China Medical University, Taichung, 406, Taiwan. sakiro920@mail.cmu.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Che-Wei</ForeName>
            <Initials>CW</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Urology, Department of Surgery, Taipei City Hospital Zhongxing Branch, Taipei, 103, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Te-Wei</ForeName>
            <Initials>TW</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Urology, Department of Surgery, Taipei City Hospital Heping Fuyou Branch, Taipei, 100, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Hsi-Ying</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Chemistry, National Pingtung University, Pingtung, 900, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Linda Yen-Chien</ForeName>
            <Initials>LY</Initials>
            <AffiliationInfo>
              <Affiliation>Nanofabrication Laboratory, Department of Electrical and Computer Engineering, University of Canterbury, Christchurch, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chia</LastName>
            <ForeName>Zi Chun</ForeName>
            <Initials>ZC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hung</LastName>
            <ForeName>Chun-Hua</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Applied Nanomedicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Wu-Chou</ForeName>
            <Initials>WC</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Applied Nanomedicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiu</LastName>
            <ForeName>Yi-Chun</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Urology, Department of Surgery, Taipei City Hospital Heping Fuyou Branch, Taipei, 100, Taiwan. DAM15@tpech.gov.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. DAM15@tpech.gov.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Exercise and Health Sciences, University of Taipei, Taipei, 100, Taiwan. DAM15@tpech.gov.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Chih-Chia</ForeName>
            <Initials>CC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan. c2huang@email.ncku.edu.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Applied Nanomedicine, National Cheng Kung University, Tainan, 70101, Taiwan. c2huang@email.ncku.edu.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Core Facility Center, National Cheng Kung University, 70101, Tainan, Taiwan. c2huang@email.ncku.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Mei-Yi</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Chemistry, National Pingtung University, Pingtung, 900, Taiwan. myliao@mail.nptu.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MOST 110-2221-E-532 -001</GrantID>
            <Agency>Ministry of Science and Technology, Taiwan</Agency>
          </Grant>
          <Grant>
            <GrantID>MOST 108-2113-M-006-012-MY3</GrantID>
            <Agency>Ministry of Science and Technology, Taiwan</Agency>
          </Grant>
          <Grant>
            <GrantID>MOST 110-2113-M-153-001</GrantID>
            <Agency>Ministry of Science and Technology, Taiwan</Agency>
          </Grant>
          <Grant>
            <GrantID>TCH No. 11001-62-004</GrantID>
            <Agency>Taipei City Hospital (TCH) and the Department of Health, Taipei City Government</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>08</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Nanobiotechnology</MedlineTA>
        <NlmUniqueID>101152208</NlmUniqueID>
        <ISSNLinking>1477-3155</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1406-65-1</RegistryNumber>
          <NameOfSubstance UI="D002734">Chlorophyll</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1K09F3G675</RegistryNumber>
          <NameOfSubstance UI="C000499">ferric oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002734" MajorTopicYN="N">Chlorophyll</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001749" MajorTopicYN="Y">Urinary Bladder Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>23</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35953837</ArticleId>
        <ArticleId IdType="pmc">PMC9367122</ArticleId>
        <ArticleId IdType="doi">10.1186/s12951-022-01575-7</ArticleId>
        <ArticleId IdType="pii">10.1186/s12951-022-01575-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941&#x2013;1953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30350310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guallar-Garrido S, Julian E. Bacillus Calmette-Guerin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020;9:1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7025668</ArticleId>
            <ArticleId IdType="pubmed">32104666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104&#x2013;121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33268841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chia ZC, Yang LX, Cheng TY, Chen YJ, Cheng HL, Hsu FT, Wang YJ, Chen YY, Huang TC, Fang YS, Huang CC. In situ formation of Au-glycopolymer nanoparticles for surface-enhanced raman scattering-based biosensing and single-cell immunity. ACS Appl Mater Interfaces. 2021;13:52295&#x2013;52307. doi: 10.1021/acsami.1c13647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.1c13647</ArticleId>
            <ArticleId IdType="pubmed">34706531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samishina EA, Blinova EV, Roshchin DA, Suslova IR, Blinov DS, Zhdanov PN, Deryabina ON, Kit&#x2019;ko OV. Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression. J Carcinog. 2019;18:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6594057</ArticleId>
            <ArticleId IdType="pubmed">31360124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Luo C, Wang J, Chen L, Chen J, Chen T, Zeng Q. Application of nanotechnology in the diagnosis and treatment of bladder cancer. J Nanobiotechnol. 2021;19:393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8626998</ArticleId>
            <ArticleId IdType="pubmed">34838048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond) 2016;11:673&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5561790</ArticleId>
            <ArticleId IdType="pubmed">27003448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YT, Hsu IL, Cheng TY, Wu WJ, Lee CW, Li TJ, Cheung CI, Chin YC, Chen HC, Chiu YC, et al. Off-resonance SERS nanoprobe-targeted screen of biomarkers for antigens recognition of bladder normal and aggressive cancer cells. Anal Chem. 2019;91:8213&#x2013;8220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31141343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Su W, Wu H, Yuan T, Yuan C, Liu J, Deng G, Gao X, Chen Z, Bao Y, et al. Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids. Nat Biomed Eng. 2020;4:704&#x2013;716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7197249</ArticleId>
            <ArticleId IdType="pubmed">32231314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, Wang Y, Williams GR, Fu L, Wu J, Wang H, Liang R, Weng X, Wei M. Multicomponent transition metal dichalcogenide nanosheets for imaging-guided photothermal and chemodynamic therapy. Adv Sci. 2020;7:2000272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7709983</ArticleId>
            <ArticleId IdType="pubmed">33304740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llop J, Lammers T. Nanoparticles for cancer diagnosis, radionuclide therapy and theranostics. ACS Nano. 2021;15:16974&#x2013;16981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7612708</ArticleId>
            <ArticleId IdType="pubmed">34748314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satpathy M, Wang L, Zielinski RJ, Qian W, Wang YA, Mohs AM, Kairdolf BA, Ji X, Capala J, Lipowska M, et al. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles. Theranostics. 2019;9:778&#x2013;795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6376473</ArticleId>
            <ArticleId IdType="pubmed">30809308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhen W, Jin L, Zhang S, Sun G, Zhang T, Xu X, Song S, Wang Y, Liu J, Zhang H. All-in-one theranostic nanoagent with enhanced reactive oxygen species generation and modulating tumor microenvironment ability for effective tumor eradication. ACS Nano. 2018;12:4886&#x2013;4893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29727164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo G, Zhang H, Shen H, Zhu C, He R, Tang J, Wang Y, Jiang X, Wang J, Bu W, Zhang X. Space-selective chemodynamic therapy of CuFe5O8 nanocubes for implant-related infections. ACS Nano. 2020;14:13391&#x2013;13405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32931252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Bu W, Ni D, Zhang S, Li Q, Yao Z, Zhang J, Yao H, Wang Z, Shi J. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized Fenton reaction. Angew Chem Int Ed. 2016;55:2101&#x2013;2106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26836344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Z, Liu Y, He M, Bu W. Chemodynamic therapy: tumour microenvironment-mediated Fenton and Fenton-like reactions. Angew Chem Int Ed. 2019;58:946&#x2013;956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30048028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon Scott J, Lemberg Kathryn M, Lamprecht Michael R, Skouta R, Zaitsev Eleina M, Gleason Caroline E, Patel Darpan N, Bauer Andras J, Cantley Alexandra M, Yang Wan S, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huo M, Wang L, Chen Y, Shi J. Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nat Commun. 2017;8:357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5572465</ArticleId>
            <ArticleId IdType="pubmed">28842577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao L, Fan K, Yan X. Iron oxide nanozyme: a multifunctional enzyme mimetic for biomedical applications. Theranostics. 2017;7:3207&#x2013;3227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5595127</ArticleId>
            <ArticleId IdType="pubmed">28900505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Z, Zhang H, Liu Y, Ni D, Zhang H, Zhang J, Yao Z, He M, Shi J, Bu W. Antiferromagnetic pyrite as the tumor microenvironment-mediated nanoplatform for self-enhanced tumor imaging and therapy. Adv Mater. 2017;29:1701683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29094389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Wang L, Zheng X, Liu S, Xie Z. Hypoxia-triggered nanoscale metal&#x2013;organic frameworks for enhanced anticancer activity. ACS Appl Mater Interfaces. 2018;10:24638&#x2013;24647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29957930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, Lu H, Lee R. Near infrared light triggered photo/immuno-therapy toward cancers. Front Bioeng Biotechnol. 2020;8:488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7264102</ArticleId>
            <ArticleId IdType="pubmed">32528941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo R, Wang S, Zhao L, Zong Q, Li T, Ling G, Zhang P. Engineered nanomaterials for synergistic photo-immunotherapy. Biomaterials. 2022;282:121425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35217344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao X, Yuan Y, Chen J, Zhang B, Li D, Zhou D, Jing P, Xu G, Wang Y, Hola K, et al. In vivo theranostics with near-infrared-emitting carbon dots-highly efficient photothermal therapy based on passive targeting after intravenous administration. Light Sci Appl. 2018;7:91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6249234</ArticleId>
            <ArticleId IdType="pubmed">30479757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin T, Yuan A, Zhao X, Lian H, Zhuang J, Chen W, Zhang Q, Liu G, Zhang S, Chen W, et al. Self-assembled tumor-targeting hyaluronic acid nanoparticles for photothermal ablation in orthotopic bladder cancer. Acta Biomater. 2017;53:427&#x2013;438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28213097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJH, Sibata CH. Photosensitizers in clinical PDT. Photodiagn Photodyn Ther. 2004;1:27&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25048062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Jiang C, Figueiro Longo JP, Azevedo RB, Zhang H, Muehlmann LA. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharm Sin B. 2018;8:137&#x2013;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5925394</ArticleId>
            <ArticleId IdType="pubmed">29719775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham TC, Nguyen VN, Choi Y, Lee S, Yoon J. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem Rev. 2021;121:13454&#x2013;13619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34582186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masomboon N, Ratanatamskul C, Lu MC. Chemical oxidation of 2,6-dimethylaniline in the fenton process. Environ Sci Technol. 2009;43:8629&#x2013;8634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20028063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koo S, Park OK, Kim J, Han SI, Yoo TY, Lee N, Kim YG, Kim H, Lim C, Bae J-S, et al. Enhanced chemodynamic therapy by Cu&#x2013;Fe peroxide nanoparticles: tumor microenvironment-mediated synergistic Fenton reaction. ACS Nano. 2022;16:2535&#x2013;2545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35080370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011;283:65&#x2013;87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21414382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ. Heavy metal toxicity and the environment. Mol Clin Environ Toxicol. 2012;101:133&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4144270</ArticleId>
            <ArticleId IdType="pubmed">22945569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin W, Liu H, Chen L, Chen J, Zhang D, Cheng Q, Yang F, Zeng Q, Chen T. Pre-clinical MRI-guided intravesical instillation theranosis of bladder cancer by tumor-selective oxygen nanogenerator. Nano Today. 2021;38:101124.</Citation>
        </Reference>
        <Reference>
          <Citation>Lin T, Zhao X, Zhao S, Yu H, Cao W, Chen W, Wei H, Guo H. O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia. Theranostics. 2018;8:990&#x2013;1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817106</ArticleId>
            <ArticleId IdType="pubmed">29463995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Neoh KG, Xu L, Kang ET, Chiong E. Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. Biomacromolecules. 2012;13:2513&#x2013;2520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22793172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang Y-T, Cheng T-Y, Kao T-L, Liao M-Y. Hollow AuxCu1&#x2013;x alloy nanoshells for surface-enhanced Raman-based tracking of bladder cancer cells followed by triggerable secretion removal. ACS Appl Nano Mater. 2020;3:7888&#x2013;7898.</Citation>
        </Reference>
        <Reference>
          <Citation>Tai YW, Chiu YC, Wu PT, Yu J, Chin YC, Wu SP, Chuang YC, Hsieh HC, Lai PS, Yu HP, Liao MY. Degradable NIR-PTT nanoagents with a potential Cu@Cu2O@polymer structure. ACS Appl Mater Interfaces. 2018;10:5161&#x2013;5174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29359551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X, Xu Y, Sun X, Wang J, Xiong L, Du X, Mao S. Graphene oxide sheets-induced growth of nanostructured Fe3O4 for a high-performance anode material of lithium ion batteries. J Mater Chem A. 2015;3:12938&#x2013;12946.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang X, Liu Y, Arandiyan H, Yang H, Bai L, Mujtaba J, Wang Q, Liu S, Sun H. Uniform Fe3O4 microflowers hierarchical structures assembled with porous nanoplates as superior anode materials for lithium-ion batteries. Appl Surf Sci. 2016;389:240&#x2013;246.</Citation>
        </Reference>
        <Reference>
          <Citation>Chang T-W, Ko H, Huang W-S, Chiu Y-C, Yang L-X, Chia Z-C, Chin Y-C, Chen Y-J, Tsai Y-T, Hsu C-W, et al. Tannic acid-induced interfacial ligand-to-metal charge transfer and the phase transformation of Fe3O4 nanoparticles for the photothermal bacteria destruction. Chem Eng J. 2022;428:131237.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang CC, Chang PY, Liu CL, Xu JP, Wu SP, Kuo WC. New insight on optical and magnetic Fe3O4 nanoclusters promising for near infrared theranostic applications. Nanoscale. 2015;7:12689&#x2013;12697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26151814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tait SL, Wang Y, Costantini G, Lin N, Baraldi A, Esch F, Petaccia L, Lizzit S, Kern K. Metal-organic coordination interactions in Fe-terephthalic acid networks on Cu(100) J Am Chem Soc. 2008;130:2108&#x2013;2113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18189402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marshall-Roth T, Libretto NJ, Wrobel AT, Anderton KJ, Pegis ML, Ricke ND, Voorhis TV, Miller JT, Surendranath Y. A pyridinic Fe-N4 macrocycle models the active sites in Fe/N-doped carbon electrocatalysts. Nat Commun. 2020;11:5283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7572418</ArticleId>
            <ArticleId IdType="pubmed">33077736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diller K, Klappenberger F, Marschall M, Hermann K, Nefedov A, Woll C, Barth JV. Self-metalation of 2H-tetraphenylporphyrin on Cu(111): an x-ray spectroscopy study. J Chem Phys. 2012;136:014705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22239798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macquet JP, Millard MM, Theophanides T. X-ray photoelectron spectroscopy of porphyrins. J Am Chem Soc. 1978;100:4741&#x2013;4746.</Citation>
        </Reference>
        <Reference>
          <Citation>Chang H, Kao MJ, Chen TL, Chen CH, Cho KC, Lai XR. Characterization of natural dye extracted from wormwood and purple cabbage for dye-sensitized solar cells. Int J Photoenergy. 2013 doi: 10.1155/2013/159502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/159502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliahmad M, Nasiri Moghaddam N. Synthesis of maghemite (&#x3b3;-Fe2O3) nanoparticles by thermal-decomposition of magnetite (Fe3O4) nanoparticles. Mater Sci. 2013;31:264&#x2013;268.</Citation>
        </Reference>
        <Reference>
          <Citation>Liao MY, Lai PS, Yu HP, Lin HP, Huang CC. Innovative ligand-assisted synthesis of NIR-activated iron oxide for cancer theranostics. Chem Commun. 2012;48:5319&#x2013;5321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22523747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockett MH, Musbat L, Kj&#xe6;r C, Houm&#xf8;ller J, Toker Y, Rubio A, Milne BF, Br&#xf8;ndsted Nielsen S. The Soret absorption band of isolated chlorophyll a and b tagged with quaternary ammonium ions. Phys Chem Chem Phys. 2015;17:25793&#x2013;25798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25873157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reimers JR, Cai Z-L, Kobayashi R, R&#xe4;tsep M, Freiberg A, Krausz E. Assignment of the Q-bands of the chlorophylls: coherence loss via Qx &#x2013; Qy mixing. Sci Rep. 2013;3:2761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3783888</ArticleId>
            <ArticleId IdType="pubmed">24067303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blau R, Epshtein Y, Pisarevsky E, Tiram G, Israeli Dangoor S, Yeini E, Krivitsky A, Eldar-Boock A, Ben-Shushan D, Gibori H, et al. Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins. Theranostics. 2018;8:3437&#x2013;3460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6037036</ArticleId>
            <ArticleId IdType="pubmed">30026858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartmans E, Tjalma JJ, Linssen MD, Allende PBG, Koller M, Jorritsma-Smit A, Elias SG, Nery MSDO, Karrenbeld A, de Vries EG, et al. Potential red-flag identification of colorectal adenomas with wide-field fluorescence molecular endoscopy. Theranostics. 2018;8:1458&#x2013;1467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5858160</ArticleId>
            <ArticleId IdType="pubmed">29556334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandori K, Fukuoka M, Ishikawa T. Effects of citrate ions on the formation of ferric oxide hydroxide particles. J Mater Sci. 1991;26:3313&#x2013;3319.</Citation>
        </Reference>
        <Reference>
          <Citation>Bee A, Massart R, Neveu S. Synthesis of very fine maghemite particles. J Magn Magn Mater. 1995;149:6&#x2013;9.</Citation>
        </Reference>
        <Reference>
          <Citation>Sengupta S, Wurthner F. Chlorophyll J-aggregates: from bioinspired dye stacks to nanotubes, liquid crystals, and biosupramolecular electronics. Acc Chem Res. 2013;46:2498&#x2013;2512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23865851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubara S, Tamiaki H. Supramolecular chlorophyll aggregates inspired from specific light-harvesting antenna &#x201c;chlorosome&#x201d;: static nanostructure, dynamic construction process, and versatile application. J Photochem Photobiol C. 2020;45:100385.</Citation>
        </Reference>
        <Reference>
          <Citation>Cai J-Q, Liu X-M, Gao Z-J, Li L-L, Wang H. Chlorophylls derivatives: photophysical properties, assemblies, nanostructures and biomedical applications. Mater Today. 2021;45:77&#x2013;92.</Citation>
        </Reference>
        <Reference>
          <Citation>Kralji&#x107; I, Mohsni S. A new method for the detection of singlet oxygen in aqueous solutions. Photochem Photobiol. 2008;28:577&#x2013;581.</Citation>
        </Reference>
        <Reference>
          <Citation>Jaque D, Martinez Maestro L, del Rosal B, Haro-Gonzalez P, Benayas A, Plaza JL, Martin Rodriguez E, Garcia Sole J. Nanoparticles for photothermal therapies. Nanoscale. 2014;6:9494&#x2013;9530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25030381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu ZT, Wang H, Li L, Liu YS, Deng XB, Huo SF, Yuan FF, Liu ZF, Tong HS, Su L. Heat stress induces apoptosis through transcription-independent p53-mediated mitochondrial pathways in human umbilical vein endothelial cell. Sci Rep. 2014;4:4469&#x2013;4469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3966036</ArticleId>
            <ArticleId IdType="pubmed">24667845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song L, Zhou L, Dai X, Wang X, Cheng R, Zhao G, Xu N. Self-destructible polysaccharide nanocomposites with unlockable Au nanorods for high-performance photothermal therapy. NPG Asia Mater. 2018;10:509&#x2013;521.</Citation>
        </Reference>
        <Reference>
          <Citation>Liao MY, Huang CC, Chang MC, Lin SF, Liu TY, Su CH, Yeh CS, Lin HP. Synthesis of magnetic hollow nanotubes based on the kirkendall effect for MR contrast agent and colorimetric hydrogen peroxide sensor. J Mater Chem. 2011;21:7974&#x2013;7981.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu Y, Yu J, Ye WC, Yao X, Zhou PP, Zhang HX, Zhao SQ, Jia LP. Spectrophotometric determination of mercury(II) ions based on their stimulation effect on the peroxidase-like activity of molybdenum disulfide nanosheets. Microchim Acta. 2016;183:2481&#x2013;2489.</Citation>
        </Reference>
        <Reference>
          <Citation>Fu GL, Sanjay ST, Zhou W, Brekken RA, Kirken RA, Li XJ. Exploration of nanoparticle-mediated photothermal effect of TMB-H2O2 colorimetric system and its application in a visual quantitative photothermal immunoassay. Anal Chem. 2018;90:5930&#x2013;5937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6177380</ArticleId>
            <ArticleId IdType="pubmed">29641893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H, Gong J, Liu Y. Indoleamine 2,3-dioxygenase regulation of immune response (review) Mol Med Rep. 2018;17:4867&#x2013;4873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29393500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham BTT, Colvin EK, Pham NTH, Kim BJ, Fuller ES, Moon EA, Barbey R, Yuen S, Rickman BH, Bryce NS, et al. Biodistribution and clearance of stable superparamagnetic maghemite iron oxide nanoparticles in mice following intraperitoneal administration. Int J Mol Sci. 2018;19:205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5796154</ArticleId>
            <ArticleId IdType="pubmed">29320407</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">35867762</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1091-6490</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>119</Volume>
            <Issue>28</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.</ArticleTitle>
        <Pagination>
          <StartPage>e2122840119</StartPage>
          <MedlinePgn>e2122840119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e2122840119</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2122840119</ELocationID>
        <Abstract>
          <AbstractText>Chromophobe (Ch) renal cell carcinoma (RCC) arises from the intercalated cell in the distal nephron. There are no proven treatments for metastatic ChRCC. A distinguishing characteristic of ChRCC is strikingly high levels of reduced (GSH) and oxidized (GSSG) glutathione. Here, we demonstrate that ChRCC-derived cells exhibit higher sensitivity to ferroptotic inducers compared with clear-cell RCC. ChRCC-derived cells are critically dependent on cystine via the cystine/glutamate antiporter xCT to maintain high levels of glutathione, making them sensitive to inhibitors of cystine uptake and cyst(e)inase. Gamma-glutamyl transferase 1 (GGT1), a key enzyme in glutathione homeostasis, is markedly suppressed in ChRCC relative to normal kidney. Importantly, GGT1 overexpression inhibits the proliferation of ChRCC cells in vitro and in vivo, suppresses cystine uptake, and decreases levels of GSH and GSSG. Collectively, these data identify ferroptosis as a metabolic vulnerability in ChRCC, providing a potential avenue for targeted therapy for these distinctive tumors.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Long</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-3905-5749</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hobeika</LastName>
            <ForeName>Charbel S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khabibullin</LastName>
            <ForeName>Damir</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-0776-7186</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Deyang</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-4321-1142</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02139.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Filippakis</LastName>
            <ForeName>Harilaos</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-9013-6344</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alchoueiry</LastName>
            <ForeName>Michel</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-8288-7212</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-6223-8423</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lam</LastName>
            <ForeName>Hilaire C</ForeName>
            <Initials>HC</Initials>
            <Identifier Source="ORCID">0000-0003-4887-3161</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsvetkov</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-7577-2342</Identifier>
            <AffiliationInfo>
              <Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02139.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Georgiou</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamb</LastName>
            <ForeName>Candice</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-6204-2156</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stone</LastName>
            <ForeName>Everett</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-2459-9762</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puigserver</LastName>
            <ForeName>Pere</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02139.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Priolo</LastName>
            <ForeName>Carmen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henske</LastName>
            <ForeName>Elizabeth P</ForeName>
            <Initials>EP</Initials>
            <Identifier Source="ORCID">0000-0001-7978-6699</Identifier>
            <AffiliationInfo>
              <Affiliation>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K01 DK116819</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 CA101942</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA216922</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1R01CA216922</GrantID>
            <Agency>HHS | NIH | National Cancer Institute (NCI)</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>07</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>48TCX9A1VT</RegistryNumber>
          <NameOfSubstance UI="D003553">Cystine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.2</RegistryNumber>
          <NameOfSubstance UI="D005723">gamma-Glutamyltransferase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.2</RegistryNumber>
          <NameOfSubstance UI="C554782">gamma-glutamyltransferase, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ULW86O013H</RegistryNumber>
          <NameOfSubstance UI="D019803">Glutathione Disulfide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="Y">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="Y">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003553" MajorTopicYN="Y">Cystine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="Y">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019803" MajorTopicYN="N">Glutathione Disulfide</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="Y">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005723" MajorTopicYN="N">gamma-Glutamyltransferase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">chromophobe renal cell carcinoma</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">gamma-glutamyl transferase 1</Keyword>
        <Keyword MajorTopicYN="N">solute carrier family 7 member 11</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>13</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35867762</ArticleId>
        <ArticleId IdType="pmc">PMC9651629</ArticleId>
        <ArticleId IdType="doi">10.1073/pnas.2122840119</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Moch H., Cubilla A. L., Humphrey P. A., Reuter V. E., Ulbright T. M., The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: Renal, penile, and testicular tumours. Eur. Urol. 70, 93&#x2013;105 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26935559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Henske E. P., Chromophobe renal cell carcinoma: New genetic and metabolic insights. Urol. Oncol. 38, 678&#x2013;681 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32444178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avulova S., et al. , Grading chromophobe renal cell carcinoma: Evidence for a four-tiered classification incorporating coagulative tumor necrosis. Eur. Urol. 79, 225&#x2013;231 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33172723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindgren D., et al. , Cell-type-specific gene programs of the normal human nephron define kidney cancer subtypes. Cell Rep. 20, 1476&#x2013;1489 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28793269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skala S. L., et al. , Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur. Urol. 78, 63&#x2013;74 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8996310</ArticleId>
            <ArticleId IdType="pubmed">32299640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linehan W. M., Ricketts C. J., The cancer genome atlas of renal cell carcinoma: Findings and clinical implications. Nat. Rev. Urol. 16, 539&#x2013;552 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31278395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis C. F., et al. ; The&#xa0;Cancer Genome Atlas Research Network, The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319&#x2013;330 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160352</ArticleId>
            <ArticleId IdType="pubmed">25155756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reznik E., et al. , Mitochondrial DNA copy number variation across human cancers. eLife 5, e10769 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4775221</ArticleId>
            <ArticleId IdType="pubmed">26901439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reznik E., Wang Q., La K., Schultz N., Sander C., Mitochondrial respiratory gene expression is suppressed in many cancers. eLife 6, e21592 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5243113</ArticleId>
            <ArticleId IdType="pubmed">28099114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y., et al. ; PCAWG Consortium, Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat. Genet. 52, 342&#x2013;352 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7058535</ArticleId>
            <ArticleId IdType="pubmed">32024997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voss M. H., et al. , Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann. Oncol. 25, 663&#x2013;668 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4229900</ArticleId>
            <ArticleId IdType="pubmed">24458473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutson T. E., et al. , A single-arm, multicenter, phase 2 study of Lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. Eur. Urol. 80, 162&#x2013;170 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33867192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarrabi K., Walzer E., Zibelman M., Immune checkpoint inhibition in advanced non-clear cell renal cell carcinoma: Leveraging success from clear cell histology into new opportunities. Cancers (Basel) 13, 3652 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8344970</ArticleId>
            <ArticleId IdType="pubmed">34359554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priolo C., et al. , Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 115, E6274&#x2013;E6282 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6142242</ArticleId>
            <ArticleId IdType="pubmed">29891694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao Y., et al. , Decreased mitochondrial DNA content drives OXPHOS dysregulation in chromophobe renal cell carcinoma. Cancer Res. 80, 3830&#x2013;3840 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32694149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S. J., et al. , Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060&#x2013;1072 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambright W. S., Fonseca R. S., Chen L., Na R., Ran Q., Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 12, 8&#x2013;17 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5312549</ArticleId>
            <ArticleId IdType="pubmed">28212525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H., et al. , Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat. Cell Biol. 22, 225&#x2013;234 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7008777</ArticleId>
            <ArticleId IdType="pubmed">32029897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng J., Conrad M., The metabolic underpinnings of ferroptosis. Cell Metab. 32, 920&#x2013;937 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33217331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W. S., et al. , Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ubellacker J. M., et al. , Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585, 113&#x2013;118 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7484468</ArticleId>
            <ArticleId IdType="pubmed">32814895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henke N., et al. , The plasma membrane channel ORAI1 mediates detrimental calcium influx caused by endogenous oxidative stress. Cell Death Dis. 4, e470 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3564003</ArticleId>
            <ArticleId IdType="pubmed">23348584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C&#xe2;mpean V., Kricke J., Ellison D., Luft F. C., Bachmann S., Localization of thiazide-sensitive Na(+)-Cl(&#x2212;) cotransport and associated gene products in mouse DCT. Am. J. Physiol. Renal Physiol. 281, F1028&#x2013;F1035 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11704553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., et al. , Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 26, 623&#x2013;633 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata Y., Yasui H., Higashikawa K., Miyamoto N., Kuge Y., Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in&#xa0;vitro and in&#xa0;vivo. PLoS One 14, e0225931 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6892486</ArticleId>
            <ArticleId IdType="pubmed">31800616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley M. A., et al. , Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85&#x2013;89 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., et al. , Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 572, 402&#x2013;406 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao Y., et al. , Endocytosis-mediated replenishment of amino acids favors cancer cell proliferation and survival in chromophobe renal cell carcinoma. Cancer Res. 80, 5491&#x2013;5501 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33115803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y., et al. , Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes Cancer 56, 719&#x2013;729 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5561006</ArticleId>
            <ArticleId IdType="pubmed">28736828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y. P., et al. , Non-canonical glutamate-cysteine ligase activity protects against ferroptosis. Cell Metab. 33, 174&#x2013;189 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7839835</ArticleId>
            <ArticleId IdType="pubmed">33357455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43&#x2013;49 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3771322</ArticleId>
            <ArticleId IdType="pubmed">23792563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H., et al. , Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging (Albany NY) 12, 12943&#x2013;12959 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7377827</ArticleId>
            <ArticleId IdType="pubmed">32601262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loboda A., Damulewicz M., Pyza E., Jozkowicz A., Dulak J., Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell. Mol. Life Sci. 73, 3221&#x2013;3247 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4967105</ArticleId>
            <ArticleId IdType="pubmed">27100828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Kensler T. W., Motohashi H., The KEAP1-NRF2 System: A thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol. Rev. 98, 1169&#x2013;1203 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9762786</ArticleId>
            <ArticleId IdType="pubmed">29717933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo de la Vega M., Chapman E., Zhang D. D., NRF2 and the hallmarks of cancer. Cancer Cell 34, 21&#x2013;43 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6039250</ArticleId>
            <ArticleId IdType="pubmed">29731393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Z., Naowarojna N., Pan Z., Zou Y., Multifaceted mechanisms mediating cystine starvation-induced ferroptosis. Nat. Commun. 12, 4792 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8352933</ArticleId>
            <ArticleId IdType="pubmed">34373463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerharz C. D., et al. , Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma. Am. J. Pathol. 146, 953&#x2013;962 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1869263</ArticleId>
            <ArticleId IdType="pubmed">7717462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choueiri T. K., Kaelin W. G. Jr., Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519&#x2013;1530 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33020645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye L. F., et al. , Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem. Biol. 15, 469&#x2013;484 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7180072</ArticleId>
            <ArticleId IdType="pubmed">31899616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., et al. , CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270&#x2013;274 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., et al. , Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem. Biophys. Res. Commun. 534, 877&#x2013;884 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33162029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopal R. K., et al. , Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc. Natl. Acad. Sci. U.S.A. 115, E6283&#x2013;E6290 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6142220</ArticleId>
            <ArticleId IdType="pubmed">29915083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henske E. P., Cornejo K. M., Wu C. L., Renal cell carcinoma in tuberous sclerosis complex. Genes (Basel) 12, 1585 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8535193</ArticleId>
            <ArticleId IdType="pubmed">34680979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J. L., et al. , Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann. Oncol. 23, 2108&#x2013;2114 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22228449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina A. M., et al. , Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest. New Drugs 30, 335&#x2013;340 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3257373</ArticleId>
            <ArticleId IdType="pubmed">20711632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsimafeyeu I., et al. , Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am. J. Clin. Oncol. 35, 251&#x2013;254 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21358295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keefe S. M., et al. , Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial. Ann. Oncol. 27, 1579&#x2013;1585 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4959924</ArticleId>
            <ArticleId IdType="pubmed">27457310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tannir N. M., et al. , Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial. Eur. Urol. 69, 866&#x2013;874 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4879109</ArticleId>
            <ArticleId IdType="pubmed">26626617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voss M. H., et al. , Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J. Clin. Oncol. 34, 3846&#x2013;3853 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5791841</ArticleId>
            <ArticleId IdType="pubmed">27601542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergmann L., et al. , A randomized phase IIa trial with temsirolimus versus sunitinib in advanced non-clear cell renal cell carcinoma: An intergroup study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncol. Res. Treat. 43, 333&#x2013;339 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32541143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansal A., et al. , Gamma-glutamyltransferase 1 promotes clear cell renal cell carcinoma initiation and progression. Mol. Cancer Res. 17, 1881&#x2013;1892 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726546</ArticleId>
            <ArticleId IdType="pubmed">31151999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corti A., Belcastro E., Dominici S., Maellaro E., Pompella A., The dark side of gamma-glutamyltransferase (GGT): Pathogenic effects of an &#x2018;antioxidant&#x2019; enzyme. Free Radic. Biol. Med. 160, 807&#x2013;819 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32916278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., et al. , Oridonin induces ferroptosis by inhibiting gamma-glutamyl cycle in TE1 cells. Phytother. Res. 35, 494&#x2013;503 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32869425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biczo G., et al. , Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models. Gastroenterology 154, 689&#x2013;703 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6369139</ArticleId>
            <ArticleId IdType="pubmed">29074451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi S., et al. , The genomic landscape of renal oncocytoma identifies a metabolic barrier to tumorigenesis. Cell Rep. 13, 1895&#x2013;1908 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4779191</ArticleId>
            <ArticleId IdType="pubmed">26655904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt L. S., Birt-Hogg-Dub&#xe9; syndrome: From gene discovery to molecularly targeted therapies. Fam. Cancer 12, 357&#x2013;364 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3637987</ArticleId>
            <ArticleId IdType="pubmed">23108783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam H. C., et al. , Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8, 64714&#x2013;64727 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5630288</ArticleId>
            <ArticleId IdType="pubmed">29029388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam H. C., et al. , p62/SQSTM1 cooperates with hyperactive mTORC1 to regulate glutathione production, maintain mitochondrial integrity, and promote tumorigenesis. Cancer Res. 77, 3255&#x2013;3267 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5485875</ArticleId>
            <ArticleId IdType="pubmed">28512249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebrahimi-Fakhari D., et al. , Impaired mitochondrial dynamics and mitophagy in neuronal models of tuberous sclerosis complex. Cell Rep. 17, 1053&#x2013;1070 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5078873</ArticleId>
            <ArticleId IdType="pubmed">27760312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torrence M. E., et al. , The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. eLife 10, e63326 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7997658</ArticleId>
            <ArticleId IdType="pubmed">33646118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Koppula P., Gan B., Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle 18, 773&#x2013;783 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6527290</ArticleId>
            <ArticleId IdType="pubmed">30907299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P., Zhang Y., Shi J., Li W., Gan B., The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J. Biol. Chem. 292, 14240&#x2013;14249 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5572906</ArticleId>
            <ArticleId IdType="pubmed">28630042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei G., Zhuang L., Gan B., mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential. BioEssays 43, e2100093 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34121197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kravtsov O., et al. , Low-grade oncocytic tumor of kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum. Pathol. 114, 9&#x2013;18 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33961838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy A., Al-bataineh M. M., Pastor-Soler N. M., Collecting duct intercalated cell function and regulation. Clin. J. Am. Soc. Nephrol. 10, 305&#x2013;324 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4317747</ArticleId>
            <ArticleId IdType="pubmed">25632105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghazi S., et al. , Multiparametric imaging reveals that mitochondria-rich intercalated cells in the kidney collecting duct have a very high glycolytic capacity. FASEB J. 34, 8510&#x2013;8525 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32367531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito K., Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas. Int. J. Urol. 26, 868&#x2013;877 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31183903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer R. J., et al. , Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376&#x2013;2381 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11981011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choueiri T. K., et al. , PD-L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol. 25, 2178&#x2013;2184 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4288138</ArticleId>
            <ArticleId IdType="pubmed">25193987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., et al. , mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat. Commun. 12, 1589 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7952727</ArticleId>
            <ArticleId IdType="pubmed">33707434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miess H., et al. , The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene 37, 5435&#x2013;5450 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6173300</ArticleId>
            <ArticleId IdType="pubmed">29872221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y., et al. , A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun. 10, 1617 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35855531</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-7634</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer medicine</Title>
          <ISOAbbreviation>Cancer Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Low ferroptosis score predicts chemotherapy responsiveness and immune-activation in colorectal cancer.</ArticleTitle>
        <Pagination>
          <StartPage>2033</StartPage>
          <EndPage>2045</EndPage>
          <MedlinePgn>2033-2045</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.4956</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Existing studies for ferroptosis and prognosis in colorectal cancer (CRC) were limited. In this study, we aim to investigate the prognostic role of ferroptosis markers in patients with CRC and exploration of its micro-environmental distributions.</AbstractText>
          <AbstractText Label="METHODS">Immunohistochemical staining was performed for CRC patients' tissue microarray. Selection and prognostic validation of markers were based on mRNA data from the cancer genome atlas (TCGA) database. Gene Set Enrichment Analysis (GSEA) was performed to indicate relative immune landmarks and hallmarks. Ferroptosis and immune contexture were examined by CIBERSORT. Survival outcomes were analyzed by Kaplan-Meier analysis and cox analysis.</AbstractText>
          <AbstractText Label="RESULTS">A panel of 42 genes was selected. Through mRNA expression difference and prognosis analysis, GPX4, NOX1 and ACSL4 were selected as candidate markers. By IHC, increased GPX4, decreased NOX1 and decreased FACL4 indicate poor prognosis and worse clinical characteristics. Ferroptosis score based on GPX4, NOX1 and ACSL4 was constructed and validated with high C-index. Low ferroptosis score can also demonstrate the better progression free survival and better adjuvant chemotherapy (ACT) responsiveness. Moreover, tumor with low ferroptosis score tend to be infiltrated with more CD4+ T cells, CD8+ T cells and less M1 macrophage. Finally, we found that IFN-&#x3b3; was potentially the central molecule at the crossroad between ferroptosis and onco-immune response.</AbstractText>
          <AbstractText Label="CONCLUSION">Ferroptosis plays important role on CRC tumor progression, ACT response and prognosis. Ferroptosis contributes to immune-supportive responses and IFN-&#x3b3; was the central molecule for this process.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-6013-0558</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Qing-Yang</ForeName>
            <Initials>QY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhi-Yuan</ForeName>
            <Initials>ZY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>De-Xiang</ForeName>
            <Initials>DX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Si-Min</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Yi-Hao</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yu-Qiu</ForeName>
            <Initials>YQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Mei-Ling</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Jian-Min</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Guo-Dong</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Surgery, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>07</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Med</MedlineTA>
        <NlmUniqueID>101595310</NlmUniqueID>
        <ISSNLinking>2045-7634</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">immune response</Keyword>
        <Keyword MajorTopicYN="N">prognosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest for the publication of this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>2</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35855531</ArticleId>
        <ArticleId IdType="pmc">PMC9883409</ArticleId>
        <ArticleId IdType="doi">10.1002/cam4.4956</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145&#x2010;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32133645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7&#x2010;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115&#x2010;132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26808342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliphant R, Nicholson GA, Horgan PG, et al. Contribution of surgical specialization to improved colorectal cancer survival. Br J Surg. 2013;100:1388&#x2010;1395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23939852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2016;15:348&#x2010;366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6531857</ArticleId>
            <ArticleId IdType="pubmed">26775689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldrovandi M, Conrad M. Ferroptosis: the good, the bad and the ugly. Cell Res. 2020;30:1061&#x2010;1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7784890</ArticleId>
            <ArticleId IdType="pubmed">33149249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhang X, Zhang J, Tan J, Li J, Song Z. Development and validation of a combined ferroptosis and immune prognostic classifier for hepatocellular carcinoma. Front Cell Dev Biol. 2020;8:596679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7785857</ArticleId>
            <ArticleId IdType="pubmed">33425905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rink JS, Lin AY, McMahon KM, et al. Targeted reduction of cholesterol uptake in cholesterol&#x2010;addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. J Biol Chem. 2020;296:100100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7949030</ArticleId>
            <ArticleId IdType="pubmed">33208460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266&#x2010;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8142022</ArticleId>
            <ArticleId IdType="pubmed">33495651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S, Yanatori I, Kong Y, Zheng H, Motooka Y, Jiang L. Ferroptosis at the crossroads of infection, aging and cancer. Cancer Sci. 2020;111:2665&#x2010;2671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7419040</ArticleId>
            <ArticleId IdType="pubmed">32437084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Du L, Qiao Y, et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol. 2019;24:101211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6526247</ArticleId>
            <ArticleId IdType="pubmed">31108460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Zhu G, Liu Y, et al. O&#x2010;GlcNAcylated c&#x2010;Jun antagonizes ferroptosis via inhibiting GSH synthesis in liver cancer. Cell Signal. 2019;63:109384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31394193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6441206</ArticleId>
            <ArticleId IdType="pubmed">30925886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B, Chen XB, Ying MD, He QJ, Cao J, Yang B. The role of ferroptosis in cancer development and treatment response. Front Pharmacol. 2017;8:992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5770584</ArticleId>
            <ArticleId IdType="pubmed">29375387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagpal A, Redvers RP, Ling X, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis. Breast Cancer Res. 2019;21:94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6693253</ArticleId>
            <ArticleId IdType="pubmed">31409375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830&#x2010;849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benson AB, Venook AP, Al&#x2010;Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:874&#x2010;901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30006429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C . Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res. 2019;31(1):117&#x2010;134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6433585</ArticleId>
            <ArticleId IdType="pubmed">30996570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osterman E, Mezheyeuski A, Sjoblom T, Glimelius B. Beyond the NCCN risk factors in colon cancer: an evaluation in a Swedish population&#x2010;based cohort. Ann Surg Oncol. 2020;27:1036&#x2010;1045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7060230</ArticleId>
            <ArticleId IdType="pubmed">31893351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Fan J, Qin X, et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol. 2019;145:725&#x2010;736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30542791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249&#x2010;264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12925520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maag JLV. gganatogram: an R package for modular visualisation of anatograms and tissues based on ggplot2. F1000Res. 2018;7:1576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6208569</ArticleId>
            <ArticleId IdType="pubmed">30467523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia JB, Wang WQ, Sun HC, et al. High expression of macrophage colony&#x2010;stimulating factor&#x2010;1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist. 2010;15:732&#x2010;743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3228006</ArticleId>
            <ArticleId IdType="pubmed">20551429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Y, Feng Q, Zheng P, et al. Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Int J Cancer. 2018;143:2271&#x2010;2280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29873076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji M, Feng Q, He G, et al. Silencing homeobox C6 inhibits colorectal cancer cell proliferation. Oncotarget. 2016;7:29216&#x2010;29227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5045391</ArticleId>
            <ArticleId IdType="pubmed">27081081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453&#x2010;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4739640</ArticleId>
            <ArticleId IdType="pubmed">25822800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge&#x2010;based approach for interpreting genome&#x2010;wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545&#x2010;15550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98&#x2010;W102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5570223</ArticleId>
            <ArticleId IdType="pubmed">28407145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Song J, Yung BC, Zhou Z, Wu A, Chen X. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater. 2018;30:e1704007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377162</ArticleId>
            <ArticleId IdType="pubmed">29356212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther. 2020;13:5429&#x2010;5441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7295539</ArticleId>
            <ArticleId IdType="pubmed">32606760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MS, Wang SF, Hsu CY, et al. CHAC1 degradation of glutathione enhances cystine&#x2010;starvation&#x2010;induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2&#x2010;eIF2alpha&#x2010;ATF4 pathway. Oncotarget. 2017;8:114588&#x2010;114602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777716</ArticleId>
            <ArticleId IdType="pubmed">29383104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy MP. Metabolic control of ferroptosis in cancer. Nat Cell Biol. 2018;20:1104&#x2010;1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30224762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X, Zhang R, Liu S, et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol. 2018;9:1371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6262051</ArticleId>
            <ArticleId IdType="pubmed">30524291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Z, Wirth AK, Chen D, et al. Nrf2&#x2010;Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6:e371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5608917</ArticleId>
            <ArticleId IdType="pubmed">28805788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Q, Chang W, Mao Y, et al. Tumor&#x2010;associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer. Clin Cancer Res. 2019;25:3896&#x2010;3907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30988081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole&#x2010;Ezea P, Swan D, Shanley D, Hesketh J. Glutathione peroxidase 4 has a major role in protecting mitochondria from oxidative damage and maintaining oxidative phosphorylation complexes in gut epithelial cells. Free Radic Biol Med. 2012;53:488&#x2010;497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22634395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug&#x2010;tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247&#x2010;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91&#x2010;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dachert J, Ehrenfeld V, Habermann K, Dolgikh N, Fulda S. Targeting ferroptosis in rhabdomyosarcoma cells. Int J Cancer. 2020;146:510&#x2010;520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31173656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elliott MR, Ravichandran KS. The dynamics of apoptotic cell clearance. Dev Cell. 2016;38:147&#x2010;160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4966906</ArticleId>
            <ArticleId IdType="pubmed">27459067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L, Kroemer G. Interferon&#x2010;gamma induces cancer cell ferroptosis. Cell Res. 2019;29:692&#x2010;693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6796847</ArticleId>
            <ArticleId IdType="pubmed">31160718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2010;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Tian C, Li Q, Xu Q. TET1 knockdown inhibits porphyromonas gingivalis LPS/IFN&#x2010;gamma&#x2010;induced M1 macrophage polarization through the NF&#x2010;kappaB pathway in THP&#x2010;1 cells. Int J Mol Sci. 2019;20(8):2023&#x2010;2038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6514734</ArticleId>
            <ArticleId IdType="pubmed">31022963</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35705143</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-1597</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Photodiagnosis and photodynamic therapy</Title>
          <ISOAbbreviation>Photodiagnosis Photodyn Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>YAP knockdown in combination with ferroptosis induction increases the sensitivity of HOS human osteosarcoma cells to pyropheophorbide- methyl ester-mediated photodynamic therapy.</ArticleTitle>
        <Pagination>
          <StartPage>102964</StartPage>
          <MedlinePgn>102964</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pdpdt.2022.102964</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1572-1000(22)00250-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">This study was designed to explore the effects of Yes-associated protein (YAP) knockdown on human osteosarcoma (HOS) cell sensitivity to Pyropheophorbide- methyl ester-mediated photodynamic therapy (MPPa-PDT), and to assess how YAP silencing in combination with treatment with the ferroptosis inducer Erastin improves HOS cell sensitivity to MPPa-PDT in an effort to better clarify the molecular mechanisms underlying these phenotypes.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">At 12&#xa0;h post-MPPa-PDT, Hoechst staining and flow cytometry were conducted to evaluate the apoptotic death of HOS cells. The expression of YAP in these cells at 12&#xa0;h post-MPPa-PDT treatment was assessed via Western blotting and immunofluorescent staining. BODIPY[581/591]-C11 was used to evaluate lipid peroxidation. Following shYAP lentiviral transduction, Western blotting was conducted to assess the expression of proteins associated with proliferation, apoptosis, and ferroptosis. EdU assays and clonogenic assays were performed to analyze cellular proliferation. Erastin-treated HOS cells were used to establish a ferroptosis model. Western blotting was used to measure ferroptosis-associated protein levels following shYAP and erastin treatment, while changes in proliferation and MDA levels in each group were examined using an MDA kit.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">At 12&#xa0;h post-MPPa-PDT, HOS cells exhibited apoptotic characteristics including nuclear fragmentation and pyknosis, with concomitant increases in apoptosis-associated proteins as detected via Western blotting and apoptotic induction as measured via flow cytometry. Phosphorylated YAP levels fell and non-phosphorylated YAP levels rose following such treatment. Transfection with shYAP was successful as a means of generating stable HOS cell lines, and Western blotting analyses of these cells revealed reductions in proteins associated with cellular proliferation together with the upregulation of apoptosis-related proteins. &#xa0;MDA assays indicated that erastin combined with YAP knockdown enhanced the sensitivity of HOS cells to MPPa-PDT treatment.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that ferroptosis and YAP knockdown can enhance osteosarcoma cell sensitivity to MPPa-PDT therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhan</LastName>
            <ForeName>Fangbiao</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Department of Orthopedics, Chongqing University Three Gorges Hospital, Chongqing Municipality Clinical Research Center for Geriatric diseases, Wanzhou, Chongqing 404000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ye</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zuo</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China; West China-Guang'an Hospital, Sichuan University, Guang'an, Sichuan 638000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Chaozheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huanhuan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Emergency Medicine, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing 404000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing 404000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Chunrong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Jiangjin Central Hospital of Chongqing, Chongqing 402260, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhiyu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Chaohua</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Qiaochu</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Haoyang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Chongqing University Three Gorges Hospital, Chongqing Municipality Clinical Research Center for Geriatric diseases, Wanzhou, Chongqing 404000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Jiangxia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Traumatology department, Chongqing university central hospital. 1#, Jiankong road, Yuzhong district, Chongqing 400014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ou</LastName>
            <ForeName>Yunsheng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, China; Orthopedic Laboratory of Chongqing Medical University, Yuzhong, Chongqing 400016, China. Electronic address: ouyunsheng2001@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>06</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Photodiagnosis Photodyn Ther</MedlineTA>
        <NlmUniqueID>101226123</NlmUniqueID>
        <ISSNLinking>1572-1000</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004952">Esters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="Y">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004952" MajorTopicYN="N">Esters</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012516" MajorTopicYN="Y">Osteosarcoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="Y">Porphyrins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">MPPa-PDT</Keyword>
        <Keyword MajorTopicYN="N">Osteosarcoma</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">YAP</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest All authors declare no commercial or financial conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>19</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35705143</ArticleId>
        <ArticleId IdType="doi">10.1016/j.pdpdt.2022.102964</ArticleId>
        <ArticleId IdType="pii">S1572-1000(22)00250-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35562364</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Which cell death modality wins the contest for photodynamic therapy of cancer?</ArticleTitle>
        <Pagination>
          <StartPage>455</StartPage>
          <MedlinePgn>455</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">455</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-022-04851-4</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) was discovered more than 100 years ago. Since then, many protocols and agents for PDT have been proposed for the treatment of several types of cancer. Traditionally, cell death induced by PDT was categorized into three types: apoptosis, cell death associated with autophagy, and necrosis. However, with the discovery of several other regulated cell death modalities in recent years, it has become clear that this is a rather simple understanding of the mechanisms of action of PDT. New observations revealed that cancer cells exposed to PDT can pass through various non-conventional cell death pathways, such as paraptosis, parthanatos, mitotic catastrophe, pyroptosis, necroptosis, and ferroptosis. Nowadays, immunogenic cell death (ICD) has become one of the most promising ways to eradicate tumor cells by activation of the T-cell adaptive immune response and induction of long-term immunological memory. ICD can be triggered by many anti-cancer treatment methods, including PDT. In this review, we critically discuss recent findings on the non-conventional cell death mechanisms triggered by PDT. Next, we emphasize the role and contribution of ICD in these PDT-induced non-conventional cell death modalities. Finally, we discuss the obstacles and propose several areas of research that will help to overcome these challenges and lead to the development of highly effective anti-cancer therapy based on PDT.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mishchenko</LastName>
            <ForeName>Tatiana</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-4463-5035</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balalaeva</LastName>
            <ForeName>Irina</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-3245-3907</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorokhova</LastName>
            <ForeName>Anastasia</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Vedunova</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Krysko</LastName>
            <ForeName>Dmitri V</ForeName>
            <Initials>DV</Initials>
            <Identifier Source="ORCID">0000-0002-9692-2047</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation. dmitri.krysko@ugent.be.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cell Death Investigation and Therapy Laboratory, Department of Human Structure and Repair, Ghent University, Ghent, Belgium. dmitri.krysko@ugent.be.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Research Institute Ghent, Ghent, Belgium. dmitri.krysko@ugent.be.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. dmitri.krysko@ugent.be.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079527" MajorTopicYN="N">Immunogenic Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>23</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35562364</ArticleId>
        <ArticleId IdType="pmc">PMC9106666</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-022-04851-4</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-022-04851-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Raab O. Uber die Wirkung, fluorescirender Stoe auf infusorien. Z Biol. 1900;39:524&#x2013;46.</Citation>
        </Reference>
        <Reference>
          <Citation>Tappeiner H, Jodlbauer A. &#xdc;ber die Wirkung der photodynamischen (fluorescierenden) Stoe auf Protozoen und Enzyme. Dtsch Arch Klin Med. 1904;39:427&#x2013;87.</Citation>
        </Reference>
        <Reference>
          <Citation>Tappeiner H, Jodlbauer A. Die Sensibilisierende Wirkung fluorieszierender Substanzer. Gesammte Untersuchungen uber die photodynamische Erscheinung. Vogel, Leipzig: F. C. W; 1907.</Citation>
        </Reference>
        <Reference>
          <Citation>Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889&#x2013;905. doi: 10.1093/jnci/90.12.889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/90.12.889</ArticleId>
            <ArticleId IdType="pmc">PMC4592754</ArticleId>
            <ArticleId IdType="pubmed">9637138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci. 2009;24:259&#x2013;68.. doi: 10.1007/s10103-008-0539-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10103-008-0539-1</ArticleId>
            <ArticleId IdType="pubmed">18247081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250&#x2013;81.. doi: 10.3322/caac.20114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.20114</ArticleId>
            <ArticleId IdType="pmc">PMC3209659</ArticleId>
            <ArticleId IdType="pubmed">21617154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo JO, Ha KS. New insights into the mechanisms for photodynamic therapy-induced cancer cell death. Int Rev Cell Mol Biol. 2012;295:139&#x2013;74. doi: 10.1016/B978-0-12-394306-4.00010-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-394306-4.00010-1</ArticleId>
            <ArticleId IdType="pubmed">22449489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther. 2004;1:279&#x2013;93. doi: 10.1016/S1572-1000(05)00007-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1572-1000(05)00007-4</ArticleId>
            <ArticleId IdType="pmc">PMC4108220</ArticleId>
            <ArticleId IdType="pubmed">25048432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwiatkowski S, Knap B, Przystupski D, Saczko J, K&#x119;dzierska E, Knap-Czop K, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098&#x2013;107. doi: 10.1016/j.biopha.2018.07.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.07.049</ArticleId>
            <ArticleId IdType="pubmed">30119176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng H, Zhou Z, Yang W, Lin LS, Wang S, Niu G, et al. Endoplasmic reticulum targeting to amplify immunogenic cell death for cancer immunotherapy. Nano Lett. 2020;20:1928&#x2013;33. doi: 10.1021/acs.nanolett.9b05210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.9b05210</ArticleId>
            <ArticleId IdType="pubmed">32073871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alzeibak R, Mishchenko TA, Shilyagina NY. Balalaeva IV, Vedunova MV, Krysko DV. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer. 2021;9:2020&#x2013;001926. doi: 10.1136/jitc-2020-001926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001926</ArticleId>
            <ArticleId IdType="pmc">PMC7802670</ArticleId>
            <ArticleId IdType="pubmed">33431631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doix B, Trempolec N, Riant O, Feron O. Low photosensitizer dose and early radiotherapy enhance antitumor immune response of photodynamic therapy-based dendritic cell vaccination. Front Oncol. 2019;9:1&#x2013;12. doi: 10.3389/fonc.2019.00811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00811</ArticleId>
            <ArticleId IdType="pmc">PMC6718637</ArticleId>
            <ArticleId IdType="pubmed">31508370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 2008;53:0031&#x2013;9155.. doi: 10.1088/0031-9155/53/12/013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1088/0031-9155/53/12/013</ArticleId>
            <ArticleId IdType="pubmed">18401068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turubanova VD, Balalaeva IV, Mishchenko TA, Catanzaro E, Alzeibak R, Peskova NN, et al. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J Immunother Cancer. 2019;7:019&#x2013;0826. doi: 10.1186/s40425-019-0826-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0826-3</ArticleId>
            <ArticleId IdType="pmc">PMC6916435</ArticleId>
            <ArticleId IdType="pubmed">31842994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turubanova VD, Mishchenko TA, Balalaeva IV, Efimova I, Peskova NN, Klapshina LG, et al. Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death. Sci Rep. 2021;11:021&#x2013;86354. doi: 10.1038/s41598-021-86354-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-86354-4</ArticleId>
            <ArticleId IdType="pmc">PMC8010109</ArticleId>
            <ArticleId IdType="pubmed">33785775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Zhang R, Tao C, Huang X, Chen Z, Li X, et al. CuS-NiS(2) nanomaterials for MRI guided phototherapy of gastric carcinoma via triggering mitochondria-mediated apoptosis and MLKL/CAPG-mediated necroptosis. Nanotoxicology. 2020;14:774&#x2013;87.. doi: 10.1080/17435390.2020.1759727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17435390.2020.1759727</ArticleId>
            <ArticleId IdType="pubmed">32401088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Han Z, Chen Y, Qi F, Fang H, Guo Z, et al. Ferroptosis photoinduced by new cyclometalated Iridium(III) Complexes and its synergism with apoptosis in tumor cell inhibition. Angew Chem Int Ed Engl. 2021;60:8174&#x2013;81. doi: 10.1002/anie.202014959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.202014959</ArticleId>
            <ArticleId IdType="pubmed">33656228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starnes CO. Coley&#x2019;s toxins in perspective. Nature. 1992;357:11&#x2013;2. doi: 10.1038/357011a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/357011a0</ArticleId>
            <ArticleId IdType="pubmed">1574121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiemann B, Starnes CO. Coley&#x2019;s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharm Ther. 1994;64:529&#x2013;64. doi: 10.1016/0163-7258(94)90023-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0163-7258(94)90023-X</ArticleId>
            <ArticleId IdType="pubmed">7724661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991&#x2013;1045. doi: 10.1146/annurev.iy.12.040194.005015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.iy.12.040194.005015</ArticleId>
            <ArticleId IdType="pubmed">8011301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301&#x2013;5. doi: 10.1126/science.1071059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1071059</ArticleId>
            <ArticleId IdType="pubmed">11951032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691&#x2013;701. doi: 10.1084/jem.20050915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050915</ArticleId>
            <ArticleId IdType="pmc">PMC2212968</ArticleId>
            <ArticleId IdType="pubmed">16365148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology. 2012;1:786&#x2013;8. doi: 10.4161/onci.19750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/onci.19750</ArticleId>
            <ArticleId IdType="pmc">PMC3429595</ArticleId>
            <ArticleId IdType="pubmed">22934283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. Embo J. 2012;31:1055&#x2013;7. doi: 10.1038/emboj.2012.2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2012.2</ArticleId>
            <ArticleId IdType="pmc">PMC3298006</ArticleId>
            <ArticleId IdType="pubmed">22252132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6:535&#x2013;45. doi: 10.1038/nrc1894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1894</ArticleId>
            <ArticleId IdType="pmc">PMC2933780</ArticleId>
            <ArticleId IdType="pubmed">16794636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860&#x2013;75. doi: 10.1038/nrc3380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3380</ArticleId>
            <ArticleId IdType="pubmed">23151605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krysko O, L&#xf8;ve Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4:156. doi: 10.1038/cddis.2013.156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2013.156</ArticleId>
            <ArticleId IdType="pmc">PMC3674363</ArticleId>
            <ArticleId IdType="pubmed">23681226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, et al. Molecular and translational classifications of DAMPs in Immunogenic Cell Death. Front Immunol. 2015;6:1&#x2013;24. doi: 10.3389/fimmu.2015.00588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2015.00588</ArticleId>
            <ArticleId IdType="pmc">PMC4653610</ArticleId>
            <ArticleId IdType="pubmed">26635802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:2019&#x2013;000337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7064135</ArticleId>
            <ArticleId IdType="pubmed">32209603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaes TL, Verschuere H, Kaczmarek A, Heyndrickx L, Wiernicki B, Delrue I, et al. Immunodominant AH1 antigen-deficient necroptotic, but not apoptotic, murine cancer cells induce antitumor protection. J Immunol. 2020;204:775&#x2013;87.. doi: 10.4049/jimmunol.1900072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1900072</ArticleId>
            <ArticleId IdType="pubmed">31900335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S, et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells. 2020;9(8).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7464343</ArticleId>
            <ArticleId IdType="pubmed">32752206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8:2020&#x2013;001369. doi: 10.1136/jitc-2020-001369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001369</ArticleId>
            <ArticleId IdType="pmc">PMC7668384</ArticleId>
            <ArticleId IdType="pubmed">33188036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X, Deng J, Liu F, Guo T, Liu M, Dai P, et al. Triggered all-active metal organic framework: ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett. 2019;19:7866&#x2013;76.. doi: 10.1021/acs.nanolett.9b02904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.9b02904</ArticleId>
            <ArticleId IdType="pubmed">31594301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soriano J, Mora-Esp&#xed; I, Alea-Reyes ME, P&#xe9;rez-Garc&#xed;a L, Barrios L, Ib&#xe1;&#xf1;ez E, et al. Cell death mechanisms in tumoral and non-tumoral human cell lines triggered by photodynamic treatments: apoptosis, necrosis and parthanatos. Sci Rep. 2017;7:1&#x2013;13. doi: 10.1038/srep41340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep41340</ArticleId>
            <ArticleId IdType="pmc">PMC5256096</ArticleId>
            <ArticleId IdType="pubmed">28112275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D. Paraptosis and photodynamic therapy: a progress report. Photochem Photobiol. 2020;96:1096&#x2013;100.. doi: 10.1111/php.13242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13242</ArticleId>
            <ArticleId IdType="pmc">PMC7483607</ArticleId>
            <ArticleId IdType="pubmed">32112410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability: Nat Rev Mol Cell Biol. 2011;12:385-92. 10.1038/nrm3115. Epub 2011 Apr 29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21527953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825&#x2013;37. doi: 10.1038/sj.onc.1207528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1207528</ArticleId>
            <ArticleId IdType="pubmed">15077146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486&#x2013;541. doi: 10.1038/s41418-017-0012-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0012-4</ArticleId>
            <ArticleId IdType="pmc">PMC5864239</ArticleId>
            <ArticleId IdType="pubmed">29362479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragkos M, Beard P. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS One. 2011;6:10. doi: 10.1371/journal.pone.0022946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0022946</ArticleId>
            <ArticleId IdType="pmc">PMC3154265</ArticleId>
            <ArticleId IdType="pubmed">21853057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613&#x2013;22.. doi: 10.1038/sj.onc.1205353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1205353</ArticleId>
            <ArticleId IdType="pubmed">11965534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adjemian S, Oltean T, Martens S, Wiernicki B, Goossens V, Vanden Berghe T, et al. Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death. Cell Death Dis. 2020;11:020&#x2013;03209.. doi: 10.1038/s41419-020-03209-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03209-y</ArticleId>
            <ArticleId IdType="pmc">PMC7684309</ArticleId>
            <ArticleId IdType="pubmed">33230108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakahata K, Miyakoda M, Suzuki K, Kodama S, Watanabe M. Heat shock induces centrosomal dysfunction, and causes non-apoptotic mitotic catastrophe in human tumour cells. Int J Hyperth. 2002;18:332&#x2013;43. doi: 10.1080/02656730210129736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/02656730210129736</ArticleId>
            <ArticleId IdType="pubmed">12079588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis. 2012;3:148. doi: 10.1038/cddis.2012.148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2012.148</ArticleId>
            <ArticleId IdType="pmc">PMC3481136</ArticleId>
            <ArticleId IdType="pubmed">23076219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, et al. Targeting the actin cytoskeleton: selective antitumor action via trapping PKC&#x25b;. Cell Death Dis. 2014;5:363. doi: 10.1038/cddis.2014.363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.363</ArticleId>
            <ArticleId IdType="pmc">PMC4454332</ArticleId>
            <ArticleId IdType="pubmed">25165884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA. 1993;90:9552&#x2013;6. doi: 10.1073/pnas.90.20.9552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.90.20.9552</ArticleId>
            <ArticleId IdType="pmc">PMC47607</ArticleId>
            <ArticleId IdType="pubmed">8105478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humeau J, Bezu L, Kepp O, Senovilla L, Liu P, Kroemer G. Quantification of eIF2&#x3b1; phosphorylation associated with mitotic catastrophe by immunofluorescence microscopy. Methods Mol Biol. 2021:1217-0_15:217-26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33786795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bezu L, Kepp O, Kroemer G. Calreticulin exposure in mitotic catastrophe. Methods Mol Biol. 2021:1217-0_14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33786794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cenklov&#xe1; V. Photodynamic therapy with TMPyP&#x2013;Porphyrine induces mitotic catastrophe and microtubule disorganization in HeLa and G361 cells, a comprehensive view of the action of the photosensitizer. J Photochem Photobio B. 2017;173:522&#x2013;37. doi: 10.1016/j.jphotobiol.2017.06.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2017.06.029</ArticleId>
            <ArticleId IdType="pubmed">28686960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cs&#xed;k G, Egyeki M, Her&#xe9;nyi L, Majer Z, T&#xf3;th K. Role of structure-proteins in the porphyrin-DNA interaction. J Photochem Photobio B. 2009;96:207&#x2013;15. doi: 10.1016/j.jphotobiol.2009.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2009.06.008</ArticleId>
            <ArticleId IdType="pubmed">19604705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara N, Mazzola M, Cai E, Wang M, Cave JW. TMPyP4, a stabilizer of nucleic acid secondary structure, is a novel acetylcholinesterase inhibitor. PLoS ONE. 2015;10:1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4581631</ArticleId>
            <ArticleId IdType="pubmed">26402367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pizova K, Bajgar R, Fillerova R, Kriegova E, Cenklova V, Langova K, et al. C-MYC and C-FOS expression changes and cellular aspects of the photodynamic reaction with photosensitizers TMPyP and ClAlPcS2. J Photochem Photobio B. 2015;142:186&#x2013;96. doi: 10.1016/j.jphotobiol.2014.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2014.12.003</ArticleId>
            <ArticleId IdType="pubmed">25545333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juarranz A, Espada J, Stockert JC, Villanueva A, Polo S, Dom&#xed;nguez V, et al. Photodamage induced by Zinc(II)-phthalocyanine to microtubules, actin, alpha-actinin and keratin of HeLa cells. Photochem Photobiol. 2001;73:283&#x2013;9. doi: 10.1562/0031-8655(2001)0730283PIBZIP2.0.CO2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1562/0031-8655(2001)0730283PIBZIP2.0.CO2</ArticleId>
            <ArticleId IdType="pubmed">11281025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vantieghem A, Xu Y, Assefa Z, Piette J, Vandenheede JR, Merlevede W, et al. Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem. 2002;277:37718&#x2013;31. doi: 10.1074/jbc.M204348200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M204348200</ArticleId>
            <ArticleId IdType="pubmed">12101183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura M, Yoshioka T, Saio M, Banno Y, Nagaoka H, Okano Y. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis. 2013;4:108. doi: 10.1038/cddis.2013.108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2013.108</ArticleId>
            <ArticleId IdType="pmc">PMC3641331</ArticleId>
            <ArticleId IdType="pubmed">23598415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mascaraque M, Delgado-Wicke P, Damian A, Lucena SR, Carrasco E, Juarranz &#xc1;. Mitotic catastrophe induced in HeLa tumor cells by photodynamic therapy with methyl-aminolevulinate. Int J Mol Sci. 2019;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429057</ArticleId>
            <ArticleId IdType="pubmed">30862116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung SH, Park JY, Yoo JO, Shin I, Kim YM, Ha KS. Identification and ultrastructural imaging of photodynamic therapy-induced microfilaments by atomic force microscopy. Ultramicroscopy. 2009;109:1428&#x2013;34. doi: 10.1016/j.ultramic.2009.07.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ultramic.2009.07.009</ArticleId>
            <ArticleId IdType="pubmed">19665305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhang HM, Yin HJ, Wei MQ, Sha H, Liu TJ, et al. Combination of a novel photosensitizer DTPP with 650 nm laser results in efficient apoptosis, arresting cell cycle and cytoskeleton protein changes in lung cancer A549 cells. Lasers Med Sci. 2015;30:77&#x2013;82. doi: 10.1007/s10103-014-1617-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10103-014-1617-1</ArticleId>
            <ArticleId IdType="pubmed">24964751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinhusen U, Badock V, Bauer A, Behrens J, Wittman-Liebold B, D&#xf6;rken B, et al. Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem. 2000;275:16345&#x2013;53. doi: 10.1074/jbc.M001458200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M001458200</ArticleId>
            <ArticleId IdType="pubmed">10748026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erenpreisa J, Cragg MS. Mitotic death: a mechanism of survival? A review. Cancer Cell Int. 2001;1:1475&#x2013;2867.. doi: 10.1186/1475-2867-1-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1475-2867-1-1</ArticleId>
            <ArticleId IdType="pmc">PMC101225</ArticleId>
            <ArticleId IdType="pubmed">11983025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casas A, Di Venosa G, Hasan T, Al B. Mechanisms of resistance to photodynamic therapy. Curr Med Chem. 2011;18:2486&#x2013;515. doi: 10.2174/092986711795843272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/092986711795843272</ArticleId>
            <ArticleId IdType="pmc">PMC3780570</ArticleId>
            <ArticleId IdType="pubmed">21568910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panzarini E, Tenuzzo B, Dini L. Photodynamic therapy-induced apoptosis of HeLa cells. Ann N Y Acad Sci. 2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19723112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Venosa G, Perotti C, Batlle A, Casas A. The role of cytoskeleton and adhesion proteins in the resistance to photodynamic therapy. Possible therapeutic interventions. Photochem Photobiol Sci. 2015;14:1451&#x2013;64.. doi: 10.1039/C4PP00445K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C4PP00445K</ArticleId>
            <ArticleId IdType="pubmed">25832889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA. 2000;97:14376&#x2013;81.. doi: 10.1073/pnas.97.26.14376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.97.26.14376</ArticleId>
            <ArticleId IdType="pmc">PMC18926</ArticleId>
            <ArticleId IdType="pubmed">11121041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontana F, Raimondi M, Marzagalli M, Di Domizio A, Limonta P. The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochim Biophys Acta Rev Cancer. 2020;2:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31904399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sperandio S, Poksay K, de Belle I, Lafuente MJ, Liu B, Nasir J, et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ. 2004;11:1066&#x2013;75. doi: 10.1038/sj.cdd.4401465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401465</ArticleId>
            <ArticleId IdType="pubmed">15195070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D, Cho WJ, Rakowski J, Kim HE, Kim HC. Effects of HPV status on responsiveness to ionizing radiation vs photodynamic therapy in head and neck cancer cell lines. Photochem Photobiol. 2020;96:652&#x2013;7. doi: 10.1111/php.13150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13150</ArticleId>
            <ArticleId IdType="pmc">PMC7015759</ArticleId>
            <ArticleId IdType="pubmed">31408910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D. Apoptosis, paraptosis and autophagy: death and survival pathways associated with photodynamic therapy. Photochem Photobiol. 2019;95:119&#x2013;25. doi: 10.1111/php.12952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.12952</ArticleId>
            <ArticleId IdType="pmc">PMC6286706</ArticleId>
            <ArticleId IdType="pubmed">29882356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D. Exploring modes of photokilling by hypericin. Photochem Photobiol. 2020;96:1101&#x2013;4. doi: 10.1111/php.13275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13275</ArticleId>
            <ArticleId IdType="pubmed">32343412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D. Hypericin accumulation as a determinant of PDT efficacy. Photochem Photobiol. 2020;96:1144&#x2013;7. doi: 10.1111/php.13302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13302</ArticleId>
            <ArticleId IdType="pubmed">32599667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D, Reiners JJ., Jr Effects of combined lysosomal and mitochondrial photodamage in a non-small-cell lung cancer cell line: the role of paraptosis. Photochem Photobiol. 2017;93:1502&#x2013;8. doi: 10.1111/php.12805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.12805</ArticleId>
            <ArticleId IdType="pmc">PMC5693656</ArticleId>
            <ArticleId IdType="pubmed">28696570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi I, Obaid G, Bano S, Hasan T, Kessel D. Photodynamic therapy: promoting in vitro efficacy of photodynamic therapy by liposomal formulations of a photosensitizing agent. Lasers Surg Med. 2018;50:499&#x2013;505. doi: 10.1002/lsm.22813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lsm.22813</ArticleId>
            <ArticleId IdType="pmc">PMC7449601</ArticleId>
            <ArticleId IdType="pubmed">29527710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho WJ, Kessel D, Rakowski J, Loughery B, Najy AJ, Pham T, et al. Photodynamic therapy as a potent radiosensitizer in head and neck squamous cell carcinoma. Cancers. 2021;13:1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7998908</ArticleId>
            <ArticleId IdType="pubmed">33801879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D. Paraptosis after ER photodamage initiated by m-tetra(hydroxyphenyl) Chlorin. Photochem Photobiol. 2021;97:1097&#x2013;100.. doi: 10.1111/php.13438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13438</ArticleId>
            <ArticleId IdType="pubmed">33934367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierroz V, Rubbiani R, Gentili C, Patra M, Mari C, Gasser G, et al. Dual mode of cell death upon the photo-irradiation of a Ru(II) polypyridyl complex in interphase or mitosis. Chem Sci. 2016;7:6115&#x2013;24.. doi: 10.1039/C6SC00387G.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C6SC00387G</ArticleId>
            <ArticleId IdType="pmc">PMC5032677</ArticleId>
            <ArticleId IdType="pubmed">27708751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo MJ, Lee DM, Kim IY, Lee D, Choi MK, Lee JY, et al. Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis. Cell Death Dis. 2019;10:019&#x2013;1360. doi: 10.1038/s41419-018-1261-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-1261-y</ArticleId>
            <ArticleId IdType="pmc">PMC6385239</ArticleId>
            <ArticleId IdType="pubmed">30796201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han L, Wang Y, Huang X, Liu F, Ma C, Feng F, et al. Specific-oxygen-supply functionalized core-shell nanoparticles for smart mutual-promotion between photodynamic therapy and gambogic acid-induced chemotherapy. Biomaterials. 2020;257:10. doi: 10.1016/j.biomaterials.2020.120228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2020.120228</ArticleId>
            <ArticleId IdType="pubmed">32736257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19:405&#x2013;14. doi: 10.1038/s41568-019-0149-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0149-1</ArticleId>
            <ArticleId IdType="pubmed">31101865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishchenko TA, Balalaeva IV, Vedunova MV, Krysko DV. Ferroptosis and photodynamic therapy synergism: enhancing anticancer treatment. Trends Cancer. 2021;7:484&#x2013;7. doi: 10.1016/j.trecan.2021.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2021.01.013</ArticleId>
            <ArticleId IdType="pubmed">33640304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoa N, Myers MP, Douglass TG, Zhang JG, Delgado C, Driggers L, et al. Molecular mechanisms of paraptosis induction: implications for a non-genetically modified tumor vaccine. PLoS ONE. 2009;4:27. doi: 10.1371/journal.pone.0004631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0004631</ArticleId>
            <ArticleId IdType="pmc">PMC2645013</ArticleId>
            <ArticleId IdType="pubmed">19247476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessel D. Pathways to paraptosis after ER photodamage in OVCAR-5 cells. Photochem Photobiol. 2019;95:1239&#x2013;42. doi: 10.1111/php.13103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13103</ArticleId>
            <ArticleId IdType="pubmed">30924537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature. 1992;358:167&#x2013;9. doi: 10.1038/358167a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/358167a0</ArticleId>
            <ArticleId IdType="pubmed">1614548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boise LH, Collins CM. Salmonella-induced cell death: apoptosis, necrosis or programmed cell death? Trends Microbiol. 2001;9:64&#x2013;7. doi: 10.1016/S0966-842X(00)01937-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0966-842X(00)01937-5</ArticleId>
            <ArticleId IdType="pubmed">11173244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99&#x2013;109. doi: 10.1038/nrmicro2070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro2070</ArticleId>
            <ArticleId IdType="pmc">PMC2910423</ArticleId>
            <ArticleId IdType="pubmed">19148178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:9. doi: 10.1016/j.biopha.2019.109595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2019.109595</ArticleId>
            <ArticleId IdType="pubmed">31710896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cookson BT, Brennan MA. Pro-Inflamm Program cell death: Trends Microbiol. 2001;9(Mar):113&#x2013;4. doi: 10.1016/s0966-842x(00)01936-3..</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0966-842x(00)01936-3.</ArticleId>
            <ArticleId IdType="pubmed">11303500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol. 2015;25:308&#x2013;15. doi: 10.1016/j.tcb.2014.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2014.12.009</ArticleId>
            <ArticleId IdType="pmc">PMC4409512</ArticleId>
            <ArticleId IdType="pubmed">25639489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao EA, Mao DP, Yudkovsky N, Bonneau R, Lorang CG, Warren SE, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci USA. 2010;107:3076&#x2013;80. doi: 10.1073/pnas.0913087107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0913087107</ArticleId>
            <ArticleId IdType="pmc">PMC2840275</ArticleId>
            <ArticleId IdType="pubmed">20133635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514&#x2013;8. doi: 10.1038/nature07725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07725</ArticleId>
            <ArticleId IdType="pmc">PMC2726264</ArticleId>
            <ArticleId IdType="pubmed">19158675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11:395&#x2013;402. doi: 10.1038/ni.1864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1864</ArticleId>
            <ArticleId IdType="pmc">PMC2887480</ArticleId>
            <ArticleId IdType="pubmed">20351692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. Eur J Immunol. 2018;48:230&#x2013;8. doi: 10.1002/eji.201746947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201746947</ArticleId>
            <ArticleId IdType="pubmed">29148036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med. 2018;215:827&#x2013;40. doi: 10.1084/jem.20172222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20172222</ArticleId>
            <ArticleId IdType="pmc">PMC5839769</ArticleId>
            <ArticleId IdType="pubmed">29432122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153&#x2013;8. doi: 10.1038/nature18629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature18629</ArticleId>
            <ArticleId IdType="pmc">PMC5539988</ArticleId>
            <ArticleId IdType="pubmed">27383986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660&#x2013;5. doi: 10.1038/nature15514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15514</ArticleId>
            <ArticleId IdType="pubmed">26375003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8:1812&#x2013;25. doi: 10.1111/j.1462-5822.2006.00751.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1462-5822.2006.00751.x</ArticleId>
            <ArticleId IdType="pubmed">16824040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayagaki N, Stowe IB, Lee BL, O&#x2019;Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526:666&#x2013;71. doi: 10.1038/nature15541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15541</ArticleId>
            <ArticleId IdType="pubmed">26375259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99&#x2013;103. doi: 10.1038/nature22393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22393</ArticleId>
            <ArticleId IdType="pubmed">28459430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J, et al. The role of pyroptosis in cancer: pro-cancer or pro-&#x201c;host&#x201d;? Cell Death Dis. 2019;10:019&#x2013;1883. doi: 10.1038/s41419-018-1261-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-1261-y</ArticleId>
            <ArticleId IdType="pmc">PMC6733901</ArticleId>
            <ArticleId IdType="pubmed">31501419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA. 2010;107:21635&#x2013;40. doi: 10.1073/pnas.1016814108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1016814108</ArticleId>
            <ArticleId IdType="pmc">PMC3003083</ArticleId>
            <ArticleId IdType="pubmed">21118981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 2012;314:24&#x2013;33. doi: 10.1016/j.canlet.2011.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2011.10.001</ArticleId>
            <ArticleId IdType="pubmed">22050907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis. 2019;24:312&#x2013;25. doi: 10.1007/s10495-019-01515-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-019-01515-1</ArticleId>
            <ArticleId IdType="pubmed">30710195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Liu W, Ning J, Wang J, Lang Y, Jin X, et al. Simvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis. Int J Biol Sci. 2018;14:406&#x2013;17. doi: 10.7150/ijbs.23542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.23542</ArticleId>
            <ArticleId IdType="pmc">PMC5930473</ArticleId>
            <ArticleId IdType="pubmed">29725262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10:254&#x2013;69. doi: 10.1158/2159-8290.CD-19-0672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0672</ArticleId>
            <ArticleId IdType="pmc">PMC7007378</ArticleId>
            <ArticleId IdType="pubmed">31796433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pizato N, Luzete BC, Kiffer L, Corr&#xea;a LH, de Oliveira Santos I, Assump&#xe7;&#xe3;o JAF, et al. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Sci Rep. 2018;8:018&#x2013;20422. doi: 10.1038/s41598-017-18535-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-18535-z</ArticleId>
            <ArticleId IdType="pmc">PMC5792438</ArticleId>
            <ArticleId IdType="pubmed">29386662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang D, He Y, Mu&#xf1;oz-Planillo R, Liu Q, N&#xfa;&#xf1;ez G. Caspase-11 requires the Pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity. 2015;43:923&#x2013;32. doi: 10.1016/j.immuni.2015.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.10.009</ArticleId>
            <ArticleId IdType="pmc">PMC4795157</ArticleId>
            <ArticleId IdType="pubmed">26572062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vasconcelos NM, Van Opdenbosch N, Van Gorp H, Parthoens E, Lamkanfi M. Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. Cell Death Differ. 2019;26:146&#x2013;61. doi: 10.1038/s41418-018-0106-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0106-7</ArticleId>
            <ArticleId IdType="pmc">PMC6294780</ArticleId>
            <ArticleId IdType="pubmed">29666477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng QZ, Yang F, Li CG, Xu LH, He XH, Mai FY, et al. Paclitaxel Enhances the Innate Immunity by Promoting NLRP3 Inflammasome Activation in Macrophages. Front Immunol. 2019;10:1&#x2013;17. doi: 10.3389/fimmu.2019.00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00001</ArticleId>
            <ArticleId IdType="pmc">PMC6361797</ArticleId>
            <ArticleId IdType="pubmed">30761140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, et al. The adaptor ASC has extracellular and &#x2018;prionoid&#x2019; activities that propagate inflammation. Nat Immunol. 2014;15:727&#x2013;37. doi: 10.1038/ni.2913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2913</ArticleId>
            <ArticleId IdType="pmc">PMC4116676</ArticleId>
            <ArticleId IdType="pubmed">24952505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baroja-Mazo A, Mart&#xed;n-S&#xe1;nchez F, Gomez AI, Mart&#xed;nez CM, Amores-Iniesta J, Compan V, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15:738&#x2013;48. doi: 10.1038/ni.2919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2919</ArticleId>
            <ArticleId IdType="pubmed">24952504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhen W, Wang Y, Song S, Zhang H. Na(2)S(2)O(8) nanoparticles trigger antitumor immunotherapy through reactive oxygen species storm and surge of tumor osmolarity. J Am Chem Soc. 2020;142:21751&#x2013;7. doi: 10.1021/jacs.0c09482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.0c09482</ArticleId>
            <ArticleId IdType="pubmed">33337859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M, Liu X, Chen H, Duan Y, Liu J, Pan Y, et al. Activation of pyroptosis by membrane-anchoring AIE photosensitizer design: new prospect for photodynamic cancer cell ablation. Angew Chem Int Ed Engl. 2021;60:9093&#x2013;8. doi: 10.1002/anie.202016399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.202016399</ArticleId>
            <ArticleId IdType="pubmed">33543534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu JX, Zhu WT, Hu JH, Yang W, Liu P, Liu QH, et al. Curcumin-loaded Poly(L-lactide-co-glycolide) microbubble-mediated sono-photodynamic therapy in liver cancer cells. Ultrasound Med Biol. 2020;46:2030&#x2013;43. doi: 10.1016/j.ultrasmedbio.2020.03.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ultrasmedbio.2020.03.030</ArticleId>
            <ArticleId IdType="pubmed">32475714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Song D, Qi L, Jiang M, Wu Y, Gan J, et al. Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis. Cancer Lett. 2021;520:143&#x2013;59. doi: 10.1016/j.canlet.2021.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2021.07.014</ArticleId>
            <ArticleId IdType="pubmed">34256094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. Cell Res. 2018;28:1171&#x2013;85. doi: 10.1038/s41422-018-0090-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-018-0090-y</ArticleId>
            <ArticleId IdType="pmc">PMC6274649</ArticleId>
            <ArticleId IdType="pubmed">30287942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie S, Wang X, Wang H. NLRP3 inflammasome mediated Interleukin-1&#x3b2; production in cancer-associated fibroblast contributes to ALA-PDT for cutaneous squamous cell carcinoma. Cancer Manag Res. 2019;11:10257&#x2013;67. doi: 10.2147/CMAR.S226356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S226356</ArticleId>
            <ArticleId IdType="pmc">PMC6912005</ArticleId>
            <ArticleId IdType="pubmed">31849516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004;64:2120&#x2013;6. doi: 10.1158/0008-5472.CAN-03-3513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-3513</ArticleId>
            <ArticleId IdType="pubmed">15026352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci. 2009;14:1116&#x2013;28. doi: 10.2741/3297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/3297</ArticleId>
            <ArticleId IdType="pmc">PMC4450718</ArticleId>
            <ArticleId IdType="pubmed">19273119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Li C, Qiao P, Xue Y, Zheng X, Chen H, et al. OGG1-initiated base excision repair exacerbates oxidative stress-induced parthanatos. Cell Death Dis. 2018;9:018&#x2013;0680. doi: 10.1038/s41419-017-0036-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-017-0036-1</ArticleId>
            <ArticleId IdType="pmc">PMC5967321</ArticleId>
            <ArticleId IdType="pubmed">29795387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu LY, Ho FM, Shiah SG, Chang Y, Lin WW. Oxidative stress initiates DNA damager MNNG-induced poly(ADP-ribose)polymerase-1-dependent parthanatos cell death. Biochem Pharmacol. 2011;81:459&#x2013;70. doi: 10.1016/j.bcp.2010.10.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2010.10.016</ArticleId>
            <ArticleId IdType="pubmed">21056551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonskaya I, Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL, Soldatenkov VA. Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding. J Biol Chem. 2005;280:17076&#x2013;83. doi: 10.1074/jbc.M413483200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M413483200</ArticleId>
            <ArticleId IdType="pubmed">15737996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, An R, Umanah GK, Park H, Nambiar K, Eacker SM, et al. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science. 2016;354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5134926</ArticleId>
            <ArticleId IdType="pubmed">27846469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol. 2014;171:2000&#x2013;16. doi: 10.1111/bph.12416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.12416</ArticleId>
            <ArticleId IdType="pmc">PMC3976618</ArticleId>
            <ArticleId IdType="pubmed">24684389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos) Sci Signal. 2011;4:2000902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3086524</ArticleId>
            <ArticleId IdType="pubmed">21467298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci. 2008;1147:233&#x2013;41. doi: 10.1196/annals.1427.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1427.014</ArticleId>
            <ArticleId IdType="pmc">PMC4454457</ArticleId>
            <ArticleId IdType="pubmed">19076445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu W, Ge R, Zhu F, Li D, Liang R, Ge J, et al. PARP-1 inhibitor-AG14361 suppresses acute allograft rejection via stabilizing CD4+FoxP3+ regulatory T cells. Pathol Res Pract. 2020;216:21. doi: 10.1016/j.prp.2020.153021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.prp.2020.153021</ArticleId>
            <ArticleId IdType="pubmed">32703489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Asp Med. 2013;34:1217&#x2013;56. doi: 10.1016/j.mam.2013.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2013.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC3657315</ArticleId>
            <ArticleId IdType="pubmed">23370117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eltze T, Boer R, Wagner T, Weinbrenner S, McDonald MC, Thiemermann C, et al. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol. 2008;74:1587&#x2013;98. doi: 10.1124/mol.108.048751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.108.048751</ArticleId>
            <ArticleId IdType="pubmed">18809672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Liu L, Tao S, Yao Y, Wang Y, Wei Q, et al. Parthanatos and its associated components: promising therapeutic targets for cancer. Pharm Res. 2021;163:7. doi: 10.1016/j.phrs.2020.105299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2020.105299</ArticleId>
            <ArticleId IdType="pubmed">33171306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112&#x2013;9. doi: 10.1038/nchembio711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio711</ArticleId>
            <ArticleId IdType="pubmed">16408008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno-Gonzalez G, Vandenabeele P, Krysko DV. Necroptosis: a novel cell death modality and its potential relevance for critical care medicine. Am J Respir Crit Care Med. 2016;194:415&#x2013;28. doi: 10.1164/rccm.201510-2106CI.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201510-2106CI</ArticleId>
            <ArticleId IdType="pubmed">27285640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347&#x2013;64. doi: 10.1038/s41422-019-0164-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-019-0164-5</ArticleId>
            <ArticleId IdType="pmc">PMC6796845</ArticleId>
            <ArticleId IdType="pubmed">30948788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Meeren L, Verduijn J, Krysko DV, Skirtach AG. AFM analysis enables differentiation between apoptosis, necroptosis, and ferroptosis in murine cancer cells. iScience. 2020;23:18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7702191</ArticleId>
            <ArticleId IdType="pubmed">33299979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newton K, Manning G. Necroptosis and inflammation. Annu Rev Biochem. 2016;85:743&#x2013;63. doi: 10.1146/annurev-biochem-060815-014830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-060815-014830</ArticleId>
            <ArticleId IdType="pubmed">26865533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209&#x2013;23. doi: 10.1016/j.immuni.2013.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.02.003</ArticleId>
            <ArticleId IdType="pubmed">23438821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 2016;15:274&#x2013;87. doi: 10.1016/j.celrep.2016.03.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.03.037</ArticleId>
            <ArticleId IdType="pubmed">27050509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C. CRIPK1 and NF-&#x3ba;B signaling in dying cells determines cross-priming of CD8+ T cells. Science. 2015;350:328&#x2013;34. doi: 10.1126/science.aad0395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad0395</ArticleId>
            <ArticleId IdType="pmc">PMC4651449</ArticleId>
            <ArticleId IdType="pubmed">26405229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin X, Ma D, Tan YX, Wang HY, Cai Z. The role of necroptosis in cancer: a double-edged sword? Biochim Biophys Acta Rev Cancer. 2019;2:259&#x2013;66. doi: 10.1016/j.bbcan.2019.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbcan.2019.01.006</ArticleId>
            <ArticleId IdType="pubmed">30716362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duprez L, Takahashi N, Van Hauwermeiren F, Vandendriessche B, Goossens V, Vanden Berghe T, et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity. 2011;35:908&#x2013;18. doi: 10.1016/j.immuni.2011.09.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.09.020</ArticleId>
            <ArticleId IdType="pubmed">22195746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA. 2010;107:2574&#x2013;9. doi: 10.1073/pnas.0915018107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0915018107</ArticleId>
            <ArticleId IdType="pmc">PMC2823886</ArticleId>
            <ArticleId IdType="pubmed">20133797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coupienne I, Fettweis G, Rubio N, Agostinis P, Piette J. 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochem Photobio Sci. 2011;10:1868&#x2013;78. doi: 10.1039/c1pp05213f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c1pp05213f</ArticleId>
            <ArticleId IdType="pubmed">22033613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun M, Zhou C, Zeng H, Puebla-Osorio N, Damiani E, Chen J, et al. Hiporfin-mediated photodynamic therapy in preclinical treatment of osteosarcoma. Photochem Photobiol. 2015;91:533&#x2013;44. doi: 10.1111/php.12424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.12424</ArticleId>
            <ArticleId IdType="pubmed">25619546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki Y, Akimoto J, Moritake K, Hironaka C, Fujiwara Y. Photodynamic therapy using talaporfin sodium induces concentration-dependent programmed necroptosis in human glioblastoma T98G cells. Lasers Med Sci. 2015;30:1739&#x2013;45. doi: 10.1007/s10103-015-1783-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10103-015-1783-9</ArticleId>
            <ArticleId IdType="pubmed">26109138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammadalipour Z, Rahmati M, Khataee A, Moosavi MA. Differential effects of N-TiO(2) nanoparticle and its photo-activated form on autophagy and necroptosis in human melanoma A375 cells. J Cell Physiol. 2020;235:8246&#x2013;59. doi: 10.1002/jcp.29479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.29479</ArticleId>
            <ArticleId IdType="pubmed">31989650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Cheung YK, Ng DKP, Fong WP. Immunogenic necroptosis in the anti-tumor photodynamic action of BAM-SiPc, a silicon(IV) phthalocyanine-based photosensitizer. Cancer Immunol Immunother. 2021;70:485&#x2013;95. doi: 10.1007/s00262-020-02700-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-020-02700-x</ArticleId>
            <ArticleId IdType="pubmed">32839829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Ng DKP, Fong WP. Antitumor immunity induced by the photodynamic action of BAM-SiPc, a silicon (IV) phthalocyanine photosensitize. Cell Mol Immunol. 2019;16:676&#x2013;8. doi: 10.1038/s41423-019-0239-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-019-0239-8</ArticleId>
            <ArticleId IdType="pmc">PMC6804861</ArticleId>
            <ArticleId IdType="pubmed">31076728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung HY, Lo PC, Ng DK, Fong WP. Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model. Cell Mol Immunol. 2017;14:223&#x2013;34. doi: 10.1038/cmi.2015.84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cmi.2015.84</ArticleId>
            <ArticleId IdType="pmc">PMC5301155</ArticleId>
            <ArticleId IdType="pubmed">26388236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Wang X, Zhao B, Zhang R, Xie Z, He Y, et al. CuS-MnS(2) nano-flowers for magnetic resonance imaging guided photothermal/photodynamic therapy of ovarian cancer through necroptosis. Nanoscale. 2019;11:12983&#x2013;9. doi: 10.1039/C9NR03114F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9NR03114F</ArticleId>
            <ArticleId IdType="pubmed">31264665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med. 2019;133:130&#x2013;43. doi: 10.1016/j.freeradbiomed.2018.09.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.09.043</ArticleId>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234&#x2013;45. doi: 10.1016/j.chembiol.2008.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2008.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;8. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285&#x2013;96. doi: 10.1016/S1535-6108(03)00050-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00050-3</ArticleId>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:020&#x2013;2298. doi: 10.1038/s41419-019-2210-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2210-0</ArticleId>
            <ArticleId IdType="pmc">PMC6997353</ArticleId>
            <ArticleId IdType="pubmed">32015325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol. 2020;30:478&#x2013;90. doi: 10.1016/j.tcb.2020.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2020.02.009</ArticleId>
            <ArticleId IdType="pmc">PMC7230071</ArticleId>
            <ArticleId IdType="pubmed">32413317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#x2019;Herde K, Krysko DV. Ferroptosis: oxidized PEs trigger death. Nat Chem Biol. 2017;13:4&#x2013;5. doi: 10.1038/nchembio.2261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2261</ArticleId>
            <ArticleId IdType="pubmed">27842067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10:019&#x2013;09277. doi: 10.1038/s41467-018-07905-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07905-4</ArticleId>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016;12:497&#x2013;503. doi: 10.1038/nchembio.2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2079</ArticleId>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrams RP, Carroll WL, Woerpel KA. Five-membered ring peroxide selectively initiates ferroptosis in cancer cells. ACS Chem Biol. 2016;11:1305&#x2013;12. doi: 10.1021/acschembio.5b00900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.5b00900</ArticleId>
            <ArticleId IdType="pmc">PMC5507670</ArticleId>
            <ArticleId IdType="pubmed">26797166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, et al. FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol. 2018;14:507&#x2013;15. doi: 10.1038/s41589-018-0031-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-018-0031-6</ArticleId>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165&#x2013;76. doi: 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shishido Y, Amisaki M, Matsumi Y, Yakura H, Nakayama Y, Miyauchi W, et al. Antitumor effect of 5-Aminolevulinic acid through ferroptosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2021;28:3996&#x2013;4006. doi: 10.1245/s10434-020-09334-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-020-09334-4</ArticleId>
            <ArticleId IdType="pubmed">33210267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11:986&#x2013;94. doi: 10.1038/nnano.2016.168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nnano.2016.168</ArticleId>
            <ArticleId IdType="pmc">PMC5198777</ArticleId>
            <ArticleId IdType="pubmed">27668795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Liu T, Li Y, Lau J, Yang Z, Fan W, et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 2018;12:11355&#x2013;65. doi: 10.1021/acsnano.8b06201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06201</ArticleId>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, et al. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano. 2018;12:12181&#x2013;92. doi: 10.1021/acsnano.8b05860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b05860</ArticleId>
            <ArticleId IdType="pubmed">30458111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Q, Wang K, Zhang X, Ouyang B, Liu H, Pang Z, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small. 2020;16:27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32338436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Ma Y, Yuan Q, Hu H, Hu X, Qian Z, et al. Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy. ACS Nano. 2020;14:3414&#x2013;25. doi: 10.1021/acsnano.9b09426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.9b09426</ArticleId>
            <ArticleId IdType="pubmed">32155051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gij&#xf3;n M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;4. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao X, Yang B, Wang S, Dai Z, Zhang D, Zheng X, et al. A novel multifunctional FePt/BP nanoplatform for synergistic photothermal/photodynamic/chemodynamic cancer therapies and photothermally-enhanced immunotherapy. J Mater Chem B. 2020;8:8010&#x2013;21. doi: 10.1039/D0TB00411A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0TB00411A</ArticleId>
            <ArticleId IdType="pubmed">32766612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu T, Shi L, Yu C, Dong Y, Qiu F, Shen L, et al. Ferroptosis promotes photodynamic therapy: supramolecular photosensitizer-inducer nanodrug for enhanced cancer treatment. Theranostics. 2019;9:3293&#x2013;307. doi: 10.7150/thno.32867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.32867</ArticleId>
            <ArticleId IdType="pmc">PMC6567978</ArticleId>
            <ArticleId IdType="pubmed">31244955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Pu Y, Li S, Gao W, He B. PDT-enhanced ferroptosis by a polymer nanoparticle with pH-activated singlet oxygen generation and superb biocompatibility for cancer therapy. Biomacromolecules. 2021;22:1167&#x2013;76. doi: 10.1021/acs.biomac.0c01679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.biomac.0c01679</ArticleId>
            <ArticleId IdType="pubmed">33566577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Ma X, Xie L, Chen W, Xu Z, Song E, et al. Iron-based nanoparticles for MR imaging-guided ferroptosis in combination with photodynamic therapy to enhance cancer treatment. Nanoscale. 2021;13:4855&#x2013;70. doi: 10.1039/D0NR08757B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0NR08757B</ArticleId>
            <ArticleId IdType="pubmed">33624647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo H, Inoue M. Dormancy in cancer. Cancer Sci. 2019;110:474&#x2013;80. doi: 10.1111/cas.13917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13917</ArticleId>
            <ArticleId IdType="pmc">PMC6361606</ArticleId>
            <ArticleId IdType="pubmed">30575231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247&#x2013;50. doi: 10.1038/nature24297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24297</ArticleId>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos AF, de Almeida DRQ, Terra LF, Wailemann RAM, Gomes VM, Arini GS, et al. Fluence rate determines PDT efficiency in breast cancer cells displaying different GSH levels. Photochem Photobiol. 2020;96:658&#x2013;67. doi: 10.1111/php.13182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13182</ArticleId>
            <ArticleId IdType="pubmed">31742700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos AF, Inague A, Arini GS, Terra LF, Wailemann RAM, Pimentel AC, et al. Distinct photo-oxidation-induced cell death pathways lead to selective killing of human breast cancer cells. Cell Death Dis. 2020;11:020&#x2013;03275. doi: 10.1038/s41419-019-2210-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2210-0</ArticleId>
            <ArticleId IdType="pmc">PMC7736888</ArticleId>
            <ArticleId IdType="pubmed">33318476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aniogo EC, George BP, Abrahamse H. Molecular effectors of photodynamic therapy-mediated resistance to cancer cells. Int J Mol Sci. 2021;22:1&#x2013;13. doi: 10.3390/ijms222413182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms222413182</ArticleId>
            <ArticleId IdType="pmc">PMC8704319</ArticleId>
            <ArticleId IdType="pubmed">34947979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivarola VA, Cogno IS. Optimization of photodynamic therapy response by survivin gene. In book: Resistance to Photodynamic Therapy in Cancer. Germany: Springer: Berlin/Heidelberg; 2015. p. 163&#x2013;82.</Citation>
        </Reference>
        <Reference>
          <Citation>I&#x15f;eri OD, Kars MD, Arpaci F, G&#xfc;nd&#xfc;z U. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol. 2010;65:447&#x2013;55. doi: 10.1007/s00280-009-1048-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-009-1048-z</ArticleId>
            <ArticleId IdType="pubmed">19543729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen XY, Zacal N, Singh G, Rainbow AJ. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem Photobiol. 2005;81:306&#x2013;13. doi: 10.1562/2004-07-22-RA-242.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1562/2004-07-22-RA-242.1</ArticleId>
            <ArticleId IdType="pubmed">15560738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahmoradi Ghahe S, Kosicki K, Wojew&#xf3;dzka M, Majchrzak BA, Fogtman A, Iwanicka-Nowicka R, et al. Increased DNA repair capacity augments resistance of glioblastoma cells to photodynamic therapy. DNA Repair. 2021;104:103136. doi: 10.1016/j.dnarep.2021.103136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dnarep.2021.103136</ArticleId>
            <ArticleId IdType="pubmed">34044336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodossiou TA, Olsen CE, Jonsson M, Kubin A, Hothersall JS, Berg K. The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy. Redox Biol. 2017;12:191&#x2013;7. doi: 10.1016/j.redox.2017.02.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2017.02.018</ArticleId>
            <ArticleId IdType="pmc">PMC5333531</ArticleId>
            <ArticleId IdType="pubmed">28254657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoyama Y, Shigeto T, Miura R, Kobayashi A, Mizunuma M, Yamauchi A, et al. Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences. Oncol Lett. 2017;13:4933&#x2013;8. doi: 10.3892/ol.2017.6095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6095</ArticleId>
            <ArticleId IdType="pmc">PMC5452891</ArticleId>
            <ArticleId IdType="pubmed">28588733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girotti AW. Nitric oxide-mediated resistance to antitumor photodynamic therapy. Photochem Photobiol. 2020;96:500&#x2013;5. doi: 10.1111/php.13163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13163</ArticleId>
            <ArticleId IdType="pmc">PMC7085955</ArticleId>
            <ArticleId IdType="pubmed">31545517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girotti AW. Upregulation of nitric oxide in tumor cells as a negative adaptation to photodynamic therapy. Lasers Surg Med. 2018;50:590&#x2013;8. doi: 10.1002/lsm.22807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lsm.22807</ArticleId>
            <ArticleId IdType="pubmed">29504635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao Y, Ou Y, Yin H, Chen Y, Zhong S, Gao Y, et al. Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-&#x3b1; methyl ester-mediated photodynamic therapy. Int J Oncol. 2017;51:1427&#x2013;38. doi: 10.3892/ijo.2017.4136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2017.4136</ArticleId>
            <ArticleId IdType="pmc">PMC5642392</ArticleId>
            <ArticleId IdType="pubmed">29048645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostinis P, Buytaert E, Breyssens H, Hendrickx N. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci. 2004;3:721&#x2013;9. doi: 10.1039/b315237e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/b315237e</ArticleId>
            <ArticleId IdType="pubmed">15295626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan X, Chen B, Cui Y, Zhou L, Wu C, Yang Z, et al. Ready player one? Autophagy shapes resistance to photodynamic therapy in cancers. Apoptosis. 2018;23:587&#x2013;606. doi: 10.1007/s10495-018-1489-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-018-1489-0</ArticleId>
            <ArticleId IdType="pubmed">30288638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamarr&#xf3;n A, Lucena SR, Salazar N, Sanz-Rodr&#xed;guez F, Ja&#xe9;n P, Gilaberte Y, et al. Isolation and characterization of PDT-resistant cancer cells. Photochem Photobio Sci. 2015;14:1378&#x2013;89. doi: 10.1039/C4PP00448E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C4PP00448E</ArticleId>
            <ArticleId IdType="pubmed">25740707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilchez ML, Rodr&#xed;guez LB, Palacios RE, Prucca CG, Caverz&#xe1;n MD, Caputto BL, et al. Isolation and initial characterization of human glioblastoma cells resistant to photodynamic therapy. Photodiagnosis Photodyn Ther. 2021;33:102097. doi: 10.1016/j.pdpdt.2020.102097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pdpdt.2020.102097</ArticleId>
            <ArticleId IdType="pubmed">33232818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morton CA, Szeimies RM, Braathen LR. Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2020. Eur J Dermatol: EJD. 2021;31:17&#x2013;21. doi: 10.1684/ejd.2021.3973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1684/ejd.2021.3973</ArticleId>
            <ArticleId IdType="pmc">PMC8120754</ArticleId>
            <ArticleId IdType="pubmed">33648910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang ZJ, Huang YP, Li XX, Liu ZT, Liu K, Deng XF, et al. A novel ferroptosis-related 4-gene prognostic signature for cholangiocarcinoma and photodynamic therapy. Front Oncol. 2021;11:747445. doi: 10.3389/fonc.2021.747445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.747445</ArticleId>
            <ArticleId IdType="pmc">PMC8545875</ArticleId>
            <ArticleId IdType="pubmed">34712611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva A, Stockert JC, Ca&#xf1;ete M, Acedo P. A new protocol in photodynamic therapy: enhanced tumour cell death by combining two different photosensitizers. Photochem Photobiol Sci. 2010;9:295&#x2013;7. doi: 10.1039/b9pp00153k.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/b9pp00153k</ArticleId>
            <ArticleId IdType="pubmed">20221454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng XH, Nie X, Liu HY, Fang YM, Zhao Y, Xia LX. TMPyP4 promotes cancer cell migration at low doses, but induces cell death at high doses. Sci Rep. 2016;6:1&#x2013;8. doi: 10.1038/s41598-016-0001-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-016-0001-8</ArticleId>
            <ArticleId IdType="pmc">PMC4879555</ArticleId>
            <ArticleId IdType="pubmed">27221067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barata JF, Zamarr&#xf3;n A, Neves MG, Faustino MA, Tom&#xe9; AC, Cavaleiro JA, et al. Photodynamic effects induced by meso-tris(pentafluorophenyl)corrole and its cyclodextrin conjugates on cytoskeletal components of HeLa cells. Eur J Med Chem. 2015;92:135&#x2013;44. doi: 10.1016/j.ejmech.2014.12.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2014.12.025</ArticleId>
            <ArticleId IdType="pubmed">25549553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhang HM, Yin HJ, Zheng LQ, Wei MQ, Sha H, et al. Combination of a novel photosensitizer DTPP with 650 nm laser results in efficient apoptosis and cytoskeleton collapse in breast cancer MCF-7 cells. Cell Biochem Biophys. 2014;69:549&#x2013;54. doi: 10.1007/s12013-014-9830-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12013-014-9830-x</ArticleId>
            <ArticleId IdType="pubmed">24477573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radzi R, Osaki T, Tsuka T, Imagawa T, Minami S, Nakayama Y, et al. Photodynamic hyperthermal therapy with indocyanine green (ICG) induces apoptosis and cell cycle arrest in B16F10 murine melanoma cells. J Vet Med Sci. 2012;74:545&#x2013;51. doi: 10.1292/jvms.11-0464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1292/jvms.11-0464</ArticleId>
            <ArticleId IdType="pubmed">22146339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao J, Xue J, Dai Y, Liu H, Chen N, Jia L, et al. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser PHOTOCYANINE: ROS production, apoptosis, cell cycle arrest. Eur J Cancer. 2012;48:2086&#x2013;96. doi: 10.1016/j.ejca.2011.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2011.10.013</ArticleId>
            <ArticleId IdType="pubmed">22265427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares AR, Neves MG, Tom&#x201a; AC, Iglesias-de la Cruz MC, Zamarr&#xa2;n A, Carrasco E, et al. Glycophthalocyanines as photosensitizers for triggering mitotic catastrophe and apoptosis in cancer cells. Chem Res Toxicol. 2012;25:940&#x2013;51. doi: 10.1021/tx300035a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/tx300035a</ArticleId>
            <ArticleId IdType="pubmed">22394248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia C, Wang Y, Chen W, Yu W, Wang B, Li T. New hydrophilic/lipophilic tetra-&#x3b1;-(4-carboxyphenoxy) phthalocyanine zinc-mediated photodynamic therapy inhibits the proliferation of human hepatocellular carcinoma Bel-7402 cells by triggering apoptosis and arresting cell cycle. Molecules. 2011;16:1389&#x2013;401. doi: 10.3390/molecules16021389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules16021389</ArticleId>
            <ArticleId IdType="pmc">PMC6259621</ArticleId>
            <ArticleId IdType="pubmed">21301411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rello-Varona S, Stockert JC, Ca&#xf1;ete M, Acedo P, Villanueva A. Mitotic catastrophe induced in HeLa cells by photodynamic treatment with Zn(II)-phthalocyanine. Int J Oncol. 2008;32:1189&#x2013;96. doi: 10.3892/ijo_32_6_1189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo_32_6_1189</ArticleId>
            <ArticleId IdType="pubmed">18497980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gunaydin G, Gedik ME, Ayan S. Photodynamic therapy for the treatment and diagnosis of cancer-a review of the current clinical status. Front Chem. 2021;9:686303. doi: 10.3389/fchem.2021.686303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fchem.2021.686303</ArticleId>
            <ArticleId IdType="pmc">PMC8365093</ArticleId>
            <ArticleId IdType="pubmed">34409014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamblin MR MP. History of PDT: the first hundred years. In book: Advances in Photodynamic Therapy: Basic, Translational and Clinical. MA, USA, 2008: Artech House; 2008. p. 1-12.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamblin MR. Photodynamic therapy for cancer: what&#x2019;s past is prologue. Photochem Photobiol. 2020;96:506&#x2013;16. doi: 10.1111/php.13190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13190</ArticleId>
            <ArticleId IdType="pmc">PMC7282978</ArticleId>
            <ArticleId IdType="pubmed">31820824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbadhikary P, George BP, Abrahamse H. Recent advances in photosensitizers as multifunctional theranostic agents for imaging-guided photodynamic therapy of cancer. Theranostics. 2021;11:9054&#x2013;88. doi: 10.7150/thno.62479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.62479</ArticleId>
            <ArticleId IdType="pmc">PMC8419035</ArticleId>
            <ArticleId IdType="pubmed">34522227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo PC, Rodr&#xed;guez-Morgade MS, Pandey RK, Ng DKP, Torres T, Dumoulin F. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer. Chem Soc Rev. 2020;49:1041&#x2013;56. doi: 10.1039/C9CS00129H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9CS00129H</ArticleId>
            <ArticleId IdType="pubmed">31845688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Champeau M, Vignoud S, Mortier L, Mordon S. Photodynamic therapy for skin cancer: How to enhance drug penetration? J Photochem Photobio B. 2019;197:111544. doi: 10.1016/j.jphotobiol.2019.111544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2019.111544</ArticleId>
            <ArticleId IdType="pubmed">31295716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicola M, Williams B. Current indications for photodynamic therapy in retina and ocular oncology. Curr Ophthalmol Rep. 2021;9:1&#x2013;10. doi: 10.1007/s40135-021-00272-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40135-021-00272-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yano T, Minamide T, Takashima K, Nakajo K, Kadota T, Yoda Y. Clinical practice of photodynamic therapy using talaporfin sodium for esophageal cancer. J Clin Med. 2021;10:1&#x2013;9. doi: 10.3390/jcm10132785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm10132785</ArticleId>
            <ArticleId IdType="pmc">PMC8268336</ArticleId>
            <ArticleId IdType="pubmed">34202917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuhara H, Yamamoto S, Karashima T, Inoue K. Photodynamic diagnosis and therapy for urothelial carcinoma and prostate cancer: new imaging technology and therapy. Int J Clin Oncol. 2021;26:18&#x2013;25. doi: 10.1007/s10147-020-01704-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10147-020-01704-y</ArticleId>
            <ArticleId IdType="pubmed">32451769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubrak T, Karakula M, Czop M, Kawczyk-Krupka A, Aebisher D. Advances in management of bladder cancer-the role of photodynamic therapy. Molecules. 2022;27:1&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8838614</ArticleId>
            <ArticleId IdType="pubmed">35163996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akopov A, Papayan G. Photodynamic theranostics of central lung cancer: present state and future prospects. Photodiagnosis Photodyn Ther. 2021;33:102203. doi: 10.1016/j.pdpdt.2021.102203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pdpdt.2021.102203</ArticleId>
            <ArticleId IdType="pubmed">33529744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilyadova A, Ishchenko A, Shiryaev A, Alekseeva P, Efendiev K, Karpova R, et al. Phototheranostics of cervical neoplasms with chlorin e6 photosensitizer. Cancers. 2022;14:1&#x2013;15. doi: 10.3390/cancers14010211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers14010211</ArticleId>
            <ArticleId IdType="pmc">PMC8750251</ArticleId>
            <ArticleId IdType="pubmed">35008375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermandel M, Dupont C, Lecomte F, Leroy HA, Tuleasca C, Mordon S, et al. Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. J neuro-Oncol. 2021;152:501&#x2013;14. doi: 10.1007/s11060-021-03718-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-021-03718-6</ArticleId>
            <ArticleId IdType="pubmed">33743128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schipmann S, M&#xfc;ther M, St&#xf6;gbauer L, Zimmer S, Brokinkel B, Holling M, et al. Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. Journal of neurosurgery. 2020:1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31978877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komolibus K, Fisher C, Swartling J, Svanberg S, Svanberg K, Andersson-Engels S. Perspectives on interstitial photodynamic therapy for malignant tumors. J Biomed Opt. 2021;26:070604-1-070604-23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8299827</ArticleId>
            <ArticleId IdType="pubmed">34302323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18:181&#x2013;91. doi: 10.1016/S1470-2045(16)30661-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30661-1</ArticleId>
            <ArticleId IdType="pubmed">28007457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee SM, El-Sheikh S, Malhotra A, Mosse CA, Parker S, Williams NR, et al. Photodynamic Therapy in Primary Breast Cancer. Journal of clinical medicine. 2020;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7074474</ArticleId>
            <ArticleId IdType="pubmed">32050675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leroy HA, Baert G, Guerin L, Delhem N, Mordon S, Reyns N, et al. Interstitial Photodynamic Therapy for Glioblastomas: A Standardized Procedure for Clinical Use. Cancers (Basel). 2021;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8616201</ArticleId>
            <ArticleId IdType="pubmed">34830908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lietke S, Schmutzer M, Schwartz C, Weller J, Siller S, Aumiller M, et al. Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences. Cancers (Basel). 2021;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8067827</ArticleId>
            <ArticleId IdType="pubmed">33917116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Civantos FJ, Karakullukcu B, Biel M, Silver CE, Rinaldo A, Saba NF, et al. A Review of Photodynamic Therapy for Neoplasms of the Head and Neck. Adv Ther. 2018;35:324&#x2013;40. doi: 10.1007/s12325-018-0659-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-018-0659-3</ArticleId>
            <ArticleId IdType="pubmed">29417455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isabelle M, Davis S, Li Z, Gunn J, Hoopes P, Pereira S, et al. Tissue photosensitizer dosimetry using spectrally-resolved fluorescence for pre-clinical and clinical verteporfin-PDT of pancreatic cancer. Prog Biomed Opt Imaging - Proc Spie. 2012;8210:18.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamagishi K, Kirino I, Takahashi I, Amano H, Takeoka S, Morimoto Y, et al. Tissue-adhesive wirelessly powered optoelectronic device for metronomic photodynamic cancer therapy. Nat Biomed Eng. 2019;3:27&#x2013;36. doi: 10.1038/s41551-018-0261-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41551-018-0261-7</ArticleId>
            <ArticleId IdType="pubmed">30932063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies N, Wilson BC. Interstitial in vivo ALA-PpIX mediated metronomic photodynamic therapy (mPDT) using the CNS-1 astrocytoma with bioluminescence monitoring. Photodiagnosis Photodyn Ther. 2007;4:202&#x2013;12. doi: 10.1016/j.pdpdt.2007.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pdpdt.2007.06.002</ArticleId>
            <ArticleId IdType="pubmed">25047439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bento CO, Pantale&#xe3;o L, de Souza MB, Vilar EAG, Luiz RR, Filho PJS, et al. Comparison of clinical and histologic findings in daylight photodynamic therapy for skin field cancerization: A randomized controlled four-arm study on physical methods-assisted delivery of methyl aminolevulinate. Photodiagnosis Photodyn Ther. 2021;35:102404. doi: 10.1016/j.pdpdt.2021.102404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pdpdt.2021.102404</ArticleId>
            <ArticleId IdType="pubmed">34133958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CN, Hsu R, Chen H, Wong TW Daylight Photodynamic Therapy: An Update. Molecules. 2020;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7664668</ArticleId>
            <ArticleId IdType="pubmed">33171665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. y. 2012;31:1062&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3298003</ArticleId>
            <ArticleId IdType="pubmed">22252128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XY, Maswikiti EP, Zhu JY, Ma YL, Zheng P, Yu Y, et al. Photodynamic therapy combined with immunotherapy for an advanced esophageal cancer with an obstruction post metal stent implantation: A case report and literature review. Photodiagnosis Photodyn Ther. 2022;37:102671. doi: 10.1016/j.pdpdt.2021.102671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pdpdt.2021.102671</ArticleId>
            <ArticleId IdType="pubmed">34864195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer. 2019;2:8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31401103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiners JJ, Jr, Agostinis P, Berg K, Oleinick NL, Kessel D. Assessing autophagy in the context of photodynamic therapy. Autophagy. 2010;6:7&#x2013;18. doi: 10.4161/auto.6.1.10220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/auto.6.1.10220</ArticleId>
            <ArticleId IdType="pmc">PMC2861993</ArticleId>
            <ArticleId IdType="pubmed">19855190</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35532958</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>07</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>07</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-3773</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>61</Volume>
            <Issue>28</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Angewandte Chemie (International ed. in English)</Title>
          <ISOAbbreviation>Angew Chem Int Ed Engl</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Biodegradable Iridium(III) Coordination Polymer for Enhanced Two-Photon Photodynamic Therapy Using an Apoptosis-Ferroptosis Hybrid Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>e202205429</StartPage>
          <MedlinePgn>e202205429</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/anie.202205429</ELocationID>
        <Abstract>
          <AbstractText>The clinical application of photodynamic therapy is hindered by the high glutathione concentration, poor cancer-targeting properties, poor drug loading into delivery systems, and an inefficient activation of the cell death machinery in cancer cells. To overcome these limitations, herein, the formulation of a promising Ir[III] complex into a biodegradable coordination polymer (IrS NPs) is presented. The nanoparticles were found to remain stable under physiological conditions but deplete glutathione and disintegrate into the monomeric metal complexes in the tumor microenvironment, causing an enhanced therapeutic effect. The nanoparticles were found to selectively accumulate in the mitochondria where these trigger cell death by hybrid apoptosis and ferroptosis pathways through the photoinduced production of singlet oxygen and superoxide anion radicals. This study presents the first example of a coordination polymer that can efficiently cause cancer cell death by apoptosis and ferroptosis upon irradiation, providing an innovative approach for cancer therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ke</LastName>
            <ForeName>Libing</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Fangmian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lina</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karges</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Liangnian</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chao</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4153-5303</Identifier>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MOE Key Laboratory of Theoretical Organic Chemistry and Functional Molecule, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, 400201, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Angew Chem Int Ed Engl</MedlineTA>
        <NlmUniqueID>0370543</NlmUniqueID>
        <ISSNLinking>1433-7851</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056831">Coordination Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>44448S9773</RegistryNumber>
          <NameOfSubstance UI="D007495">Iridium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056831" MajorTopicYN="Y">Coordination Complexes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007495" MajorTopicYN="N">Iridium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bioinorganic Chemistry</Keyword>
        <Keyword MajorTopicYN="N">Iridium</Keyword>
        <Keyword MajorTopicYN="N">Medicinal Inorganic Chemistry</Keyword>
        <Keyword MajorTopicYN="N">Metals in Medicine</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic Therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>11</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35532958</ArticleId>
        <ArticleId IdType="doi">10.1002/anie.202205429</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>L. Cheng, C. Wang, L. Feng, K. Yang, Z. Liu, Chem. Rev. 2014, 114, 10869-10939;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Li, J. F. Lovell, J. Yoon, X. Chen, Nat. Rev. Clin. Oncol. 2020, 17, 657-674;</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Guo, Y. Zou, H. He, J. Rao, S. Ji, X. Cui, H. Ke, Y. Deng, H. Yang, C. Chen, Y. Zhao, H. Chen, Adv. Mater. 2016, 28, 10155-10164;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Zhao, J. Liu, J. Fan, H. Chao, X. Peng, Chem. Soc. Rev. 2021, 50, 4185-4219;</Citation>
        </Reference>
        <Reference>
          <Citation>A. Kamkaew, S. H. Lim, H. B. Lee, L. V. Kiew, L. Y. Chung, K. Burgess, Chem. Soc. Rev. 2013, 42, 77-88;</Citation>
        </Reference>
        <Reference>
          <Citation>K. Liu, Y. Liu, Y. Yao, H. Yuan, S. Wang, Z. Wang, X. Zhang, Angew. Chem. Int. Ed. 2013, 52, 8285-8289;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2013, 125, 8443-8447.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Zhou, J. Song, L. Nie, X. Chen, Chem. Soc. Rev. 2016, 45, 6597-6626;</Citation>
        </Reference>
        <Reference>
          <Citation>M. Li, J. Xia, R. Tian, J. Wang, J. Fan, J. Du, S. Long, X. Song, J. W. Foley, X. Peng, J. Am. Chem. Soc. 2018, 140, 14851-14859;</Citation>
        </Reference>
        <Reference>
          <Citation>S. H. C. Askes, S. Bonnet, Nat. Chem. Rev. 2018, 2, 437-452;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Liu, C. Zhang, T. W. Rees, L. Ke, L. Ji, H. Chao, Coord. Chem. Rev. 2018, 363, 17-28;</Citation>
        </Reference>
        <Reference>
          <Citation>A. Sharma, J. F. Arambula, S. Koo, R. Kumar, H. Singh, J. L. Sessler, J. S. Kim, Chem. Soc. Rev. 2019, 48, 771-813;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Chen, W. Zhang, G. Zhu, J. Xie, X. Chen, Nat. Rev. Mater. 2017, 2, 17024.</Citation>
        </Reference>
        <Reference>
          <Citation>P. Kuppusamy, H. Li, G. Ilangovan, A. J. Cardounel, J. L. Zweier, K. Yamada, M. C. Krishna, J. B. Mitchell, Cancer Res. 2002, 62, 307-312.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Wang, W. Wu, J. Liu, P. N. Manghnani, F. Hu, D. Ma, C. Teh, B. Wang, B. Liu, ACS Nano 2019, 13, 6879-6890;</Citation>
        </Reference>
        <Reference>
          <Citation>C. Liu, D. Wang, S. Zhang, Y. Cheng, F. Yang, Y. Xing, T. Xu, H. Dong, X. Zhang, ACS Nano 2019, 13, 4267-4277;</Citation>
        </Reference>
        <Reference>
          <Citation>C. Wang, F. Cao, Y. Ruan, X. Jia, W. Zhen, X. Jiang, Angew. Chem. Int. Ed. 2019, 58, 9846-9850;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2019, 131, 9951-9955;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Sun, K. Du, J. Diao, X. Cai, F. Feng, S. Wang, Angew. Chem. Int. Ed. 2020, 59, 12122-12128;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2020, 132, 12220-12226;</Citation>
        </Reference>
        <Reference>
          <Citation>E. Ju, K. Dong, Z. Chen, Z. Liu, C. Liu, Y. Huang, Z. Wang, F. Pu, J. Ren, X. Qu, Angew. Chem. Int. Ed. 2016, 55, 11467-11471;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2016, 128, 11639-11643.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>F. Meng, W. E. Hennink, Z. Zhong, Biomaterials 2009, 30, 2180-2198;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Zhang, K. Wu, H. Sun, J. Zhang, J. Yuan, Z. Zhong, ACS Appl. Mater. Interfaces 2018, 10, 1597-1604;</Citation>
        </Reference>
        <Reference>
          <Citation>F. X. Wang, J. H. Liang, H. Zhang, Z. H. Wang, Q. Wan, C. P. Tan, L. N. Ji, Z. W. Mao, ACS Appl. Mater. Interfaces 2019, 11, 13123-13133;</Citation>
        </Reference>
        <Reference>
          <Citation>C. Gao, F. Tang, J. Zhang, S. M. Y. Lee, R. Wang, J. Mater. Chem. B 2017, 5, 2337-2346;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Guo, Y. Cheng, X. Zhao, Y. Luo, J. Chen, W. E. Yuan, J. Nanobiotechnol. 2018, 16, 74;</Citation>
        </Reference>
        <Reference>
          <Citation>A. C. Kauffman, A. S. Piotrowski-Daspit, K. H. Nakazawa, Y. Jiang, A. Datye, W. M. Saltzman, Biomacromolecules 2018, 19, 3861-3873.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>W. Jiang, X. Luo, L. Wei, S. Yuan, J. Cai, X. Jiang, Y. Hu, Small 2021, 17, 2102695;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Cao, S. Zhong, Q. Wang, C. Chen, J. Tian, W. Zhang, J. Mater. Chem. B 2020, 8, 478-483;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Fan, G. Yan, Z. Zhao, X. Hu, W. Zhang, H. Liu, X. Fu, T. Fu, X. B. Zhang, W. Tan, Angew. Chem. Int. Ed. 2016, 55, 5477-5482;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2016, 128, 5567-5572;</Citation>
        </Reference>
        <Reference>
          <Citation>W. Zhang, J. Lu, X. Gao, P. Li, W. Zhang, Y. Ma, H. Wang, B. Tang, Angew. Chem. Int. Ed. 2018, 57, 4891-4896;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2018, 130, 4985-4990;</Citation>
        </Reference>
        <Reference>
          <Citation>S. Y. Yin, G. Song, Y. Yang, Y. Zhao, P. Wang, L. M. Zhu, X. Yin, X. B. Zhang, Adv. Funct. Mater. 2019, 29, 1901417.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>C. Liang, X. Zhang, M. Yang, X. Dong, Adv. Mater. 2019, 31, 1904197;</Citation>
        </Reference>
        <Reference>
          <Citation>W. S. Yang, R. SriRamaratnam, M. E. Welsch, K. Shimada, R. Skouta, V. S. Viswanathan, J. H. Cheah, P. A. Clemons, A. F. Shamji, C. B. Clish, L. M. Brown, A. W. Girotti, V. W. Cornish, S. L. Schreiber, B. R. Stockwell, Cell 2014, 156, 317-331;</Citation>
        </Reference>
        <Reference>
          <Citation>B. Niu, K. Liao, Y. Zhou, T. Wen, G. Quan, X. Pan, C. Wu, Biomaterials 2021, 277, 121110.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>S. Imstepf, V. Pierroz, R. Rubbiani, M. Felber, T. Fox, G. Gasser, R. Alberto, Angew. Chem. Int. Ed. 2016, 55, 2792-2795;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2016, 128, 2842-2845;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Chen, R. Guan, C. Zhang, J. Huang, L. Ji, H. Chao, Coord. Chem. Rev. 2016, 310, 16-40;</Citation>
        </Reference>
        <Reference>
          <Citation>L. Zeng, P. Gupta, Y. Chen, E. Wang, L. Ji, H. Chao, Z. S. Chen, Chem. Soc. Rev. 2017, 46, 5771-5804;</Citation>
        </Reference>
        <Reference>
          <Citation>S. Monro, K. L. Col&#xf3;n, H. Yin, J. Roque, P. Konda, S. Gujar, R. P. Thummel, L. Lilge, C. G. Cameron, S. A. McFarland, Chem. Rev. 2019, 119, 797-828;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Karges, Angew. Chem. Int. Ed. 2022, 61, e202112236;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2022, 134, e202112236.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>A. Zamora, G. Vigueras, V. Rodr&#xed;guez, M. D. Santana, J. Ruiz, Coord. Chem. Rev. 2018, 360, 34-76;</Citation>
        </Reference>
        <Reference>
          <Citation>S. Kuang, L. Sun, X. Zhang, X. Liao, T. W. Rees, L. Zeng, Y. Chen, X. Zhang, L. Ji, H. Chao, Angew. Chem. Int. Ed. 2020, 59, 20697-20703;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2020, 132, 20878-20884;</Citation>
        </Reference>
        <Reference>
          <Citation>L. He, C. P. Tan, R.-R. Ye, Y. Z. Zhao, Y. H. Liu, Q. Zhao, L. N. Ji, Z. W. Mao, Angew. Chem. Int. Ed. 2014, 53, 12137-12141;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2014, 126, 12333-12337;</Citation>
        </Reference>
        <Reference>
          <Citation>K. Qiu, Y. Chen, T. W. Rees, L. Ji, H. Chao, Coord. Chem. Rev. 2019, 378, 66-86;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Zhou, J. Li, K. Y. Zhang, S. Liu, Q. Zhao, Coord. Chem. Rev. 2022, 453, 214334.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Wang, F. Chen, J. Zhang, J. Sun, X. Zhao, Y. Zhu, W. Wei, J. Zhao, Z. Guo, Sci. China Chem. 2020, 63, 65-72;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Yuan, Z. Han, Y. Chen, F. Qi, H. Fang, Z. Guo, S. Zhang, W. He, Angew. Chem. Int. Ed. 2021, 60, 8174-8181;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2021, 133, 8255-8262.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Sun, D. Zhao, G. Wang, Y. Wang, L. Cao, J. Sun, Q. Jiang, Z. He, Acta Pharm. Sin. B 2020, 10, 1382-1396;</Citation>
        </Reference>
        <Reference>
          <Citation>F. Wei, S. Kuang, T. W. Rees, X. Liao, J. Liu, D. Luo, J. Wang, X. Zhang, L. Ji, H. Chao, Biomaterials 2021, 276, 121064;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Li, N. Kwon, T. Guo, Z. Liu, J. Yoon, Angew. Chem. Int. Ed. 2018, 57, 11522-11531;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2018, 130, 11694-11704;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Liu, S. Wu, Y. Liu, H. Zhang, M. Zhang, Z. Tang, Y. Wang, T. Gong, Z. Yao, X. Fang, W. Bu, Biomaterials 2020, 234, 119762.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Wang, S. Sun, Z. Zhang, D. Shi, Adv. Mater. 2018, 30, 1705660;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Tian, X. Liu, L. Dong, X. Ren, H. Liu, C. A. H. Price, Y. Li, G. Wang, Q. Yang, J. Liu, Adv. Sci. 2019, 6, 1900807.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Ma, Q. Mou, D. Yan, X. Zhu, VIEW 2020, 1, 20200062;</Citation>
        </Reference>
        <Reference>
          <Citation>H. C. Fischer, W. C. W. Chan, Curr. Opin. Biotechnol. 2007, 18, 565-571;</Citation>
        </Reference>
        <Reference>
          <Citation>X.-Q. Zhou, M. Xiao, V. Ramu, J. Hilgendorf, X. Li, P. Papadopoulou, M. A. Siegler, A. Kros, W. Sun, S. Bonnet, J. Am. Chem. Soc. 2020, 142, 10383-10399;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Li, D. Lee, J. D. Huang, J. Yoon, Angew. Chem. Int. Ed. 2018, 57, 9885-9890;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2018, 130, 10033-10038;</Citation>
        </Reference>
        <Reference>
          <Citation>L. Zhou, T. Qiu, F. Lv, L. Liu, J. Ying, S. Wang, Adv. Healthcare Mater. 2018, 7, 1800670.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Ke, F. Wei, X. Liao, T. W. Rees, S. Kuang, Z. Liu, Y. Chen, L. Ji, H. Chao, Nanoscale 2021, 13, 7590-7599.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>G. L. Ellman, Arch. Biochem. Biophys. 1959, 82, 70-77;</Citation>
        </Reference>
        <Reference>
          <Citation>R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen, Z. Zhong, J. Controlled Release 2011, 152, 2-12;</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Dong, L. Feng, Y. Hao, Q. Li, M. Chen, Z. Yang, H. Zhao, Z. Liu, Chem 2020, 6, 1391-1407.</Citation>
        </Reference>
        <Reference>
          <Citation>S. P. Y. Li, J. Shum, K. K. W. Lo, Dalton Trans. 2019, 48, 9692-9702.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Sang, F. Cao, W. Li, L. Zhang, Y. You, Q. Deng, K. Dong, J. Ren, X. Qu, J. Am. Chem. Soc. 2020, 142, 5177-5183.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Shi, C. Yan, Z. Guo, W. Chi, J. Wei, W. Liu, X. Liu, H. Tian, W. H. Zhu, Nat. Commun. 2020, 11, 793.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>O. Zilka, R. Shah, B. Li, J. P. Friedmann Angeli, M. Griesser, M. Conrad, D. A. Pratt, ACS Cent. Sci. 2017, 3, 232-243;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Zhang, B.-Y. Fan, Y.-L. Pang, W.-Y. Shen, X. Wang, C.-X. Zhao, W.-X. Li, C. Liu, X.-H. Kong, G.-Z. Ning, S.-Q. Feng, X. Yao, Neural Regen. Res. 2020, 15, 1539-1545.</Citation>
        </Reference>
        <Reference>
          <Citation>A. C. del Valle, C. K. Yeh, Y. F. Huang, Adv. Healthcare Mater. 2020, 9, 2000864.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Li, X. Wang, T. Zhang, C. Wang, Z. Huang, X. Luo, Y. Deng, J. Pharm. Sci. 2015, 10, 81-98;</Citation>
        </Reference>
        <Reference>
          <Citation>B. Purushothaman, J. Lee, S. Hong, J. M. Song, J. Nanobiotechnol. 2020, 18, 102;</Citation>
        </Reference>
        <Reference>
          <Citation>T. K&#xf6;ker, N. Tang, C. Tian, W. Zhang, X. Wang, R. Martel, F. Pinaud, Nat. Commun. 2018, 9, 607.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35351131</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-3155</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of nanobiotechnology</Title>
          <ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.</ArticleTitle>
        <Pagination>
          <StartPage>161</StartPage>
          <MedlinePgn>161</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">161</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-022-01360-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical studies have shown that the efficacy of programmed cell death receptor-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors on glioblastoma (GBM) is much lower than what is expected because of the low immunogenicity of GBM. Ferroptosis of cancer cells can induce the maturation of dendritic cells (DC cells) and increase the activity of T cell. The activated T cells release IFN-, which subsequently induces the ferroptosis of cancer cells. Thus, the aim of this paper is to set up a new GBM-targeted drug delivery system (Fe3O4-siPD-L1@M-BV2) to boost ferroptosis for immunotherapy of drug-resistant GBM.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fe3O4-siPD-L1@M-BV2 significantly increased the accumulation of siPD-L1 and Fe[2+] in orthotopic drug-resistant GBM tissue in mice. Fe3O4-siPD-L1@M-BV2 markedly decreased the protein expression of PD-L1 and increased the ratio between effector T cells and regulatory T cells in orthotopic drug-resistant GBM tissue. Moreover, Fe3O4-siPD-L1@M-BV2 induced ferroptosis of GBM cells and maturation of DC cell, and it also increased the ratio between M1-type microglia and M2-type microglia in orthotopic drug-resistant GBM tissue. Finally, the growth of orthotopic drug-resistant GBM in mice was significantly inhibited by Fe3O4-siPD-L1@M-BV2.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The mutual cascade amplification effect between ferroptosis and immune reactivation induced by Fe3O4-siPD-L1@M-BV2 significantly inhibited the growth of orthotopic drug-resistant GBM and prolonged the survival time of orthotopic drug-resistant GBM mice.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Bao</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ji</LastName>
            <ForeName>Qifeng</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Miao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Bangle</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mei</LastName>
            <ForeName>Qibing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Daozhou</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China. ldzhhnxh@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Siyuan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6092-4406</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China. zhousy@fmmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Department of Pharmacology, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China. zhousy@fmmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81872803</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>82073775</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2021ZDLSF03-08</GrantID>
            <Agency>Shaanxi Province Key Research and Development Projects of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2020JQ-458</GrantID>
            <Agency>Shaanxi Natural Science Foundation</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Nanobiotechnology</MedlineTA>
        <NlmUniqueID>101152208</NlmUniqueID>
        <ISSNLinking>1477-3155</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drug-resistant glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Microglia</Keyword>
        <Keyword MajorTopicYN="N">siPD-L1</Keyword>
      </KeywordList>
      <CoiStatement>There is no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35351131</ArticleId>
        <ArticleId IdType="pmc">PMC8962245</ArticleId>
        <ArticleId IdType="doi">10.1186/s12951-022-01360-6</ArticleId>
        <ArticleId IdType="pii">10.1186/s12951-022-01360-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ma Y, Zhang J, Rui Y, Rolle J, Xu T, Qian Z, et al. Depletion of glioma stem cells by synergistic inhibition of mtor and c-myc with a biological camouflaged cascade brain-targeting nanosystem. Biomaterials. 2021;268:120564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33296794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Sun X, Wang Y, Yan C, Liu Y, Li J, et al. Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment. Adv Mater. 2020;32:2000416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32374446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Awah C U, Winter J, Mazdoom C M, Ogunwobi O O. Nsun6, an RNA methyltransferase of 5-mc controls glioblastoma response to temozolomide (TMZ) via nelfb and rps6kb2 interaction. Cancer Biol Ther. 2021:1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8726740</ArticleId>
            <ArticleId IdType="pubmed">34705606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Li X, Gao F, de Groot JF, Koul D, Yung W. Parp-mediated parylation of MGMT is critical to promote repair of temozolomide-induced o6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021;23:920&#x2013;931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8168825</ArticleId>
            <ArticleId IdType="pubmed">33433610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey A, Islam S, Patel R, Acevedo-Duncan M. The interruption of atypical PKC signaling and temozolomide combination therapy against glioblastoma. Cell Signal. 2021;77:109819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33147518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Lu C, Zhou P, Zhao L, Lyu X, Yin J, et al. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling. Neuro Oncol. 2021;23:611&#x2013;624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8041353</ArticleId>
            <ArticleId IdType="pubmed">32926734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang P, Wang G, Liu X, Wang Z, Wang J, Gao W. Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy. Biomaterials. 2021;264:120447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33069137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng C, Song Q, Zhao H, Kong Y, Sun L, Liu X, et al. A nanoplatform to boost multi-phases of cancer-immunity-cycle for enhancing immunotherapy. J Control Release. 2021;339:403&#x2013;415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34655676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu C, Li Q. Current advances in pd-1/pd-l1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Crit Rev Oncol/Hematol. 2020;151:102965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32442903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20:1100&#x2013;1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31358997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of pd-1/pd-l1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Canc Res. 2019 doi: 10.1186/s13046-019-1085-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1085-3</ArticleId>
            <ArticleId IdType="pmc">PMC6380009</ArticleId>
            <ArticleId IdType="pubmed">30777100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N&#xfa;&#xf1;ez N, Stowe CL, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12:444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7815781</ArticleId>
            <ArticleId IdType="pubmed">33469002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8113440</ArticleId>
            <ArticleId IdType="pubmed">33976133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, et al. Immune suppression in gliomas. J Neurooncol. 2021;151:3&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7843555</ArticleId>
            <ArticleId IdType="pubmed">32542437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanza M, Casili G, Campolo M, Paterniti I, Colarossi C, Mare M, et al. Immunomodulatory effect of microglia-released cytokines in gliomas. Brain Sci. 2021 doi: 10.3390/brainsci11040466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/brainsci11040466</ArticleId>
            <ArticleId IdType="pmc">PMC8067679</ArticleId>
            <ArticleId IdType="pubmed">33917013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magana-Maldonado R, Chavez-Cortez EG, Olascoaga-Arellano NK, Lopez-Mejia M, Maldonado-Leal FM, Sotelo J, et al. Immunological evasion in glioblastoma. Biomed Res Int. 2016;2016:7487313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4884578</ArticleId>
            <ArticleId IdType="pubmed">27294132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K, Xu K, He Y, Lu L, Mao Y, Gao P, et al. Functionalized tumor-targeting nanosheets exhibiting Fe(II) overloading and GSH consumption for ferroptosis activation in liver tumor. Small. 2021;17:2102046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34448349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830&#x2013;849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gij&#xf3;n M, Kennedy PD, Johnson JK, et al. Cd8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiland A, Wang Y, Wu W, Lan X, Han X, Li Q, et al. Ferroptosis and its role in diverse brain diseases. Mol Neurobiol. 2019;56:4880&#x2013;4893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506411</ArticleId>
            <ArticleId IdType="pubmed">30406908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Wang T, Yu H, Feng B, Zhou L, Zhou F, et al. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Sci Immunol. 2019 doi: 10.1126/sciimmunol.aau6584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aau6584</ArticleId>
            <ArticleId IdType="pubmed">31300478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng S, Liu F, Lin L, Yan N, Wang Y, Xu C, et al. Nanozyme-mediated cascade reaction based on metal-organic framework for synergetic chemo-photodynamic tumor therapy. J Control Release. 2020;328:631&#x2013;639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32950593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-pd-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477&#x2013;486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6408961</ArticleId>
            <ArticleId IdType="pubmed">30742122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Q, Wang K, Zhang X, Ouyang B, Liu H, Pang Z, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small. 2020;16:2001704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32338436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yost KE, Chang HY, Satpathy AT. Recruiting T cells in cancer immunotherapy. Science (American Association for the Advancement of Science) 2021;372:130&#x2013;131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33833111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H, Wu X, Zhao G, Feng K, Ni K, Sun X. Renal clearable ultrasmall single-crystal Fe nanoparticles for highly selective and effective ferroptosis therapy and immunotherapy. J Am Chem Soc. 2021;143:15812&#x2013;15823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34473493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subhan MA, Torchilin VP. SiRNA based drug design, quality, delivery and clinical translation. Nanomed Nanotechnol Biol Med. 2020;29:102239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32544449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mousazadeh H, Pilehvar-Soltanahmadi Y, Dadashpour M, Zarghami N. Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. J Control Release. 2021;330:1046&#x2013;1070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33188829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding L, Tang S, Wyatt TA, Knoell DL, Oupicky D. Pulmonary siRNA delivery for lung disease: review of recent progress and challenges. J Control Release. 2021;330:977&#x2013;991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33181203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Fu X, Jia J, Wikerholmen T, Xi K, Kong Y, et al. Glioblastoma therapy using codelivery of cisplatin and glutathione peroxidase targeting SiRNA from iron oxide nanoparticles. ACS Appl Mater Interfaces. 2020;12:43408&#x2013;43421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32885649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soetaert F, Korangath P, Serantes D, Fiering S, Ivkov R. Cancer therapy with iron oxide nanoparticles: agents of thermal and immune therapies. Adv Drug Deliv Rev. 2020;163&#x2013;164:65&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7736167</ArticleId>
            <ArticleId IdType="pubmed">32603814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurer V, Altin S, Ag SD, Zarinwall A, Temel B, Vogt PM, et al. In-vitro application of magnetic hybrid niosomes: targeted siRNA-delivery for enhanced breast cancer therapy. Pharmaceutics. 2021 doi: 10.3390/pharmaceutics13030394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics13030394</ArticleId>
            <ArticleId IdType="pmc">PMC8002368</ArticleId>
            <ArticleId IdType="pubmed">33809700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Barbosa N, Garcia JG, Cifuentes J, Castro LM, Vargas F, Ostos C, et al. Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer's. Drug Deliv. 2020;27:864&#x2013;875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8216449</ArticleId>
            <ArticleId IdType="pubmed">32515999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Xu Q, Huang T, Ling D, Gao J. New insights into biocompatible iron oxide nanoparticles: a potential booster of gene delivery to stem cells. Small. 2020;16:2001588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32725792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Israel LL, Galstyan A, Holler E, Ljubimova JY. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J Control Release. 2020;320:45&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7641100</ArticleId>
            <ArticleId IdType="pubmed">31923537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furtado D, Bj&#xf6;rnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood&#x2013;brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30:1801362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30066406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao S, Cheng Y, Liu M, Ji Q, Zhang B, Mei Q, et al. Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme. J Control Release. 2021;336:54&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34129862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutmann DH, Kettenmann H. Microglia/brain macrophages as central drivers of brain tumor pathobiology. Neuron. 2019;104:442&#x2013;449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7288606</ArticleId>
            <ArticleId IdType="pubmed">31697921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19:20&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4876023</ArticleId>
            <ArticleId IdType="pubmed">26713745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong T, Cai Y, Sun F, Chen J, Su Z, Shuai X, et al. A nanodrug incorporating sirna pd-l1 and birinapant for enhancing tumor immunotherapy. Biomater Sci. 2021 doi: 10.1039/D1BM01299A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D1BM01299A</ArticleId>
            <ArticleId IdType="pubmed">34714906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee S, Chatterjee A, Jana S, Dey S, Roy H, Das MK, et al. Transforming growth factor beta orchestrates PD-l1 enrichment in tumor-derived exosomes and mediates cd8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. Carcinogenesis. 2021;42:38&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32832992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Likittrakulwong W, Poolprasert P, Srikaeo K. Effects of extraction methods on protein properties obtained from paddy rice and germinated paddy rice. PeerJ. 2021;9:e11365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8103913</ArticleId>
            <ArticleId IdType="pubmed">33987028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korolev D, Shumilo M, Shulmeyster G, Krutikov A, Golovkin A, Mishanin A, et al. Hemolytic activity, cytotoxicity, and antimicrobial effects of human albumin- and polysorbate-80-coated silver nanoparticles. Nanomaterials (Basel). 2021 doi: 10.3390/nano11061484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nano11061484</ArticleId>
            <ArticleId IdType="pmc">PMC8227625</ArticleId>
            <ArticleId IdType="pubmed">34205084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Lu J, Wang J, Hao P, Li C, Qi L, et al. Redox-sensitive polymeric micelles with aggregation-induced emission for bioimaging and delivery of anticancer drugs. J Nanobiotechnol. 2021;19:14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7791786</ArticleId>
            <ArticleId IdType="pubmed">33413405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson EA, Rocha-Ferreira E, Hagberg H, Mallard C, Ek CJ. Function and biomarkers of the blood-brain barrier in a neonatal germinal matrix haemorrhage model. Cells-Basel. 2021;10:1677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8303246</ArticleId>
            <ArticleId IdType="pubmed">34359845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Setordzi P, Chang X, Liu Z, Wu Y, Zuo D. The recent advances of pd-1 and pd-l1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol. 2021;895:173867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33460617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, et al. Pd-1/pd-l1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021 doi: 10.3390/ijms22105123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22105123</ArticleId>
            <ArticleId IdType="pmc">PMC8151504</ArticleId>
            <ArticleId IdType="pubmed">34066087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for glioma: current management and future application. Cancer Lett. 2020;476:1&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32044356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia L, Song H, Fan W, Song Y, Wang G, Li X, et al. The association between high mobility group box 1 chromatin protein and mitotic chromosomes in glioma cells. Oncol Lett. 2020;19:745&#x2013;752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6924194</ArticleId>
            <ArticleId IdType="pubmed">31897190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Yan L, Jiang F, Lu Y, Zeng N, Yang S, et al. Identification of a ferroptosis-related signature associated with prognosis and immune infiltration in adrenocortical carcinoma. Int J Endocrinol. 2021;2021:4654302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8318759</ArticleId>
            <ArticleId IdType="pubmed">34335745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, et al. Immunogenic cell death induction by ionizing radiation. Front Immunol. 2021;12:705361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8417736</ArticleId>
            <ArticleId IdType="pubmed">34489957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murao A, Aziz M, Wang H, Brenner M, Wang P. Release mechanisms of major damps. Apoptosis. 2021;26:152&#x2013;162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8016797</ArticleId>
            <ArticleId IdType="pubmed">33713214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem Biol. 2020;27:420&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7166192</ArticleId>
            <ArticleId IdType="pubmed">32160513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma J, Chen CC, Li M. Macrophages/microglia in the glioblastoma tumor microenvironment. Int J Mol Sci. 2021 doi: 10.3390/ijms22115775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22115775</ArticleId>
            <ArticleId IdType="pmc">PMC8198046</ArticleId>
            <ArticleId IdType="pubmed">34071306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Wang J, Yao X, Wu S, Tian W, Gan C, et al. Programmed cell death 10 mediated cxcl2-cxcr2 signaling in regulating tumor-associated microglia/macrophages recruitment in glioblastoma. Front Immunol. 2021;12:637053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8182060</ArticleId>
            <ArticleId IdType="pubmed">34108959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages. Cell. 2018;175:442&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30290143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed cell death ligand 1 (pd-l1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018;6:1260&#x2013;1273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30012633</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35247637</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-5905</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>283</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomaterials</Title>
          <ISOAbbreviation>Biomaterials</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework.</ArticleTitle>
        <Pagination>
          <StartPage>121449</StartPage>
          <MedlinePgn>121449</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biomaterials.2022.121449</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0142-9612(22)00088-6</ELocationID>
        <Abstract>
          <AbstractText>Designing and developing nanomedicine based on the tumor microenvironment (TME) for effective cancer treatment is highly desirable. In this work, polyvinyl pyrrolidone (PVP) dispersed nanoscale metal-organic framework (NMOF) of Fe-TCPP (TCPP = tetrakis (4-carboxyphenyl) porphyrin) loaded with hypoxia-activable prodrug tirapazamine (TPZ) and coated by the cancer cell membrane (CM) is constructed (the formed nanocomposite denoted as PFTT@CM). Due to the functionalization with the homologous cancer cell membrane, PFTT@CM is camouflaged to evade the immune clearance and preferentially accumulates at the tumor site. Once internalized by cancer cells, PFTT@CM is activated by the TME through redox reaction and Fenton reaction between Fe[3+] in nano-platform and endogenous glutathione (GSH) and hydrogen peroxide (H2O2) to promote GSH exhausting as well as OH and O2 production, which triggers ferroptosis and dramatically enhances photodynamic therapy (PDT) efficacy. Subsequently, the PDT process mediated by TCPP and light would consume oxygen and aggravate tumor hypoxia to further activate the prodrug TPZ for cancer chemotherapy. As a consequence, the TME-driven PFTT@CM nano-platform not only demonstrated its TME modulation ability but also showed a sequential synergistic therapy, which eventually inhibited the cancer cell proliferation. This multimodal nano-platform is expected to shed light on the design of TME-activatable reaction to reinforce the synergistic therapeutic outcome and facilitate the development of effective cancer nanomedicine.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Wei-Lun</ForeName>
            <Initials>WL</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Nai-Han</ForeName>
            <Initials>NH</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yi-Bang</ForeName>
            <Initials>YB</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Zhi-Qiang</ForeName>
            <Initials>ZQ</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zhong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, 510515, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wen-Hua</ForeName>
            <Initials>WH</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, 215123, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China. Electronic address: sunbb@smu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jin-Xiang</ForeName>
            <Initials>JX</Initials>
            <AffiliationInfo>
              <Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China. Electronic address: jxchen@smu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biomaterials</MedlineTA>
        <NlmUniqueID>8100316</NlmUniqueID>
        <ISSNLinking>0142-9612</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000073396">Metal-Organic Frameworks</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073396" MajorTopicYN="Y">Metal-Organic Frameworks</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer cell membrane coating</Keyword>
        <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Homologous targeting</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35247637</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biomaterials.2022.121449</ArticleId>
        <ArticleId IdType="pii">S0142-9612(22)00088-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35177209</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1347-8648</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>148</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmacological sciences</Title>
          <ISOAbbreviation>J Pharmacol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Artesunate induces ferroptosis via modulation of p38 and ERK signaling pathway in glioblastoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>300</StartPage>
          <EndPage>306</EndPage>
          <MedlinePgn>300-306</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jphs.2022.01.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1347-8613(22)00007-X</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is implicated in various tumors, including glioblastoma. Artesunate (ART), an anti-malarial drug, exerted antitumor properties in several cancer types. However, the role of ferroptosis in the inhibiting effect of artesunate on glioblastoma remains unclear. The purpose of this study was to investigate the effects of ART on the ferroptosis of glioblastoma and to elucidate the underlying mechanisms. We found that ART inhibited the proliferation of glioblastoma cells in vitro and glioblastoma tumorigenesis in vivo. Characteristic changes of ferroptosis were observed in ART group, including GSH depletion, lipid peroxidation and iron overload. Meanwhile, the protein level of GPX4 were lower in ART group than that in control group. Ferrostatin-1, a ferroptosis inhibitor, could rescue the cell death induced by ART in U251 cells. Further examination of the mechanism revealed that the effect of ART on ferroptosis was partially governed by regulating iron homeostasis and p38 and ERK signaling pathway. These findings support that ART triggers ferroptosis in glioblastoma and might be a potential therapeutic agent for glioblastoma treatment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 The Authors. Production and hosting by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Qingxin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infection Management, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China; Department of Neurosurgery, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Shanxin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infection Management, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Che</LastName>
            <ForeName>Fengyuan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China; Central Laboratory, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China. Electronic address: che1971@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Xiaosong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infection Management, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China; Central Laboratory, Linyi People's Hospital, Shandong University, Linyi, Shandong, 276003, China. Electronic address: zxs_sdu@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>J Pharmacol Sci</MedlineTA>
        <NlmUniqueID>101167001</NlmUniqueID>
        <ISSNLinking>1347-8613</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>60W3249T9M</RegistryNumber>
          <NameOfSubstance UI="D000077332">Artesunate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077332" MajorTopicYN="N">Artesunate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Artesunate</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">Glutathione peroxidase 4</Keyword>
        <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35177209</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jphs.2022.01.007</ArticleId>
        <ArticleId IdType="pii">S1347-8613(22)00007-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35173188</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long noncoding RNA ADAMTS9-AS1 represses ferroptosis of endometrial stromal cells by regulating the miR-6516-5p/GPX4 axis in endometriosis.</ArticleTitle>
        <Pagination>
          <StartPage>2618</StartPage>
          <MedlinePgn>2618</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2618</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-04963-z</ELocationID>
        <Abstract>
          <AbstractText>Endometriosis (EMs) is one of the most frequent diseases of reproductive-age women and is characterized by the growth of endometrial tissues beyond the uterus. The enhanced proliferative and migratory potential of endometrial stromal cells (ESCs) plays an important role in the progression of EMs. Mounting studies have demonstrated that long noncoding RNAs (lncRNAs) exert an important role in regulating the development and progression of EMs. Given the aberrant expression of lncRNA ADAMTS9-AS1 in ectopic endometrium (ecEM), we investigated the biological effect of ADAMTS9-AS1 on ESC proliferation and migration and explored the underlying mechanism. The current data showed that ADAMTS9-AS1 expression was significantly upregulated in ecEM compared with eutopic endometrium (euEM) in patients with EMs and in a murine model of EMs. Functionally, ADAMTS9-AS1 knockdown in ectopic ESCs (EESCs) decreased cell viability and migration, whereas ADAMTS9-AS1 overexpression in normal ESCs (NESCs) enhanced cell viability and migration. More importantly, the effect of ADAMTS9-AS1 inhibition on decreasing ESC viability was significantly blocked by ferrostatin-1 (Fer-1, a ferroptosis inhibitor), and ADAMTS9-AS1 overexpression repressed erastin (a ferroptosis activator)-induced cell death. Furthermore, the regulatory role of ADAMTS9-AS1 in ferroptosis was defined and evidenced by increased reactive oxygen species (ROS) levels and malonyl dialdehyde (MDA) content and decreased expression of glutathione peroxidase 4 (GPX4) after ADAMTS9-AS1 inhibition. Mechanistically, ADAMTS9-AS1 functioned as a competing endogenous RNA (ceRNA) by sponging miR-6516-5p to derepress the expression of GPX4, the critical repressor of ferroptosis. Taken together, these results demonstrate that upregulated ADAMTS9-AS1 accelerates ESC proliferation and migration by regulating miR-6516-5p/GPX4-dependent ferroptosis and may be a potential target for the treatment of EMs.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wan</LastName>
            <ForeName>Yiting</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Gu</LastName>
            <ForeName>Cancan</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Jueying</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sui</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zuo</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Yanhua</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China. songyanhua728@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No. 274 Middle Zhijiang Road, Shanghai, 200071, China. cj1275@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C000611332">glutathione peroxidase 4, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.-</RegistryNumber>
          <NameOfSubstance UI="D000071119">ADAMTS9 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.-</RegistryNumber>
          <NameOfSubstance UI="C545434">Adamts9 protein, mouse</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000071119" MajorTopicYN="N">ADAMTS9 Protein</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004717" MajorTopicYN="N">Endometrium</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35173188</ArticleId>
        <ArticleId IdType="pmc">PMC8850595</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-04963-z</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-04963-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Deiana D, Gessa S, Anardu M, et al. Genetics of endometriosis: A comprehensive review. Gynecol. Endocrinol. 2019;35:553&#x2013;558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30909768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koninckx PR, Ussia A, Adamyan L, Wattiez A, Gomel V, Martin DC. Pathogenesis of endometriosis: The genetic/epigenetic theory. Fertil. Steril. 2019;111:327&#x2013;340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corachan A, Pellicer N, Pellicer A, Ferrero H. Novel therapeutic targets to improve IVF outcomes in endometriosis patients: A review and future prospects. Hum. Reprod. Update. 2021;27:923&#x2013;972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33930149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horton J, Sterrenburg M, Lane S, Maheshwari A, Li TC, Cheong Y. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: A systematic review and meta-analysis. Hum. Reprod. Update. 2019;25:592&#x2013;632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31318420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghafouri-Fard S, Shoorei H, Taheri M. Role of non-coding RNAs in the pathogenesis of endometriosis. Front. Oncol. 2020;10:1370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7417625</ArticleId>
            <ArticleId IdType="pubmed">32850438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhang J, Liu X, Wei B, Zhan L. Long noncoding RNAs in endometriosis: Biological functions, expressions, and mechanisms. J. Cell. Physiol. 2021;236:6&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32506425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 2016;17:47&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26666209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Lim KH, Yang S, Joo JY. Long non-coding RNAs in brain tumors: Roles and potential as therapeutic targets. J. Hematol. Oncol. 2021;14:77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8114507</ArticleId>
            <ArticleId IdType="pubmed">33980320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keniry A, Oxley D, Monnier P, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat. Cell Biol. 2012;14:659&#x2013;665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3389517</ArticleId>
            <ArticleId IdType="pubmed">22684254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>da Rocha ST, Heard E. Novel players in X inactivation: Insights into Xist-mediated gene silencing and chromosome conformation. Nat. Struct. Mol. Biol. 2017;24:197&#x2013;204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28257137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grote P, Wittler L, Hendrix D, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev. Cell. 2013;24:206&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149175</ArticleId>
            <ArticleId IdType="pubmed">23369715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Qian Y, Ye M, et al. Distinct expression profile of lncRNA in endometrial carcinoma. Oncol. Rep. 2016;36:3405&#x2013;3412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27748922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou C, Zhang T, Liu F, et al. The differential expression of mRNAs and long noncoding RNAs between ectopic and eutopic endometria provides new insights into adenomyosis. Mol. BioSyst. 2016;12:362&#x2013;370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26662114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Wu W, Zhu H, et al. Knockdown of long noncoding RNA CCDC144NL-AS1 attenuates migration and invasion phenotypes in endometrial stromal cells from endometriosisdagger. Biol. Reprod. 2019;100:939&#x2013;949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30496345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan J, Jiang S, Jiang Y, et al. Data mining and expression analysis of differential lncRNA ADAMTS9-AS1 in prostate cancer. Front. Genet. 2019;10:1377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7049946</ArticleId>
            <ArticleId IdType="pubmed">32153626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui L, Chen S, Wang D, Yang Q. LINC01116 promotes proliferation and migration of endometrial stromal cells by targeting FOXP1 via sponging miR-9-5p in endometriosis. J. Cell Mol. Med. 2021;25:2000&#x2013;2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7882988</ArticleId>
            <ArticleId IdType="pubmed">33372387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic. Biol. Med. 2019;133:130&#x2013;143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng SW, Norwitz SG, Taylor HS, Norwitz ER. Endometriosis: The role of iron overload and ferroptosis. Reprod. Sci. 2020;27:1383&#x2013;1390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32077077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 2014;10:9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, et al. Ferroptosis: Process and function. Cell Death Differ. 2016;23:369&#x2013;379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy AA, Santanam N, Morales AJ, Parthasarathy S. Lysophosphatidyl choline, a chemotactic factor for monocytes/T-lymphocytes is elevated in endometriosis. J. Clin. Endocrinol. Metab. 1998;83:2110&#x2013;2113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9626147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arumugam K, Yip YC. De novo formation of adhesions in endometriosis: The role of iron and free radical reactions. Fertil. Steril. 1995;64:62&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7789581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lousse JC, Defrere S, Van Langendonckt A, et al. Iron storage is significantly increased in peritoneal macrophages of endometriosis patients and correlates with iron overload in peritoneal fluid. Fertil. Steril. 2009;91:1668&#x2013;1675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18396284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mashima T, Iwasaki R, Kawata N, et al. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. Br. J. Cancer. 2019;121:846&#x2013;856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6889183</ArticleId>
            <ArticleId IdType="pubmed">31607750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariani M, Vigano P, Gentilini D, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum. Reprod. 2012;27:2010&#x2013;2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22588001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato T, Yasuda K, Matsushita K, et al. Interleukin-1/-33 signaling pathways as therapeutic targets for endometriosis. Front. Immunol. 2019;10:2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6714064</ArticleId>
            <ArticleId IdType="pubmed">31507610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Somigliana E, Vigano P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum. Reprod. 1999;14:2944&#x2013;2950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10601076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daikoku T, Tranguch S, Friedman DB, Das SK, Smith DF, Dey SK. Proteomic analysis identifies immunophilin FK506 binding protein 4 (FKBP52) as a downstream target of Hoxa10 in the periimplantation mouse uterus. Mol. Endocrinol. 2005;19:683&#x2013;697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15528267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, Zhang C, Huang M, Lin J, Fan X, Ni T. TRIM26 induces ferroptosis to inhibit hepatic stellate cell activation and mitigate liver fibrosis through mediating SLC7A11 ubiquitination. Front. Cell Dev. Biol. 2021;9:644901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8044755</ArticleId>
            <ArticleId IdType="pubmed">33869196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Zhang C, Wu Y, He W, Gou X. Identification and analysis of long non-coding RNA related miRNA sponge regulatory network in bladder urothelial carcinoma. Cancer Cell Int. 2019;19:327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6892182</ArticleId>
            <ArticleId IdType="pubmed">31827401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Li J, Mi Q, et al. Long non-coding RNA ADAMTS9-AS1 suppresses colorectal cancer by inhibiting the Wnt/beta-catenin signalling pathway and is a potential diagnostic biomarker. J. Cell Mol. Med. 2020;24:11318&#x2013;11329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7576284</ArticleId>
            <ArticleId IdType="pubmed">32889785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gentilini D, Vigano P, Somigliana E, et al. Endometrial stromal cells from women with endometriosis reveal peculiar migratory behavior in response to ovarian steroids. Fertil. Steril. 2010;93:706&#x2013;715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19022426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomson DW, Dinger ME. Endogenous microRNA sponges: Evidence and controversy. Nat. Rev. Genet. 2016;17:272&#x2013;283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27040487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai J, Wang B, Wang T, Ren W. Identification of functional lncRNAs associated with ovarian endometriosis based on a ceRNA network. Front. Genet. 2021;12:534054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7873467</ArticleId>
            <ArticleId IdType="pubmed">33584822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong N, Wang X. miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146&#x2013;D152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383922</ArticleId>
            <ArticleId IdType="pubmed">25378301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Defrere S, Lousse JC, Gonzalez-Ramos R, Colette S, Donnez J, Van Langendonckt A. Potential involvement of iron in the pathogenesis of peritoneal endometriosis. Mol. Hum. Reprod. 2008;14:377&#x2013;385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18508952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Fu Z, Dai C, et al. LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci. Rep. 2016;6:38983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5150236</ArticleId>
            <ArticleId IdType="pubmed">27941916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Li H, Hu Y, Wang F. Long non-coding RNA ADAMTS9-AS1 exacerbates cell proliferation, migration, and invasion via triggering of the PI3K/AKT/mTOR pathway in hepatocellular carcinoma cells. Am. J. Transl. Res. 2020;12:5696&#x2013;5707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7540114</ArticleId>
            <ArticleId IdType="pubmed">33042449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Tu Q, Yu L, et al. LncRNA ADAMTS9-AS1, as prognostic marker, promotes cell proliferation and EMT in colorectal cancer. Hum. Cell. 2020;33:1133&#x2013;1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32918700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 2011;146:353&#x2013;358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3235919</ArticleId>
            <ArticleId IdType="pubmed">21802130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Yu Q. Endometriosis-related ceRNA network to identify predictive biomarkers of endometrial receptivity. Epigenomics. 2019;11:147&#x2013;167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30638056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mai H, Xu H, Lin H, et al. LINC01541 functions as a ceRNA to modulate the Wnt/beta-catenin pathway by decoying miR-506-5p in endometriosis. Reprod. Sci. 2021;28:665&#x2013;674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32833189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Yu C, Kang R, Kroemer G, Tang D. Cellular degradation systems in ferroptosis. Cell Death Differ. 2021;28:1135&#x2013;1148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8027807</ArticleId>
            <ArticleId IdType="pubmed">33462411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 2016;73:2195&#x2013;2209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang YY, Wu CH, Liu CH, et al. association between the genetic variants of glutathione peroxidase 4 and severity of endometriosis. Int. J. Environ. Res. Public Health. 2020;17:5089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7400372</ArticleId>
            <ArticleId IdType="pubmed">32679649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai RX, Tang ZY. Long non-coding RNA H19 regulates Bcl-2, Bax and phospholipid hydroperoxide glutathione peroxidase expression in spontaneous abortion. Exp. Ther. Med. 2021;21:41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7706391</ArticleId>
            <ArticleId IdType="pubmed">33273971</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35154576</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1942-0994</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2022</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Oxidative medicine and cellular longevity</Title>
          <ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferrostatin-1 and 3-Methyladenine Ameliorate Ferroptosis in OVA-Induced Asthma Model and in IL-13-Challenged BEAS-2B Cells.</ArticleTitle>
        <Pagination>
          <StartPage>9657933</StartPage>
          <MedlinePgn>9657933</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9657933</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/9657933</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis was reported to be involved in the occurrence and development of asthma. However, the potential mechanism underlying the role of ferroptosis in asthma remains unclear. In this study, we established the mouse asthma model following the ovalbumin (OVA) method in C57BL/6 mice and the cell model with IL-13 induction in bronchial epithelial cells (BEAS-2B cells). Treatment of ferrostatin-1 (Ferr-1) and 3-methyladenine (3-MA) decreased iron deposition in IL-13-induced BEAS-2B cells and lung tissues of asthma mice, opposite to that in bronchoalveolar lavage fluid (BALF). Meanwhile, excessive lipid peroxidation asthma model in vivo and in vitro was alleviated by Ferr-1 or 3-MA treatment. In addition, Ferr-1 and 3-MA inhibited the expression of LC-3 in these cells and lung tissues of mice. Moreover, Ferr-1 and 3-MA also suppressed the production of inflammatory cytokines (IL-1, IL-6, and TNF-) and oxidative stress factors (ROS and MDA), while promoting the level of SOD, in vivo and in vitro. Furthermore, application of Ferr-1 exhibited a greater inhibitory effect on iron release and lipid peroxidation in IL-13-induced BEAS-2B cells and asthma mice than 3-MA, accompanied with a weaker effect on ferritinophagy than 3-MA. Collectively, Ferr-1 and 3-MA ameliorated asthma in vivo and in vitro through inhibiting ferroptosis, providing a new strategy for the clinical treatment of asthma.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Nan Yang and Yunxiao Shang.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Nan</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-5939-2318</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shang</LastName>
            <ForeName>Yunxiao</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-7522-0855</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oxid Med Cell Longev</MedlineTA>
        <NlmUniqueID>101479826</NlmUniqueID>
        <ISSNLinking>1942-0994</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003514">Cyclohexylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018793">Interleukin-13</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573944">ferrostatin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5142-23-4</RegistryNumber>
          <NameOfSubstance UI="C025946">3-methyladenine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9006-59-1</RegistryNumber>
          <NameOfSubstance UI="D010047">Ovalbumin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JAC85A2161</RegistryNumber>
          <NameOfSubstance UI="D000225">Adenine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000225" MajorTopicYN="N">Adenine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003514" MajorTopicYN="N">Cyclohexylamines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018793" MajorTopicYN="N">Interleukin-13</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010047" MajorTopicYN="N">Ovalbumin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35154576</ArticleId>
        <ArticleId IdType="pmc">PMC8837457</ArticleId>
        <ArticleId IdType="doi">10.1155/2022/9657933</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ebmeier S., Thayabaran D., Braithwaite I., B&#xe9;namara C., Weatherall M., Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012) Lancet . 2017;390(10098):935&#x2013;945. doi: 10.1016/S0140-6736(17)31448-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)31448-4</ArticleId>
            <ArticleId IdType="pubmed">28797514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sockrider M., Fussner L. What Is Asthma? American Journal of Respiratory and Critical Care Medicine . 2020;202(9):P25&#x2013;P26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33124914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nunes C., Pereira A. M., Morais-Almeida M. Asthma costs and social impact. Asthma Research and Practice . 2017;3(1):p. 1. doi: 10.1186/s40733-016-0029-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40733-016-0029-3</ArticleId>
            <ArticleId IdType="pmc">PMC5219738</ArticleId>
            <ArticleId IdType="pubmed">28078100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito S., Tenconi R., Lelii M., et al. Possible molecular mechanisms linking air pollution and asthma in children. BMC Pulmonary Medicine . 2014;14:p. 31. doi: 10.1186/1471-2466-14-31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2466-14-31</ArticleId>
            <ArticleId IdType="pmc">PMC3941253</ArticleId>
            <ArticleId IdType="pubmed">24581224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S. J., Lemberg K. M., Lamprecht M. R., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell . 2012;149(5):1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R., Shchepinov M. S., Pratt D. A. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Central Science . 2018;4(3):387&#x2013;396. doi: 10.1021/acscentsci.7b00589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00589</ArticleId>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J. P., Schneider M., Proneth B., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature Cell Biology . 2014;16(12):1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan V. E., Mao G., Qu F., et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology . 2017;13(1):81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang W., Dong M., Teng F., et al. Environmental allergens house dust mite-induced asthma is associated with ferroptosis in the lungs. Experimental and Therapeutic Medicine . 2021;22(6):p. 1483. doi: 10.3892/etm.2021.10918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2021.10918</ArticleId>
            <ArticleId IdType="pmc">PMC8576623</ArticleId>
            <ArticleId IdType="pubmed">34765024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banno A., Reddy A. T., Lakshmi S. P., Reddy R. C. Bidirectional interaction of airway epithelial remodeling and inflammation in asthma. Clinical Science (London, England) . 2020;134(9):1063&#x2013;1079. doi: 10.1042/CS20191309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/CS20191309</ArticleId>
            <ArticleId IdType="pubmed">32369100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel S. E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine . 2012;18(5):716&#x2013;725. doi: 10.1038/nm.2678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2678</ArticleId>
            <ArticleId IdType="pubmed">22561835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel S. E., Tyurina Y. Y., Zhao J., et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell . 2017;171(3):628&#x2013;641.e26. doi: 10.1016/j.cell.2017.09.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.044</ArticleId>
            <ArticleId IdType="pmc">PMC5683852</ArticleId>
            <ArticleId IdType="pubmed">29053969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P., Feng Y., Li H., et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cellular &amp; Molecular Biology Letters . 2020;25(1):p. 10. doi: 10.1186/s11658-020-00205-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11658-020-00205-0</ArticleId>
            <ArticleId IdType="pmc">PMC7045739</ArticleId>
            <ArticleId IdType="pubmed">32161620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miotto G., Rossetto M., di Paolo M. L., et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biology . 2020;28, article 101328 doi: 10.1016/j.redox.2019.101328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2019.101328</ArticleId>
            <ArticleId IdType="pmc">PMC6812032</ArticleId>
            <ArticleId IdType="pubmed">31574461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slavin S. A., Leonard A., Grose V., Fazal F., Rahman A. Autophagy inhibitor 3-methyladenine protects against endothelial cell barrier dysfunction in acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology . 2018;314(3):L388&#x2013;L396. doi: 10.1152/ajplung.00555.2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00555.2016</ArticleId>
            <ArticleId IdType="pmc">PMC5900361</ArticleId>
            <ArticleId IdType="pubmed">29074492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y. T., Tan H. L., Shui G., et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. The Journal of Biological Chemistry . 2010;285(14):10850&#x2013;10861. doi: 10.1074/jbc.M109.080796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.080796</ArticleId>
            <ArticleId IdType="pmc">PMC2856291</ArticleId>
            <ArticleId IdType="pubmed">20123989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Q., Zeng C., Dong L., Wu Y., Huang Q., Wu Y. Inhibition of ferroptosis processes ameliorates cognitive impairment in kainic acid-induced temporal lobe epilepsy in rats. American Journal of Translational Research . 2019;11(2):875&#x2013;884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6413264</ArticleId>
            <ArticleId IdType="pubmed">30899387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., An P., Xie E., et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology . 2017;66(2):449&#x2013;465. doi: 10.1002/hep.29117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29117</ArticleId>
            <ArticleId IdType="pmc">PMC5573904</ArticleId>
            <ArticleId IdType="pubmed">28195347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silveira J. S., Antunes G. L., Kaiber D. B., et al. Autophagy induces eosinophil extracellular traps formation and allergic airway inflammation in a murine asthma model. Journal of Cellular Physiology . 2020;235(1):267&#x2013;280. doi: 10.1002/jcp.28966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.28966</ArticleId>
            <ArticleId IdType="pubmed">31206674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J. N., Suh D. H., Trinh H. K., Chwae Y. J., Park H. S., Shin Y. S. The role of autophagy in allergic inflammation: a new target for severe asthma. Experimental &amp; Molecular Medicine . 2016;48(7, article e243) doi: 10.1038/emm.2016.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emm.2016.38</ArticleId>
            <ArticleId IdType="pmc">PMC4973311</ArticleId>
            <ArticleId IdType="pubmed">27364893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali M. K., Kim R. Y., Brown A. C., et al. Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma. The European Respiratory Journal . 2020;55(4):p. 1901340. doi: 10.1183/13993003.01340-2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01340-2019</ArticleId>
            <ArticleId IdType="pubmed">32184317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S. T., Wang C. Z. Regulatory T cells and asthma. Journal of Zhejiang University. Science. B . 2018;19(9):663&#x2013;673. doi: 10.1631/jzus.B1700346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1631/jzus.B1700346</ArticleId>
            <ArticleId IdType="pmc">PMC6137416</ArticleId>
            <ArticleId IdType="pubmed">30178633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fahy J. V. Type 2 inflammation in asthma--present in most, absent in many. Nature Reviews. Immunology . 2015;15(1):57&#x2013;65. doi: 10.1038/nri3786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3786</ArticleId>
            <ArticleId IdType="pmc">PMC4390063</ArticleId>
            <ArticleId IdType="pubmed">25534623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T., Naguro I., Ichijo H. Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. Biochimica et Biophysica Acta - General Subjects . 2019;1863(9):1398&#x2013;1409. doi: 10.1016/j.bbagen.2019.06.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2019.06.010</ArticleId>
            <ArticleId IdType="pubmed">31229492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen F., Hou L., Zhu L., et al. Effects of selenide chitosan sulfate on glutathione system in hepatocytes and specific pathogen-free chickens. Poultry Science . 2020;99(8):3979&#x2013;3986. doi: 10.1016/j.psj.2020.04.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psj.2020.04.024</ArticleId>
            <ArticleId IdType="pmc">PMC7597923</ArticleId>
            <ArticleId IdType="pubmed">32731985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Liu W., Liu F., et al. Corrigendum to &#x201c;IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer&#x201d;. Oxidative Medicine and Cellular Longevity . 2020;2020:2. doi: 10.1155/2020/6901472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/6901472</ArticleId>
            <ArticleId IdType="pmc">PMC7641259</ArticleId>
            <ArticleId IdType="pubmed">33194006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Sanchez D., Fontecha-Barriuso M., Martinez-Moreno J. M., et al. Ferroptosis y nefropatia. Nefrologia (Engl Ed). . 2020;40(4):384&#x2013;394. doi: 10.1016/j.nefroe.2020.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nefroe.2020.09.006</ArticleId>
            <ArticleId IdType="pubmed">32624210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang C., Zhang X., Yang M., Dong X. Recent progress in ferroptosis inducers for cancer therapy. Advanced Materials . 2019;31(51, article e1904197) doi: 10.1002/adma.201904197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201904197</ArticleId>
            <ArticleId IdType="pubmed">31595562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang W., Dong M., Teng F., et al. TMT-based quantitative proteomics reveals suppression of SLC3A2 and ATP1A3 expression contributes to the inhibitory role of acupuncture on airway inflammation in an OVA-induced mouse asthma model. Biomedicine &amp; Pharmacotherapy . 2021;134, article 111001 doi: 10.1016/j.biopha.2020.111001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2020.111001</ArticleId>
            <ArticleId IdType="pubmed">33341053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F., Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radical Biology &amp; Medicine . 2020;152:175&#x2013;185. doi: 10.1016/j.freeradbiomed.2020.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.02.027</ArticleId>
            <ArticleId IdType="pubmed">32165281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Hou W., Song X., et al. Ferroptosis: process and function. Cell Death and Differentiation . 2016;23(3):369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan N., Zhang J. Iron metabolism, ferroptosis, and the links with Alzheimer's disease. Frontiers in Neuroscience . 2020;13:p. 1443. doi: 10.3389/fnins.2019.01443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2019.01443</ArticleId>
            <ArticleId IdType="pmc">PMC7000453</ArticleId>
            <ArticleId IdType="pubmed">32063824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou B., Liu J., Kang R., Klionsky D. J., Kroemer G., Tang D. Ferroptosis is a type of autophagy-dependent cell death. Seminars in Cancer Biology . 2020;66:89&#x2013;100. doi: 10.1016/j.semcancer.2019.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2019.03.002</ArticleId>
            <ArticleId IdType="pubmed">30880243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N., Wang W., Zhou H., et al. Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. Free Radical Biology &amp; Medicine . 2020;160:303&#x2013;318. doi: 10.1016/j.freeradbiomed.2020.08.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.08.009</ArticleId>
            <ArticleId IdType="pubmed">32846217</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35122867</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0712</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>919</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmacology</Title>
          <ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS.</ArticleTitle>
        <Pagination>
          <StartPage>174797</StartPage>
          <MedlinePgn>174797</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2022.174797</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-2999(22)00058-9</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) is noninvasive, low toxicity, and photo-selective, but may be resisted by malignant cells. A previous study found chlorin e6 (Ce6) mediated PDT showed drug resistance in lung cancer cells (LLC), which may be associated with PDT-induced DNA damage response (DDR). DDR may up-regulate glutathione peroxidase 4 (GPX4), which in turn degrade ROS induced by PDT. However, dihydroartemisinin (DHA) was found to down-regulate GPX4. Accordingly, the DHA was hypothesized to improve the resistance to PDT. The present work explores the mechanism of Ce6 mediated drug resistance and reveals whether DHA can enhance the efficacy of PDT by suppressing GPX4. The in vitro experiments found Ce6 treatment did not inhibit the viability of LLC within 6 h without inducing significant apoptosis, suggesting LLC were resistant to PDT. Further investigation demonstrated PDT could damage DNA and up-regulate GPX4, thus degrading the generated ROS. DHA effectively inhibited the viability of LLC and induced apoptosis. Importantly, DHA displayed a prominent inhibitory effect on the GPX4 expression and thereby triggered ferroptosis. Combining DHA with Ce6 for treatment of LLC resulted in the suppressed GPX4 and elevated ROS. Finally, the findings showed DHA combined with Ce6 exhibited superb anti-lung cancer efficacy. In summary, Ce6 PDT damages DNA, up-regulates GPX4 to degrade ROS, thereby inducing drug resistance. Down-regulation of GPX4 by DHA-triggered ferroptosis significantly enhances the efficacy of PDT. This study provides an outstanding theoretical basis for the regulation of the intratumoral redox system and improving PDT efficacy against lung cancer by herbal monomer DHA.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Respiratory, Taihe Hospital of Shiyan, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Pathology, Sinopharm DongFeng General Hospital, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liu-Gen</ForeName>
            <Initials>LG</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Respiratory, Taihe Hospital of Shiyan, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Xing-Chun</ForeName>
            <Initials>XC</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Pathology, Sinopharm DongFeng General Hospital, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Qian-Li</ForeName>
            <Initials>QL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Zi-Yi</ForeName>
            <Initials>ZY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xi-Yong</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Qi-Rui</ForeName>
            <Initials>QR</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Ting-Ting</ForeName>
            <Initials>TT</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Respiratory, Taihe Hospital of Shiyan, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Hua-Zhen</ForeName>
            <Initials>HZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Donghu Avenue No.185, Wuhan, 430072, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Donghu Avenue No.185, Wuhan, 430072, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mei-Fang</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory, Taihe Hospital of Shiyan, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China. Electronic address: wmfpps02@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tong-Fei</ForeName>
            <Initials>TF</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Respiratory, Taihe Hospital of Shiyan, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Department of Pathology, Sinopharm DongFeng General Hospital, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Renmin road No. 30, Shiyan, Hubei, 442000, China. Electronic address: 20130021@hbmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharmacol</MedlineTA>
        <NlmUniqueID>1254354</NlmUniqueID>
        <ISSNLinking>0014-2999</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S2CCF3T1Z</RegistryNumber>
          <NameOfSubstance UI="C062985">phytochlorin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6A9O50735X</RegistryNumber>
          <NameOfSubstance UI="C039060">artenimol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="N">Chlorophyllides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chlorin e6 (Ce6)</Keyword>
        <Keyword MajorTopicYN="N">Dihydroartemisinin (DHA)</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">GPX4</Keyword>
        <Keyword MajorTopicYN="N">Lung cancer</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic effect (PDT)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35122867</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejphar.2022.174797</ArticleId>
        <ArticleId IdType="pii">S0014-2999(22)00058-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35115492</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models.</ArticleTitle>
        <Pagination>
          <StartPage>676</StartPage>
          <MedlinePgn>676</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">676</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-27948-4</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a nonapoptotic cell death process that requires cellular iron and the accumulation of lipid peroxides. In progressive rheumatoid arthritis (RA), synovial fibroblasts proliferate abnormally in the presence of reactive oxygen species (ROS) and elevated lipid oxidation. Here we show, using a collagen-induced arthritis (CIA) mouse model, that imidazole ketone erastin (IKE), a ferroptosis inducer, decreases fibroblast numbers in the synovium. Data from single-cell RNA sequencing further identify two groups of fibroblasts that have distinct susceptibility to IKE-induced ferroptosis, with the ferroptosis-resistant fibroblasts associated with an increased TNF-related transcriptome. Mechanistically, TNF signaling promotes cystine uptake and biosynthesis of glutathione (GSH) to protect fibroblasts from ferroptosis. Lastly, low dose IKE together with etanercept, a TNF antagonist, induce ferroptosis in fibroblasts and attenuate arthritis progression in the CIA model. Our results thus imply that the combination of TNF inhibitors and ferroptosis inducers may serve as a potential candidate for RA therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wu</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-9718-5499</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. jiaowubio@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China. jiaowubio@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. jiaowubio@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Feng</LastName>
            <ForeName>Zhuan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Chen</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Shanghai University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Xijing 986 Hospital Department, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bian</LastName>
            <ForeName>Huijie</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geng</LastName>
            <ForeName>Jiejie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Zhao-Hui</ForeName>
            <Initials>ZH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Xianghui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pei</LastName>
            <ForeName>Zhuo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Yifei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Liu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yilin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ruo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nan</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xuejun</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-8670-3828</Identifier>
            <AffiliationInfo>
              <Affiliation>Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. jiangx@mskcc.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhi-Nan</ForeName>
            <Initials>ZN</Initials>
            <Identifier Source="ORCID">0000-0001-5512-4623</Identifier>
            <AffiliationInfo>
              <Affiliation>National Translational Science Center for Molecular Medicine &amp; Department of Cell Biology, Fourth Military Medical University, Xi'an, China. znchen@fmmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-8391-4945</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. zhuping@fmmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000079424">Tumor Necrosis Factor Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000705694">imidazole ketone erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OP401G7OJC</RegistryNumber>
          <NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Rev Rheumatol. 2022 Apr;18(4):186</RefSource>
          <PMID Version="1">35273386</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001169" MajorTopicYN="N">Arthritis, Experimental</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068800" MajorTopicYN="N">Etanercept</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013583" MajorTopicYN="N">Synovial Membrane</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079424" MajorTopicYN="N">Tumor Necrosis Factor Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35115492</ArticleId>
        <ArticleId IdType="pmc">PMC8813949</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-021-27948-4</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-021-27948-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011;365:2205&#x2013;2219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22150039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannini D, et al. One year in review 2020: pathogenesis of rheumatoid arthritis. Clin. Exp. Rheumatol. 2020;38:387&#x2013;397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32324123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328&#x2013;2337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28612747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvagni E, et al. One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2020;38:181&#x2013;194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32213264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338&#x2013;2348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28612748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang XJ, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Bio. 2021;22:266&#x2013;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8142022</ArticleId>
            <ArticleId IdType="pubmed">33495651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Jiang XJ, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol. 2020;30:478&#x2013;490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7230071</ArticleId>
            <ArticleId IdType="pubmed">32413317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng JS, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32:920&#x2013;937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33217331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107&#x2013;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8026611</ArticleId>
            <ArticleId IdType="pubmed">33268902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q, Liu J, Kang R, Zhou B, Tang D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 2019;510:278&#x2013;283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masoumi, M. et al. Destructive roles of fibroblast-like synoviocytes in chronic inflammation and joint damage in rheumatoid arthritis. Inflammation, 10.1007/s10753-020-01371-1 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33113036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat. Rev. Rheumatol. 2020;16:316&#x2013;333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7987137</ArticleId>
            <ArticleId IdType="pubmed">32393826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank-Bertoncelj M, Gay S. The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis. Arthritis Res. Ther. 2014;16:117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4075141</ArticleId>
            <ArticleId IdType="pubmed">25165988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phull AR, Nasir B, Haq IU, Kim SJ. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis. Chem. Biol. Interact. 2018;281:121&#x2013;136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29258867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 2017;19:110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5452638</ArticleId>
            <ArticleId IdType="pubmed">28569176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2&#x2032;-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health C. 2009;27:120&#x2013;139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19412858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014;2014:360438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4066722</ArticleId>
            <ArticleId IdType="pubmed">24999379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res. Ther. 2004;6:265&#x2013;278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1064874</ArticleId>
            <ArticleId IdType="pubmed">15535839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 2019;26:623&#x2013;633 e629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croft AP, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019;570:246&#x2013;251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6690841</ArticleId>
            <ArticleId IdType="pubmed">31142839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat. Rev. Rheumatol. 2016;12:472&#x2013;485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27383913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 2016;12:49&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4809675</ArticleId>
            <ArticleId IdType="pubmed">26656660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007;7:429&#x2013;442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17525752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georganas C, et al. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J. Immunol. 2000;165:7199&#x2013;7206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11120852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, K. K., Sheppard, D. &amp; Chapman, H. A. TGF-beta1 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10, 10.1101/cshperspect.a022293 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5880172</ArticleId>
            <ArticleId IdType="pubmed">28432134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lapadula G, et al. Adalimumab in the treatment of immune-mediated diseases. Int. J. Immunopathol. Pharm. 2014;27:33&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24774505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541&#x2013;1550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23515142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572:402&#x2013;406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic. Biol. Med. 2020;152:175&#x2013;185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32165281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Jiang X. To eat or not to eat-the metabolic flavor of ferroptosis. Curr. Opin. Cell Biol. 2018;51:58&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5949249</ArticleId>
            <ArticleId IdType="pubmed">29175614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu SC, et al. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30:42&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2704241</ArticleId>
            <ArticleId IdType="pubmed">18601945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 2001;107:7&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC198552</ArticleId>
            <ArticleId IdType="pubmed">11134171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yemelyanov A, et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene. 2006;25:387&#x2013;398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16170348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefevre S, Meier FM, Neumann E, Muller-Ladner U. Role of synovial fibroblasts in rheumatoid arthritis. Curr. Pharm. Des. 2015;21:130&#x2013;141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25163744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiener HP, Brenner MB. Building the synovium: cadherin-11 mediates fibroblast-like synoviocyte cell-to-cell adhesion. Arthritis Res. Ther. 2005;7:49&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1065331</ArticleId>
            <ArticleId IdType="pubmed">15743489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Magilnick N, Ou X, Lu SC. Tumour necrosis factor alpha induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor kappaB and activator protein-1. Biochem. J. 2005;391:399&#x2013;408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1276939</ArticleId>
            <ArticleId IdType="pubmed">16011481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi PL, et al. HO-1 induction by CO-RM2 attenuates TNF-alpha-induced cytosolic phospholipase A2 expression via inhibition of PKCalpha-dependent NADPH oxidase/ROS and NF-kappaB. Mediators Inflamm. 2014;2014:279171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3927740</ArticleId>
            <ArticleId IdType="pubmed">24616552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu. Rev. Nutr. 2018;38:97&#x2013;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8118195</ArticleId>
            <ArticleId IdType="pubmed">30130469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popivanova BK, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008;118:560&#x2013;570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213370</ArticleId>
            <ArticleId IdType="pubmed">18219394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, P. et al. Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. Nat. Immunol., 10.1038/s41590-021-00993-3 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8609402</ArticleId>
            <ArticleId IdType="pubmed">34385713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao, Y. et al. Selenium-GPX4 axis protects follicular helper T cells from ferroptosis. Nat. Immunol., 10.1038/s41590-021-00996-0 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34413521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luczaj W, et al. The onset of lipid peroxidation in rheumatoid arthritis: consequences and monitoring. Free Radic. Res. 2016;50:304&#x2013;313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26764956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon CH, et al. Hypoxia appears at pre-arthritic stage and shows co-localization with early synovial inflammation in collagen induced arthritis. Clin. Exp. Rheumatol. 2008;26:646&#x2013;648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18799097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun. Rev. 2008;7:567&#x2013;573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2585037</ArticleId>
            <ArticleId IdType="pubmed">18625446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WH, et al. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer. Mol. Cancer Res. 2020;18:79&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6942206</ArticleId>
            <ArticleId IdType="pubmed">31641008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem. 2004;279:32869&#x2013;32881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15155767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springe. Semin. Immunopathol. 2003;25:3&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12904888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann J, et al. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 1999;42:650&#x2013;658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10211878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo, D. et al. HBEGF(+) macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci. Transl. Med.11, 10.1126/scitranslmed.aau8587 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726376</ArticleId>
            <ArticleId IdType="pubmed">31068444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floros KV, et al. MYCN-amplified neuroblastoma is addicted to iron and vulnerable to inhibition of the system Xc-/glutathione axis. Cancer Res. 2021;81:1896&#x2013;1908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33483374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, et al. Sulfasalazineinduced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncol. Rep. 2019;42:826&#x2013;838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31173262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuart T, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888&#x2013;1902 e1821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6687398</ArticleId>
            <ArticleId IdType="pubmed">31178118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prus E, Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytom. A. 2008;73:22&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18044720</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35077153</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1944-8252</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS applied materials &amp; interfaces</Title>
          <ISOAbbreviation>ACS Appl Mater Interfaces</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced ROS-Boosted Phototherapy against Pancreatic Cancer via Nrf2-Mediated Stress-Defense Pathway Suppression and Ferroptosis Induction.</ArticleTitle>
        <Pagination>
          <StartPage>6404</StartPage>
          <EndPage>6416</EndPage>
          <MedlinePgn>6404-6416</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsami.1c22861</ELocationID>
        <Abstract>
          <AbstractText>In situ oxygen generation is the most common strategy to boost reactive oxygen species (ROS) for enhancing the efficacy of phototherapy in cancer, including photodynamic therapy (PDT) and photothermal therapy (PTT). However, hyperoxidation or hyperthermia often triggers stress-defense pathways and promotes tumor cell survival, thus severely limiting the therapeutic efficacy. To overcome the tumor hypoxia and thermal resistance existing in phototherapy, we constructed a self-synergistic nanoplatform for tumors by incorporating brusatol, a nuclear factor erythroid 2-related factor (Nrf2) inhibitor, into the silica nanonetwork. It was then sequentially decorated with MnO2 and the photosensitizer chlorin e6 (Ce6) and then coated with poly(ethylene glycol)-folate (PEG-FA)-functionalized polydopamine (PDA) (designated as brusatol/silica@MnO2/Ce6@PDA-PEG-FA). As an oxygen generator, MnO2 can promote ROS production, which not only directly enhances Ce6-mediated PDT but also strengthens PDA-mediated PTT by attacking heat shock proteins (HSPs). Particularly, brusatol could efficiently inhibit the activation of Nrf2 defense pathway under hyperoxidation and hyperthermia and cause glutathione peroxidase 4 (GPX4) and ferritin heavy chain (FTH) inactivation, thereby inducing ferroptosis and ultimately enhancing the phototherapeutic effects. By exploiting these features, brusatol/silica@MnO2/Ce6@PDA-PEG-FA exhibited excellent antitumor efficacy with enhanced PDT and PTT both in in vitro and in vivo studies. Overall, our work highlights a promising strategy against hypoxia- and hyperthermia-associated resistance in phototherapy via suppressing stress-defense system and inducing ferroptosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tao</LastName>
            <ForeName>Weiwei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, School of Chinese Medicine &amp; School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Neng</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Xiaolan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, School of Chinese Medicine &amp; School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Pengfei</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Cai</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, School of Chinese Medicine &amp; School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Che</LastName>
            <ForeName>Chuntao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Dongdong</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, School of Chinese Medicine &amp; School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Jinao</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-0610-5981</Identifier>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-5912-6108</Identifier>
            <AffiliationInfo>
              <Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Appl Mater Interfaces</MedlineTA>
        <NlmUniqueID>101504991</NlmUniqueID>
        <ISSNLinking>1944-8244</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017895">Manganese Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036702">Quassins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C552831">poly(ethylene glycol)-folate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C568283">polydopamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>14907-98-3</RegistryNumber>
          <NameOfSubstance UI="C020237">brusatol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
          <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S2CCF3T1Z</RegistryNumber>
          <NameOfSubstance UI="C062985">phytochlorin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>64J2OA7MH3</RegistryNumber>
          <NameOfSubstance UI="C027424">manganese oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7631-86-9</RegistryNumber>
          <NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>935E97BOY8</RegistryNumber>
          <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="N">Chlorophyllides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006979" MajorTopicYN="N">Hyperthermia, Induced</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007259" MajorTopicYN="N">Infrared Rays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017895" MajorTopicYN="N">Manganese Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010087" MajorTopicYN="N">Oxides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036702" MajorTopicYN="N">Quassins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012822" MajorTopicYN="N">Silicon Dioxide</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nrf2</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">brusatol</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">phototherapy</Keyword>
        <Keyword MajorTopicYN="N">stress-defense pathway</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35077153</ArticleId>
        <ArticleId IdType="doi">10.1021/acsami.1c22861</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34983546</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer</Title>
          <ISOAbbreviation>Mol Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>11</StartPage>
          <MedlinePgn>11</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">11</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12943-021-01466-9</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Hepatocellular carcinoma (HCC) is among the most common forms of cancer and is associated with poor patient outcomes. The emergence of therapeutic resistance has hampered the efficacy of targeted treatments employed to treat HCC patients to date. In this study, we conducted a series of CRISPR/Cas9 screens to identify genes associated with synthetic lethality capable of improving HCC patient clinical responses.</AbstractText>
          <AbstractText Label="METHODS">CRISPR-based loss-of-function genetic screens were used to target 18,053 protein-coding genes in HCC cells to identify chemotherapy-related synthetic lethal genes in these cells. Synergistic effects were analyzed through in vitro and in vivo analyses, while related mechanisms were explored through RNA-seq and metabolomics analyses. Potential inhibitors of identified genetic targets were selected through high-throughput virtual screening.</AbstractText>
          <AbstractText Label="RESULTS">The inhibition of phosphoseryl-tRNA kinase (PSTK) was found to increase HCC cell sensitivity to chemotherapeutic treatment. PSTK was associated with the suppression of chemotherapy-induced ferroptosis in HCC cells, and the depletion of PSTK resulted in the inactivation of glutathione peroxidative 4 (GPX4) and the disruption of glutathione (GSH) metabolism owing to the inhibition of selenocysteine and cysteine synthesis, thus enhancing the induction of ferroptosis upon targeted chemotherapeutic treatment. Punicalin, an agent used to treat hepatitis B virus (HBV), was identified as a possible PSTK inhibitor that exhibited synergistic efficacy when applied together with Sorafenib to treat HCC in vitro and in vivo.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These results highlight a key role for PSTK as a mediator of resistance to targeted therapeutic treatment in HCC cells that functions by suppressing ferroptotic induction. PSTK inhibitors may thus represent ideal candidates for overcoming drug resistance in HCC.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Chen</LastName>
            <ForeName>Yiran</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Oncology, Peking University Cancer Hospital and Institute, 1 Life Park Road, Life Science Park of Zhongguancun, Changping, Beijing, 102206, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Peking University International Hospital, Beijing, 102206, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lan</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of RNA Biology, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of RNA Biology, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Xiaosong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Boao Evergrande International Hospital, Qionghai, 571400, Hainan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Peking University International Hospital, Beijing, 102206, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Oncology, Peking University Cancer Hospital and Institute, 1 Life Park Road, Life Science Park of Zhongguancun, Changping, Beijing, 102206, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ju</LastName>
            <ForeName>Gaoda</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Oncology, Peking University Cancer Hospital and Institute, 1 Life Park Road, Life Science Park of Zhongguancun, Changping, Beijing, 102206, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Guangtao</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of RNA Biology, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. seagtsong@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, 510005, China. seagtsong@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lou</LastName>
            <ForeName>Jizhong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of RNA Biology, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. jlou@ibp.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Oncology, Peking University Cancer Hospital and Institute, 1 Life Park Road, Life Science Park of Zhongguancun, Changping, Beijing, 102206, P.R. China. junliang@pkuih.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Peking University International Hospital, Beijing, 102206, China. junliang@pkuih.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Mol Cancer</MedlineTA>
        <NlmUniqueID>101147698</NlmUniqueID>
        <ISSNLinking>1476-4598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="C000709508">PSTK protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CRISPR library screening</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">PSTK</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interests</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34983546</ArticleId>
        <ArticleId IdType="pmc">PMC8725338</ArticleId>
        <ArticleId IdType="doi">10.1186/s12943-021-01466-9</ArticleId>
        <ArticleId IdType="pii">10.1186/s12943-021-01466-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England) 2018;391:1301-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29307467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243&#x2013;253. doi: 10.1007/s11523-017-0484-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11523-017-0484-7</ArticleId>
            <ArticleId IdType="pubmed">28299600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Mattia E, Cecchin E, Guardascione M, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25:3870&#x2013;3896. doi: 10.3748/wjg.v25.i29.3870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v25.i29.3870</ArticleId>
            <ArticleId IdType="pmc">PMC6689804</ArticleId>
            <ArticleId IdType="pubmed">31413525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvisi D, Eferl R. CDK4/6 inhibition and sorafenib: a menage a deux in HCC therapy? Gut. 2017;66:1179&#x2013;1180. doi: 10.1136/gutjnl-2016-313547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-313547</ArticleId>
            <ArticleId IdType="pubmed">28057692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Littman SJ, Brus C, Burkart A. A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma. 2015;33:277-.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadian K, Stockwell BR. SnapShot: Ferroptosis. Cell. 2020;181:1188&#x2013;11e1. doi: 10.1016/j.cell.2020.04.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.04.039</ArticleId>
            <ArticleId IdType="pmc">PMC8157339</ArticleId>
            <ArticleId IdType="pubmed">32470402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden BT. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830&#x2013;849. doi: 10.1016/j.ccell.2019.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.04.002</ArticleId>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie J, Lin B, Zhou M, Wu L, Zheng T. Role of ferroptosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2018;144:2329&#x2013;2337. doi: 10.1007/s00432-018-2740-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-018-2740-3</ArticleId>
            <ArticleId IdType="pubmed">30167889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523. doi: 10.7554/eLife.02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.02523</ArticleId>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nature reviews Genetics. 2015;16:299&#x2013;311. doi: 10.1038/nrg3899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg3899</ArticleId>
            <ArticleId IdType="pmc">PMC4503232</ArticleId>
            <ArticleId IdType="pubmed">25854182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colic M, Wang G, Zimmermann M, et al. Identifying chemogenetic interactions from CRISPR screens with drugZ. Genome medicine. 2019;11:52. doi: 10.1186/s13073-019-0665-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-019-0665-3</ArticleId>
            <ArticleId IdType="pmc">PMC6706933</ArticleId>
            <ArticleId IdType="pubmed">31439014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart T, Chandrashekhar M, Aregger M, et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 2015;163:1515&#x2013;1526. doi: 10.1016/j.cell.2015.11.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.11.015</ArticleId>
            <ArticleId IdType="pubmed">26627737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019;9:910&#x2013;925. doi: 10.1158/2159-8290.CD-19-0125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0125</ArticleId>
            <ArticleId IdType="pmc">PMC6606338</ArticleId>
            <ArticleId IdType="pubmed">31048320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Jin H, Gao D, et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol. 2018;69:1057&#x2013;1065. doi: 10.1016/j.jhep.2018.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2018.07.004</ArticleId>
            <ArticleId IdType="pubmed">30030148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Vegna S, Jin H, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019;574:268&#x2013;272. doi: 10.1038/s41586-019-1607-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1607-3</ArticleId>
            <ArticleId IdType="pmc">PMC6858884</ArticleId>
            <ArticleId IdType="pubmed">31578521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Wang H, Lieftink C, et al. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut. 2020;69:727&#x2013;736. doi: 10.1136/gutjnl-2019-318506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2019-318506</ArticleId>
            <ArticleId IdType="pubmed">31519701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei L, Lee D, Law CT, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10:4681. doi: 10.1038/s41467-019-12606-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-12606-7</ArticleId>
            <ArticleId IdType="pmc">PMC6794322</ArticleId>
            <ArticleId IdType="pubmed">31615983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson BA, Xu XM, Kryukov GV, et al. Identification and characterization of phosphoseryl-tRNA [Ser] Sec kinase. Proc Natl Acad Sci U S A. 2004;101:12848&#x2013;12853. doi: 10.1073/pnas.0402636101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0402636101</ArticleId>
            <ArticleId IdType="pmc">PMC516484</ArticleId>
            <ArticleId IdType="pubmed">15317934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba S, Itoh Y, Sekine S, Yokoyama S. Structural basis for the major role of O-phosphoseryl-tRNA kinase in the UGA-specific encoding of selenocysteine. Mol Cell. 2010;39:410&#x2013;420. doi: 10.1016/j.molcel.2010.07.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2010.07.018</ArticleId>
            <ArticleId IdType="pubmed">20705242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science. 2003;300:1439&#x2013;1443. doi: 10.1126/science.1083516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1083516</ArticleId>
            <ArticleId IdType="pubmed">12775843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mair B, Tomic J, Masud SN, et al. Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies. Cell reports 2019;27:599-615.e12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30970261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu J, Berisa M, Schworer S, Qin W, Cross JR, Thompson CB. Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation. Cell Metab. 2019;30:865&#x2013;876. doi: 10.1016/j.cmet.2019.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2019.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC6961654</ArticleId>
            <ArticleId IdType="pubmed">31607565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Li X, Han X, Liu R, Fang J. Targeting the Thioredoxin System for Cancer Therapy. Trends Pharmacol Sci. 2017;38:794&#x2013;808. doi: 10.1016/j.tips.2017.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2017.06.001</ArticleId>
            <ArticleId IdType="pubmed">28648527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Cai D, Zhang L, et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral research. 2016;134:97&#x2013;107. doi: 10.1016/j.antiviral.2016.08.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.antiviral.2016.08.026</ArticleId>
            <ArticleId IdType="pmc">PMC5653380</ArticleId>
            <ArticleId IdType="pubmed">27591143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64:488&#x2013;500. doi: 10.1002/hep.28574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28574</ArticleId>
            <ArticleId IdType="pmc">PMC4956496</ArticleId>
            <ArticleId IdType="pubmed">27015352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rohr-Udilova N, Sieghart W, Eferl R, et al. Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology. 2012;55:1112&#x2013;1121. doi: 10.1002/hep.24808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.24808</ArticleId>
            <ArticleId IdType="pubmed">22105228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlisle AE, Lee N, Matthew-Onabanjo AN, et al. Selenium detoxification is required for cancer-cell survival. Nature metabolism. 2020;2:603&#x2013;611. doi: 10.1038/s42255-020-0224-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42255-020-0224-7</ArticleId>
            <ArticleId IdType="pmc">PMC7455022</ArticleId>
            <ArticleId IdType="pubmed">32694795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin J, Ren W, Yang G, et al. L-Cysteine metabolism and its nutritional implications. Mol Nutr Food Res. 2016;60:134&#x2013;146. doi: 10.1002/mnfr.201500031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mnfr.201500031</ArticleId>
            <ArticleId IdType="pubmed">25929483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85&#x2013;89. doi: 10.1126/science.aaw9872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaw9872</ArticleId>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, Liu F, Deng J, et al. Electron-Accepting Micelles Deplete Reduced Nicotinamide Adenine Dinucleotide Phosphate and Impair Two Antioxidant Cascades for Ferroptosis-Induced Tumor Eradication. ACS nano. 2020;14:14715&#x2013;14730. doi: 10.1021/acsnano.0c00764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.0c00764</ArticleId>
            <ArticleId IdType="pubmed">33156626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee D, Xu IM, Chiu DK, et al. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology. 2019;69:1768&#x2013;1786. doi: 10.1002/hep.30467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.30467</ArticleId>
            <ArticleId IdType="pmc">PMC8690574</ArticleId>
            <ArticleId IdType="pubmed">30561826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soula M, Weber RA, Zilka O, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat Chem Biol. 2020;16:1351&#x2013;1360. doi: 10.1038/s41589-020-0613-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-020-0613-y</ArticleId>
            <ArticleId IdType="pmc">PMC8299533</ArticleId>
            <ArticleId IdType="pubmed">32778843</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34965379</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4164</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>82</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cell</Title>
          <ISOAbbreviation>Mol Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Persister cancer cells: Iron addiction and vulnerability to ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>728</StartPage>
          <EndPage>740</EndPage>
          <MedlinePgn>728-740</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2021.12.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1097-2765(21)01038-8</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a unique type of non-apoptotic cell death resulting from the unrestrained occurrence of peroxidized phospholipids, which are subject to iron-mediated production of lethal oxygen radicals. This cell death modality has been detected across many organisms, including in mammals, where it can be used as a defense mechanism against pathogens or even harnessed by T cells to sensitize tumor cells toward effective killing. Conversely, ferroptosis is considered one of the main cell death mechanisms promoting degenerative diseases. Emerging evidence suggests that ferroptosis represents a vulnerability in certain cancers. Here, we critically review recent advances linking ferroptosis vulnerabilities of dedifferentiating and persister cancer cells to the dependency of these cells on iron, a potential Achilles heel for small-molecule intervention. We provide a perspective on the mechanisms reliant on iron that contribute to the persister cancer cell state and how this dependency may be exploited for therapeutic benefits.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rodriguez</LastName>
            <ForeName>Raphal</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Biology of Cancer at Institut Curie, PSL Research University, CNRS UMR 3666, INSERM U1143, Paris, France. Electronic address: raphael.rodriguez@curie.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreiber</LastName>
            <ForeName>Stuart L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA. Electronic address: stuart_schreiber@harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conrad</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Metabolism and Cell Death, Helmholtz Zentrum Mnchen, 85764 Neuherberg, Germany; Pirogov National Research Medical University, Laboratory of Experimental Oncology, Moscow 117997, Russia. Electronic address: marcus.conrad@helmholtz-muenchen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>U01 CA217848</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Cell</MedlineTA>
        <NlmUniqueID>9802571</NlmUniqueID>
        <ISSNLinking>1097-2765</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="Y">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Declaration of interests R.R. is a founder of SideROS. S.L.S. is a shareholder and serves on the board of directors of Jnana Therapeutics and Kojin Therapeutics; is a shareholder of Forma Therapeutics and Decibel Therapeutics; is a shareholder and advises Kisbee Therapeutics, Belharra Therapeutics, Vividian Therapeutics, Exo Therapeutics, and Eikonizo Therapeutics; serves on the scientific advisory boards of Eisai, Ono Pharma Foundation, Biogen, and F-Prime Capital Partners, and the board of advisers of the Genomics Institute of the Novartis Research Foundation; and is a Novartis Faculty Scholar. M.C. is a founder and shareholder of ROSCUE Therapeutics GmbH and is a member of the Molecular Cell advisory board.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>20</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34965379</ArticleId>
        <ArticleId IdType="mid">NIHMS1762271</ArticleId>
        <ArticleId IdType="pmc">PMC9152905</ArticleId>
        <ArticleId IdType="doi">10.1016/j.molcel.2021.12.001</ArticleId>
        <ArticleId IdType="pii">S1097-2765(21)01038-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abrams RP, Carroll WL, and Woerpel KA (2016). Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. ACS Chem Biol 11, 1305&#x2013;1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldrovandi M, and Conrad M. (2020). Ferroptosis: the Good, the Bad and the Ugly. Cell research 30, 1061&#x2013;1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldrovandi M, Fedorova M, and Conrad M. (2021). Juggling with lipids, a game of Russian roulette. Trends Endocrinol Metab 32, 463&#x2013;473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arensman MD, Yang XS, Leahy DM, Toral-Barza L, Mileski M, Rosfjord EC, Wang F, Deng S, Myers JS, Abraham RT, et al. (2019). Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. Proc Natl Acad Sci U S A 116, 9533&#x2013;9542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, et al. (2020). Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, et al. (2017). Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene 36, 4089&#x2013;4099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batlle E, and Clevers H. (2017). Cancer stem cells revisited. Nat Med 23, 1124&#x2013;1134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boumahdi S, and de Sauvage FJ (2020). The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 19, 39&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brutsch SH., Wang CC., Li L., Stender H., Neziroglu N., Richter C., Kuhn H., and Borchert A. (2015). Expression of inactive glutathione peroxidase 4 leads to embryonic lethality, and inactivation of the alox15 gene does not rescue such knock-in mice. Antioxid Redox Signal 22, 281&#x2013;293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caneque T, and Rodriguez R. (2019). Diverse engineering . Nature chemistry 11, 499&#x2013;500.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen MS, and White MC (2007). A predictably selective aliphatic C-H oxidation reaction for complex molecule synthesis. Science 318, 783&#x2013;787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MS, and White MC (2010). Combined effects on selectivity in Fe-catalyzed methylene oxidation. Science 327, 566&#x2013;571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Liu Y, Lan T, Qin W, Zhu Y, Qin K, Gao J, Wang H, Hou X, Chen N, et al. (2018). Quantitative Profiling of Protein Carbonylations in Ferroptosis by an Aniline-Derived Probe. J Am Chem Soc 140, 4712&#x2013;4720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord ENJ, Smith AC, et al. (2014). Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515, 431&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chouchani ET, Pell VR, James AM, Work LM, Saeb-Parsy K, Frezza C, Krieg T, and Murphy MP (2016). A Unifying Mechanism for Mitochondrial Superoxide Production during Ischemia-Reperfusion Injury. Cell Metab 23, 254&#x2013;263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Lorenz SM, and Proneth B. (2021). Targeting Ferroptosis: New Hope for As-Yet-Incurable Diseases. Trends Mol Med 27, 113&#x2013;122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, and Pratt DA (2019). The chemical basis of ferroptosis. Nat Chem Biol 15, 1137&#x2013;1147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, and Sato H. (2012). The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (&#x2212;) : cystine supplier and beyond. Amino Acids 42, 231&#x2013;246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, Triplett K, Lamb C, Alters SE, Rowlinson S, et al. (2017). Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med 23, 120&#x2013;127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, Superti-Furga G, and Stockwell BR (2015). Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol 10, 1604&#x2013;1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Grocin AG, Xavier da Silva TN, Panzilius E, Scheel CH, et al. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693&#x2013;698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13, 91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, and Stockwell BR (2003). Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton JK, Furst L, Cai LL, Viswanathan VS, and Schreiber SL (2020a). Structure-activity relationships of GPX4 inhibitor warheads. Bioorg Med Chem Lett 30, 127538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton JK, Furst L, Ruberto RA, Moosmayer D, Hilpmann A, Ryan MJ, Zimmermann K, Cai LL, Niehues M, Badock V, et al. (2020b). Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol 16, 497&#x2013;506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Krysko DV, and Conrad M. (2019). Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer 19, 405&#x2013;414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, et al. (2014). Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16, 1180&#x2013;1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Bravo-San Pedro JM, and Kroemer G. (2014). Organelle-specific initiation of cell death. Nat Cell Biol 16, 728&#x2013;736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Pan Q, Zhang W, Xiang J, and Jiang X. (2016). Ferroptosis is an autophagic cell death process. Cell research 26, 1021&#x2013;1032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Quadri N, Ramasamy R, and Jiang X. (2015). Glutaminolysis and Transferrin Regulate Ferroptosis. Mol Cell 59, 298&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, Heindel DW, Zuckerman DS, Bos PH, Reznik E, et al. (2018). FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 14, 507&#x2013;515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gascon S., Murenu E., Masserdotti G., Ortega F., Russo GL., Petrik D., Deshpande A., Heinrich C., Karow M., Robertson SP., et al.. (2016). Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming. Cell stem cell 18, 396&#x2013;409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gout PW, Buckley AR, Simms CR, and Bruchovsky N. (2001). Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15, 1633&#x2013;1640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greer EL, and Shi Y. (2012). Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13, 343&#x2013;357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffith OW, and Meister A. (1979). Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254, 7558&#x2013;7560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gryzik M, Asperti M, Denardo A, Arosio P, and Poli M. (2021). NCOA4-mediated ferritinophagy promotes ferroptosis induced by erastin, but not by RSL3 in HeLa cells. Biochim Biophys Acta Mol Cell Res 1868, 118913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, and Lander ES (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645&#x2013;659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hentze MW, Muckenthaler MU, Galy B, and Camaschella C. (2010). Two to tango: regulation of Mammalian iron metabolism. Cell 142, 24&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homma T, Kobayashi S, Sato H, and Fujii J. (2021). Superoxide produced by mitochondrial complex III plays a pivotal role in the execution of ferroptosis induced by cysteine starvation. Arch Biochem Biophys 700, 108775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, Kang R, and Tang D. (2016). Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12, 1425&#x2013;1428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, Roveri A, Peng X, Porto Freitas F, Seibt T, et al. (2018). Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell 172, 409&#x2013;422 e421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al. (2011). CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(&#x2212;) and thereby promotes tumor growth. Cancer Cell 19, 387&#x2013;400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13, 81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasukabe T, Honma Y, Okabe-Kado J, Higuchi Y, Kato N, and Kumakura S. (2016). Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncol Rep 36, 968&#x2013;976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I, Conrad M, Turker MZ, Gao M, Jiang X, et al. (2016). Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol 11, 977&#x2013;985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Muller C, Zandkarimi F, Merl-Pham J, Bao X, Anastasov N, Kossl J, et al. (2020). GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling. ACS Cent Sci 6, 41&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krebs AM., Mitschke J., Lasierra Losada M., Schmalhofer O., Boerries M., Busch H., Boettcher M., Mougiakakos D., Reichardt W., Bronsert P., et al.. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19, 518&#x2013;529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kremer DM, Nelson BS, Lin L, Yarosz EL, Halbrook CJ, Kerk SA, Sajjakulnukit P, Myers A, Thurston G, Hou SW, et al. (2021). GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nature communications 12, 4860.</Citation>
        </Reference>
        <Reference>
          <Citation>Lambert AW, and Weinberg RA (2021). Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer 21, 325&#x2013;338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larraufie MH, Yang WS, Jiang E, Thomas AG, Slusher BS, and Stockwell BR (2015). Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorg Med Chem Lett 25, 4787&#x2013;4792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H, Yoo SE, Na R, Walter CA, Richardson A, and Ran Q. (2009). Short form glutathione peroxidase 4 is the essential isoform required for survival and somatic mitochondrial functions. J Biol Chem 284, 30836&#x2013;30844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, et al. (2019). Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A 116, 9433&#x2013;9442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llabani E, Hicklin RW, Lee HY, Motika SE, Crawford LA, Weerapana E, and Hergenrother PJ (2019). Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis. Nature chemistry 11, 521&#x2013;532.</Citation>
        </Reference>
        <Reference>
          <Citation>Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, Ward CC, Cho K, Patti GJ, Nomura DK, et al. (2019). Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell Chem Biol 26, 420&#x2013;432 e429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mai TT, Hamai A, Hienzsch A, Caneque T, Muller S, Wicinski J, Cabaud O, Leroy C, David A, Acevedo V, et al. (2017). Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nature chemistry 9, 1025&#x2013;1033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890907</ArticleId>
            <ArticleId IdType="pubmed">28937680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, Koppula P, Wu S, Zhuang L, Fang B, et al. (2021). DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586&#x2013;590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8895686</ArticleId>
            <ArticleId IdType="pubmed">33981038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marine JC, Dawson SJ, and Dawson MA (2020). Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer 20, 743&#x2013;756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33033407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, and Kopf M. (2015). T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med 212, 555&#x2013;568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387287</ArticleId>
            <ArticleId IdType="pubmed">25824823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, Carrer A, Salz TH, Natsume S, et al. (2017). Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet 49, 367&#x2013;376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5695682</ArticleId>
            <ArticleId IdType="pubmed">28092686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei J, Webb S, Zhang B, and Shu HB (2006). The p53-inducible apoptotic protein AMID is not required for normal development and tumor suppression. Oncogene 25, 849&#x2013;856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16186796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moosmayer D, Hilpmann A, Hoffmann J, Schnirch L, Zimmermann K, Badock V, Furst L, Eaton JK, Viswanathan VS, Schreiber SL, et al. (2021). Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162. Acta Crystallogr D Struct Biol 77, 237&#x2013;248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7869902</ArticleId>
            <ArticleId IdType="pubmed">33559612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muckenthaler MU, Rivella S, Hentze MW, and Galy B. (2017). A Red Carpet for Iron Metabolism. Cell 168, 344&#x2013;361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5706455</ArticleId>
            <ArticleId IdType="pubmed">28129536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller S, Sindikubwabo F, Caneque T, Lafon A, Versini A, Lombard B, Loew D, Wu TD, Ginestier C, Charafe-Jauffret E, et al. (2020). CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nature chemistry 12, 929&#x2013;938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7612580</ArticleId>
            <ArticleId IdType="pubmed">32747755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto MA, Huang RY, Jackson RA, and Thiery JP (2016). Emt: 2016. Cell 166, 21&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27368099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hutter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, et al. (2021). Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576&#x2013;582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9209846</ArticleId>
            <ArticleId IdType="pubmed">34381210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantopoulos K, Porwal SK, Tartakoff A, and Devireddy L. (2012). Mechanisms of mammalian iron homeostasis. Biochemistry 51, 5705&#x2013;5724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3572738</ArticleId>
            <ArticleId IdType="pubmed">22703180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, et al. (2005). Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 280, 37423&#x2013;37429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16144837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M., Kusumi R., Hamashima S., Kobayashi S., Sasaki S., Komiyama Y., Izumikawa T., Conrad M., Bannai S., and Sato H. (2018). The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin&#x2019;s cytotoxicity in cancer cells. Sci Rep 8, 968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5772355</ArticleId>
            <ArticleId IdType="pubmed">29343855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M, Onuma K, Domon M, Hasegawa S, Suzuki A, Kusumi R, Hino R, Kakihara N, Kanda Y, Osaki M, et al. (2020). Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of mice. Int J Cancer 147, 3224&#x2013;3235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32818320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, Zapukhlyak M, Berning P, Brandle M, Jarboui MA, et al. (2021). Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL. Blood 138, 871&#x2013;884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33876201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, Hubert CG, Mack SC, Jarrar AM, Karl RT, et al. (2015). Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell 28, 441&#x2013;455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4646058</ArticleId>
            <ArticleId IdType="pubmed">26461092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schrader M, and Fahimi HD (2006). Peroxisomes and oxidative stress. Biochim Biophys Acta 1763, 1755&#x2013;1766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17034877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreiber SL (1980). Fragmentation reactions of .alpha.-alkoxy hydroperoxides and application to the synthesis of the macrolide (.+&#x2212;.)-recifeiolide. Journal of the American Chemical Society 102, 6163&#x2013;6165.</Citation>
        </Reference>
        <Reference>
          <Citation>Schreiber SL, Kotz JD, Li M, Aube J, Austin CP, Reed JC, Rosen H, White EL, Sklar LA, Lindsley CW, et al. (2015). Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell 161, 1252&#x2013;1265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4564295</ArticleId>
            <ArticleId IdType="pubmed">26046436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C, Plesnila N, Kremmer E, Radmark O, Wurst W, et al. (2008). Glutathione Peroxidase 4 Senses and Translates Oxidative Stress into 12/15-Lipoxygenase Dependent- and AIF-Mediated Cell Death. Cell Metab 8, 237&#x2013;248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18762024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, et al. (2017). Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5542814</ArticleId>
            <ArticleId IdType="pubmed">28607484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Shchepinov MS, and Pratt DA (2018). Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent Sci 4, 387&#x2013;396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2851638</ArticleId>
            <ArticleId IdType="pubmed">20371346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen S, Vagner S, and Robert C. (2020). Persistent Cancer Cells: The Deadly Survivors. Cell 183, 860&#x2013;874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33186528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ, and Stockwell BR (2016). Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol 12, 497&#x2013;503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soula M, Weber RA, Zilka O, Alwaseem H, La K, Yen F, Molina H, Garcia-Bermudez J, Pratt DA, and Birsoy K. (2020). Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat Chem Biol 16, 1351&#x2013;1360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8299533</ArticleId>
            <ArticleId IdType="pubmed">32778843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, et al. (2010). Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28, 649&#x2013;660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7444750</ArticleId>
            <ArticleId IdType="pubmed">20178109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tonnus W, Meyer C, Steinebach C, Belavgeni A, von Massenhausen A, Gonzalez NZ, Maremonti F, Gembardt F, Himmerkus N, Latk M, et al. (2021). Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury. Nature communications 12, 4402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8292346</ArticleId>
            <ArticleId IdType="pubmed">34285231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, and Torti FM (2013). Iron and cancer: more ore to be mined. Nat Rev Cancer 13, 342&#x2013;355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4036554</ArticleId>
            <ArticleId IdType="pubmed">23594855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, and Torti FM (2020). Iron: The cancer connection. Mol Aspects Med 75, 100860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC9107937</ArticleId>
            <ArticleId IdType="pubmed">32340745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao PJ., Achanta G., Arlinghaus RB., Liu J., et al.. (2006). Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241&#x2013;252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16959615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripathi SK, and Biswal BK (2020). Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent. Pharmacol Res 156, 104772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32283222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turcu AL, Versini A, Khene N, Gaillet C, Caneque T, Muller S, and Rodriguez R. (2020). DMT1 Inhibitors Kill Cancer Stem Cells by Blocking Lysosomal Iron Translocation. Chemistry 26, 7369&#x2013;7373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32083771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, Gu Z, McCormick ML, Durham AB, Spitz DR, et al. (2020). Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585, 113&#x2013;118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7484468</ArticleId>
            <ArticleId IdType="pubmed">32814895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinogradova M, Gehling VS, Gustafson A, Arora S, Tindell CA, Wilson C, Williamson KE, Guler GD, Gangurde P, Manieri W, et al. (2016). An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol 12, 531&#x2013;538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27214401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, et al. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Yen FS, Zhu XG, Timson RC, Weber R, Xing C, Liu Y, Allwein B, Luo H, Yeh HW, et al. (2021). SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells. Nature 599, 136&#x2013;140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34707288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber RA, Yen FS, Nicholson SPV, Alwaseem H, Bayraktar EC, Alam M, Timson RC, La K, Abu-Remaileh M, Molina H, et al. (2020). Maintaining Iron Homeostasis Is the Key Role of Lysosomal Acidity for Cell Proliferation. Mol Cell 77, 645&#x2013;655 e647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7176020</ArticleId>
            <ArticleId IdType="pubmed">31983508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani S, Palmer M, Stockwell BR, Schreiber SL, et al. (2012). Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett 22, 1822&#x2013;1826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3528973</ArticleId>
            <ArticleId IdType="pubmed">22297109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams ED, Gao D, Redfern A, and Thompson EW (2019). Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat Rev Cancer 19, 716&#x2013;732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7055151</ArticleId>
            <ArticleId IdType="pubmed">31666716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie S, Sun W, Zhang C, Dong B, Yang J, Hou M, Xiong L, Cai B, Liu X, and Xue W. (2021). Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy. ACS Nano 15, 7179&#x2013;7194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33861924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu W, Barrientos T, and Andrews NC (2013). Iron and copper in mitochondrial diseases. Cell Metab 17, 319&#x2013;328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3594794</ArticleId>
            <ArticleId IdType="pubmed">23473029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Qin Z, Ma J, Cao W, and Zhang P. (2020). Recent progress in nanotechnology based ferroptotic therapies for clinical applications. Eur J Pharmacol 880, 173198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32473167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi Y., Kasukabe T., and Kumakura S. (2018). Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol 52, 1011&#x2013;1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29393418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J, Zhang Z, and Wang X. (2021). Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1. Mol Cell 81, 355&#x2013;369 e310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33321093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, et al. (2020). Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 21, 341&#x2013;352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7250738</ArticleId>
            <ArticleId IdType="pubmed">32300252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, and Stockwell BR (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 15, 234&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, Uchida K, O&#x2019;Connor OA, and Stockwell BR (2019). Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem Biol 26, 623&#x2013;633 e629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, Shah R, Li B, Friedmann Angeli JP, Griesser M, Conrad M, and Pratt DA (2017). On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent Sci 3, 232&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, Paradkar S, Boehnke N, Deik AA, Reinhardt F, et al. (2020a). Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 585, 603&#x2013;608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8051864</ArticleId>
            <ArticleId IdType="pubmed">32939090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Li H, Graham ET, Deik AA, Eaton JK, Wang W, Sandoval-Gomez G, Clish CB, Doench JG, and Schreiber SL (2020b). Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat Chem Biol 16, 302&#x2013;309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7353921</ArticleId>
            <ArticleId IdType="pubmed">32080622</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34962017</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7006</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer science</Title>
          <ISOAbbreviation>Cancer Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanomedicine targets iron metabolism for cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>828</StartPage>
          <EndPage>837</EndPage>
          <MedlinePgn>828-837</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.15250</ELocationID>
        <Abstract>
          <AbstractText>Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side-effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron-regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Liangru</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-9666-4682</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Hanqing</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ruifang</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Motao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nie</LastName>
            <ForeName>Guangjun</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>KY09040029</GrantID>
            <Agency>Research Foundation of Guangzhou First People's Hospital</Agency>
          </Grant>
          <Grant>
            <GrantID>NSKF202004</GrantID>
            <Agency>Start-up Foundation of NCNST, CAS</Agency>
          </Grant>
          <Grant>
            <GrantID>NSKF202007</GrantID>
            <Agency>Start-up Foundation of NCNST, CAS</Agency>
          </Grant>
          <Grant>
            <GrantID>GJTD-2018-03</GrantID>
            <Agency>K.C. Wong Education Foundation</Agency>
          </Grant>
          <Grant>
            <GrantID>31820103004</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>321171370</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cancer Sci</MedlineTA>
        <NlmUniqueID>101168776</NlmUniqueID>
        <ISSNLinking>1347-9032</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019190" MajorTopicYN="N">Iron Overload</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050997" MajorTopicYN="Y">Nanomedicine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron metabolism</Keyword>
        <Keyword MajorTopicYN="N">iron reductive therapy</Keyword>
        <Keyword MajorTopicYN="N">nanodrug delivery system</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflict of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34962017</ArticleId>
        <ArticleId IdType="pmc">PMC8898713</ArticleId>
        <ArticleId IdType="doi">10.1111/cas.15250</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adam AC, Bornh&#xf6;vd C, Prokisch H, Neupert W, Hell K. The Nfs1 interacting protein Isd11 has an essential role in Fe/S cluster biogenesis in mitochondria. EMBO J. 2006;25:174&#x2010;183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1356348</ArticleId>
            <ArticleId IdType="pubmed">16341090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda Y, Imao M, Satoh A, et al. Iron&#x2010;induced skeletal muscle atrophy involves an Akt&#x2010;forkhead box O3&#x2013;E3 ubiquitin ligase&#x2010;dependent pathway. J Trace ElemMed Biol. 2016;35:66&#x2010;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27049128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DG, Kam MK, Lee S&#x2010;R, Lee HJ, Lee D&#x2010;S. Peroxiredoxin 5 deficiency exacerbates iron overload&#x2010;induced neuronal death via ER&#x2010;mediated mitochondrial fission in mouse hippocampus. Cell Death Dis. 2020;11:204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7090063</ArticleId>
            <ArticleId IdType="pubmed">32205843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Chang W, Wu H, et al. Pan&#x2010;cancer analysis of iron metabolic landscape across the Cancer Genome Atlas. J Cell Physiol. 2020;235:1013&#x2010;1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31240715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, Manz DH, Paul BT, Blanchette&#x2010;Farra N, Torti FM. Iron and cancer. Annu Rev Nutr. 2018;38:97&#x2010;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8118195</ArticleId>
            <ArticleId IdType="pubmed">30130469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung M, Mertens C, Tomat E, Br&#xfc;ne B. Iron as a central player and promising target in cancer progression. Int J Mol Sci. 2019;20:273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6359419</ArticleId>
            <ArticleId IdType="pubmed">30641920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou J, Jiang Y, Zhao J, et al. Dp44mT, an iron chelator, suppresses growth and induces apoptosis via RORA&#x2010;mediated NDRG2&#x2010;IL6/JAK2/STAT3 signaling in glioma. Cell Oncol. 2020;43:461&#x2010;475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32207044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le NTV, Richardson DR. Potent iron chelators increase the mRNA levels of the universal cyclin&#x2010;dependent kinase inhibitor p21 CIP1/WAF1, but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis. 2003;24:1045&#x2010;1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12807743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang H, Han M, Xue J, et al. Renal clearable nanochelators for iron overload therapy. Nat Commun. 2019;10:5134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6853917</ArticleId>
            <ArticleId IdType="pubmed">31723130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corc&#xe9; V, Gouin SG, Renaud S, Gaboriau F, Deniaud D. Recent advances in cancer treatment by iron chelators. Bioorg Med Chem Lett. 2016;26:251&#x2010;256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26684852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed SA, Hasan MN, Bagchi D, et al. Combating essential metal toxicity: Key information from optical spectroscopy. ACS Omega. 2020;5:15666&#x2010;15672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7331209</ArticleId>
            <ArticleId IdType="pubmed">32637841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266&#x2010;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8142022</ArticleId>
            <ArticleId IdType="pubmed">33495651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafner M, Mills CE, Subramanian K, et al. Multiomics profiling establishes the polypharmacology of FDA&#x2010;approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26:1067&#x2010;1080.e1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6936329</ArticleId>
            <ArticleId IdType="pubmed">31178407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JX, Hou MF, Sun WS, et al. Sequential PDT and PTT using dual&#x2010;modal single&#x2010;walled carbon nanohorns synergistically promote systemic immune responses against tumor metastasis and relapse. Adv Sci. 2020;7:2001088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7435231</ArticleId>
            <ArticleId IdType="pubmed">32832363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma V, Sharma AK, Punj V, Priya P. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. Semin Cancer Biol. 2019;59:133&#x2010;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31408722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Li MY, Gao XM, Chen YH, Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J Hematol Oncol. 2019;12:137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6918551</ArticleId>
            <ArticleId IdType="pubmed">31847897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi JJ, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20&#x2010;37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5575742</ArticleId>
            <ArticleId IdType="pubmed">27834398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu G, Chen X. Host&#x2010;guest chemistry in supramolecular theranostics. Theranostics. 2019;9:3041&#x2010;3074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6567976</ArticleId>
            <ArticleId IdType="pubmed">31244941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhong X, Liu Z, Cheng L. Recent progress of chemodynamic therapy&#x2010;induced combination cancer therapy. Nano Today. 2020;35:100946.</Citation>
        </Reference>
        <Reference>
          <Citation>Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A. Effects of curcumin on mitochondria in neurodegenerative diseases. BioFactors. 2020;46:5&#x2010;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31580521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawada H, Hao H, Naito Y, et al. Aortic iron overload with oxidative stress and inflammation in human and murine abdominal aortic aneurysm. Arterioscl Throm Vas. 2015;35:1507&#x2010;1514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25882069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Raaij S, van Swelm R, Bouman K, et al. Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease. Sci Rep. 2018;8:9353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6008459</ArticleId>
            <ArticleId IdType="pubmed">29921869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Y, Li X, Dong DD, Zhang B, Xue YR, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8:916&#x2010;931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6048407</ArticleId>
            <ArticleId IdType="pubmed">30034931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary K, Promsote W, Ananth S, et al. Iron overload accelerates the progression of diabetic retinopathy in association with increased retinal renin expression. Sci Rep. 2018;8:3025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5813018</ArticleId>
            <ArticleId IdType="pubmed">29445185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology. 2006;130:2087&#x2010;2098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16762631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing X, Lin J, Du T, et al. Iron overload is associated with accelerated progression of osteoarthritis: The role of DMT1 mediated iron homeostasis. Front Cell Dev Biol. 2021;8:594509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7813682</ArticleId>
            <ArticleId IdType="pubmed">33469535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Wang Z, Ye J, Mei S, Zhang J. Identification of iron metabolism&#x2010;related genes as prognostic indicators for lower&#x2010;grade glioma. Front Oncol. 2021;11:729103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8458946</ArticleId>
            <ArticleId IdType="pubmed">34568059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidman JD. The presence of mucosal iron in the fallopian tube supports the "incessant menstruation hypothesis" for ovarian carcinoma. Int J Gynecol Pathol. 2013;32:454&#x2010;458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23896711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron&#x2010;induced persistent oxidative stress. Clin Cancer Res. 2008;14:32&#x2010;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18172249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen J, Sheng X, Chang Z, et al. Iron metabolism regulates p53 signaling through direct heme&#x2010;p53 interaction and modulation of p53 localization, stability, and function. Cell Rep. 2014;7:180&#x2010;193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4219651</ArticleId>
            <ArticleId IdType="pubmed">24685134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Q, Chen J, Feng J, Wang J. E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin. Cell Death Dis. 2018;9:987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6155336</ArticleId>
            <ArticleId IdType="pubmed">30250199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipper CH, Karmi O, Sohn YS, et al. Structure of the human monomeric NEET protein MiNT and its role in regulating iron and reactive oxygen species in cancer cells. Proc Natl Acad Sci U S A. 2018;115:272&#x2010;277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777063</ArticleId>
            <ArticleId IdType="pubmed">29259115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittler R, Darash&#x2010;Yahana M, Sohn YS, et al. NEET proteins: A new link between iron metabolism, reactive oxygen species, and cancer. Antioxid Redox Signal. 2019;30:1083&#x2010;1095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29463105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raggi C, Gammella E, Correnti M, et al. Dysregulation of iron metabolism in cholangiocarcinoma stem&#x2010;like cells. Sci Rep. 2017;7:17667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5732280</ArticleId>
            <ArticleId IdType="pubmed">29247214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchette&#x2010;Farra N, Kita D, Konstorum A, et al. Contribution of three&#x2010;dimensional architecture and tumor&#x2010;associated fibroblasts to hepcidin regulation in breast cancer. Oncogene. 2018;37:4013&#x2010;4032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6054540</ArticleId>
            <ArticleId IdType="pubmed">29695834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q, Wu W&#x2010;S, Su L, et al. Mitochondrial ferritin is a hypoxia&#x2010;inducible factor 1&#x3b1;&#x2010;inducible gene that protects from hypoxia&#x2010;induced cell death in brain. Antioxid Redox Signal. 2018;30:198&#x2010;212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29402144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holley CK, Kang YJ, Kuo C&#x2010;F, Abidian MR, Majd S. Development and in vitro assessment of an anti&#x2010;tumor nano&#x2010;formulation. Colloids Surf B Biointerfaces. 2019;184:110481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31539751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tevlin R, Longaker MT, Wan DC. Deferoxamine to minimize fibrosis during radiation therapy. Adv Wound Care. 2021. doi:10.1089/wound.2021.0021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/wound.2021.0021</ArticleId>
            <ArticleId IdType="pubmed">34074152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keeler B, Brookes M. Iron chelation: A potential therapeutic strategy in oesophageal cancer. Br J Pharmacol. 2012;168:1313&#x2010;1315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3596638</ArticleId>
            <ArticleId IdType="pubmed">23278384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedford M, Ford S, Horniblow R, Iqbal T, Tselepis C. Iron chelation in the treatment of cancer: A new role for deferasirox? J Clin Pharmacol. 2013;53:885&#x2010;891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23740857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang J, Zhao X, Wang X, et al. Targeted co&#x2010;delivery of the iron chelator deferoxamine and a HIF1&#x3b1; inhibitor impairs pancreatic tumor growth. ACS Nano. 2019;13:2176&#x2010;2189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30676731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The hallmarks of ferroptosis. Annu Rev Canc Biol. 2019;3:35&#x2010;54.</Citation>
        </Reference>
        <Reference>
          <Citation>Hao SH, Yu J, He WM, et al. Cysteine dioxygenase 1 mediates erastin&#x2010;induced ferroptosis in human gastric cancer cells. Neoplasia. 2017;19:1022&#x2010;1032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5686465</ArticleId>
            <ArticleId IdType="pubmed">29144989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Henson EE, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4973350</ArticleId>
            <ArticleId IdType="pubmed">27441659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Chen L, Chen C, et al. Targeting ferroptosis in breast cancer. Biomark Res. 2020;8:58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7643412</ArticleId>
            <ArticleId IdType="pubmed">33292585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alim I, Caulfield JT, Chen Y, et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. Cell. 2019;177:1262&#x2010;1279.e25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31056284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen J, Chen H, Ren Z, Zhang P, Chen J, Jiang S. Ultrasmall iron oxide nanoparticles induced ferroptosis via Beclin1/ATG5&#x2010;dependent autophagy pathway. Nano Converg. 2021;8:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8017028</ArticleId>
            <ArticleId IdType="pubmed">33796911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trujillo&#x2010;Alonso V, Pratt EC, Zong H, et al. FDA&#x2010;approved ferumoxytol displays anti&#x2010;leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019;14:616&#x2010;622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6554053</ArticleId>
            <ArticleId IdType="pubmed">30911166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanganeh S, Hutter G, Spitler R, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro&#x2010;inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11:986&#x2010;994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5198777</ArticleId>
            <ArticleId IdType="pubmed">27668795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian XQ, Zhang J, Gu Z, Chen Y. Nanocatalysts&#x2010;augmented Fenton chemical reaction for nanocatalytic tumor therapy. Biomaterials. 2019;211:1&#x2010;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31075521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Liu B, Liu QQ, Du KK, Wang ZF, He NY. Nanomaterial&#x2010;induced ferroptosis for cancer specific therapy. Coordin Chem Rev. 2019;382:160&#x2010;180.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou ZJ, Song JB, Tian R, et al. Activatable singlet oxygen generation from lipid hydroperoxide nanoparticles for cancer therapy. Angew Chem Int Edit. 2017;56:6492&#x2010;6496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5634745</ArticleId>
            <ArticleId IdType="pubmed">28470979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung YS, Lim WT, Park JY, Kim YH. Effect of pH on Fenton and Fenton&#x2010;like oxidation. Environ Technol. 2009;30:183&#x2010;190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19278159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y&#x2010;J, Liu X&#x2010;Y, Xing L, Wan X, Chang X, Jiang H&#x2010;L. Fenton reaction&#x2010;independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32143060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huo M, Wang L, Chen Y, Shi J. Tumor&#x2010;selective catalytic nanomedicine by nanocatalyst delivery. Nat Commun. 2017;8:357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5572465</ArticleId>
            <ArticleId IdType="pubmed">28842577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K&#x2010;T, Lu Y&#x2010;J, Chiu S&#x2010;C, Chang W&#x2010;C, Chuang E&#x2010;Y, Lu S&#x2010;Y. Heterogeneous Fenton reaction enabled selective colon cancerous cell treatment. Sci Rep. 2018;8:16580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6224383</ArticleId>
            <ArticleId IdType="pubmed">30410055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao W, Liu X, Lv Y, et al. Nanolongan with multiple on&#x2010;demand conversions for ferroptosis&#x2010;apoptosis combined anticancer therapy. ACS Nano. 2019;13:260&#x2010;273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30616348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue C&#x2010;C, Li M&#x2010;H, Zhao Y, et al. Tumor microenvironment&#x2010;activatable Fe&#x2010;doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells. Sci Adv. 2020;6:eaax1346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7190311</ArticleId>
            <ArticleId IdType="pubmed">32494659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S, Jiang Y, Li J, Pu K. Semiconducting polycomplex nanoparticles for photothermal ferrotherapy of cancer. Angew Chem Int Ed Engl. 2020;59:10633&#x2010;10638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32207214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Zhao X, Huang J, et al. Transformable hybrid semiconducting polymer nanozyme for second near&#x2010;infrared photothermal ferrotherapy. Nat Commun. 2020;11:1857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7170847</ArticleId>
            <ArticleId IdType="pubmed">32312987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min H, Qi Y, Zhang Y, et al. A graphdiyne oxide&#x2010;based iron sponge with photothermally enhanced tumor&#x2010;specific Fenton chemistry. Adv Mater. 2020;32:2000038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32596808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360&#x2010;378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33907315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Liu S, Li C, et al. Discovery of a novel ferroptosis inducer&#x2010;talaroconvolutin A&#x2014;killing colorectal cancer cells in vitro and in vivo. Cell Death Dis. 2020;11:988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7673992</ArticleId>
            <ArticleId IdType="pubmed">33203867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Li F, Lu G&#x2010;H, et al. Engineering magnetosomes for ferroptosis/immunomodulation synergism in cancer. ACS Nano. 2019;13:5662&#x2010;5673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31046234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Q, Wang K, Zhang X, et al. Platelet membrane&#x2010;camouflaged magnetic nanoparticles for ferroptosis&#x2010;enhanced cancer immunotherapy. Small. 2020;16:2001704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32338436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan C, Sun Y, Tian Y, et al. Irradiated tumor cell&#x2010;derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv. 2020;6:eaay9789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7096163</ArticleId>
            <ArticleId IdType="pubmed">32232155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai E, Han L, Liu J, et al. Autophagy&#x2010;dependent ferroptosis drives tumor&#x2010;associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16:2069&#x2010;2083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7595620</ArticleId>
            <ArticleId IdType="pubmed">31920150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cr&#xe9;pin R, Goenaga A&#x2010;L, Jullienne B, et al. Development of human single&#x2010;chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010;70:5497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20530676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato I, Umemura M, Mitsudo K, et al. Simultaneous hyperthermia&#x2010;chemotherapy with controlled drug delivery using single&#x2010;drug nanoparticles. Sci Rep. 2016;6:24629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4840378</ArticleId>
            <ArticleId IdType="pubmed">27103308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Deng T, Liu R, et al. CAF secreted miR&#x2010;522 suppresses ferroptosis and promotes acquired chemo&#x2010;resistance in gastric cancer. Mol Cancer. 2020;19:43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7045485</ArticleId>
            <ArticleId IdType="pubmed">32106859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Gao H, Zhang Y, Liu G, Niu G, Chen X. Functional ferritin nanoparticles for biomedical applications. Front Chem Sci Eng. 2017;11:633&#x2010;646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5831262</ArticleId>
            <ArticleId IdType="pubmed">29503759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1:10&#x2010;29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5689513</ArticleId>
            <ArticleId IdType="pubmed">29313004</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34944434</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2218-273X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomolecules</Title>
          <ISOAbbreviation>Biomolecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Insight into the Double-Edged Role of Ferroptosis in Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1790</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biom11121790</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis, a newly described type of iron-dependent programmed cell death that is distinct from apoptosis, necroptosis, and other types of cell death, is involved in lipid peroxidation (LP), reactive oxygen species (ROS) production, and mitochondrial dysfunction. Accumulating evidence has highlighted vital roles for ferroptosis in multiple diseases, including acute kidney injury, cancer, hepatic fibrosis, Parkinson's disease, and Alzheimer's disease. Therefore, ferroptosis has become one of the research hotspots for disease treatment and attracted extensive attention in recent years. This review mainly summarizes the relationship between ferroptosis and various diseases classified by the system, including the urinary system, digestive system, respiratory system, nervous system. In addition, the role and molecular mechanism of multiple inhibitors and inducers for ferroptosis are further elucidated. A deeper understanding of the relationship between ferroptosis and multiple diseases may provide new strategies for researching diseases and drug development based on ferroptosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-7781-3478</Identifier>
            <AffiliationInfo>
              <Affiliation>Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Ruohan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Clinical Medicine, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huizhen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Clinical Medicine, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Huarun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Clinical Medicine, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Keke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Clinical Medicine, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Shuangshuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yanzhang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Biomolecules</MedlineTA>
        <NlmUniqueID>101596414</NlmUniqueID>
        <ISSNLinking>2218-273X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004066" MajorTopicYN="N">Digestive System Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014570" MajorTopicYN="N">Urologic Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">inducers</Keyword>
        <Keyword MajorTopicYN="N">inhibitors</Keyword>
        <Keyword MajorTopicYN="N">systemic diseases</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>1</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34944434</ArticleId>
        <ArticleId IdType="pmc">PMC8699194</ArticleId>
        <ArticleId IdType="doi">10.3390/biom11121790</ArticleId>
        <ArticleId IdType="pii">biom11121790</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., Stockwell B.R. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016;26:165&#x2013;176. doi: 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X., Ping J., Wen Y., Wu Y. The Mechanism of Ferroptosis and Applications in Tumor Treatment. Front. Pharm. 2020;11:1061. doi: 10.3389/fphar.2020.01061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.01061</ArticleId>
            <ArticleId IdType="pmc">PMC7388725</ArticleId>
            <ArticleId IdType="pubmed">32774303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashraf A., So P.W. Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer&#x2019;s Disease. Front. Aging Neurosci. 2020;12:196. doi: 10.3389/fnagi.2020.00196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2020.00196</ArticleId>
            <ArticleId IdType="pmc">PMC7371849</ArticleId>
            <ArticleId IdType="pubmed">32760266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell B.R., Friedmann Angeli J.P., Bayir H., Bush A.I., Conrad M., Dixon S.J., Fulda S., Gasc&#xf3;n S., Hatzios S.K., Kagan V.E., et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai O., Yasuzawa T., Sumikawa Y., Ueta T., Imai H., Sawabe A., Ueshima S. Role of GPx4 in human vascular endothelial cells, and the compensatory activity of brown rice on GPx4 ablation condition. Pathophysiology. 2017;24:9&#x2013;15. doi: 10.1016/j.pathophys.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pathophys.2016.11.002</ArticleId>
            <ArticleId IdType="pubmed">27964880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Liu W., Liu F., Wang Q., Song M., Yu Q., Tang K., Teng T., Wu D., Wang X., et al. IMCA Induces Ferroptosis Mediated by SLC7A11 through the AMPK/mTOR Pathway in Colorectal Cancer. Oxidative Med. Cell. Longev. 2020;2020:1675613. doi: 10.1155/2020/6901472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/6901472</ArticleId>
            <ArticleId IdType="pmc">PMC7641259</ArticleId>
            <ArticleId IdType="pubmed">33194006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skonieczna M., Cieslar-Pobuda A., Saenko Y., Foksinski M., Olinski R., Rzeszowska-Wolny J., Wiechec E. The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation. Med. Chem. 2017;13:477&#x2013;483. doi: 10.2174/1573406413666170421102353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1573406413666170421102353</ArticleId>
            <ArticleId IdType="pubmed">28427245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., SriRamaratnam R., Welsch M.E., Shimada K., Skouta R., Viswanathan V.S., Cheah J.H., Clemons P.A., Shamji A.F., Clish C.B., et al. Regulation of ferroptotic cancer cell death by GPX. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B., Vandenabeele P., Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830&#x2013;849. doi: 10.1016/j.ccell.2019.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.04.002</ArticleId>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GBD 2016 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990&#x2013;2017: A systematic analysis for the Global Burden of Disease Study. Lancet. 2018;392:1923&#x2013;1994. doi: 10.1016/S0140-6736(18)32225-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)32225-6</ArticleId>
            <ArticleId IdType="pmc">PMC6227755</ArticleId>
            <ArticleId IdType="pubmed">30496105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z., Zhang H., Yang S.K., Wu X., He D., Cao K., Zhang W. Emerging Role of Ferroptosis in Acute Kidney Injury. Oxidative Med. Cell. Longev. 2019;2019:8010614. doi: 10.1155/2019/8010614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/8010614</ArticleId>
            <ArticleId IdType="pmc">PMC6875218</ArticleId>
            <ArticleId IdType="pubmed">31781351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singbartl K., Formeck C.L., Kellum J.A. Kidney-Immune System Crosstalk in AKI. Semin. Nephrol. 2019;39:96&#x2013;106. doi: 10.1016/j.semnephrol.2018.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semnephrol.2018.10.007</ArticleId>
            <ArticleId IdType="pubmed">30606411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z., Wu J., Xu H., Zhou C., Han B., Zhu H., Hu Z., Ma Z., Ming Z., Yao Y., et al. XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury. Cell Death Dis. 2020;11:629. doi: 10.1038/s41419-020-02871-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-02871-6</ArticleId>
            <ArticleId IdType="pmc">PMC7429848</ArticleId>
            <ArticleId IdType="pubmed">32796819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z., Zhang H., Yi B., Yang S., Liu J., Hu J., Wang J., Cao K., Zhang W. VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis. Cell Death Dis. 2020;11:73. doi: 10.1038/s41419-020-2256-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2256-z</ArticleId>
            <ArticleId IdType="pmc">PMC6989512</ArticleId>
            <ArticleId IdType="pubmed">31996668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drummond G.S., Baum J., Greenberg M., Lewis D., Abraham N.G. HO-1 overexpression and underexpression: Clinical implications. Arch. Biochem. Biophys. 2019;673:108073. doi: 10.1016/j.abb.2019.108073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.abb.2019.108073</ArticleId>
            <ArticleId IdType="pmc">PMC6748652</ArticleId>
            <ArticleId IdType="pubmed">31425676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adedoyin O., Boddu R., Traylor A., Lever J.M., Bolisetty S., George J.F., Agarwal A. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am. J. Physiol. Renal. Physiol. 2018;314:F702&#x2013;F714. doi: 10.1152/ajprenal.00044.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00044.2017</ArticleId>
            <ArticleId IdType="pmc">PMC6031916</ArticleId>
            <ArticleId IdType="pubmed">28515173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su L., Jiang X., Yang C., Zhang J., Chen B., Li Y., Yao S., Xie Q., Gomez H., Murugan R., et al. Pannexin 1 mediates ferroptosis that contributes to renal ischemia/reperfusion injury. J. Biol. Chem. 2019;294:19395&#x2013;19404. doi: 10.1074/jbc.RA119.010949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA119.010949</ArticleId>
            <ArticleId IdType="pmc">PMC6916502</ArticleId>
            <ArticleId IdType="pubmed">31694915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo L., Zhang T., Wang F., Chen X., Xu H., Zhou C., Chen M., Yu F., Wang S., Yang D., et al. Targeted inhibition of Rev-erb-alpha/beta limits ferroptosis to ameliorate folic acid-induced acute kidney injury. Br. J. Pharmacol. 2021;178:328&#x2013;345. doi: 10.1111/bph.15283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.15283</ArticleId>
            <ArticleId IdType="pubmed">33068011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang S., Xiao X. Ferroptosis and kidney diseases. Int. Urol. Nephrol. 2020;52:497&#x2013;503. doi: 10.1007/s11255-019-02335-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11255-019-02335-7</ArticleId>
            <ArticleId IdType="pubmed">31768804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leemans J.C., Kors L., Anders H.J., Florquin S. Pattern recognition receptors and the inflammasome in kidney disease. Nat. Rev. Nephrol. 2014;10:398&#x2013;414. doi: 10.1038/nrneph.2014.91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneph.2014.91</ArticleId>
            <ArticleId IdType="pubmed">24890433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Sanchez D., Fontecha-Barriuso M., Martinez-Moreno J.M., Ramos A.M., Sanchez-Ni&#xf1;o M.D., Guerrero-Hue M., Moreno J.A., Ortiz A., Sanz A.B. Ferroptosis and kidney disease. Nefrologia. 2020;40:384&#x2013;394. doi: 10.1016/j.nefro.2020.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nefro.2020.03.005</ArticleId>
            <ArticleId IdType="pubmed">32624210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q., Liu J., Kang R., Zhou B., Tang D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 2019;510:278&#x2013;283. doi: 10.1016/j.bbrc.2019.01.090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.01.090</ArticleId>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 2011;11:85&#x2013;95. doi: 10.1038/nrc2981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2981</ArticleId>
            <ArticleId IdType="pubmed">21258394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.H., Ding C.C., Sun T., Rupprecht G., Lin C.C., Hsu D., Chi J.T. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Cell Rep. 2019;28:2501&#x2013;2508.e2504. doi: 10.1016/j.celrep.2019.07.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2019.07.107</ArticleId>
            <ArticleId IdType="pubmed">31484063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PDQ Pediatric Treatment Editorial Board . PDQ Cancer Information Summaries. National Cancer Institute (US); Bethesda, MD, USA: 2002. Neuroblastoma Treatment (PDQ&#xae;): Health Professional Version.</Citation>
        </Reference>
        <Reference>
          <Citation>Ogor P., Yoshida T., Koike M., Kakizuka A. VCP relocalization limits mitochondrial activity, GSH depletion and ferroptosis during starvation in PC3 prostate cancer cells. Genes Cells Devoted Mol. Cell. Mech. 2021;26:570&#x2013;582. doi: 10.1111/gtc.12872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/gtc.12872</ArticleId>
            <ArticleId IdType="pubmed">34033175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tousignant K.D., Rockstroh A., Poad B.L.J., Talebi A., Young R.S.E., Taherian Fard A., Gupta R., Zang T., Wang C., Lehman M.L., et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab. 2020;8:11. doi: 10.1186/s40170-020-00217-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40170-020-00217-6</ArticleId>
            <ArticleId IdType="pmc">PMC7304214</ArticleId>
            <ArticleId IdType="pubmed">32577235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nassar Z.D., Mah C.Y., Dehairs J., Burvenich I.J., Irani S., Centenera M.M., Helm M., Shrestha R.K., Moldovan M., Don A.S., et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. eLife. 2020;9:e54166. doi: 10.7554/eLife.54166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.54166</ArticleId>
            <ArticleId IdType="pmc">PMC7386908</ArticleId>
            <ArticleId IdType="pubmed">32686647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blomme A., Ford C.A., Mui E., Patel R., Ntala C., Jamieson L.E., Planque M., McGregor G.H., Peixoto P., Hervouet E., et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat. Commun. 2020;11:2508. doi: 10.1038/s41467-020-16126-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-16126-7</ArticleId>
            <ArticleId IdType="pmc">PMC7237503</ArticleId>
            <ArticleId IdType="pubmed">32427840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X., Zou L., Chen W., Yang T., Luo J., Wu K., Shu F., Tan X., Yang Y., Cen S., et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol. Res. 2021;164:105305. doi: 10.1016/j.phrs.2020.105305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2020.105305</ArticleId>
            <ArticleId IdType="pubmed">33197601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Guo S., Wang S., Li X., Hou D., Li H., Wang L., Xu Y., Ma B., Wang H., et al. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicol. Environ. Saf. 2021;220:112376. doi: 10.1016/j.ecoenv.2021.112376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ecoenv.2021.112376</ArticleId>
            <ArticleId IdType="pubmed">34051661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi J., Zhu J., Wu J., Thompson C.B., Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc. Natl. Acad. Sci. USA. 2020;117:31189&#x2013;31197. doi: 10.1073/pnas.2017152117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2017152117</ArticleId>
            <ArticleId IdType="pmc">PMC7733797</ArticleId>
            <ArticleId IdType="pubmed">33229547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Minikes A.M., Gao M., Bian H., Li Y., Stockwell B.R., Chen Z.N., Jiang X. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572:402&#x2013;406. doi: 10.1038/s41586-019-1426-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1426-6</ArticleId>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Y., Yang H., Lin R., Jiang K., Wang B.M. The role of ferroptosis in digestive system cancer. Oncol. Lett. 2019;18:2159&#x2013;2164. doi: 10.3892/ol.2019.10568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.10568</ArticleId>
            <ArticleId IdType="pmc">PMC6676710</ArticleId>
            <ArticleId IdType="pubmed">31402933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394&#x2013;424. doi: 10.3322/caac.21492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21492</ArticleId>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Deng T., Liu R., Ning T., Yang H., Liu D., Zhang Q., Lin D., Ge S., Bai M., et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol. Cancer. 2020;19:43. doi: 10.1186/s12943-020-01168-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-020-01168-8</ArticleId>
            <ArticleId IdType="pmc">PMC7045485</ArticleId>
            <ArticleId IdType="pubmed">32106859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao S., Yu J., He W., Huang Q., Zhao Y., Liang B., Zhang S., Wen Z., Dong S., Rao J., et al. Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells. Neoplasia. 2017;19:1022&#x2013;1032. doi: 10.1016/j.neo.2017.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2017.10.005</ArticleId>
            <ArticleId IdType="pmc">PMC5686465</ArticleId>
            <ArticleId IdType="pubmed">29144989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Yang S., Feng X., Zheng Y., Zhou J., Wang H., Zhang Y., Sun H., He C. The modification of ferroptosis and abnormal lipometabolism through overexpression and knockdown of potential prognostic biomarker perilipin2 in gastric carcinoma. Gastric Cancer. 2020;23:241&#x2013;259. doi: 10.1007/s10120-019-01004-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10120-019-01004-z</ArticleId>
            <ArticleId IdType="pubmed">31520166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Z., Deng G., Li Y., Huang H., Sun X., Shi H., Yao X., Gao L., Ju Y., Luo M. Actinidia chinensis Planch prevents proliferation and migration of gastric cancer associated with apoptosis, ferroptosis activation and mesenchymal phenotype suppression. Biomed. Pharmacother. 2020;126:110092. doi: 10.1016/j.biopha.2020.110092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2020.110092</ArticleId>
            <ArticleId IdType="pubmed">32203890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S., Qiu T., Yao X., Wang N., Jiang L., Jia X., Tao Y., Wang Z., Pei P., Zhang J., et al. Arsenic induces pancreatic dysfunction and ferroptosis via mitochondrial ROS-autophagy-lysosomal pathway. J. Hazard. Mater. 2020;384:121390. doi: 10.1016/j.jhazmat.2019.121390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhazmat.2019.121390</ArticleId>
            <ArticleId IdType="pubmed">31735470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu S., Zhang Q., Sun X., Zeh H.J., 3rd, Lotze M.T., Kang R., Tang D. HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Res. 2017;77:2064&#x2013;2077. doi: 10.1158/0008-5472.CAN-16-1979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1979</ArticleId>
            <ArticleId IdType="pmc">PMC5392369</ArticleId>
            <ArticleId IdType="pubmed">28130223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shintoku R., Takigawa Y., Yamada K., Kubota C., Yoshimoto Y., Takeuchi T., Koshiishi I., Torii S. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL. Cancer Sci. 2017;108:2187&#x2013;2194. doi: 10.1111/cas.13380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13380</ArticleId>
            <ArticleId IdType="pmc">PMC5666033</ArticleId>
            <ArticleId IdType="pubmed">28837253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eling N., Reuter L., Hazin J., Hamacher-Brady A., Brady N.R. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2015;2:517&#x2013;532. doi: 10.18632/oncoscience.160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncoscience.160</ArticleId>
            <ArticleId IdType="pmc">PMC4468338</ArticleId>
            <ArticleId IdType="pubmed">26097885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J.J., Chen J.T., Hua L., Yao K.H., Wang C.Y. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/beta-catenin signaling pathway. Biomed. Pharmacother. 2017;85:472&#x2013;478. doi: 10.1016/j.biopha.2016.11.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2016.11.053</ArticleId>
            <ArticleId IdType="pubmed">27890434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo K.H., Verma C.S., Lane D.P. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014;13:217&#x2013;236. doi: 10.1038/nrd4236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4236</ArticleId>
            <ArticleId IdType="pubmed">24577402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L., Kon N., Li T., Wang S.J., Su T., Hibshoosh H., Baer R., Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen L.D., Qi W.H., Bai J.J., Zuo C.Y., Bai D.L., Gao W.D., Zong X.L., Hao T.T., Ma Y., Cao G.C. Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation. Anat. Rec. 2021;304:313&#x2013;322. doi: 10.1002/ar.24378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ar.24378</ArticleId>
            <ArticleId IdType="pubmed">31961485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X., Zhang R., Liu S., Duan T., Zhai L., Zhang M., Han X., Xiang Y., Huang X., Lin H., et al. RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer. Front. Pharmacol. 2018;9:1371. doi: 10.3389/fphar.2018.01371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.01371</ArticleId>
            <ArticleId IdType="pmc">PMC6262051</ArticleId>
            <ArticleId IdType="pubmed">30524291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Du L., Qiao Y., Zhang X., Zheng W., Wu Q., Chen Y., Zhu G., Liu Y., Bian Z., et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol. 2019;24:101211. doi: 10.1016/j.redox.2019.101211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2019.101211</ArticleId>
            <ArticleId IdType="pmc">PMC6526247</ArticleId>
            <ArticleId IdType="pubmed">31108460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleire L., Skeie B.S., Netland I.A., Forde H.E., Dodoo E., Selheim F., Leiss L., Heggdal J.I., Pedersen P.H., Wang J., et al. Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc&#x2212;, leading to glutathione depletion. Oncogene. 2015;34:5951&#x2013;5959. doi: 10.1038/onc.2015.60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.60</ArticleId>
            <ArticleId IdType="pubmed">25798841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013;53:401&#x2013;426. doi: 10.1146/annurev-pharmtox-011112-140320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-011112-140320</ArticleId>
            <ArticleId IdType="pmc">PMC4680839</ArticleId>
            <ArticleId IdType="pubmed">23294312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Ou Z., Chen R., Niu X., Chen D., Kang R., Tang D. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173&#x2013;184. doi: 10.1002/hep.28251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie J., Lin B., Zhou M., Wu L., Zheng T. Role of ferroptosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2018;144:2329&#x2013;2337. doi: 10.1007/s00432-018-2740-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-018-2740-3</ArticleId>
            <ArticleId IdType="pubmed">30167889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Niu X., Chen R., He W., Chen D., Kang R., Tang D. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64:488&#x2013;500. doi: 10.1002/hep.28574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28574</ArticleId>
            <ArticleId IdType="pmc">PMC4956496</ArticleId>
            <ArticleId IdType="pubmed">27015352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geldenhuys W.J., Leeper T.C., Carroll R.T. mitoNEET as a novel drug target for mitochondrial dysfunction. Drug Discov. Today. 2014;19:1601&#x2013;1606. doi: 10.1016/j.drudis.2014.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2014.05.001</ArticleId>
            <ArticleId IdType="pubmed">24814435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui M., Jiang X., Chen J., Yang H., Zhu Y. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed. Pharmacother. 2018;106:125&#x2013;133. doi: 10.1016/j.biopha.2018.06.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.06.060</ArticleId>
            <ArticleId IdType="pubmed">29957462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsurusaki S., Tsuchiya Y., Koumura T., Nakasone M., Sakamoto T., Matsuoka M., Imai H., Yuet-Yin Kok C., Okochi H., Nakano H., et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019;10:449. doi: 10.1038/s41419-019-1678-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1678-y</ArticleId>
            <ArticleId IdType="pmc">PMC6579767</ArticleId>
            <ArticleId IdType="pubmed">31209199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong Z., Liu R., Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway. Biomed. Pharmacother. 2019;109:2043&#x2013;2053. doi: 10.1016/j.biopha.2018.11.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.11.030</ArticleId>
            <ArticleId IdType="pubmed">30551460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butt Y., Kurdowska A., Allen T.C. Acute Lung Injury: A Clinical and Molecular Review. Arch. Pathol. Lab. Med. 2016;140:345&#x2013;350. doi: 10.5858/arpa.2015-0519-RA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2015-0519-RA</ArticleId>
            <ArticleId IdType="pubmed">27028393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gowda S.N.S., Raviraj R., Nagarajan D., Zhao W. Radiation-induced lung injury: Impact on macrophage dysregulation and lipid alteration&#x2014;A review. Immunopharmacol. Immunotoxicol. 2019;41:370&#x2013;379. doi: 10.1080/08923973.2018.1533025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08923973.2018.1533025</ArticleId>
            <ArticleId IdType="pubmed">30442050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riley P.A. Free radicals in biology: Oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol. 1994;65:27&#x2013;33. doi: 10.1080/09553009414550041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09553009414550041</ArticleId>
            <ArticleId IdType="pubmed">7905906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basit F., van Oppen L.M., Sch&#xf6;ckel L., Bossenbroek H.M., van Emst-de Vries S.E., Hermeling J.C., Grefte S., Kopitz C., Heroult M., Hgm Willems P., et al. Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis. 2017;8:e2716. doi: 10.1038/cddis.2017.133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2017.133</ArticleId>
            <ArticleId IdType="pmc">PMC5386536</ArticleId>
            <ArticleId IdType="pubmed">28358377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Skouta R., Himmerkus N., Mulay S.R., Dewitz C., De Zen F., Prokai A., Zuchtriegel G., Krombach F., Welz P.S., et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA. 2014;111:16836&#x2013;16841. doi: 10.1073/pnas.1415518111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1415518111</ArticleId>
            <ArticleId IdType="pmc">PMC4250130</ArticleId>
            <ArticleId IdType="pubmed">25385600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Zhuang X., Qiao T. Role of ferroptosis in the process of acute radiation-induced lung injury in mice. Biochem. Biophys. Res. Commun. 2019;519:240&#x2013;245. doi: 10.1016/j.bbrc.2019.08.165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.08.165</ArticleId>
            <ArticleId IdType="pubmed">31493867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN. Int. J. Cancer. 2015;136:E359&#x2013;E386. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaminskyy V.O., Piskunova T., Zborovskaya I.B., Tchevkina E.M., Zhivotovsky B. Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation. Autophagy. 2012;8:1032&#x2013;1044. doi: 10.4161/auto.20123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/auto.20123</ArticleId>
            <ArticleId IdType="pmc">PMC3429541</ArticleId>
            <ArticleId IdType="pubmed">22562073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Yan H., Xu X., Liu H., Wu C., Zhao L. Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. Oncol. Lett. 2020;19:323&#x2013;333. doi: 10.3892/ol.2019.11066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.11066</ArticleId>
            <ArticleId IdType="pmc">PMC6923844</ArticleId>
            <ArticleId IdType="pubmed">31897145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso B.R., Hare D.J., Bush A.I., Roberts B.R. Glutathione peroxidase 4: A new player in neurodegeneration? Mol. Psychiatry. 2017;22:328&#x2013;335. doi: 10.1038/mp.2016.196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2016.196</ArticleId>
            <ArticleId IdType="pubmed">27777421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayton S., Lei P., Hare D.J., Duce J.A., George J.L., Adlard P.A., McLean C., Rogers J.T., Cherny R.A., Finkelstein D.I., et al. Parkinson&#x2019;s disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J. Neurosci. 2015;35:3591&#x2013;3597. doi: 10.1523/JNEUROSCI.3439-14.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3439-14.2015</ArticleId>
            <ArticleId IdType="pmc">PMC6605561</ArticleId>
            <ArticleId IdType="pubmed">25716857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You L.H., Li F., Wang L., Zhao S.E., Wang S.M., Zhang L.L., Zhang L.H., Duan X.L., Yu P., Chang Y.Z. Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson&#x2019;s disease. Neuroscience. 2015;284:234&#x2013;246. doi: 10.1016/j.neuroscience.2014.09.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2014.09.071</ArticleId>
            <ArticleId IdType="pubmed">25301748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N., von Rechenberg M., Zaganjor E., Bauer A.J., Yang W.S., Fridman D.J., Wolpaw A.J., Smukste I., Peltier J.M., Boniface J.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;868. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., Stockwell B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 2008;15:234&#x2013;245. doi: 10.1016/j.chembiol.2008.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2008.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P., Chen L., Zhao Q., Du X., Bi M., Li Y., Jiao Q., Jiang H. Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson&#x2019;s disease. Free Radic. Biol. Med. 2020;152:227&#x2013;234. doi: 10.1016/j.freeradbiomed.2020.03.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.03.015</ArticleId>
            <ArticleId IdType="pubmed">32217194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briggs R., Kennelly S.P., O&#x2019;Neill D. Drug treatments in Alzheimer&#x2019;s disease. Clin. Med. 2016;16:247&#x2013;253. doi: 10.7861/clinmedicine.16-3-247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7861/clinmedicine.16-3-247</ArticleId>
            <ArticleId IdType="pmc">PMC5922703</ArticleId>
            <ArticleId IdType="pubmed">27251914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA. 1986;83:4913&#x2013;4917. doi: 10.1073/pnas.83.13.4913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.13.4913</ArticleId>
            <ArticleId IdType="pmc">PMC323854</ArticleId>
            <ArticleId IdType="pubmed">3088567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Chen W.D., Wang Y.D. &#x3b2;-Amyloid: The key peptide in the pathogenesis of Alzheimer&#x2019;s disease. Front. Pharmacol. 2015;6:221. doi: 10.3389/fphar.2015.00221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2015.00221</ArticleId>
            <ArticleId IdType="pmc">PMC4588032</ArticleId>
            <ArticleId IdType="pubmed">26483691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selkoe D.J. Alzheimer disease and aducanumab: Adjusting our approach. Nat. Rev. Neurol. 2019;15:365&#x2013;366. doi: 10.1038/s41582-019-0205-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-019-0205-1</ArticleId>
            <ArticleId IdType="pubmed">31138932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altamura S., Muckenthaler M.U. Iron toxicity in diseases of aging: Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and atherosclerosis. J. Alzheimers Dis. 2009;16:879&#x2013;895. doi: 10.3233/JAD-2009-1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-2009-1010</ArticleId>
            <ArticleId IdType="pubmed">19387120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayton S., Wang Y., Diouf I., Schneider J.A., Brockman J., Morris M.C., Bush A.I. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol. Psychiatry. 2020;25:2932&#x2013;2941. doi: 10.1038/s41380-019-0375-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41380-019-0375-7</ArticleId>
            <ArticleId IdType="pmc">PMC6698435</ArticleId>
            <ArticleId IdType="pubmed">30778133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashraf A., Jeandriens J., Parkes H.G., So P.W. Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer&#x2019;s disease: Evidence of ferroptosis. Redox Biol. 2020;32:101494. doi: 10.1016/j.redox.2020.101494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2020.101494</ArticleId>
            <ArticleId IdType="pmc">PMC7083890</ArticleId>
            <ArticleId IdType="pubmed">32199332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quintana C., Bellefqih S., Laval J.Y., Guerquin-Kern J.L., Wu T.D., Avila J., Ferrer I., Arranz R., Pati&#xf1;o C. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer&#x2019;s disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 2006;153:42&#x2013;54. doi: 10.1016/j.jsb.2005.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsb.2005.11.001</ArticleId>
            <ArticleId IdType="pubmed">16364657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambright W.S., Fonseca R.S., Chen L., Na R., Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8&#x2013;17. doi: 10.1016/j.redox.2017.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2017.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC5312549</ArticleId>
            <ArticleId IdType="pubmed">28212525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrom Q.T., Gittleman H., Farah P., Ondracek A., Chen Y., Wolinsky Y., Stroup N.E., Kruchko C., Barnholtz-Sloan J.S. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006. Neuro Oncol. 2013;15((Suppl. 2)):ii1&#x2013;ii56. doi: 10.1093/neuonc/not151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/not151</ArticleId>
            <ArticleId IdType="pmc">PMC3798196</ArticleId>
            <ArticleId IdType="pubmed">24137015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee A., Youssef I., Osborn V.W., Safdieh J., Becker D.J., Schreiber D. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis. J. Clin. Neurosci. 2018;51:85&#x2013;90. doi: 10.1016/j.jocn.2018.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2018.02.009</ArticleId>
            <ArticleId IdType="pubmed">29483008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alifieris C., Trafalis D.T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 2015;152:63&#x2013;82. doi: 10.1016/j.pharmthera.2015.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2015.05.005</ArticleId>
            <ArticleId IdType="pubmed">25944528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J., Fan Y.Q., Liu B.H., Zhou H., Wang J.M., Chen Q.X. ACSL4 suppresses glioma cells proliferation via activating ferroptosis. Oncol. Rep. 2020;43:147&#x2013;158. doi: 10.3892/or.2019.7419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2019.7419</ArticleId>
            <ArticleId IdType="pmc">PMC6912066</ArticleId>
            <ArticleId IdType="pubmed">31789401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falk Delgado A., Zommorodi S., Falk Delgado A. Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma. Curr. Oncol. Rep. 2019;21:54. doi: 10.1007/s11912-019-0798-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-019-0798-y</ArticleId>
            <ArticleId IdType="pmc">PMC6486528</ArticleId>
            <ArticleId IdType="pubmed">31028497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo M., Wu L., Zhang K., Wang H., Zhang T., Gutierrez L., O&#x2019;Connell D., Zhang P., Li Y., Gao T., et al. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death. Differ. 2018;25:1457&#x2013;1472. doi: 10.1038/s41418-017-0053-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0053-8</ArticleId>
            <ArticleId IdType="pmc">PMC6113319</ArticleId>
            <ArticleId IdType="pubmed">29348676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11&#x2013;20. doi: 10.1016/j.cmet.2007.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2007.10.002</ArticleId>
            <ArticleId IdType="pubmed">18177721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Monian P., Quadri N., Ramasamy R., Jiang X. Glutaminolysis and Transferrin Regulate Ferroptosis. Mol. Cell. 2015;59:298&#x2013;308. doi: 10.1016/j.molcel.2015.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2015.06.011</ArticleId>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felker G.M., Thompson R.E., Hare J.M., Hruban R.H., Clemetson D.E., Howard D.L., Baughman K.L., Kasper E.K. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 2000;342:1077&#x2013;1084. doi: 10.1056/NEJM200004133421502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM200004133421502</ArticleId>
            <ArticleId IdType="pubmed">10760308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yen H.C., Oberley T.D., Vichitbandha S., Ho Y.S., St Clair D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Investig. 1996;98:1253&#x2013;1260. doi: 10.1172/JCI118909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI118909</ArticleId>
            <ArticleId IdType="pmc">PMC507548</ArticleId>
            <ArticleId IdType="pubmed">8787689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong Y., Liu X., Lee C.P., Chua B.H., Ho Y.S. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic. Biol. Med. 2006;41:46&#x2013;55. doi: 10.1016/j.freeradbiomed.2006.02.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2006.02.024</ArticleId>
            <ArticleId IdType="pubmed">16781452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miura T., Muraoka S., Ogiso T. Adriamycin-induced lipid peroxidation of erythrocyte membranes in the presence of ferritin and the inhibitory effect of ceruloplasmin. Biol. Pharm. Bull. 1993;16:664&#x2013;667. doi: 10.1248/bpb.16.664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1248/bpb.16.664</ArticleId>
            <ArticleId IdType="pubmed">8401398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tadokoro T., Ikeda M., Ide T., Deguchi H., Ikeda S., Okabe K., Ishikita A., Matsushima S., Koumura T., Yamada K.I., et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. 2020;5:e132747. doi: 10.1172/jci.insight.132747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.132747</ArticleId>
            <ArticleId IdType="pmc">PMC7253028</ArticleId>
            <ArticleId IdType="pubmed">32376803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X., Zhu S., Chen P., Hou W., Wen Q., Liu J., Xie Y., Liu J., Klionsky D.J., Kroemer G., et al. AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc&#x2212; Activity. Curr. Biol. 2018;28:2388&#x2013;2399.e5. doi: 10.1016/j.cub.2018.05.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2018.05.094</ArticleId>
            <ArticleId IdType="pmc">PMC6081251</ArticleId>
            <ArticleId IdType="pubmed">30057310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y., Palte M.J., Deik A.A., Li H., Eaton J.K., Wang W., Tseng Y.Y., Deasy R., Kost-Alimova M., Dan&#x10d;&#xed;k V., et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun. 2019;10:1617. doi: 10.1038/s41467-019-09277-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09277-9</ArticleId>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S., Proneth B., Tyurina Y.Y., Panzilius E., Kobayashi S., Ingold I., Irmler M., Beckers J., Aichler M., Walch A., et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 2017;13:91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louandre C., Ezzoukhry Z., Godin C., Barbare J.C., Mazi&#xe8;re J.C., Chauffert B., Galmiche A. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer. 2013;133:1732&#x2013;1742. doi: 10.1002/ijc.28159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.28159</ArticleId>
            <ArticleId IdType="pubmed">23505071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louandre C., Marcq I., Bouhlal H., Lachaier E., Godin C., Saidak Z., Francois C., Chatelain D., Debuysscher V., Barbare J.C., et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 2015;356:971&#x2013;977. doi: 10.1016/j.canlet.2014.11.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.11.014</ArticleId>
            <ArticleId IdType="pubmed">25444922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285&#x2013;296. doi: 10.1016/S1535-6108(03)00050-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00050-3</ArticleId>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata Y., Yasui H., Higashikawa K., Miyamoto N., Kuge Y. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. PLoS ONE. 2019;14:e0225931. doi: 10.1371/journal.pone.0225931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0225931</ArticleId>
            <ArticleId IdType="pmc">PMC6892486</ArticleId>
            <ArticleId IdType="pubmed">31800616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Li Y., Zhang R., Wang F., Wang T., Jiao Y. The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. Onco Targets Ther. 2020;13:5429&#x2013;5441. doi: 10.2147/OTT.S254995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S254995</ArticleId>
            <ArticleId IdType="pmc">PMC7295539</ArticleId>
            <ArticleId IdType="pubmed">32606760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang D., Maldonado E.N. VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation. Adv. Cancer Res. 2018;138:41&#x2013;69. doi: 10.1016/bs.acr.2018.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/bs.acr.2018.02.002</ArticleId>
            <ArticleId IdType="pmc">PMC6234976</ArticleId>
            <ArticleId IdType="pubmed">29551129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M., Kusumi R., Hamashima S., Kobayashi S., Sasaki S., Komiyama Y., Izumikawa T., Conrad M., Bannai S., Sato H. The ferroptosis inducer erastin irreversibly inhibits system Xc&#x2212; and synergizes with cisplatin to increase cisplatin&#x2019;s cytotoxicity in cancer cells. Sci. Rep. 2018;8:968. doi: 10.1038/s41598-018-19213-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-19213-4</ArticleId>
            <ArticleId IdType="pmc">PMC5772355</ArticleId>
            <ArticleId IdType="pubmed">29343855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E.H., Shin D., Lee J., Jung A.R., Roh J.L. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Cancer Lett. 2018;432:180&#x2013;190. doi: 10.1016/j.canlet.2018.06.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.06.018</ArticleId>
            <ArticleId IdType="pubmed">29928961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J., You J.H., Shin D., Roh J.L. Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis. Theranostics. 2020;10:7775&#x2013;7786. doi: 10.7150/thno.46903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.46903</ArticleId>
            <ArticleId IdType="pmc">PMC7359084</ArticleId>
            <ArticleId IdType="pubmed">32685019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H., Yang C., Jian L., Guo S., Chen R., Li K., Qu F., Tao K., Fu Y., Luo F., et al. Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncol. Rep. 2019;42:826&#x2013;838. doi: 10.3892/or.2019.7189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2019.7189</ArticleId>
            <ArticleId IdType="pubmed">31173262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Codenotti S., Poli M., Asperti M., Zizioli D., Marampon F., Fanzani A. Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines. J. Cancer Res. Clin. Oncol. 2018;144:1717&#x2013;1730. doi: 10.1007/s00432-018-2699-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-018-2699-0</ArticleId>
            <ArticleId IdType="pubmed">29971532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vu&#x10d;kovi&#x107; A.M., Bosello Travain V., Bordin L., Cozza G., Miotto G., Rossetto M., Toppo S., Venerando R., Zaccarin M., Maiorino M., et al. Inactivation of the glutathione peroxidase GPx4 by the ferroptosis-inducing molecule RSL3 requires the adaptor protein 14-3-3&#x3b5;. FEBS Lett. 2020;594:611&#x2013;624. doi: 10.1002/1873-3468.13631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.13631</ArticleId>
            <ArticleId IdType="pubmed">31581313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye J., Jiang X., Dong Z., Hu S., Xiao M. Low-Concentration PTX And RSL3 Inhibits Tumor Cell Growth Synergistically by Inducing Ferroptosis In Mutant p53 Hypopharyngeal Squamous Carcinoma. Cancer Manag. Res. 2019;11:9783&#x2013;9792. doi: 10.2147/CMAR.S217944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S217944</ArticleId>
            <ArticleId IdType="pmc">PMC6876222</ArticleId>
            <ArticleId IdType="pubmed">31819616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Lu S., He C., Wang C., Wang L., Piao M., Chi G., Luo Y., Ge P. RSL3 induced autophagic death in glioma cells via causing glycolysis dysfunction. Biochem. Biophys. Res. Commun. 2019;518:590&#x2013;597. doi: 10.1016/j.bbrc.2019.08.096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.08.096</ArticleId>
            <ArticleId IdType="pubmed">31445705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O., Shah R., Li B., Friedmann Angeli J.P., Griesser M., Conrad M., Pratt D.A. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci. 2017;3:232&#x2013;243. doi: 10.1021/acscentsci.7b00028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horwath M.C., Bell-Horwath T.R., Lescano V., Krishnan K., Merino E.J., Deepe G.S., Jr. Antifungal Activity of the Lipophilic Antioxidant Ferrostatin. ChemBioChem. 2017;18:2069&#x2013;2078. doi: 10.1002/cbic.201700105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbic.201700105</ArticleId>
            <ArticleId IdType="pubmed">28783875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao J.Y., Dixon S.J. Mechanisms of ferroptosis. Cell Mol. Life Sci. 2016;73:2195&#x2013;2209. doi: 10.1007/s00018-016-2194-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2194-1</ArticleId>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q., Li Q.Q., Jia J.N., Sun Q.Y., Zhou H.H., Jin W.L., Mao X.Y. Baicalein Exerts Neuroprotective Effects in FeCl3-Induced Posttraumatic Epileptic Seizures via Suppressing Ferroptosis. Front. Pharmacol. 2019;10:638. doi: 10.3389/fphar.2019.00638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.00638</ArticleId>
            <ArticleId IdType="pmc">PMC6568039</ArticleId>
            <ArticleId IdType="pubmed">31231224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., Stockwell B.R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 2014;10:9&#x2013;17. doi: 10.1038/nchembio.1416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1416</ArticleId>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Song X., Sun X., Huang J., Zhong M., Lotze M.T., Zeh H.J.R., Kang R., Tang D. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem. Biophys. Res. Commun. 2016;473:775&#x2013;780. doi: 10.1016/j.bbrc.2016.03.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.03.052</ArticleId>
            <ArticleId IdType="pubmed">27037021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y., Tiziani S., Park G., Kaul M., Paternostro G. Cellular protection using Flt3 and PI3K&#x3b1; inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. Nat. Commun. 2014;5:3672. doi: 10.1038/ncomms4672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms4672</ArticleId>
            <ArticleId IdType="pmc">PMC4128233</ArticleId>
            <ArticleId IdType="pubmed">24739485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K., Zhu X., Zhang K., Wu Z., Sun S., Zhou F., Zhu L. Neuroprotective Effect of Puerarin on Glutamate-Induced Cytotoxicity in Differentiated Y-79 Cells via Inhibition of ROS Generation and Ca2+ Influx. Int. J. Mol. Sci. 2016;17:1109. doi: 10.3390/ijms17071109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17071109</ArticleId>
            <ArticleId IdType="pmc">PMC4964484</ArticleId>
            <ArticleId IdType="pubmed">27409614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Tan H., Daniels J.D., Zandkarimi F., Liu H., Brown L.M., Uchida K., O&#x2019;Connor O.A., Stockwell B.R. Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem. Biol. 2019;26:623&#x2013;633. doi: 10.1016/j.chembiol.2019.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2019.01.008</ArticleId>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan J., Lo M., Dockery P., Mahon S., Karp C.M., Buckley A.R., Lam S., Gout P.W., Wang Y.Z. The Xc&#x2212; cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: Use of sulfasalazine. Cancer Chemother. Pharmacol. 2009;64:463&#x2013;472. doi: 10.1007/s00280-008-0894-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-008-0894-4</ArticleId>
            <ArticleId IdType="pubmed">19104813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L., Na R., Gu M., Richardson A., Ran Q. Lipid peroxidation up-regulates BACE1 expression in vivo: A possible early event of amyloidogenesis in Alzheimer&#x2019;s disease. J. Neurochem. 2008;107:197&#x2013;207. doi: 10.1111/j.1471-4159.2008.05603.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2008.05603.x</ArticleId>
            <ArticleId IdType="pmc">PMC2716044</ArticleId>
            <ArticleId IdType="pubmed">18680556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galmiche A., Chauffert B., Barbare J.C. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 2014;346:159&#x2013;162. doi: 10.1016/j.canlet.2013.12.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.12.028</ArticleId>
            <ArticleId IdType="pubmed">24380851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K., Skouta R., Kaplan A., Yang W.S., Hayano M., Dixon S.J., Brown L.M., Valenzuela C.A., Wolpaw A.J., Stockwell B.R. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 2016;12:497&#x2013;503. doi: 10.1038/nchembio.2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2079</ArticleId>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu C., Zhao W., Yu J., Li S., Lin L., Chen X. Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells. Sci. Rep. 2018;8:574. doi: 10.1038/s41598-017-18935-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-18935-1</ArticleId>
            <ArticleId IdType="pmc">PMC5766540</ArticleId>
            <ArticleId IdType="pubmed">29330409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Monian P., Jiang X. Metabolism and iron signaling in ferroptotic cell death. Oncotarget. 2015;6:35145&#x2013;35146. doi: 10.18632/oncotarget.5671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5671</ArticleId>
            <ArticleId IdType="pmc">PMC4742090</ArticleId>
            <ArticleId IdType="pubmed">26387139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J.P., Schneider M., Proneth B., Tyurina Y.Y., Tyurin V.A., Hammond V.J., Herbach N., Aichler M., Walch A., Eggenhofer E., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014;16:1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita M., Freigang S., Schneider C., Conrad M., Bornkamm G.W., Kopf M. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J. Exp. Med. 2015;212:555&#x2013;568. doi: 10.1084/jem.20140857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20140857</ArticleId>
            <ArticleId IdType="pmc">PMC4387287</ArticleId>
            <ArticleId IdType="pubmed">25824823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torii S., Shintoku R., Kubota C., Yaegashi M., Torii R., Sasaki M., Suzuki T., Mori M., Yoshimoto Y., Takeuchi T., et al. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem. J. 2016;473:769&#x2013;777. doi: 10.1042/BJ20150658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20150658</ArticleId>
            <ArticleId IdType="pubmed">26759376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Zhang S., Gong X., Tam S., Xiao D., Liu S., Tao Y. The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. Mol. Cancer. 2020;19:39. doi: 10.1186/s12943-020-01157-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-020-01157-x</ArticleId>
            <ArticleId IdType="pmc">PMC7045519</ArticleId>
            <ArticleId IdType="pubmed">32103754</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34938072</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1178-2013</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>International journal of nanomedicine</Title>
          <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Curcumin Nanoparticles Inhibiting Ferroptosis for the Enhanced Treatment of Intracerebral Hemorrhage.</ArticleTitle>
        <Pagination>
          <StartPage>8049</StartPage>
          <EndPage>8065</EndPage>
          <MedlinePgn>8049-8065</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S334965</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Intracerebral hemorrhage (ICH) is a form of severe stroke, the pathology of which is tied closely to a recently discovered form of programmed cell death known as ferroptosis. Curcumin (Cur) is a common phenolic compound extracted from the rhizome of Curcuma longa capable of hematoma volume and associated neurological damage in the context of ICH. Despite exhibiting therapeutic promise, the efficacy of Cur is challenged by its poor water solubility, limited oral bioavailability and inability to efficiently transit across the physiological barriers. Polymer-based nanoparticles (NPs) have widely been employed to aid in drug delivery efforts owing to their ideal biocompatibility and their ability to improve the bioavailability and pharmacokinetics of specific drugs of interest.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we encapsulated Cur in NPs (Cur-NPs) and explored the effect of these Cur-NPs to enhance Cur delivery both in vitro and in vivo. Furthermore, we evaluated the anti-ferroptosis effect of Cur-NPs in ICH model mice and erastin-treated HT22 murine hippocampal cells.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The resultant Cur-NPs were spherical and exhibited a particle size of 127.31&#xb1;2.73 nm, a PDI of 0.21&#xb1;0.01 and a zeta potential of -0.25&#xb1;0.02 mV. When applied to Madin Darby canine kidney (MDCK) cells in vitro, these Cur-NPs were nonspecifically internalized via multiple endocytic pathways, with plasma membrane microcapsules and clathrin-mediated uptake being the dominant mechanisms. Within cells, these NPs accumulated in lysosomes, endoplasmic reticulum and mitochondria. Cur-NPs were capable of passing through physiological barriers in a zebrafish model system. When administrated to C57BL/6 mice, they significantly improved Cur delivery to the brain. Most notably, when administered to ICH model mice, Cur-NPs achieved superior therapeutic outcomes relative to other treatments. In a final series of experiments, these Cur-NPs were shown to suppress erastin-induced ferroptosis in HT22 murine hippocampal cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These Cur-NPs represent a promising means of improving Cur delivery to the brain and thereby better treating ICH.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 Yang et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yang</LastName>
            <ForeName>Cong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Han</LastName>
            <ForeName>Mengmeng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Ruoyu</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Ligui</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory Animal Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Lining</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Shiyu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Chen</LastName>
            <ForeName>Tongkai</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-4347-0155</Identifier>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Mo</LastName>
            <ForeName>Yousheng</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-7599-6015</Identifier>
            <AffiliationInfo>
              <Affiliation>The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Int J Nanomedicine</MedlineTA>
        <NlmUniqueID>101263847</NlmUniqueID>
        <ISSNLinking>1176-9114</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>IT942ZTH98</RegistryNumber>
          <NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003474" MajorTopicYN="Y">Curcumin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Intracerebral hemorrhage</Keyword>
        <Keyword MajorTopicYN="N">blood-brain barrier</Keyword>
        <Keyword MajorTopicYN="N">brain delivery</Keyword>
        <Keyword MajorTopicYN="N">curcumin</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">nanoparticles</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no potential conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34938072</ArticleId>
        <ArticleId IdType="pmc">PMC8685769</ArticleId>
        <ArticleId IdType="doi">10.2147/IJN.S334965</ArticleId>
        <ArticleId IdType="pii">334965</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ding D, Sekar P, Moomaw CJ, et al. Venous Thromboembolism in Patients With Spontaneous Intracerebral Hemorrhage: a Multicenter Study. Neurosurgery. 2019;84:E304&#x2013;304E310. doi:10.1093/neuros/nyy333</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuros/nyy333</ArticleId>
            <ArticleId IdType="pubmed">30011018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>B&#xe9;jot Y, Blanc C, Delpont B, et al. Increasing early ambulation disability in spontaneous intracerebral hemorrhage survivors. Neurology. 2018;90:e2017&#x2013;2017e2024. doi:10.1212/WNL.0000000000005633</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000005633</ArticleId>
            <ArticleId IdType="pubmed">29728525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou SY, Cui GZ, Yan XL, et al. Mechanism of ferroptosis and its relationships with other types of programmed cell death: insights for potential interventions after intracerebral hemorrhage. Front Neurosci. 2020;14:589042. doi:10.3389/fnins.2020.589042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2020.589042</ArticleId>
            <ArticleId IdType="pmc">PMC7691292</ArticleId>
            <ArticleId IdType="pubmed">33281547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen B, Chen Z, Liu M, et al. Inhibition of neuronal ferroptosis in the acute phase of intracerebral hemorrhage shows long-term cerebroprotective effects. Brain Res Bull. 2019;153:122&#x2013;132. doi:10.1016/j.brainresbull.2019.08.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2019.08.013</ArticleId>
            <ArticleId IdType="pubmed">31442590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273&#x2013;285. doi:10.1016/j.cell.2017.09.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Liu Y, Wu P, et al. Inhibition of ferroptosis alleviates early brain injury after subarachnoid hemorrhage in vitro and in vivo via reduction of lipid peroxidation. Cell Mol Neurobiol. 2021;41(2):263&#x2013;278. doi:10.1007/s10571-020-00850-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10571-020-00850-1</ArticleId>
            <ArticleId IdType="pubmed">32314126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiland A, Wang Y, Wu W, et al. Ferroptosis and Its Role in Diverse Brain Diseases. Mol Neurobiol. 2019;56(7):4880&#x2013;4893. doi:10.1007/s12035-018-1403-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-018-1403-3</ArticleId>
            <ArticleId IdType="pmc">PMC6506411</ArticleId>
            <ArticleId IdType="pubmed">30406908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Li Y, Zhang H, et al. Neuroendoscopic surgery versus craniotomy for supratentorial hypertensive intracerebral hemorrhage: a systematic review and meta-analysis. World Neurosurg. 2020;134:477&#x2013;488. doi:10.1016/j.wneu.2019.10.115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2019.10.115</ArticleId>
            <ArticleId IdType="pubmed">31669683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemphill JC 3rd, Amin-Hanjani S. Cerebellar Intracerebral hemorrhage: time for evidence-based treatment. JAMA. 2019;322:1355&#x2013;1356. doi:10.1001/jama.2019.14673</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2019.14673</ArticleId>
            <ArticleId IdType="pubmed">31593256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuramatsu JB, Biffi A, Gerner ST, et al. Association of surgical hematoma evacuation vs conservative treatment with functional outcome in patients with cerebellar intracerebral hemorrhage. JAMA. 2019;322:1392&#x2013;1403. doi:10.1001/jama.2019.13014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2019.13014</ArticleId>
            <ArticleId IdType="pmc">PMC6784768</ArticleId>
            <ArticleId IdType="pubmed">31593272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holste K, Xia F, Garton H, et al. The role of complement in brain injury following intracerebral hemorrhage: a review. Exp Neurol. 2021;340:113654. doi:10.1016/j.expneurol.2021.113654</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2021.113654</ArticleId>
            <ArticleId IdType="pmc">PMC8119338</ArticleId>
            <ArticleId IdType="pubmed">33617886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng C, Huang S, Zhou X, et al. Interventional ultrasound assisted early local hemostatic drug therapy in traumatic intracerebral hemorrhage. Ultrasound Med Biol. 2020;46:180&#x2013;187. doi:10.1016/j.ultrasmedbio.2019.08.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ultrasmedbio.2019.08.021</ArticleId>
            <ArticleId IdType="pubmed">31582179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng S, Feng S, Wang W, Zhao F, Gong Y. Biomarker and drug target discovery using quantitative proteomics post-intracerebral hemorrhage stroke in the rat brain. J Mol Neurosci. 2018;66:639&#x2013;648. doi:10.1007/s12031-018-1206-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-018-1206-z</ArticleId>
            <ArticleId IdType="pmc">PMC6267379</ArticleId>
            <ArticleId IdType="pubmed">30430305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HL, Zeng H, Xu MB, et al. Efficacy and safety of chinese herbal medicine for primary intracerebral hemorrhage: a systematic review of randomized controlled trials. Front Pharmacol. 2019;10:1139. doi:10.3389/fphar.2019.01139</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.01139</ArticleId>
            <ArticleId IdType="pmc">PMC6796400</ArticleId>
            <ArticleId IdType="pubmed">31649531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong W, Yang B, Wang L, et al. Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling. Toxicol Appl Pharmacol. 2018;346:28&#x2013;36. doi:10.1016/j.taap.2018.03.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2018.03.020</ArticleId>
            <ArticleId IdType="pubmed">29571711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Taweel GM. Neurobehavioral protective properties of curcumin against the mercury chloride treated mice offspring. Saudi j Biol Sci. 2019;26:736&#x2013;743. doi:10.1016/j.sjbs.2018.10.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sjbs.2018.10.016</ArticleId>
            <ArticleId IdType="pmc">PMC6486524</ArticleId>
            <ArticleId IdType="pubmed">31048998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Tang L, Li GS, Wang J. The anti-inflammatory effects of curcumin on renal ischemia-reperfusion injury in rats. Ren Fail. 2018;40:680&#x2013;686. doi:10.1080/0886022X.2018.1544565</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/0886022X.2018.1544565</ArticleId>
            <ArticleId IdType="pmc">PMC6282432</ArticleId>
            <ArticleId IdType="pubmed">30741618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang BF, Cui ZW, Zhong ZH, et al. Curcumin attenuates brain edema in mice with intracerebral hemorrhage through inhibition of AQP4 and AQP9 expression. Acta Pharmacol Sin. 2015;36:939&#x2013;948. doi:10.1038/aps.2015.47</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2015.47</ArticleId>
            <ArticleId IdType="pmc">PMC4564884</ArticleId>
            <ArticleId IdType="pubmed">26119880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Souza Ferreira SB, Bruschi ML. Improving the bioavailability of curcumin: is micro/nanoencapsulation the key. Ther Deliv. 2019;10:83&#x2013;86. doi:10.4155/tde-2018-0075</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/tde-2018-0075</ArticleId>
            <ArticleId IdType="pubmed">30729886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Zhang X, Qiu L. The anti-tumor efficacy of curcumin when delivered by size/charge-changing multistage polymeric micelles based on amphiphilic poly(&#x3b2;-amino ester) derivates. Biomaterials. 2014;35(10):3467&#x2013;3479. doi:10.1016/j.biomaterials.2013.12.096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2013.12.096</ArticleId>
            <ArticleId IdType="pubmed">24439418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Deng L, Cai Z, et al. Liposomes coated with thiolated chitosan as drug carriers of curcumin. Mater Sci Eng C Mater Biol Appl. 2017;80:156&#x2013;164. doi:10.1016/j.msec.2017.05.136</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msec.2017.05.136</ArticleId>
            <ArticleId IdType="pubmed">28866151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luan L, Chi Z, Liu C. Chinese white wax solid lipid nanoparticles as a novel nanocarrier of curcumin for inhibiting the formation of staphylococcus aureus biofilms. Nanomaterials. 2019;9(5):763. doi:10.3390/nano9050763</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nano9050763</ArticleId>
            <ArticleId IdType="pmc">PMC6567159</ArticleId>
            <ArticleId IdType="pubmed">31109013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ten-Dom&#xe9;nech I, Mart&#xed;nez-P&#xe9;rez-Cejuela H, Sim&#xf3;-Alfonso EF, Torres-Cartas S, Meseguer-Lloret S, Herrero-Mart&#xed;nez JM. Polymer-based materials modified with magnetite nanoparticles for enrichment of phospholipids. Talanta. 2018;180:162&#x2013;167. doi:10.1016/j.talanta.2017.12.042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.talanta.2017.12.042</ArticleId>
            <ArticleId IdType="pubmed">29332795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park K, Skidmore S, Hadar J, et al. Injectable, long-acting PLGA formulations: analyzing PLGA and understanding microparticle formation. J Control Release. 2019;304:125&#x2013;134. doi:10.1016/j.jconrel.2019.05.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2019.05.003</ArticleId>
            <ArticleId IdType="pubmed">31071374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mondal L, Mukherjee B, Das K, et al. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice. Int J Nanomedicine. 2019;14:8073&#x2013;8094. doi:10.2147/IJN.S220740</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S220740</ArticleId>
            <ArticleId IdType="pmc">PMC6790403</ArticleId>
            <ArticleId IdType="pubmed">31632019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutta D, Paul B, Mukherjee B, et al. Nanoencapsulated betulinic acid analogue distinctively improves colorectal carcinoma in vitro and in vivo. Sci Rep. 2019;9(1):11506. doi:10.1038/s41598-019-47743-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-47743-y</ArticleId>
            <ArticleId IdType="pmc">PMC6687831</ArticleId>
            <ArticleId IdType="pubmed">31395908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asai M, Zhao D, Kumar SK. Accurate estimation of the polymer coverage of hairy nanoparticles. Soft Matter. 2018;14:7906&#x2013;7915. doi:10.1039/C8SM01311J</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8SM01311J</ArticleId>
            <ArticleId IdType="pubmed">30230511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teresi R, Marullo S, Gambarotti C, et al. Improvement of oxidation resistance of polymer-based nanocomposites through sonication of carbonaceous nanoparticles. Ultrason Sonochem. 2020;61:104807. doi:10.1016/j.ultsonch.2019.104807</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ultsonch.2019.104807</ArticleId>
            <ArticleId IdType="pubmed">31670245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua Z, Jones JR, Thomas M, Arno MC, Souslov A, Wilks TR. Anisotropic polymer nanoparticles with controlled dimensions from the morphological transformation of isotropic seeds. Nat Commun. 2019;10(1):5406. doi:10.1038/s41467-019-13263-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-13263-6</ArticleId>
            <ArticleId IdType="pmc">PMC6881314</ArticleId>
            <ArticleId IdType="pubmed">31776334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer&#x2019;s disease Tg2576 mice. AAPS J. 2013;15:324&#x2013;336. doi:10.1208/s12248-012-9444-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12248-012-9444-4</ArticleId>
            <ArticleId IdType="pmc">PMC3675736</ArticleId>
            <ArticleId IdType="pubmed">23229335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Song J, Chow SF, Chow AH, Zheng Y. Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation. Int J Pharm. 2015;494:479&#x2013;489. doi:10.1016/j.ijpharm.2015.08.052</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2015.08.052</ArticleId>
            <ArticleId IdType="pubmed">26302857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He B, Jia Z, Du W, et al. The transport pathways of polymer nanoparticles in MDCK epithelial cells. Biomaterials. 2013;34:4309&#x2013;4326. doi:10.1016/j.biomaterials.2013.01.100</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2013.01.100</ArticleId>
            <ArticleId IdType="pubmed">23478037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fako VE, Furgeson DY. Zebrafish as a correlative and predictive model for assessing biomaterial nanotoxicity. Adv Drug Deliv Rev. 2009;61:478&#x2013;486. doi:10.1016/j.addr.2009.03.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2009.03.008</ArticleId>
            <ArticleId IdType="pubmed">19389433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, He B, Xiong MH, et al. The effect of hydrophilic and hydrophobic structure of amphiphilic polymeric micelles on their transport in epithelial MDCK cells. Biomaterials. 2013;34(26):6284&#x2013;6298. doi:10.1016/j.biomaterials.2013.05.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2013.05.006</ArticleId>
            <ArticleId IdType="pubmed">23714243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Ma T, Huang C, et al. Efficiency of transcellular transport and efflux of flavonoids with different glycosidic units from flavonoids of Litsea coreana L. in a MDCK epithelial cell monolayer model. Eur J Pharm Sci. 2014;53:69&#x2013;76. doi:10.1016/j.ejps.2013.12.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2013.12.010</ArticleId>
            <ArticleId IdType="pubmed">24365259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1&#x2013;2):183&#x2013;189. doi:10.1016/j.jchromb.2007.03.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2007.03.010</ArticleId>
            <ArticleId IdType="pubmed">17400527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo Y, Duan L, Yang Y, et al. Nanoparticles improved resveratrol brain delivery and its therapeutic efficacy against intracerebral hemorrhage. Nanoscale. 2021;13:3827&#x2013;3840. doi:10.1039/D0NR06249A</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0NR06249A</ArticleId>
            <ArticleId IdType="pubmed">33565555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacks D, Baxter B, Campbell B, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612&#x2013;632. doi:10.1177/1747493018778713</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1747493018778713</ArticleId>
            <ArticleId IdType="pubmed">29786478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei W, Min W, Hui D, Yun L, An X. Effect of Surface Modification on Cellular Internalization of Fe3O4 Nanoparticles in Strong Static Magnetic Field. J Nanosci Nanotechnol. 2015;15(7):5184&#x2013;5192. doi:10.1166/jnn.2015.9841</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1166/jnn.2015.9841</ArticleId>
            <ArticleId IdType="pubmed">26373103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jat D, Parihar P, Kothari SC, Parihar MS. Curcumin reduces oxidative damage by increasing reduced glutathione and preventing membrane permeability transition in isolated brain mitochondria. Cell Mol Biol. 2013;59(Suppl):OL1899&#x2013;1905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24461330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A. 2012;109(40):16288&#x2013;16293. doi:10.1073/pnas.1210096109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1210096109</ArticleId>
            <ArticleId IdType="pmc">PMC3479596</ArticleId>
            <ArticleId IdType="pubmed">22991470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauser AK, Mitov MI, Daley EF, McGarry RC, Anderson KW, Hilt JZ. Targeted iron oxide nanoparticles for the enhancement of radiation therapy. Biomaterials. 2016;105:127&#x2013;135. doi:10.1016/j.biomaterials.2016.07.032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2016.07.032</ArticleId>
            <ArticleId IdType="pmc">PMC5321199</ArticleId>
            <ArticleId IdType="pubmed">27521615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HY, Cao PP, He ZY, et al. Targeted imaging and targeted therapy of breast cancer cells via fluorescent double template-imprinted polymer coated silicon nanoparticles by an epitope approach. Nanoscale. 2019;11(36):17018&#x2013;17030. doi:10.1039/C9NR04655K</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9NR04655K</ArticleId>
            <ArticleId IdType="pubmed">31502627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Wu Y, Yuan S, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res. 2018;1701:112&#x2013;125. doi:10.1016/j.brainres.2018.09.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2018.09.012</ArticleId>
            <ArticleId IdType="pubmed">30205109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai H, Matsuoka M, Kumagai T, Sakamoto T, Koumura T. Lipid Peroxidation-Dependent Cell Death Regulated by GPx4 and Ferroptosis. Curr Top Microbiol Immunol. 2017;403:143&#x2013;170. doi:10.1007/82_2016_508</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/82_2016_508</ArticleId>
            <ArticleId IdType="pubmed">28204974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR. A powerful cell-protection system prevents cell death by ferroptosis. Nature. 2019;575(7784):597&#x2013;598. doi:10.1038/d41586-019-03145-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-019-03145-8</ArticleId>
            <ArticleId IdType="pmc">PMC7262969</ArticleId>
            <ArticleId IdType="pubmed">31768036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Luo M, Zhang K, et al. Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. Nat Commun. 2020;11(1):433. doi:10.1038/s41467-020-14324-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-14324-x</ArticleId>
            <ArticleId IdType="pmc">PMC6978386</ArticleId>
            <ArticleId IdType="pubmed">31974380</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34928015</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2366-9608</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Small methods</Title>
          <ISOAbbreviation>Small Methods</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanoprotection Against Retinal Pigment Epithelium Degeneration via Ferroptosis Inhibition.</ArticleTitle>
        <Pagination>
          <StartPage>e2100848</StartPage>
          <MedlinePgn>e2100848</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/smtd.202100848</ELocationID>
        <Abstract>
          <AbstractText>Lethal oxidative stress and ferrous ion accumulation-mediated degeneration/death in retinal pigment epithelium (RPE) exert an indispensable impact on retinal degenerative diseases with irreversible visual impairment, especially in age-related macular degeneration (AMD), but corresponding pathogenesis-oriented medical intervention remains controversial. In this study, the potent iron-binding nanoscale Prussian blue analogue KCa[Fe[III] (CN)6 ] (CaPB) with high biocompatibility is designed to inhibit RPE death and subsequently photoreceptor cell degeneration. In mice, CaPB effectively prevents RPE degeneration and ultimately fulfills superior therapeutic outcomes upon a single intravitreal injection: significant rescue of retinal structures and visual function. Through high-throughput RNA sequencing and sophisticated biochemistry evaluations, the findings initially unveil that CaPB nanoparticles protect against RPE degradation by inhibiting ferroptotic cell fate. Together with the facile, large-scale preparations and in vivo biosafety, it is believed that the synthesized CaPB therapeutic nanoparticles are promising for future clinical treatment of diverse retinal diseases involving pathological iron-dependent ferroptosis, including AMD.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Zhimin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huo</LastName>
            <ForeName>Minfeng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ju</LastName>
            <ForeName>Yahan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Xiaochan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Ni</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Huiqin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Dandan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Xianqun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-8206-3325</Identifier>
            <AffiliationInfo>
              <Affiliation>Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>82071004</GrantID>
            <Agency>National Natural Science Foundations of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81870687</GrantID>
            <Agency>National Natural Science Foundations of China</Agency>
          </Grant>
          <Grant>
            <GrantID>51672303</GrantID>
            <Agency>National Natural Science Foundations of China</Agency>
          </Grant>
          <Grant>
            <GrantID>51722211</GrantID>
            <Agency>National Natural Science Foundations of China</Agency>
          </Grant>
          <Grant>
            <GrantID>22005327</GrantID>
            <Agency>National Natural Science Foundations of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2018YFC1106100</GrantID>
            <Agency>National Key R&amp;D program of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2016YFA0203700</GrantID>
            <Agency>National Key R&amp;D program of China</Agency>
          </Grant>
          <Grant>
            <GrantID>18XD1404300</GrantID>
            <Agency>Program of Shanghai Subject Chief Scientist</Agency>
          </Grant>
          <Grant>
            <GrantID>19JC1415503</GrantID>
            <Agency>Key program of Shanghai Science and Technology Commission</Agency>
          </Grant>
          <Grant>
            <GrantID>20161316</GrantID>
            <Agency>Municipal Education Commission-Gaofeng Clinical Medicine</Agency>
          </Grant>
          <Grant>
            <GrantID>20DZ2270800</GrantID>
            <Agency>Science and Technology Commission of Shanghai</Agency>
          </Grant>
          <Grant>
            <GrantID>18XD1404300</GrantID>
            <Agency>Program of Shanghai Subject Chief Scientist</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Small Methods</MedlineTA>
        <NlmUniqueID>101724536</NlmUniqueID>
        <ISSNLinking>2366-9608</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005295">Ferrocyanides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007452">Iodates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U558PCS5Z9</RegistryNumber>
          <NameOfSubstance UI="C032285">sodium iodate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005295" MajorTopicYN="N">Ferrocyanides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007452" MajorTopicYN="N">Iodates</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Prussian blue analogue</Keyword>
        <Keyword MajorTopicYN="N">age-related macular degeneration</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron-binding</Keyword>
        <Keyword MajorTopicYN="N">retinal pigment epithelium</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34928015</ArticleId>
        <ArticleId IdType="doi">10.1002/smtd.202100848</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>K. Manian, C. Galloway, S. Dalvi, A. Emanuel, J. Mereness, W. Black, L. Winschel, C. Soto, Y. Li, Y. Song, W. DeMaria, A. Kumar, I. Slukvin, M. Schwartz, W. Murphy, B. Anand-Apte, M. Chung, D. Benoit, R. Singh, Cell Stem Cell 2021, 28, 978.</Citation>
        </Reference>
        <Reference>
          <Citation>S. George, F. Lu, M. Rao, L. Leach, J. Gross, Prog. Retinal Eye Res. 2021, 100969.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Wang, Z. Tang, P. Gu, Cell Death Dis. 2020, 11, 793</Citation>
        </Reference>
        <Reference>
          <Citation>M. Fleckenstein, T. Keenan, R. Guymer, U. Chakravarthy, S. Schmitz-Valckenberg, C. Klaver, W. Wong, E. Chew, Nat. Rev. Dis. Primers 2021, 7, 31.</Citation>
        </Reference>
        <Reference>
          <Citation>B. Yu, J. Ma, J. Li, D. Wang, Z. Wang, S. Wang, Nat. Commun. 2020, 11, 2549.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Tang, Y. Ju, X. Dai, N. Ni, Y. Liu, D. Zhang, H. Gao, H. Sun, J. Zhang, P. Gu, Redox Biol. 2021, 43, 101971.</Citation>
        </Reference>
        <Reference>
          <Citation>P. Hahn, A. H. Milam, J. L. Dunaief, Arch. Ophthalmol. 2003, 121, 1099.</Citation>
        </Reference>
        <Reference>
          <Citation>A. G. J&#xfc;nemann, P. Stopa, B. Michalke, A. Chaudhri, U. Reulbach, C. Huchzermeyer, U. Schl&#xf6;tzer-Schrehardt, F. E. Kruse, E. Zrenner, R. Rejdak, PLoS One 2013, 8, e56734.</Citation>
        </Reference>
        <Reference>
          <Citation>a) W. Shu, J. Dunaief, Pharmaceuticals 2018, 11, 112;</Citation>
        </Reference>
        <Reference>
          <Citation>b) D. Song, G. Ying, J. Dunaief, R. Bhuyan, Y. Li, M. Maguire, J. Grunwald, E. Daniel, S. Hagstrom, D. Martin, Retina 2019, 39, 1965.</Citation>
        </Reference>
        <Reference>
          <Citation>P. E. Hallaway, J. W. Eaton, S. S. Panter, B. E. Hedlund, Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 10108.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Y. Cao, S. J. Dixon, Cell. Mol. Life Sci. 2016, 73, 2195.</Citation>
        </Reference>
        <Reference>
          <Citation>H. L. Persson, Z. Yu, O. Tirosh, J. W. Eaton, U. T. Brunk, F. Radic, Biol. Med. 2003, 34, 1295.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Wang, H. Yang, D. Yanagisawa, J. P. Bellier, K. Morino, S. Zhao, P. Liu, P. Vigers, I. Tooyama, Neurobiol. Aging 2016, 47, 168.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Wang, B. Yu, H. Alamri, S. Yarabarla, M. H. Kim, S. D. Huang, Angew. Chem., Int. Ed. Engl. 2018, 57, 2214.</Citation>
        </Reference>
        <Reference>
          <Citation>Q. Zhang, Q. Guo, Q. Chen, X. Zhao, S. Pennycook, H. Chen, Adv. Sci. 2020, 7, 1902576.</Citation>
        </Reference>
        <Reference>
          <Citation>R. N. Mitra, R. Gao, M. Zheng, M. J. Wu, M. A. Voinov, A. I. Smirnov, T. I. Smirnova, K. Wang, S. Chavala, Z. Han, ACS Nano 2017, 11, 4669.</Citation>
        </Reference>
        <Reference>
          <Citation>L. L. Wong, S. M. Hirst, Q. N. Pye, C. M. Reilly, S. Seal, J. F. McGinnis, PLoS One 2013, 8, e58431.</Citation>
        </Reference>
        <Reference>
          <Citation>G. You, J. Hou, Y. Xu, L. Miao, Y. Ao, B. Xing, Rev. Environ. Contam. Toxicol. 2021, 253, 155.</Citation>
        </Reference>
        <Reference>
          <Citation>a) H. Wu, L. Liu, L. Song, M. Ma, N. Gu, Y. Zhang, ACS Nano 2019, 13, 14013;</Citation>
        </Reference>
        <Reference>
          <Citation>b) A. Mohammad, Y. Yang, M. A. Khan, P. J. Faustino, J. Pharm. Biomed. Anal. 2015, 103, 85.</Citation>
        </Reference>
        <Reference>
          <Citation>J. F. Maya-Vetencourt, G. Manfredi, M. Mete, E. Colombo, M. Bramini, S. Di Marco, D. Shmal, G. Mantero, M. Dipalo, A. Rocchi, M. L. DiFrancesco, E. D. Papaleo, A. Russo, J. Barsotti, C. Eleftheriou, F. Di Maria, V. Cossu, F. Piazza, L. Emionite, F. Ticconi, C. Marini, G. Sambuceti, G. Pertile, G. Lanzani, F. Benfenati, Nat. Nanotechnol. 2020, 15, 698.</Citation>
        </Reference>
        <Reference>
          <Citation>A. Lakkaraju, A. Umapathy, L. Tan, L. Daniele, N. Philp, K. Boesze-Battaglia, D. Williams, Prog. Retinal Eye Res. 2020, 78, 100846.</Citation>
        </Reference>
        <Reference>
          <Citation>M. T. Ngo, B. A. C. Harley, Biomaterials 2019, 198, 122.</Citation>
        </Reference>
        <Reference>
          <Citation>a) W. Shu, B. H. Baumann, Y. Song, Y. Liu, X. Wu, J. L. Dunaief, Redox Biol. 2020, 34, 101469;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Y. Sun, Y. Zheng, C. Wang, Y. Liu, Cell Death Dis. 2018, 9, 753;</Citation>
        </Reference>
        <Reference>
          <Citation>c) B. Liu, W. Wang, A. Shah, M. Yu, Y. Liu, L. He, J. Dang, L. Yang, M. Yan, Y. Ying, Z. Tang, K. Liu, Cell Death Dis. 2021, 12, 230.</Citation>
        </Reference>
        <Reference>
          <Citation>K. H. Aung, H. Liu, Z. Ke, S. Jiang, J. Huang, Front. Pharmacol. 2020, 11, 566699.</Citation>
        </Reference>
        <Reference>
          <Citation>Q. Zhang, M. Raoof, Y. Chen, Y. Sumi, T. Sursal, W. Junger, K. Brohi, K. Itagaki, C. J. Hauser, Nature 2010, 464, 104.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Ju, Z. Tang, X. Dai, H. Gao, J. Zhang, Y. Liu, Y. Yang, N. Ni, D. Zhang, Y. Wang, N. Sun, L. Yin, M. Luo, J. Zhang, P. Gu, Br. J. Pharmacol. 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>a) K. Li, K. Xu, Y. He, L. Lu, Y. Mao, P. Gao, G. Liu, J. Wu, Y. Zhang, Y. Xiang, Z. Luo, K. Cai, Small 2021, 17, 2102046;</Citation>
        </Reference>
        <Reference>
          <Citation>b) J. Gao, T. Luo, J. Wang, Nat. Commun. 2021, 12, 5311.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Zhao, D. Yasumura, X. Li, M. Matthes, M. Lloyd, G. Nielsen, K. Ahern, M. Snyder, D. Bok, J. L. Dunaief, M. M. LaVail, D. Vollrath, J. Clin. Invest. 2011, 121, 369.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Tang, F. Jiang, Y. Zhang, Y. Zhang, X. H. YuanYang, Y. Wang, D. Zhang, N. Ni, F. Liu, M. Luo, X. Fan, W. Zhang, P. Gu, Biomaterials 2019, 194, 57.</Citation>
        </Reference>
        <Reference>
          <Citation>a) G. Schnabolk, E. Obert, N. K. Banda, B. Rohrer, Invest. Ophthalmol. Visual Sci. 2020, 61, 11;</Citation>
        </Reference>
        <Reference>
          <Citation>b) N. Zhang, X. Zhang, P. E. Girardot, M. A. Chrenek, J. T. Sellers, Y. Li, Y. K. Kim, V. R. Summers, S. Ferdous, D. A. Shelton, J. H. Boatright, J. M. Nickerson, Transl. Vis. Sci. Technol. 2021, 10, 10.</Citation>
        </Reference>
        <Reference>
          <Citation>A. V. Menon, J. Liu, H. P. Tsai, L. Zeng, S. Yang, A. Asnani, J. Kim, Blood 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>T. Zou, L. Gao, Y. Zeng, Q. Li, Y. Li, S. Chen, X. Hu, X. Chen, C. Fu, H. Xu, Z. Yin, Nat. Commun. 2019, 10, 1205.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Mohamed, I. Sharma, A. S. Ibrahim, H. Saleh, N. M. Elsherbiny, S. Fulzele, K. Elmasry, S. B. Smith, M. Al-Shabrawey, A. Tawfik, Sci. Rep. 2017, 7, 11952.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34924133</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1347-8648</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>148</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmacological sciences</Title>
          <ISOAbbreviation>J Pharmacol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.</ArticleTitle>
        <Pagination>
          <StartPage>73</StartPage>
          <EndPage>85</EndPage>
          <MedlinePgn>73-85</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jphs.2021.09.008</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1347-8613(21)00094-3</ELocationID>
        <Abstract>
          <AbstractText>Although sorafenib (Sora) shows improved efficacy in clinical liver cancer therapy, its therapeutic efficacy is still greatly limited due to side effects as well as drug resistance. Thus new drug intervention strategies are imperative. Our research showed the combined application of Dihydroartemisinin (DHA) and Sora had a synergistic inhibitory effect on HepG2 and SW480 cells, and DHA enhanced Sora efficacy on xenograft tumor in nude mice. DHA and Sora significantly inhibited the cell energy metabolism by decreasing the ATP synthesis rate of oxidative phosphorylation and glycolysis rate, and induced ferroptosis by increasing the level of lipid reactive oxygen species (L-ROS), labile iron pool (LIP) as well as malondialdehyde (MDA) and decreasing the level of glutathione (GSH) in HepG2 cells. In addition, DHA and Sora significantly decreased the levels of SLC7A11 (xCT), GCLC, GPX4, and HO-1 protein in HepG2 cells. Importantly, the above-mentioned indicators changed more significantly after the combined application of DHA and Sora as compared with Sora. In conclusion, DHA and Sora had the same mechanism, and the combined application of them could have a synergistic anti-tumor effect by inducing ferroptosis and inhibiting energy metabolism in HepG2 cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 The Authors. Production and hosting by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: cuizhao1124@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Huajing</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center and Institute of Chinese Meteria Medica, China Academy of Traditional Chinese Medical Sciences, Beijing 100700, China. Electronic address: whjdd91@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shuo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center and Institute of Chinese Meteria Medica, China Academy of Traditional Chinese Medical Sciences, Beijing 100700, China. Electronic address: sureli0420@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Tingting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: qt17839918906@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Hang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: shihang0202@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Ji</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center and Institute of Chinese Meteria Medica, China Academy of Traditional Chinese Medical Sciences, Beijing 100700, China. Electronic address: mj890.com@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lanfang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: lflee1973@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Guihua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: xingcong2206@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Tingliang</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center and Institute of Chinese Meteria Medica, China Academy of Traditional Chinese Medical Sciences, Beijing 100700, China. Electronic address: tljiang@icmm.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Canghai</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center and Institute of Chinese Meteria Medica, China Academy of Traditional Chinese Medical Sciences, Beijing 100700, China. Electronic address: chli@icmm.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>J Pharmacol Sci</MedlineTA>
        <NlmUniqueID>101167001</NlmUniqueID>
        <ISSNLinking>1347-8613</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6A9O50735X</RegistryNumber>
          <NameOfSubstance UI="C039060">artenimol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dihydroartemisinin</Keyword>
        <Keyword MajorTopicYN="N">Drug combined application</Keyword>
        <Keyword MajorTopicYN="N">Energy metabolism</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Sorafenib</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest All authors declared that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34924133</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jphs.2021.09.008</ArticleId>
        <ArticleId IdType="pii">S1347-8613(21)00094-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34898184</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1936-086X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS nano</Title>
          <ISOAbbreviation>ACS Nano</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Complementing Cancer Photodynamic Therapy with Ferroptosis through Iron Oxide Loaded Porphyrin-Grafted Lipid Nanoparticles.</ArticleTitle>
        <Pagination>
          <StartPage>20164</StartPage>
          <EndPage>20180</EndPage>
          <MedlinePgn>20164-20180</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsnano.1c08108</ELocationID>
        <Abstract>
          <AbstractText>Nanomaterials that combine multimodality imaging and therapeutic functions within a single nanoplatform have drawn extensive attention for molecular medicines and biological applications. Herein, we report a theranostic nanoplatform based on a relatively smaller (&lt;20 nm) iron oxide loaded porphyrin-grafted lipid nanoparticles (Fe3O4@PGL NPs). The amphiphilic PGL easily self-assembled on the hydrophobic exterior surface of ultrasmall Fe3O4 NPs, resulting in a final ultrasmall Fe3O4@PGL NPs with diameter of 10 nm. The excellent self-assembling nature of the as-synthesized PGL NPs facilitated a higher loading of porphyrins, showed a negligible dark toxicity, and demonstrated an excellent photodynamic effect against HT-29 cancer cells in vitro. The in vivo experimental results further confirmed that Fe3O4@PGL NPs were ideally qualified for both the fluorescence and magnetic resonance (MR) imaging guided nanoplatforms to track the biodistribution and therapeutic responses of NPs as well as to simultaneously trigger the generation of highly cytotoxic reactive oxygen species (ROS) necessary for excellent photodynamic therapy (PDT). After recording convincing therapeutic responses, we further evaluated the ability of Fe3O4@PGL NPs/Fe3O4@Lipid NPs for ferroptosis therapy (FT) via tumor microenvironment (TME) modulation for improved anticancer activity. We hypothesized that tumor-associated macrophages (TAMs) could significantly improve the efficacy of FT by accelerating the Fenton reaction in vitro. In our results, the Fe ions released in vitro directly contributed to the Fenton reaction, whereas the presence of RAW 264.7 macrophages further accelerated the ROS generation as observed by the fluorescence imaging. The significant increase in the ROS during the coincubation of NPs, endocytosed by HT-29 cells and RAW264.7 cells, further induced increased cellular toxicity of cancer cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Xiaolong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, Peking University Third Hospital, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing 100871, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois 60637, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhattarai</LastName>
            <ForeName>Pravin</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing 100871, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biophotonics, Phutung Research Institute, Kathmandu 12335, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hameed</LastName>
            <ForeName>Sadaf</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing 100871, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Life Sciences, University of Central Punjab, Lahore 54000, Pakistan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Yida</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Zhifei</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0001-6231-3692</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing 100871, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Nano</MedlineTA>
        <NlmUniqueID>101313589</NlmUniqueID>
        <ISSNLinking>1936-0851</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1K09F3G675</RegistryNumber>
          <NameOfSubstance UI="C000499">ferric oxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="Y">Porphyrins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron oxide</Keyword>
        <Keyword MajorTopicYN="N">macrophages</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">porphyrin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>17</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34898184</ArticleId>
        <ArticleId IdType="doi">10.1021/acsnano.1c08108</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34831207</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis: Cancer Stem Cells Rely on Iron until "to Die for" It.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2981</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10112981</ELocationID>
        <Abstract>
          <AbstractText>Cancer stem cells (CSCs) are a distinct subpopulation of tumor cells with stem cell-like features. Able to initiate and sustain tumor growth and mostly resistant to anti-cancer therapies, they are thought responsible for tumor recurrence and metastasis. Recent accumulated evidence supports that iron metabolism with the recent discovery of ferroptosis constitutes a promising new lead in the field of anti-CSC therapeutic strategies. Indeed, iron uptake, efflux, storage and regulation pathways are all over-engaged in the tumor microenvironment suggesting that the reprogramming of iron metabolism is a crucial occurrence in tumor cell survival. In particular, recent studies have highlighted the importance of iron metabolism in the maintenance of CSCs. Furthermore, the high concentration of iron found in CSCs, as compared to non-CSCs, underlines their iron addiction. In line with this, if iron is an essential macronutrient that is nevertheless highly reactive, it represents their Achilles' heel by inducing ferroptosis cell death and therefore providing opportunities to target CSCs. In this review, we first summarize our current understanding of iron metabolism and its regulation in CSCs. Then, we provide an overview of the current knowledge of ferroptosis and discuss the role of autophagy in the (regulation of) ferroptotic pathways. Finally, we discuss the potential therapeutic strategies that could be used for inducing ferroptosis in CSCs to treat cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cosialls</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Necker-Enfants Malades (INEM), Inserm U1151-CNRS UMR 8253, Universit Paris Descartes-Sorbonne Paris Cit, F-75993 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El Hage</LastName>
            <ForeName>Rima</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Necker-Enfants Malades (INEM), Inserm U1151-CNRS UMR 8253, Universit Paris Descartes-Sorbonne Paris Cit, F-75993 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dos Santos</LastName>
            <ForeName>Lela</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Necker-Enfants Malades (INEM), Inserm U1151-CNRS UMR 8253, Universit Paris Descartes-Sorbonne Paris Cit, F-75993 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Chang</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Breast Tumor Center, Sun Yat-sen Memorial Hospital, Guangzhou 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mehrpour</LastName>
            <ForeName>Maryam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Necker-Enfants Malades (INEM), Inserm U1151-CNRS UMR 8253, Universit Paris Descartes-Sorbonne Paris Cit, F-75993 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hama</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-7921-4014</Identifier>
            <AffiliationInfo>
              <Affiliation>Institut Necker-Enfants Malades (INEM), Inserm U1151-CNRS UMR 8253, Universit Paris Descartes-Sorbonne Paris Cit, F-75993 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">cancer stem cells</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron metabolism</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34831207</ArticleId>
        <ArticleId IdType="pmc">PMC8616391</ArticleId>
        <ArticleId IdType="doi">10.3390/cells10112981</ArticleId>
        <ArticleId IdType="pii">cells10112981</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torti S.V., Torti F.M. Iron: The cancer connection. Mol. Asp. Med. 2020;75:100860. doi: 10.1016/j.mam.2020.100860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2020.100860</ArticleId>
            <ArticleId IdType="pubmed">32340745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C., Zhang F. Iron homeostasis and tumorigenesis: Molecular mechanisms and therapeutic opportunities. Protein Cell. 2015;6:88&#x2013;100. doi: 10.1007/s13238-014-0119-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-014-0119-z</ArticleId>
            <ArticleId IdType="pmc">PMC4312762</ArticleId>
            <ArticleId IdType="pubmed">25476483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mu&#xf1;oz M., G&#xf3;mez-Ram&#xed;rez S., Mart&#xed;n-Monta&#xf1;ez E., Auerbach M. Perioperative anemia management in colorectal cancer patients: A pragmatic approach. World J. Gastroenterol. 2014;20:1972&#x2013;1985. doi: 10.3748/wjg.v20.i8.1972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i8.1972</ArticleId>
            <ArticleId IdType="pmc">PMC3934467</ArticleId>
            <ArticleId IdType="pubmed">24587673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantopoulos K., Porwal S.K., Tartakoff A., Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51:5705&#x2013;5724. doi: 10.1021/bi300752r.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi300752r</ArticleId>
            <ArticleId IdType="pmc">PMC3572738</ArticleId>
            <ArticleId IdType="pubmed">22703180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta. 2012;1823:1434&#x2013;1443. doi: 10.1016/j.bbamcr.2012.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2012.01.014</ArticleId>
            <ArticleId IdType="pmc">PMC4048856</ArticleId>
            <ArticleId IdType="pubmed">22306005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manz D.H., Blanchette N.L., Paul B.T., Torti F.M., Torti S.V. Iron and cancer: Recent insights. Ann. N. Y. Acad. Sci. 2016;1368:149&#x2013;161. doi: 10.1111/nyas.13008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.13008</ArticleId>
            <ArticleId IdType="pmc">PMC4870095</ArticleId>
            <ArticleId IdType="pubmed">26890363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muckenthaler M.U., Rivella S., Hentze M.W., Galy B. A Red Carpet for Iron Metabolism. Cell. 2017;168:344&#x2013;361. doi: 10.1016/j.cell.2016.12.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.12.034</ArticleId>
            <ArticleId IdType="pmc">PMC5706455</ArticleId>
            <ArticleId IdType="pubmed">28129536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walcher L., Kistenmacher A.-K., Suo H., Kitte R., Dluczek S., Strau&#xdf; A., Blaudszun A.-R., Yevsa T., Fricke S., Kossatz-Boehlert U. Cancer Stem Cells&#x2014;Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front. Immunol. 2020;11:1280. doi: 10.3389/fimmu.2020.01280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01280</ArticleId>
            <ArticleId IdType="pmc">PMC7426526</ArticleId>
            <ArticleId IdType="pubmed">32849491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marquardt S., Solanki M., Spitschak A., Vera J., P&#xfc;tzer B.M. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. Semin. Cancer Biol. 2018;53:90&#x2013;109. doi: 10.1016/j.semcancer.2018.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2018.06.006</ArticleId>
            <ArticleId IdType="pubmed">29966677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xfc;ller S., Sindikubwabo F., Ca&#xf1;eque T., Lafon A., Versini A., Lombard B., Loew D., Wu T.-D., Ginestier C., Charafe-Jauffret E., et al. CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nat. Chem. 2020;12:929&#x2013;938. doi: 10.1038/s41557-020-0513-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41557-020-0513-5</ArticleId>
            <ArticleId IdType="pubmed">32747755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA. 2003;100:3983&#x2013;3988. doi: 10.1073/pnas.0530291100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0530291100</ArticleId>
            <ArticleId IdType="pmc">PMC153034</ArticleId>
            <ArticleId IdType="pubmed">12629218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomita H., Tanaka K., Tanaka T., Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7:11018&#x2013;11032. doi: 10.18632/oncotarget.6920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.6920</ArticleId>
            <ArticleId IdType="pmc">PMC4905455</ArticleId>
            <ArticleId IdType="pubmed">26783961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith C., Gasparetto M., Humphries K., Pollyea D.A., Vasiliou V., Jordan C.T. Aldehyde dehydrogenases in acute myeloid leukemia: AML and ALDHs. Ann. N. Y. Acad. Sci. 2014;1310:58&#x2013;68. doi: 10.1111/nyas.12414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.12414</ArticleId>
            <ArticleId IdType="pubmed">24641679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blume R., Rempel E., Manta L., Saeed B.R., Wang W., Raffel S., Ermakova O., Eckstein V., Benes V., Trumpp A., et al. The molecular signature of AML with increased ALDH activity suggests a stem cell origin. Leuk. Lymphoma. 2018;59:2201&#x2013;2210. doi: 10.1080/10428194.2017.1422862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10428194.2017.1422862</ArticleId>
            <ArticleId IdType="pubmed">29334844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasper M., Schafer A., Piontek G., Teufel J., Brockhoff G., Ringel F., Heindl S., Zimmer C., Schlegel J. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncology. 2010;12:1024&#x2013;1033. doi: 10.1093/neuonc/noq070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noq070</ArticleId>
            <ArticleId IdType="pmc">PMC3018920</ArticleId>
            <ArticleId IdType="pubmed">20627895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y., Dallaglio K., Chen Y., Robinson W.A., Robinson S.E., McCarter M.D., Wang J., Gonzalez R., Thompson D.C., Norris D.A., et al. ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets: ALDH + Cancer Stem Cells in Human Melanoma. Stem Cells. 2012;30:2100&#x2013;2113. doi: 10.1002/stem.1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1193</ArticleId>
            <ArticleId IdType="pmc">PMC3448863</ArticleId>
            <ArticleId IdType="pubmed">22887839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell. 2007;1:555&#x2013;567. doi: 10.1016/j.stem.2007.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2007.08.014</ArticleId>
            <ArticleId IdType="pmc">PMC2423808</ArticleId>
            <ArticleId IdType="pubmed">18371393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourseau-Guilmain E., Griveau A., Benoit J.-P., Garcion E. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS ONE. 2011;6:e25515. doi: 10.1371/journal.pone.0025515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0025515</ArticleId>
            <ArticleId IdType="pmc">PMC3180456</ArticleId>
            <ArticleId IdType="pubmed">21966538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glumac P.M., LeBeau A.M. The role of CD133 in cancer: A concise review. Clin. Transl. Med. 2018;7:e18. doi: 10.1186/s40169-018-0198-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40169-018-0198-1</ArticleId>
            <ArticleId IdType="pmc">PMC6035906</ArticleId>
            <ArticleId IdType="pubmed">29984391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y.-C., Yo Y.-T., Lee H.-Y., Liao Y.-P., Chao T.-K., Su P.-H., Lai H.-C. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am. J. Pathol. 2012;180:1159&#x2013;1169. doi: 10.1016/j.ajpath.2011.11.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2011.11.015</ArticleId>
            <ArticleId IdType="pubmed">22222226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective Identification of Tumorigenic Prostate Cancer Stem Cells. Cancer Res. 2005;65:10946&#x2013;10951. doi: 10.1158/0008-5472.CAN-05-2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-2018</ArticleId>
            <ArticleId IdType="pubmed">16322242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., et al. Identification of cells initiating human melanomas. Nature. 2008;451:345&#x2013;349. doi: 10.1038/nature06489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06489</ArticleId>
            <ArticleId IdType="pmc">PMC3660705</ArticleId>
            <ArticleId IdType="pubmed">18202660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalerba P., Dylla S.J., Park I.-K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA. 2007;104:10158&#x2013;10163. doi: 10.1073/pnas.0703478104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0703478104</ArticleId>
            <ArticleId IdType="pmc">PMC1891215</ArticleId>
            <ArticleId IdType="pubmed">17548814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA. 2007;104:973&#x2013;978. doi: 10.1073/pnas.0610117104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0610117104</ArticleId>
            <ArticleId IdType="pmc">PMC1783424</ArticleId>
            <ArticleId IdType="pubmed">17210912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okano M., Konno M., Kano Y., Kim H., Kawamoto K., Ohkuma M., Haraguchi N., Yokobori T., Mimori K., Yamamoto H., et al. Human colorectal CD24+ cancer stem cells are susceptible to epithelial-mesenchymal transition. Int. J. Oncol. 2014;45:575&#x2013;580. doi: 10.3892/ijo.2014.2462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2014.2462</ArticleId>
            <ArticleId IdType="pubmed">24858473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemper K., Grandela C., Medema J.P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget. 2010;1:387&#x2013;395. doi: 10.18632/oncotarget.173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.173</ArticleId>
            <ArticleId IdType="pmc">PMC3248116</ArticleId>
            <ArticleId IdType="pubmed">21311095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dana H. CD166 as a Stem Cell Marker? A Potential Target for Therapy Colorectal Cancer? JSRT. 2016;1:226&#x2013;229. doi: 10.15406/jsrt.2016.01.00041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15406/jsrt.2016.01.00041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zakaria N., Yusoff N.M., Zakaria Z., Lim M.N., Baharuddin P.J.N., Fakiruddin K.S., Yahaya B. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer. 2015;15:84. doi: 10.1186/s12885-015-1086-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-015-1086-3</ArticleId>
            <ArticleId IdType="pmc">PMC4349658</ArticleId>
            <ArticleId IdType="pubmed">25881239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Yu D., Zhang H., He H., Zhang C., Zhao W., Shao R. CD133 + EpCAM + Phenotype Possesses More Characteristics of Tumor Initiating Cells in Hepatocellular Carcinoma Huh7 Cells. Int. J. Biol. Sci. 2012;8:992&#x2013;1004. doi: 10.7150/ijbs.4454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.4454</ArticleId>
            <ArticleId IdType="pmc">PMC3421230</ArticleId>
            <ArticleId IdType="pubmed">22904667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of Pancreatic Cancer Stem Cells. Cancer Res. 2007;67:1030&#x2013;1037. doi: 10.1158/0008-5472.CAN-06-2030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-2030</ArticleId>
            <ArticleId IdType="pubmed">17283135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saini V., Hose C.D., Monks A., Nagashima K., Han B., Newton D.L., Millione A., Shah J., Hollingshead M.G., Hite K.M., et al. Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in Osteosarcoma. PLoS ONE. 2012;7:e41401. doi: 10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210</ArticleId>
            <ArticleId IdType="pmc">PMC3411700</ArticleId>
            <ArticleId IdType="pubmed">22870217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemper K., Sprick M.R., de Bree M., Scopelliti A., Vermeulen L., Hoek M., Zeilstra J., Pals S.T., Mehmet H., Stassi G., et al. The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation. Cancer Res. 2010;70:719&#x2013;729. doi: 10.1158/0008-5472.CAN-09-1820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1820</ArticleId>
            <ArticleId IdType="pubmed">20068153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Z.F., Ho D.W., Ng M.N., Lau C.K., Yu W.C., Ngai P., Chu P.W.K., Lam C.T., Poon R.T.P., Fan S.T. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153&#x2013;166. doi: 10.1016/j.ccr.2008.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.01.013</ArticleId>
            <ArticleId IdType="pubmed">18242515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997;3:730&#x2013;737. doi: 10.1038/nm0797-730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0797-730</ArticleId>
            <ArticleId IdType="pubmed">9212098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong Y., Yoshida S., Saito Y., Doi T., Nagatoshi Y., Fukata M., Saito N., Yang S.M., Iwamoto C., Okamura J., et al. CD34+CD38+CD19+ as well as CD34+CD38&#x2212;CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008;22:1207&#x2013;1213. doi: 10.1038/leu.2008.83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2008.83</ArticleId>
            <ArticleId IdType="pubmed">18418410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drakesmith H., Nemeth E., Ganz T. Ironing out Ferroportin. Cell Metab. 2015;22:777&#x2013;787. doi: 10.1016/j.cmet.2015.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2015.09.006</ArticleId>
            <ArticleId IdType="pmc">PMC4635047</ArticleId>
            <ArticleId IdType="pubmed">26437604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vela D., Vela-Gaxha Z. Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. Exp. Mol. Med. 2018;50:e436. doi: 10.1038/emm.2017.273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emm.2017.273</ArticleId>
            <ArticleId IdType="pmc">PMC5903825</ArticleId>
            <ArticleId IdType="pubmed">29391539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonberg D.L., Miller T.E., Wu Q., Flavahan W.A., Das N.K., Hale J.S., Hubert C.G., Mack S.C., Jarrar A.M., Karl R.T., et al. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell. 2015;28:441&#x2013;455. doi: 10.1016/j.ccell.2015.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.09.002</ArticleId>
            <ArticleId IdType="pmc">PMC4646058</ArticleId>
            <ArticleId IdType="pubmed">26461092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mai T.T., Hama&#xef; A., Hienzsch A., Ca&#xf1;eque T., M&#xfc;ller S., Wicinski J., Cabaud O., Leroy C., David A., Acevedo V., et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat. Chem. 2017;9:1025&#x2013;1033. doi: 10.1038/nchem.2778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchem.2778</ArticleId>
            <ArticleId IdType="pmc">PMC5890907</ArticleId>
            <ArticleId IdType="pubmed">28937680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hama&#xef; A., Ca&#xf1;eque T., M&#xfc;ller S., Mai T.T., Hienzsch A., Ginestier C., Charafe-Jauffret E., Codogno P., Mehrpour M., Rodriguez R. An iron hand over cancer stem cells. Autophagy. 2017;13:1465&#x2013;1466. doi: 10.1080/15548627.2017.1327104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2017.1327104</ArticleId>
            <ArticleId IdType="pmc">PMC5584845</ArticleId>
            <ArticleId IdType="pubmed">28613094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanvorachote P., Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. Am. J. Physiol. Cell Physiol. 2016;310:C728&#x2013;C739. doi: 10.1152/ajpcell.00322.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00322.2015</ArticleId>
            <ArticleId IdType="pubmed">26911281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rychtarcikova Z., Lettlova S., Tomkova V., Korenkova V., Langerova L., Simonova E., Zjablovskaja P., Alberich-Jorda M., Neuzil J., Truksa J. Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget. 2017;8:6376&#x2013;6398. doi: 10.18632/oncotarget.14093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14093</ArticleId>
            <ArticleId IdType="pmc">PMC5351639</ArticleId>
            <ArticleId IdType="pubmed">28031527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raggi C., Gammella E., Correnti M., Buratti P., Forti E., Andersen J.B., Alpini G., Glaser S., Alvaro D., Invernizzi P., et al. Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Sci. Rep. 2017;7:17667. doi: 10.1038/s41598-017-17804-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-17804-1</ArticleId>
            <ArticleId IdType="pmc">PMC5732280</ArticleId>
            <ArticleId IdType="pubmed">29247214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchette-Farra N., Kita D., Konstorum A., Tesfay L., Lemler D., Hegde P., Claffey K.P., Torti F.M., Torti S.V. Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. Oncogene. 2018;37:4013&#x2013;4032. doi: 10.1038/s41388-018-0243-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0243-y</ArticleId>
            <ArticleId IdType="pmc">PMC6054540</ArticleId>
            <ArticleId IdType="pubmed">29695834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bootcov M.R., Bauskin A.R., Valenzuela S.M., Moore A.G., Bansal M., He X.Y., Zhang H.P., Donnellan M., Mahler S., Pryor K., et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. USA. 1997;94:11514&#x2013;11519. doi: 10.1073/pnas.94.21.11514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.94.21.11514</ArticleId>
            <ArticleId IdType="pmc">PMC23523</ArticleId>
            <ArticleId IdType="pubmed">9326641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park Y.J., Lee H., Lee J.-H. Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep. 2010;43:91&#x2013;96. doi: 10.5483/BMBRep.2010.43.2.091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2010.43.2.091</ArticleId>
            <ArticleId IdType="pubmed">20193126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasahara A., Tominaga K., Nishimura T., Yano M., Kiyokawa E., Noguchi M., Noguchi M., Kanauchi H., Ogawa T., Minato H., et al. An autocrine/paracrine circuit of growth differentiation factor (GDF) 15 has a role for maintenance of breast cancer stem-like cells. Oncotarget. 2017;8:24869&#x2013;24881. doi: 10.18632/oncotarget.15276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15276</ArticleId>
            <ArticleId IdType="pmc">PMC5421895</ArticleId>
            <ArticleId IdType="pubmed">28206960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basuli D., Tesfay L., Deng Z., Paul B., Yamamoto Y., Ning G., Xian W., McKeon F., Lynch M., Crum C.P., et al. Iron addiction: A novel therapeutic target in ovarian cancer. Oncogene. 2017;36:4089&#x2013;4099. doi: 10.1038/onc.2017.11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.11</ArticleId>
            <ArticleId IdType="pmc">PMC5540148</ArticleId>
            <ArticleId IdType="pubmed">28319068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S., Christova T., Perusini S., Alizadeh S., Bao R.-Y., Miller B.W., Hurren R., Jitkova Y., Gronda M., Isaac M., et al. Wnt inhibitor screen reveals iron dependence of &#x3b2;-catenin signaling in cancers. Cancer Res. 2011;71:7628&#x2013;7639. doi: 10.1158/0008-5472.CAN-11-2745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2745</ArticleId>
            <ArticleId IdType="pubmed">22009536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyard M., Fatih N., Monnier A., Island M.L., Aubry M., Leroyer P., Bouvet R., Chal&#xe8;s G., Mosser J., Lor&#xe9;al O., et al. Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. Osteoporos. Int. 2012;23:2435&#x2013;2445. doi: 10.1007/s00198-011-1871-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00198-011-1871-z</ArticleId>
            <ArticleId IdType="pubmed">22237814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L., Shi P., Zhao G., Xu J., Peng W., Zhang J., Zhang G., Wang X., Dong Z., Chen F., et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct. Target. Ther. 2020;5:8. doi: 10.1038/s41392-020-0110-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-0110-5</ArticleId>
            <ArticleId IdType="pmc">PMC7005297</ArticleId>
            <ArticleId IdType="pubmed">32296030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West N.R., Murray J.I., Watson P.H. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene. 2014;33:1485&#x2013;1494. doi: 10.1038/onc.2013.105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2013.105</ArticleId>
            <ArticleId IdType="pubmed">23584474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie G., Yao Q., Liu Y., Du S., Liu A., Guo Z., Sun A., Ruan J., Chen L., Ye C., et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int. J. Oncol. 2012;40:1171&#x2013;1179. doi: 10.3892/ijo.2011.1275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2011.1275</ArticleId>
            <ArticleId IdType="pmc">PMC3584811</ArticleId>
            <ArticleId IdType="pubmed">22134360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marotta L.L.C., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., Bloushtain-Qimron N., Kim J.J., Choudhury S.A., Maruyama R., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24&#x2212; stem cell-like breast cancer cells in human tumors. J. Clin. Investig. 2011;121:2723&#x2013;2735. doi: 10.1172/JCI44745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI44745</ArticleId>
            <ArticleId IdType="pmc">PMC3223826</ArticleId>
            <ArticleId IdType="pubmed">21633165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo L., Chen C., Shi M., Wang F., Chen X., Diao D., Hu M., Yu M., Qian L., Guo N. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. 2013;32:5272&#x2013;5282. doi: 10.1038/onc.2012.573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.573</ArticleId>
            <ArticleId IdType="pubmed">23318420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobello N., Biamonte F., Pisanu M.E., Faniello M.C., Jakopin &#x17d;., Chiarella E., Giovannone E.D., Mancini R., Ciliberto G., Cuda G., et al. Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. Oncotarget. 2016;7:62019&#x2013;62033. doi: 10.18632/oncotarget.11495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11495</ArticleId>
            <ArticleId IdType="pmc">PMC5308708</ArticleId>
            <ArticleId IdType="pubmed">27566559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samimi A., Khodayar M.J., Alidadi H., Khodadi E. The Dual Role of ROS in Hematological Malignancies: Stem Cell Protection and Cancer Cell Metastasis. Stem. Cell Rev. Rep. 2020;16:262&#x2013;275. doi: 10.1007/s12015-019-09949-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-019-09949-5</ArticleId>
            <ArticleId IdType="pubmed">31912368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi C.I., Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J. Cell Physiol. 2012;227:421&#x2013;430. doi: 10.1002/jcp.22764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.22764</ArticleId>
            <ArticleId IdType="pubmed">21448925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780&#x2013;783. doi: 10.1038/nature07733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07733</ArticleId>
            <ArticleId IdType="pmc">PMC2778612</ArticleId>
            <ArticleId IdType="pubmed">19194462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold C.R., Mangesius J., Skvortsova I.-I., Ganswindt U. The Role of Cancer Stem Cells in Radiation Resistance. Front. Oncol. 2020;10:164. doi: 10.3389/fonc.2020.00164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.00164</ArticleId>
            <ArticleId IdType="pmc">PMC7044409</ArticleId>
            <ArticleId IdType="pubmed">32154167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim Y.S., Kang M.J., Cho Y.M. Low production of reactive oxygen species and high DNA repair: Mechanism of radioresistance of prostate cancer stem cells. Anticancer Res. 2013;33:4469&#x2013;4474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24123017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaramuzzino L., Lucchino V., Scalise S., Lo Conte M., Zannino C., Sacco A., Biamonte F., Parrotta E.I., Costanzo F.S., Cuda G. Uncovering the Metabolic and Stress Responses of Human Embryonic Stem Cells to FTH1 Gene Silencing. Cells. 2021;10:2431. doi: 10.3390/cells10092431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10092431</ArticleId>
            <ArticleId IdType="pmc">PMC8469604</ArticleId>
            <ArticleId IdType="pubmed">34572080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zolea F., Battaglia A.M., Chiarella E., Malanga D., Marco C.D., Bond H.M., Morrone G., Costanzo F., Biamonte F. Ferritin Heavy Subunit Silencing Blocks the Erythroid Commitment of K562 Cells via miR-150 up-Regulation and GATA-1 Repression. Int. J. Mol. Sci. 2017;18:2167. doi: 10.3390/ijms18102167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18102167</ArticleId>
            <ArticleId IdType="pmc">PMC5666848</ArticleId>
            <ArticleId IdType="pubmed">29039805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salatino A., Aversa I., Battaglia A.M., Sacco A., Di Vito A., Santamaria G., Chirillo R., Veltri P., Tradigo G., Di Cello A., et al. H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS. Oxidative Med. Cell. Longev. 2019;2019:1&#x2013;13. doi: 10.1155/2019/3461251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/3461251</ArticleId>
            <ArticleId IdType="pmc">PMC6875340</ArticleId>
            <ArticleId IdType="pubmed">31781333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani S.A., Guo W., Liao M.-J., Eaton E.Ng., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell. 2008;133:704&#x2013;715. doi: 10.1016/j.cell.2008.03.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2008.03.027</ArticleId>
            <ArticleId IdType="pmc">PMC2728032</ArticleId>
            <ArticleId IdType="pubmed">18485877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aversa I., Zolea F., Ieran&#xf2; C., Bulotta S., Trotta A.M., Faniello M.C., De Marco C., Malanga D., Biamonte F., Viglietto G., et al. Epithelial-to-mesenchymal transition in FHC-silenced cells: The role of CXCR4/CXCL12 axis. J. Exp. Clin. Cancer Res. 2017;36:104. doi: 10.1186/s13046-017-0571-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-017-0571-8</ArticleId>
            <ArticleId IdType="pmc">PMC5543736</ArticleId>
            <ArticleId IdType="pubmed">28774348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R., Luo C., Mines M., Zhang J., Fan G.-H. Chemokine CXCL12 Induces Binding of Ferritin Heavy Chain to the Chemokine Receptor CXCR4, Alters CXCR4 Signaling, and Induces Phosphorylation and Nuclear Translocation of Ferritin Heavy Chain. J. Biol. Chem. 2006;281:37616&#x2013;37627. doi: 10.1074/jbc.M607266200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M607266200</ArticleId>
            <ArticleId IdType="pubmed">17056593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang K.-H., Tian H.-Y., Gao X., Lei W.-W., Hu Y., Wang D.-M., Pan X.-C., Yu M.-L., Xu G.-J., Zhao F.-K., et al. Ferritin Heavy Chain&#x2013;Mediated Iron Homeostasis and Subsequent Increased Reactive Oxygen Species Production Are Essential for Epithelial-Mesenchymal Transition. Cancer Res. 2009;69:5340&#x2013;5348. doi: 10.1158/0008-5472.CAN-09-0112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-0112</ArticleId>
            <ArticleId IdType="pubmed">19531652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chirillo R., Aversa I., Di Vito A., Salatino A., Battaglia A.M., Sacco A., Di Sanzo M.A., Faniello M.C., Quaresima B., Palmieri C., et al. FtH-Mediated ROS Dysregulation Promotes CXCL12/CXCR4 Axis Activation and EMT-Like Trans-Differentiation in Erythroleukemia K562 Cells. Front. Oncol. 2020;10:698. doi: 10.3389/fonc.2020.00698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.00698</ArticleId>
            <ArticleId IdType="pmc">PMC7214836</ArticleId>
            <ArticleId IdType="pubmed">32432042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong A.-H., Wei P., Zhang S., Yao J., Yuan Y., Zhou A.-D., Lang F.F., Heimberger A.B., Rao G., Huang S. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res. 2015;75:2337&#x2013;2348. doi: 10.1158/0008-5472.CAN-14-2800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2800</ArticleId>
            <ArticleId IdType="pmc">PMC4452436</ArticleId>
            <ArticleId IdType="pubmed">25832656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S., Zhao B.S., Zhou A., Lin K., Zheng S., Lu Z., Chen Y., Sulman E.P., Xie K., B&#xf6;gler O., et al. m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell. 2017;31:591&#x2013;606.E6. doi: 10.1016/j.ccell.2017.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.02.013</ArticleId>
            <ArticleId IdType="pmc">PMC5427719</ArticleId>
            <ArticleId IdType="pubmed">28344040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Yuan Q., Xie L. The AlkB Family of Fe (II)/Alpha-Ketoglutarate-Dependent Dioxygenases Modulates Embryogenesis through Epigenetic Regulation. Curr. Stem Cell Res. Ther. 2018;13:136&#x2013;143. doi: 10.2174/1574888X12666171027105532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1574888X12666171027105532</ArticleId>
            <ArticleId IdType="pubmed">29076432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C., Zhi W.I., Lu H., Samanta D., Chen I., Gabrielson E., Semenza G.L. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016;7:64527&#x2013;64542. doi: 10.18632/oncotarget.11743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11743</ArticleId>
            <ArticleId IdType="pmc">PMC5323097</ArticleId>
            <ArticleId IdType="pubmed">27590511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X., Zhang C., Qi S., Guo S., Chen Y., Du E., Zhang H., Wang X., Liu R., Qiao B., et al. Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress. Oncotarget. 2016;7:84893&#x2013;84906. doi: 10.18632/oncotarget.12753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12753</ArticleId>
            <ArticleId IdType="pmc">PMC5356707</ArticleId>
            <ArticleId IdType="pubmed">27768596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giovannetti E., Zucali P.A., Assaraf Y.G., Funel N., Gemelli M., Stark M., Thunnissen E., Hou Z., Muller I.B., Struys E.A., et al. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: Clinical evidence and new pharmacological tools. Ann. Oncol. 2017;28:2725&#x2013;2732. doi: 10.1093/annonc/mdx499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx499</ArticleId>
            <ArticleId IdType="pmc">PMC5808668</ArticleId>
            <ArticleId IdType="pubmed">28945836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R.-H., Li C., Xu X., Zheng Y., Xiao C., Zerfas P., Cooperman S., Eckhaus M., Rouault T., Mishra L., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005;2:399&#x2013;409. doi: 10.1016/j.cmet.2005.10.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2005.10.010</ArticleId>
            <ArticleId IdType="pubmed">16330325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Di X., Torti S.V., Torti F.M. Ferritin H induction by histone deacetylase inhibitors. Biochem. Pharmacol. 2010;80:316&#x2013;324. doi: 10.1016/j.bcp.2010.04.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2010.04.008</ArticleId>
            <ArticleId IdType="pmc">PMC2913600</ArticleId>
            <ArticleId IdType="pubmed">20385107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y.-F., Zhang J., Su Y., Shen Y.-Y., Jiang D.-X., Hou Y.-Y., Geng M.-Y., Ding J., Chen Y. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat. Commun. 2017;8:274. doi: 10.1038/s41467-017-00350-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-00350-9</ArticleId>
            <ArticleId IdType="pmc">PMC5561105</ArticleId>
            <ArticleId IdType="pubmed">28819251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roatsch M., Hoffmann I., Abboud M.I., Hancock R.L., Tarhonskaya H., Hsu K.-F., Wilkins S.E., Yeh T.-L., Lippl K., Serrer K., et al. The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases. ACS Chem. Biol. 2019;14:1737&#x2013;1750. doi: 10.1021/acschembio.9b00289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.9b00289</ArticleId>
            <ArticleId IdType="pubmed">31287655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarno F., Papulino C., Franci G., Andersen J.H., Cautain B., Melardo C., Altucci L., Nebbioso A. 3-Chloro-N&#x2019;-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy. Front. Pharmacol. 2018;9:1006. doi: 10.3389/fphar.2018.01006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.01006</ArticleId>
            <ArticleId IdType="pmc">PMC6137965</ArticleId>
            <ArticleId IdType="pubmed">30245629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao L.-L., Liu H., Yue Z., Liu L., Pei L., Gu J., Wang H., Jia M. Iron chelation inhibits cancer cell growth and modulates global histone methylation status in colorectal cancer. Biometals. 2018;31:797&#x2013;805. doi: 10.1007/s10534-018-0123-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10534-018-0123-5</ArticleId>
            <ArticleId IdType="pubmed">29951879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006;7:21&#x2013;33. doi: 10.1038/nrg1748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg1748</ArticleId>
            <ArticleId IdType="pubmed">16369569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69&#x2013;80. doi: 10.1016/j.cell.2010.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.02.027</ArticleId>
            <ArticleId IdType="pmc">PMC2851638</ArticleId>
            <ArticleId IdType="pubmed">20371346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583&#x2013;594. doi: 10.1016/j.cell.2010.04.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.04.020</ArticleId>
            <ArticleId IdType="pmc">PMC2882693</ArticleId>
            <ArticleId IdType="pubmed">20478252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Hou W., Song X., Yu Y., Huang J., Sun X., Kang R., Tang D. Ferroptosis: Process and function. Cell Death Differ. 2016;23:369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell B.R., Friedmann Angeli J.P., Bayir H., Bush A.I., Conrad M., Dixon S.J., Fulda S., Gasc&#xf3;n S., Hatzios S.K., Kagan V.E., et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L., Vitale I., Aaronson S.A., Abrams J.M., Adam D., Agostinis P., Alnemri E.S., Altucci L., Amelio I., Andrews D.W., et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486&#x2013;541. doi: 10.1038/s41418-017-0012-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0012-4</ArticleId>
            <ArticleId IdType="pmc">PMC5864239</ArticleId>
            <ArticleId IdType="pubmed">29362479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N., von Rechenberg M., Zaganjor E., Bauer A.J., Yang W.S., Fridman D.J., Wolpaw A.J., Smukste I., Peltier J.M., Boniface J.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;868. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J.P., Schneider M., Proneth B., Tyurina Y.Y., Tyurin V.A., Hammond V.J., Herbach N., Aichler M., Walch A., Eggenhofer E., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014;16:1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray P.D., Huang B.-W., Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal. 2012;24:981&#x2013;990. doi: 10.1016/j.cellsig.2012.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2012.01.008</ArticleId>
            <ArticleId IdType="pmc">PMC3454471</ArticleId>
            <ArticleId IdType="pubmed">22286106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan V.E., Mao G., Qu F., Angeli J.P.F., Doll S., Croix C.S., Dar H.H., Liu B., Tyurin V.A., Ritov V.B., et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 2017;13:81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao J.Y., Dixon S.J. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 2016;73:2195&#x2013;2209. doi: 10.1007/s00018-016-2194-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2194-1</ArticleId>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#x2019;Herde K., Krysko D.V. Ferroptosis: Oxidized PEs trigger death. Nat. Chem. Biol. 2017;13:4&#x2013;5. doi: 10.1038/nchembio.2261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2261</ArticleId>
            <ArticleId IdType="pubmed">27842067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louandre C., Ezzoukhry Z., Godin C., Barbare J.-C., Mazi&#xe8;re J.-C., Chauffert B., Galmiche A. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer. 2013;133:1732&#x2013;1742. doi: 10.1002/ijc.28159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.28159</ArticleId>
            <ArticleId IdType="pubmed">23505071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Monian P., Quadri N., Ramasamy R., Jiang X. Glutaminolysis and Transferrin Regulate Ferroptosis. Mol. Cell. 2015;59:298&#x2013;308. doi: 10.1016/j.molcel.2015.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2015.06.011</ArticleId>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., Stockwell B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 2008;15:234&#x2013;245. doi: 10.1016/j.chembiol.2008.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2008.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli J.P.F., Shah R., Pratt D.A., Conrad M. Ferroptosis Inhibition: Mechanisms and Opportunities. Trends Pharmacol. Sci. 2017;38:489&#x2013;498. doi: 10.1016/j.tips.2017.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2017.02.005</ArticleId>
            <ArticleId IdType="pubmed">28363764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yant L.J., Ran Q., Rao L., Van Remmen H., Shibatani T., Belter J.G., Motta L., Richardson A., Prolla T.A. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic. Biol. Med. 2003;34:496&#x2013;502. doi: 10.1016/S0891-5849(02)01360-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0891-5849(02)01360-6</ArticleId>
            <ArticleId IdType="pubmed">12566075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Skouta R., Himmerkus N., Mulay S.R., Dewitz C., De Zen F., Prokai A., Zuchtriegel G., Krombach F., Welz P.-S., et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA. 2014;111:16836&#x2013;16841. doi: 10.1073/pnas.1415518111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1415518111</ArticleId>
            <ArticleId IdType="pmc">PMC4250130</ArticleId>
            <ArticleId IdType="pubmed">25385600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R., Dixon S.J., Wang J., Dunn D.E., Orman M., Shimada K., Rosenberg P.A., Lo D.C., Weinberg J.M., Linkermann A., et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 2014;136:4551&#x2013;4556. doi: 10.1021/ja411006a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja411006a</ArticleId>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao S., Liang B., Huang Q., Dong S., Wu Z., He W., Shi M. Metabolic networks in ferroptosis. Oncol. Lett. 2018;15:5405&#x2013;5411. doi: 10.3892/ol.2018.8066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.8066</ArticleId>
            <ArticleId IdType="pmc">PMC5844144</ArticleId>
            <ArticleId IdType="pubmed">29556292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J., Hewett S.J., Huang Y., Lambros M., Gout P.W., Kalivas P.W., Massie A., Smolders I., Methner A., Pergande M., et al. The cystine/glutamate antiporter system xc&#x2212; in health and disease: From molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 2013;18:522&#x2013;555. doi: 10.1089/ars.2011.4391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2011.4391</ArticleId>
            <ArticleId IdType="pmc">PMC3545354</ArticleId>
            <ArticleId IdType="pubmed">22667998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latunde-Dada G.O. Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim. Biophys. Acta Gen. Subj. 2017;1861:1893&#x2013;1900. doi: 10.1016/j.bbagen.2017.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2017.05.019</ArticleId>
            <ArticleId IdType="pubmed">28552631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayano M., Yang W.S., Corn C.K., Pagano N.C., Stockwell B.R. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016;23:270&#x2013;278. doi: 10.1038/cdd.2015.93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.93</ArticleId>
            <ArticleId IdType="pmc">PMC4716307</ArticleId>
            <ArticleId IdType="pubmed">26184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K., Skouta R., Kaplan A., Yang W.S., Hayano M., Dixon S.J., Brown L.M., Valenzuela C.A., Wolpaw A.J., Stockwell B.R. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 2016;12:497&#x2013;503. doi: 10.1038/nchembio.2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2079</ArticleId>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S., Freitas F.P., Shah R., Aldrovandi M., da Silva M.C., Ingold I., Goya Grocin A., Xavier da Silva T.N., Panzilius E., Scheel C.H., et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693&#x2013;698. doi: 10.1038/s41586-019-1707-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1707-0</ArticleId>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishan S., Jansson P.J., Gutierrez E., Lane D.J.R., Richardson D.E.S., Sahni S. Iron metabolism and autophagy: A poorly explored relationship that has important consequences for health and disease. Nagoya J. Med. Sci. 2015;77:1&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4361502</ArticleId>
            <ArticleId IdType="pubmed">25797965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias J.D., Pontano Vaites L., Nissim S., Biancur D.E., Kim A.J., Wang X., Liu Y., Goessling W., Kimmelman A.C., Harper J.W. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. eLife. 2015;4:e10308. doi: 10.7554/eLife.10308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.10308</ArticleId>
            <ArticleId IdType="pmc">PMC4592949</ArticleId>
            <ArticleId IdType="pubmed">26436293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Monian P., Pan Q., Zhang W., Xiang J., Jiang X. Ferroptosis is an autophagic cell death process. Cell. Res. 2016;26:1021&#x2013;1032. doi: 10.1038/cr.2016.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2016.95</ArticleId>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W., Xie Y., Song X., Sun X., Lotze M.T., Zeh H.J., Kang R., Tang D. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425&#x2013;1428. doi: 10.1080/15548627.2016.1187366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1187366</ArticleId>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J., Wang T., Li Y., Zhou Y., Wang X., Yu X., Ren X., An Y., Wu Y., Sun W., et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic. Biol. Med. 2019;131:356&#x2013;369. doi: 10.1016/j.freeradbiomed.2018.12.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.12.011</ArticleId>
            <ArticleId IdType="pubmed">30557609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin R., Zhang Z., Chen L., Zhou Y., Zou P., Feng C., Wang L., Liang G. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. Cancer Lett. 2016;381:165&#x2013;175. doi: 10.1016/j.canlet.2016.07.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2016.07.033</ArticleId>
            <ArticleId IdType="pubmed">27477901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu S., Zhang Q., Sun X., Zeh H.J., Lotze M.T., Kang R., Tang D. HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Res. 2017;77:2064&#x2013;2077. doi: 10.1158/0008-5472.CAN-16-1979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1979</ArticleId>
            <ArticleId IdType="pmc">PMC5392369</ArticleId>
            <ArticleId IdType="pubmed">28130223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Z., Geng Y., Lu X., Shi Y., Wu G., Zhang M., Shan B., Pan H., Yuan J. Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc. Natl. Acad. Sci. USA. 2019;116:2996&#x2013;3005. doi: 10.1073/pnas.1819728116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1819728116</ArticleId>
            <ArticleId IdType="pmc">PMC6386716</ArticleId>
            <ArticleId IdType="pubmed">30718432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K., Czaja M.J. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ. 2013;20:3&#x2013;11. doi: 10.1038/cdd.2012.63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2012.63</ArticleId>
            <ArticleId IdType="pmc">PMC3524634</ArticleId>
            <ArticleId IdType="pubmed">22595754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z., Yuan Y., Meng Y., Rong Y., Bai H., Chen L. Autophagy upregulation ameliorates cell injury in Sequestosome 1 knockout podocytes in vitro. Biochem. Biophys. Res. Commun. 2017;490:98&#x2013;103. doi: 10.1016/j.bbrc.2017.05.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.05.102</ArticleId>
            <ArticleId IdType="pubmed">28600173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder B., Schulze R.J., Weller S.G., Sletten A.C., Casey C.A., McNiven M.A. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. Hepatology. 2015;61:1896&#x2013;1907. doi: 10.1002/hep.27667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27667</ArticleId>
            <ArticleId IdType="pmc">PMC4441591</ArticleId>
            <ArticleId IdType="pubmed">25565581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M., Chen P., Liu J., Zhu S., Kroemer G., Klionsky D.J., Lotze M.T., Zeh H.J., Kang R., Tang D. Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv. 2019;5:eaaw2238. doi: 10.1126/sciadv.aaw2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aaw2238</ArticleId>
            <ArticleId IdType="pmc">PMC6656546</ArticleId>
            <ArticleId IdType="pubmed">31355331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X., Zhu S., Chen P., Hou W., Wen Q., Liu J., Xie Y., Liu J., Klionsky D.J., Kroemer G., et al. AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc&#x2212; Activity. Curr. Biol. 2018;28:2388&#x2013;2399.e5. doi: 10.1016/j.cub.2018.05.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2018.05.094</ArticleId>
            <ArticleId IdType="pmc">PMC6081251</ArticleId>
            <ArticleId IdType="pubmed">30057310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z., Yao Z., Wang L., Ding H., Shao J., Chen A., Zhang F., Zheng S. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy. 2018;14:2083&#x2013;2103. doi: 10.1080/15548627.2018.1503146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2018.1503146</ArticleId>
            <ArticleId IdType="pmc">PMC6984765</ArticleId>
            <ArticleId IdType="pubmed">30081711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye F., Chai W., Xie M., Yang M., Yu Y., Cao L., Yang L. HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRASQ61L cells. Am. J. Cancer Res. 2019;9:730&#x2013;739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6511643</ArticleId>
            <ArticleId IdType="pubmed">31105999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D., Kang R., Livesey K.M., Cheh C.-W., Farkas A., Loughran P., Hoppe G., Bianchi M.E., Tracey K.J., Zeh H.J., et al. Endogenous HMGB1 regulates autophagy. J. Cell. Biol. 2010;190:881&#x2013;892. doi: 10.1083/jcb.200911078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200911078</ArticleId>
            <ArticleId IdType="pmc">PMC2935581</ArticleId>
            <ArticleId IdType="pubmed">20819940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D., Kang R., Cheh C.-W., Livesey K.M., Liang X., Schapiro N.E., Benschop R., Sparvero L.J., Amoscato A.A., Tracey K.J., et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010;29:5299&#x2013;5310. doi: 10.1038/onc.2010.261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2010.261</ArticleId>
            <ArticleId IdType="pmc">PMC2945431</ArticleId>
            <ArticleId IdType="pubmed">20622903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Liu J., Xu Y., Wu R., Chen X., Song X., Zeh H., Kang R., Klionsky D.J., Wang X., et al. Tumor heterogeneity in autophagy-dependent ferroptosis. Autophagy. 2021;17:1&#x2013;14. doi: 10.1080/15548627.2021.1872241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2021.1872241</ArticleId>
            <ArticleId IdType="pubmed">33404288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J.-F., Yan X.-M., Lan B., Lei Y.-R., Li X.-H., Gao S., Guo Y.-F., Guo F. Molecular mechanisms of synergistic induction of apoptosis by the combination therapy with hyperthermia and cisplatin in prostate cancer cells. Biochem. Biophys. Res. Commun. 2016;479:159&#x2013;165. doi: 10.1016/j.bbrc.2016.08.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.08.060</ArticleId>
            <ArticleId IdType="pubmed">27524236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y.-Q., Chang S.-Y., Wu Q., Gou Y.-J., Jia L., Cui Y.-M., Yu P., Shi Z.-H., Wu W.-S., Gao G., et al. The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. Front. Aging Neurosci. 2016;8:308. doi: 10.3389/fnagi.2016.00308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2016.00308</ArticleId>
            <ArticleId IdType="pmc">PMC5167726</ArticleId>
            <ArticleId IdType="pubmed">28066232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Ou Z., Chen R., Niu X., Chen D., Kang R., Tang D. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173&#x2013;184. doi: 10.1002/hep.28251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu K.C., Cui J.Y., Klaassen C.D. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol. Sci. 2011;123:590&#x2013;600. doi: 10.1093/toxsci/kfr183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/toxsci/kfr183</ArticleId>
            <ArticleId IdType="pmc">PMC3179677</ArticleId>
            <ArticleId IdType="pubmed">21775727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adedoyin O., Boddu R., Traylor A., Lever J.M., Bolisetty S., George J.F., Agarwal A. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am. J. Physiol. Renal. Physiol. 2018;314:F702&#x2013;F714. doi: 10.1152/ajprenal.00044.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00044.2017</ArticleId>
            <ArticleId IdType="pmc">PMC6031916</ArticleId>
            <ArticleId IdType="pubmed">28515173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin D., Kim E.H., Lee J., Roh J.-L. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic. Biol. Med. 2018;129:454&#x2013;462. doi: 10.1016/j.freeradbiomed.2018.10.426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.10.426</ArticleId>
            <ArticleId IdType="pubmed">30339884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D., Tavana O., Chu B., Erber L., Chen Y., Baer R., Gu W. NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. Mol. Cell. 2017;68:224&#x2013;232.e4. doi: 10.1016/j.molcel.2017.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2017.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC5683418</ArticleId>
            <ArticleId IdType="pubmed">28985506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg A.D., Dudek A.M., Ferreira G.B., Verfaillie T., Vandenabeele P., Krysko D.V., Mathieu C., Agostinis P. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy. 2013;9:1292&#x2013;1307. doi: 10.4161/auto.25399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/auto.25399</ArticleId>
            <ArticleId IdType="pubmed">23800749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Wang Y., Liu J., Kang R., Tang D. Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death. Cancer Gene Ther. 2021;28:55&#x2013;63. doi: 10.1038/s41417-020-0182-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41417-020-0182-y</ArticleId>
            <ArticleId IdType="pubmed">32457486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Swanda R.V., Nie L., Liu X., Wang C., Lee H., Lei G., Mao C., Koppula P., Cheng W., et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat. Commun. 2021;12:1589. doi: 10.1038/s41467-021-21841-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-21841-w</ArticleId>
            <ArticleId IdType="pmc">PMC7952727</ArticleId>
            <ArticleId IdType="pubmed">33707434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B., Chen X.B., Ying M.D., He Q.J., Cao J., Yang B. The Role of Ferroptosis in Cancer Development and Treatment Response. Front. Pharmacol. 2017;8:992. doi: 10.3389/fphar.2017.00992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2017.00992</ArticleId>
            <ArticleId IdType="pmc">PMC5770584</ArticleId>
            <ArticleId IdType="pubmed">29375387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang R., Kroemer G., Tang D. The tumor suppressor protein p53 and the ferroptosis network. Free Radic. Biol. Med. 2019;133:162&#x2013;168. doi: 10.1016/j.freeradbiomed.2018.05.074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.05.074</ArticleId>
            <ArticleId IdType="pmc">PMC6251771</ArticleId>
            <ArticleId IdType="pubmed">29800655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J., Zhang C., Wang J., Hu W., Feng Z. The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway. Int. J. Mol. Sci. 2020;21:8387. doi: 10.3390/ijms21218387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21218387</ArticleId>
            <ArticleId IdType="pmc">PMC7664917</ArticleId>
            <ArticleId IdType="pubmed">33182266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L., Kon N., Li T., Wang S.-J., Su T., Hibshoosh H., Baer R., Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ou Y., Wang S.-J., Li D., Chu B., Gu W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl. Acad. Sci. USA. 2016;113:E6806&#x2013;E6812. doi: 10.1073/pnas.1607152113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1607152113</ArticleId>
            <ArticleId IdType="pmc">PMC5098629</ArticleId>
            <ArticleId IdType="pubmed">27698118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA. 2010;107:7455&#x2013;7460. doi: 10.1073/pnas.1001006107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1001006107</ArticleId>
            <ArticleId IdType="pmc">PMC2867677</ArticleId>
            <ArticleId IdType="pubmed">20378837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Zhu S., Song X., Sun X., Fan Y., Liu J., Zhong M., Yuan H., Zhang L., Billiar T.R., et al. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell. Rep. 2017;20:1692&#x2013;1704. doi: 10.1016/j.celrep.2017.07.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.07.055</ArticleId>
            <ArticleId IdType="pubmed">28813679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam C.S.-C., Cheung A.H.-K., Wong S.K.-M., Wan T.M.-H., Ng L., Chow A.K.-M., Cheng N.S.-M., Pak R.C.-H., Li H.-S., Man J.H.-W., et al. Prognostic significance of CD26 in patients with colorectal cancer. PLoS ONE. 2014;9:e98582. doi: 10.1371/journal.pone.0098582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0098582</ArticleId>
            <ArticleId IdType="pmc">PMC4037185</ArticleId>
            <ArticleId IdType="pubmed">24870408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang R., Law W.L., Chu A.C.Y., Poon J.T., Lam C.S.C., Chow A.K.M., Ng L., Cheung L.W.H., Lan X.R., Lan H.Y., et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010;6:603&#x2013;615. doi: 10.1016/j.stem.2010.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2010.04.001</ArticleId>
            <ArticleId IdType="pubmed">20569697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D., Chu B., Yang X., Liu Z., Jin Y., Kon N., Rabadan R., Jiang X., Stockwell B.R., Gu W. iPLA2&#x3b2;-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat. Commun. 2021;12:3644. doi: 10.1038/s41467-021-23902-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-23902-6</ArticleId>
            <ArticleId IdType="pmc">PMC8206155</ArticleId>
            <ArticleId IdType="pubmed">34131139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi M., Li J., Chen S., Cai J., Ban Y., Peng Q., Zhou Y., Zeng Z., Peng S., Li X., et al. Emerging role of lipid metabolism alterations in Cancer stem cells. J. Exp. Clin. Cancer Res. 2018;37:118. doi: 10.1186/s13046-018-0784-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-018-0784-5</ArticleId>
            <ArticleId IdType="pmc">PMC6003041</ArticleId>
            <ArticleId IdType="pubmed">29907133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujihara K.M., Zhang B.Z., Clemons N.J. Opportunities for Ferroptosis in Cancer Therapy. Antioxidants. 2021;10:986. doi: 10.3390/antiox10060986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/antiox10060986</ArticleId>
            <ArticleId IdType="pmc">PMC8235304</ArticleId>
            <ArticleId IdType="pubmed">34205617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birsen R., Larrue C., Decroocq J., Johnson N., Guiraud N., Gotanegre M., Cantero-Aguilar L., Grignano E., Huynh T., Fontenay M., et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2021 doi: 10.3324/haematol.2020.259531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2020.259531</ArticleId>
            <ArticleId IdType="pubmed">33406814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D.S., Duong C.P., Haupt S., Montgomery K.G., House C.M., Azar W.J., Pearson H.B., Fisher O.M., Read M., Guerra G.R., et al. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 2017;8:14844. doi: 10.1038/ncomms14844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14844</ArticleId>
            <ArticleId IdType="pmc">PMC5379068</ArticleId>
            <ArticleId IdType="pubmed">28348409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones C.L., Stevens B.M., D&#x2019;Alessandro A., Culp-Hill R., Reisz J.A., Pei S., Gustafson A., Khan N., DeGregori J., Pollyea D.A., et al. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019;134:389&#x2013;394. doi: 10.1182/blood.2019898114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2019898114</ArticleId>
            <ArticleId IdType="pmc">PMC6659257</ArticleId>
            <ArticleId IdType="pubmed">31101624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., Oshima M., Ikeda T., Asaba R., Yagi H., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc&#x2212; and thereby promotes tumor growth. Cancer Cell. 2011;19:387&#x2013;400. doi: 10.1016/j.ccr.2011.01.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.01.038</ArticleId>
            <ArticleId IdType="pubmed">21397861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagano O. Cancer therapy targeted to CD44v-xCT-mediated antioxidant system. Ann. Oncol. 2016;27:vii40. doi: 10.1093/annonc/mdw485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa M., Tsuchihashi K., Ishimoto T., Yae T., Motohara T., Sugihara E., Onishi N., Masuko T., Yoshizawa K., Kawashiri S., et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73:1855&#x2013;1866. doi: 10.1158/0008-5472.CAN-12-3609-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3609-T</ArticleId>
            <ArticleId IdType="pubmed">23319806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Ou Z., Xie M., Kang R., Fan Y., Niu X., Wang H., Cao L., Tang D. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene. 2015;34:5617&#x2013;5625. doi: 10.1038/onc.2015.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.32</ArticleId>
            <ArticleId IdType="pmc">PMC4640181</ArticleId>
            <ArticleId IdType="pubmed">25728673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D., Kang R., Livesey K.M., Kroemer G., Billiar T.R., Van Houten B., Zeh H.J., Lotze M.T. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab. 2011;13:701&#x2013;711. doi: 10.1016/j.cmet.2011.04.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2011.04.008</ArticleId>
            <ArticleId IdType="pmc">PMC3293110</ArticleId>
            <ArticleId IdType="pubmed">21641551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen L., Qi Z., Zhu Y., Song X., Xuan C., Ben P., Lan L., Luo L., Yin Z. Phosphorylated heat shock protein 27 promotes lipid clearance in hepatic cells through interacting with STAT3 and activating autophagy. Cell. Signal. 2016;28:1086&#x2013;1098. doi: 10.1016/j.cellsig.2016.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2016.05.008</ArticleId>
            <ArticleId IdType="pubmed">27185187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C.-L., Uthaya Kumar D.B., Punj V., Xu J., Sher L., Tahara S.M., Hess S., Machida K. NANOG Metabolically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism. Cell Metab. 2016;23:206&#x2013;219. doi: 10.1016/j.cmet.2015.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2015.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC4715587</ArticleId>
            <ArticleId IdType="pubmed">26724859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marzenell P., Hagen H., Sellner L., Zenz T., Grinyte R., Pavlov V., Daum S., Mokhir A. Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells. J. Med. Chem. 2013;56:6935&#x2013;6944. doi: 10.1021/jm400754c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm400754c</ArticleId>
            <ArticleId IdType="pubmed">23931109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagen H., Marzenell P., Jentzsch E., Wenz F., Veldwijk M.R., Mokhir A. Aminoferrocene-based prodrugs activated by reactive oxygen species. J. Med. Chem. 2012;55:924&#x2013;934. doi: 10.1021/jm2014937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm2014937</ArticleId>
            <ArticleId IdType="pubmed">22185340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trujillo-Alonso V., Pratt E.C., Zong H., Lara-Martinez A., Kaittanis C., Rabie M.O., Longo V., Becker M.W., Roboz G.J., Grimm J., et al. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat. Nanotechnol. 2019;14:616&#x2013;622. doi: 10.1038/s41565-019-0406-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41565-019-0406-1</ArticleId>
            <ArticleId IdType="pmc">PMC6554053</ArticleId>
            <ArticleId IdType="pubmed">30911166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sagasser J., Ma B.N., Baecker D., Salcher S., Hermann M., Lamprecht J., Angerer S., Obexer P., Kircher B., Gust R. A New Approach in Cancer Treatment: Discovery of Chlorido[N,N&#x2019;-disalicylidene-1,2-phenylenediamine]iron(III) Complexes as Ferroptosis Inducers. J. Med. Chem. 2019;62:8053&#x2013;8061. doi: 10.1021/acs.jmedchem.9b00814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.9b00814</ArticleId>
            <ArticleId IdType="pubmed">31369259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J., Luo T., Wang J. Gene interfered-ferroptosis therapy for cancers. Nat. Commun. 2021;12:5311. doi: 10.1038/s41467-021-25632-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-25632-1</ArticleId>
            <ArticleId IdType="pmc">PMC8423858</ArticleId>
            <ArticleId IdType="pubmed">34493724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H., Yang C., Jian L., Guo S., Chen R., Li K., Qu F., Tao K., Fu Y., Luo F., et al. Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncol. Rep. 2019;42:826&#x2013;838. doi: 10.3892/or.2019.7189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2019.7189</ArticleId>
            <ArticleId IdType="pubmed">31173262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki S., Shintani S., Hirata Y., Suina K., Semba T., Yamasaki J., Umene K., Ishikawa M., Saya H., Nagano O. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. Oncotarget. 2018;9:33832&#x2013;33843. doi: 10.18632/oncotarget.26112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26112</ArticleId>
            <ArticleId IdType="pmc">PMC6173468</ArticleId>
            <ArticleId IdType="pubmed">30333913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gout P.W., Buckley A.R., Simms C.R., Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc&#x2212; cystine transporter: A new action for an old drug. Leukemia. 2001;15:1633&#x2013;1640. doi: 10.1038/sj.leu.2402238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.leu.2402238</ArticleId>
            <ArticleId IdType="pubmed">11587223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi Y., Kasukabe T., Kumakura S. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int. J. Oncol. 2018;52:1011&#x2013;1022. doi: 10.3892/ijo.2018.4259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2018.4259</ArticleId>
            <ArticleId IdType="pubmed">29393418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert S.M., Buckingham S.C., Campbell S.L., Robel S., Holt K.T., Ogunrinu-Babarinde T., Warren P.P., White D.M., Reid M.A., Eschbacher J.M., et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci. Transl. Med. 2015;7:289ra86. doi: 10.1126/scitranslmed.aaa8103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaa8103</ArticleId>
            <ArticleId IdType="pmc">PMC4503260</ArticleId>
            <ArticleId IdType="pubmed">26019222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robe P.A., Martin D.H., Nguyen-Khac M.T., Artesi M., Deprez M., Albert A., Vanbelle S., Califice S., Bredel M., Bours V. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009;9:372. doi: 10.1186/1471-2407-9-372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-9-372</ArticleId>
            <ArticleId IdType="pmc">PMC2771045</ArticleId>
            <ArticleId IdType="pubmed">19840379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachaier E., Louandre C., Godin C., Saidak Z., Baert M., Diouf M., Chauffert B., Galmiche A. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34:6417&#x2013;6422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25368241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw A.T., Winslow M.M., Magendantz M., Ouyang C., Dowdle J., Subramanian A., Lewis T.A., Maglathin R.L., Tolliday N., Jacks T. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl. Acad. Sci. USA. 2011;108:8773&#x2013;8778. doi: 10.1073/pnas.1105941108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1105941108</ArticleId>
            <ArticleId IdType="pmc">PMC3102385</ArticleId>
            <ArticleId IdType="pubmed">21555567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y., Xie Y., Cao L., Yang L., Yang M., Lotze M.T., Zeh H.J., Kang R., Tang D. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell. Oncol. 2015;2:e1054549. doi: 10.1080/23723556.2015.1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/23723556.2015.1054549</ArticleId>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., SriRamaratnam R., Welsch M.E., Shimada K., Skouta R., Viswanathan V.S., Cheah J.H., Clemons P.A., Shamji A.F., Clish C.B., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malfa G.A., Tomasello B., Acquaviva R., Genovese C., La Mantia A., Cammarata F.P., Ragusa M., Renis M., Di Giacomo C. Betula etnensis Raf. (Betulaceae) Extract Induced HO-1 Expression and Ferroptosis Cell Death in Human Colon Cancer Cells. Int. J. Mol. Sci. 2019;20:2723. doi: 10.3390/ijms20112723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20112723</ArticleId>
            <ArticleId IdType="pmc">PMC6600233</ArticleId>
            <ArticleId IdType="pubmed">31163602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler M.M., Andia A.A., Liu H., Csuka J.M., Hurlocker B., Vaiana C.A., Heindel D.W., Zuckerman D.S., Bos P.H., Reznik E., et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol. 2018;14:507&#x2013;515. doi: 10.1038/s41589-018-0031-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-018-0031-6</ArticleId>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrams R.P., Carroll W.L., Woerpel K.A. Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. ACS Chem. Biol. 2016;11:1305&#x2013;1312. doi: 10.1021/acschembio.5b00900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.5b00900</ArticleId>
            <ArticleId IdType="pmc">PMC5507670</ArticleId>
            <ArticleId IdType="pubmed">26797166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eling N., Reuter L., Hazin J., Hamacher-Brady A., Brady N.R. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2015;2:517&#x2013;532. doi: 10.18632/oncoscience.160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncoscience.160</ArticleId>
            <ArticleId IdType="pmc">PMC4468338</ArticleId>
            <ArticleId IdType="pubmed">26097885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang N.-D., Tan S.-H., Ng S., Shi Y., Zhou J., Tan K.S.W., Wong W.-S.F., Shen H.-M. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J. Biol. Chem. 2014;289:33425&#x2013;33441. doi: 10.1074/jbc.M114.564567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.564567</ArticleId>
            <ArticleId IdType="pmc">PMC4246098</ArticleId>
            <ArticleId IdType="pubmed">25305013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ooko E., Saeed M.E.M., Kadioglu O., Sarvi S., Colak M., Elmasaoudi K., Janah R., Greten H.J., Efferth T. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22:1045&#x2013;1054. doi: 10.1016/j.phymed.2015.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phymed.2015.08.002</ArticleId>
            <ArticleId IdType="pubmed">26407947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang N., Zeng G.-Z., Yin J.-L., Bian Z.-X. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt&#x2019;s Lymphoma. Biochem. Biophys. Res. Commun. 2019;519:533&#x2013;539. doi: 10.1016/j.bbrc.2019.09.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.09.023</ArticleId>
            <ArticleId IdType="pubmed">31537387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Mi Y., Zhang X., Ma Q., Song Y., Zhang L., Wang D., Xing J., Hou B., Li H., et al. Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. J. Exp. Clin. Cancer Res. 2019;38:402. doi: 10.1186/s13046-019-1413-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1413-7</ArticleId>
            <ArticleId IdType="pmc">PMC6743121</ArticleId>
            <ArticleId IdType="pubmed">31519193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bebber C.M., Thomas E.S., Stroh J., Chen Z., Androulidaki A., Schmitt A., H&#xf6;hne M.N., St&#xfc;ker L., de P&#xe1;dua Alves C., Khonsari A., et al. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nat. Commun. 2021;12:2048. doi: 10.1038/s41467-021-22336-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-22336-4</ArticleId>
            <ArticleId IdType="pmc">PMC8024350</ArticleId>
            <ArticleId IdType="pubmed">33824345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S., Henson E.S., Chen Y., Gibson S.B. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307. doi: 10.1038/cddis.2016.208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.208</ArticleId>
            <ArticleId IdType="pmc">PMC4973350</ArticleId>
            <ArticleId IdType="pubmed">27441659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S., Dielschneider R.F., Henson E.S., Xiao W., Choquette T.R., Blankstein A.R., Chen Y., Gibson S.B. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS ONE. 2017;12:e0182921. doi: 10.1371/journal.pone.0182921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0182921</ArticleId>
            <ArticleId IdType="pmc">PMC5565111</ArticleId>
            <ArticleId IdType="pubmed">28827805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gentric G., Kieffer Y., Mieulet V., Goundiam O., Bonneau C., Nemati F., Hurbain I., Raposo G., Popova T., Stern M.-H., et al. PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers. Cell Metab. 2019;29:156&#x2013;173.e10. doi: 10.1016/j.cmet.2018.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2018.09.002</ArticleId>
            <ArticleId IdType="pmc">PMC6331342</ArticleId>
            <ArticleId IdType="pubmed">30244973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley M.A., Kremer D.M., Maurer H.C., DelGiorno K.E., Lee H.-J., Purohit V., Sagalovskiy I.R., Ma A., Kapilian J., Firl C.E.M., et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85&#x2013;89. doi: 10.1126/science.aaw9872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaw9872</ArticleId>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer S.L., Saha A., Liu J., Tadi S., Tiziani S., Yan W., Triplett K., Lamb C., Alters S.E., Rowlinson S., et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat. Med. 2017;23:120&#x2013;127. doi: 10.1038/nm.4232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4232</ArticleId>
            <ArticleId IdType="pmc">PMC5218918</ArticleId>
            <ArticleId IdType="pubmed">27869804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Green M., Choi J.E., Gij&#xf3;n M., Kennedy P.D., Johnson J.K., Liao P., Lang X., Kryczek I., Sell A., et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjarnadottir O., Romero Q., Bendahl P.-O., Jirstr&#xf6;m K., Ryd&#xe9;n L., Loman N., Uhl&#xe9;n M., Johannesson H., Rose C., Grabau D., et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res. Treat. 2013;138:499&#x2013;508. doi: 10.1007/s10549-013-2473-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-013-2473-6</ArticleId>
            <ArticleId IdType="pubmed">23471651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graf H., J&#xfc;ngst C., Straub G., Dogan S., Hoffmann R.-T., Jakobs T., Reiser M., Waggershauser T., Helmberger T., Walter A., et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion. 2008;78:34&#x2013;38. doi: 10.1159/000156702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000156702</ArticleId>
            <ArticleId IdType="pubmed">18797167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kornblau S.M., Banker D.E., Stirewalt D., Shen D., Lemker E., Verstovsek S., Estrov Z., Faderl S., Cortes J., Beran M., et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: A phase 1 study. Blood. 2007;109:2999&#x2013;3006. doi: 10.1182/blood-2006-08-044446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2006-08-044446</ArticleId>
            <ArticleId IdType="pmc">PMC1852228</ArticleId>
            <ArticleId IdType="pubmed">17158228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sondergaard T.E., Pedersen P.T., Andersen T.L., S&#xf8;e K., Lund T., Ostergaard B., Garnero P., Delaisse J.-M., Plesner T. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol. Oncol. 2009;27:17&#x2013;22. doi: 10.1002/hon.869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hon.869</ArticleId>
            <ArticleId IdType="pubmed">18668701</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34791597</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1749-0774</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Human cell</Title>
          <ISOAbbreviation>Hum Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>HSP27 protects against ferroptosis of glioblastoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>238</StartPage>
          <EndPage>249</EndPage>
          <MedlinePgn>238-249</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13577-021-00645-6</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis, as an new form of non-apoptotic regulated cell death, plays an important role in human cancers. Although it is reported that HSP27 is an novel regulator of ferroptosis in cancer, it remains unknown how HSP27 affects ferroptosis in glioma. In this study, we examined the effect of HSP27 on the ferroptosis of glioblasotma. HSP27 overexpression protects glioblastoma cells from erastin-induced ferroptosis while HSP27 depletion promotes erastin-induced ferroptosis of glioblastoma. Notably, HSP27 phosphorylation is required for the protective function of HSP27 in erastin-induced ferroptosis. Overall, our study reveal novel molecular mechanisms of ferroptosis in glioma and also identify HSP27 as a negative regulator of ferroptosis and a potential target for the treatment of glioma.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s) under exclusive licence to Japan Human Cell Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Fanen</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Si</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Liguo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhou</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Baohui</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shenqi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. shenqiz@whu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. shenqiz@whu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qianxue</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0002-9413-1030</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. chenqx666@whu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. chenqx666@whu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>82072764</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2042021kf0089</GrantID>
            <Agency>Fundamental Research Funds for the Central Universities</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Hum Cell</MedlineTA>
        <NlmUniqueID>8912329</NlmUniqueID>
        <ISSNLinking>0914-7470</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055551" MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Erastin</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">HSP27</Keyword>
        <Keyword MajorTopicYN="N">Phosphorylation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>7</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34791597</ArticleId>
        <ArticleId IdType="doi">10.1007/s13577-021-00645-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s13577-021-00645-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a &#x201c;state of the science&#x201d; review. Neuro Oncol. 2014;16:896&#x2013;913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nou087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70025-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison BR, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J, Fan YQ, Liu BH, Zhou H, Wang JM, Chen QX. ACSL4 suppresses glioma cells proliferation via activating ferroptosis. Oncol Rep. 2020;43:147&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31789401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P, Zhou J, Zhang Q, Dow A, Saripalli AL, Kryczek I, Wei S, Szeliga W, Vatan L, Stone EM, Georgiou G, Cieslik M, Wahl DR, Morgan MA, Chinnaiyan AM, Lawrence TS, Zou W. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, Zhuang L, Chen G, Xiao ZD, Hung MC, Chen J, Huang P, Li W, Gan B. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0178-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JH, Jung YJ, Choi B, Lee NL, Lee HJ, Kwak SY, Kwon Y, Na Y, Lee YS. Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules. Oncotarget. 2016;7:53178&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge H, Du J, Xu J, Meng X, Tian J, Yang J, Liang H. SUMOylation of HSP27 by small ubiquitin-like modifier 2/3 promotes proliferation and invasion of hepatocellular carcinoma cells. Cancer Biol Ther. 2017;18:552&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384047.2017.1345382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X, Wang H, Cao L, Tang D. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene. 2015;34:5617&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.32</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 2017;19:139&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/now247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, Zhang W, Bao Z, Jiang T. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteomics Bioinform. 2021. https://doi.org/10.1016/j.gpb.2020.10.005 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gpb.2020.10.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann AJ, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Weng J, Yu L, Huang Q, Jiang Y, Guo X. Role of TLR4-p38 MAPK-Hsp27 signal pathway in LPS-induced pulmonary epithelial hyperpermeability. BMC Pulm Med. 2018;18:178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12890-018-0735-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sreekanth GP, Chuncharunee A, Sirimontaporn A, Panaampon J, Noisakran S, Yenchitsomanus PT, Limjindaporn T. SB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 Phosphorylation. PLoS ONE. 2016;11:e0149486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0149486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golembieski WA, Thomas SL, Schultz CR, Yunker CK, McClung HM, Lemke N, Cazacu S, Barker T, Sage EH, Brodie C, Rempel SA. HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. Glia. 2008;56:1061&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye H, Huang H, Cao F, Chen M, Zheng X, Zhan R. HSPB1 enhances SIRT2-mediated G6PD activation and promotes glioma cell proliferation. PLoS ONE. 2016;11:4285.</Citation>
        </Reference>
        <Reference>
          <Citation>Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA. Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer. 2012;11:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-11-20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2020. https://doi.org/10.1016/j.gpb.2020.10.005 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gpb.2020.10.005</ArticleId>
            <ArticleId IdType="pubmed">33000412</ArticleId>
            <ArticleId IdType="pmc">8310547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adedoyin O, Boddu R, Traylor A, Lever JM, Bolisetty S, George JF, Agarwal A. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am J Physiol Renal Physiol. 2018;314:F702&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00044.2017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L, Yin Z. HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with beta-arrestin2. Cell Signal. 2014;26:594&#x2013;602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2013.11.033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, Gerthoffer WT. A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem. 1999;274:24211&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.34.24211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T, Iino M, Goto K. Sec6 enhances cell migration and suppresses apoptosis by elevating the phosphorylation of p38 MAPK, MK2, and HSP27. Cell Signal. 2018;49:1&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2018.04.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K, Young MM, Aregawi DG, Glantz MJ, Zacharia BE, Specht CS, Wang HG, Li W. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-19193-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee PP, Li W. Tumor necrosis: a synergistic consequence of metabolic stress and inflammation. BioEssays. 2021;43:e2100029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bies.202100029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai E, Han L, Liu J, Xie Y, Zeh HJ, Kang R, Bai L, Tang D. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun. 2020;11:6339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-20154-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-020-00462-0</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34699654</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7006</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer science</Title>
          <ISOAbbreviation>Cancer Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis resistance determines high susceptibility of murine A/J strain to iron-induced renal carcinogenesis.</ArticleTitle>
        <Pagination>
          <StartPage>65</StartPage>
          <EndPage>78</EndPage>
          <MedlinePgn>65-78</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.15175</ELocationID>
        <Abstract>
          <AbstractText>Cancer susceptibility is a critical factor in the understanding of carcinogenesis. Intraperitoneal (i.p.) injection of an iron chelate, ferric nitrilotriacetate (Fe-NTA), produces hydroxyl radicals via Fenton reaction to induce ferroptosis in renal proximal tubules. Rats or mice subjected to repeated i.p. injections of Fe-NTA develop renal cell carcinoma (RCC). To elucidate the molecular mechanisms that cause susceptibility to renal carcinogenesis, we first established an inter-strain difference in the susceptibility to Fe-NTA-induced renal carcinogenesis in mice. Based on a previous observation of a low incidence of RCC with this model in C57BL/6J strain mice, we investigated A/J strain mice here, which demonstrated significantly higher susceptibility to Fe-NTA-induced renal carcinogenesis. Homozygous deletion of the Cdkn2a/2b tumor suppressor locus was detected for the first time in A/J strain mice. Focusing on ferroptosis and iron metabolism, we explored the mechanisms involved that lead to the difference in RCC development. We compared the protective responses in the kidney of A/J and C57BL/6J strains after Fe-NTA treatment. After 3-week Fe-NTA treatment, A/J mice maintained higher levels of expression of glutathione peroxidase 4 and xCT (SLC7A11), leading to a lower level of lipid peroxidation. Simultaneously, A/J mice had decreased expression of transferrin receptor and increased expression of ferritin to greater degrees than C57BL/6 mice. After a single Fe-NTA injection, higher levels of oxidative cell damage and cytosolic catalytic Fe(II) were observed in C57BL/6J mice, accompanied by a greater increase in lipocalin-2. Lipocalin-2 deficiency significantly decreased oxidative renal damage. Our results suggest that a genetic trait favoring ferroptosis resistance contributes to high susceptibility to Fe-NTA-induced RCC in A/J strain.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akatsuka</LastName>
            <ForeName>Shinya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guang Hua</ForeName>
            <Initials>GH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mori</LastName>
            <ForeName>Kiyoshi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Clinical Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology and Kidney Research, Shizuoka General Hospital, Shizuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-0615-7001</Identifier>
            <AffiliationInfo>
              <Affiliation>Aichi Cancer Center Research Institute, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toyokuni</LastName>
            <ForeName>Shinya</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5757-1109</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Low-temperature Plasma Sciences, Nagoya University, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>JPMJCR19H4</GrantID>
            <Agency>JST CREST</Agency>
          </Grant>
          <Grant>
            <GrantID>JP19H05462</GrantID>
            <Agency>JSPS</Agency>
          </Grant>
          <Grant>
            <GrantID>JP20H05502</GrantID>
            <Agency>JSPS</Agency>
          </Grant>
          <Grant>
            <Agency>Princess Takamatsu Cancer Research</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cancer Sci</MedlineTA>
        <NlmUniqueID>101168776</NlmUniqueID>
        <ISSNLinking>1347-9032</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027201">Cationic Amino Acid Transporter 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C417743">Cdkn2a protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493968">Cdkn2b protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050762">Cyclin-Dependent Kinase Inhibitor p15</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071068">Lipocalin-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C420826">Slc7a1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126469-30-5</RegistryNumber>
          <NameOfSubstance UI="C071332">Lcn2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>KA90006V9D</RegistryNumber>
          <NameOfSubstance UI="D009571">Nitrilotriacetic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Z3U5ED15B9</RegistryNumber>
          <NameOfSubstance UI="C020326">ferric nitrilotriacetate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027201" MajorTopicYN="N">Cationic Amino Acid Transporter 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050762" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p15</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019941" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071068" MajorTopicYN="N">Lipocalin-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009571" MajorTopicYN="N">Nitrilotriacetic Acid</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017384" MajorTopicYN="Y">Sequence Deletion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">animal models</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron</Keyword>
        <Keyword MajorTopicYN="N">lipocalins</Keyword>
        <Keyword MajorTopicYN="N">renal cell carcinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>17</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34699654</ArticleId>
        <ArticleId IdType="pmc">PMC8748236</ArticleId>
        <ArticleId IdType="doi">10.1111/cas.15175</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Toyokuni S. Iron and thiols as two major players in carcinogenesis: friends or foes? Front Pharmacol. 2014;5:5&#x2010;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4147246</ArticleId>
            <ArticleId IdType="pubmed">25221514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. 2020;16:77&#x2010;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31554933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawabata H. Transferrin and transferrin receptors update. Free Radic Biol Med. 2019;133:46&#x2010;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29969719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanatori I, Kishi F. DMT1 and iron transport. Free Radic Biol Med. 2019;133:55&#x2010;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30055235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sponsel HT, Alfrey AC, Hammond WS, et al. Effect of iron on renal tubular epithelial cells. Kidney Int. 1996;50:436&#x2010;444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8840271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebina Y, Okada S, Hamazaki S, et al. Nephrotoxicity and renal cell carcinoma after use of iron&#x2010; and aluminum&#x2010;nitrilotriacetate complexes in rats. J Natl Cancer Inst. 1986;76:107&#x2010;113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martines AMF, Masereeuw R, Tjalsma H, et al. Iron metabolism in the pathogenesis of iron&#x2010;induced kidney injury. Nat Rev Nephrol. 2013;9:385&#x2010;398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23670084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894&#x2010;906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26318520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S, Ito F, Yamashita K, Okazaki Y, Akatsuka S. Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis. Free Radic Biol Med. 2017;108:610&#x2010;626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28433662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada S, Minamiyama Y, Hamazaki S, Toyokuni S, Sotomatsu A. Glutathione cycle dependency of ferric nitrilotriacetate&#x2010;induced lipid peroxidation in mouse proximal renal tubules. Arch Biochem Biophys. 1993;301:138&#x2010;142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8095133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada S. Iron&#x2010;induced tissue damage and cancer: the role of reactive oxygen species&#x2010;free radicals. Pathol Int. 1996;46:311&#x2010;332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8809878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 1987;47:1867&#x2010;1869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3815378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li GH, Akatsuka S, Chew SH, et al. Fenton reaction&#x2010;induced renal carcinogenesis in Mutyh&#x2010;deficient mice exhibits less chromosomal aberrations than the rat model. Pathol Int. 2017;67:564&#x2010;574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29027306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S. Iron&#x2010;induced carcinogenesis: The role of redox regulation. Free Radic Biol Med. 1996;20:553&#x2010;566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8904296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S. The origin and future of oxidative stress pathology: from the recognition of carcinogenesis as an iron addiction with ferroptosis&#x2010;resistance to non&#x2010;thermal plasma therapy. Pathol Int. 2016;66:245&#x2010;259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26931176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akatsuka S, Yamashita Y, Ohara H, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One. 2012;7:1&#x2010;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3430702</ArticleId>
            <ArticleId IdType="pubmed">22952676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med. 2002;33:1037&#x2010;1046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12374615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehrer JP. The Haber&#x2010;Weiss reaction and mechanisms of toxicity. Toxicology. 2000;149:43&#x2010;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10963860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron&#x2010;dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2010;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73:2195&#x2010;2209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y, Zak O, Aisen P, Harrison SC, Walz T. Structure of the human transferrin receptor&#x2010;transferrin complex. Cell. 2004;116:565&#x2010;576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14980223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, Schorpp K, Jin J, et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 2020;30:3411&#x2010;3423.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7172030</ArticleId>
            <ArticleId IdType="pubmed">32160546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao X, Yeoh BS, Vijay&#x2010;Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr. 2017;37:103&#x2010;130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28628361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917&#x2010;921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15531878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukaide T, Hattori Y, Misawa N, et al. Histological detection of catalytic ferrous iron with the selective turn&#x2010;on fluorescent probe RhoNox&#x2010;1 in a Fenton reaction&#x2010;based rat renal carcinogenesis model. Free Radic Res. 2014;48:990&#x2010;995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24580501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S. Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr. 2011;48:46&#x2010;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3022063</ArticleId>
            <ArticleId IdType="pubmed">21297911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maas AM, Bretz AC, Mack E, Stiewe T. Targeting p73 in cancer. Cancer Lett. 2013;332:229&#x2010;236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21903324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuch B, Zhang J. Genetic predisposition to renal cell carcinoma: Implications for counseling, testing, screening, and management. J Clin Oncol. 2018;36:3560&#x2010;3566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30372385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482:419&#x2010;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5319403</ArticleId>
            <ArticleId IdType="pubmed">28212725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165&#x2010;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S, Yanatori I, Kong Y, et al. Ferroptosis at the crossroads of infection, aging and cancer. Cancer Sci. 2020;111:2665&#x2010;2671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7419040</ArticleId>
            <ArticleId IdType="pubmed">32437084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The hallmarks of ferroptosis. Annu Rev Cancer Biol. 2019;3:35&#x2010;54.</Citation>
        </Reference>
        <Reference>
          <Citation>Meyron&#x2010;Holtz EG, Ghosh MC, Iwai K, et al. Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J. 2004;23:386&#x2010;395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1271751</ArticleId>
            <ArticleId IdType="pubmed">14726953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith CP, Lee WK, Haley M, et al. Proximal tubule transferrin uptake is modulated by cellular iron and mediated by apical membrane megalin&#x2010;cubilin complex and transferrin receptor 1. J Biol Chem. 2019;294:7025&#x2010;7036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6497946</ArticleId>
            <ArticleId IdType="pubmed">30833328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T, Naguro I, Ichijo H. Iron homeostasis and iron&#x2010;regulated ROS in cell death, senescence and human diseases. Biochim Biophys Acta &#x2010; Gen Subj. 2019;1863:1398&#x2010;1409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31229492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swaminathan S. Iron homeostasis pathways as therapeutic targets in acute kidney injury. Nephron. 2018;140:156&#x2010;159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6165684</ArticleId>
            <ArticleId IdType="pubmed">29982259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta &#x2010; Rev Cancer. 2012;1826:129&#x2010;169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3362670</ArticleId>
            <ArticleId IdType="pubmed">22513004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T, Iwasa Y, Kondo S, Hiai H, Toyokuni S. High incidence of allelic loss on chromosome 5 and inactivation of p15(INK4B) and p16(INK4A) tumor suppressor genes in oxystress&#x2010;induced renal cell carcinoma of rats. Oncogene. 1999;18:3793&#x2010;3797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10391689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiroyasu M, Ozeki M, Kohda H, et al. Specific allelic loss of p16 INK4A tumor suppressor gene after weeks of iron&#x2010;mediated oxidative damage during rat renal carcinogenesis. Am J Pathol. 2002;160:419&#x2010;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1850668</ArticleId>
            <ArticleId IdType="pubmed">11839561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akatsuka S, Li GH, Toyokuni S. Superiority of rat over murine model for studies on the evolution of cancer genome. Free Radic Res. 2018;52:1323&#x2010;1327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29669465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan H&#x2010;F, Zou T, Tuo Q&#x2010;Z, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021;6(1):49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7858612</ArticleId>
            <ArticleId IdType="pubmed">33536413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to iron out cancer. Cancer Cell. 2019;35:830&#x2010;849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppenol WH, Hider RH. Iron and redox cycling. Do&#x2019;s and don&#x2019;ts. Free Radic Biol Med. 2019;133:3&#x2010;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30236787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breitzig M, Bhimineni C, Lockey R, Kolliputi N. 4&#x2010;Hydroxy&#x2010;2&#x2010;nonenal: a critical target in oxidative stress? Am J Physiol &#x2010; Cell Physiol. 2016;311:C537&#x2010;C543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5129750</ArticleId>
            <ArticleId IdType="pubmed">27385721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, SriRamaratnam R, Welsch M, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2010;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson N, Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models. Front Pharmacol. 2014;5:1&#x2010;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4112806</ArticleId>
            <ArticleId IdType="pubmed">25120486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gammella E, Buratti P, Cairo G, Recalcati S. The transferrin receptor: the cellular iron gate. Metallomics. 2017;9:1367&#x2010;1375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28671201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen EI, Birn H. Megalin and cubilin: Multifunctional endocytic receptors. Nat Rev Mol Cell Biol. 2002;3:258&#x2010;268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11994745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011;434:365&#x2010;381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3048577</ArticleId>
            <ArticleId IdType="pubmed">21348856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson CP, Shen M, Eisenstein RS, Leibold EA. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta &#x2010; Mol Cell Res. 2012;1823:1468&#x2010;1483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3675657</ArticleId>
            <ArticleId IdType="pubmed">22610083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taguchi S, Hidaka S, Yanai M, et al. Renal hemosiderosis presenting with acute kidney Injury and macroscopic hematuria in Immunoglobulin A nephropathy: a case report. BMC Nephrol. 2021;22:1&#x2010;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8048362</ArticleId>
            <ArticleId IdType="pubmed">33858363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu G, Ahn JH, Chang SY, et al. Lipocalin&#x2010;2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem. 2012;287:4808&#x2010;4817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3281654</ArticleId>
            <ArticleId IdType="pubmed">22117066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin&#x2010;siderophore&#x2010;iron complex rescues the kidney from ischemia&#x2010;reperfusion injury. J Clin Invest. 2005;115:610&#x2010;621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC548316</ArticleId>
            <ArticleId IdType="pubmed">15711640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawar RD, Pitashny M, Gindea S, et al. Neutrophil gelatinase&#x2010;associated lipocalin is instrumental in the pathogenesis of antibody&#x2010;mediated nephritis in mice. Arthritis Rheum. 2012;64:1620&#x2010;1631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3325360</ArticleId>
            <ArticleId IdType="pubmed">22083497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou BO, Zhang J&#x2010;Y, Liu X&#x2010;S, et al. Tom20 senses iron&#x2010;activated ROS signaling to promote melanoma cell pyroptosis. Cell Res. 2018;28:1171&#x2010;1185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6274649</ArticleId>
            <ArticleId IdType="pubmed">30287942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alarifi S, Ali D, Alkahtani S, Alhader MS. Iron oxide nanoparticles induce oxidative stress, DNA damage, and caspase activation in the human breast cancer cell line. Biol Trace Elem Res. 2014;159:416&#x2010;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24748114</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34673014</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2968</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>193</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical pharmacology</Title>
          <ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells.</ArticleTitle>
        <Pagination>
          <StartPage>114813</StartPage>
          <MedlinePgn>114813</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2021.114813</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-2952(21)00429-9</ELocationID>
        <Abstract>
          <AbstractText>Recent studies have verified that inducing reactive oxygen species (ROS) is one of the gemcitabine anti-tumor mechanisms of action. Human carbonyl reductase 1 (CBR1) plays an important role in protecting cells against oxidative damage. However, it is unclear whether CBR1 is involved in pancreatic cancer (PC) progression and resistance to gemcitabine. Based on the GEPIA database, we analyzed tumor tissue samples from PC patients using immunohistochemistry (IHC) and revealed that CBR1 was highly expressed in PC tissues and that this was significantly correlated with the clinicopathological features of PC. Genetic inhibition of CBR1 suppressed PC cell proliferation by regulating ROS generation. Furthermore, gemcitabine upregulated CBR1 expression, which could limit the anti-tumor activity of gemcitabine, and attenuation of CBR1 enhanced gemcitabine sensitivity in vitro and in vivo. Additionally, we report that chrysin directly binds to CBR1, which inhibited its enzymatic activity both at the molecular and cellular levels. Inhibition of CBR1 by chrysin increased cellular ROS levels and led to ROS-dependent autophagy, which resulted in the degradation of ferritin heavy polypeptide 1 (FTH1) and an increase in the intracellular free iron level that participates in ferroptosis in PC cells. Finally, our results showed that chrysin enhanced PC sensitivity to gemcitabine by inducing ferroptotic death in vitro and in vivo. Collectively, these findings indicate that CBR1 is a potential therapeutic target for PC treatment. In addition, we elucidated a novel mechanism underlying the anti-tumor effects of chrysin.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Weilan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China; The Third Peoples Hospital of Qingdao, Huangdao District, Qingdao, Shandong 266400, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qiaoyun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Daolai</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jiayu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Shuyang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong 264003, PR China. Electronic address: shuyangxie@aliyun.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Maolei</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 264003, PR China. Electronic address: xumaolei1234@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem Pharmacol</MedlineTA>
        <NlmUniqueID>0101032</NlmUniqueID>
        <ISSNLinking>0006-2952</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0W860991D6</RegistryNumber>
          <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3CN01F5ZJ5</RegistryNumber>
          <NameOfSubstance UI="C043561">chrysin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.-</RegistryNumber>
          <NameOfSubstance UI="D000429">Alcohol Oxidoreductases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.1.184</RegistryNumber>
          <NameOfSubstance UI="C531129">CBR1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000093542">Gemcitabine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000429" MajorTopicYN="N">Alcohol Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000093542" MajorTopicYN="N">Gemcitabine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Carbonyl reductase 1</Keyword>
        <Keyword MajorTopicYN="N">Chrysin</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Gemcitabine resistance</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>20</Hour>
          <Minute>48</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34673014</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bcp.2021.114813</ArticleId>
        <ArticleId IdType="pii">S0006-2952(21)00429-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34672122</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2198-3844</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</Title>
          <ISOAbbreviation>Adv Sci (Weinh)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Trojan Horse-Like Nano-AIE Aggregates Based on Homologous Targeting Strategy and Their Photodynamic Therapy in Anticancer Application.</ArticleTitle>
        <Pagination>
          <StartPage>e2102561</StartPage>
          <MedlinePgn>e2102561</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2102561</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/advs.202102561</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) has become a promising candidate for cancer theranostics; however, traditional photosensitizers (PSs) usually exhibit weak fluorescence and poor reactive oxygen species (ROS) generation efficiency when aggregated. Recently, aggregation-induced emission (AIE) luminogens have shown great potential in the development of novel PSs owing to their excellent aggregation-induced ROS generation (AIG-ROS) activity. However, there are still concerns that must be addressed. In this study, two near-infrared (NIR) emitters (PI and PTI) are synthesized with AIG-ROS characteristic. PTI exhibit a valuable redder emission with more effective intersystem crossing (ISC) process than PI. The two AIE-active PSs show excellent lipid droplet (LD)-specific targeting ability. The detailed therapeutic mechanism of PDT in LDs specificity is also investigated. The mechanism of oxidation of polyunsaturated fatty acids (PUFAs) in LDs to form toxic lipid peroxides (LPOs) and thereby causing cellular ferroptosis is confirmed first. Homologous targeting is also used to achieve tumor targeting via coating PSs with active cancer cell membranes. Biomimetic aggregates exhibit good targeting ability, and an improved PDT antitumor effect via AIG-ROS activity. These findings offer a clear route to develop advanced PSs with good targeting specificity. A template has also been provided for studying the therapeutic mechanism of AIE-active PSs.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Advanced Science published by Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AIE Institute, State Key Laboratory of Luminescent Materials and Devices, Center for Aggregation-Induced Emission, Key Laboratory of Luminescence from Molecular Aggregates of Guangdong Province, South China University of Technology, Guangzhou, 510640, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Rongyuan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou, 215006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Materials Science and Engineering, Nanchang Hangkong University, Nanchang, 330063, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Rong</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>AIE Institute, State Key Laboratory of Luminescent Materials and Devices, Center for Aggregation-Induced Emission, Key Laboratory of Luminescence from Molecular Aggregates of Guangdong Province, South China University of Technology, Guangzhou, 510640, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AIE Institute, State Key Laboratory of Luminescent Materials and Devices, Center for Aggregation-Induced Emission, Key Laboratory of Luminescence from Molecular Aggregates of Guangdong Province, South China University of Technology, Guangzhou, 510640, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhiming</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-3047-3285</Identifier>
            <AffiliationInfo>
              <Affiliation>AIE Institute, State Key Laboratory of Luminescent Materials and Devices, Center for Aggregation-Induced Emission, Key Laboratory of Luminescence from Molecular Aggregates of Guangdong Province, South China University of Technology, Guangzhou, 510640, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Jianquan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, 215006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Weijie</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou, 215006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Ben Zhong</ForeName>
            <Initials>BZ</Initials>
            <AffiliationInfo>
              <Affiliation>AIE Institute, State Key Laboratory of Luminescent Materials and Devices, Center for Aggregation-Induced Emission, Key Laboratory of Luminescence from Molecular Aggregates of Guangdong Province, South China University of Technology, Guangzhou, 510640, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shenzhen Institute of Aggregate Science and Technology, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>21788102</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>21975077</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>51603127</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2017YFE0132200</GrantID>
            <Agency>National Key R&amp;D Program of China</Agency>
          </Grant>
          <Grant>
            <GrantID>BLB19J008</GrantID>
            <Agency>Open Research Project of Military Logistics Support Department</Agency>
          </Grant>
          <Grant>
            <GrantID>2019ZD04</GrantID>
            <Agency>Fundamental Research Funds for the Central Universities</Agency>
          </Grant>
          <Grant>
            <GrantID>2020A1515011542</GrantID>
            <Agency>Natural Science Foundation of Guangdong Province</Agency>
          </Grant>
          <Grant>
            <GrantID>2019B030301003</GrantID>
            <Agency>Fund of Key Laboratory of Luminescence from Molecular Aggregates of Guangdong Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Adv Sci (Weinh)</MedlineTA>
        <NlmUniqueID>101664569</NlmUniqueID>
        <ISSNLinking>2198-3844</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008054">Lipid Peroxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005453" MajorTopicYN="N">Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008054" MajorTopicYN="N">Lipid Peroxides</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">aggregation-induced ROS generation</Keyword>
        <Keyword MajorTopicYN="N">homologous targeting</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">therapeutic mechanism</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34672122</ArticleId>
        <ArticleId IdType="pmc">PMC8655165</ArticleId>
        <ArticleId IdType="doi">10.1002/advs.202102561</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Levy J. G., Obochi M., Photochem. Photobiol. 1996, 64, 737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8931369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougherty T. J., Gomer C. J., Henderson B. W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q., JNCI, J. Natl. Cancer Inst. 1998, 90, 889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4592754</ArticleId>
            <ArticleId IdType="pubmed">9637138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi J., Ou H., Liu Q., Ding D., Aggregate 2021, 2, 95.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang C., Zeng Z., Cui D., He S., Jiang Y., Li J., Huang J., Pu K., Nat. Commun. 2021, 12, 2934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8131624</ArticleId>
            <ArticleId IdType="pubmed">34006860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strojan P., Hutcheson K. A., Eisbruch A., Beitler J. J., Langendijk J. A., Lee A. W. M., Corry J., Mendenhall W. M., Smee R., Rinaldo A., Ferlito A., Cancer Treat. Rev. 2017, 59, 79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5902026</ArticleId>
            <ArticleId IdType="pubmed">28759822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanamoto S., Umeda M., Kioi M., Kirita T., Yamashita T., Hiratsuka H., Yokoo S., Tanzawa H., Uzawa N., Shibahara T., Ota Y., Kurita H., Okura M., Hamakawa H., Kusukawa J., Tohnai I., Cancer Chemother. Pharmacol. 2018, 81, 549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29383483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper J. S., Zhang Q., Pajak T. F., Forastiere A. A., Jacobs J., Saxman S. B., Kish J. A., Kim H. E., Cmelak A. J., Rotman M., Lustig R., Ensley J. F., Thorstad W., Schultz C. J., Yom S. S., Ang K. K., Int. J. Radiat. Oncol., Biol., Phys. 2012, 84, 1198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3465463</ArticleId>
            <ArticleId IdType="pubmed">22749632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai J., Li Y., Long Z., Jiang R., Zhuang Z., Wang Z., Zhao Z., Lou X., Xia F., Tang B. Z., ACS Nano 2020, 14, 854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31820925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang C.&#x2010;C., Chen Y.&#x2010;N., Wang Y.&#x2010;Y., Huang Y.&#x2010;C., Lin S.&#x2010;Y., Huang R.&#x2010;Y., Jang Y.&#x2010;Y., Yang C.&#x2010;C., Huang Y.&#x2010;F., Chang C.&#x2010;W., ACS Appl. Mater. Interfaces 2020, 12, 30021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32594734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang J., Wang L., Loredo A., Cole C., Xiao H., Chem. Sci. 2020, 11, 6701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473402</ArticleId>
            <ArticleId IdType="pubmed">32953031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougherty T. J., Grindey G. B., Fiel R., Weishaupt K. R., Boyle D. G., JNCI, J. Natl. Cancer Inst. 1975, 55, 115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1159805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oleinick N. L., Morris R. L., Photochem. Photobiol. Sci. 2002, 1, 1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12659143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu F., Xu S., Liu B., Adv. Mater. 2018, 30, 1801350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30066341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang Z., Dai J., Yu M., Li J., Shen P., Hu R., Lou X., Zhao Z., Tang B. Z., Chem. Sci. 2020, 11, 3405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8515424</ArticleId>
            <ArticleId IdType="pubmed">34745515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang M., Zhang Z., Song N., Li M., Sun P., Chen X., Wang D., Tang B. Z., Aggregate 2020, 1, 80.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao J., Wu W., Sun J., Guo S., Chem. Soc. Rev. 2013, 42, 5323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23450221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweitzer C., Schmidt R., Chem. Rev. 2003, 103, 1685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12744692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castano A. P., Demidova T. N., Hamblin M. R., Photodiagn. Photodyn. Ther. 2005, 2, 1.&lt;./bib&gt;</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4108176</ArticleId>
            <ArticleId IdType="pubmed">25048553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan Q., Zhang R., Zhuang Z., Li Y., Huang Y., Wang Z., Zhang W., Hou J., Tang B. Z., Adv. Funct. Mater. 2020, 30, 2002057.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu B., Goel S., Ni D., Ellison P. A., Siamof C. M., Jiang D., Cheng L., Kang L., Yu F., Liu Z., Barnhart T. E., He Q., Zhang H., Cai W., Adv. Mater. 2018, 30, 1704934.</Citation>
        </Reference>
        <Reference>
          <Citation>An J., Hu Y.&#x2010;G., Li C., Hou X.&#x2010;L., Cheng K., Zhang B., Zhang R.&#x2010;Y., Li D.&#x2010;Y., Liu S.&#x2010;J., Liu B., Zhu D., Zhao Y.&#x2010;D., Biomaterials 2020, 230, 119636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31785776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao H., Yang Y., Li J., Aggregate 2020, 1, 69.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeng Z., Pu K., Adv. Funct. Mater. 2020, 30, 2004397.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J., Zhen X., Lyu Y., Jiang Y., Huang J., Pu K., ACS Nano 2018, 12, 8520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30071159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt K., Brovelli S., Coropceanu V., Beljonne D., Cornil J., Bazzini C., Caronna T., Tubino R., Meinardi F., Shuai Z., Br&#xe9;das J.&#x2010;L., J. Phys. Chem. A 2007, 111, 10490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17910425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J. Y., Mak N. K., Yow C. M. N., Fung M. C., Chiu L. C., Leung W. N., Cheung N. H., Photochem. Photobiol. 2007, 72, 541.</Citation>
        </Reference>
        <Reference>
          <Citation>Woodburn K. W., Fan Q., Miles D. R., Kessel D., Luo Y., Young S. W., Photochem. Photobiol. 1997, 65, 410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9077121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Free Radical Biol. Med. 2001, 30, 825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11295525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terao J., Matsushita S., J. Am. Oil Chem. Soc. 1977, 54, 234.</Citation>
        </Reference>
        <Reference>
          <Citation>Schafer F. Q., Wang H. P., Kelley E. E., Cueno K. L., Martin S. M., Buettner R., Biol. Chem. 2002, 383, 672.</Citation>
        </Reference>
        <Reference>
          <Citation>Mu C., Wang J., Barraza K. M., Zhang X., Beauchamp J. L., Angew. Chem., Int. Ed. 2019, 58, 8082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31016864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W. S., SriRamaratnam R., Welsch M. E., Shimada K., Skouta R., Viswanathan V. S., Cheah J. H., Clemons P. A., Shamji A. F., Clish C. B., Brown L. M., Girotti A. W., Cornish V. W., Schreiber S. L., Stockwell B. R., Cell 2014, 156, 317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh S., Serafini R., Love C. C., Teague S. R., Hern&#xe1;ndez&#x2010;Avil&#xe9;s C., LaCaze K. A., Varner D. D., Anim. Reprod. Sci. 2019, 211, 106199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31785628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunday M. O., Sakugawa H., Geochem. J. 2017, 51, 571.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J., Cao F., Yin H., Huang Z., Lin Z., Mao N., Sun B., Wang G., Cell Death Dis. 2020, 11, 88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6997353</ArticleId>
            <ArticleId IdType="pubmed">32015325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Hou W., Song X., Yu Y., Huang J., Sun X., Kang R., Tang D., Cell Death Differ. 2016, 23, 369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrams R. P., Carroll W. L., Woerpel K. A., ACS Chem. Biol. 2016, 11, 1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5507670</ArticleId>
            <ArticleId IdType="pubmed">26797166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N., von Rechenberg M., Zaganjor E., Bauer A. J., Yang W. S., Fridman D. J., Wolpaw A. J., Smukste I., Peltier J. M., Boniface J. J., Smith R., Lessnick S. L., Sahasrabudhe S., Stockwell B. R., Nature 2007, 447, 865.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang S., Hu F., Pan Y., Ng L. G., Liu B., Adv. Funct. Mater. 2019, 29, 1902717.</Citation>
        </Reference>
        <Reference>
          <Citation>Antaris A. L., Chen H., Diao S., Ma Z., Zhang Z., Zhu S., Wang J., Lozano A. X., Fan Q., Chew L., Zhu M., Cheng K., Hong X., Dai H., Cheng Z., Nat. Commun. 2017, 8, 15269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5454457</ArticleId>
            <ArticleId IdType="pubmed">28524850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Wan Q., Zhang R., Situ B., Ni K., Gao J., Feng X., Zhang P., Wang Z., Qin A., Tang B. Z., ACS Nano 2021, 15, 9924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34096697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang K., Wan J., Zhang S., Zhang Y., Lee S.&#x2010;T., Liu Z., ACS Nano 2011, 5, 516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21162527</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34648917</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0038</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>809</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Gene</Title>
          <ISOAbbreviation>Gene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>145992</StartPage>
          <MedlinePgn>145992</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2021.145992</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(21)00587-4</ELocationID>
        <Abstract>
          <AbstractText>Renal cell carcinoma (RCC) is a common type of urological cancer and is often diagnosed at an advanced stage. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is used as second-line therapy for sorafenib- or sunitinib-refractory metastatic RCC. However, the clinical benefits of Everolimus are often hampered by drug resistance. Ferroptosis is a novel form of regulated cell death that has recently been implicated in the development and therapeutic responses to different cancers. RSL3 ((1S,3R)-RSL3) and Erastin are two experimental compounds that can induce ferroptosis. In the present study, we evaluated the anti-tumor effects of Everolimus in combination with RSL3 or Erastin in RCC. Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in RCC cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Moreover, the forced expression of GPX4 abrogated ferroptosis induced by the combined treatment of Everolimus and RSL3/Erastin. Taken together, these results demonstrated that Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment and it may also help to overcome the limitation in clinical applicability of Everolimus.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yangyun</LastName>
            <ForeName>Wang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guowei</LastName>
            <ForeName>Shi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shufen</LastName>
            <ForeName>Shi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo Yinzhou No 2. Hospital, Ningbo, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jie</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medical, Ningbo University, Ningbo, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rui</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medical, Ningbo University, Ningbo, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Ren</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo Yinzhou No 2. Hospital, Ningbo, China. Electronic address: nbrenyu@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Gene</MedlineTA>
        <NlmUniqueID>7706761</NlmUniqueID>
        <ISSNLinking>0378-1119</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587550">RSL3 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9HW64Q8G6G</RegistryNumber>
          <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Erastin</Keyword>
        <Keyword MajorTopicYN="N">Everolimus</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">RSL3</Keyword>
        <Keyword MajorTopicYN="N">Renal cell carcinoma</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34648917</ArticleId>
        <ArticleId IdType="doi">10.1016/j.gene.2021.145992</ArticleId>
        <ArticleId IdType="pii">S0378-1119(21)00587-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34646381</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1838-7640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Theranostics</Title>
          <ISOAbbreviation>Theranostics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ultrasound (US)-activated redox dyshomeostasis therapy reinforced by immunogenic cell death (ICD) through a mitochondrial targeting liposomal nanosystem.</ArticleTitle>
        <Pagination>
          <StartPage>9470</StartPage>
          <EndPage>9491</EndPage>
          <MedlinePgn>9470-9491</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.62984</ELocationID>
        <Abstract>
          <AbstractText>Introduction: An imbalance in redox homeostasis consistently inhibits tumor cell proliferation and further causes tumor regression. Thus, synchronous glutaminolysis inhibition and intracellular reactive oxygen (ROS) accumulation cause severe redox dyshomeostasis, which may potentially become a new therapeutic strategy to effectively combat cancer. Methods: Mitochondrial-targeting liposomal nanoparticles (abbreviated MLipRIR NPs) are synthesized by the encapsulation of R162 (inhibitor of glutamate dehydrogenase 1 [GDH1]) and IR780 (a hydrophobic sonosensitizer) within the lipid bilayer, which are exploited for ultrasound (US)-activated tumor dyshomeostasis therapy reinforced by immunogenic cell death (ICD). Results: R162 released from MLipRIR NPs disrupts the glutaminolysis pathway in mitochondria, resulting in downregulated enzymatic activity of glutathione peroxidase (GPx). In addition, loaded IR780 can generate high levels of ROS under US irradiation, which not only interrupts mitochondrial respiration to induce apoptosis but also consumes local glutathione (GSH). GSH depletion accompanied by GPx deactivation causes severe ferroptosis of tumor cells through the accumulation of lipid peroxides. Such intracellular redox dyshomeostasis effectively triggers immunogenic cell death (ICD), which can activate antitumor immunity for the suppression of both primary and distant tumors with the aid of immune checkpoint blockade. Conclusions: Taking advantage of multimodal imaging for therapy guidance, this nanoplatform may potentiate systemic tumor eradication with high certainty. Taken together, this state-of-the-art paradigm may provide useful insights for cancer management by disrupting redox homeostasis.</AbstractText>
          <CopyrightInformation>&#xa9; The author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Junjie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Han</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Xiaodan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Ultrasound Molecular Imaging, Institute of Ultrasound Imaging, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhigang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Yuejun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Silkworm Genome Biology, School of Materials and Energy, Southwest University, Chongqing 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Theranostics</MedlineTA>
        <NlmUniqueID>101552395</NlmUniqueID>
        <ISSNLinking>1838-7640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C548458">2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindolium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000090783">Nanoparticle Drug Delivery System</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.4.1.2</RegistryNumber>
          <NameOfSubstance UI="D005969">Glutamate Dehydrogenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.4.1.3</RegistryNumber>
          <NameOfSubstance UI="C561840">GLUD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005969" MajorTopicYN="N">Glutamate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079527" MajorTopicYN="N">Immunogenic Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090783" MajorTopicYN="N">Nanoparticle Drug Delivery System</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014464" MajorTopicYN="N">Ultrasonic Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">drug delivery</Keyword>
        <Keyword MajorTopicYN="N">liposome</Keyword>
        <Keyword MajorTopicYN="N">redox dyshomeostasis</Keyword>
        <Keyword MajorTopicYN="N">sonodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">targeting</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34646381</ArticleId>
        <ArticleId IdType="pmc">PMC8490505</ArticleId>
        <ArticleId IdType="doi">10.7150/thno.62984</ArticleId>
        <ArticleId IdType="pii">thnov11p9470</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ursini F, Maiorino M, Forman HJ. Redox homeostasis: the golden mean of healthy living. Redox Biol. 2016;8:205&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4732014</ArticleId>
            <ArticleId IdType="pubmed">26820564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garza-Lombo C, Pappa A, Panayiotidis MI, Franco R. Redox homeostasis, oxidative stress and mitophagy. Mitochondrion. 2020;51:105&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7062406</ArticleId>
            <ArticleId IdType="pubmed">31972372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Q, Yu W, Ye J, Liu M, Liu W, Zhang C. et al. Nanotherapeutics interfere with cellular redox homeostasis for highly improved photodynamic therapy. Biomaterials. 2019;224:119500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31557591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 2017;44:532&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29145191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G. et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192&#x2013;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7062874</ArticleId>
            <ArticleId IdType="pubmed">32060354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4055301</ArticleId>
            <ArticleId IdType="pubmed">24845678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Villani RM, Wang H, Simpson MJ, Roberts MS, Tang M. et al. The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018;37:266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6211502</ArticleId>
            <ArticleId IdType="pubmed">30382874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Z-M, Liu Y-Y, Ni D-L, Zhou J-J, Zhang M, Zhao P-R. et al. Biodegradable nanoprodrugs: &#x201c;delivering&#x201d; ROS to cancer cells for molecular dynamic therapy. Adv Mater. 2020;32:1904011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31793717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Zhao P, Gong T, Wang H, Jiang X, Cheng H. et al. Redox dyshomeostasis strategy for hypoxic tumor therapy based on DNAzyme-loaded electrophilic ZIFs. Angew Chem Int Ed. 2020;59:22537&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32856362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z. et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015;27:257&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4325424</ArticleId>
            <ArticleId IdType="pubmed">25670081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5484415</ArticleId>
            <ArticleId IdType="pubmed">27492215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. P Natl Acad Sci USA. 2007;104:19345&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2148292</ArticleId>
            <ArticleId IdType="pubmed">18032601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu N, Yang M, Gaur U, Xu H, Yao Y, Li D. Alpha-ketoglutarate: physiological functions and applications. Biomol Ther (Seoul) 2016;24:1&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4703346</ArticleId>
            <ArticleId IdType="pubmed">26759695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35:3619&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5225500</ArticleId>
            <ArticleId IdType="pubmed">26592449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coloff JL, Murphy JP, Braun CR, Harris IS, Shelton LM, Kami K. et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 2016;23:867&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27133130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Shi L, Chen D, Ren A, Gao T, Zhao M. Functional analysis of the role of glutathione peroxidase (GPx) in the ROS signaling pathway, hyphal branching and the regulation of ganoderic acid biosynthesis in Ganoderma lucidum. Fungal Genet Biol. 2015;82:168&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26216672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dworzanski J, Strycharz-Dudziak M, Kliszczewska E, Kielczykowska M, Dworzanska A, Drop B. et al. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity in patients with diabetes mellitus type 2 infected with Epstein-Barr virus. PLoS One. 2020;15:e0230374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094858</ArticleId>
            <ArticleId IdType="pubmed">32210468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno-Sanchez R, Marin-Hernandez A, Gallardo-Perez JC, Pacheco-Velazquez SC, Robledo-Cadena DX, Padilla-Flores JA. et al. Physiological role of glutamate dehydrogenase in cancer cells. Front Oncol. 2020;10:429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7160333</ArticleId>
            <ArticleId IdType="pubmed">32328457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang R, Li X, Wu Y, Zhang G, Liu X, Li Y. et al. EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma. Oncogene. 2020;39:2975&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32034306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y. et al. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell. 2018;69:87&#x2013;99. e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777230</ArticleId>
            <ArticleId IdType="pubmed">29249655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju HQ, Lin JF, Tian T, Xie D, Xu RH. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5:231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7542157</ArticleId>
            <ArticleId IdType="pubmed">33028807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52:1496&#x2013;516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8080614</ArticleId>
            <ArticleId IdType="pubmed">32943735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Son S, Kim JH, Wang X, Zhang C, Yoon SA, Shin J. et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev. 2020;49:3244&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32337527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Zhao SJ, Lin CW, Zheng XL, Lan MH. Recent advances in nanomaterials for sonodynamic therapy. Nano Res. 2020;13:2898&#x2013;908.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Wang M, Dai Z. The molecular design of and challenges relating to sensitizers for cancer sonodynamic therapy. Mater Chem Front. 2020;4:2223&#x2013;34.</Citation>
        </Reference>
        <Reference>
          <Citation>Lafond M, Yoshizawa S, Umemura SI. Sonodynamic therapy: advances and challenges in clinical translation. J Ultrasound Med. 2019;38:567&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30338863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhong X, Bai L, Xu J, Gong F, Dong Z. et al. Ultrafine titanium monoxide (TiO1+x) nanorods for enhanced sonodynamic therapy. J Am Chem Soc. 2020;142:6527&#x2013;37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32191455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canavese G, Ancona A, Racca L, Canta M, Dumontel B, Barbaresco F. et al. Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer. Chem Eng J. 2018;340:155&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6420022</ArticleId>
            <ArticleId IdType="pubmed">30881202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu LH, Wan Y, Li C, Qi C, He T, Yang C. et al. Biodegradable calcium phosphate nanotheranostics with tumor-specific activatable cascade catalytic reactions-augmented photodynamic therapy. Adv Funct Mater. 2021;31:2009848.</Citation>
        </Reference>
        <Reference>
          <Citation>Ye LF, Chaudhary KR, Zandkarimi F, Harken AD, Kinslow CJ, Upadhyayula PS. et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem Biol. 2020;15:469&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7180072</ArticleId>
            <ArticleId IdType="pubmed">31899616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Yi H, Song J, Huang J, Yang K, Tan B. et al. Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced deep-penetration sonodynamic cancer therapy. ACS Appl Mater Interfaces. 2019;11:9355&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30734551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YK, Zhou QF, Deng ZT, Pan M, Liu X, Wu JR. et al. IR-780 Dye as a sonosensitizer for sonodynamic therapy of breast tumor. Sci Rep-Uk. 2016;6:25968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4865802</ArticleId>
            <ArticleId IdType="pubmed">27174006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan K, Zhang Y, Mu C, Xu Q, Jing X, Wang D. et al. Versatile nanoplatforms with enhanced photodynamic therapy: designs and applications. Theranostics. 2020;10:7287&#x2013;318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7330854</ArticleId>
            <ArticleId IdType="pubmed">32641993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu LH, Wan Y, Qi C, He J, Li C, Yang C. et al. Nanocatalytic theranostics with glutathione depletion and enhanced reactive oxygen species generation for efficient cancer therapy. Adv Mater. 2021;33:e2006892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33394515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu P, Chen Y, Shi J. Nanoenzyme-augmented cancer sonodynamic therapy by catalytic tumor oxygenation. ACS Nano. 2018;12:3780&#x2013;95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29613770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alves CG, Lima-Sousa R, de Melo-Diogo D, Louro RO, Correia IJ. IR780 based nanomaterials for cancer imaging and photothermal, photodynamic and combinatorial therapies. Int J Pharm. 2018;542:164&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29549013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song C, Li Y, Li T, Yang Y, Huang Z, de la Fuente JM. et al. Long-circulating drug-dye-based micelles with ultrahigh pH-sensitivity for deep tumor penetration and superior chemo-photothermal therapy. Adv Funct Mater. 2020;30:1906309.</Citation>
        </Reference>
        <Reference>
          <Citation>Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7691519</ArticleId>
            <ArticleId IdType="pubmed">33243969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med. 2019;23:4854&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6653385</ArticleId>
            <ArticleId IdType="pubmed">31210425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Y, Kuai R, Xu Y, Ochyl LJ, Irvine DJ, Moon JJ. Immunogenic cell death amplified by co-localized adjuvant delivery for cancer immunotherapy. Nano Lett. 2017;17:7387&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5821496</ArticleId>
            <ArticleId IdType="pubmed">29144754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Feng X, Wan C, Lovell JF, Jin H, Ding J. Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy. Asian J Pharm Sci. 2020;16:129&#x2013;132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8105413</ArticleId>
            <ArticleId IdType="pubmed">33995609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao Y, Liang C, Tao H, Du Y, Wu D, Dong Z. et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci Adv. 2020;6:eaaz4204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7056299</ArticleId>
            <ArticleId IdType="pubmed">32181368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng P, Ding B, Jiang Z, Xu W, Li G, Ding J. et al. Ultrasound-augmented mitochondrial calcium ion overload by calcium nanomodulator to induce immunogenic cell death. Nano Lett. 2021;21:2088&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33596078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng P, Ding B, Shi R, Jiang Z, Xu W, Li G. et al. A multichannel Ca2+ nanomodulator for multilevel mitochondrial destruction-mediated cancer therapy. Adv Mater. 2021;33:2007426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33675268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue C, Yang Y, Song J, Alfranca G, Zhang C, Zhang Q. et al. Mitochondria-targeting near-infrared light-triggered thermosensitive liposomes for localized photothermal and photodynamic ablation of tumors combined with chemotherapy. Nanoscale. 2017;9:11103&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28741634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue W, Chen L, Yu L, Zhou B, Yin H, Ren W. et al. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nat Commun. 2019;10:2025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6497709</ArticleId>
            <ArticleId IdType="pubmed">31048681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.</Citation>
        </Reference>
        <Reference>
          <Citation>Caputo F, Clogston J, Calzolai L, Rosslein M, Prina-Mello A. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J Control Release. 2019;299:31&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30797868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5897557</ArticleId>
            <ArticleId IdType="pubmed">29650952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen MK, Pedersen JN, Marie R. Size and surface charge characterization of nanoparticles with a salt gradient. Nat Commun. 2020;11:2337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7214416</ArticleId>
            <ArticleId IdType="pubmed">32393750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Matos MBC, Deckers R, van Elburg B, Lajoinie G, de Miranda BS, Versluis M. et al. Ultrasound-sensitive liposomes for triggered macromolecular drug delivery: formulation and in vitro characterization. Front Pharmacol. 2019;10:1463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6906197</ArticleId>
            <ArticleId IdType="pubmed">31866867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu X, Shen C, Li H, Goldys EM, Deng W. X-ray induced photodynamic therapy (PDT) with a mitochondria-targeted liposome delivery system. J Nanobiotechnology. 2020;18:87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7288491</ArticleId>
            <ArticleId IdType="pubmed">32522291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Zhou S, Zhang X, Li C, Ji S, Mao H. et al. Mitochondrion-specific dendritic lipopeptide liposomes for targeted sub-cellular delivery. Nat Commun. 2021;12:2390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8062597</ArticleId>
            <ArticleId IdType="pubmed">33888699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28301735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noh I, Lee D, Kim H, Jeong CU, Lee Y, Ahn JO. et al. Enhanced photodynamic cancer treatment by mitochondria-targeting and brominated near-infrared fluorophores. Adv Sci (Weinh) 2018;5:1700481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5867131</ArticleId>
            <ArticleId IdType="pubmed">29593951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Yang J, Luo L, Jiang M, Qin B, Yin H. et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun. 2019;10:3349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6659660</ArticleId>
            <ArticleId IdType="pubmed">31350406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N. et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6997353</ArticleId>
            <ArticleId IdType="pubmed">32015325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He T, Xu H, Zhang Y, Yi S, Cui R, Xing S. et al. Glucose oxidase-instructed traceable self-oxygenation/hyperthermia dually enhanced cancer starvation therapy. Theranostics. 2020;10:1544&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6993236</ArticleId>
            <ArticleId IdType="pubmed">32042321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sethuraman SN, Singh MP, Patil G, Li ST, Fiering S, Hoopes PJ. et al. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity. Theranostics. 2020;10:3397&#x2013;412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7069083</ArticleId>
            <ArticleId IdType="pubmed">32206098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kielbik M, Szulc-Kielbik I, Klink M. Calreticulin-multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients. Cells. 2021;10:130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7827772</ArticleId>
            <ArticleId IdType="pubmed">33440842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7064135</ArticleId>
            <ArticleId IdType="pubmed">32209603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. Front Physiol. 2015;6:93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387954</ArticleId>
            <ArticleId IdType="pubmed">25904867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JY, Yan YY, Li JJ, Adhikari R, Fu LW. PD-1/PD-L1 based combinational cancer therapy: icing on the cake. Front Pharmacol. 2020;11:722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7247431</ArticleId>
            <ArticleId IdType="pubmed">32528284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kepp O, Zitvogel L, Kroemer G. Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade. OncoImmunology. 2019;8:e1637188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6791413</ArticleId>
            <ArticleId IdType="pubmed">31646079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai S, Chen Z, Wang Y, Wang M, Wu J, Tong Y. et al. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy. Theranostics. 2021;11:1970&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7778587</ArticleId>
            <ArticleId IdType="pubmed">33408792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Ju R, Gao H, Huang Y, Guo L, Zhang D. Targeting glutamine utilization to block metabolic adaptation of tumor cells under the stress of carboxyamidotriazole-induced nutrients unavailability. Acta Pharm Sin B. 2021 DOI: 10.1016/j.apsb.2021.07.008.</Citation>
        </Reference>
        <Reference>
          <Citation>Mat&#xe9;s JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, M&#xe1;rquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol. 2020;98:34&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31100352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y. Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: progress and perspectives. Adv Ther. 2020;3:1900215.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang KK, Zhang YF, Wang J, Yuan A, Sun MJ, Wu JH. et al. Self-assembled IR780-loaded transferrin nanoparticles as an imaging, targeting and PDT/PTT agent for cancer therapy. Sci Rep. 2016;6:27421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4899881</ArticleId>
            <ArticleId IdType="pubmed">27263444</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34643088</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8301</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Future oncology (London, England)</Title>
          <ISOAbbreviation>Future Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway.</ArticleTitle>
        <Pagination>
          <StartPage>149</StartPage>
          <EndPage>161</EndPage>
          <MedlinePgn>149-161</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2021-0883</ELocationID>
        <Abstract>
          <AbstractText>Background: Chemoresistance usually occurs in ovarian cancer. We aimed to explore the mechanisms of chemoresistance. Methods: Western blotting assay was used to detect the expression of GALNT14. Further cell function experiments were performed to investigate the effect of GALNT14 in ovarian cancer. Results: GALNT14 is significantly upregulated in ovarian cancer. Downregulation of GALNT14 significantly inhibits both apoptosis and ferroptosis of ovarian cancer cells. A further mechanism assay illustrated that downregulation of GALNT14 suppresses the activity of the mTOR pathway through modifying O-glycosylation of EGFR. Finally, an additive effect promoting cell death occurs with a combination of an mTOR inhibitor and cisplatin. Conclusion: Our study might provide a promising method to overcome cisplatin resistance for patients with ovarian cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hua-Wen</ForeName>
            <Initials>HW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Mu-Biao</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xue</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Shu-Xian</ForeName>
            <Initials>SX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jing-Ya</ForeName>
            <Initials>JY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Peng-Fei</ForeName>
            <Initials>PF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, The First Affiliated Hospital of Faculty of Medicine Macau University of Science &amp; Technology, Zhuhai, Guangdong 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiao-Yu</ForeName>
            <Initials>XY</Initials>
            <Identifier Source="ORCID">0000-0003-3343-5003</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Future Oncol</MedlineTA>
        <NlmUniqueID>101256629</NlmUniqueID>
        <ISSNLinking>1479-6694</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>624KN6GM2T</RegistryNumber>
          <NameOfSubstance UI="C401859">temsirolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.1.-</RegistryNumber>
          <NameOfSubstance UI="D017350">N-Acetylgalactosaminyltransferases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.1.41</RegistryNumber>
          <NameOfSubstance UI="C471038">UDP-N-acetyl-D-galactosamine polypeptide N-acetylgalactosaminyltransferase 14, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017350" MajorTopicYN="N">N-Acetylgalactosaminyltransferases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010053" MajorTopicYN="N">Ovary</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EGFR</Keyword>
        <Keyword MajorTopicYN="N">GALNT14</Keyword>
        <Keyword MajorTopicYN="N">chemotherapy resistance</Keyword>
        <Keyword MajorTopicYN="N">glycosylation</Keyword>
        <Keyword MajorTopicYN="N">protein stability</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>8</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34643088</ArticleId>
        <ArticleId IdType="doi">10.2217/fon-2021-0883</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34630843</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1942-0994</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2021</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Oxidative medicine and cellular longevity</Title>
          <ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting Ferroptosis for Lung Diseases: Exploring Novel Strategies in Ferroptosis-Associated Mechanisms.</ArticleTitle>
        <Pagination>
          <StartPage>1098970</StartPage>
          <MedlinePgn>1098970</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1098970</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/1098970</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is an iron-dependent regulated necrosis characterized by the peroxidation damage of lipid molecular containing unsaturated fatty acid long chain on the cell membrane or organelle membrane after cellular deactivation restitution system, resulting in the cell membrane rupture. Ferroptosis is biochemically and morphologically distinct and disparate from other forms of regulated cell death. Recently, mounting studies have investigated the mechanism of ferroptosis, and numerous proteins play vital roles in regulating ferroptosis. With detailed studies, emerging evidence indicates that ferroptosis is found in multiple lung diseases, demonstrating that ferroptosis appears to be particularly important for lung diseases. The mounting interest in ferroptosis drugs specifically targeting the ferroptosis mechanism holds substantial therapeutic promise in lung diseases. The present review emphatically summarizes the functions and integrated molecular mechanisms of ferroptosis in various lung diseases, proposing that multiangle regulation of ferroptosis might be a promising strategy for the clinical treatment of lung diseases.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Tian-Liang Ma et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Tian-Liang</ForeName>
            <Initials>TL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Engineering Research Center of Biomedical Metal and Ceramic Implants, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ci</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jing-Xian</ForeName>
            <Initials>JX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hui-Hui</ForeName>
            <Initials>HH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chen-Yu</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-7348-2376</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Cha-Xiang</ForeName>
            <Initials>CX</Initials>
            <Identifier Source="ORCID">0000-0002-8505-8724</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Basic Medical Science, Central South University, Changsha, Hunan 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oxid Med Cell Longev</MedlineTA>
        <NlmUniqueID>101479826</NlmUniqueID>
        <ISSNLinking>1942-0994</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declared no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>59</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34630843</ArticleId>
        <ArticleId IdType="pmc">PMC8494591</ArticleId>
        <ArticleId IdType="doi">10.1155/2021/1098970</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zhou M., Wang H., Zeng X., et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 2019;394(10204):1145&#x2013;1158. doi: 10.1016/S0140-6736(19)30427-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)30427-1</ArticleId>
            <ArticleId IdType="pmc">PMC6891889</ArticleId>
            <ArticleId IdType="pubmed">31248666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Liu S. M., Yu X. H., Tang S. L., Tang C. K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents . 2020;55(5):p. 105951. doi: 10.1016/j.ijantimicag.2020.105951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105951</ArticleId>
            <ArticleId IdType="pmc">PMC7139247</ArticleId>
            <ArticleId IdType="pubmed">32234466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S. J., Lemberg K. M., Lamprecht M. R., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell . 2012;149(5):1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y., Hou W., Song X., et al. Ferroptosis: process and function. Cell Death and Differentiation . 2016;23(3):369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L., Dixon S. J. Ferroptosis and Brain Injury. Developmental Neuroscience . 2018;40(5-6):382&#x2013;395. doi: 10.1159/000496922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000496922</ArticleId>
            <ArticleId IdType="pmc">PMC6658337</ArticleId>
            <ArticleId IdType="pubmed">30820017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W., Li W., Leng Y., Xiong Y., Xia Z. Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress. DNA and Cell Biology . 2020;39(2):210&#x2013;225. doi: 10.1089/dna.2019.5097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/dna.2019.5097</ArticleId>
            <ArticleId IdType="pubmed">31809190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musani A. I. Pulmonary disease. The Medical Clinics of North America . 2019;103(3):xix&#x2013;xx. doi: 10.1016/j.mcna.2019.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mcna.2019.02.001</ArticleId>
            <ArticleId IdType="pubmed">30955525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida M., Minagawa S., Araya J., et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. Nature Communications . 2019;10(1):p. 3145. doi: 10.1038/s41467-019-10991-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10991-7</ArticleId>
            <ArticleId IdType="pmc">PMC6637122</ArticleId>
            <ArticleId IdType="pubmed">31316058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H., Li F., Niu J. Y., et al. Ferroptosis was involved in the oleic acid-induced acute lung injury in mice. Sheng Li Xue Bao . 2019;71(5):689&#x2013;697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31646322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Duan L., Yuan S., Zhuang X., Qiao T., He J. Ferroptosis inhibitor alleviates radiation-induced lung fibrosis (RILF) via down-regulation of TGF-&#x3b2;1. Journal of Inflammation . 2019;16(1):p. 11. doi: 10.1186/s12950-019-0216-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12950-019-0216-0</ArticleId>
            <ArticleId IdType="pmc">PMC6542066</ArticleId>
            <ArticleId IdType="pubmed">31160885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang Y., Wang Q. Iron and lung cancer. Cancer Letters . 2019;464:56&#x2013;61. doi: 10.1016/j.canlet.2019.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2019.08.007</ArticleId>
            <ArticleId IdType="pubmed">31437477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao J. Y., Dixon S. J. Mechanisms of ferroptosis. Cellular and Molecular Life Sciences . 2016;73(11-12):2195&#x2013;2209. doi: 10.1007/s00018-016-2194-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2194-1</ArticleId>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatesh D., O'Brien N. A., Zandkarimi F., et al. MDM2 and MDMX promote ferroptosis by PPAR&#x3b1;-mediated lipid remodeling. Genes &amp; Development . 2020;34(7-8):526&#x2013;543. doi: 10.1101/gad.334219.119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.334219.119</ArticleId>
            <ArticleId IdType="pmc">PMC7111265</ArticleId>
            <ArticleId IdType="pubmed">32079652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y., Xie Y., Cao L., et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular &amp; Cellular Oncology . 2015;2(4, article e1054549) doi: 10.1080/23723556.2015.1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/23723556.2015.1054549</ArticleId>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdalkader M., Lampinen R., Kanninen K. M., Malm T. M., Liddell J. R. Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Frontiers in Neuroscience . 2018;12:p. 466. doi: 10.3389/fnins.2018.00466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00466</ArticleId>
            <ArticleId IdType="pmc">PMC6048292</ArticleId>
            <ArticleId IdType="pubmed">30042655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti S. V., Torti F. M. Iron and cancer: more ore to be mined. Nature Reviews. Cancer . 2013;13(5):342&#x2013;355. doi: 10.1038/nrc3495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3495</ArticleId>
            <ArticleId IdType="pmc">PMC4036554</ArticleId>
            <ArticleId IdType="pubmed">23594855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M., Kagan V. E., Bayir H., et al. Regulation of lipid peroxidation and ferroptosis in diverse species. Genes &amp; Development . 2018;32(9-10):602&#x2013;619. doi: 10.1101/gad.314674.118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.314674.118</ArticleId>
            <ArticleId IdType="pmc">PMC6004068</ArticleId>
            <ArticleId IdType="pubmed">29802123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W. S., Kim K. J., Gaschler M. M., Patel M., Shchepinov M. S., Stockwell B. R. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proceedings of the National Academy of Sciences of the United States of America . 2016;113(34):E4966&#x2013;E4975. doi: 10.1073/pnas.1603244113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1603244113</ArticleId>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan V. E., Mao G., Qu F., et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology . 2017;13(1):81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S., Proneth B., Tyurina Y. Y., et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nature Chemical Biology . 2017;13(1):91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Yi J., Zhu J., et al. Role of mitochondria in ferroptosis. Molecular Cell . 2019;73(2):354&#x2013;363.e3. doi: 10.1016/j.molcel.2018.10.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2018.10.042</ArticleId>
            <ArticleId IdType="pmc">PMC6338496</ArticleId>
            <ArticleId IdType="pubmed">30581146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ingold I., Berndt C., Schmitt S., et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell . 2018;172(3):409&#x2013;422.e21. doi: 10.1016/j.cell.2017.11.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.11.048</ArticleId>
            <ArticleId IdType="pubmed">29290465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N., von Rechenberg M., Zaganjor E., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature . 2007;447(7146):865&#x2013;869. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y. Q., Chang S. Y., Wu Q., et al. The protective role of mitochondrial ferritin on erastin-induced ferroptosis. Frontiers in Aging Neuroscience . 2016;8:p. 308. doi: 10.3389/fnagi.2016.00308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2016.00308</ArticleId>
            <ArticleId IdType="pmc">PMC5167726</ArticleId>
            <ArticleId IdType="pubmed">28066232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W. S., SriRamaratnam R., Welsch M. E., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell . 2014;156(1-2):317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiorino M., Conrad M., Ursini F. GPx4, lipid peroxidation, and cell death: discoveries, rediscoveries, and open issues. Antioxidants &amp; Redox Signaling . 2018;29(1):61&#x2013;74. doi: 10.1089/ars.2017.7115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2017.7115</ArticleId>
            <ArticleId IdType="pubmed">28462584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F., Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radical Biology &amp; Medicine . 2020;152:175&#x2013;185. doi: 10.1016/j.freeradbiomed.2020.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.02.027</ArticleId>
            <ArticleId IdType="pubmed">32165281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J., Hewett S. J., Huang Y., et al. The cystine/glutamate antiporter system x (c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxidants &amp; Redox Signaling . 2013;18(5):522&#x2013;555. doi: 10.1089/ars.2011.4391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2011.4391</ArticleId>
            <ArticleId IdType="pmc">PMC3545354</ArticleId>
            <ArticleId IdType="pubmed">22667998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayano M., Yang W. S., Corn C. K., Pagano N. C., Stockwell B. R. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death and Differentiation . 2016;23(2):270&#x2013;278. doi: 10.1038/cdd.2015.93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.93</ArticleId>
            <ArticleId IdType="pmc">PMC4716307</ArticleId>
            <ArticleId IdType="pubmed">26184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao J., Chen X., Jiang L., et al. DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nature Communications . 2020;11(1):p. 1251. doi: 10.1038/s41467-020-15109-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-15109-y</ArticleId>
            <ArticleId IdType="pmc">PMC7060199</ArticleId>
            <ArticleId IdType="pubmed">32144268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadian K. Ferroptosis suppressor protein 1 (FSP1) and coenzyme Q10 cooperatively suppress ferroptosis. Biochemistry . 2020;59(5):637&#x2013;638. doi: 10.1021/acs.biochem.0c00030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.biochem.0c00030</ArticleId>
            <ArticleId IdType="pubmed">32003211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du M. Y., Duan J. X., Zhang C. Y., et al. Psoralen attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting myofibroblast activation and collagen deposition. Cell Biology International . 2020;44(1):98&#x2013;107. doi: 10.1002/cbin.11205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbin.11205</ArticleId>
            <ArticleId IdType="pubmed">31329322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K., Hendricks J. M., Li Z., et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature . 2019;575(7784):688&#x2013;692. doi: 10.1038/s41586-019-1705-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1705-2</ArticleId>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S., Freitas F. P., Shah R., et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature . 2019;575(7784):693&#x2013;698. doi: 10.1038/s41586-019-1707-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1707-0</ArticleId>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai E., Zhang W., Cong D., Kang R., Wang J., Tang D. AIFM2 blocks ferroptosis independent of ubiquinol metabolism. Biochemical and Biophysical Research Communications . 2020;523(4):966&#x2013;971. doi: 10.1016/j.bbrc.2020.01.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2020.01.066</ArticleId>
            <ArticleId IdType="pubmed">31964528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santoro M. M. The Antioxidant Role of Non-mitochondrial CoQ10: Mystery Solved! Cell Metabolism . 2020;31(1):13&#x2013;15. doi: 10.1016/j.cmet.2019.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2019.12.007</ArticleId>
            <ArticleId IdType="pubmed">31951565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cronin S. J. F., Seehus C., Weidinger A., et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature . 2018;563(7732):564&#x2013;568. doi: 10.1038/s41586-018-0701-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0701-2</ArticleId>
            <ArticleId IdType="pmc">PMC6438708</ArticleId>
            <ArticleId IdType="pubmed">30405245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soula M., Weber R. A., Zilka O., et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nature Chemical Biology . 2020;16(12):1351&#x2013;1360. doi: 10.1038/s41589-020-0613-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-020-0613-y</ArticleId>
            <ArticleId IdType="pmc">PMC8299533</ArticleId>
            <ArticleId IdType="pubmed">32778843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraft V. A. N., Bezjian C. T., Pfeiffer S., et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Central Science . 2020;6(1):41&#x2013;53. doi: 10.1021/acscentsci.9b01063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.9b01063</ArticleId>
            <ArticleId IdType="pmc">PMC6978838</ArticleId>
            <ArticleId IdType="pubmed">31989025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Peng Y., Xie Y., et al. Antiferroptotic activity of non-oxidative dopamine. Biochemical and Biophysical Research Communications . 2016;480(4):602&#x2013;607. doi: 10.1016/j.bbrc.2016.10.099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.10.099</ArticleId>
            <ArticleId IdType="pubmed">27793671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K., Hayano M., Pagano N. C., Stockwell B. R. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chemical Biology . 2016;23(2):225&#x2013;235. doi: 10.1016/j.chembiol.2015.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2015.11.016</ArticleId>
            <ArticleId IdType="pmc">PMC4792701</ArticleId>
            <ArticleId IdType="pubmed">26853626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Ou Z., Chen R., et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology . 2016;63(1):173&#x2013;184. doi: 10.1002/hep.28251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S. J., Li D., Ou Y., et al. Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Reports . 2016;17(2):366&#x2013;373. doi: 10.1016/j.celrep.2016.09.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.09.022</ArticleId>
            <ArticleId IdType="pmc">PMC5227654</ArticleId>
            <ArticleId IdType="pubmed">27705786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Ou Z., Xie M., et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene . 2015;34(45):5617&#x2013;5625. doi: 10.1038/onc.2015.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.32</ArticleId>
            <ArticleId IdType="pmc">PMC4640181</ArticleId>
            <ArticleId IdType="pubmed">25728673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W., Xie Y., Song X., et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy . 2016;12(8):1425&#x2013;1428. doi: 10.1080/15548627.2016.1187366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1187366</ArticleId>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q., Liu J., Kang R., Zhou B., Tang D. The release and activity of HMGB1 in ferroptosis. Biochemical and Biophysical Research Communications . 2019;510(2):278&#x2013;283. doi: 10.1016/j.bbrc.2019.01.090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.01.090</ArticleId>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye F., Chai W., Xie M., et al. HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRASQ61L cells. American Journal of Cancer Research . 2019;9(4):730&#x2013;739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6511643</ArticleId>
            <ArticleId IdType="pubmed">31105999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y., Li H., Graham E. T., et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nature Chemical Biology . 2020;16(3):302&#x2013;309. doi: 10.1038/s41589-020-0472-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-020-0472-6</ArticleId>
            <ArticleId IdType="pmc">PMC7353921</ArticleId>
            <ArticleId IdType="pubmed">32080622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan B., Ai Y., Sun Q., et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Molecular Cell . 2020;81(2):355&#x2013;369.e10. doi: 10.1016/j.molcel.2020.11.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2020.11.024</ArticleId>
            <ArticleId IdType="pubmed">33321093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding J., Wang K., Liu W., et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature . 2016;535(7610):111&#x2013;116. doi: 10.1038/nature18590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature18590</ArticleId>
            <ArticleId IdType="pubmed">27281216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Sun L., Su L., et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Molecular Cell . 2014;54(1):133&#x2013;146. doi: 10.1016/j.molcel.2014.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2014.03.003</ArticleId>
            <ArticleId IdType="pubmed">24703947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H., Guo P., Xie X., Wang Y., Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. Journal of Cellular and Molecular Medicine . 2017;21(4):648&#x2013;657. doi: 10.1111/jcmm.13008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.13008</ArticleId>
            <ArticleId IdType="pmc">PMC5345622</ArticleId>
            <ArticleId IdType="pubmed">27860262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao C., Liu X., Zhang Y., et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature . 2021;593(7860):586&#x2013;590. doi: 10.1038/s41586-021-03539-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03539-7</ArticleId>
            <ArticleId IdType="pubmed">33981038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee P. P., Wei Y., Kim S. Y., et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nature Communications . 2020;11(1):p. 5424. doi: 10.1038/s41467-020-19193-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-19193-y</ArticleId>
            <ArticleId IdType="pmc">PMC7591536</ArticleId>
            <ArticleId IdType="pubmed">33110073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cotter T. G. Apoptosis and cancer: the genesis of a research field. Nature Reviews. Cancer . 2009;9(7):501&#x2013;507. doi: 10.1038/nrc2663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2663</ArticleId>
            <ArticleId IdType="pubmed">19550425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng D. W., Lei Q., Zhu J. Y., et al. Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy. Nano Letters . 2017;17(1):284&#x2013;291. doi: 10.1021/acs.nanolett.6b04060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.6b04060</ArticleId>
            <ArticleId IdType="pubmed">28027643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mou Y., Wang J., Wu J., et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. Journal of Hematology &amp; Oncology . 2019;12(1):p. 34. doi: 10.1186/s13045-019-0720-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-019-0720-y</ArticleId>
            <ArticleId IdType="pmc">PMC6441206</ArticleId>
            <ArticleId IdType="pubmed">30925886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y. S., Lee D. H., Choudry H. A., Bartlett D. L., Lee Y. J. Ferroptosis-induced endoplasmic reticulum stress: cross-talk between ferroptosis and apoptosis. Molecular Cancer Research . 2018;16(7):1073&#x2013;1076. doi: 10.1158/1541-7786.Mcr-18-0055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.Mcr-18-0055</ArticleId>
            <ArticleId IdType="pmc">PMC6030493</ArticleId>
            <ArticleId IdType="pubmed">29592897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>di Fazio P., Waldegger P., Jabari S., et al. Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer. Oncotarget . 2016;7(20):28998&#x2013;29010. doi: 10.18632/oncotarget.8585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8585</ArticleId>
            <ArticleId IdType="pmc">PMC5045373</ArticleId>
            <ArticleId IdType="pubmed">27058414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang M., Chen Z., Wu D., Chen L. Ferritinophagy/ferroptosis: iron-related newcomers in human diseases. Journal of Cellular Physiology . 2018;233(12):9179&#x2013;9190. doi: 10.1002/jcp.26954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.26954</ArticleId>
            <ArticleId IdType="pubmed">30076709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowdle W. E., Nyfeler B., Nagel J., et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nature Cell Biology . 2014;16(11):1069&#x2013;1079. doi: 10.1038/ncb3053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3053</ArticleId>
            <ArticleId IdType="pubmed">25327288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B., Chen X. B., Ying M. D., He Q. J., Cao J., Yang B. The role of ferroptosis in cancer development and treatment response. Frontiers in Pharmacology . 2018;8:p. 992. doi: 10.3389/fphar.2017.00992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2017.00992</ArticleId>
            <ArticleId IdType="pmc">PMC5770584</ArticleId>
            <ArticleId IdType="pubmed">29375387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida G. J. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. Journal of Hematology &amp; Oncology . 2017;10(1):p. 67. doi: 10.1186/s13045-017-0436-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-017-0436-9</ArticleId>
            <ArticleId IdType="pmc">PMC5345270</ArticleId>
            <ArticleId IdType="pubmed">28279189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Monian P., Pan Q., Zhang W., Xiang J., Jiang X. Ferroptosis is an autophagic cell death process. Cell Research . 2016;26(9):1021&#x2013;1032. doi: 10.1038/cr.2016.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2016.95</ArticleId>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauckman K. A., Mysorekar I. U. Ferritinophagy drives uropathogenic Escherichia coli persistence in bladder epithelial cells. Autophagy . 2016;12(5):850&#x2013;863. doi: 10.1080/15548627.2016.1160176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1160176</ArticleId>
            <ArticleId IdType="pmc">PMC4854542</ArticleId>
            <ArticleId IdType="pubmed">27002654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai Y., Lam H. C., Lei X. Dissecting programmed cell death with small molecules. Accounts of Chemical Research . 2020;53(5):1034&#x2013;1045. doi: 10.1021/acs.accounts.9b00600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.accounts.9b00600</ArticleId>
            <ArticleId IdType="pubmed">32297735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degterev A., Huang Z., Boyce M., et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature Chemical Biology . 2005;1(2):112&#x2013;119. doi: 10.1038/nchembio711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio711</ArticleId>
            <ArticleId IdType="pubmed">16408008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xfc;ller T., Dewitz C., Schmitz J., et al. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cellular and Molecular Life Sciences . 2017;74(19):3631&#x2013;3645. doi: 10.1007/s00018-017-2547-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-017-2547-4</ArticleId>
            <ArticleId IdType="pmc">PMC5589788</ArticleId>
            <ArticleId IdType="pubmed">28551825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenz C., Faust D., Linz B., et al. t-BuOOH induces ferroptosis in human and murine cell lines. Archives of Toxicology . 2018;92(2):759&#x2013;775. doi: 10.1007/s00204-017-2066-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00204-017-2066-y</ArticleId>
            <ArticleId IdType="pubmed">28975372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tonnus W., Linkermann A. "Death is my heir"--ferroptosis connects cancer pharmacogenomics and ischemia-reperfusion injury. Cell Chemical Biology . 2016;23(2):202&#x2013;203. doi: 10.1016/j.chembiol.2016.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2016.02.005</ArticleId>
            <ArticleId IdType="pubmed">26971867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case C. L., Kohler L. J., Lima J. B., et al. Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to Legionella pneumophila. Proceedings of the National Academy of Sciences of the United States of America . 2013;110(5):1851&#x2013;1856. doi: 10.1073/pnas.1211521110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1211521110</ArticleId>
            <ArticleId IdType="pmc">PMC3562791</ArticleId>
            <ArticleId IdType="pubmed">23307811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danthi P. Viruses and the diversity of cell death. Annual Review of Virology . 2016;3(1):533&#x2013;553. doi: 10.1146/annurev-virology-110615-042435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-virology-110615-042435</ArticleId>
            <ArticleId IdType="pubmed">27501259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao Q., Yu J. S., Wang Y., Ma D., Zhou J., Lou X. 3-Difluoroalkyl quaternary oxindoles inhibit macrophage pyroptosis by blocking inflammasome recruitment of caspase-1. ACS Medicinal Chemistry Letters . 2020;11(7):1392&#x2013;1401. doi: 10.1021/acsmedchemlett.0c00070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.0c00070</ArticleId>
            <ArticleId IdType="pmc">PMC7357214</ArticleId>
            <ArticleId IdType="pubmed">32676145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proneth B., Conrad M. Ferroptosis and necroinflammation, a yet poorly explored link. Cell Death and Differentiation . 2019;26(1):14&#x2013;24. doi: 10.1038/s41418-018-0173-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0173-9</ArticleId>
            <ArticleId IdType="pmc">PMC6294786</ArticleId>
            <ArticleId IdType="pubmed">30082768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed J. C., Pellecchia M. Ironing out cell death mechanisms. Cell . 2012;149(5):963&#x2013;965. doi: 10.1016/j.cell.2012.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.05.009</ArticleId>
            <ArticleId IdType="pubmed">22632964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang R., Xu J., Zhang B., et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. Journal of Hematology &amp; Oncology . 2020;13(1):p. 110. doi: 10.1186/s13045-020-00946-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-020-00946-7</ArticleId>
            <ArticleId IdType="pmc">PMC7418434</ArticleId>
            <ArticleId IdType="pubmed">32778143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tay M. Z., Poh C. M., R&#xe9;nia L., MacAry P. A., Ng L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews. Immunology . 2020;20(6):363&#x2013;374. doi: 10.1038/s41577-020-0311-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId>
            <ArticleId IdType="pmc">PMC7187672</ArticleId>
            <ArticleId IdType="pubmed">32346093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gouda M. M., Bhandary Y. P. Acute lung injury: IL-17A-mediated inflammatory pathway and its regulation by curcumin. Inflammation . 2019;42(4):1160&#x2013;1169. doi: 10.1007/s10753-019-01010-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-019-01010-4</ArticleId>
            <ArticleId IdType="pubmed">31011925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldonyte R., Bagdonas E., Raudoniute J., Bruzauskaite I. Novel aspects of pathogenesis and regeneration mechanisms in COPD. International Journal of Chronic Obstructive Pulmonary Disease . 2015;10:995&#x2013;1013. doi: 10.2147/COPD.S82518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/COPD.S82518</ArticleId>
            <ArticleId IdType="pmc">PMC4459624</ArticleId>
            <ArticleId IdType="pubmed">26082624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan T. H. G., Paliogiannis P., Nasrallah G. K., et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cellular and Molecular Life Sciences . 2021;78(5):2031&#x2013;2057. doi: 10.1007/s00018-020-03693-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-020-03693-7</ArticleId>
            <ArticleId IdType="pmc">PMC7669490</ArticleId>
            <ArticleId IdType="pubmed">33201251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang R., Chen R., Zhang Q., et al. HMGB1 in health and disease. Molecular Aspects of Medicine . 2014;40:1&#x2013;116. doi: 10.1016/j.mam.2014.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2014.05.001</ArticleId>
            <ArticleId IdType="pmc">PMC4254084</ArticleId>
            <ArticleId IdType="pubmed">25010388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NaveenKumar S. K., Hemshekhar M., Kemparaju K., Girish K. S. Hemin-induced platelet activation and ferroptosis is mediated through ROS-driven proteasomal activity and inflammasome activation: protection by melatonin. Biochimica et Biophysica Acta - Molecular Basis of Disease . 2019;1865(9):2303&#x2013;2316. doi: 10.1016/j.bbadis.2019.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2019.05.009</ArticleId>
            <ArticleId IdType="pubmed">31102787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z., Shi L., Wang Y., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine . 2020;8(4):420&#x2013;422. doi: 10.1016/s2213-2600(20)30076-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2213-2600(20)30076-x</ArticleId>
            <ArticleId IdType="pmc">PMC7164771</ArticleId>
            <ArticleId IdType="pubmed">32085846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C., Zhang X. R., Ju Z. Y., He W. F. Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019. Zhonghua Shao Shang Za Zhi . 2020;36:471&#x2013;475. doi: 10.3760/cma.j.cn501120-20200224-00088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.cn501120-20200224-00088</ArticleId>
            <ArticleId IdType="pubmed">32114747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Habib H. M., Ibrahim S., Zaim A., Ibrahim W. H. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomedicine &amp; Pharmacotherapy . 2021;136:p. 111228. doi: 10.1016/j.biopha.2021.111228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2021.111228</ArticleId>
            <ArticleId IdType="pmc">PMC7836924</ArticleId>
            <ArticleId IdType="pubmed">33454595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin D., Kim E. H., Lee J., Roh J. L. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radical Biology &amp; Medicine . 2018;129:454&#x2013;462. doi: 10.1016/j.freeradbiomed.2018.10.426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.10.426</ArticleId>
            <ArticleId IdType="pubmed">30339884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O., Shah R., Li B., et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Central Science . 2017;3(3):232&#x2013;243. doi: 10.1021/acscentsci.7b00028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y., Li X., Cheng Y., Yang M., Wang R. Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion. The FASEB Journal . 2020;34(12):16262&#x2013;16275. doi: 10.1096/fj.202001758R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.202001758R</ArticleId>
            <ArticleId IdType="pubmed">33070393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oyaizu T., Fung S. Y., Shiozaki A., et al. Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury. Intensive Care Medicine . 2012;38(5):894&#x2013;905. doi: 10.1007/s00134-012-2498-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-012-2498-z</ArticleId>
            <ArticleId IdType="pubmed">22349424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu L., Yan J., Jiang Z., Song Z., Luo F., Peng Q. Low-intensity pulsed ultrasound pretreatment inhibits HMGB1 expression and attenuates lung ischemia-reperfusion injury in rats via the cholinergic anti-inflammatory pathway. Nan Fang Yi Ke Da Xue Xue Bao . 2018;38(9):1061&#x2013;1065. doi: 10.12122/j.issn.1673-4254.2018.09.06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12122/j.issn.1673-4254.2018.09.06</ArticleId>
            <ArticleId IdType="pmc">PMC6744187</ArticleId>
            <ArticleId IdType="pubmed">30377098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalogeris T., Baines C. P., Krenz M., Korthuis R. J. Cell biology of ischemia/reperfusion injury. International Review of Cell and Molecular Biology . 2012;298:229&#x2013;317. doi: 10.1016/b978-0-12-394309-5.00006-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/b978-0-12-394309-5.00006-7</ArticleId>
            <ArticleId IdType="pmc">PMC3904795</ArticleId>
            <ArticleId IdType="pubmed">22878108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmerman B. J., Granger D. N. Mechanisms of reperfusion injury. The American Journal of the Medical Sciences . 1994;307(4):284&#x2013;292. doi: 10.1097/00000441-199404000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000441-199404000-00009</ArticleId>
            <ArticleId IdType="pubmed">8160724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ovechkin A. V., Lominadze D., Sedoris K. C., Robinson T. W., Tyagi S. C., Roberts A. M. Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. Archives of Physiology and Biochemistry . 2007;113(1):1&#x2013;12. doi: 10.1080/13813450601118976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13813450601118976</ArticleId>
            <ArticleId IdType="pmc">PMC3182489</ArticleId>
            <ArticleId IdType="pubmed">17522980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fei L., Jingyuan X., Fangte L., et al. Preconditioning with rHMGB1 ameliorates lung ischemia-reperfusion injury by inhibiting alveolar macrophage pyroptosis via the Keap1/Nrf2/HO-1 signaling pathway. Journal of Translational Medicine . 2020;18(1):p. 301. doi: 10.1186/s12967-020-02467-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-020-02467-w</ArticleId>
            <ArticleId IdType="pmc">PMC7405465</ArticleId>
            <ArticleId IdType="pubmed">32758258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iadecola C., Anrather J. The immunology of stroke: from mechanisms to translation. Nature Medicine . 2011;17(7):796&#x2013;808. doi: 10.1038/nm.2399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2399</ArticleId>
            <ArticleId IdType="pmc">PMC3137275</ArticleId>
            <ArticleId IdType="pubmed">21738161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A., Kukreti R., Saso L., Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules . 2019;24(8):p. 1583. doi: 10.3390/molecules24081583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules24081583</ArticleId>
            <ArticleId IdType="pmc">PMC6514564</ArticleId>
            <ArticleId IdType="pubmed">31013638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiang Z., Dong H., Xia Y., Chai D., Hu R., Jiang H. Nrf2 and STAT3 alleviates ferroptosis-mediated IIR-ALI by regulating SLC7A11. Oxidative Medicine and Cellular Longevity . 2020;2020:16. doi: 10.1155/2020/5146982.5146982</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/5146982</ArticleId>
            <ArticleId IdType="pmc">PMC7520693</ArticleId>
            <ArticleId IdType="pubmed">33014271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan H.-F., Tuo Q. Z., Yin Q. Z., Lei P. The pathological role of ferroptosis in ischemia/reperfusion-related injury. Zoological Research . 2020;41(3):220&#x2013;230. doi: 10.24272/j.issn.2095-8137.2020.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24272/j.issn.2095-8137.2020.042</ArticleId>
            <ArticleId IdType="pmc">PMC7231469</ArticleId>
            <ArticleId IdType="pubmed">32314558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada N., Karasawa T., Wakiya T., et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis. American Journal of Transplantation . 2020;20(6):1606&#x2013;1618. doi: 10.1111/ajt.15773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.15773</ArticleId>
            <ArticleId IdType="pubmed">31909544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Feng D., Wang Z., et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death and Differentiation . 2019;26(11):2284&#x2013;2299. doi: 10.1038/s41418-019-0299-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0299-4</ArticleId>
            <ArticleId IdType="pmc">PMC6889315</ArticleId>
            <ArticleId IdType="pubmed">30737476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wichniak A., Kania A., Siemi&#x144;ski M., Cuba&#x142;a W. J. Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders. International Journal of Molecular Sciences . 2021;22(16):p. 8623. doi: 10.3390/ijms22168623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22168623</ArticleId>
            <ArticleId IdType="pmc">PMC8395320</ArticleId>
            <ArticleId IdType="pubmed">34445329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Cao Y., Xiao J., et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death and Differentiation . 2020;27(9):2635&#x2013;2650. doi: 10.1038/s41418-020-0528-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-020-0528-x</ArticleId>
            <ArticleId IdType="pmc">PMC7429834</ArticleId>
            <ArticleId IdType="pubmed">32203170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pourgholamhossein F., Rasooli R., Pournamdari M., et al. Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression. Food and Chemical Toxicology . 2018;112:39&#x2013;46. doi: 10.1016/j.fct.2017.12.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2017.12.034</ArticleId>
            <ArticleId IdType="pubmed">29273418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., He F., Li P., Hardwidge P. R., Li N., Peng Y. The role of innate immunity in pulmonary infections. BioMed Research International . 2021;2021:14. doi: 10.1155/2021/6646071.6646071</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/6646071</ArticleId>
            <ArticleId IdType="pmc">PMC7847335</ArticleId>
            <ArticleId IdType="pubmed">33553427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathew D., Giles J. R., Baxter A. E., et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science . 2020;369(6508):p. eabc8511. doi: 10.1126/science.abc8511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abc8511</ArticleId>
            <ArticleId IdType="pmc">PMC7402624</ArticleId>
            <ArticleId IdType="pubmed">32669297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan X., Huang W., Ye B., et al. Changes of hematological and immunological parameters in COVID-19 patients. International Journal of Hematology . 2020;112(4):553&#x2013;559. doi: 10.1007/s12185-020-02930-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12185-020-02930-w</ArticleId>
            <ArticleId IdType="pmc">PMC7354745</ArticleId>
            <ArticleId IdType="pubmed">32656638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misharin A. V., Morales-Nebreda L., Mutlu G. M., Budinger G. R. S., Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. American Journal of Respiratory Cell and Molecular Biology . 2013;49(4):503&#x2013;510. doi: 10.1165/rcmb.2013-0086MA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2013-0086MA</ArticleId>
            <ArticleId IdType="pmc">PMC3824047</ArticleId>
            <ArticleId IdType="pubmed">23672262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding L., Yang J., Zhang C., Zhang X., Gao P. Neutrophils modulate fibrogenesis in chronic pulmonary diseases. Frontiers in Medicine . 2021;8:p. 616200. doi: 10.3389/fmed.2021.616200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2021.616200</ArticleId>
            <ArticleId IdType="pmc">PMC8110706</ArticleId>
            <ArticleId IdType="pubmed">33987189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caramori G., Casolari P., Barczyk A., Durham A. L., di Stefano A., Adcock I. COPD immunopathology. Seminars in Immunopathology . 2016;38(4):497&#x2013;515. doi: 10.1007/s00281-016-0561-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-016-0561-5</ArticleId>
            <ArticleId IdType="pmc">PMC4897000</ArticleId>
            <ArticleId IdType="pubmed">27178410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo C., Lei M., Zhang Y., et al. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma. Journal of Cellular and Molecular Medicine . 2020;24(2):1233&#x2013;1244. doi: 10.1111/jcmm.14719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.14719</ArticleId>
            <ArticleId IdType="pmc">PMC6991688</ArticleId>
            <ArticleId IdType="pubmed">31779055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J. P., Krysko D. V., Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nature Reviews. Cancer . 2019;19(7):405&#x2013;414. doi: 10.1038/s41568-019-0149-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0149-1</ArticleId>
            <ArticleId IdType="pubmed">31101865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu G., Peng W., Cai Q., et al. Construction and validation of a 15-gene ferroptosis signature in lung adenocarcinoma. PeerJ . 2021;9, article e11687 doi: 10.7717/peerj.11687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7717/peerj.11687</ArticleId>
            <ArticleId IdType="pmc">PMC8272465</ArticleId>
            <ArticleId IdType="pubmed">34277151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Futosi K., Fodor S., M&#xf3;csai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. International Immunopharmacology . 2013;17(3):638&#x2013;650. doi: 10.1016/j.intimp.2013.06.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2013.06.034</ArticleId>
            <ArticleId IdType="pmc">PMC3827506</ArticleId>
            <ArticleId IdType="pubmed">23994464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu W., Deng H., Hu S., et al. Role of ferroptosis in lung diseases. Journal of Inflammation Research . 2021;14:2079&#x2013;2090. doi: 10.2147/jir.S307081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/jir.S307081</ArticleId>
            <ArticleId IdType="pmc">PMC8144020</ArticleId>
            <ArticleId IdType="pubmed">34045882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C., Sun S., Johnson T., et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Reports . 2021;35(11):p. 109235. doi: 10.1016/j.celrep.2021.109235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.109235</ArticleId>
            <ArticleId IdType="pubmed">34133924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Green M., Choi J. E., et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature . 2019;569(7755):270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu G., Huang H., Xu S., et al. Prognostic value of ferroptosis-related genes in patients with lung adenocarcinoma. Thoracic Cancer . 2021;12(12):1890&#x2013;1899. doi: 10.1111/1759-7714.13998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1759-7714.13998</ArticleId>
            <ArticleId IdType="pmc">PMC8201541</ArticleId>
            <ArticleId IdType="pubmed">33979897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu Z., Liu T., Liu C., et al. Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal activities. Nano Letters . 2021;21(15):6471&#x2013;6479. doi: 10.1021/acs.nanolett.1c01401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.1c01401</ArticleId>
            <ArticleId IdType="pubmed">34292757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J. P., Schneider M., Proneth B., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature Cell Biology . 2014;16(12):1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothe T., Gruber F., Uderhardt S., et al. 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. The Journal of Clinical Investigation . 2015;125(5):1944&#x2013;1954. doi: 10.1172/JCI78490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI78490</ArticleId>
            <ArticleId IdType="pmc">PMC4463199</ArticleId>
            <ArticleId IdType="pubmed">25844901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., DuBois R. N. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis . 2015;36(10):1085&#x2013;1093. doi: 10.1093/carcin/bgv123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgv123</ArticleId>
            <ArticleId IdType="pmc">PMC5006153</ArticleId>
            <ArticleId IdType="pubmed">26354776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galanopoulos M., Gkeros F., Doukatas A., et al. COVID-19 pandemic: pathophysiology and manifestations from the gastrointestinal tract. World Journal of Gastroenterology . 2020;26(31):4579&#x2013;4588. doi: 10.3748/wjg.v26.i31.4579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v26.i31.4579</ArticleId>
            <ArticleId IdType="pmc">PMC7445869</ArticleId>
            <ArticleId IdType="pubmed">32884218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavezzi A., Troiani E., Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clinics and Practice . 2020;10(2):24&#x2013;30. doi: 10.4081/cp.2020.1271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4081/cp.2020.1271</ArticleId>
            <ArticleId IdType="pmc">PMC7267810</ArticleId>
            <ArticleId IdType="pubmed">32509258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Li H., Jiang X., Shi W., Shen Z., Li M. Hepcidin is directly regulated by insulin and plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes . 2014;63(5):1506&#x2013;1518. doi: 10.2337/db13-1195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db13-1195</ArticleId>
            <ArticleId IdType="pubmed">24379355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banchini F., Vallisa D., Maniscalco P., Capelli P. Iron overload and hepcidin overexpression could play a key role in COVID infection, and may explain vulnerability in elderly, diabetics, and obese patients. Acta Biomed . 2020;91(3, article e2020013) doi: 10.23750/abm.v91i3.9826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.23750/abm.v91i3.9826</ArticleId>
            <ArticleId IdType="pmc">PMC7716981</ArticleId>
            <ArticleId IdType="pubmed">32921750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edeas M., Saleh J., Peyssonnaux C. Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis? International Journal of Infectious Diseases . 2020;97:303&#x2013;305. doi: 10.1016/j.ijid.2020.05.110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2020.05.110</ArticleId>
            <ArticleId IdType="pmc">PMC7264936</ArticleId>
            <ArticleId IdType="pubmed">32497811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T., Stockwell B. R. The development of the concept of ferroptosis. Free Radical Biology &amp; Medicine . 2019;133:130&#x2013;143. doi: 10.1016/j.freeradbiomed.2018.09.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.09.043</ArticleId>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta . 2012;1823(9):1434&#x2013;1443. doi: 10.1016/j.bbamcr.2012.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2012.01.014</ArticleId>
            <ArticleId IdType="pmc">PMC4048856</ArticleId>
            <ArticleId IdType="pubmed">22306005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs W., Lammens M., Kerckhofs A., et al. Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. ESC Heart Failure . 2020;7(6):3772&#x2013;3781. doi: 10.1002/ehf2.12958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ehf2.12958</ArticleId>
            <ArticleId IdType="pmc">PMC7607145</ArticleId>
            <ArticleId IdType="pubmed">32959998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bay&#x131;r H., Anthonymuthu T. S., Tyurina Y. Y., et al. Achieving life through death: redox biology of lipid peroxidation in ferroptosis. Cell Chemical Biology . 2020;27(4):387&#x2013;408. doi: 10.1016/j.chembiol.2020.03.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2020.03.014</ArticleId>
            <ArticleId IdType="pmc">PMC7218794</ArticleId>
            <ArticleId IdType="pubmed">32275865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Skouta R., Himmerkus N., et al. Synchronized renal tubular cell death involves ferroptosis. Proceedings of the National Academy of Sciences of the United States of America . 2014;111(47):16836&#x2013;16841. doi: 10.1073/pnas.1415518111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1415518111</ArticleId>
            <ArticleId IdType="pmc">PMC4250130</ArticleId>
            <ArticleId IdType="pubmed">25385600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Y., Wang L., Ma X., et al. Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/&#x3b2;-catenin signaling pathway. Stem Cell Research &amp; Therapy . 2020;11(1):p. 2. doi: 10.1186/s13287-019-1492-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13287-019-1492-6</ArticleId>
            <ArticleId IdType="pmc">PMC6942368</ArticleId>
            <ArticleId IdType="pubmed">31900217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mokra D., Mikolka P., Kosutova P., Mokry J. Corticosteroids in acute lung injury: the dilemma continues. International Journal of Molecular Sciences . 2019;20(19):p. 4765. doi: 10.3390/ijms20194765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20194765</ArticleId>
            <ArticleId IdType="pmc">PMC6801694</ArticleId>
            <ArticleId IdType="pubmed">31557974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P., Feng Y., Li H., et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cellular &amp; Molecular Biology Letters . 2020;25(1):p. 10. doi: 10.1186/s11658-020-00205-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11658-020-00205-0</ArticleId>
            <ArticleId IdType="pmc">PMC7045739</ArticleId>
            <ArticleId IdType="pubmed">32161620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu Y. B., Wan B. B., Liu G., et al. Nrf2 protects against seawater drowning-induced acute lung injury via inhibiting ferroptosis. Respiratory Research . 2020;21(1):p. 232. doi: 10.1186/s12931-020-01500-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12931-020-01500-2</ArticleId>
            <ArticleId IdType="pmc">PMC7488337</ArticleId>
            <ArticleId IdType="pubmed">32907551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishi K. ABO blood group typing in forensic autopsies. Nihon H&#x14d;igaku Zasshi . 2005;59(2):111&#x2013;117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16296382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshpande R., Zou C. Pseudomonas aeruginosa induced cell death in acute lung injury and acute respiratory distress syndrome. International Journal of Molecular Sciences . 2020;21(15):p. 5356. doi: 10.3390/ijms21155356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21155356</ArticleId>
            <ArticleId IdType="pmc">PMC7432812</ArticleId>
            <ArticleId IdType="pubmed">32731491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzm&#xe1;n E. A. Regulated cell death signaling pathways and marine natural products that target them. Marine Drugs . 2019;17(2):p. 76. doi: 10.3390/md17020076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/md17020076</ArticleId>
            <ArticleId IdType="pmc">PMC6410226</ArticleId>
            <ArticleId IdType="pubmed">30678065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muthumalage T., Rahman I. Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts. Toxicology and Applied Pharmacology . 2019;382:p. 114713. doi: 10.1016/j.taap.2019.114713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2019.114713</ArticleId>
            <ArticleId IdType="pmc">PMC6917034</ArticleId>
            <ArticleId IdType="pubmed">31437494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H., Lv H., Li H., Ci X., Peng L. Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-&#x3ba;B pathways. Cell Communication and Signaling: CCS . 2019;17(1):p. 62. doi: 10.1186/s12964-019-0366-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-019-0366-y</ArticleId>
            <ArticleId IdType="pmc">PMC6558832</ArticleId>
            <ArticleId IdType="pubmed">31186013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S., Bi J., Yang L., et al. Serum irisin levels are decreased in patients with sepsis, and exogenous irisin suppresses ferroptosis in the liver of septic mice. Clinical and Translational Medicine . 2020;10(5, article e173) doi: 10.1002/ctm2.173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ctm2.173</ArticleId>
            <ArticleId IdType="pmc">PMC7522760</ArticleId>
            <ArticleId IdType="pubmed">32997405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou J. S., Zhao L. P., Huang Z. H., et al. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine . 2021;80:p. 153370. doi: 10.1016/j.phymed.2020.153370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phymed.2020.153370</ArticleId>
            <ArticleId IdType="pubmed">33113504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao X., Lu Z., Lin V., et al. MicroRNA miR-24-3p reduces apoptosis and regulates Keap1-Nrf2 pathway in mouse cardiomyocytes responding to ischemia/reperfusion injury. Oxidative Medicine and Cellular Longevity . 2018;2018:9. doi: 10.1155/2018/7042105.7042105</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/7042105</ArticleId>
            <ArticleId IdType="pmc">PMC6304907</ArticleId>
            <ArticleId IdType="pubmed">30622671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmoud A. M., Hussein O. E., Abd el-Twab S. M., Hozayen W. G. Ferulic acid protects against methotrexate nephrotoxicityviaactivation of Nrf2/ARE/HO-1 signaling and PPAR&#x3b3;, and suppression of NF-&#x3ba;B/NLRP3 inflammasome axis. Food &amp; Function . 2019;10(8):4593&#x2013;4607. doi: 10.1039/c9fo00114j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c9fo00114j</ArticleId>
            <ArticleId IdType="pubmed">31289794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H., Qiang Z., Chai D., et al. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging (Albany NY) . 2020;12(13):12943&#x2013;12959. doi: 10.18632/aging.103378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/aging.103378</ArticleId>
            <ArticleId IdType="pmc">PMC7377827</ArticleId>
            <ArticleId IdType="pubmed">32601262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge W., Zhao K., Wang X., et al. iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding. Cancer Cell . 2017;32(5):561&#x2013;573.e6. doi: 10.1016/j.ccell.2017.09.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.09.008</ArticleId>
            <ArticleId IdType="pubmed">29033244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C. Y., Zhang Q., Xun Z., et al. Increases of iASPP-Keap1 interaction mediated by syringin enhance synaptic plasticity and rescue cognitive impairments via stabilizing Nrf2 in Alzheimer's models. Redox Biology . 2020;36:p. 101672. doi: 10.1016/j.redox.2020.101672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2020.101672</ArticleId>
            <ArticleId IdType="pmc">PMC7452088</ArticleId>
            <ArticleId IdType="pubmed">32828017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N., Wang W., Zhou H., et al. Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. Free Radical Biology &amp; Medicine . 2020;160:303&#x2013;318. doi: 10.1016/j.freeradbiomed.2020.08.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.08.009</ArticleId>
            <ArticleId IdType="pubmed">32846217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z., Li H., Zhang Q., et al. Discovery of indolinone-based multikinase inhibitors as potential therapeutics for idiopathic pulmonary fibrosis. ACS Medicinal Chemistry Letters . 2017;8(11):1142&#x2013;1147. doi: 10.1021/acsmedchemlett.7b00164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.7b00164</ArticleId>
            <ArticleId IdType="pmc">PMC5682619</ArticleId>
            <ArticleId IdType="pubmed">29152045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong Y., Wang N., Liu N., Dong H. Lipid peroxidation and GPX4 inhibition are common causes for myofibroblast differentiation and ferroptosis. DNA and Cell Biology . 2019;38(7):725&#x2013;733. doi: 10.1089/dna.2018.4541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/dna.2018.4541</ArticleId>
            <ArticleId IdType="pubmed">31140862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanoni M., Cortesi M., Zamagni A., Tesei A. The role of mesenchymal stem cells in radiation-induced lung fibrosis. International Journal of Molecular Sciences . 2019;20(16):p. 3876. doi: 10.3390/ijms20163876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20163876</ArticleId>
            <ArticleId IdType="pmc">PMC6719901</ArticleId>
            <ArticleId IdType="pubmed">31398940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiappori A., Folli C., Balbi F., et al. CD4+CD25highCD127&#x2212; regulatory T-cells in COPD: smoke and drugs effect. World Allergy Organization Journal . 2016;9:p. 5. doi: 10.1186/s40413-016-0095-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40413-016-0095-2</ArticleId>
            <ArticleId IdType="pmc">PMC4751712</ArticleId>
            <ArticleId IdType="pubmed">26904157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park E. J., Park Y. J., Lee S. J., Lee K., Yoon C. Whole cigarette smoke condensates induce ferroptosis in human bronchial epithelial cells. Toxicology Letters . 2019;303:55&#x2013;66. doi: 10.1016/j.toxlet.2018.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2018.12.007</ArticleId>
            <ArticleId IdType="pubmed">30579903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang M. J., Lee C. G., Lee J. Y., et al. Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice. The Journal of Clinical Investigation . 2008;118:2771&#x2013;2784. doi: 10.1172/jci32709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci32709</ArticleId>
            <ArticleId IdType="pmc">PMC2483678</ArticleId>
            <ArticleId IdType="pubmed">18654661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Stockwell B. R., Krautwald S., Anders H. J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nature Reviews. Immunology . 2014;14(11):759&#x2013;767. doi: 10.1038/nri3743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3743</ArticleId>
            <ArticleId IdType="pubmed">25324125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torre L. A., Siegel R. L., Jemal A. Lung cancer statistics. Advances in Experimental Medicine and Biology . 2016;893:1&#x2013;19. doi: 10.1007/978-3-319-24223-1_1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-24223-1_1</ArticleId>
            <ArticleId IdType="pubmed">26667336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad R. M., Muqbil I., Lowe L., et al. Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology . 2015;35(Suppl):S78&#x2013;S103. doi: 10.1016/j.semcancer.2015.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2015.03.001</ArticleId>
            <ArticleId IdType="pmc">PMC4720504</ArticleId>
            <ArticleId IdType="pubmed">25936818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D., Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduction and Targeted Therapy . 2020;5(1):p. 108. doi: 10.1038/s41392-020-00216-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00216-5</ArticleId>
            <ArticleId IdType="pmc">PMC7327075</ArticleId>
            <ArticleId IdType="pubmed">32606298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia X., Fan X., Zhao M., Zhu P. The relationship between ferroptosis and tumors: a novel landscape for therapeutic approach. Current Gene Therapy . 2019;19(2):117&#x2013;124. doi: 10.2174/1566523219666190628152137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1566523219666190628152137</ArticleId>
            <ArticleId IdType="pmc">PMC7046989</ArticleId>
            <ArticleId IdType="pubmed">31264548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Zhang S., Gong X., et al. The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. Molecular Cancer . 2020;19(1):p. 39. doi: 10.1186/s12943-020-01157-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-020-01157-x</ArticleId>
            <ArticleId IdType="pmc">PMC7045519</ArticleId>
            <ArticleId IdType="pubmed">32103754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berkers C. R., Maddocks O. D. K., Cheung E. C., Mor I., Vousden K. H. Metabolic regulation by p53 family members. Cell Metabolism . 2013;18(5):617&#x2013;633. doi: 10.1016/j.cmet.2013.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2013.06.019</ArticleId>
            <ArticleId IdType="pmc">PMC3824073</ArticleId>
            <ArticleId IdType="pubmed">23954639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai Y., Zhang Z., Li J., et al. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma. Biochemical and Biophysical Research Communications . 2019;519(4):659&#x2013;666. doi: 10.1016/j.bbrc.2019.09.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.09.032</ArticleId>
            <ArticleId IdType="pubmed">31542233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfeifhofer-Obermair C., Tymoszuk P., Petzer V., Weiss G., Nairz M. Iron in the tumor microenvironment-connecting the dots. Frontiers in Oncology . 2018;8:p. 549. doi: 10.3389/fonc.2018.00549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2018.00549</ArticleId>
            <ArticleId IdType="pmc">PMC6275298</ArticleId>
            <ArticleId IdType="pubmed">30534534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thanan R., Oikawa S., Yongvanit P., et al. Inflammation-induced protein carbonylation contributes to poor prognosis for cholangiocarcinoma. Free Radical Biology &amp; Medicine . 2012;52(8):1465&#x2013;1472. doi: 10.1016/j.freeradbiomed.2012.01.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.01.018</ArticleId>
            <ArticleId IdType="pubmed">22377619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez S. W., Sviderskiy V. O., Terzi E. M., et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature . 2017;551(7682):639&#x2013;643. doi: 10.1038/nature24637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24637</ArticleId>
            <ArticleId IdType="pmc">PMC5808442</ArticleId>
            <ArticleId IdType="pubmed">29168506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y., Mao C., Yang R., et al. EGLN1/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics . 2017;7(13):3293&#x2013;3305. doi: 10.7150/thno.19988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.19988</ArticleId>
            <ArticleId IdType="pmc">PMC5595132</ArticleId>
            <ArticleId IdType="pubmed">28900510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y., He Y., Liu S., Tao Y. Chromatin remodeling factor lymphoid-specific helicase inhibits ferroptosis through lipid metabolic genes in lung cancer progression. Chinese Journal of Cancer . 2017;36(1):p. 82. doi: 10.1186/s40880-017-0248-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40880-017-0248-x</ArticleId>
            <ArticleId IdType="pmc">PMC5644172</ArticleId>
            <ArticleId IdType="pubmed">29037212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J., Xu B., Han Q., et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Research and Treatment . 2018;50(2):445&#x2013;460. doi: 10.4143/crt.2016.572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4143/crt.2016.572</ArticleId>
            <ArticleId IdType="pmc">PMC5912137</ArticleId>
            <ArticleId IdType="pubmed">28494534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Sui S., Wang L., et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. Journal of Cellular Physiology . 2020;235(4):3425&#x2013;3437. doi: 10.1002/jcp.29232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.29232</ArticleId>
            <ArticleId IdType="pubmed">31556117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P., Wu Q., Feng J., et al. Erianin, a novel dibenzyl compound in dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Signal Transduction and Targeted Therapy . 2020;5(1):p. 51. doi: 10.1038/s41392-020-0149-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-0149-3</ArticleId>
            <ArticleId IdType="pmc">PMC7205607</ArticleId>
            <ArticleId IdType="pubmed">32382060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Yan H., Xu X., Liu H., Wu C., Zhao L. Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. Oncology Letters . 2020;19:323&#x2013;333. doi: 10.3892/ol.2019.11066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.11066</ArticleId>
            <ArticleId IdType="pmc">PMC6923844</ArticleId>
            <ArticleId IdType="pubmed">31897145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C., Yang M., Deng J., Li P., Su W., Jiang R. Upregulation and activation of p53 by erastin-induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells. Oncology Reports . 2018;40:2363&#x2013;2370. doi: 10.3892/or.2018.6585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2018.6585</ArticleId>
            <ArticleId IdType="pubmed">30066882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan X., Lin Z., Jiang D., et al. Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis. Oncology Letters . 2019;17:3001&#x2013;3008. doi: 10.3892/ol.2019.9888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.9888</ArticleId>
            <ArticleId IdType="pmc">PMC6365906</ArticleId>
            <ArticleId IdType="pubmed">30854078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon O. S., Kwon E. J., Kong H. J., et al. Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosis. Redox Biology . 2020;37:p. 101719. doi: 10.1016/j.redox.2020.101719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2020.101719</ArticleId>
            <ArticleId IdType="pmc">PMC7519368</ArticleId>
            <ArticleId IdType="pubmed">32979793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gai C., Yu M., Li Z., et al. Acetaminophen sensitizing erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small-cell lung cancer. Journal of Cellular Physiology . 2020;235(4):3329&#x2013;3339. doi: 10.1002/jcp.29221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.29221</ArticleId>
            <ArticleId IdType="pubmed">31541463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villalpando-Rodriguez G. E., Blankstein A. R., Konzelman C., Gibson S. B. Lysosomal destabilizing drug siramesine and the dual tyrosine kinase inhibitor lapatinib induce a synergistic ferroptosis through reduced heme oxygenase-1 (HO-1) levels. Oxidative Medicine and Cellular Longevity . 2019;2019:14. doi: 10.1155/2019/9561281.9561281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/9561281</ArticleId>
            <ArticleId IdType="pmc">PMC6766165</ArticleId>
            <ArticleId IdType="pubmed">31636810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan B., Liao F., Shi Z. Z., et al. Dihydroartemisinin inhibits the proliferation, colony formation and induces ferroptosis of lung cancer cells by inhibiting PRIM2/SLC7A11 axis. Oncotargets and Therapy . 2020;13:10829&#x2013;10840. doi: 10.2147/OTT.S248492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S248492</ArticleId>
            <ArticleId IdType="pmc">PMC7602909</ArticleId>
            <ArticleId IdType="pubmed">33149601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer L. D., Jordan A. T., Maloney K. N., et al. Zinc intoxication induces ferroptosis in A549 human lung cells. Metallomics . 2019;11(5):982&#x2013;993. doi: 10.1039/c8mt00360b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c8mt00360b</ArticleId>
            <ArticleId IdType="pmc">PMC6531343</ArticleId>
            <ArticleId IdType="pubmed">30968088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M., Mao C., Ouyang L., et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death and Differentiation . 2019;26(11):2329&#x2013;2343. doi: 10.1038/s41418-019-0304-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0304-y</ArticleId>
            <ArticleId IdType="pmc">PMC6889193</ArticleId>
            <ArticleId IdType="pubmed">30787392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gai C., Liu C., Wu X., et al. MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells. Cell Death &amp; Disease . 2020;11(9):p. 751. doi: 10.1038/s41419-020-02939-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-02939-3</ArticleId>
            <ArticleId IdType="pmc">PMC7490417</ArticleId>
            <ArticleId IdType="pubmed">32929075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao C., Wang X., Liu Y., et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Research . 2018;78:canres.3454.2017&#x2013;canres.3454.3496. doi: 10.1158/0008-5472.CAN-17-3454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3454</ArticleId>
            <ArticleId IdType="pmc">PMC8073197</ArticleId>
            <ArticleId IdType="pubmed">29588351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y., Zhao X., Huang J., et al. Transformable hybrid semiconducting polymer nanozyme for second near- infrared photothermal ferrotherapy. Nature Communications . 2020;11(1):p. 1857. doi: 10.1038/s41467-020-15730-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-15730-x</ArticleId>
            <ArticleId IdType="pmc">PMC7170847</ArticleId>
            <ArticleId IdType="pubmed">32312987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye L. F., Chaudhary K. R., Zandkarimi F., et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chemical Biology . 2020;15(2):469&#x2013;484. doi: 10.1021/acschembio.9b00939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.9b00939</ArticleId>
            <ArticleId IdType="pmc">PMC7180072</ArticleId>
            <ArticleId IdType="pubmed">31899616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan L. Q., Wang C., Lu D. F., Zhao X. D., Tan L. H., Chen X. Induction of apoptosis and ferroptosis by a tumor suppressing magnetic field through ROS-mediated DNA damage. Aging (Albany NY) . 2020;12(4):3662&#x2013;3681. doi: 10.18632/aging.102836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/aging.102836</ArticleId>
            <ArticleId IdType="pmc">PMC7066880</ArticleId>
            <ArticleId IdType="pubmed">32074079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang M., Qiao M., Zhao C., Deng J., Li X., Zhou C. Targeting ferroptosis for cancer therapy: exploring novel strategies from its mechanisms and role in cancers. Translational Lung Cancer Research . 2020;9(4):1569&#x2013;1584. doi: 10.21037/tlcr-20-341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tlcr-20-341</ArticleId>
            <ArticleId IdType="pmc">PMC7481593</ArticleId>
            <ArticleId IdType="pubmed">32953528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W., Du Y., Liang X., et al. Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer. Biomaterials . 2019;217:p. 119264. doi: 10.1016/j.biomaterials.2019.119264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2019.119264</ArticleId>
            <ArticleId IdType="pubmed">31260883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Minikes A. M., Gao M., et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature . 2019;572(7769):402&#x2013;406. doi: 10.1038/s41586-019-1426-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1426-6</ArticleId>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel S. E., Tyurina Y. Y., Zhao J., et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell . 2017;171(3):628&#x2013;641.e26. doi: 10.1016/j.cell.2017.09.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.044</ArticleId>
            <ArticleId IdType="pmc">PMC5683852</ArticleId>
            <ArticleId IdType="pubmed">29053969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J., Dar H. H., Deng Y., et al. PEBP1 acts as a rheostat between prosurvival autophagy and ferroptotic death in asthmatic epithelial cells. Proceedings of the National Academy of Sciences of the United States of America . 2020;117(25):14376&#x2013;14385. doi: 10.1073/pnas.1921618117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1921618117</ArticleId>
            <ArticleId IdType="pmc">PMC7321965</ArticleId>
            <ArticleId IdType="pubmed">32513718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha E. H., Choi J. P., Kwon H. S., et al. Endothelial Sox17 promotes allergic airway inflammation. The Journal of Allergy and Clinical Immunology . 2019;144(2):561&#x2013;573.e6. doi: 10.1016/j.jaci.2019.02.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2019.02.034</ArticleId>
            <ArticleId IdType="pubmed">30928652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geering B., Stoeckle C., Conus S., Simon H. U. Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends in Immunology . 2013;34(8):398&#x2013;409. doi: 10.1016/j.it.2013.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2013.04.002</ArticleId>
            <ArticleId IdType="pubmed">23665135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler M. M., Andia A. A., Liu H., et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nature Chemical Biology . 2018;14(5):507&#x2013;515. doi: 10.1038/s41589-018-0031-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-018-0031-6</ArticleId>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Chen H., Xuan N., et al. Induction of ferroptosis-like cell death of eosinophils exerts synergistic effects with glucocorticoids in allergic airway inflammation. Thorax . 2020;75(11):918&#x2013;927. doi: 10.1136/thoraxjnl-2020-214764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thoraxjnl-2020-214764</ArticleId>
            <ArticleId IdType="pubmed">32759385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dar H. H., Tyurina Y. Y., Mikulska-Ruminska K., et al. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. The Journal of Clinical Investigation . 2018;128(10):4639&#x2013;4653. doi: 10.1172/JCI99490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI99490</ArticleId>
            <ArticleId IdType="pmc">PMC6159971</ArticleId>
            <ArticleId IdType="pubmed">30198910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dar H. H., Anthonymuthu T. S., Ponomareva L. A., et al. A new thiol-independent mechanism of epithelial host defense against Pseudomonas aeruginosa: iNOS/NO&#x2022; sabotage of theft-ferroptosis. Redox Biology . 2021;45:p. 102045. doi: 10.1016/j.redox.2021.102045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2021.102045</ArticleId>
            <ArticleId IdType="pmc">PMC8227829</ArticleId>
            <ArticleId IdType="pubmed">34167028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral E. P., Costa D. L., Namasivayam S., et al. A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis. The Journal of Experimental Medicine . 2019;216(3):556&#x2013;570. doi: 10.1084/jem.20181776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20181776</ArticleId>
            <ArticleId IdType="pmc">PMC6400546</ArticleId>
            <ArticleId IdType="pubmed">30787033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghafoori P., Marks L. B., Vujaskovic Z., Kelsey C. R. Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) . 2008;22:37&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18251282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Zhuang X., Qiao T. Role of ferroptosis in the process of acute radiation-induced lung injury in mice. Biochemical and Biophysical Research Communications . 2019;519(2):240&#x2013;245. doi: 10.1016/j.bbrc.2019.08.165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.08.165</ArticleId>
            <ArticleId IdType="pubmed">31493867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortezavi A., Salemi S., Kranzb&#xfc;hler B., et al. Inhibition of autophagy significantly increases the antitumor effect of abiraterone in prostate cancer. World Journal of Urology . 2019;37(2):351&#x2013;358. doi: 10.1007/s00345-018-2385-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00345-018-2385-5</ArticleId>
            <ArticleId IdType="pubmed">29951789</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34627266</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-3155</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of nanobiotechnology</Title>
          <ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Simvastatin induced ferroptosis for triple-negative breast cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>311</StartPage>
          <MedlinePgn>311</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">311</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-021-01058-1</ELocationID>
        <Abstract>
          <AbstractText>Triple-negative breast cancer (TNBC), a management of aggressive breast cancer, remains an unmet medical challenge. Although a wave of efforts had spurred to design novel therapeutic method of TNBC, unpredictable prognosis with lacking effective therapeutic targets along with the resistance to apoptosis seriously limited survival benefits. Ferroptosis is a non-apoptotic form of cell death that is induced by excessive lipid peroxidation, which provide an innovative way to combat cancer. Emerging evidence suggests that ferroptosis plays an important role in the treatment of TNBC cells. Herein, a novel ferroptosis nanomedicine was prepared by loading simvastatin (SIM), a ferroptosis drug, into zwitterionic polymer coated magnetic nanoparticles (Fe3O4@PCBMA) to improve the therapeutic effect of TNBC. The as-obtained Fe3O4@PCBMA-SIM nanoparticles demonstrated more cytotoxicity against MDA-MB-231 than MCF-7 due to the higher expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), which demonstrated that statins could effectively kill TNBC. Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis. What's more, PCBMA endows Fe3O4@PCBMA longer blood circulation performance to enhance their accumulation at tumor sites. Given that Fe3O4 have proven for clinical applications by the U.S. Food and Drug Administration (FDA) and SIM could induce cancer cell ferroptosis, the developed Fe3O4@PCBMA-SIM nanosystem would have great potential in clinics for overcoming the drug resistance brought about by apoptotic drugs to cancer cells.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Xianxian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Ruihong</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Yongbin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering, Stanford University, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Men</LastName>
            <ForeName>Yongzhi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Haibao</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4587-0977</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute for Translational Brain Research, Fudan University, Shanghai, 200032, China. haibaopeng@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Wuli</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China. wlyang@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>Grant Nos. 51933002</GrantID>
            <Agency>national natural science foundation of china</Agency>
          </Grant>
          <Grant>
            <GrantID>51873041</GrantID>
            <Agency>national natural science foundation of china</Agency>
          </Grant>
          <Grant>
            <GrantID>81902756</GrantID>
            <Agency>national natural science foundation of china</Agency>
          </Grant>
          <Grant>
            <GrantID>20XD1400400</GrantID>
            <Agency>program of shanghai academic research leader</Agency>
          </Grant>
          <Grant>
            <GrantID>No. K2021-19</GrantID>
            <Agency>the open project of state key laboratory of molecular engineering of polymers</Agency>
          </Grant>
          <Grant>
            <GrantID>No.19Y1439900</GrantID>
            <Agency>shanghai sailing program</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Nanobiotechnology</MedlineTA>
        <NlmUniqueID>101152208</NlmUniqueID>
        <ISSNLinking>1477-3155</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058185">Magnetite Nanoparticles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AGG2FN16EV</RegistryNumber>
          <NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058185" MajorTopicYN="N">Magnetite Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019821" MajorTopicYN="Y">Simvastatin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Controlled release</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Long circulation</Keyword>
        <Keyword MajorTopicYN="N">Simvastatin</Keyword>
        <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>20</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34627266</ArticleId>
        <ArticleId IdType="pmc">PMC8502296</ArticleId>
        <ArticleId IdType="doi">10.1186/s12951-021-01058-1</ArticleId>
        <ArticleId IdType="pii">10.1186/s12951-021-01058-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71:209&#x2013;249. doi: 10.3322/caac.21660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21660</ArticleId>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Liu H, Li L, Guo ZY, Song J, Yang XY, Wan GY, Li RS, Wang YS. Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment. Bioact Mater. 2021;6:3865&#x2013;3878. doi: 10.1016/j.bioactmat.2021.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bioactmat.2021.04.004</ArticleId>
            <ArticleId IdType="pmc">PMC8076651</ArticleId>
            <ArticleId IdType="pubmed">33937590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC, Chai WJ, Li DQ, Bai F, Bertucci F, Hu X, Jiang YZ, Shao ZM. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33:51&#x2013;64. doi: 10.1016/j.cmet.2020.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2020.10.012</ArticleId>
            <ArticleId IdType="pubmed">33181091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714&#x2013;726. doi: 10.1038/nrc3599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3599</ArticleId>
            <ArticleId IdType="pubmed">24060863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73:2195&#x2013;2209. doi: 10.1007/s00018-016-2194-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2194-1</ArticleId>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SF, Li FY, Qiao RR, Hu X, Liao HR, Chen LM, Wu JH, Wu HB, Zhao M, Liu JN, Chen R, Ma XB, Kim D, Sun JH, Davis TP, Chen CY, Tian J, Hyeon T, Ling D. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano. 2018;12:12380&#x2013;12392. doi: 10.1021/acsnano.8b06399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06399</ArticleId>
            <ArticleId IdType="pubmed">30495919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, Wang SB, Feng J, Zhang XZ. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano. 2018;12:12181&#x2013;12192. doi: 10.1021/acsnano.8b05860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b05860</ArticleId>
            <ArticleId IdType="pubmed">30458111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An Y, Zhu JD, Liu F, Deng J, Meng X, Liu GQ, Wu HY, Fan AP, Wang Z, Zhao YJ. Boosting the ferroptotic antitumor efficacy via site-specific amplification of tailored lipid peroxidation. ACS Appl Mater Interfaces. 2019;11:29655&#x2013;29666. doi: 10.1021/acsami.9b10954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.9b10954</ArticleId>
            <ArticleId IdType="pubmed">31359759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453&#x2013;457. doi: 10.1038/nature23007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature23007</ArticleId>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li HY, Shi W, Li XH, Hu YM, Fang Y, Ma HM. Ferroptosis accompanied by &#x2022;OH generation and cytoplasmic viscosity increase revealed via dual-functional fluorescence probe. J Am Chem Soc. 2019;141:18301&#x2013;18307. doi: 10.1021/jacs.9b09722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.9b09722</ArticleId>
            <ArticleId IdType="pubmed">31644876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450&#x2013;465. doi: 10.1016/j.ccr.2013.08.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.08.020</ArticleId>
            <ArticleId IdType="pmc">PMC3931310</ArticleId>
            <ArticleId IdType="pubmed">24094812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu MY, Gai CC, Li ZHR, Ding DJ, Zheng J, Zhang WF, Lv SJ, Li WT. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019;110:3173&#x2013;3182. doi: 10.1111/cas.14181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.14181</ArticleId>
            <ArticleId IdType="pmc">PMC6778638</ArticleId>
            <ArticleId IdType="pubmed">31464035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomark Prev. 2008;17:88&#x2013;94. doi: 10.1158/1055-9965.EPI-07-0531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1055-9965.EPI-07-0531</ArticleId>
            <ArticleId IdType="pubmed">18199714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin Y, Liu L, Zhao Z, Yin L, Bauer N, Nwaeburu CC, Gladkich J, Gross W, Hackert T, Sticht C, Gretz N, Strobel O, Herr I. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Cancer Lett. 2018;426:14&#x2013;24. doi: 10.1016/j.canlet.2018.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.04.001</ArticleId>
            <ArticleId IdType="pubmed">29627496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161&#x2013;172. doi: 10.1016/j.cell.2015.01.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.01.036</ArticleId>
            <ArticleId IdType="pmc">PMC4525717</ArticleId>
            <ArticleId IdType="pubmed">25815993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu HT, Guo PY, Xie XZ, Wang Y, Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21:648&#x2013;657. doi: 10.1111/jcmm.13008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.13008</ArticleId>
            <ArticleId IdType="pmc">PMC5345622</ArticleId>
            <ArticleId IdType="pubmed">27860262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165&#x2013;176. doi: 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli JPF, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, Radmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, Forster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR, O'Donnell VB, Kagan VE, Schick JA, Conrad M. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner GJ. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem. 2000;275:28110&#x2013;28119. doi: 10.1074/jbc.M001280200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M001280200</ArticleId>
            <ArticleId IdType="pubmed">10821829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Liu B, Liu QQ, Du KK, Wang ZF, He NY. Nanomaterial-induced ferroptosis for cancer specific therapy. Coord Chem Rev. 2019;382:160&#x2013;180. doi: 10.1016/j.ccr.2018.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2018.12.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:1&#x2013;12.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang Q, Liu Y, Guo RR, Yao XX, Sung S, Pang ZQ, Yang WL. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials. 2019;192:292&#x2013;308. doi: 10.1016/j.biomaterials.2018.11.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2018.11.021</ArticleId>
            <ArticleId IdType="pubmed">30465973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Sun ZK, Deng YH, Zou Y, Li CY, Guo XH, Xiong LQ, Gao Y, Li FY, Zhao DY. Highly water-dispersible biocompatible magnetite particles with low cytotoxicity stabilized by citrate groups. Angew Chem Int Ed. 2009;48:5875&#x2013;5879. doi: 10.1002/anie.200901566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.200901566</ArticleId>
            <ArticleId IdType="pubmed">19579243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Xue H, Cao ZQ, Keefe A, Wang JN, Jiang SY. Multifunctional and degradable zwitterionic nanogels for targeted delivery, enhanced MR imaging, reduction-sensitive drug release, and renal clearance. Biomaterials. 2011;32:4604&#x2013;4608. doi: 10.1016/j.biomaterials.2011.02.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2011.02.064</ArticleId>
            <ArticleId IdType="pubmed">21453965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng SJ, Ouyang BS, Men YZ, Du Y, Cao YB, Xie RH, Pang ZQ, Shen S, Yang WL. Biodegradable zwitterionic polymer membrane coating endowing nanoparticles with ultra-long circulation and enhanced tumor photothermal therapy. Biomaterials. 2020;231:119680. doi: 10.1016/j.biomaterials.2019.119680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2019.119680</ArticleId>
            <ArticleId IdType="pubmed">31864018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Zhang YT, Yang P, Jin S, Yu M, Guo J, Wang CC. Fabrication of polymeric microgels using reflux-precipitation polymerization and its application for phosphoprotein enrichment. J Mater Chem B. 2014;2:2575&#x2013;2582. doi: 10.1039/c3tb21359e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c3tb21359e</ArticleId>
            <ArticleId IdType="pubmed">32261424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai SY, Ma YH, Chen YY, Li D, Cao J, Liu YJ, Cai MT, Xie XX, Chen YW, Luo XL. Synthesis of an amphiphilic block copolymer containing zwitterionic sulfobetaine as a novel pH-sensitive drug carrier. Polym Chem. 2014;5:1285&#x2013;1297. doi: 10.1039/C3PY01325A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C3PY01325A</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A. The spatiotemporal evolution of lymph node spread in early breast cancer. Clin Cancer Res. 2018;24:4763&#x2013;4770. doi: 10.1158/1078-0432.CCR-17-3374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-3374</ArticleId>
            <ArticleId IdType="pmc">PMC6296441</ArticleId>
            <ArticleId IdType="pubmed">29891724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Tang M. Corrigendum to PM2.5 induces ferroptosis in human endothelial cells through iron overload and redox imbalance. Environ Pollut (Barking, Essex: 1987). 2021;276:113640. doi: 10.1016/j.envpol.2019.113640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.envpol.2019.113640</ArticleId>
            <ArticleId IdType="pubmed">32241623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo SD, Yao XX, Jiang Q, Wang K, Zhang YY, Peng HB, Yang WL. Dihydroartemisinin-loaded magnetic nanoparticles for enhanced chemodynamic therapy. Front Pharmacol. 2020;11:226. doi: 10.3389/fphar.2020.00226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00226</ArticleId>
            <ArticleId IdType="pmc">PMC7076125</ArticleId>
            <ArticleId IdType="pubmed">32210814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucky SS, Idris NM, Li ZQ, Huang K, Soo KC, Zhang Y. Titania coated upconversion nanoparticles for near-infrared light triggered photodynamic therapy. ACS Nano. 2015;9:191&#x2013;205. doi: 10.1021/nn503450t.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/nn503450t</ArticleId>
            <ArticleId IdType="pubmed">25564723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011;286:11314&#x2013;11327. doi: 10.1074/jbc.M110.193714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.193714</ArticleId>
            <ArticleId IdType="pmc">PMC3064188</ArticleId>
            <ArticleId IdType="pubmed">21199873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016;2:270&#x2013;278. doi: 10.1038/cdd.2015.93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.93</ArticleId>
            <ArticleId IdType="pmc">PMC4716307</ArticleId>
            <ArticleId IdType="pubmed">26184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed JC, Pellecchia M. Ironing out cell death mechanisms. Cell. 2012;149:963&#x2013;965. doi: 10.1016/j.cell.2012.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.05.009</ArticleId>
            <ArticleId IdType="pubmed">22632964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev. 2016;116:2826&#x2013;2885. doi: 10.1021/acs.chemrev.5b00148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.chemrev.5b00148</ArticleId>
            <ArticleId IdType="pubmed">26799741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng H, Li XL, Peng Q, Wang X, Chen JP, Li YD. Monodisperse magnetic single-crystal ferrite microspheres. Angew Chem Int Ed. 2005;44:2782&#x2013;2785. doi: 10.1002/anie.200462551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.200462551</ArticleId>
            <ArticleId IdType="pubmed">15798982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao XX, Yang P, Jin ZK, Jiang Q, Guo RR, Xie RH, He QJ, Yang WL. Multifunctional nanoplatform for photoacoustic imaging-guided combined therapy enhanced by CO induced ferroptosis. Biomaterials. 2019;197:268&#x2013;283. doi: 10.1016/j.biomaterials.2019.01.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2019.01.026</ArticleId>
            <ArticleId IdType="pubmed">30677556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryu JH, Jiwpanich S, Chacko R, Bickerton S, Thayumanavan S. Surface-functionalizable polymer nanogels with facile hydrophobic guest encapsulation capabilities. J Am Chem Soc. 2010;132:8246. doi: 10.1021/ja102316a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja102316a</ArticleId>
            <ArticleId IdType="pubmed">20504022</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34593794</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>5733</StartPage>
          <MedlinePgn>5733</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">5733</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-25990-w</ELocationID>
        <Abstract>
          <AbstractText>In addition to increasing the expression of programmed death-ligand 1 (PD-L1), tumor cells can also secrete exosomal PD-L1 to suppress T cell activity. Emerging evidence has revealed that exosomal PD-L1 resists immune checkpoint blockade, and may contribute to resistance to therapy. In this scenario, suppressing the secretion of tumor-derived exosomes may aid therapy. Here, we develop an assembly of exosome inhibitor (GW4869) and ferroptosis inducer (Fe[3+]) via amphiphilic hyaluronic acid. Cooperation between the two active components in the constructed nanounit induces an anti-tumor immunoresponse to B16F10 melanoma cells and stimulates cytotoxic T lymphocytes and immunological memory. The nanounit enhances the response to PD-L1 checkpoint blockade and may represent a therapeutic strategy for enhancing the response to this therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Guohao</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Xie</LastName>
            <ForeName>Lisi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Bei</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wenxi</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ye</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Yunlu</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4023-7320</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. yldai@um.edu.mo.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. yldai@um.edu.mo.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, 999078, China. yldai@um.edu.mo.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001597">Benzylidene Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498919">Cd274 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C468773">GW 4869</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9004-61-9</RegistryNumber>
          <NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001597" MajorTopicYN="N">Benzylidene Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006820" MajorTopicYN="N">Hyaluronic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34593794</ArticleId>
        <ArticleId IdType="pmc">PMC8484261</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-021-25990-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-021-25990-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450&#x2013;461. doi: 10.1016/j.ccell.2015.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.03.001</ArticleId>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1&#x2013;mediated inhibition. Science. 2017;355:1428. doi: 10.1126/science.aaf1292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaf1292</ArticleId>
            <ArticleId IdType="pmc">PMC6286077</ArticleId>
            <ArticleId IdType="pubmed">28280247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Niel G, D&#x2019;Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 2018;19:213&#x2013;228. doi: 10.1038/nrm.2017.125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2017.125</ArticleId>
            <ArticleId IdType="pubmed">29339798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poggio M, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414&#x2013;427. doi: 10.1016/j.cell.2019.02.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.02.016</ArticleId>
            <ArticleId IdType="pmc">PMC6499401</ArticleId>
            <ArticleId IdType="pubmed">30951669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Elements of cancer immunity and the cancer&#x2013;immune set point. Nature. 2017;541:321&#x2013;330. doi: 10.1038/nature21349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature21349</ArticleId>
            <ArticleId IdType="pubmed">28102259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, et al. 1D coordination polymer nanofibers for low-temperature photothermal therapy. Adv. Mater. 2017;29:1703588. doi: 10.1002/adma.201703588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201703588</ArticleId>
            <ArticleId IdType="pubmed">28833643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014;65:185&#x2013;202. doi: 10.1146/annurev-med-092012-112807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-med-092012-112807</ArticleId>
            <ArticleId IdType="pubmed">24188664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efimova I, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer. 2020;8:2020&#x2013;001369. doi: 10.1136/jitc-2020-001369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001369</ArticleId>
            <ArticleId IdType="pmc">PMC7668384</ArticleId>
            <ArticleId IdType="pubmed">33188036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q, Liu J, Kang R, Zhou B, Tang D. The release and activity of HMGB1 in ferroptosis. Biochem Biophys. Res Commun. 2019;510:278&#x2013;283. doi: 10.1016/j.bbrc.2019.01.090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.01.090</ArticleId>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luberto C, et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 2002;277:41128&#x2013;41139. doi: 10.1074/jbc.M206747200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M206747200</ArticleId>
            <ArticleId IdType="pubmed">12154098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JL, et al. Identification of neutrophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutrophil exocytosis and inflammation: DRUGGABILITY OF THE SMALL GTPase Rab27a. J. Biol. Chem. 2016;291:25965&#x2013;25982. doi: 10.1074/jbc.M116.741884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.741884</ArticleId>
            <ArticleId IdType="pmc">PMC5207069</ArticleId>
            <ArticleId IdType="pubmed">27702998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer. 2004;4:528&#x2013;539. doi: 10.1038/nrc1391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1391</ArticleId>
            <ArticleId IdType="pubmed">15229478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eliaz RE, Szoka FC., Jr Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001;61:2592&#x2013;2601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11289136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ying WW, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 2012;11:475&#x2013;484. doi: 10.1158/1535-7163.MCT-11-0755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-11-0755</ArticleId>
            <ArticleId IdType="pubmed">22144665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al. Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy. ACS Nano. 2014;8:12250&#x2013;12258. doi: 10.1021/nn506130t.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/nn506130t</ArticleId>
            <ArticleId IdType="pubmed">25402600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao S, et al. Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy. Biomaterials. 2017;112:324&#x2013;335. doi: 10.1016/j.biomaterials.2016.10.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2016.10.030</ArticleId>
            <ArticleId IdType="pubmed">27776285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, et al. Exosomes mediate the cell-to-cell transmission of IFN-&#x3b1;-induced antiviral activity. Nat. Immunol. 2013;14:793&#x2013;803. doi: 10.1038/ni.2647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2647</ArticleId>
            <ArticleId IdType="pubmed">23832071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, et al. Advances in engineering cells for cancer immunotherapy. Theranostics. 2019;9:7889&#x2013;7905. doi: 10.7150/thno.38583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.38583</ArticleId>
            <ArticleId IdType="pmc">PMC6831467</ArticleId>
            <ArticleId IdType="pubmed">31695806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107&#x2013;125. doi: 10.1038/s41422-020-00441-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId>
            <ArticleId IdType="pmc">PMC8026611</ArticleId>
            <ArticleId IdType="pubmed">33268902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu DS, et al. Inhibiting the system xC&#x2212;/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 2017;8:14844. doi: 10.1038/ncomms14844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14844</ArticleId>
            <ArticleId IdType="pmc">PMC5379068</ArticleId>
            <ArticleId IdType="pubmed">28348409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;692. doi: 10.1038/s41586-019-1705-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1705-2</ArticleId>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat. Rev. Immunol. 2018;18:527&#x2013;535. doi: 10.1038/s41577-018-0009-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-018-0009-3</ArticleId>
            <ArticleId IdType="pubmed">29662120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braum&#xfc;ller H, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494:361&#x2013;365. doi: 10.1038/nature11824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11824</ArticleId>
            <ArticleId IdType="pubmed">23376950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382&#x2013;386. doi: 10.1038/s41586-018-0392-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0392-8</ArticleId>
            <ArticleId IdType="pmc">PMC6095740</ArticleId>
            <ArticleId IdType="pubmed">30089911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodoraki M-N, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 2018;24:896&#x2013;905. doi: 10.1158/1078-0432.CCR-17-2664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2664</ArticleId>
            <ArticleId IdType="pmc">PMC6126905</ArticleId>
            <ArticleId IdType="pubmed">29233903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu P, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl Acad. Sci. USA. 2012;109:6187&#x2013;6192. doi: 10.1073/pnas.1203479109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1203479109</ArticleId>
            <ArticleId IdType="pmc">PMC3341063</ArticleId>
            <ArticleId IdType="pubmed">22474386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crescitelli R, et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J. Extracell. Vesicles. 2020;9:1722433. doi: 10.1080/20013078.2020.1722433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/20013078.2020.1722433</ArticleId>
            <ArticleId IdType="pmc">PMC7034452</ArticleId>
            <ArticleId IdType="pubmed">32128073</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34585181</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2047-4849</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>21</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomaterials science</Title>
          <ISOAbbreviation>Biomater Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RBC-derived nanosystem with enhanced ferroptosis triggered by oxygen-boosted phototherapy for synergized tumor treatment.</ArticleTitle>
        <Pagination>
          <StartPage>7228</StartPage>
          <EndPage>7236</EndPage>
          <MedlinePgn>7228-7236</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d1bm00175b</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic and ferroptosis therapies for cancer treatment are restricted by the scarcity of oxygen and Fe in cancer cells, and the complicated structure of delivery systems. Herein, a red blood cell-derived vehicle (RDV) inherently enriched with hemoglobin co-delivers a photosensitizer, Ce6, and a ferroptosis promoter, sorafenib (SRF) into cancer cells for boosting oxygen and providing iron, which leads to enhanced PDT and stronger ferroptosis therapy. Damage to the RDV membrane under local irradation leads to SRF release at the tumor site for tumor-targeted therapy. The lipid membrane of the RDV could also improve the drug delivery efficiency in vitro and in vivo. The novel nanosystem exhibited enhanced tumor killing efficacy and improved safety compared with traditional PDT and ferroptosis therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wenjun</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Shanghai University of Medicine &amp; Health Sciences Affiliated Sixth People's Hospital South Campus/Shanghai Fengxian District Central Hospital, Shanghai 201499, China. zx12orthopaedics@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jieyuan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Shanghai Sixth People's Hospital, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Shanghai University of Medicine &amp; Health Sciences Affiliated Sixth People's Hospital South Campus/Shanghai Fengxian District Central Hospital, Shanghai 201499, China. zx12orthopaedics@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Weifeng</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Shanghai University of Medicine &amp; Health Sciences Affiliated Sixth People's Hospital South Campus/Shanghai Fengxian District Central Hospital, Shanghai 201499, China. zx12orthopaedics@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Junjie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Shanghai University of Medicine &amp; Health Sciences Affiliated Sixth People's Hospital South Campus/Shanghai Fengxian District Central Hospital, Shanghai 201499, China. zx12orthopaedics@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Haijun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Southern Medical University Affiliated Fengxian Hospital/Shanghai Fengxian District Central Hospital, China. xiaohaijun89@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jingwei</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-1083-5023</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Shanghai University of Medicine &amp; Health Sciences Affiliated Sixth People's Hospital South Campus/Shanghai Fengxian District Central Hospital, Shanghai 201499, China. zx12orthopaedics@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biomater Sci</MedlineTA>
        <NlmUniqueID>101593571</NlmUniqueID>
        <ISSNLinking>2047-4830</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>29</Day>
          <Hour>7</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34585181</ArticleId>
        <ArticleId IdType="doi">10.1039/d1bm00175b</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34549863</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-8355</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biology international</Title>
          <ISOAbbreviation>Cell Biol Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulated lytic cell death in breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>12</StartPage>
          <EndPage>33</EndPage>
          <MedlinePgn>12-33</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cbin.11705</ELocationID>
        <Abstract>
          <AbstractText>Breast cancer (BC) is a very common cancer among women and one of the primary causes of death in women worldwide. Because BC has different molecular subtypes, the challenges associated with targeted therapy have increased significantly, and the identification of new therapeutic targets has become increasingly urgent. Blocking apoptosis and inhibiting cell death are important characteristics of malignant tumours, including BC. Under adverse conditions, including exposure to antitumour therapy, inhibition of cell death programmes can promote cancerous transformation and the survival of cancer cells. Therefore, inducing cell death in cancer cells is fundamentally important and provides new opportunities for potential therapeutic interventions. Lytic forms of cell death, primarily pyroptosis, necroptosis and ferroptosis, are different from apoptosis owing to their characteristic lysis, that is, the production of cellular components, to guide beneficial immune responses, and the application of lytic cell death (LCD) in the field of tumour therapy has attracted considerable interest from researchers. The latest clinical research results confirm that lytic death signalling cascades involve the BC cell immune response and resistance to therapies used in clinical practice. In this review, we discuss the current knowledge regarding the various forms of LCD, placing a special emphasis on signalling pathways and their implications in BC, which may facilitate the development of novel and optimal strategies for the clinical treatment of BC.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 International Federation for Cell Biology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Mingcheng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lirong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Xiaojing</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-7717-8411</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yundi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Marine Resource Utilization in South China Sea, Hainan University, Haikou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Chunling</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Veterinary Medicine, Jilin University, Changchun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Mingyuan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xiaobing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Jianhe</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>College of Animal Science and Veterinary Medicine, Henan Institute of Science and Technology, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Liancheng</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>College of Veterinary Medicine, Jilin University, Changchun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>32172876</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>31972715</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>202102110101</GrantID>
            <Agency>Key Specialized Research and Development Breakthrough Program in Henan Province</Agency>
          </Grant>
          <Grant>
            <GrantID>2021HYTP038</GrantID>
            <Agency>Young Talent Lifting Project in Henan Province</Agency>
          </Grant>
          <Grant>
            <GrantID>2020GGJS163</GrantID>
            <Agency>Youth Backbone Teacher Project of Colleges and Universities of Henan Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Biol Int</MedlineTA>
        <NlmUniqueID>9307129</NlmUniqueID>
        <ISSNLinking>1065-6995</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079404" MajorTopicYN="N">Regulated Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">breast cancer</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">lytic cell death</Keyword>
        <Keyword MajorTopicYN="N">necroptosis</Keyword>
        <Keyword MajorTopicYN="N">pyroptosis</Keyword>
        <Keyword MajorTopicYN="N">targeted therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>8</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34549863</ArticleId>
        <ArticleId IdType="doi">10.1002/cbin.11705</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Adeloye, D., Sowunmi, O. Y., Jacobs, W., David, R. A., Adeosun, A. A., Amuta, A. O., Misra, S., Gadanya, M., Auta, A., Harhay, M. O., &amp; Chan, K. Y. (2018). Estimating the incidence of breast cancer in Africa: A systematic review and meta-analysis. Journal of Global Health, 8, 010419. https://doi.org/10.7189/jogh.08.010419</Citation>
        </Reference>
        <Reference>
          <Citation>Berghe, T. V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., &amp; Vandenabeele, P. (2014). Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nature Reviews Molecular Cell Biology, 15, 135-147. https://doi.org/10.1038/nrm3737</Citation>
        </Reference>
        <Reference>
          <Citation>Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., Bassik, M. C., Nomura, D. K., Dixon, S. J., &amp; Olzmann, J. A. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature, 575, 688-692. https://doi.org/10.1038/s41586-019-1705-2</Citation>
        </Reference>
        <Reference>
          <Citation>Bertrand, M. J., Milutinovic, S., Dickson, M. K., Ho, C. W., Boudreault, A., &amp; Durkin, J. (2008). cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Molecular Cell, 30, 689-700. https://doi.org/10.1016/j.molcel.2008.05.014</Citation>
        </Reference>
        <Reference>
          <Citation>Bogdan, A. R., Miyazawa, M., Hashimoto, K., &amp; Tsuji, Y. (2016). Regulators of iron homeostasis: New players in metabolism, cell death, and disease. Trends in Biochemical Sciences, 41, 274-286. https://doi.org/10.1016/j.tibs.2015.11.012</Citation>
        </Reference>
        <Reference>
          <Citation>Bozec, D., Iuga, A. C., Roda, G., Dahan, S., &amp; Yeretssian, G. (2016). Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis. Oncotarget, 7, 46384-46400. https://doi.org/10.18632/oncotarget.10135</Citation>
        </Reference>
        <Reference>
          <Citation>Broz, P., von Moltke, J., Jones, J. W., Vance, R. E., &amp; Monack, D. M. (2010). Differential Requirement for caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host &amp; Microbe, 8, 471-483. https://doi.org/10.1016/j.chom.2010.11.007</Citation>
        </Reference>
        <Reference>
          <Citation>Burgener, S. S., Leborgne, N. G. F., Snipas, S. J., Salvesen, G. S., Bird, P. I., &amp; Benarafa, C. (2019). Cathepsin G inhibition by Serpinb1 and Serpinb6 prevents programmed necrosis in neutrophils and monocytes and reduces GSDMD-driven inflammation. Cell Reports, 27, 3646-3656. https://doi.org/10.1016/j.celrep.2019.05.065</Citation>
        </Reference>
        <Reference>
          <Citation>Case, C. L., &amp; Roy, C. R. (2011). Asc modulates the function of NLRC4 in response to infection of macrophages by Legionella pneumophila. mBio, 2, e00117-11. https://doi.org/10.1128/mBio.00117-11</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, G. Y., &amp; Nunez, G. (2010). Sterile inflammation: Sensing and reacting to damage. Nature Reviews Immunology, 10, 826-837. https://doi.org/10.1038/nri2873</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, L., Lin, Z., Liu, L., Zhang, X., Shi, W., Ge, D., &amp; Sun, Y. (2019). Fe(2+)/Fe(3+) ions chelated with ultrasmall polydopamine nanoparticles induce ferroptosis for cancer therapy. ACS Biomaterials Science &amp; Engineering, 5, 4861-4869. https://doi.org/10.1021/acsbiomaterials.9b00461</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, M. S., Wang, S. F., Hsu, C. Y., Yin, P. H., Yeh, T. S., Lee, H. C., &amp; Tseng, L. M. (2017). CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2alpha-ATF4 pathway. Oncotarget, 8, 114588-114602. https://doi.org/10.18632/oncotarget.23055</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, Q., Shi, P., Wang, Y., Zou, D., Wu, X., Wang, D., Hu, Q., Zou, Y., Huang, Z., Ren, J., Lin, Z., &amp; Gao, X. (2019). GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity. Journal of Molecular Cell Biology, 11, 496-508. https://doi.org/10.1093/jmcb/mjy056</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, X., Li, W., Ren, J., Huang, D., He, W. T., Song, Y., Yang, C., Li, W., Zheng, X., Chen, P., &amp; Han, J. (2014). Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Research, 24, 105-121. https://doi.org/10.1038/cr.2013.171</Citation>
        </Reference>
        <Reference>
          <Citation>Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., &amp; Chan, F. K. (2009). Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell, 137, 1112-1123. https://doi.org/10.1016/j.cell.2009.05.037</Citation>
        </Reference>
        <Reference>
          <Citation>Conos, S. A., Chen, K. W., De Nardo, D., Hara, H., Whitehead, L., Nunez, G., Masters, S. L., Murphy, J. M., Schroder, K., Vaux, D. L., Lawlor, K. E., Lindqvist, L. M., &amp; Vince, J. E. (2017). Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proceedings of the National Academy of Sciences of the United States of America, 114, E961-E969. https://doi.org/10.1073/pnas.1613305114</Citation>
        </Reference>
        <Reference>
          <Citation>Cookson, B. T., &amp; Brennan, M. A. (2001). Pro-inflammatory programmed cell death. Trends in Microbiology, 9, 113-114. https://doi.org/10.1016/S0966-842X(00)01936-3</Citation>
        </Reference>
        <Reference>
          <Citation>Croes, L., Beyens, M., Fransen, E., Ibrahim, J., Berghe, W. V., Suls, A., Peeters, M., Pauwels, P., Camp, G. V., &amp; de Beeck, K. O. (2018). Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer. Clinical Epigenetics, 10, 51. https://doi.org/10.1186/s13148-018-0479-y</Citation>
        </Reference>
        <Reference>
          <Citation>Dinarvand, N., Khanahmad, H., Hakimian, S. M., Sheikhi, A., Rashidi, B., &amp; Pourfarzam, M. (2020). Evaluation of long-chain acyl-coenzyme A synthetase 4 (ACSL4) expression in human breast cancer. Research in Pharmaceutical Sciences, 15, 48-56. https://doi.org/10.4103/1735-5362.278714</Citation>
        </Reference>
        <Reference>
          <Citation>Ding, J. J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J. J., Sun, H., Wang, D., &amp; Shao, F. (2016). Pore-forming activity and structural autoinhibition of the gasdermin family. Nature, 540, 111-116. https://doi.org/10.1038/nature18590</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B. III, &amp; Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149, 1060-1072. https://doi.org/10.1016/j.cell.2012.03.042</Citation>
        </Reference>
        <Reference>
          <Citation>Doll, S., &amp; Conrad, M. (2017). Iron and ferroptosis: A still ill-defined liaison. IUBMB Life, 69, 423-434. https://doi.org/10.1002/iub.1616</Citation>
        </Reference>
        <Reference>
          <Citation>Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Grocin, A. G., da Silva, T. N. X., Panzilius, E., Scheel, C. H., Mour&#xe3;o, A., Buday, K., Sato, M., Wanninger, J., Vignane, T., Mohana, V., Rehberg, M., Flatley, A., Schepers, A., &#x2026; Conrad, M. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature, 575, 693-698. https://doi.org/10.1038/s41586-019-1707-0</Citation>
        </Reference>
        <Reference>
          <Citation>Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., Prokisch, H., Tr&#xfc;mbach, D., Mao, G., Qu, F., Bayir, H., F&#xfc;llekrug, J., Scheel, C. H., Wurst, W., Schick, J. A., &#x2026; Conrad, M. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nature Chemical Biology, 13, 91-98. https://doi.org/10.1038/nchembio.2239</Citation>
        </Reference>
        <Reference>
          <Citation>Dondelinger, Y., Declercq, W., Montessuit, S., Roelandt, R., Goncalves, A., Bruggeman, I., Hulpiau, P., Weber, K., Sehon, C. A., Marquis, R. W., Bertin, J., Gough, P. J., Savvides, S., Martinou, J., Bertrand, M. J. M., &amp; Vandenabeele, P. (2014). MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Reports, 7, 971-981. https://doi.org/10.1016/j.celrep.2014.04.026</Citation>
        </Reference>
        <Reference>
          <Citation>Dovey, C. M., Diep, J., Clarke, B. P., Hale, A. T., McNamara, D. E., Guo, H., Brown, N. W. Jr., Cao, J. Y., Grace, C. R., Gough, P. J., Bertin, J., Dixon, S. J., Fiedler, D., Mocarski, E. S., Kaiser, W. J., Moldoveanu, T., York, J. D., &amp; Carette, J. E. (2018). MLKL requires the inositol phosphate code to execute necroptosis. Molecular Cell, 70, 936-948. https://doi.org/10.1016/j.molcel.2018.05.010</Citation>
        </Reference>
        <Reference>
          <Citation>Draganov, D., Gopalakrishna-Pillai, S., Chen, Y.-R., Zuckerman, N., Moeller, S., Wang, C., Ann, D., &amp; Lee, P. P. (2015). Modulation of P2X4/P2X7/pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Scientific Reports, 5, 16222. https://doi.org/10.1038/srep16222</Citation>
        </Reference>
        <Reference>
          <Citation>Eguchi, A., Wree, A., &amp; Feldstein, A. E. (2014). Biomarkers of liver cell death. Journal of Hepatology, 60, 1063-1074. https://doi.org/10.1016/j.jhep.2013.12.026</Citation>
        </Reference>
        <Reference>
          <Citation>Fan, J. X., Deng, R. H., Wang, H., Liu, X. H., Wang, X. N., Qin, R., Jin, X., Lei, T., Zheng, D., Zhou, P., Sun, Y., &amp; Zhang, X. (2019). Epigenetics-based tumor cells pyroptosis for enhancing the immunological effect of chemotherapeutic nanocarriers. Nano Letters, 19, 8049-8058. https://doi.org/10.1021/acs.nanolett.9b03245</Citation>
        </Reference>
        <Reference>
          <Citation>Feng, S., Fox, D., &amp; Man, S. M. (2018). Mechanisms of gasdermin family members in inflammasome signaling and cell death. Journal of Molecular Biology, 430, 3068-3080. https://doi.org/10.1016/j.jmb.2018.07.002</Citation>
        </Reference>
        <Reference>
          <Citation>Fink, S. L., &amp; Cookson, B. T. (2005). Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infection and Immunity, 73, 1907-1916. https://doi.org/10.1128/IAI.73.4.1907-1916.2005</Citation>
        </Reference>
        <Reference>
          <Citation>Flamme, M., Cressey, P. B., Lu, C., Bruno, P. M., Eskandari, A., Hemann, M. T., Hogarth, G., &amp; Suntharalingam, K. (2017). Induction of necroptosis in cancer stem cells using a nickel(II)dithiocarbamate phenanthroline complex. Chemistry-a European Journal, 23, 9674-9682. https://doi.org/10.1002/chem.201701837</Citation>
        </Reference>
        <Reference>
          <Citation>Forcina, G. C., &amp; Dixon, S. J. (2019). GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics, 19, 1800311. https://doi.org/10.1002/pmic.201800311</Citation>
        </Reference>
        <Reference>
          <Citation>Frank, D., &amp; Vince, J. E. (2019). Pyroptosis versus necroptosis: Similarities, differences, and crosstalk. Cell Death and Differentiation, 26, 99-114. https://doi.org/10.1038/s41418-018-0212-6</Citation>
        </Reference>
        <Reference>
          <Citation>Fritsch, M., Gunther, S. D., Schwarzer, R., Albert, M. C., Schorn, F., Werthenbach, J. P., Schiffmann, L. M., Stair, N., Stocks, H., Seeger, J. M., Lamkanfi, M., Kr&#xf6;nke, M., Pasparakis, M., &amp; Kashkar, H. (2019). Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature, 575, 683-687. https://doi.org/10.1038/s41586-019-1770-6</Citation>
        </Reference>
        <Reference>
          <Citation>Fujikane, T., Nishikawa, N., Toyota, M., Suzuki, H., Nojima, M., Maruyama, R., Ashida, M., Ohe-Toyota, M., Kai, M., Nishidate, T., Sasaki, Y., Ohmura, T., Hirata, K., &amp; Tokino, T. (2010). Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Research and Treatment, 122, 699-710. https://doi.org/10.1007/s10549-009-0600-1</Citation>
        </Reference>
        <Reference>
          <Citation>Fulda, S. (2014). Therapeutic exploitation of necroptosis for cancer therapy. Seminars in Cell and Developmental Biology, 35, 51-56. https://doi.org/10.1146/annurev-pathol-052016-100247</Citation>
        </Reference>
        <Reference>
          <Citation>Galluzzi, L., Kepp, O., Chan, F. K., &amp; Kroemer, G. (2017). Necroptosis: Mechanisms and relevance to disease. Annual Review of Pathology, 12, 103-130. https://doi.org/10.1146/annurev-pathol-052016-100247</Citation>
        </Reference>
        <Reference>
          <Citation>Galluzzi, L., Vanden Berghe, T., Vanlangenakker, N., Buettner, S., Eisenberg, T., Vandenabeele, P., Madeo, F., &amp; Kroemer, G. (2011). Programmed necrosis from molecules to health and disease. International Review of Cell and Molecular Biology, 289, 1-35. 10.10.1016/B978-0-12-386039-2.00001-8</Citation>
        </Reference>
        <Reference>
          <Citation>Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., Annicchiarico-Petruzzelli, M., Antonov, A. V., Arama, E., Baehrecke, E. H., Barlev, N. A., Bazan, N. G., Bernassola, F., Bertrand, M., Bianchi, K., &#x2026; Turk, B. (2018). Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 25, 486-541. https://doi.org/10.1038/s41418-017-0012-4</Citation>
        </Reference>
        <Reference>
          <Citation>Gao, M. H., Monian, P., Pan, Q. H., Zhang, W., Xiang, J., &amp; Jiang, X. J. (2016). Ferroptosis is an autophagic cell death process. Cell Research, 26, 1021-1032. https://doi.org/10.1038/cr.2016.95</Citation>
        </Reference>
        <Reference>
          <Citation>Gautheron, J., Gores, G. J., &amp; Rodrigues, C. M. P. (2020). Lytic cell death in metabolic liver disease. Journal of Hepatology, 73, 394-408. https://doi.org/10.1016/j.jhep.2020.04.001</Citation>
        </Reference>
        <Reference>
          <Citation>Gillet, J. P., &amp; Gottesman, M. M. (2010). Mechanisms of multidrug resistance in cancer. Methods in Molecular Biology, 596, 47-76. https://doi.org/10.1007/978-1-60761-416-6_4</Citation>
        </Reference>
        <Reference>
          <Citation>Gordon, R. R., &amp; Nelson, P. S. (2012). Cellular senescence and cancer chemotherapy resistance. Drug Resistance Updates, 15, 123-131. https://doi.org/10.1016/j.drup.2012.01.002</Citation>
        </Reference>
        <Reference>
          <Citation>Guo, B., Fu, S., Zhang, J., Liu, B., &amp; Li, Z. (2016). Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Scientific Reports, 6, 36107. https://doi.org/10.1038/srep36107</Citation>
        </Reference>
        <Reference>
          <Citation>Guo, H., Gilley, R. P., Fisher, A., Lane, R., Landsteiner, V. J., Ragan, K. B., Dovey, C. M., Carette, J. E., Upton, J. W., Mocarski, E. S., &amp; Kaiser, W. J. (2018). Species-independent contribution of ZBP1/DAI/DLM-1-triggered necroptosis in host defense against HSV1. Cell Death &amp; Disease, 9, 816. https://doi.org/10.1038/s41419-018-0868-3</Citation>
        </Reference>
        <Reference>
          <Citation>Gutierrez, K. D., Davis, M. A., Daniels, B. P., Olsen, T. M., Ralli-Jain, P., Tait, S. W., M. G. Jr., Oberst, A. (2017). MLKL activation triggers NLRP3-mediated processing and release of IL-1beta independently of gasdermin-D. Journal of Immunology, 198, 2156-2164. https://doi.org/10.4049/jimmunol.1601757</Citation>
        </Reference>
        <Reference>
          <Citation>Han, J. H., Zhong, C. Q., &amp; Zhang, D. W. (2011). Programmed necrosis: Backup to and competitor with apoptosis in the immune system. Nature Immunology, 12, 1143-1149. https://doi.org/10.1038/ni.2159</Citation>
        </Reference>
        <Reference>
          <Citation>Han, W., Li, L., Qiu, S., Lu, Q., Pan, Q., Gu, Y., Luo, J., &amp; Hu, X. (2007). Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Molecular Cancer Therapeutics, 6, 1641-1649. https://doi.org/10.1158/1535-7163.MCT-06-0511</Citation>
        </Reference>
        <Reference>
          <Citation>Hanahan, D., &amp; Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013</Citation>
        </Reference>
        <Reference>
          <Citation>Hanggi, K., Vasilikos, L., Valls, A. F., Yerbes, R., Knop, J., Spilgies, L. M., Rieck, K., Misra, T., Bertin, J., Gough, P. J., Schmidt, T., de Almod&#xf2;var, C. R., &amp; Wong, W. W. (2017). RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function. Cell Death &amp; Disease, 8, e2588. https://doi.org/10.1038/cddis.2017.20</Citation>
        </Reference>
        <Reference>
          <Citation>Hao, S., Liang, B., Huang, Q., Dong, S., Wu, Z., He, W., &amp; Shi, M. (2018). Metabolic networks in ferroptosis. Oncology Letters, 15, 5405-5411. https://doi.org/10.3892/ol.2018.8066</Citation>
        </Reference>
        <Reference>
          <Citation>Harbeck, N., &amp; Gnant, M. (2017). Breast cancer. Lancet, 389, 1134-1150. https://doi.org/10.1016/S0140-6736(16)31891-8</Citation>
        </Reference>
        <Reference>
          <Citation>Hartman, M. L., &amp; Czyz, M. (2012). Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: From theory to potential cancer therapy. Anti-Cancer Agents in Medicinal Chemistry, 12, 966-981. https://doi.org/10.2174/187152012802650084</Citation>
        </Reference>
        <Reference>
          <Citation>Hasegawa, M., Takahashi, H., Rajabi, H., Alam, M., Suzuki, Y., Yin, L., Tagde, A., Maeda, T., Hiraki, M., Sukhatme, V. P., &amp; Kufe, D. (2016). Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget, 7, 11756-11769. https://doi.org/10.18632/oncotarget.7598</Citation>
        </Reference>
        <Reference>
          <Citation>Hayano, M., Yang, W. S., Corn, C. K., Pagano, N. C., &amp; Stockwell, B. R. (2016). Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death and Differentiation, 23, 270-278. https://doi.org/10.1038/cdd.2015.93</Citation>
        </Reference>
        <Reference>
          <Citation>He, S., Jiang, Y., Li, J., &amp; Pu, K. (2020). Semiconducting polycomplex nanoparticles for photothermal ferrotherapy of cancer. Angewandte Chemie-International Edition in English, 59, 10633-10638. https://doi.org/10.1002/ange.202003004</Citation>
        </Reference>
        <Reference>
          <Citation>He, S. D., Liang, Y. Q., Shao, F., &amp; Wang, X. D. (2011). Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proceedings of the National Academy of Sciences of the United States of America, 108, 20054-20059. https://doi.org/10.1073/pnas.1116302108</Citation>
        </Reference>
        <Reference>
          <Citation>He, Y. J., Liu, X. Y., Xing, L., Wan, X., Chang, X., &amp; Jiang, H. L. (2020). Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials, 241, 119911. https://doi.org/10.1016/j.biomaterials.2020.119911</Citation>
        </Reference>
        <Reference>
          <Citation>Hergueta-Redondo, M., Sarrio, D., Molina-Crespo, A., Vicario, R., Bernado-Morales, C., Martinez, L., Rojo-Sebasti&#xe1;n, A., Serra-Musach, J., Mota, A., Mart&#xed;nez-Ram&#xed;rez, A., Castilla, M. A., Gonz&#xe1;lez-Martin, A., Pernas, S., Cano, A., Cortes, J., Nuciforo, P. G., Peg, V., Palacios, J., Pujana, M. A., &#x2026; Moreno-Bueno, G. (2016). Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget, 7, 56295-56308. https://doi.org/10.18632/oncotarget.10787</Citation>
        </Reference>
        <Reference>
          <Citation>Hillegass, J. M., Miller, J. M., MacPherson, M. B., Westbom, C. M., Sayan, M., Thompson, J. K., Macura, S. L., Perkins, T. N., Beuschel, S. L., Alexeeva, V., Pass, H. I., Steele, C., Mossman, B. T., &amp; Shukla, A. (2013). Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Particle and Fibre Toxicology, 10, 39. https://doi.org/10.1186/1743-8977-10-39</Citation>
        </Reference>
        <Reference>
          <Citation>Holohan, C., Van Schaeybroeck, S., Longley, D. B., &amp; Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13, 714-726. https://doi.org/10.1038/nrc3599</Citation>
        </Reference>
        <Reference>
          <Citation>Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M. T., Zeh, H. J., Kang, R., &amp; Tang, D. (2016). Autophagy promotes ferroptosis by degradation of ferritin. Autophagy, 12, 1425-1428. https://doi.org/10.1080/15548627.2016.1187366</Citation>
        </Reference>
        <Reference>
          <Citation>Huang, D., Zheng, X., Wang, Z. A., Chen, X., He, W. T., Zhang, Y., Xu, J., Zhao, H., Shi, W., Wang, X., Zhu, Y., &amp; Han, J. (2017). The MLKL channel in necroptosis is an octamer formed by tetramers in a dyadic process. Molecular and Cellular Biology, 37, e00497-16. https://doi.org/10.1128/MCB.00497-16</Citation>
        </Reference>
        <Reference>
          <Citation>Huo, M., Wang, L., Wang, Y., Chen, Y., &amp; Shi, J. (2019). Nanocatalytic tumor therapy by single-atom catalysts. ACS Nano, 13, 2643-2653. https://doi.org/10.1021/acsnano.9b00457</Citation>
        </Reference>
        <Reference>
          <Citation>Iozzo, R. V. (1999). The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. Journal of Biological Chemistry, 274, 18843-18846. https://doi.org/10.1074/jbc.274.27.18843</Citation>
        </Reference>
        <Reference>
          <Citation>Jacobsen, A. V., Lowes, K. N., Tanzer, M. C., Lucet, I. S., Hildebrand, J. M., Petrie, E. J., van Delft, M. F., Liu, Z., Conos, S. A., Zhang, J., Huang, D. C. S., Silke, J., Lessene, G., &amp; Murphy, J. M. (2016). HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. Cell Death &amp; Disease, 7, e2051. https://doi.org/10.1038/cddis.2015.386</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang, Q., Wang, K., Zhang, X., Ouyang, B., Liu, H., Pang, Z., &amp; Yang, W. (2020). Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small, 16, e2001704. https://doi.org/10.1002/smll.202001704</Citation>
        </Reference>
        <Reference>
          <Citation>Jiao, D., Cai, Z., Choksi, S., Ma, D., Choe, M., Kwon, H. J., Baik, J. Y., Rowan, B. G., Liu, C., &amp; Liu, Z. (2018). Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis. Cell Research, 28, 868-870. https://doi.org/10.1038/s41422-018-0058-y</Citation>
        </Reference>
        <Reference>
          <Citation>Kagan, V. E., Mao, G. W., Qu, F., Angeli, J. P. F., Doll, S., St Croix, C., Dar, H. H., Liu, B., Tyurin, V. A., Ritov, V. B., Kapralov, A. A., Amoscato, A. A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S. &#x2026; Bay&#x131;r, H. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology, 13, 81-90. https://doi.org/10.1038/nchembio.2238</Citation>
        </Reference>
        <Reference>
          <Citation>Kaiser, W. J., Sridharan, H., Huang, C., Mandal, P., Upton, J. W., Gough, P. J., Sehon, C. A., Marquis, R. W., Bertin, J., &amp; Mocarski, E. S. (2013). Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. Journal of Biological Chemistry, 288, 31268-31279. https://doi.org/10.1074/jbc.M113.462341</Citation>
        </Reference>
        <Reference>
          <Citation>Kambara, H., Liu, F., Zhang, X., Liu, P., Bajrami, B., Teng, Y., Zhao, L., Zhou, S., Yu, H., Zhou, W., Silberstein, L. E., Cheng, T., Han, M., Xu, Y., &amp; Luo, H. R. (2018). Gasdermin D exerts anti-inflammatory effects by promoting neutrophil death. Cell Reports, 22, 2924-2936. https://doi.org/10.2139/ssrn.3155714</Citation>
        </Reference>
        <Reference>
          <Citation>Khaw-On, P., Pompimon, W., &amp; Banjerdpongchai, R. (2019). Goniothalamin induces necroptosis and anoikis in human invasive breast cancer MDA-MB-231 cells. International Journal of Molecular Sciences, 20, 3953. https://doi.org/10.3390/ijms20163953</Citation>
        </Reference>
        <Reference>
          <Citation>Khorsandi, L., Orazizadeh, M., Niazvand, F., Abbaspour, M. R., Mansouri, E., &amp; Khodadadi, A. (2017). Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. Bratislavsk&#xe9; Lek&#xe1;rske Listy, 118, 123-128. https://doi.org/10.4149/BLL_2017_025</Citation>
        </Reference>
        <Reference>
          <Citation>Kim, M. S., Lebron, C., Nagpal, J. K., Chae, Y. K., Chang, X., Huang, Y., Chuang, T., Yamashita, K., Trink, B., Ratovitski, E. A., Califano, J. A., &amp; Sidransky, D. (2008). Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochemical and Biophysical Research Communications, 370, 38-43. https://doi.org/10.1016/j.bbrc.2008.03.026</Citation>
        </Reference>
        <Reference>
          <Citation>Koehler, H., Cotsmire, S., Langland, J., Kibler, K. V., Kalman, D., Upton, J. W., Mocarski, E. S., &amp; Jacobs, B. L. (2017). Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3. Proceedings of the National Academy of Sciences of the United States of America, 114, 11506-11511. https://doi.org/10.1073/pnas.1700999114</Citation>
        </Reference>
        <Reference>
          <Citation>Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., Fuentes-Mattei, E., Ellies, L. G., Knudson, C. M., Lee, M., Yeung, S. J., Cassel, S. L., Sutterwala, F. S., &amp; Zhang, W. (2016). Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. Nature Communications, 7, 13007. https://doi.org/10.1038/ncomms13007</Citation>
        </Reference>
        <Reference>
          <Citation>Koo, G. B., Morgan, M. J., Lee, D. G., Kim, W. J., Yoon, J. H., Koo, J. S., Kim, S. I., Kim, S. J., Son, M. K., Hong, S. S., Levy, J. M. M., Pollyea, D. A., Jordan, C. T., Yan, P., Frankhouser, D., Nicolet, D., Maharry, K., Marcucci, G., Choi, K. S., &#x2026; Kim, Y. (2015). Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Research, 25, 707-725. https://doi.org/10.1038/cr.2015.56</Citation>
        </Reference>
        <Reference>
          <Citation>Kovacs, S. B., &amp; Miao, E. A. (2017). Gasdermins: Effectors of pyroptosis. Trends in Cell Biology, 27, 673-684. https://doi.org/10.1016/j.tcb.2017.05.005</Citation>
        </Reference>
        <Reference>
          <Citation>Kreuzaler, P., &amp; Watson, C. J. (2012). Killing a cancer: What are the alternatives? Nature Reviews Cancer, 12, 411-424. https://doi.org/10.1038/nrc3264</Citation>
        </Reference>
        <Reference>
          <Citation>Kryukov, G. V., Castellano, S., Novoselov, S. V., Lobanov, A. V., Zehtab, O., Guigo, R., &amp; Gladyshev, N. V. (2003). Characterization of mammalian selenoproteomes. Science, 300, 1439-1443.</Citation>
        </Reference>
        <Reference>
          <Citation>Kuriakose, T., Man, S. M., Malireddi, R. K. S., Karki, R., Kesavardhana, S., Place, D. E., Neale, G., Vogel, P., &amp; Kanneganti, T. (2016). ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Science Immunology, 1, aag2045. https://doi.org/10.1126/sciimmunol.aag2045</Citation>
        </Reference>
        <Reference>
          <Citation>Li, X., Guo, J., Ding, A. P., Qi, W. W., Zhang, P. H., Lv, J., Qiu, W., &amp; Sun, Z. (2017). Association of mixed lineage kinase domain-like protein expression with prognosis in patients with colon cancer. Technology in Cancer Research &amp; Treatment, 16, 428-434. https://doi.org/10.1177/1533034616655909</Citation>
        </Reference>
        <Reference>
          <Citation>Li, Y., Tian, X., Liu, X., &amp; Gong, P. (2018). Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways. Carcinogenesis, 39, 700-707. https://doi.org/10.1093/carcin/bgy039</Citation>
        </Reference>
        <Reference>
          <Citation>Lin, Y. S., Shen, Y. C., Wu, C. Y., Tsai, Y. Y., Yang, Y. H., Lin, Y. Y., Kuan, F., Lu, C., Chang, G., Tsai, M., Hsu, C., Yeh, R., Yang, P., Lee, I., Shu, L., Cheng, Y., Liu, H., Wu, Y., Wu, Y., &amp; Chang, D. (2019). Danshen improves survival of patients with breast cancer and dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells. Frontiers in Pharmacology, 10, 1226. https://doi.org/10.3389/fphar.2019.01226</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, S., Liu, H., Johnston, A., Hanna-Addams, S., Reynoso, E., Xiang, Y., &amp; Wang, Z. (2017). MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis. Proceedings of the National Academy of Sciences of the United States of America, 114, E7450-E7459. https://doi.org/10.1073/pnas.1707531114</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, S. Z., Chen, Q., Quan, P. L., Zhang, M., Zhang, S. K., Guo, L. W., Sun, X., &amp; Wang, C. (2016). Cancer incidence and mortality in Henan province, 2012. Chinese Journal of Cancer Research, 28, 275-285. https://doi.org/10.21147/j.issn.1000-9604.2016.03.02</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, T., Liu, W., Zhang, M., Yu, W., Gao, F., Li, C., Wang, S., Feng, J., &amp; Zhang, X. (2018). Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano, 12, 12181-12192. https://doi.org/10.1021/acsnano.8b05860</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, X., Zhou, M., Mei, L., Ruan, J., Hu, Q., Peng, J., Su, H., Liao, H., Liu, S., Liu, W., Wang, H., Huang, Q., Li, F., &amp; Li, C. (2016). Key roles of necroptotic factors in promoting tumor growth. Oncotarget, 7, 22219-22233. https://doi.org/10.18632/oncotarget.7924</Citation>
        </Reference>
        <Reference>
          <Citation>Llabani, E., Hicklin, R. W., Lee, H. Y., Motika, S. E., Crawford, L. A., Weerapana, E., &amp; Hergenrother, P. J. (2019). Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis. Nature Chemistry, 11, 521-532. https://doi.org/10.1038/s41557-019-0261-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma, S., Dielschneider, R. F., Henson, E. S., Xiao, W., Choquette, T. R., Blankstein, A. R., Chen, Y., &amp; Gibson, S. B. (2017). Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One, 12, e0182921. https://doi.org/10.1371/journal.pone.0182921</Citation>
        </Reference>
        <Reference>
          <Citation>Maelfait, J., Liverpool, L., Bridgeman, A., Ragan, K. B., Upton, J. W., &amp; Rehwinkel, J. (2017). Sensing of viral and endogenous RNA by ZBP1/DAI induces necroptosis. EMBO Journal, 36, 2529-2543. https://doi.org/10.15252/embj.201796476</Citation>
        </Reference>
        <Reference>
          <Citation>Mai, T. T., Hamai, A., Hienzsch, A., Caneque, T., Muller, S., Wicinski, J., Cabaud, O., Leroy, C., David, A., Acevedo, V., Ryo, A., Ginestier, C., Birnbaum, D., Charafe-Jauffret, E., Codogno, P., Mehrpour, M., &amp; Rodriguez, R. (2017). Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nature Chemistry, 9, 1025-1033. https://doi.org/10.1038/nchem.2778</Citation>
        </Reference>
        <Reference>
          <Citation>Mancias, J. D., Wang, X., Gygi, S. P., Harper, J. W., &amp; Kimmelman, A. C. (2014). Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature, 509, 105-109. https://doi.org/10.1038/nature13148</Citation>
        </Reference>
        <Reference>
          <Citation>Mansur, A. A. P., Mansur, H. S., Leonel, A. G., Carvalho, I. C., Lage, M. C. G., Carvalho, S. M., Krambrock, K., &amp; Lobato, Z. I. P. (2020). Supramolecular magnetonanohybrids for multimodal targeted therapy of triple-negative breast cancer cells. Journal of Materials Chemistry B: Materials for Biology and Medicine, 8, 7166-7188. https://doi.org/10.1039/D0TB01175D</Citation>
        </Reference>
        <Reference>
          <Citation>Martinon, F., Burns, K., &amp; Tschopp, J. (2002). The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell, 10, 417-426. https://doi.org/10.1016/S1097-2765(02)00599-3</Citation>
        </Reference>
        <Reference>
          <Citation>Masuda, Y., Futamura, M., Kamino, H., Nakamura, Y., Kitamura, N., Ohnishi, S., Miyamoto, Y., Ichikawa, H., Ohta, T., Ohki, M., Kiyono, T., Egami, H., Baba, H., &amp; Arakawa, H. (2006). The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage. Journal of Human Genetics, 51, 652-664. https://doi.org/10.1007/s10038-006-0004-6</Citation>
        </Reference>
        <Reference>
          <Citation>Mbaveng, A. T., Bitchagno, G. T. M., Kuete, V., Tane, P., &amp; Efferth, T. (2019). Cytotoxicity of ungeremine towards multi-factorial drug resistant cancer cells and induction of apoptosis, ferroptosis, necroptosis and autophagy. Phytomedicine, 60, 152832. https://doi.org/10.1016/j.phymed.2019.152832</Citation>
        </Reference>
        <Reference>
          <Citation>McAnena, P. F., McGuire, A., Ramli, A., Curran, C., Malone, C., McLaughlin, R., Barry, K., Brown, J. A. L., &amp; Kerin, M. J. (2018). Breast cancer subtype discordance: Impact on post-recurrence survival and potential treatment options. BMC Cancer, 18, 203. https://doi.org/10.1186/s12885-018-4101-7</Citation>
        </Reference>
        <Reference>
          <Citation>Mitra, S., &amp; Dash, R. (2018). Natural products for the management and prevention of breast cancer. Evidence-Based Complementary and Alternative Medicine, 2018, 8324696. https://doi.org/10.1155/2018/8324696</Citation>
        </Reference>
        <Reference>
          <Citation>Molina-Crespo, A., Cadete, A., Sarrio, D., Gamez-Chiachio, M., Martinez, L., Chao, K., Olivera, A., Gonella, A., D&#xed;az, E., Palacios, J., Dhal, P. K., Besev, M., Rodr&#xed;guez-Serrano, M., Bermejo, M. L. G., Trivi&#xf1;o, J. C., Cano, A., Garc&#xed;a-Fuentes, M., Herzberg, O., Torres, D., &#x2026; Moreno-Bueno, G. (2019). Intracellular delivery of an antibody targeting gasdermin-B reduces HER2 breast cancer aggressiveness. Clinical Cancer Research, 25, 4846-4858. https://doi.org/10.1158/1078-0432.CCR-18-2381</Citation>
        </Reference>
        <Reference>
          <Citation>Moriwaki, K., Bertin, J., Gough, P. J., Orlowski, G. M., &amp; Chan, F. K. (2015). Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death &amp; Disease, 6, e1636. https://doi.org/10.1038/cddis.2015.16</Citation>
        </Reference>
        <Reference>
          <Citation>Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., &amp; Li, B. (2019). Ferroptosis, a new form of cell death: Opportunities and challenges in cancer. Journal of Hematology &amp; Oncology, 12, 34. https://doi.org/10.1186/s13045-019-0720-y</Citation>
        </Reference>
        <Reference>
          <Citation>Murphy, J. M., Czabotar, P. E., Hildebrand, J. M., Lucet, I. S., Zhang, J. G., Alvarez-Diaz, S., Lewis, R., Lalaoui, N., Metcalf, D., Webb, A. I., Young, S. N., Varghese, L. N., Tannahill, G. M., Hatchell, E. C., Majewski, I. J., Okamoto, T., Dobson, R. C. J., Hilton, D. J., Babon, J. J., &#x2026; Alexander, W. S. (2013). The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity, 39, 443-453. https://doi.org/10.1016/j.immuni.2013.06.018</Citation>
        </Reference>
        <Reference>
          <Citation>Nagpal, A., Redvers, R. P., Ling, X., Ayton, S., Fuentes, M., Tavancheh, E., Diala, I., Lalani, A., Loi, S., David, S., Anderson, R. L., Smith, Y., Merino, D., Denoyer, D., &amp; Pouliot, N. (2019). Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis. Breast Cancer Research, 21, 94. https://doi.org/10.1186/s13058-019-1177-1</Citation>
        </Reference>
        <Reference>
          <Citation>Naito, M. G., Xu, D., Amin, P., Lee, J., Wang, H., Li, W., Kelliher, M., Pasparakis, M., &amp; Yuan, J. (2020). Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke. Proceedings of the National Academy of Sciences of the United States of America, 117, 4959-4970. https://doi.org/10.1073/pnas.1916427117</Citation>
        </Reference>
        <Reference>
          <Citation>Najjar, M., Saleh, D., Zelic, M., Nogusa, S., Shah, S., Tai, A., Finger, J. N., Polykratis, A., Gough, P. J., Bertin, J., Whalen, M., Pasparakis, M., Balachandran, S., Kelliher, M., Poltorak, A., &amp; Degterev, A. (2016). RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4. Immunity, 45, 46-59. https://doi.org/10.1016/j.immuni.2016.06.007</Citation>
        </Reference>
        <Reference>
          <Citation>Newton, K., Hildebrand, J. M., Shen, Z., Rodriguez, D., Alvarez-Diaz, S., Petersen, S., Shah, S., Dugger, D. L., Huang, C., Auwerx, J., Vandenabeele, P., Green, D. R., Ashkenazi, A., Dixit, V. M., Kaiser, W. J., Strasser, A., Degterev, A., &amp; Silke, J. (2014). Is SIRT2 required for necroptosis? Nature, 506, E4-E6. https://doi.org/10.1038/nature13024</Citation>
        </Reference>
        <Reference>
          <Citation>Novohradsky, V., Markova, L., Kostrhunova, H., Travnicek, Z., Brabec, V., &amp; Kasparkova, J. (2019). An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis. Scientific Reports, 9, 13327. https://doi.org/10.1038/s41598-019-49774-x</Citation>
        </Reference>
        <Reference>
          <Citation>Orlando, U. D., Castillo, A. F., Medrano, M. A. R., Solano, A. R., Maloberti, P. M., &amp; Podesta, E. J. (2019). Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Biochemical Pharmacology, 159, 52-63. https://doi.org/10.1016/j.bcp.2018.11.005</Citation>
        </Reference>
        <Reference>
          <Citation>Orning, P., Weng, D., Starheim, K., Ratner, D., Best, Z., Lee, B., Brooks, A., Xia, S., Wu, H., Kelliher, M. A., Berger, S. B., Gough, P. J., Bertin, J., Proulx, M. M., Goguen, J. D., Kayagaki, N., Fitzgerald, K. A., &amp; Lien, E. (2018). Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science, 362, 1064-1069. https://doi.org/10.1126/science.aau2818</Citation>
        </Reference>
        <Reference>
          <Citation>Orozco, S., Yatim, N., Werner, M. R., Tran, H., Gunja, S. Y., Tait, S. W. G., Albert, M. L., Green, D. R., &amp; Oberst, A. (2014). RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis. Cell Death and Differentiation, 21, 1511-1521. https://doi.org/10.1038/cdd.2014.76</Citation>
        </Reference>
        <Reference>
          <Citation>Panganiban, R. A., Sun, M., Dahlin, A., Park, H. R., Kan, M., Himes, B. E., Mitchel, J. A., Iribarren, C., Jorgenson, E., Randell, S. H., Israel, E., Tantisira, K., Shore, S., Park, J., Weiss, S. T., Wu, A. C., &amp; Lu, Q. (2018). A functional splice variant associated with decreased asthma risk abolishes the ability of gasdermin B to induce epithelial cell pyroptosis. Journal of Allergy and Clinical Immunology, 142, 1469-1478. https://doi.org/10.1016/j.jaci.2017.11.040</Citation>
        </Reference>
        <Reference>
          <Citation>Pawlikowska, M., Jedrzejewski, T., Brozyna, A. A., &amp; Wrotek, S. (2020). Protein-bound polysaccharides from Coriolus versicolor induce RIPK1/RIPK3/MLKL-mediated necroptosis in ER-positive breast cancer and amelanotic melanoma cells. Cellular Physiology and Biochemistry, 54, 591-604. https://doi.org/10.33594/000000242</Citation>
        </Reference>
        <Reference>
          <Citation>Pedrera, L., Espiritu, R. A., Ros, U., Weber, J., Schmitt, A., Stroh, J., Hailfinger, S., von Karstedt, S., &amp; Garc&#xed;a-S&#xe1;ez, A. J. (2020). Ferroptotic pores induce Ca(2+) fluxes and ESCRT-III activation to modulate cell death kinetics. Cell Death and Differentiation, 28, 1644-1657. https://doi.org/10.1101/867564</Citation>
        </Reference>
        <Reference>
          <Citation>Perez, M. A., Magtanong, L., Dixon, S. J., &amp; Watts, J. L. (2020). Dietary lipids induce ferroptosis in Caenorhabditis elegans and human cancer cells. Developmental Cell, 54, 447-453. https://doi.org/10.1016/j.devcel.2020.06.019</Citation>
        </Reference>
        <Reference>
          <Citation>Pizato, N., Luzete, B. C., Kiffer, L., Correa, L. H., de Oliveira Santos, I., Assumpcao, J. A. F., Ito, M. K., &amp; Magalh&#xe3;es, K. G. (2018). Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Scientific Reports, 8, 1952. https://doi.org/10.1038/s41598-018-20422-0</Citation>
        </Reference>
        <Reference>
          <Citation>Power, E. J., Chin, M. L., &amp; Haq, M. M. (2018). Breast cancer incidence and risk reduction in the Hispanic population. Cureus, 10, e2235. https://doi.org/10.7759/cureus.2235</Citation>
        </Reference>
        <Reference>
          <Citation>Raposo, T. P., Beirao, B. C. B., Pang, L. Y., Queiroga, F. L., &amp; Argyle, D. J. (2015). Inflammation and cancer: Till death tears them apart. Veterinary Journal, 205, 161-174. https://doi.org/10.1016/j.tvjl.2015.04.015</Citation>
        </Reference>
        <Reference>
          <Citation>Ringel-Scaia, V. M., Beitel-White, N., Lorenzo, M. F., Brock, R. M., Huie, K. E., Coutermarsh-Ott, S., Eden, K., McDaniel, D. K., Verbridge, S. S., Rossmeisl, J. H. Jr., Oestreich, K. J., Davalos, R. V., &amp; Allen, I. C. (2019). High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity. EBioMedicine, 44, 112-125. https://doi.org/10.1016/j.ebiom.2019.05.036</Citation>
        </Reference>
        <Reference>
          <Citation>Rogers, C., Erkes, D. A., Nardone, A., Aplin, A. E., Fernandes-Alnemri, T., &amp; Alnemri, E. S. (2019). Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nature Communications, 10, 1689. https://doi.org/10.1038/s41467-019-09397-2</Citation>
        </Reference>
        <Reference>
          <Citation>Sakle, N. S., More, S. A., &amp; Mokale, S. N. (2020). Chemomodulatory effects of Alysicarpus vaginalis extract via mitochondria-dependent apoptosis and necroptosis in breast cancer. Nutrition and Cancer, 72, 1243-1253. https://doi.org/10.1080/01635581.2019.1670855</Citation>
        </Reference>
        <Reference>
          <Citation>Sang, M., Luo, R., Bai, Y., Dou, J., Zhang, Z., Liu, F., Feng, F., &amp; Liu, W. (2019a). BHQ-cyanine-based &#x201c;Off-On&#x201d; long-circulating assembly as a ferroptosis amplifier for cancer treatment: A lipid-peroxidation burst device. ACS Applied Materials &amp; Interfaces, 11, 42873-42884. https://doi.org/10.1021/acsami.9b12469</Citation>
        </Reference>
        <Reference>
          <Citation>Sang, M., Luo, R., Bai, Y., Dou, J., Zhang, Z., Liu, F., Feng, F., Xu, J., &amp; Liu, W. (2019b). Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics, 9, 6209-6223. https://doi.org/10.7150/thno.36283</Citation>
        </Reference>
        <Reference>
          <Citation>Schmidt, S. V., Seibert, S., Walch-Rueckheim, B., Vicinus, B., Kamionka, E. -M., Pahne-Zeppenfeld, J., Solomayer, E., Kim, Y., Bohle, R. M., &amp; Smola, S. (2015). RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1 alpha release, and efficient paracrine dendritic cell activation. Oncotarget, 6, 8635-8647. https://doi.org/10.18632/oncotarget.3249</Citation>
        </Reference>
        <Reference>
          <Citation>Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., Culmsee, C., Plesnila, N., Kremmer, E., R&#xe5;dmark, O., Wurst, W., Bornkamm, G. W., Schweizer, U., &amp; Conrad, M. (2008). Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metabolism, 8, 237-248. https://doi.org/10.1016/j.cmet.2008.07.005</Citation>
        </Reference>
        <Reference>
          <Citation>Shahsavari, Z., Karami-Tehrani, F., &amp; Salami, S. (2018). Targeting cell necroptosis and apoptosis induced by shikonin via receptor interacting protein kinases in estrogen receptor positive breast cancer cell line, MCF-7. Anti-Cancer Agents in Medicinal Chemistry, 18, 245-254. https://doi.org/10.2174/1871520617666170919164055</Citation>
        </Reference>
        <Reference>
          <Citation>Shahsavari, Z., Karami-Tehrani, F., Salami, S., &amp; Ghasemzadeh, M. (2016). RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: Necroptosis as a desperate programmed suicide pathway. Tumor Biology, 37, 4479-4491. https://doi.org/10.1007/s13277-015-4258-5</Citation>
        </Reference>
        <Reference>
          <Citation>Shen, Z., Liu, T., Li, Y., Lau, J., Yang, Z., Fan, W., Zhou, Z., Shi, C., Ke, C., Bregadze, V. I., Mandal, S. K., Liu, Y., Li, Z., Xue, T., Zhu, G., Munasinghe, J., Niu, G., Wu, A., &amp; Chen, X. (2018). Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano, 12, 11355-11365. https://doi.org/10.1021/acsnano.8b06201</Citation>
        </Reference>
        <Reference>
          <Citation>Shi, J. J., Gao, W. Q., &amp; Shao, F. (2017). Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends in Biochemical Sciences, 42, 245-254. https://doi.org/10.1016/j.tibs.2016.10.004</Citation>
        </Reference>
        <Reference>
          <Citation>Shi, J. J., Zhao, Y., Wang, K., Shi, X. Y., Wang, Y., Huang, H. W., Zhuang, Y., Cai, T., Wang, F., &amp; Shao, F. (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature, 526, 660-665. https://doi.org/10.1038/nature15514</Citation>
        </Reference>
        <Reference>
          <Citation>Shi, Y., Ren, J., Liang, C., Wang, F., Li, W., &amp; Li, X. (2019). GSDME influences sensitivity of breast cancer MCF-7 cells to paclitaxel by regulating cell pyroptosis. Chinese Journal of Cancer Biotherapy, 26, 146-151.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimada, K., Skouta, R., Kaplan, A., Yang, W. S., Hayano, M., Dixon, S. J., Brown, L. M., Valenzuela, C. A., Wolpaw, A. J., &amp; Stockwell, B. R. (2016). Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nature Chemical Biology, 12, 497-503. https://doi.org/10.1038/nchembio.2079</Citation>
        </Reference>
        <Reference>
          <Citation>Stoll, G., Ma, Y., Yang, H., Kepp, O., Zitvogel, L., &amp; Kroemer, G. (2017). Pro-necrotic molecules impact local immunosurveillance in human breast cancer. Oncoimmunology, 6, e1299302. https://doi.org/10.1080/2162402X.2017.1299302</Citation>
        </Reference>
        <Reference>
          <Citation>Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., &amp; Wang, X. (2012). Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell, 148, 213-227. https://doi.org/10.1016/j.cell.2011.11.031</Citation>
        </Reference>
        <Reference>
          <Citation>Sun, X., Ou, Z., Xie, M., Kang, R., Fan, Y., Niu, X., Wang, H., Cao, L., &amp; Tang, D. (2015). HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene, 34, 5617-5625. https://doi.org/10.1038/onc.2015.32</Citation>
        </Reference>
        <Reference>
          <Citation>Tan, Y., &amp; Kagan, J. C. (2019). Innate immune signaling organelles display natural and programmable signaling flexibility. Cell, 177, 384-398. https://doi.org/10.1016/j.cell.2019.01.039</Citation>
        </Reference>
        <Reference>
          <Citation>Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padro, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van 't Veer, L. J., Polyak, K., McCormick, F., &amp; Gray, J. W. (2013). Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell, 24, 450-465. https://doi.org/10.1016/j.ccr.2013.08.020</Citation>
        </Reference>
        <Reference>
          <Citation>Upton, J. W., Kaiser, W. J., &amp; Mocarski, E. S. (2012). DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host &amp; Microbe, 11, 290-297. https://doi.org/10.1016/j.chom.2012.01.016</Citation>
        </Reference>
        <Reference>
          <Citation>Vanlangenakker, N., Vanden Berghe, T., &amp; Vandenabeele, P. (2012). Many stimuli pull the necrotic trigger, an overview. Cell Death and Differentiation, 19, 75-86. https://doi.org/10.1038/cdd.2011.164</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, H., Sun, L., Su, L., Rizo, J., Liu, L., Wang, L. F., Wang, F., &amp; Wang, X. (2014). Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Molecular Cell, 54, 133-146. https://doi.org/10.1177/1533034616655909</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, Q., Wang, Y., Ding, J., Wang, C., Zhou, X., Gao, W., Huang, H., Shao, F., &amp; Liu, Z. (2020). A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature, 579, 421-426. https://doi.org/10.1038/s41586-020-2079-1</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, S., Yang, L., Cho, H. Y., Dean Chueng, S. T., Zhang, H., Zhang, Q., &amp; Lee, K. (2019). Programmed degradation of a hierarchical nanoparticle with redox and light responsivity for self-activated photo-chemical enhanced chemodynamic therapy. Biomaterials, 224, 119498. https://doi.org/10.1016/j.biomaterials.2019.119498</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, T., Jin, Y., Yang, W., Zhang, L., Jin, X., Liu, X., He, Y., &amp; Li, X. (2017). Necroptosis in cancer: An angel or a demon? Tumour Biology, 39, 1010428317711539. https://doi.org/10.1177/1010428317711539</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, Y. P., Gao, W. Q., Shi, X. Y., Ding, J. J., Liu, W., He, H. B., Wang, K., &amp; Shao, F. (2017). Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature, 547, 99-103. https://doi.org/10.1038/nature22393</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, Z. G., Jiang, H., Chen, S., Du, F. H., &amp; Wang, X. D. (2012). The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell, 148, 228-243. https://doi.org/10.1016/j.cell.2011.11.030</Citation>
        </Reference>
        <Reference>
          <Citation>Warner, G. J., Berry, M. J., Moustafa, M. E., Carlson, B. A., Hatfield, D. L., &amp; Faust, J. R. (2000). Inhibition of selenoprotein synthesis by selenocysteine tRNA(Ser Sec) lacking isopentenyladenosine. Journal of Biological Chemistry, 275, 28110-28119. https://doi.org/10.1074/jbc.M001280200</Citation>
        </Reference>
        <Reference>
          <Citation>Wei, C., Wang, Y., &amp; Li, X. (2018). The role of Hippo signal pathway in breast cancer metastasis. OncoTargets and Therapy, 11, 2185-2193. https://doi.org/10.2147/OTT.S157058</Citation>
        </Reference>
        <Reference>
          <Citation>Weinlich, R., Oberst, A., Beere, H. M., &amp; Green, D. R. (2017). Necroptosis in development, inflammation and disease. Nature Reviews Molecular Cell Biology, 18, 127-136. https://doi.org/10.1038/nrm.2016.149</Citation>
        </Reference>
        <Reference>
          <Citation>Wen, Q., Liu, J., Kang, R., Zhou, B., &amp; Tang, D. (2019). The release and activity of HMGB1 in ferroptosis. Biochemical and Biophysical Research Communications, 510, 278-283. https://doi.org/10.1016/j.bbrc.2019.01.090</Citation>
        </Reference>
        <Reference>
          <Citation>Westbom, C., Thompson, J. K., Leggett, A., MacPherson, M., Beuschel, S., Pass, H., Vacek, P., &amp; Shukla, A. (2015). Inflammasome modulation by chemotherapeutics in malignant mesothelioma. PLoS One, 10, e0145404. https://doi.org/10.1371/journal.pone.0145404</Citation>
        </Reference>
        <Reference>
          <Citation>Wilson, N. S., Dixit, V., &amp; Ashkenazi, A. (2009). Death receptor signal transducers: Nodes of coordination in immune signaling networks. Nature Immunology, 10, 348-355. https://doi.org/10.1038/ni.1714</Citation>
        </Reference>
        <Reference>
          <Citation>Wu, J., Huang, Z., Ren, J., Zhang, Z., He, P., Li, Y., Ma, J., Chen, W., Zhang, Y., Zhou, X., Yang, Z., Wu, S., Chen, L., &amp; Han, J. (2013). Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Research, 23, 994-1006. https://doi.org/10.1038/cr.2013.91</Citation>
        </Reference>
        <Reference>
          <Citation>Xia, X. J., Wang, X., Cheng, Z., Qin, W. H., Lei, L. C., Jiang, J. Q., &amp; Hu, J. H. (2019). The role of pyroptosis in cancer: Pro-cancer or pro-&#x201c;host&#x201d;? Cell Death &amp; Disease, 10, 650. https://doi.org/10.1038/s41419-019-1883-8</Citation>
        </Reference>
        <Reference>
          <Citation>Xia, X. J., Wang, X., Zheng, Y., Jiang, J. Q., &amp; Hu, J. H. (2019). What role does pyroptosis play in microbial infection? Journal of Cellular Physiology, 234, 7885-7892. https://doi.org/10.1002/jcp.27909</Citation>
        </Reference>
        <Reference>
          <Citation>Xiong, H., Wang, C., Wang, Z., Jiang, Z., Zhou, J., &amp; Yao, J. (2019). Intracellular cascade activated nanosystem for improving ER plus breast cancer therapy through attacking GSH-mediated metabolic vulnerability. Journal of Controlled Release, 309, 145-157. https://doi.org/10.1016/j.jconrel.2019.07.029</Citation>
        </Reference>
        <Reference>
          <Citation>Xuan, Y., &amp; Hu, X. (2009). Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Letters, 274, 233-242. https://doi.org/10.1016/j.canlet.2008.09.029</Citation>
        </Reference>
        <Reference>
          <Citation>Yan, B., Ai, Y., Sun, Q., Ma, Y., Cao, Y., Wang, J., Zhang, Z., &amp; Wang, X. (2021). Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Molecular Cell, 81, 355-369. https://doi.org/10.1016/j.molcel.2020.11.024</Citation>
        </Reference>
        <Reference>
          <Citation>Yang, D., He, Y., Munoz-Planillo, R., Liu, Q., &amp; Nunez, G. (2015). Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity, 43, 923-932. https://doi.org/10.1016/j.immuni.2015.10.009</Citation>
        </Reference>
        <Reference>
          <Citation>Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., &amp; Stockwell, B. R. (2016). Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proceedings of the National Academy of Sciences of the United States of America, 113, E4966-E4975. https://doi.org/10.1073/pnas.1603244113</Citation>
        </Reference>
        <Reference>
          <Citation>Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., Brown, L. M., Girotti, A. W., Cornish, V. W., Schreiber, S. L., &amp; Stockwell, B. R. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell, 156, 317-331. https://doi.org/10.1016/j.cell.2013.12.010</Citation>
        </Reference>
        <Reference>
          <Citation>Ye, J., Zhang, R., Wu, F., Zhai, L., Wang, K., Xiao, M., Xie, Y., &amp; Sui, X. (2018). Non-apoptotic cell death in malignant tumor cells and natural compounds. Cancer Letters, 420, 210-227. https://doi.org/10.1016/j.canlet.2018.01.061</Citation>
        </Reference>
        <Reference>
          <Citation>Yehuda, S., Rabinovitz, S., Carasso, R. L., &amp; Mostofsky, D. I. (2002). The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiology of Aging, 23, 843-853. https://doi.org/10.1016/S0197-4580(02)00074-X</Citation>
        </Reference>
        <Reference>
          <Citation>Yu, H., Yang, C., Jian, L., Guo, S., Chen, R., Li, K., Qu, F., Tao, K., Fu, Y., Luo, F., &amp; Liu, S. (2019). Sulfasalazineinduced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncology Reports, 42, 826-838. https://doi.org/10.3892/or.2019.7189</Citation>
        </Reference>
        <Reference>
          <Citation>Yu, M., Gai, C., Li, Z., Ding, D., Zheng, J., Zhang, W., Lv, S., &amp; Li, W. (2019). Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Prevention Research, 110, 3173-3182. https://doi.org/10.1111/cas.14181</Citation>
        </Reference>
        <Reference>
          <Citation>Yuan, H., Li, X. M., Zhang, X. Y., Kang, R., &amp; Tang, D. L. (2016). CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochemical and Biophysical Research Communications, 478, 838-844. https://doi.org/10.1016/j.bbrc.2016.08.034</Citation>
        </Reference>
        <Reference>
          <Citation>Yue, L., Dai, Z., Chen, X., Liu, C., Hu, Z., Song, B., &amp; Zheng, X. (2018). Development of a novel FePt-based multifunctional ferroptosis agent for high-efficiency anticancer therapy. Nanoscale, 10, 17858-17864. https://doi.org/10.1039/C8NR05150J</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang, Z., Zhang, Y., Xia, S., Kong, Q., Li, S., Liu, X., Junqueira, C., Meza-Sosa, K. F., Mok, T. M. Y., Ansara, J., Sengupta, S., Yao, Y., Wu, H., &amp; Lieberman, J. (2020). Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature, 579, 415-420. https://doi.org/10.1038/s41586-020-2071-9</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao, J., Jitkaew, S., Cai, Z., Choksi, S., Li, Q., Luo, J., &amp; Liu, z (2012). Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proceedings of the National Academy of Sciences of the United States of America, 109, 5322-5327. https://doi.org/10.1073/pnas.1200012109</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao, P., Wang, M., Chen, M., Chen, Z., Peng, X., Zhou, F., Song, J., &amp; Qu, J. (2020). Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy. Biomaterials, 254, 120142. https://doi.org/10.1016/j.biomaterials.2020.120142.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao, X. M., Chen, Z., Zhao, J. B., Zhang, P. P., Pu, Y. F., Jiang, S. H., Hou, J. J., Cui, Y. M., Jia, X. L., &amp; Zhang, S. Q. (2016). Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis. Cell Death &amp; Disease, 7, e2089. https://doi.org/10.1038/cddis.2015.390</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao, Y., Zhao, W., Lim, Y. C., &amp; Liu, T. (2019). Salinomycin-loaded gold nanoparticles for treating cancer stem cells by ferroptosis-induced cell death. Molecular Pharmaceutics, 16, 2532-1539. https://doi.org/10.1021/acs.molpharmaceut.9b00132</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou, Z., He, H., Wang, K., Shi, X., Wang, Y., Su, Y., Wang, Y., Li, D., Liu, W., Zhang, y, Shen, L., Han, W., Shen, L., Ding, J., &amp; Shao, F. (2020). Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science, 368, eaaz7548. https://doi.org/10.1126/science.aaz7548</Citation>
        </Reference>
        <Reference>
          <Citation>Zou, Y., Henry, W. S., Ricq, E. L., Graham, E. T., Phadnis, V. V., Maretich, P., Paradkar, S., Boehnke, N., Deik, A. A., Reinhardt, F., Eaton, J. K., Ferguson, B., Wang, W., Fairman, J., Keys, H. R., Dan&#x10d;&#xed;k, V., Clish, C. B., Clemons, P. A., Hammond, P. T., &#x2026; Schreiber, S. L. (2020). Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature, 585, 603-608. https://doi.org/10.1038/s41586-020-2732-8</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34523352</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1748-6963</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>26</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nanomedicine (London, England)</Title>
          <ISOAbbreviation>Nanomedicine (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multifunctional MnO2-based nanoplatform-induced ferroptosis and apoptosis for synergetic chemoradiotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>2343</StartPage>
          <EndPage>2361</EndPage>
          <MedlinePgn>2343-2361</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2217/nnm-2021-0286</ELocationID>
        <Abstract>
          <AbstractText>Background: Radiosensitizers that can effectively consume glutathione provide broad prospects for enhancing the efficacy and reducing the side effects of radiotherapy. Aim: To explore the potential role of CuS@mSiO2@MnO2 nanocomposites in synergetic chemoradiotherapy. Methods: Nanocomposites were characterized by transmission electron microscopy, UV-Vis spectrometry and dynamic light scattering and were loaded with doxorubicin (DOX). The uptake and biodistribution of nanocomposites were observed by CCK8 assay, MRI and confocal laser scanning microscopy. The radiosensitization effect of nanocomposites and nanocomposites/DOX was assessed both in vitro and in vivo. Results:In vitro application of nanocomposites, with an average diameter of 30 nm and -potential of 13.2  0.4 mV, in combination with radiotherapy, depleted glutathione and induced ferroptosis and apoptosis. Nanocomposites/DOX exhibited tumor cell damage in vivo. Conclusion: We propose that this glutathione-depleting nanosystem could be a radiosensitizer as well as a drug transporter.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0003-1763-5312</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 650 Xin Songjiang Road, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200333, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Trauma Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 650 Xin Songjiang Road, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Sihui</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 650 Xin Songjiang Road, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Minyi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chemistry &amp; Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xijian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chemistry &amp; Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Guoying</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Trauma Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 650 Xin Songjiang Road, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Reproductive Medicine Center, Department of Obstetrics &amp; Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 650 Xin Songjiang Road, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Sufang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 650 Xin Songjiang Road, Shanghai, 201620, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nanomedicine (Lond)</MedlineTA>
        <NlmUniqueID>101278111</NlmUniqueID>
        <ISSNLinking>1743-5889</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017895">Manganese Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017895" MajorTopicYN="Y">Manganese Compounds</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010087" MajorTopicYN="N">Oxides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">glutathione</Keyword>
        <Keyword MajorTopicYN="N">multifunctional nanoplatform</Keyword>
        <Keyword MajorTopicYN="N">radiotherapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34523352</ArticleId>
        <ArticleId IdType="doi">10.2217/nnm-2021-0286</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34482088</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-5905</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>277</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomaterials</Title>
          <ISOAbbreviation>Biomaterials</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>121110</StartPage>
          <MedlinePgn>121110</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biomaterials.2021.121110</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0142-9612(21)00466-X</ELocationID>
        <Abstract>
          <AbstractText>Glutathione (GSH) is an important member of cellular antioxidative system. In cancer cells, a high level of GSH is indispensable to scavenge excessive reactive oxygen species (ROS) and detoxify xenobiotics, which make it a potential target for cancer therapy. Plenty of studies have shown that loss of intracellular GSH makes cancer cells more susceptible to oxidative stress and chemotherapeutic agents. GSH depletion has been proved to improve the therapeutic efficacy of ROS-based therapy (photodynamic therapy, sonodynamic therapy, and chemodynamic therapy), ferroptosis, and chemotherapy. In this review, various strategies for GSH depletion used in cancer therapy are comprehensively summarized and discussed. First, the functions of GSH in cancer cells are analyzed to elucidate the necessity of GSH depletion in cancer therapy. Then, the synthesis and metabolism of GSH are briefly introduced to bring up some crucial targets for GSH modulation. Finally, different approaches to GSH depletion in the literature are classified and discussed in detail according to their mechanisms. Particularly, functional materials with GSH-consuming ability based on nanotechnology are elaborated due to their unique advantages and potentials. This review presents the ingenious application of GSH-depleting strategy in cancer therapy for improving the outcomes of various therapeutic regimens, which may provide useful guidance for designing intelligent drug delivery system.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Niu</LastName>
            <ForeName>Boyi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Kaixin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yixian</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quan</LastName>
            <ForeName>Guilan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Jinan University, Guangzhou, 510632, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. Electronic address: panxin2@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Chuanbin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China; College of Pharmacy, Jinan University, Guangzhou, 510632, China. Electronic address: wuchuanb@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biomaterials</MedlineTA>
        <NlmUniqueID>8100316</NlmUniqueID>
        <ISSNLinking>0142-9612</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">Drug resistance</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glutathione depletion</Keyword>
        <Keyword MajorTopicYN="N">Nanomaterials</Keyword>
        <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>20</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34482088</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biomaterials.2021.121110</ArticleId>
        <ArticleId IdType="pii">S0142-9612(21)00466-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34482070</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2352-3964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>71</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>EBioMedicine</Title>
          <ISOAbbreviation>EBioMedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>103560</StartPage>
          <MedlinePgn>103560</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">103560</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2021.103560</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2352-3964(21)00353-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent evidence shows that inducing ferroptosis may improve efficacy of tumor therapy. However, ferroptosis-related genes have been little studied in patients with breast cancer especially in the neoadjuvant setting. ACSL4 and GPX4 have been well established as the positive and negative regulator of ferroptosis, respectively. This study aimed to explore the predictive value of ACSL4 and GPX4 for patients with breast cancer administered neoadjuvant chemotherapy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This study included patients treated with paclitaxel-cisplatin-based neoadjuvant chemotherapy. Immunohistochemistry staining of ACSL4 and GPX4 was carried out on the core needle biopsy specimens. Logistic regression was performed to explore the predictive biomarkers of pathological complete response (pCR). Survival analyses were examined by log-rank test and Cox proportional hazard regression.</AbstractText>
          <AbstractText Label="FINDINGS" NlmCategory="RESULTS">A total of 199 patients were included for the analyses. Both ACSL4 expression and ACSL4/GPX4 combination status could serve as independent predictive factors for pCR. The interaction for pCR was observed between ACSL4 and clinical tumor stage. Besides, ACSL4 expression, GPX4 expression, and their combination status were independent prognostic factors for disease-free survival. Analyses of the Kaplan-Meier Plotter database suggested that higher ACSL4 expression is related to better overall survival, and higher GPX4 expression is related to better distant metastasis-free survival. Pathway analyses revealed that ACSL4 and GPX4 might function in crucial pathways including apoptosis, autophagy, cell adhesion, lipid metabolism, etc. INTERPRETATION: This study revealed the critical value of ACSL4 and GPX4 serving as novel predictive and prognostic biomarkers for patients with breast cancer receiving neoadjuvant chemotherapy. It might be a novel strategy to induce ferroptosis to promote chemosensitivity. Future studies are required to elucidate the potential mechanisms.</AbstractText>
          <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was supported by Shanghai Natural Science Foundation [grant number 19ZR1431100], Clinical Research Plan of Shanghai Hospital Development Center [grant numbers SHDC2020CR3003A, 16CR3065B, and 12016231], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Youth Medical Talents - Specialist Program [grant number 2018-15], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Outstanding Youth Medical Talents [grant number 2018-16], Shanghai Collaborative Innovation Center for Translational Medicine [grant number TM201908], Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University [grant numbers YG2017QN49, ZH2018QNA42, and YG2019QNA28], Nurturing Fund of Renji Hospital [grant numbers PYMDT-002, PY2018-IIC-01, PY2018-III-15, and PYIII20-09], Science and Technology Commission of Shanghai Municipality [grant numbers 20DZ2201600 and 15JC1402700], and Shanghai Municipal Key Clinical Specialty.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sha</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yaqian</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Chenwei</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheng</LastName>
            <ForeName>Xiaonan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Ziping</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yaohui</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China. Electronic address: wangyaohui@renji.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Yanping</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Liheng</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Shuguang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Wenjin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China. Electronic address: yinwenjin@renji.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Jinsong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China. Electronic address: lujingsong@renji.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>EBioMedicine</MedlineTA>
        <NlmUniqueID>101647039</NlmUniqueID>
        <ISSNLinking>2352-3964</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D003066">Coenzyme A Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.3</RegistryNumber>
          <NameOfSubstance UI="C019143">long-chain-fatty-acid-CoA ligase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003066" MajorTopicYN="N">Coenzyme A Ligases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ACSL4</Keyword>
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">GPX4</Keyword>
        <Keyword MajorTopicYN="N">Neoadjuvant chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">Pathological complete response</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare no potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>20</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34482070</ArticleId>
        <ArticleId IdType="pmc">PMC8417304</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ebiom.2021.103560</ArticleId>
        <ArticleId IdType="pii">S2352-3964(21)00353-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Korde L.A., Somerfield M.R., Carey L.A., Crews J.R., Denduluri N., Hwang E.S. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485&#x2013;1505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8274745</ArticleId>
            <ArticleId IdType="pubmed">33507815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164&#x2013;172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24529560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houssami N., Macaskill P., von Minckwitz G., Marinovich M.L., Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342&#x2013;3354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22766518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortazar P., Geyer C.E. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441&#x2013;1446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25727556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778&#x2013;785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18258986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Yu C., Luo M., Cen C., Qiu J., Zhang S. Ferroptosis in cancer treatment: another way to Rome. Front Oncol. 2020;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7546896</ArticleId>
            <ArticleId IdType="pubmed">33102227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., SriRamaratnam R., Welsch M.E., Shimada K., Skouta R., Viswanathan V.S. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seibt T.M., Proneth B., Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2019;133:144&#x2013;152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30219704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer M.J., Viswanathan V.S., Ryan M.J., Bole D., Eaton J.K., Matov A. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan V.E., Mao G., Qu F., Angeli J.P., Doll S., Croix C.S. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.S., Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016;26(3):165&#x2013;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S., Proneth B., Tyurina Y.Y., Panzilius E., Kobayashi S., Ingold I. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H., Li X., Zhang X., Kang R., Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338&#x2013;1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Sui S., Wang L., Li H., Zhang L., Xu S. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020;235(4):3425&#x2013;3437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31556117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J., Xu B., Han Q., Zhou H., Xia Y., Gong C. Ferroptosis: a novel anti-tumor action for Cisplatin. Cancer Res Treat. 2018;50(2):445&#x2013;460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912137</ArticleId>
            <ArticleId IdType="pubmed">28494534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv C., Qu H., Zhu W., Xu K., Xu A., Jia B. Low-dose paclitaxel inhibits tumor cell growth by Regulating Glutaminolysis in colorectal carcinoma cells. Front Pharmacol. 2017;8:244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5415623</ArticleId>
            <ArticleId IdType="pubmed">28522974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannakakou P., Robey R., Fojo T., Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20(29):3806&#x2013;3813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11439344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S., Henson E.S., Chen Y., Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7(7):e2307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4973350</ArticleId>
            <ArticleId IdType="pubmed">27441659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S., Dielschneider R.F., Henson E.S., Xiao W., Choquette T.R., Blankstein A.R. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One. 2017;12(8)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5565111</ArticleId>
            <ArticleId IdType="pubmed">28827805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X., Stockwell B.R., Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266&#x2013;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8142022</ArticleId>
            <ArticleId IdType="pubmed">33495651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L., Xu S., Yin W., Lin Y., Du Y., Jiang Y. Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. Oncotarget. 2017;8(45):79305&#x2013;79314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5668042</ArticleId>
            <ArticleId IdType="pubmed">29108309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bethea T.N., Rosenberg L., Castro-Webb N., Lunetta K.L., Sucheston-Campbell L.E., Ruiz-Narvaez E.A. Family history of cancer in relation to breast cancer subtypes in African American Women. Cancer Epidemiol Biomark Prev. 2016;25(2):366&#x2013;373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4767636</ArticleId>
            <ArticleId IdType="pubmed">26721669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997&#x2013;4013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24101045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curigliano G., Burstein H.J., Winer E.P., Gnant M., Dubsky P., Loibl S. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700&#x2013;1712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6246241</ArticleId>
            <ArticleId IdType="pubmed">28838210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodenhuis S., Mandjes I.A.M., Wesseling J., van de Vijver M.J., Peeters M., Sonke G.S. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol. 2010;21(3):481&#x2013;487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19717533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Z., Hu Q., Zhuo Q., Zhu Y., Fan G., Liu M. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Am J Cancer Res. 2020;10(4):1182&#x2013;1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7191101</ArticleId>
            <ArticleId IdType="pubmed">32368394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J., Ding C., Chen Y., Hu W., Lu Y., Wu W. ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis. Oncogenesis. 2020;9(4):42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7190855</ArticleId>
            <ArticleId IdType="pubmed">32350243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G.Q., Benthani F.A., Wu J., Liang D., Bian Z.X., Jiang X. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 2020;27(1):242&#x2013;254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7205875</ArticleId>
            <ArticleId IdType="pubmed">31114026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayr L., Grabherr F., Schw&#xe4;rzler J., Reitmeier I., Sommer F., Gehmacher T. Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. Nat Commun. 2020;11(1):1775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7156516</ArticleId>
            <ArticleId IdType="pubmed">32286299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Yang J., Ye Y., Chen G., Zhang Y., Wu H. SPTBN1 prevents primary osteoporosis by modulating osteoblasts proliferation and differentiation and blood vessels formation in bone. Front Cell Dev Biol. 2021;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8017174</ArticleId>
            <ArticleId IdType="pubmed">33816505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Cancer Genome Atlas Research Network. https://www.cancer.gov/tcga (accessed on 31th December 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Goldman M.J., Craft B., Hastie M., Repe&#x10d;ka K., McDade F., Kamath A. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675&#x2013;678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7386072</ArticleId>
            <ArticleId IdType="pubmed">32444850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyorffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725&#x2013;731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20020197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang da W., Sherman B.T., Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2615629</ArticleId>
            <ArticleId IdType="pubmed">19033363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang da W., Sherman B.T., Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19131956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu G., Wang L.G., Han Y., He Q.Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284&#x2013;287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3339379</ArticleId>
            <ArticleId IdType="pubmed">22455463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J.H., Liu S., Zhou H., Qu L.H., Yang J.H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92&#x2013;D97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3964941</ArticleId>
            <ArticleId IdType="pubmed">24297251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szklarczyk D., Gable A.L., Lyon D., Junge A., Wyder S., Huerta-Cepas J. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2013;D613. D607-d13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuster J.J. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191&#x2013;192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1985169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altman D.G., De Stavola B.L., Love S.B., Stepniewska K.A. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72(2):511&#x2013;518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2033978</ArticleId>
            <ArticleId IdType="pubmed">7640241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rusolo F., Capone F., Pasquale R., Angiolillo A., Colonna G., Castello G. Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines. Oncol Lett. 2017;13(4):2411&#x2013;2417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5403638</ArticleId>
            <ArticleId IdType="pubmed">28454412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cejas P., Garcia-Cabezas M.A., Casado E., Belda-Iniesta C., De Castro J., Fresno J.A. Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma. Free Radic Res. 2007;41(6):681&#x2013;687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17516241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X., Li Y., Wang J., Wen X., Marcus M.T., Daniels G. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS One. 2013;8(10):e77060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3796543</ArticleId>
            <ArticleId IdType="pubmed">24155918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monaco M.E., Creighton C.J., Lee P., Zou X., Topham M.K., Stafforini DM. Expression of long-chain fatty Acyl-CoA Synthetase 4 in Breast and prostate cancers is associated with sex steroid hormone receptor negativity. Transl Oncol. 2010;3(2):91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2847316</ArticleId>
            <ArticleId IdType="pubmed">20360933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yen M.C., Kan J.Y., Hsieh C.J., Kuo P.L., Hou M.F., Hsu YL. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance. Oncol Rep. 2017;37(6):3253&#x2013;3260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28498416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinarvand N., Khanahmad H., Hakimian S.M., Sheikhi A., Rashidi B., Pourfarzam M. Evaluation of long-chain acyl-coenzyme A synthetase 4 (ACSL4) expression in human breast cancer. Res Pharm Sci. 2020;15(1):48&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7053294</ArticleId>
            <ArticleId IdType="pubmed">32180816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo A.F., Orlando U.D., Maloberti P.M., Prada J.G., Dattilo M.A., Solano A.R. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis. Cell Mol Life Sci. 2021;78(6):2893&#x2013;2910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33068124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maloberti P.M., Duarte A.B., Orlando U.D., Pasqualini M.E., Solano A.R., Lopez-Otin C. Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells. PLoS One. 2010;5(11):e15540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2978721</ArticleId>
            <ArticleId IdType="pubmed">21085606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W.J., Sun Y.F., Jin A.L., Lv L.H., Zhu J., Wang B.L. BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death Dis. 2020;11(10):895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7581528</ArticleId>
            <ArticleId IdType="pubmed">33093445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao D., Wang X., Zhang W. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer. BMC Cancer. 2018;18(1):328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5870062</ArticleId>
            <ArticleId IdType="pubmed">29580231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlando U.D., Castillo A.F., Medrano M.A.R., Solano A.R., Maloberti P.M., Podesta E.J. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Biochem Pharm. 2019;159:52&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30414939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edlich F. BCL-2 proteins and apoptosis: recent insights and unknowns. Biochem Biophys Res Commun. 2018;500(1):26&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28676391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogerio F., Jordao H., Vieira A.S., Maria C.C., Santos de Rezende A.C., Pereira G.A. Bax and Bcl-2 expression and TUNEL labeling in lumbar enlargement of neonatal rats after sciatic axotomy and melatonin treatment. Brain Res. 2006;1112(1):80&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16890920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell B.R., Friedmann Angeli J.P., Bayir H., Bush A.I., Conrad M., Dixon S.J. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson D., Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplas. 2004;9(3):221&#x2013;236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15557796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin A.M., Blackwood M.A., Antin-Ozerkis D., Shih H.A., Calzone K., Colligon T.A. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001;19(8):2247&#x2013;2253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11304778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Reviews. 1999;99(9):2467&#x2013;2498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11749487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heeke A.L., Pishvaian M.J., Lynce F., Xiu J., Brody J.R., Chen W.J. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2018 PO.17.00286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6139373</ArticleId>
            <ArticleId IdType="pubmed">30234181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y., Zhou F., Jiang F., Lu H., Wang J., Cheng C. PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. Chin J Cancer Res. 2014;26(2):142&#x2013;147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4000905</ArticleId>
            <ArticleId IdType="pubmed">24826054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817&#x2013;2826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15591335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luporsi E., Andre F., Spyratos F., Martin P.M., Jacquemier J., Penault-Llorca F. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132(3):895&#x2013;915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3332349</ArticleId>
            <ArticleId IdType="pubmed">22048814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W.C., Wang C.Y., Hung Y.H., Weng T.Y., Yen M.C., Lai M.D. Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme a synthetase family in cancer. PloS One. 2016;11(5)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4865206</ArticleId>
            <ArticleId IdType="pubmed">27171439</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34473493</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-5126</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>143</Volume>
            <Issue>38</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Chemical Society</Title>
          <ISOAbbreviation>J Am Chem Soc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Renal Clearable Ultrasmall Single-Crystal Fe Nanoparticles for Highly Selective and Effective Ferroptosis Therapy and Immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>15812</StartPage>
          <EndPage>15823</EndPage>
          <MedlinePgn>15812-15823</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/jacs.1c07471</ELocationID>
        <Abstract>
          <AbstractText>Iron-based nanoparticles have attracted much attention because of their ability to induce ferroptosis via a catalyzing Fenton reaction and to further potentiate immunotherapy. However, current iron-based nanoparticles need to be used in cooperation with other treatments or be applied in a high dose for effective therapy because of their low reactive oxygen species production efficacy. Here, we synthesized ultrasmall single-crystal Fe nanoparticles (bcc-USINPs) that stayed stable in a normal physiological environment but were highly active in a tumor microenvironment because of the selective acidic etching of an Fe3O4 shell and the exposure of the Fe(0) core. The bcc-USINPs could efficiently induce tumor cell ferroptosis and immunogenetic cell death at a very low concentration. Intravenous injection of iRGD-bcc-USINPs at three doses of 1 mg/kg could effectively suppress the tumor growth, promote the maturation of dendritic cells, and trigger the adaptive T cell response. Combined with programmed death-ligand 1 (PD-L1) immune checkpoint blockade immunotherapy, the iRGD-bcc-USINP-mediated ferroptosis therapy greatly potentiated the immune response and developed strong immune memory. In addition, these USINPs were quickly renal excreted with no side effects in normal tissues. These iRGD-bcc-USINPs provide a simple, safe, effective, and selectively tumor-responsive Fe(0) delivery system for ferroptosis-based immunotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, Department of Pharmaceutical Analysis, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Xiyao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, Department of Pharmaceutical Analysis, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Guizhen</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, Department of Pharmaceutical Analysis, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Kai</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, Department of Pharmaceutical Analysis, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Kaiyuan</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-8152-6746</Identifier>
            <AffiliationInfo>
              <Affiliation>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Building 76, Cambridge, Massachusetts 02142, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Xiaolian</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-9549-4741</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, Department of Pharmaceutical Analysis, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Chem Soc</MedlineTA>
        <NlmUniqueID>7503056</NlmUniqueID>
        <ISSNLinking>0002-7863</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>17</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34473493</ArticleId>
        <ArticleId IdType="doi">10.1021/jacs.1c07471</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34415804</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1029-2330</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of drug targeting</Title>
          <ISOAbbreviation>J Drug Target</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targetting ferroptosis for blood cell-related diseases.</ArticleTitle>
        <Pagination>
          <StartPage>244</StartPage>
          <EndPage>258</EndPage>
          <MedlinePgn>244-258</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/1061186X.2021.1971237</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is an iron-dependent cell death pathway and participates in various diseases. Current evidence suggests that ferroptosis can obviously affect the function of blood cells. This paper aims to elaborate the role of ferroptosis in blood cells and related diseases. First, abnormal ferroptosis damages the developing red blood cells by breaking systemic iron homeostasis, leading to erythropoiesis suppression and anaemia. Ferroptosis mediates neutrophils recruitment and neutrophil extracellular trap formation (NETosis). In T-cells, ferroptosis induces a novel point of synergy between immunotherapy and radiotherapy. Additionally, ferroptosis may mediate B cells differentiation, antibody responses and lymphoma. Nevertheless, increased ferroptosis can ameliorate acute myeloid leukaemia and T-cell leukaemia/lymphoma by inducing iron-dependent cancer cells death. Besides, ferroptosis activates platelets by increasing P-selectin, thus causing thromboembolism. Ferroptosis mediates virus infection and parasite infection by driving T-cell death and preventing T-cell immunity. Interestingly, ferroptosis is also considered as a critical player in COVID-19 infections, while targetting ferroptosis may also improve thromboembolism and prognosis in patients with COVID-19 infection. Overall, the crucial role of ferroptosis in blood cells will show a new therapeutic potential in blood cell-related diseases.HighlightsFerroptosis shows a new therapeutic potential for blood cell-related diseases.Ferroptosis damages erythropoiesis and thus induces anaemia.Ferroptosis induces platelet activation and leads to thromboembolism.Ferroptosis regulates T-cell and B-cell immunity, which participant in infectious diseases.Inversely, ferroptosis ameliorates acute myeloid leukaemia and T-cell leukaemia.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhe</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacy and Pharmacology, College of Basic Medical Science, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China, Hengyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Jinyong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacy and Pharmacology, College of Basic Medical Science, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China, Hengyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Nian</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Affiliated Nanhua Hospital, University of South China, Hengyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Linxi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacy and Pharmacology, College of Basic Medical Science, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China, Hengyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Drug Target</MedlineTA>
        <NlmUniqueID>9312476</NlmUniqueID>
        <ISSNLinking>1026-7158</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001773" MajorTopicYN="N">Blood Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">anaemia</Keyword>
        <Keyword MajorTopicYN="N">infectious diseases</Keyword>
        <Keyword MajorTopicYN="N">leukaemia</Keyword>
        <Keyword MajorTopicYN="N">thromboembolism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>17</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34415804</ArticleId>
        <ArticleId IdType="doi">10.1080/1061186X.2021.1971237</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34373736</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1838-7640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>17</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Theranostics</Title>
          <ISOAbbreviation>Theranostics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy.</ArticleTitle>
        <Pagination>
          <StartPage>8185</StartPage>
          <EndPage>8196</EndPage>
          <MedlinePgn>8185-8196</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.59121</ELocationID>
        <Abstract>
          <AbstractText>Background: Efficient and specific induction of cell death in liver cancer is urgently needed. In this study, we aimed to design an exosome-based platform to deliver ferroptosis inducer (Erastin, Er) and photosensitizer (Rose Bengal, RB) into tumor tissues with high specificity. Methods: Exosome donor cells (HEK293T) were transfected with control or CD47-overexpressing plasmid. Exosomes were isolated and loaded with Er and RB via sonication method. Hepa1-6 cell xenograft C57BL/6 model was injected with control and engineered exosomes via tail vein. In vivo distribution of the injected exosomes was analyzed via tracking the fluorescence labeled exosomes. Photodynamic therapy was conducted by 532 nm laser irradiation. The therapeutic effects on hepatocellular carcinoma and toxic side-effects were systemically analyzed. Results: CD47 was efficiently loaded on the exosomes from the donor cells when CD47 was forced expressed by transfection. CD47 surface functionalization (Exos[CD47]) made the exosomes effectively escape the phagocytosis of mononuclear phagocyte system (MPS), and thus increased the distribution in tumor tissues. Erastin and RB could be effectively encapsulated into exosomes after sonication, and the drug-loaded exosomes (Er/RB@Exos[CD47]) strongly induced ferroptosis both in vitro and in vivo in tumor cells after irradiation of 532 nm laser. Moreover, compared with the control exosomes (Er/RB@Exos[Ctrl]), Er/RB@Exos[CD47] displayed much lower toxicity in liver. Conclusion: The engineered exosomes composed of CD47, Erastin, and Rose Bengal, induce obvious ferroptosis in hepatocellular carcinoma (HCC) with minimized toxicity in liver and kidney. The proposed exosomes would provide a promising strategy to treat types of malignant tumors.</AbstractText>
          <CopyrightInformation>&#xa9; The author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Jianbing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Zhuo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Cong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory, The Second People's Hospital of Hefei, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, 710032, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Mengying</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, 710032, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Desheng</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Theranostics</MedlineTA>
        <NlmUniqueID>101552395</NlmUniqueID>
        <ISSNLinking>1838-7640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051928">CD47 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497894">CD47 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1ZPG1ELY14</RegistryNumber>
          <NameOfSubstance UI="D012395">Rose Bengal</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051928" MajorTopicYN="N">CD47 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="Y">Piperazines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012395" MajorTopicYN="N">Rose Bengal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">exosomes</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">synergistic effects</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34373736</ArticleId>
        <ArticleId IdType="pmc">PMC8344009</ArticleId>
        <ArticleId IdType="doi">10.7150/thno.59121</ArticleId>
        <ArticleId IdType="pii">thnov11p8185</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33433946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29307467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inarrairaegui M, Melero I, Sangro B. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Clin Cancer Res. 2018;24:1518&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29138342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24060863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Z, Yang Z, Xie L, DeWitt JP, Chen Y. Cancer therapy in the necroptosis era. Cell Death Differ. 2016;23:748&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4832112</ArticleId>
            <ArticleId IdType="pubmed">26915291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Wang F, Hu C, Zhou Y, Gao H, Hu J. The progress and perspective of nanoparticle-enabled tumor metastasis treatment. Acta Pharm Sin B. 2020;10:2037&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7714986</ArticleId>
            <ArticleId IdType="pubmed">33304778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mou Y, Wang J, Wu J, He D, Zhang C, Duan C. et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6441206</ArticleId>
            <ArticleId IdType="pubmed">30925886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ. Ferroptosis: bug or feature? Immunol Rev. 2017;277:150&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28462529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SF, Liao HW, Li FY, Ling DS. A mini-review and perspective on ferroptosis-inducing strategies in cancer therapy. Chinese Chemical Letters. 2019;30:847&#x2013;52.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang Q, Wang K, Zhang XY, Ouyang BS, Liu HX, Pang ZQ, Platelet Membrane-Camouflaged Magnetic Nanoparticles for Ferroptosis-Enhanced Cancer Immunotherapy. Small. 2020. 16. doi: 10.1002/smll.202001704.</Citation>
        </Reference>
        <Reference>
          <Citation>Hao S, Yu J, He W, Huang Q, Zhao Y, Liang B. et al. Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells. Neoplasia. 2017;19:1022&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5686465</ArticleId>
            <ArticleId IdType="pubmed">29144989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi Y, Kasukabe T, Kumakura S. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol. 2018;52:1011&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29393418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C. et al. Ferroptosis: A Novel Anti-tumor Action for Cisplatin. Cancer Res Treat. 2018;50:445&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912137</ArticleId>
            <ArticleId IdType="pubmed">28494534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Niu X, Chen R, He W, Chen D, Kang R. et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64:488&#x2013;500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4956496</ArticleId>
            <ArticleId IdType="pubmed">27015352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A. et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3931310</ArticleId>
            <ArticleId IdType="pubmed">24094812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W. et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019;110:3173&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778638</ArticleId>
            <ArticleId IdType="pubmed">31464035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12724736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Wang JH, Liu Q, Huang H, Chen M, Li K. et al. Rose-bengal-conjugated gold nanorods for in vivo photodynamic and photothermal oral cancer therapies. Biomaterials. 2014;35:1954&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24331707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Q, Zhang S, Yang Q, Zhang T, Wei XQ, Jiang L. et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials. 2013;34:8521&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23932500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65:21&#x2013;3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22580334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arvizo R, Bhattacharya R, Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opinion on Drug Delivery. 2010;7:753&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874072</ArticleId>
            <ArticleId IdType="pubmed">20408736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen R, Xu X, Tao Y, Qian Z, Yu Y. Exosomes in hepatocellular carcinoma: a new horizon. Cell Commun Signal. 2019;17:1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6323788</ArticleId>
            <ArticleId IdType="pubmed">30616541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roma-Rodrigues C, Raposo LR, Cabral R, Paradinha F, Baptista PV, Fernandes AR. Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy. Int J Mol Sci. 2017; 18. doi: 10.4143/crt. 2016. 572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5297795</ArticleId>
            <ArticleId IdType="pubmed">28098821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6095740</ArticleId>
            <ArticleId IdType="pubmed">30089911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487&#x2013;514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31220978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498&#x2013;503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5538883</ArticleId>
            <ArticleId IdType="pubmed">28607485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu X, Li Z, Han X, Zhen L, Luo C, Liu M. et al. Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis. Theranostics. 2019;9:2618&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525995</ArticleId>
            <ArticleId IdType="pubmed">31131057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni D, Wei H, Chen W, Bao Q, Rosenkrans ZT, Barnhart TE. et al. Ceria Nanoparticles Meet Hepatic Ischemia-Reperfusion Injury: The Perfect Imperfection. Adv Mater. 2019;31:e1902956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6773480</ArticleId>
            <ArticleId IdType="pubmed">31418951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni D, Ferreira CA, Barnhart TE, Quach V, Yu B, Jiang D. et al. Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc. 2018;140:14971&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6310174</ArticleId>
            <ArticleId IdType="pubmed">30336003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni D, Jiang D, Ehlerding EB, Huang P, Cai W. Radiolabeling Silica-Based Nanoparticles via Coordination Chemistry: Basic Principles, Strategies, and Applications. Acc Chem Res. 2018;51:778&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5878690</ArticleId>
            <ArticleId IdType="pubmed">29489335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Zhou X, Gao X, Bai D, Dong Y, Sun W. et al. Fusion protein engineered exosomes for targeted degradation of specific RNAs in lysosomes: a proof-of-concept study. J Extracell Vesicles. 2020;9:1816710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7580726</ArticleId>
            <ArticleId IdType="pubmed">33133429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319521</ArticleId>
            <ArticleId IdType="pubmed">22310103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kibria G, Ramos EK, Lee KE, Bedoyan S, Huang S, Samaeekia R. et al. A rapid, automated surface protein profiling of single circulating exosomes in human blood. Sci Rep. 2016;6:36502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5098148</ArticleId>
            <ArticleId IdType="pubmed">27819324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2775564</ArticleId>
            <ArticleId IdType="pubmed">19632178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Zhou X, Wei M, Gao X, Zhao L, Shi R. et al. In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR/dCas9. Nano Lett. 2019;19:19&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30517011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL. et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12:655&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4809755</ArticleId>
            <ArticleId IdType="pubmed">26586551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao MH, Monian P, Pan QH, Zhang W, Xiang J, Jiang XJ. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CL, Nydes M, Shanley KL, Morales Pantoja IE, Howard TA, Bizzozero OA. Reduced expression of the ferroptosis inhibitor glutathione peroxidase-4 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurochem. 2019;148:426&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6347488</ArticleId>
            <ArticleId IdType="pubmed">30289974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Deng X, Xie X, Liu Y, Friedmann Angeli JP, Lai L. Activation of Glutathione Peroxidase 4 as a Novel Anti-inflammatory Strategy. Front Pharmacol. 2018;9:1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6178849</ArticleId>
            <ArticleId IdType="pubmed">30337875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Liu T, Li Y, Lau J, Yang Z, Fan W. et al. Fenton-Reaction-Acceleratable Magnetic Nanoparticles for Ferroptosis Therapy of Orthotopic Brain Tumors. ACS Nano. 2018;12:11355&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Bu WB, Ni DL, Zhang SJ, Li Q, Yao ZW. et al. Synthesis of Iron Nanometallic Glasses and Their Application in Cancer Therapy by a Localized Fenton Reaction. Angew Chem Int Edit. 2016;55:2101&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26836344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng DW, Lei Q, Zhu JY, Fan JX, Li CX, Li C. et al. Switching Apoptosis to Ferroptosis: Metal-Organic Network for High-Efficiency Anticancer Therapy. Nano Lett. 2017;17:284&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28027643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO. et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3209659</ArticleId>
            <ArticleId IdType="pubmed">21617154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol. 1991;53:549&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1830395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barile L, Vassalli G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28202367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yong SB, Song Y, Kim HJ, Ain QU, Kim YH. Mononuclear phagocytes as a target, not a barrier, for drug delivery. J Control Release. 2017;259:53&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28108325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10856220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP&#x3b1; signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276:145&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28258703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRP&#x3b1; Immune Checkpoint. Immunity. 2020;52:742&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7340539</ArticleId>
            <ArticleId IdType="pubmed">32433947</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34350694</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1613-6829</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>38</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Small (Weinheim an der Bergstrasse, Germany)</Title>
          <ISOAbbreviation>Small</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Sustainability of Energy Conversion Inhibition for Tumor Ferroptosis Therapy and Chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>e2102695</StartPage>
          <MedlinePgn>e2102695</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/smll.202102695</ELocationID>
        <Abstract>
          <AbstractText>The hyperactive energy metabolism mostly contributes the tumor cells growth and proliferation. Herein, the intelligent nanoparticles (P-B-D NPs) obtained by loading BAY-876 and doxorubicin (Dox)-Duplex into nanoparticles composed of disulfide bond (S(?)S) containing polymer are reported, which provide an efficient resistance of tumor cells energy metabolism and tumor growth to conquer malignant tumor. In response to the reducing microenvironment of tumor tissue, the S(?)S bond can be disintegrated by intracellular glutathione to block the synthesis of lipid repair enzyme-glutathione peroxidase 4 for ferroptosis therapy. More importantly, the released BAY-876 can inhibit the functionality of glucose transporter 1, restricting the glucose uptake of tumor cells to a low energy metabolism status. Meanwhile, Dox-Duplex can interact with ATP to reduce intracellular ATP content and release Dox to kill tumor cells. Collectively, this work offers a new idea for restricting tumor cells energy metabolism to inhibit their proliferation.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Materials Engineering, College of Engineering and Applied Sciences, Nanjing University, Jiangsu, 210093, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Xingyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Materials Engineering, College of Engineering and Applied Sciences, Nanjing University, Jiangsu, 210093, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Lulu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of South Florida, 4202 E. Fowler Ave, Tampa, FL, 33620, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Shanmei</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Nantong Vocational University, Nantong, 226019, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Jianfeng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of South Florida, 4202 E. Fowler Ave, Tampa, FL, 33620, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xiqun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Polymer Science &amp; Engineering, College of Chemistry &amp; Chemical Engineering, Nanjing University, Nanjing, 210093, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-5394-6743</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Materials Engineering, College of Engineering and Applied Sciences, Nanjing University, Jiangsu, 210093, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Small</MedlineTA>
        <NlmUniqueID>101235338</NlmUniqueID>
        <ISSNLinking>1613-6810</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BAY-876</Keyword>
        <Keyword MajorTopicYN="N">Glut1</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">metabolic inhibition</Keyword>
        <Keyword MajorTopicYN="N">self-assembly</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34350694</ArticleId>
        <ArticleId IdType="doi">10.1002/smll.202102695</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>W. Jiang, X. Han, T. Zhang, D. Xie, H. Zhang, Y. Hu, Adv. Healthcare Mater. 2020, 9, 1901303.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Jiang, C. Zhang, A. Ahmed, Y. Zhao, Y. Deng, Y. Ding, J. Cai, Y. Hu, Adv. Healthcare Mater. 2019, 8, 1900972.</Citation>
        </Reference>
        <Reference>
          <Citation>D. Xia, D. Hang, Y. Li, W. Jiang, J. Zhu, Y. Ding, H. Gu, Y. Hu, ACS Nano 2020, 14, 15654.</Citation>
        </Reference>
        <Reference>
          <Citation>D. Huo, J. Zhu, G. Chen, Q. Chen, C. Zhang, X. Luo, W. Jiang, X. Jiang, Z. Gu, Y. Hu, Nat. Commun. 2019, 10, 10.</Citation>
        </Reference>
        <Reference>
          <Citation>K. Yang, S. Zhang, G. Zhang, X. Sun, S.-T. Lee, Z. Liu, Nano Lett. 2010, 10, 3318.</Citation>
        </Reference>
        <Reference>
          <Citation>A. M. Gobin, M. H. Lee, N. J. Halas, W. D. James, R. A. Drezek, J. L. West, Nano Lett. 2007, 7, 1929.</Citation>
        </Reference>
        <Reference>
          <Citation>R. H. Fang, C.-M. J. Hu, B. T. Luk, W. Gao, J. A. Copp, Y. Tai, D. E. O'Connor, L. Zhang, Nano Lett. 2014, 14, 2181.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Zhang, D. Xia, J. Liu, D. Huo, X. Jiang, Y. Hu, Adv. Funct. Mater. 2020, 30, 2000189.</Citation>
        </Reference>
        <Reference>
          <Citation>P. Vaupel, F. Kallinowski, P. Okunieff, Cancer Res. 1989, 49, 6449.</Citation>
        </Reference>
        <Reference>
          <Citation>H. Pelicano, D. S. Martin, R. H. Xu, P. Huang, Oncogene 2006, 25, 4633.</Citation>
        </Reference>
        <Reference>
          <Citation>P. Vaupel, Semin. Radiat. Oncol. 2004, 14, 198.</Citation>
        </Reference>
        <Reference>
          <Citation>W.-H. Chen, G.-F. Luo, Q. Lei, S. Hong, W.-X. Qiu, L.-H. Liu, S.-X. Cheng, X.-Z. Zhang, ACS Nano 2017, 11, 1419.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Wang, J. Chen, X. Liang, H. Han, H. Wang, Y. Yang, Q. Li, Mol. Pharmaceutics 2017, 14, 2323.</Citation>
        </Reference>
        <Reference>
          <Citation>P. Zhao, M. Zheng, Z. Luo, X. Fan, Z. Sheng, P. Gong, Z. Chen, B. Zhang, D. Ni, Y. Ma, L. Cai, Adv. Healthcare Mater. 2016, 5, 2161.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Lai, B. R. Shah, Y. Zhang, L. Yang, K.-B. Lee, ACS Nano 2015, 9, 5234.</Citation>
        </Reference>
        <Reference>
          <Citation>M. G. V. Heiden, L. C. Cantley, C. B. Thompson, Science 2009, 324, 1029.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Szablewski, Biochim. Biophys. Acta, Rev. Cancer 2013, 1835, 164.</Citation>
        </Reference>
        <Reference>
          <Citation>S. N. Reske, K. G. Grillenberger, G. Glatting, M. Port, M. Hildebrandt, F. Gansauge, H. G. Beger, J. Nucl. Med. 1997, 38, 1344.</Citation>
        </Reference>
        <Reference>
          <Citation>K. Adekola, S. T. Rosen, M. Shanmugam, Curr. Opin. Oncol. 2012, 24, 650.</Citation>
        </Reference>
        <Reference>
          <Citation>M. Mamede, T. Higashi, M. Kitaichi, K. Ishizu, T. Ishimori, Y. Nakamoto, K. Yanagihara, M. Li, F. Tanaka, H. Wada, T. Manabet, T. Saga, Neoplasia 2005, 7, 369.</Citation>
        </Reference>
        <Reference>
          <Citation>G. Cantuaria, A. Fagotti, G. Ferrandina, A. Magalhaes, M. Nadji, R. Angioli, M. Penalver, S. Mancuso, G. Scambia, Cancer 2001, 92, 1144.</Citation>
        </Reference>
        <Reference>
          <Citation>G. Karageorgis, E. S. Reckzeh, J. Ceballos, M. Schwalfenberg, S. Sievers, C. Ostermann, A. Pahl, S. Ziegler, H. Waldmann, Nat. Chem. 2018, 10, 1103.</Citation>
        </Reference>
        <Reference>
          <Citation>T. Amann, C. Hellerbrand, Expert Opin. Ther. Targets 2009, 13, 1411.</Citation>
        </Reference>
        <Reference>
          <Citation>Y.-D. Wang, S.-J. Li, J.-X. Liao, Technol. Cancer Res. Treat. 2013, 12, 525.</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Shen, Q. Tian, Y. Sun, J.-J. Xu, D. Ye, H.-Y. Chen, Anal. Chem. 2017, 89, 13610.</Citation>
        </Reference>
        <Reference>
          <Citation>Z. Zhou, Q. Zhang, M. Zhang, H. Li, G. Chen, C. Qian, D. Oupicky, M. Sun, Theranostics 2018, 8, 4604.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Mo, T. Jiang, W. Sun, Z. Gu, Biomaterials 2015, 50, 67.</Citation>
        </Reference>
        <Reference>
          <Citation>V. Vultaggio-Poma, A. C. Sarti, F. Di Virgilio, Cells 2020, 9, 2496.</Citation>
        </Reference>
        <Reference>
          <Citation>F. Di Virgilio, A. C. Sarti, S. Falzoni, E. De Marchi, E. Adinolfi, Nat. Rev. Cancer 2018, 18, 601.</Citation>
        </Reference>
        <Reference>
          <Citation>S.-S. Wan, L. Zhang, X.-Z. Zhang, ACS Cent. Sci. 2019, 5, 327.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Mo, T. Jiang, R. DiSanto, W. Tai, Z. Gu, Nat. Commun. 2014, 5, 3364.</Citation>
        </Reference>
        <Reference>
          <Citation>Q. Wu, W. ba-alawi, G. Deblois, J. Cruickshank, S. Duan, E. Lima-Fernandes, J. Haight, S. A. M. Tonekaboni, A.-M. Fortier, H. Kuasne, T. D. McKee, H. Mahmoud, M. Kushida, S. Cameron, N. Dogan-Artun, W. Chen, Y. Nie, L. X. Zhang, R. N. Vellanki, S. Zhou, P. Prinos, B. G. Wouters, P. B. Dirks, S. J. Done, M. Park, D. W. Cescon, B. Haibe-Kains, M. Lupien, C. H. Arrowsmith, Nat. Commun. 2020, 11, 11.</Citation>
        </Reference>
        <Reference>
          <Citation>S. Lu, F. Zhao, Q. Zhang, P. Chen, Int. J. Mol. Sci. 2018, 19, 319.</Citation>
        </Reference>
        <Reference>
          <Citation>G.-H. Wang, G.-L. Huang, Y. Zhao, X.-X. Pu, T. Li, J.-J. Deng, J.-T. Lin, J. Mater. Chem. B 2016, 4, 3832.</Citation>
        </Reference>
        <Reference>
          <Citation>D. He, X. He, K. Wang, M. Chen, Y. Zhao, Z. Zou, J. Mater. Chem. B 2013, 1, 1552.</Citation>
        </Reference>
        <Reference>
          <Citation>W. S. Yang, R. SriRamaratnam, M. E. Welsch, K. Shimada, R. Skouta, V. S. Viswanathan, J. H. Cheah, P. A. Clemons, A. F. Shamji, C. B. Clish, L. M. Brown, A. W. Girotti, V. W. Cornish, S. L. Schreiber, B. R. Stockwell, Cell 2014, 156, 317.</Citation>
        </Reference>
        <Reference>
          <Citation>A. L. Harris, Nat. Rev. Cancer 2002, 2, 38.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34262021</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.</ArticleTitle>
        <Pagination>
          <StartPage>705</StartPage>
          <MedlinePgn>705</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">705</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-021-03996-y</ELocationID>
        <Abstract>
          <AbstractText>Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal cancer with limited treatment options. Cisplatin (DDP) is used as a mainstay of chemotherapeutic agents in combination with other drugs or radiotherapy for PDAC therapy. However, DDP exhibits severe side-effects that can lead to discontinuation of therapy, and the acquired drug resistance of tumor cells presents serious clinical obstacles. Therefore, it is imperative to develop a more effective and less toxic therapeutic strategy. We and others have previously discovered that dihydroartemisinin (DHA) represents a safe and promising therapeutic agent to preferentially induce cancer cell ferroptosis. In the present study, we find that DHA could intensively strengthen the cytotoxicity of DDP and significantly reduce its effective concentrations both in vitro and in vivo. Combination of DHA and DDP synergistically inhibits the proliferation and induces DNA damage of PDAC cells. Mechanically, the combinative treatment impairs mitochondrial homeostasis, characterized by destroyed mitochondrial morphology, decreased respiratory capacity, reduced ATP production, and accumulated mitochondria-derived ROS. Further studies show that ferroptosis contributes to the cytotoxic effects in PDAC cells under the challenge of DHA and DDP, together with catastrophic accumulation of free iron and unrestricted lipid peroxidation. Moreover, pharmacologic depleting of the free iron reservoir or reconstituted expression of FTH contributes to the tolerance of DHA/DDP-induced ferroptosis, while iron addition accelerates the ferroptotic cell death. In summary, these results provide experimental evidence that DHA acts synergistically with DDP and renders PDAC cells vulnerable to ferroptosis, which may act as a promising therapeutic strategy.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Du</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-7519-8531</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Yanchun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Central Laboratory, Affiliated Hangzhou first people's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Xueying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Wanye</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Bengbu Medical College, Bengbu, Anhui, 233000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Chaoting</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jing</LastName>
            <ForeName>Qiangan</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Luyang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huanjuan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Lijuan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Hangzhou Ninth People's Hospital, Hangzhou, Zhejiang, 310014, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yonglie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. lab_zyl@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tong</LastName>
            <ForeName>Xiangmin</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-4175-0321</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. tongxiangmin@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bengbu Medical College, Bengbu, Anhui, 233000, China. tongxiangmin@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China. tongxiangmin@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Phase I Clinical Research Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. tongxiangmin@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-2121-7025</Identifier>
            <AffiliationInfo>
              <Affiliation>Bengbu Medical College, Bengbu, Anhui, 233000, China. nancywangying@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China. nancywangying@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Phase I Clinical Research Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. nancywangying@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6A9O50735X</RegistryNumber>
          <NameOfSubstance UI="C039060">artenimol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34262021</ArticleId>
        <ArticleId IdType="pmc">PMC8280115</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-021-03996-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-021-03996-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437&#x2013;50. doi: 10.1016/S1535-6108(03)00309-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00309-X</ArticleId>
            <ArticleId IdType="pubmed">14706336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91&#x2013;100. doi: 10.1016/j.tibs.2013.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2013.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC3955735</ArticleId>
            <ArticleId IdType="pubmed">24388967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17:153&#x2013;68. doi: 10.1038/s41575-019-0245-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-019-0245-4</ArticleId>
            <ArticleId IdType="pubmed">32005945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai LH, Hsu KW, Chiang CM, Yang HJ, Liu YH, Yang SF, et al. Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer. Sci Rep. 2020;10:17817. doi: 10.1038/s41598-020-73659-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-73659-z</ArticleId>
            <ArticleId IdType="pmc">PMC7576602</ArticleId>
            <ArticleId IdType="pubmed">33082357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7&#x2013;34. doi: 10.3322/caac.21551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21551</ArticleId>
            <ArticleId IdType="pubmed">30620402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bebber CM, M&#xfc;ller F, Prieto Clemente L, Weber J, von Karstedt S. Ferroptosis in cancer cell biology. Cancers. 2020;12:164. doi: 10.3390/cancers12010164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12010164</ArticleId>
            <ArticleId IdType="pmc">PMC7016816</ArticleId>
            <ArticleId IdType="pubmed">31936571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira JA, Peixoto A, Neves M, Gaiteiro C, Reis CA, Assaraf YG, et al. Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation. Drug Resist Updat. 2016;24:34&#x2013;54. doi: 10.1016/j.drup.2015.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drup.2015.11.003</ArticleId>
            <ArticleId IdType="pubmed">26830314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992;10:574&#x2013;9. doi: 10.1200/JCO.1992.10.4.574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1992.10.4.574</ArticleId>
            <ArticleId IdType="pubmed">1372350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi YM, Kim HK, Shim W, Anwar MA, Kwon JW, Kwon HK, et al. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS ONE. 2015;10:e0135083. doi: 10.1371/journal.pone.0135083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0135083</ArticleId>
            <ArticleId IdType="pmc">PMC4527592</ArticleId>
            <ArticleId IdType="pubmed">26247588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Oliveira G, Freire PP, Cury SS, de Moraes D, Oliveira JS, Dal-Pai-Silva M, et al. An integrated meta-analysis of secretome and proteome identify potential biomarkers of pancreatic ductal adenocarcinoma. Cancers. 2020;12:716. doi: 10.3390/cancers12030716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12030716</ArticleId>
            <ArticleId IdType="pmc">PMC7140071</ArticleId>
            <ArticleId IdType="pubmed">32197468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Wang K. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cell Biol Int. 2019;43:1245&#x2013;56. doi: 10.1002/cbin.11121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbin.11121</ArticleId>
            <ArticleId IdType="pubmed">30811078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat. 2017;50:445&#x2013;60. doi: 10.4143/crt.2016.572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4143/crt.2016.572</ArticleId>
            <ArticleId IdType="pmc">PMC5912137</ArticleId>
            <ArticleId IdType="pubmed">28494534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A. Drug repurposing in oncology. Lancet Oncol. 2020;21:e543. doi: 10.1016/S1470-2045(20)30610-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30610-0</ArticleId>
            <ArticleId IdType="pubmed">33271100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146:855&#x2013;8. doi: 10.1016/j.cell.2011.08.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.08.024</ArticleId>
            <ArticleId IdType="pmc">PMC3414217</ArticleId>
            <ArticleId IdType="pubmed">21907397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flobinus A, Taudon N, Desbordes M, Labrosse B, Simon F, Mazeron MC, et al. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. J Antimicrob Chemother. 2014;69:34&#x2013;40. doi: 10.1093/jac/dkt346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkt346</ArticleId>
            <ArticleId IdType="pubmed">24003183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res. 2003;48:231&#x2013;6. doi: 10.1016/S1043-6618(03)00107-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1043-6618(03)00107-5</ArticleId>
            <ArticleId IdType="pubmed">12860439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luan S, Zhong H, Zhao X, Yang J, Jing Y, Liu D, et al. Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin. Eur J Med Chem. 2017;141:584&#x2013;95. doi: 10.1016/j.ejmech.2017.10.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2017.10.023</ArticleId>
            <ArticleId IdType="pubmed">29102180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu W, Chen SS, Zhang JL, Lou XE, Zhou HJ. Dihydroartemisinin induces autophagy by suppressing NF-&#x3ba;B activation. Cancer Lett. 2014;343:239&#x2013;48. doi: 10.1016/j.canlet.2013.09.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.09.035</ArticleId>
            <ArticleId IdType="pubmed">24099910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan X, Li P, Zhan Y, Qi M, Liu J, An Z, et al. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in non-small cell lung cancer cells harboring EGFR or RAS mutation. Biochem Pharmacol. 2018;150:72&#x2013;85. doi: 10.1016/j.bcp.2018.01.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2018.01.031</ArticleId>
            <ArticleId IdType="pubmed">29360439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beccafico S, Morozzi G, Marchetti MC, Riccardi C, Sidoni A, Donato R, et al. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis. 2015;36:1071&#x2013;83. doi: 10.1093/carcin/bgv098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgv098</ArticleId>
            <ArticleId IdType="pubmed">26153023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Bio Med. 2018;131:356&#x2013;69. doi: 10.1016/j.freeradbiomed.2018.12.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.12.011</ArticleId>
            <ArticleId IdType="pubmed">30557609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, Schorpp K, Jin J, Yozwiak CE, Hoffstrom BG, Decker AM, et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 2020;30:3411&#x2013;23. doi: 10.1016/j.celrep.2020.02.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.02.049</ArticleId>
            <ArticleId IdType="pmc">PMC7172030</ArticleId>
            <ArticleId IdType="pubmed">32160546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang ND, Tan SH, Ng S, Shi Y, Zhou J, Tan KS, et al. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem. 2014;289:33425&#x2013;41. doi: 10.1074/jbc.M114.564567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.564567</ArticleId>
            <ArticleId IdType="pmc">PMC4246098</ArticleId>
            <ArticleId IdType="pubmed">25305013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen GQ, Benthani FA, Wu J, Liang D, Bian ZX, Jiang X. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 2020;27:242&#x2013;54. doi: 10.1038/s41418-019-0352-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0352-3</ArticleId>
            <ArticleId IdType="pmc">PMC7205875</ArticleId>
            <ArticleId IdType="pubmed">31114026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carneiro Benedito A, El-Deiry Wafik S. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395&#x2013;417. doi: 10.1038/s41571-020-0341-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-020-0341-y</ArticleId>
            <ArticleId IdType="pmc">PMC8211386</ArticleId>
            <ArticleId IdType="pubmed">32203277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greco G, Catanzaro E, Fimognari C. Natural products as inducers of non-canonical cell death: a weapon against cancer. Cancers. 2021;13:304. doi: 10.3390/cancers13020304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13020304</ArticleId>
            <ArticleId IdType="pmc">PMC7830727</ArticleId>
            <ArticleId IdType="pubmed">33467668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan Meagan B, Corcoran Ryan B. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709&#x2013;20. doi: 10.1038/s41571-018-0105-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-018-0105-0</ArticleId>
            <ArticleId IdType="pubmed">30275515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonam D, Lessnick Stephen L, Hahn William C, Stockwell Brent R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285&#x2013;96. doi: 10.1016/S1535-6108(03)00050-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00050-3</ArticleId>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234&#x2013;45. doi: 10.1016/j.chembiol.2008.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2008.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;8. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JL, Wang Z, Hu W, Chen SS, Lou XE, Zhou HJ. DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma. Microvasc Res. 2013;87:14&#x2013;24. doi: 10.1016/j.mvr.2013.02.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mvr.2013.02.006</ArticleId>
            <ArticleId IdType="pubmed">23466284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Ni W, Deng Z, Liu M, She L, Xie Q. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress. Fundam Clin Pharmacol. 2017;31:301&#x2013;10. doi: 10.1111/fcp.12266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/fcp.12266</ArticleId>
            <ArticleId IdType="pubmed">28078787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley Michael A, Kremer Daniel M, Carlo Maurer H, Delgiorno Kathleen E, Lee H-J, Purohit V, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85&#x2013;89. doi: 10.1126/science.aaw9872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaw9872</ArticleId>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342&#x2013;55. doi: 10.1038/nrc3495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3495</ArticleId>
            <ArticleId IdType="pmc">PMC4036554</ArticleId>
            <ArticleId IdType="pubmed">23594855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107&#x2013;25. doi: 10.1038/s41422-020-00441-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId>
            <ArticleId IdType="pmc">PMC8026611</ArticleId>
            <ArticleId IdType="pubmed">33268902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu S, Zhang Q, Sun X, Zeh Herbert J, Lotze Michael T, Kang R, et al. HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res. 2017;77:2064&#x2013;77. doi: 10.1158/0008-5472.CAN-16-1979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1979</ArticleId>
            <ArticleId IdType="pmc">PMC5392369</ArticleId>
            <ArticleId IdType="pubmed">28130223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173&#x2013;84. doi: 10.1002/hep.28251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poursaitidis I, Wang X, Crighton T, Labuschagne C, Mason D, Cramer SL, et al. Oncogene-selective sensitivity to synchronous cell death following modulation of the amino acid nutrient cystine. Cell Rep. 2017;18:2547&#x2013;56. doi: 10.1016/j.celrep.2017.02.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.02.054</ArticleId>
            <ArticleId IdType="pmc">PMC5368412</ArticleId>
            <ArticleId IdType="pubmed">28297659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu D, Gu J, Chen Y, Kang W, Wang X, Wu H. Current strategies to combat cisplatin-induced ototoxicity. Front Pharmacol. 2020;11:999. doi: 10.3389/fphar.2020.00999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00999</ArticleId>
            <ArticleId IdType="pmc">PMC7350523</ArticleId>
            <ArticleId IdType="pubmed">32719605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. doi: 10.1016/j.bioorg.2019.102925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bioorg.2019.102925</ArticleId>
            <ArticleId IdType="pubmed">31003078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Sui S, Wang L, Li H, Zhang L, Xu S, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020;235:3425&#x2013;37. doi: 10.1002/jcp.29232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.29232</ArticleId>
            <ArticleId IdType="pubmed">31556117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Hou D, Liu Q, Wu T, Guo H, Zhang X, et al. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol. Ther. 2015;16:1548&#x2013;56. doi: 10.1080/15384047.2015.1071738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384047.2015.1071738</ArticleId>
            <ArticleId IdType="pmc">PMC5391513</ArticleId>
            <ArticleId IdType="pubmed">26176175</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34238297</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-3155</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of nanobiotechnology</Title>
          <ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hypoxia-responsive nanoreactors based on self-enhanced photodynamic sensitization and triggered ferroptosis for cancer synergistic therapy.</ArticleTitle>
        <Pagination>
          <StartPage>204</StartPage>
          <MedlinePgn>204</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">204</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-021-00952-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Photodynamic therapy (PDT), a typical reactive oxygen species (ROS)-dependent treatment with high controllability, has emerged as an alternative cancer therapy modality but its therapeutic efficacy is still unsatisfactory due to the limited light penetration and constant oxygen consumption. With the development of another ROS-dependent paradigm ferroptosis, several efforts have been made to conquer the poor efficacy by combining these two approaches; however the biocompatibility, tumor-targeting capacity and clinical translation prospect of current studies still exist great concerns. Herein, a novel hypoxia-responsive nanoreactor BCFe@SRF with sorafenib (SRF) loaded inside, constructed by covalently connecting chlorin e6 conjugated bovine serum albumin (BSA-Ce6) and ferritin through azobenzene (Azo) linker, were prepared to offer unmatched opportunities for high-efficient PDT and ferroptosis synergistic therapy.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The designed BCFe@SRF exhibited appropriate size distribution, stable dispersity, excellent ROS generation property, controllable drug release capacity, tumor accumulation ability, and outstanding biocompatibility. Importantly, the BCFe@SRF could be degraded under hypoxia environment to release BSA-Ce6 for laser-triggered PDT, ferritin for iron-catalyzed Fenton reaction and SRF for tumor antioxidative defense disruption. Meanwhile, besides PDT effects, it was found that BCFe@SRF mediated treatment upon laser irradiation in hypoxic environment not only could accelerate lipid peroxidation (LPO) generation but also could deplete intracellular glutathione (GSH) and decrease glutathione peroxidase (GPX4) expression, which was believed as three symbolic events during ferroptosis. All in all, the BCFe@SRF nanoreactor, employing multiple cascaded pathways to promote intracellular ROS accumulation, presented remarkably outstanding antitumor effects both in vitro and in vivo.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BCFe@SRF could serve as a promising candidate for synergistic PDT and ferroptosis therapy, which is applicable to boost oxidative damage within tumor site and will be informative to future design of ROS-dependent therapeutic nanoplatforms.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaoyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, 350002, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiaolong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Feida</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, 350002, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeng</LastName>
            <ForeName>Yongyi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Xinyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China. lxy.1210@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China. lxy.1210@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaolong</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-3096-4981</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, 350002, People's Republic of China. xiaoloong.liu@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China. xiaoloong.liu@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China. xiaoloong.liu@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. xiaoloong.liu@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jingfeng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, 350002, People's Republic of China. drjingfeng@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China. drjingfeng@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, People's Republic of China. drjingfeng@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. drjingfeng@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fujian Cancer Hospital &amp; Fujian Medical University Cancer Hospital, Fuzhou, 350014, People's Republic of China. drjingfeng@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81871483</GrantID>
            <Agency>Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2020J02010</GrantID>
            <Agency>Natural Science Foundation of Fujian Province of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2019Y0013</GrantID>
            <Agency>Guiding Project of Fujian Provincial Department of Science &amp; Technology</Agency>
          </Grant>
          <Grant>
            <GrantID>2018Y9119</GrantID>
            <Agency>Joint Funds for the Innovation of Science and Technology, Fujian Province</Agency>
          </Grant>
          <Grant>
            <GrantID>2019Y9046</GrantID>
            <Agency>Joint Funds for the Innovation of Science and Technology, Fujian Province</Agency>
          </Grant>
          <Grant>
            <GrantID>2019Y9108</GrantID>
            <Agency>Joint Funds for the Innovation of Science and Technology, Fujian Province</Agency>
          </Grant>
          <Grant>
            <GrantID>2020-S-wt7</GrantID>
            <Agency>Scientific Foundation of Fuzhou Municipal Health Commission</Agency>
          </Grant>
          <Grant>
            <GrantID>2020-S-wp6</GrantID>
            <Agency>Scientific Foundation of Fuzhou Municipal Health Commission</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Nanobiotechnology</MedlineTA>
        <NlmUniqueID>101152208</NlmUniqueID>
        <ISSNLinking>1477-3155</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S2CCF3T1Z</RegistryNumber>
          <NameOfSubstance UI="C062985">phytochlorin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="N">Chlorophyllides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D041681" MajorTopicYN="N">NIH 3T3 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036103" MajorTopicYN="N">Nanotechnology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="N">Porphyrins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Hypoxia-responsive</Keyword>
        <Keyword MajorTopicYN="N">Oxidation treatment</Keyword>
        <Keyword MajorTopicYN="N">Photodynamic therapy (PDT)</Keyword>
        <Keyword MajorTopicYN="N">Protein-based nanoparticle</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34238297</ArticleId>
        <ArticleId IdType="pmc">PMC8265128</ArticleId>
        <ArticleId IdType="doi">10.1186/s12951-021-00952-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s12951-021-00952-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tang ZM, Liu YY, Ni DL, Zhou JJ, Zhang M, Zhao PR, Lv B, Wang H, Jin DY, Bu WB. Biodegradable nanoprodrugs: "delivering" ROS to cancer cells for molecular dynamic therapy. Adv Mater. 2020;32:1904011. doi: 10.1002/adma.201904011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201904011</ArticleId>
            <ArticleId IdType="pubmed">31793717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jasim KA, Gesquiere AJ. Ultrastable and biofunctionalizable conjugated polymer nanoparticles with encapsulated iron for ferroptosis assisted chemodynamic therapy. Mol Pharm. 2019;16:4852&#x2013;4866. doi: 10.1021/acs.molpharmaceut.9b00737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00737</ArticleId>
            <ArticleId IdType="pubmed">31613630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang B, Ding L, Yao H, Chen Y, Shi J. A metal-organic framework (MOF) fenton nanoagent-enabled nanocatalytic cancer therapy in synergy with autophagy inhibition. Adv Mater. 2020;32:e1907152. doi: 10.1002/adma.201907152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201907152</ArticleId>
            <ArticleId IdType="pubmed">32053261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M, Ding Y, Li L. Recent progress in the augmentation of reactive species with nanoplatforms for cancer therapy. Nanoscale. 2019;11:19658&#x2013;19683. doi: 10.1039/C9NR06651A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9NR06651A</ArticleId>
            <ArticleId IdType="pubmed">31612164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Z, Liang P, Xie J, Song C, Tang C, Wang Y, Yin X, Cai Y, Han W, Dong X. Carrier-free nano-integrated strategy for synergetic cancer anti-angiogenic therapy and phototherapy. Chem Sci. 2019;10:2778&#x2013;2784. doi: 10.1039/C8SC04123G.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8SC04123G</ArticleId>
            <ArticleId IdType="pmc">PMC6419942</ArticleId>
            <ArticleId IdType="pubmed">30996997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Liu R, Xu Y, Qian L, Dai Z. Photosensitizer nanoparticles boost photodynamic therapy for pancreatic cancer treatment. Nano-Micro Lett. 2021;13:1&#x2013;16. doi: 10.1007/s40820-020-00525-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40820-020-00525-y</ArticleId>
            <ArticleId IdType="pmc">PMC8187547</ArticleId>
            <ArticleId IdType="pubmed">34138222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding L, Lin X, Lin Z, Wu Y, Liu X, Liu J, Wu M, Zhang X, Zeng Y. Cancer cell-targeted photosensitizer and therapeutic protein co-delivery nanoplatform based on a metal-organic framework for enhanced synergistic photodynamic and protein therapy. ACS Appl Mater Interfaces. 2020;12:36906&#x2013;36916. doi: 10.1021/acsami.0c09657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.0c09657</ArticleId>
            <ArticleId IdType="pubmed">32706242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Wu M, Li M, Cai Z, Sun H, Tan X, Li J, Zeng Y, Liu X, Liu J. Photo-responsive hollow silica nanoparticles for light-triggered genetic and photodynamic synergistic therapy. Acta Biomater. 2018;76:178&#x2013;192. doi: 10.1016/j.actbio.2018.07.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actbio.2018.07.007</ArticleId>
            <ArticleId IdType="pubmed">30078423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo PC, Rodriguez-Morgade MS, Pandey RK, Ng DKP, Torres T, Dumoulin F. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer. Chem Soc Rev. 2020;49:1041&#x2013;1056. doi: 10.1039/C9CS00129H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9CS00129H</ArticleId>
            <ArticleId IdType="pubmed">31845688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Zhou H, Zhao Y, Lu L, Zhang J, Cheng W, Song X, Zheng Y, Chen C, Tang J. Time-course effect of ultrasmall superparamagnetic iron oxide nanoparticles on intracellular iron metabolism and ferroptosis activation. Nanotoxicology. 2021;15:366&#x2013;379. doi: 10.1080/17435390.2021.1872112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17435390.2021.1872112</ArticleId>
            <ArticleId IdType="pubmed">33455495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X, Deng J, Liu F, Guo T, Liu M, Dai P, Fan A, Wang Z, Zhao Y. Triggered all-active metal organic framework: ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett. 2019;19:7866&#x2013;7876. doi: 10.1021/acs.nanolett.9b02904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.9b02904</ArticleId>
            <ArticleId IdType="pubmed">31594301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu JJ, Chen Y, Li ZH, Peng SY, Sun Y, Zhang XZ. Augment of oxidative damage with enhanced photodynamic process and MTH1 inhibition for tumor therapy. Nano Lett. 2019;19:5568&#x2013;5576. doi: 10.1021/acs.nanolett.9b02112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.9b02112</ArticleId>
            <ArticleId IdType="pubmed">31262183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Z, Liu Y, He M, Bu W. Chemodynamic therapy: Tumour microenvironment-mediated fenton and fenton-like reactions. Angew Chem Int Ed Engl. 2019;58:946&#x2013;956. doi: 10.1002/anie.201805664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201805664</ArticleId>
            <ArticleId IdType="pubmed">30048028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang E, Jung HS. Metal-organic complex-based chemodynamic therapy agents for cancer therapy. Chem Commun. 2020;56:8332&#x2013;8341. doi: 10.1039/D0CC03012K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0CC03012K</ArticleId>
            <ArticleId IdType="pubmed">32515445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H, Chen Y, Shi J. Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specific therapy. Chem Soc Rev. 2018;47:1938&#x2013;1958. doi: 10.1039/C7CS00471K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C7CS00471K</ArticleId>
            <ArticleId IdType="pubmed">29417106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Hua Liu S, Yin J, Yoon J. Sonodynamic and chemodynamic therapy based on organic/organometallic sensitizers. Coord Chem Rev. 2021;429:213610. doi: 10.1016/j.ccr.2020.213610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2020.213610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao YN, Zhang WX, Gao YR, Wei YN, Shu Y, Wang JH. State-of-the-art advances of copper-based nanostructures in the enhancement of chemodynamic therapy. J Mater Chem B. 2021;9:250&#x2013;266. doi: 10.1039/D0TB02360D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0TB02360D</ArticleId>
            <ArticleId IdType="pubmed">33237121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhong X, Liu Z, Cheng L. Recent progress of chemodynamic therapy-induced combination cancer therapy. Nano Today. 2020;35:100946. doi: 10.1016/j.nantod.2020.100946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nantod.2020.100946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Jin Y, Xu Z, Liu X, Bajwa SZ, Khan WS, Yu H. Stimuli-activatable nanomedicines for chemodynamic therapy of cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12:e1614. doi: 10.1002/wnan.1614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wnan.1614</ArticleId>
            <ArticleId IdType="pubmed">32011108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang B, Dai Z, Zhang G, Hu Z, Yao X, Wang S, Liu Q, Zheng X. Ultrasmall ternary FePtMn nanocrystals with acidity-triggered dual-ions release and hypoxia relief for multimodal synergistic chemodynamic/photodynamic/photothermal cancer therapy. Adv Healthc Mater. 2020;9:e1901634. doi: 10.1002/adhm.201901634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adhm.201901634</ArticleId>
            <ArticleId IdType="pubmed">32959536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H, Guo J, Shi Y, Zhao G, Sun S, Sun X. Porous yolk-shell Fe/Fe3O4 nanoparticles with controlled exposure of highly active Fe(0) for cancer therapy. Biomaterials. 2021;268:120530. doi: 10.1016/j.biomaterials.2020.120530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2020.120530</ArticleId>
            <ArticleId IdType="pubmed">33296795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Zhang X, Wang Z, Shi D. Ferroptotic nanomaterials enhance cancer therapy via boosting Fenton-reaction. J Drug Deliv Sci Technol. 2020;59:101883. doi: 10.1016/j.jddst.2020.101883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jddst.2020.101883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Song J, Yung BC, Zhou Z, Wu A, Chen X. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater. 2018;30:e1704007. doi: 10.1002/adma.201704007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201704007</ArticleId>
            <ArticleId IdType="pmc">PMC6377162</ArticleId>
            <ArticleId IdType="pubmed">29356212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Liu T, Li Y, Lau J, Yang Z, Fan W, Zhou Z, Shi C, Ke C, Bregadze VI, Mandal SK, Liu Y, Li Z, Xue T, Zhu G, Munasinghe J, Niu G, Wu A, Chen X. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 2018;12:11355&#x2013;11365. doi: 10.1021/acsnano.8b06201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06201</ArticleId>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Q, Wang K, Zhang X, Ouyang B, Liu H, Pang Z, Yang W. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small. 2020;16:e2001704. doi: 10.1002/smll.202001704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/smll.202001704</ArticleId>
            <ArticleId IdType="pubmed">32338436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Ma X, Xie L, Chen W, Xu Z, Song E, Zhu X, Song Y. Iron-based nanoparticles for MR imaging-guided ferroptosis in combination with photodynamic therapy to enhance cancer treatment. Nanoscale. 2021;13:4855&#x2013;4870. doi: 10.1039/D0NR08757B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0NR08757B</ArticleId>
            <ArticleId IdType="pubmed">33624647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu T, Shi L, Yu C, Dong Y, Qiu F, Shen L, Qian Q, Zhou G, Zhu X. Ferroptosis promotes photodynamic therapy: supramolecular photosensitizer-inducer nanodrug for enhanced cancer treatment. Theranostics. 2019;9:3293&#x2013;3307. doi: 10.7150/thno.32867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.32867</ArticleId>
            <ArticleId IdType="pmc">PMC6567978</ArticleId>
            <ArticleId IdType="pubmed">31244955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Ma Y, Yuan Q, Hu H, Hu X, Qian Z, Rolle JK, Gu Y, Li S. Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy. ACS Nano. 2020;14:3414&#x2013;3425. doi: 10.1021/acsnano.9b09426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.9b09426</ArticleId>
            <ArticleId IdType="pubmed">32155051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, Wang SB, Feng J, Zhang XZ. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano. 2018;12:12181&#x2013;12192. doi: 10.1021/acsnano.8b05860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b05860</ArticleId>
            <ArticleId IdType="pubmed">30458111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng YJ, Hu JJ, Qin SY, Zhang AQ, Zhang XZ. Recent advances in functional mesoporous silica-based nanoplatforms for combinational photo-chemotherapy of cancer. Biomaterials. 2020;232:119738. doi: 10.1016/j.biomaterials.2019.119738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2019.119738</ArticleId>
            <ArticleId IdType="pubmed">31901695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Wang X, Gu Q, Lei D, Liu X, Yao C. Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy. Biomed Mater. 2021;16:042001. doi: 10.1088/1748-605X/abe7b3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1088/1748-605X/abe7b3</ArticleId>
            <ArticleId IdType="pubmed">33601351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Xuan Z, Zhu X, Sun H, Li J, Xie Z. Near-infrared photoresponsive drug delivery nanosystems for cancer photo-chemotherapy. J Nanobiotechnol. 2020;18:108. doi: 10.1186/s12951-020-00668-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12951-020-00668-5</ArticleId>
            <ArticleId IdType="pmc">PMC7397640</ArticleId>
            <ArticleId IdType="pubmed">32746846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, Tang Z, Chen X, He Z, He X, Zhang M, Liu Y, Ren D, Zhao K, Bu W. Ferrous-cysteine&#x2013;phosphotungstate nanoagent with neutral pH fenton reaction activity for enhanced cancer chemodynamic therapy. Mater Horiz. 2019;6:369&#x2013;374. doi: 10.1039/C8MH01176A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8MH01176A</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434&#x2013;439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7812975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Distinct patterns of matrix metalloproteinase-2 and -9 expression in normal human cell lines. Oncol Rep. 2009;21:821&#x2013;826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19212645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee EJ, Lee NK, Kim IS. Bioengineered protein-based nanocage for drug delivery. Adv Drug Deliv Rev. 2016;106:157&#x2013;171. doi: 10.1016/j.addr.2016.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2016.03.002</ArticleId>
            <ArticleId IdType="pubmed">26994591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. Biomed Res Int. 2014;2014:180549. doi: 10.1155/2014/180549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/180549</ArticleId>
            <ArticleId IdType="pmc">PMC3977416</ArticleId>
            <ArticleId IdType="pubmed">24772414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandra F, Khaliq NU, Sunna A, Care A. Developing protein-based nanoparticles as versatile delivery systems for cancer therapy and imaging. Nanomaterials. 2019;9:1329. doi: 10.3390/nano9091329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nano9091329</ArticleId>
            <ArticleId IdType="pmc">PMC6781024</ArticleId>
            <ArticleId IdType="pubmed">31527483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaber M, Medhat W, Hany M, Saher N, Fang JY, Elzoghby A. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes. J Control Release. 2017;254:75&#x2013;91. doi: 10.1016/j.jconrel.2017.03.392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2017.03.392</ArticleId>
            <ArticleId IdType="pubmed">28365294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truffi M, Fiandra L, Sorrentino L, Monieri M, Corsi F, Mazzucchelli S. Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res. 2016;107:57&#x2013;65. doi: 10.1016/j.phrs.2016.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2016.03.002</ArticleId>
            <ArticleId IdType="pubmed">26968122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang M, Fan K, Zhou M, Duan D, Zheng J, Yang D, Feng J, Yan X. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc Natl Acad Sci. 2014;111:14900&#x2013;14905. doi: 10.1073/pnas.1407808111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1407808111</ArticleId>
            <ArticleId IdType="pmc">PMC4205604</ArticleId>
            <ArticleId IdType="pubmed">25267615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, 3rd, Kang R, Tang D. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425&#x2013;1428. doi: 10.1080/15548627.2016.1187366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1187366</ArticleId>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021&#x2013;1032. doi: 10.1038/cr.2016.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2016.95</ArticleId>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang RZ, Xu WN, Zheng HL, Zheng XF, Li B, Jiang LS, Jiang SD. Involvement of oxidative stress-induced annulus fibrosus cell and nucleus pulposus cell ferroptosis in intervertebral disc degeneration pathogenesis. J Cell Physiol. 2021;236:2725&#x2013;2739. doi: 10.1002/jcp.30039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.30039</ArticleId>
            <ArticleId IdType="pmc">PMC7891651</ArticleId>
            <ArticleId IdType="pubmed">32892384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 2019;10:822. doi: 10.1038/s41419-019-2064-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2064-5</ArticleId>
            <ArticleId IdType="pmc">PMC6817894</ArticleId>
            <ArticleId IdType="pubmed">31659150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wang X, Yan J, Liu Y, Yang R, Pan D, Wang L, Xu Y, Li X, Yang M. Nanoparticle ferritin-bound erastin and rapamycin: a nanodrug combining autophagy and ferroptosis for anticancer therapy. Biomater Sci. 2019;7:3779&#x2013;3787. doi: 10.1039/C9BM00653B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9BM00653B</ArticleId>
            <ArticleId IdType="pubmed">31211307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614&#x2013;622. doi: 10.1038/aps.2017.5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2017.5</ArticleId>
            <ArticleId IdType="pmc">PMC5457690</ArticleId>
            <ArticleId IdType="pubmed">28344323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835&#x2013;844. doi: 10.1038/nrd2130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd2130</ArticleId>
            <ArticleId IdType="pubmed">17016424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, De Oliveira AC, Santoro A, Raoul J-L, Forner A. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378&#x2013;390. doi: 10.1056/NEJMoa0708857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0708857</ArticleId>
            <ArticleId IdType="pubmed">18650514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Meng X, Deng J, Lu D, Zhang X, Chen Y, Zhu J, Fan A, Ding D, Kong D, Wang Z, Zhao Y. Multifunctional micelles dually responsive to hypoxia and singlet oxygen: enhanced photodynamic therapy via interactively triggered photosensitizer delivery. ACS Appl Mater Interfaces. 2018;10:17117&#x2013;17128. doi: 10.1021/acsami.8b06299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b06299</ArticleId>
            <ArticleId IdType="pubmed">29722261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Lin L, Ma X, Wang B, Liu S, Yan X, Li S, Tian H, Yu X. Light-induced hypoxia-triggered living nanocarriers for synergistic cancer therapy. ACS Appl Mater Interfaces. 2018;10:19398&#x2013;19407. doi: 10.1021/acsami.8b03506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b03506</ArticleId>
            <ArticleId IdType="pubmed">29781276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Wu M, Li J, Lan S, Zeng Y, Liu X, Liu J. Light-enhanced hypoxia-response of conjugated polymer nanocarrier for successive synergistic photodynamic and chemo-therapy. ACS Appl Mater Interfaces. 2018;10:21909&#x2013;21919. doi: 10.1021/acsami.8b06491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b06491</ArticleId>
            <ArticleId IdType="pubmed">29882654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Wu M, Bai H, Liu X, Tang G. Light-enhanced hypoxia-responsive nanoparticles for deep tumor penetration and combined chemo-photodynamic therapy. Chem Commun. 2018;54:13127&#x2013;13130. doi: 10.1039/C8CC08445A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8CC08445A</ArticleId>
            <ArticleId IdType="pubmed">30398488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai Y, Xu C, Sun X, Chen X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017;46:3830&#x2013;3852. doi: 10.1039/C6CS00592F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C6CS00592F</ArticleId>
            <ArticleId IdType="pmc">PMC5521825</ArticleId>
            <ArticleId IdType="pubmed">28516983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Phua SZF, Lim WQ, Zhang R, Feng L, Liu G, Wu H, Bindra AK, Jana D, Liu Z, Zhao Y. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy. Adv Mater. 2019;31:e1901513. doi: 10.1002/adma.201901513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201901513</ArticleId>
            <ArticleId IdType="pubmed">31069885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Wang X, Li J, Cai L, Liao F, Wu M, Zheng D, Zeng Y, Zhang Z, Liu X, Wang J, Yao C. Localized NIR-II photo-immunotherapy through the combination of photothermal ablation and in situ generated interleukin-12 cytokine for efficiently eliminating primary and abscopal tumors. Nanoscale. 2021;13:1745&#x2013;1758. doi: 10.1039/D0NR06182D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0NR06182D</ArticleId>
            <ArticleId IdType="pubmed">33432957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Liu Z. Albumin carriers for cancer theranostics: a conventional patform with new promise. Adv Mater. 2016;28:10557&#x2013;10566. doi: 10.1002/adma.201600038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201600038</ArticleId>
            <ArticleId IdType="pubmed">27111654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Zhao F, Zou Q, Li Y, Ma G, Yan X. Multitriggered tumor-responsive drug delivery vehicles based on protein and polypeptide coassembly for enhanced photodynamic tumor ablation. Small. 2016;12:5936&#x2013;5943. doi: 10.1002/smll.201602339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/smll.201602339</ArticleId>
            <ArticleId IdType="pubmed">27622681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La A, Nguyen T, Tran K, Sauble E, Tu D, Gonzalez A, Kidane TZ, Soriano C, Morgan J, Doan M, Tran K, Wang CY, Knutson MD, Linder MC. Mobilization of iron from ferritin: new steps and details. Metallomics. 2018;10:154&#x2013;168. doi: 10.1039/C7MT00284J.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C7MT00284J</ArticleId>
            <ArticleId IdType="pubmed">29260183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Yuan S, Zhang Y, Wu W, Hu Y, Jiang X. The effects of poly(zwitterions)s versus poly(ethylene glycol) surface coatings on the biodistribution of protein nanoparticles. Biomater Sci. 2016;4:1351&#x2013;1360. doi: 10.1039/C6BM00201C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C6BM00201C</ArticleId>
            <ArticleId IdType="pubmed">27426309</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34229160</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2213-2317</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Redox biology</Title>
          <ISOAbbreviation>Redox Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Non-enzymatic lipid peroxidation initiated by photodynamic therapy drives a distinct ferroptosis-like cell death pathway.</ArticleTitle>
        <Pagination>
          <StartPage>102056</StartPage>
          <MedlinePgn>102056</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">102056</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redox.2021.102056</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2213-2317(21)00215-9</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is primarily triggered by a failure of the glutathione (GSH)-glutathione peroxidase 4 (GPX4) reductive system and associated overwhelming lipid peroxidation, in which enzymes regulating polyunsaturated fatty acid (PUFA) metabolism, and in particular acyl-CoA synthetase long chain family member 4 (ACSL4), are central. Here, we found that exogenous oxygen radicals generated by photodynamic therapy (PDT) can directly peroxidize PUFAs and initiate lipid autoxidation, coinciding with cellular GSH depletion. Different from canonical ferroptosis induced by RSL3 or erastin, PDT-initiated lipid peroxidation and ferroptotis-like cell death is independent of lipoxygenase (ALOXs) and ACSL4. Especially, this form of cell death modality can be triggered in malignant cells insensitive to or acquired resistance to canonical ferroptosis inducers. We also observed a distinct iron metabolism pathway in this PDT-triggered cell death modality, in which cytosolic labile iron is decreased probably due to its relocation to mitochondria. Inhibition of the mitochondrial Ca[2+] and Fe[2+] uniporter (MCU) effectively prevented PDT-triggered lipid peroxidation and subsequent cell death. Therefore, we tentatively term this distinct ferroptosis-like cell death as liperoptosis. Moreover, using the clinically approved photosensitizer Verteporfin, PDT inhibited tumor growth through inducing prevailing ferroptosis-like cell death in a mouse xenograft model. With its site-specific advantages, these findings highlight the value of using PDT to trigger lipid peroxidation and ferroptosis-like cell death in vivo, and will benefit exploring the exact molecular mechanism of immunological effects of PDT in cancer treatment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shui</LastName>
            <ForeName>Sufang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China; Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Zenglu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China; Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China; Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conrad</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Metabolism and Cell Death, Helmholtz Zentrum Mnchen, Neuherberg, Germany; Pirogov Russian National Research Medical University, Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Guoquan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China; Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, China. Electronic address: guoquanliu@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Redox Biol</MedlineTA>
        <NlmUniqueID>101605639</NlmUniqueID>
        <ISSNLinking>2213-2317</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cell death</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Liperoptosis</Keyword>
        <Keyword MajorTopicYN="N">Lipid peroxidation</Keyword>
        <Keyword MajorTopicYN="N">PDT</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34229160</ArticleId>
        <ArticleId IdType="pmc">PMC8264218</ArticleId>
        <ArticleId IdType="doi">10.1016/j.redox.2021.102056</ArticleId>
        <ArticleId IdType="pii">S2213-2317(21)00215-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dixon S.J. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X.X. Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 2019;116:2672&#x2013;2680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377499</ArticleId>
            <ArticleId IdType="pubmed">30692261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M. Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev. 2018;32:602&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6004068</ArticleId>
            <ArticleId IdType="pubmed">29802123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan V.S. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer M.J. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J.P., Krysko D.V., Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Canc. 2019;19:405&#x2013;414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31101865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693&#x2013;698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler A. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent-and AIF-mediated cell death. Cell Metabol. 2008:237&#x2013;248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18762024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H.Z., Stockwell B.R. Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol. 2018;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5991413</ArticleId>
            <ArticleId IdType="pubmed">29795546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyurina Y.Y. Redox lipidomics technology: looking for a needle in a haystack. Chem. Phys. Lipids. 2019;221:93&#x2013;107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6714565</ArticleId>
            <ArticleId IdType="pubmed">30928338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M., Pratt D.A. The chemical basis of ferroptosis. Nat. Chem. Biol. 2019;15:1137&#x2013;1147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31740834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S., Conrad M. Iron and ferroptosis: a still ill-defined liaison. IUBMB Life. 2017;69:423&#x2013;434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28276141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan V.E. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 2017;13:81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 2017;13:91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler M.M. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol. 2018;14:507&#x2013;515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu B. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat. Cell Biol. 2019;21:579&#x2013;591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6624840</ArticleId>
            <ArticleId IdType="pubmed">30962574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felsher D.W. Cancer revoked: oncogenes as therapeutic targets. Nat. Rev. Canc. 2003;3:375&#x2013;380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12724735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu W. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy. Biomaterials. 2019;192:128&#x2013;139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30448697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girotti A.W. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J. Photochem. Photobiol., B. 2001;63:103&#x2013;113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11684457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donohoe C., Senge M.O., Arnaut L.G., Gomes-da-Silva L.C. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity. Biochim. Biophys. Acta Rev. Canc. 2019;1872</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31401103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Straten D., Mashayekhi V., De Bruijn H.S., Oliveira S., Robinson D.J. Oncologic photodynamic therapy: basic principles, current clinical status and future directions. Cancers. 2017;9:19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5332942</ArticleId>
            <ArticleId IdType="pubmed">28218708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Andrade G.P. Comparative in vitro study of photodynamic activity of hypericin and hypericinates in MCF-7 cells. J. Photochem. Photobiol., B. 2017;175:89&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28865319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vantieghem A. Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis - involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett. 1998;440:19&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9862416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M.S. Hideyo the oxidative stress-inducible cystine/glutamate antiporter, system x c&#x2212;: cystine supplier and beyond. Amino Acids. 2012;42:231&#x2013;246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21409388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F.M.M., Valente M., Ferri L., Gregolin C. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim. Biophys. Acta. 1982;710:197&#x2013;211 I.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7066358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66:449&#x2013;465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5573904</ArticleId>
            <ArticleId IdType="pubmed">28195347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alves E. Photodynamic oxidation of Escherichia coli membrane phospholipids: new insights based on lipidomics. Rapid Commun. Mass Spectrom. 2013;27:2717&#x2013;2728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24591033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su L.J. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6815535</ArticleId>
            <ArticleId IdType="pubmed">31737171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 2016;12:497&#x2013;503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli J.P. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014;16:1180&#x2013;1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miotto G. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6812032</ArticleId>
            <ArticleId IdType="pubmed">31574461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Z.M., Tang P.L., Wang Q. Iron crosses the endosomal membrane by a carrier-mediated process. Prog. Biophys. Mol. Biol. 1997;67:1&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9401416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam-Yuk-Tseung S., Gros P. Distinct targeting and recycling properties of two isoforms of the iron transporter DMT1 (NRAMP2, slc11A2) Biochemistry. 2006;45:2294&#x2013;2301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16475818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Issitt T. Neuropilin-1 controls endothelial homeostasis by regulating mitochondrial function and iron-dependent oxidative stress. iScience. 2019;11:205&#x2013;223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6327076</ArticleId>
            <ArticleId IdType="pubmed">30623799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie G.J., Sheftel A.D., Kim S.F., Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood. 2005;105:2161&#x2013;2167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15522954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J. Translocation of iron from lysosomes to mitochondria during acetaminophen-induced hepatocellular injury: protection by starch-desferal and minocycline. Free Radic. Biol. Med. 2016;97:418&#x2013;426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4996678</ArticleId>
            <ArticleId IdType="pubmed">27345134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchiyama A. Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. Hepatology. 2008;48:1644&#x2013;1654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2579320</ArticleId>
            <ArticleId IdType="pubmed">18846543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torii S. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem. J. 2016;473:769&#x2013;777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26759376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R., Shchepinov M.S., Pratt D.A. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent. Sci. 2018;4:387&#x2013;396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan B. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol. Cell. 2020;81:355&#x2013;369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33321093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat. Chem. Biol. 2020;16:302&#x2013;309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7353921</ArticleId>
            <ArticleId IdType="pubmed">32080622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent. Sci. 2017;3:232&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425&#x2013;1428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M.H. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021&#x2013;1032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon M.Y., Park E., Lee S.J., Chung S.W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 2015;6:24393&#x2013;24403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4695193</ArticleId>
            <ArticleId IdType="pubmed">26405158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hung H.I., Schwartz J.M., Maldonado E.N., Lemasters J.J., Nieminen A.L. Mitoferrin-2-dependent mitochondrial iron uptake sensitizes human head and neck squamous carcinoma cells to photodynamic therapy. J. Biol. Chem. 2013;288:677&#x2013;686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3537066</ArticleId>
            <ArticleId IdType="pubmed">23135267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M.H., Monian P., Quadri N., Ramasamy R., Jiang X.J. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell. 2015;59:298&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terzi E.M., Sviderskiy V.O., Alvarez S.W., Whiten G.C., Possemato R. Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5. Science Advances. 2021;7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8153722</ArticleId>
            <ArticleId IdType="pubmed">34039609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao C. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586&#x2013;590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33981038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos A.F. Distinct photo-oxidation-induced cell death pathways lead to selective killing of human breast cancer cells. Cell Death Dis. 2020;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7736888</ArticleId>
            <ArticleId IdType="pubmed">33318476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folch J., Lees M., Stanley G.S. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957;226:497&#x2013;509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13428781</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34170581</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-4095</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>31</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advanced materials (Deerfield Beach, Fla.)</Title>
          <ISOAbbreviation>Adv Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acidity-Activatable Dynamic Nanoparticles Boosting Ferroptotic Cell Death for Immunotherapy of Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>e2101155</StartPage>
          <MedlinePgn>e2101155</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/adma.202101155</ELocationID>
        <Abstract>
          <AbstractText>Immunotherapy shows promising therapeutic potential for long-term tumor regression. However, current cancer immunotherapy displays a low response rate due to insufficient immunogenicity of the tumor cells. To address these challenges, herein, intracellular-acidity-activatable dynamic nanoparticles for eliciting immunogenicity by inducing ferroptosis of the tumor cells are engineered. The nanoparticles are engineered by integrating an ionizable block copolymer and acid-liable phenylboronate ester (PBE) dynamic covalent bonds for tumor-specific delivery of the ferroptosis inducer, a glutathione peroxidase 4 inhibitor RSL-3. The nanoparticles can stably encapsulate RSL-3 inside the hydrophobic core via - stacking interaction with the PBE groups at neutral pH (pH = 7.4), while releasing the payload in the endocytic vesicles (pH = 5.8-6.2) by acidity-triggered cleavage of the PBE dynamic covalent bonds. Furthermore, the nanoparticles can perform acid-activatable photodynamic therapy by protonation of the ionizable core, and significantly recruit tumor-infiltrating T lymphocytes for interferon gamma secretion, and thus sensitize the tumor cells to RSL-3-inducible ferroptosis. The combination of nanoparticle-induced ferroptosis and blockade of programmed death ligand 1 efficiently inhibits growth of B16-F10 melanoma tumor and lung metastasis of 4T1 breast tumors, suggesting the promising potential of ferroptosis induction for promoting cancer immunotherapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Rundi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tianliang</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Jiayi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saeed</LastName>
            <ForeName>Madiha</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yingjie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Qiwen</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhiai</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Haijun</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-3398-0880</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Drug Research &amp; Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>51873228 : 22074043</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>20430711800</GrantID>
            <Agency>International Cooperation Project of Science and Technology Commission of Shanghai Municipality</Agency>
          </Grant>
          <Grant>
            <GrantID>2019M661667</GrantID>
            <Agency>China Postdoctoral Science Foundation</Agency>
          </Grant>
          <Grant>
            <GrantID>2019116</GrantID>
            <Agency>Shanghai Post-Doctoral Excellence Program</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Adv Mater</MedlineTA>
        <NlmUniqueID>9885358</NlmUniqueID>
        <ISSNLinking>0935-9648</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="Y">Melanoma, Experimental</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">T lymphocytes</Keyword>
        <Keyword MajorTopicYN="N">cancer immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">immune resistance</Keyword>
        <Keyword MajorTopicYN="N">immunogenic cell death</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>12</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34170581</ArticleId>
        <ArticleId IdType="doi">10.1002/adma.202101155</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>a) L. M. Coussens, Z. Werb, Nature 2002, 420, 860;</Citation>
        </Reference>
        <Reference>
          <Citation>b) R. D. Schreiber, L. J. Old, M. J. Smyth, Science 2011, 331, 1565.</Citation>
        </Reference>
        <Reference>
          <Citation>a) I. Mellman, G. Coukos, G. Dranoff, Nature 2011, 480, 480;</Citation>
        </Reference>
        <Reference>
          <Citation>b) S. A. Rosenberg, J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, K. E. Morton, C. M. Laurencot, S. M. Steinberg, D. E. White, M. E. Dudley, Clin. Cancer Res. 2011, 17, 4550;</Citation>
        </Reference>
        <Reference>
          <Citation>c) C. E. Brown, C. L. Mackall, Nat. Rev. Immunol. 2019, 19, 73;</Citation>
        </Reference>
        <Reference>
          <Citation>d) M. A. Curran, W. Montalvo, H. Yagita, J. P. Allison, Proc. Natl. Acad. Sci. USA 2010, 107, 4275.</Citation>
        </Reference>
        <Reference>
          <Citation>a) M. Maiorino, M. Conrad, F. Ursini, Antioxid. Redox Signaling 2018, 29, 61;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Q. R. Wen, J. Liu, R. Kang, B. R. Zhou, D. Tang, Biochem. Biophys. Res. Commun. 2019, 510, 278;</Citation>
        </Reference>
        <Reference>
          <Citation>c) M. Saeed, F. Chen, J. Ye, Y. Shi, T. Lammers, B. De Geest, Z. Xu, H. Yu, Adv. Mater. 2021, 33, 2008094;</Citation>
        </Reference>
        <Reference>
          <Citation>d) Q. Zhu, F. Sun, T. Li, M. Zhou, J. Ye, A. Ji, H. Wang, C. Ding, H. Chen, Z. Xu, H. Yu, Small 2021, 17, 2007882;</Citation>
        </Reference>
        <Reference>
          <Citation>e) J. Gao, H. Zhang, F. Zhou, B. Hou, M. Chen, Z. Xie, H. Yu, Chin. Chem. Lett. 2021, 32, 1929;</Citation>
        </Reference>
        <Reference>
          <Citation>f) B. Yang, J. Gao, Q. Pei, H. Xu, H. Yu, Adv. Sci. 2020, 7, 2002365.</Citation>
        </Reference>
        <Reference>
          <Citation>R. Chinnadurai, I. B. Copland, S. R. Patel, J. Galipeau, J. Immunol. 2014, 192, 1491.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Kim, A. C. Myers, L. P. Chen, D. M. Pardoll, Q. A. Truong-Tran, A. P. Lane, J. F. McDyer, L. Fortuno, R. P. Schleimer, Am. J. Respir. Cell Mol. Biol. 2005, 33, 280.</Citation>
        </Reference>
        <Reference>
          <Citation>C. M. Wilke, S. Wei, L. Wang, I. Kryczek, J. Kao, W. P. Zou, Cancer Immunol. Immunother. 2011, 60, 1529.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Wang, M. Green, J. Choi, M. Gij&#xf3;n, P. Kennedy, J. Johnson, P. Liao, X. Lang, I. Kryczek, A. Sell, H. Xia, J. Zhou, G. Li, J. Li, W. Li, S. Wei, L. Vatan, H. Zhang, W. Szeliga, W. Gu, R. Liu, T. S. Lawrence, C. Lamb, Y. Tanno, M. Cieslik, E. Stone, G. Georgiou, T. A. Chan, A. Chinnaiyan, W. Zou, Nature 2019, 569, 270.</Citation>
        </Reference>
        <Reference>
          <Citation>a) W. Yang, R. SriRamaratnam, M. E. Welsch, K. Shimada, R. Skouta, V. S. Viswanathan, J. H. Cheah, P. A. Clemons, A. F. Shamji, C. B. Clish, L. M. Brown, A. W. Girotti, V. W. Cornish, S. L. Schreiber, B. R. Stockwell, Cell 2014, 56, 317;</Citation>
        </Reference>
        <Reference>
          <Citation>b) Q. Jiang, K. Wang, X. Zhang, B. Ouyang, H. Liu, Z. Pang, W. Yang, Small 2020, 16, 2001704;</Citation>
        </Reference>
        <Reference>
          <Citation>c) H. Xiong, C. Wang, Z. Wang, H. Lu, J. Yao, J. Controlled Release 2021, 332, 539.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Ubellacker, A. Tasdogan, V. Ramesh, B. Shen, E. C. Mitchell, M. S. Martin-Sandoval, Z. M. Gu, M. L. McCormick, A. B. Durham, D. R. Spitz, Z. Y. Zhao, T. P. Mathews, S. J. Morrison, Nature 2020, 585, 113.</Citation>
        </Reference>
        <Reference>
          <Citation>a) B. Hou, L. Zhou, H. Wang, M. Saeed, D. Wang, Z. Xu, Y. Li, H. Yu, Adv. Mater. 2020, 32, 1907210;</Citation>
        </Reference>
        <Reference>
          <Citation>b) D. Wang, T. Wang, J. Liu, H. Yu, S. Jiao, B. Feng, F. Zhou, Y. Fu, Q. Yin, P. Zhang, Z. Zhang, Z. Zhou, Y. Li, Nano Lett. 2016, 16, 5503;</Citation>
        </Reference>
        <Reference>
          <Citation>c) X. J. Xu, R. H. Liu, L. D. Li, Chem. Commun. 2015, 51, 16733.</Citation>
        </Reference>
        <Reference>
          <Citation>J. R. Casey, S. Grinstein, J. Orlowski, Nat. Rev. Mol. Cell Biol. 2010, 11, 50.</Citation>
        </Reference>
        <Reference>
          <Citation>a) T. Wang, D. Wang, H. Yu, M. Wang, J. Liu, B. Feng, F. Zhou, Q. Yin, Z. Zhang, Y. Huang, Y. Li, ACS Nano 2016, 10, 3496;</Citation>
        </Reference>
        <Reference>
          <Citation>b) T. Wang, D. Wang, J. Liu, B. Feng, F. Zhou, H. Zhang, L. Zhou, Q. Yin, H. Yu, Y. Li, Nano Lett. 2017, 17, 5429.</Citation>
        </Reference>
        <Reference>
          <Citation>a) K. Zhou, Y. Wang, X. Huang, K. Luby-Phelps, B. D. Sumer, J. Gao, Angew. Chem., Int. Ed. 2011, 50, 6109;</Citation>
        </Reference>
        <Reference>
          <Citation>b) H. Kobayashi, M. Ogawa, R. Alford, P. L. Choyke, Y. Urano, Chem. Rev. 2010, 110, 2620.</Citation>
        </Reference>
        <Reference>
          <Citation>D. Wang, T. Wang, H. Yu, B. Feng, L. Zhou, F. Zhou, B. Hou, H. Zhang, M. Luo, Y. Li, Sci. Immunol. 2019, 4, eaau6584.</Citation>
        </Reference>
        <Reference>
          <Citation>a) F. Zhou, J. Gao, Z. Xu, T. Li, A. Gao, F. Sun, F. Wang, W. Wang, Y. Geng, F. Zhang, Z. Xu, H. Yu, Nano Today 2021, 36, 101025;</Citation>
        </Reference>
        <Reference>
          <Citation>b) T. Wang, D. Wang, H. Yu, B. Feng, F. Zhou, L. Zhou, H. Zhang, S. Jiao, Y. Li, Nat. Commun. 2018, 9, 1532.</Citation>
        </Reference>
        <Reference>
          <Citation>P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Cell 2017, 168, 707.</Citation>
        </Reference>
        <Reference>
          <Citation>a) B. Gupta, T. T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R. A. Weinberg, E. S. Lander, Cell 2009, 138, 645;</Citation>
        </Reference>
        <Reference>
          <Citation>b) V. S. Viswanathan, M. J. Ryan, H. D. Dhruv, S. Gill, O. M. Eichhoff, B. Seashore-Ludlow, S. D. Kaffenberger, J. K. Eaton, K. Shimada, A. J. Aguirre, S. R. Viswanathan, S. Chattopadhyay, P. Tamayo, W. S. Yang, M. G. Rees, S. Chen, Z. V. Boskovic, S. Javaid, C. Huang, X. Wu, Y.-Y. Tseng, E. M. Roider, D. Gao, J. M. Cleary, B. M. Wolpin, J. P. Mesirov, D. A. Haber, J. A. Engelman, J. S. Boehm, J. D. Kotz, C. S. Hon, Y. Chen, W. C. Hahn, M. P. Levesque, J. G. Doench, M. E. Berens, A. F. Shamji, P. A. Clemons, B. R. Stockwell, S. L. Schreiber, Nature 2017, 547, 453.</Citation>
        </Reference>
        <Reference>
          <Citation>a) A. E. Karnoub, A. B. Dash, A. P. Vo, A. Sullivan, M. W. Brooks, G. W. Bell, A. L. Richardson, K. Polyak, R. Tubo, R. A. Weinberg, Nature 2007, 449, 557;</Citation>
        </Reference>
        <Reference>
          <Citation>b) M. J. Hangauer, V. S. Viswanathan, M. J. Ryan, D. Bole, J. K. Eaton, A. Matov, J. Galeas, H. D. Dhruv, M. E. Berens, S. L. Schreiber, F. McCormick, M. T. McManus, Nature 2017, 551, 247.</Citation>
        </Reference>
        <Reference>
          <Citation>a) N. J. Nordmann, A. P. Michael, Clin. Neurol. Neurosurg. 2021, 201, 106430;</Citation>
        </Reference>
        <Reference>
          <Citation>b) M. Osuchowski, D. Bartusik-Aebisher, F. Osuchowski, D. Aebisher, Photodiagn. Photodyn. Ther. 2021, 33, 102158.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34160772</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>07</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1699-3055</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title>
          <ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis: an iron-dependent cell death form linking metabolism, diseases, immune cell and targeted therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>12</EndPage>
          <MedlinePgn>1-12</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-021-02669-8</ELocationID>
        <Abstract>
          <AbstractText>Compared with the traditional forms of cell death-apoptosis, necrosis and autophagy, ferroptosis is a novel form of iron-dependent programmed cell death forms which is different from the above traditional forms of cell death. Brent R Stockwell, a Professor of Columbia University, firstly proposed that this from of cell death was named ferroptosis in 2012. The main characteristics of ferroptosis is increasing iron loading and driving a lot of lipid peroxide generated and ultimately lead to cell death. In this paper, the mechanism of ferroptosis, relationship between ferroptosis and common diseases and immune state of body are reviewed, and the inhibitors and inducers related to ferroptosis that have been found are summarized to provide medicine exploration targeted of ferroptosis and reference for the research in the future.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. Federaci&#xf3;n de Sociedades Espa&#xf1;olas de Oncolog&#xed;a (FESEO).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shengxian</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-2671-4733</Identifier>
            <AffiliationInfo>
              <Affiliation>National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China. L914694127@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China. huangyong503@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>No. 82072340</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Clin Transl Oncol</MedlineTA>
        <NlmUniqueID>101247119</NlmUniqueID>
        <ISSNLinking>1699-048X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004194" MajorTopicYN="N">Disease</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008660" MajorTopicYN="N">Metabolism</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Common clinical diseases</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Immune cells</Keyword>
        <Keyword MajorTopicYN="N">Targeted therapy</Keyword>
        <Keyword MajorTopicYN="N">Tumor</Keyword>
      </KeywordList>
      <CoiStatement>The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>12</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34160772</ArticleId>
        <ArticleId IdType="pmc">PMC8220428</ArticleId>
        <ArticleId IdType="doi">10.1007/s12094-021-02669-8</ArticleId>
        <ArticleId IdType="pii">10.1007/s12094-021-02669-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3(3):285&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234&#x2013;245. doi: 10.1016/j.chembiol.2008.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2008.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32(6):920&#x2013;937. doi: 10.1016/j.cmet.2020.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2020.10.011</ArticleId>
            <ArticleId IdType="pubmed">33217331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59(2):298&#x2013;308. doi: 10.1016/j.molcel.2015.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2015.06.011</ArticleId>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas JP, Geiger PG, Maiorino M, Ursini F, Girotti AW. Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim Biophys Acta. 1990;1045(3):252&#x2013;260. doi: 10.1016/0005-2760(90)90128-K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0005-2760(90)90128-K</ArticleId>
            <ArticleId IdType="pubmed">2386798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016;23(2):270&#x2013;278. doi: 10.1038/cdd.2015.93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.93</ArticleId>
            <ArticleId IdType="pmc">PMC4716307</ArticleId>
            <ArticleId IdType="pubmed">26184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Sui S, Wang L, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020;235(4):3425&#x2013;3437. doi: 10.1002/jcp.29232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.29232</ArticleId>
            <ArticleId IdType="pubmed">31556117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274(17):11455&#x2013;11458. doi: 10.1074/jbc.274.17.11455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.17.11455</ArticleId>
            <ArticleId IdType="pubmed">10206947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bridges RJ, Natale NR, Patel SA. System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol. 2012;165(1):20&#x2013;34. doi: 10.1111/j.1476-5381.2011.01480.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2011.01480.x</ArticleId>
            <ArticleId IdType="pmc">PMC3252963</ArticleId>
            <ArticleId IdType="pubmed">21564084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Tavana O, Chu B, et al. NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. Mol Cell. 2017;68(1):224&#x2013;232 e224. doi: 10.1016/j.molcel.2017.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2017.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC5683418</ArticleId>
            <ArticleId IdType="pubmed">28985506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181&#x2013;1192. doi: 10.1038/s41556-018-0178-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0178-0</ArticleId>
            <ArticleId IdType="pmc">PMC6170713</ArticleId>
            <ArticleId IdType="pubmed">30202049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Zhu S, Chen P, et al. AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc(-) Activity. Curr Biol. 2018;28(15):2388&#x2013;2399 e2385. doi: 10.1016/j.cub.2018.05.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2018.05.094</ArticleId>
            <ArticleId IdType="pmc">PMC6081251</ArticleId>
            <ArticleId IdType="pubmed">30057310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis&#x2013;a critical review. Crit Rev Oncol Hematol. 2014;89(1):1&#x2013;15. doi: 10.1016/j.critrevonc.2013.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2013.10.008</ArticleId>
            <ArticleId IdType="pubmed">24275533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basuli D, Tesfay L, Deng Z, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017;36(29):4089&#x2013;4099. doi: 10.1038/onc.2017.11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.11</ArticleId>
            <ArticleId IdType="pmc">PMC5540148</ArticleId>
            <ArticleId IdType="pubmed">28319068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham CG, Bubici C, Zazzeroni F, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell. 2004;119(4):529&#x2013;542. doi: 10.1016/j.cell.2004.10.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2004.10.017</ArticleId>
            <ArticleId IdType="pubmed">15537542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orino K, Lehman L, Tsuji Y, Ayaki H, Torti SV, Torti FM. Ferritin and the response to oxidative stress. Biochem J. 2001;357:241&#x2013;247. doi: 10.1042/bj3570241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bj3570241</ArticleId>
            <ArticleId IdType="pmc">PMC1221947</ArticleId>
            <ArticleId IdType="pubmed">11415455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X, Cai Z, Wang H, et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis. Circ Res. 2020;127(4):486&#x2013;501. doi: 10.1161/CIRCRESAHA.120.316509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.120.316509</ArticleId>
            <ArticleId IdType="pubmed">32349646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509(7498):105&#x2013;109. doi: 10.1038/nature13148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13148</ArticleId>
            <ArticleId IdType="pmc">PMC4180099</ArticleId>
            <ArticleId IdType="pubmed">24695223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26(9):1021&#x2013;1032. doi: 10.1038/cr.2016.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2016.95</ArticleId>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113(34):E4966&#x2013;4975. doi: 10.1073/pnas.1603244113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1603244113</ArticleId>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Zhang F, An P, et al. Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood. 2011;118(7):1912&#x2013;1922. doi: 10.1182/blood-2011-01-330324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-01-330324</ArticleId>
            <ArticleId IdType="pubmed">21705499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Zhang F, Guo X, An P, Tao Y, Wang F. Ferroportin1 in hepatocytes and macrophages is required for the efficient mobilization of body iron stores in mice. Hepatology. 2012;56(3):961&#x2013;971. doi: 10.1002/hep.25746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.25746</ArticleId>
            <ArticleId IdType="pubmed">22473803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090&#x2013;2093. doi: 10.1126/science.1104742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1104742</ArticleId>
            <ArticleId IdType="pubmed">15514116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parrow NL, Fleming RE. Bone morphogenetic proteins as regulators of iron metabolism. Annu Rev Nutr. 2014;34:77&#x2013;94. doi: 10.1146/annurev-nutr-071813-105646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-nutr-071813-105646</ArticleId>
            <ArticleId IdType="pmc">PMC7713507</ArticleId>
            <ArticleId IdType="pubmed">24995692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353&#x2013;358. doi: 10.1182/blood-2006-07-033969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2006-07-033969</ArticleId>
            <ArticleId IdType="pubmed">16946298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165&#x2013;176. doi: 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Winter GE, Musavi LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol. 2015;10(7):1604&#x2013;1609. doi: 10.1021/acschembio.5b00245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.5b00245</ArticleId>
            <ArticleId IdType="pmc">PMC4509420</ArticleId>
            <ArticleId IdType="pubmed">25965523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, Kang R, Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338&#x2013;1343. doi: 10.1016/j.bbrc.2016.08.124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.08.124</ArticleId>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579&#x2013;591. doi: 10.1038/s41556-019-0305-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0305-6</ArticleId>
            <ArticleId IdType="pmc">PMC6624840</ArticleId>
            <ArticleId IdType="pubmed">30962574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Zhu S, Song X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017;20(7):1692&#x2013;1704. doi: 10.1016/j.celrep.2017.07.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.07.055</ArticleId>
            <ArticleId IdType="pubmed">28813679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WH, Ding CC, Sun T, et al. The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep. 2019;28(10):2501&#x2013;2508 e2504. doi: 10.1016/j.celrep.2019.07.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2019.07.107</ArticleId>
            <ArticleId IdType="pubmed">31484063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307. doi: 10.1038/cddis.2016.208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.208</ArticleId>
            <ArticleId IdType="pmc">PMC4973350</ArticleId>
            <ArticleId IdType="pubmed">27441659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Wang H, Yang X, et al. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. Signal Transduct Target Ther. 2020;5(1):138. doi: 10.1038/s41392-020-00253-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00253-0</ArticleId>
            <ArticleId IdType="pmc">PMC7393508</ArticleId>
            <ArticleId IdType="pubmed">32732975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15(11):709&#x2013;720. doi: 10.1038/s41571-018-0105-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-018-0105-0</ArticleId>
            <ArticleId IdType="pubmed">30275515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ingold I, Berndt C, Schmitt S, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell. 2018;172(3):409&#x2013;422 e421. doi: 10.1016/j.cell.2017.11.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.11.048</ArticleId>
            <ArticleId IdType="pubmed">29290465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the Hallmarks of Cancer. Cancer Cell. 2018;34(1):21&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6039250</ArticleId>
            <ArticleId IdType="pubmed">29731393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341&#x2013;352. doi: 10.1038/s41580-020-0237-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-020-0237-9</ArticleId>
            <ArticleId IdType="pmc">PMC7250738</ArticleId>
            <ArticleId IdType="pubmed">32300252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Duan L, He X, et al. A combined model of human iPSC&#x2010;derived liver organoids and hepatocytes reveals ferroptosis in DGUOK mutant mtDNA depletion syndrome. Adv Sci. 2021;8(10):2004680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8132052</ArticleId>
            <ArticleId IdType="pubmed">34026460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes&#x2013;many genes, common mechanisms. Neuromuscul Disord. 2010;20(7):429&#x2013;437. doi: 10.1016/j.nmd.2010.03.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2010.03.017</ArticleId>
            <ArticleId IdType="pubmed">20444604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filosto M, Mancuso M, Tomelleri G, et al. Hepato-cerebral syndrome: genetic and pathological studies in an infant with a dGK mutation. Acta Neuropathol. 2004;108(2):168&#x2013;171. doi: 10.1007/s00401-004-0872-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-004-0872-9</ArticleId>
            <ArticleId IdType="pubmed">15150663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013;10(2):186&#x2013;198. doi: 10.1007/s13311-013-0177-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-013-0177-6</ArticleId>
            <ArticleId IdType="pmc">PMC3625391</ArticleId>
            <ArticleId IdType="pubmed">23385875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pronicka E, Weglewska-Jurkiewicz A, Taybert J, et al. Post mortem identification of deoxyguanosine kinase (DGUOK) gene mutations combined with impaired glucose homeostasis and iron overload features in four infants with severe progressive liver failure. J Appl Genet. 2011;52(1):61&#x2013;66. doi: 10.1007/s13353-010-0008-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13353-010-0008-y</ArticleId>
            <ArticleId IdType="pmc">PMC3026684</ArticleId>
            <ArticleId IdType="pubmed">21107780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X, Wang H, Han D, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116(7):2672&#x2013;2680. doi: 10.1073/pnas.1821022116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1821022116</ArticleId>
            <ArticleId IdType="pmc">PMC6377499</ArticleId>
            <ArticleId IdType="pubmed">30692261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Proneth B. Broken hearts: Iron overload, ferroptosis and cardiomyopathy. Cell Res. 2019;29(4):263&#x2013;264. doi: 10.1038/s41422-019-0150-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-019-0150-y</ArticleId>
            <ArticleId IdType="pmc">PMC6461867</ArticleId>
            <ArticleId IdType="pubmed">30809018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, An P, Xie E, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66(2):449&#x2013;465. doi: 10.1002/hep.29117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29117</ArticleId>
            <ArticleId IdType="pmc">PMC5573904</ArticleId>
            <ArticleId IdType="pubmed">28195347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Jiang L, Wang H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood. 2020;136(6):726&#x2013;739. doi: 10.1182/blood.2019002907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2019002907</ArticleId>
            <ArticleId IdType="pmc">PMC7414596</ArticleId>
            <ArticleId IdType="pubmed">32374849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca LG. The role of iron in brain ageing and neurodegenerative disorders. The Lancet Neurology. 2014;13(10):1045&#x2013;1060. doi: 10.1016/S1474-4422(14)70117-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(14)70117-6</ArticleId>
            <ArticleId IdType="pmc">PMC5672917</ArticleId>
            <ArticleId IdType="pubmed">25231526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? Mol Psychiatry. 2017;22(3):328&#x2013;335. doi: 10.1038/mp.2016.196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2016.196</ArticleId>
            <ArticleId IdType="pubmed">27777421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao WD, Pang P, Zhou XT, et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer's disease. Cell Death Differ. 2021;28:1548&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8166828</ArticleId>
            <ArticleId IdType="pubmed">33398092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raz E, Jensen JH, Ge Y, et al. Brain iron quantification in mild traumatic brain injury: a magnetic field correlation study. AJNR Am J Neuroradiol. 2011;32(10):1851&#x2013;1856. doi: 10.3174/ajnr.A2637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A2637</ArticleId>
            <ArticleId IdType="pmc">PMC3848044</ArticleId>
            <ArticleId IdType="pubmed">21885717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ondruschka B, Schuch S, Pohlers D, Franke H, Dressler J. Acute phase response after fatal traumatic brain injury. Int J Legal Med. 2018;132(2):531&#x2013;539. doi: 10.1007/s00414-017-1768-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00414-017-1768-2</ArticleId>
            <ArticleId IdType="pubmed">29306988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rui T, Wang H, Li Q, et al. Deletion of ferritin H in neurons counteracts the protective effect of melatonin against traumatic brain injury-induced ferroptosis. J Pineal Res. 2021;70(2):e12704. doi: 10.1111/jpi.12704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12704</ArticleId>
            <ArticleId IdType="pubmed">33206394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao WD, Zhou XT, Zhou LT, et al. Targeting miR-124/Ferroportin signaling ameliorated neuronal cell death through inhibiting apoptosis and ferroptosis in aged intracerebral hemorrhage murine model. Aging Cell. 2020;19(11):e13235. doi: 10.1111/acel.13235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/acel.13235</ArticleId>
            <ArticleId IdType="pmc">PMC7681046</ArticleId>
            <ArticleId IdType="pubmed">33068460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw J, Chakraborty A, Nag A, Chattopadyay A, Dasgupta AK, Bhattacharyya M. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. Eur J Haematol. 2017;99(5):399&#x2013;408. doi: 10.1111/ejh.12936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.12936</ArticleId>
            <ArticleId IdType="pubmed">28815805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Yin W, Zhu L, et al. Iron Drives T Helper Cell Pathogenicity by Promoting RNA-Binding Protein PCBP1-Mediated Proinflammatory Cytokine Production. Immunity. 2018;49(1):80&#x2013;92 e87. doi: 10.1016/j.immuni.2018.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.05.008</ArticleId>
            <ArticleId IdType="pubmed">29958803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Yang Y, Wang X, et al. Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and Tet-dependent mechanism. Nucleic Acids Res. 2014;42(3):1593&#x2013;1605. doi: 10.1093/nar/gkt1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkt1090</ArticleId>
            <ArticleId IdType="pmc">PMC3919571</ArticleId>
            <ArticleId IdType="pubmed">24214992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muri J, Thut H, Bornkamm GW, Kopf M. B1 and marginal zone B cells but not follicular B2 cells require Gpx4 to prevent lipid peroxidation and ferroptosis. Cell Rep. 2019;29(9):2731&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31775041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Li C, Wu Q, et al. Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses. Nat Commun. 2019;10(1):2935. doi: 10.1038/s41467-019-11002-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-11002-5</ArticleId>
            <ArticleId IdType="pmc">PMC6610088</ArticleId>
            <ArticleId IdType="pubmed">31270335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Minikes AM, Gao M, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572(7769):402&#x2013;406. doi: 10.1038/s41586-019-1426-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1426-6</ArticleId>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453&#x2013;457. doi: 10.1038/nature23007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature23007</ArticleId>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, Kim WD, Kim SK, Moon DH, Lee SJ. TGF-beta1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells. Cell Death Dis. 2020;11(5):406. doi: 10.1038/s41419-020-2618-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2618-6</ArticleId>
            <ArticleId IdType="pmc">PMC7260246</ArticleId>
            <ArticleId IdType="pubmed">32471991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo X, Gong HB, Gao HY, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28(6):1971&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8185102</ArticleId>
            <ArticleId IdType="pubmed">33432112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nairz M, Schroll A, Haschka D, et al. Lipocalin-2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response. Eur J Immunol. 2015;45(11):3073&#x2013;3086. doi: 10.1002/eji.201545569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201545569</ArticleId>
            <ArticleId IdType="pmc">PMC4688458</ArticleId>
            <ArticleId IdType="pubmed">26332507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Harrington L, Trebicka E, et al. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest. 2009;119(11):3322&#x2013;3328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2769199</ArticleId>
            <ArticleId IdType="pubmed">19809161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pereira M, Chen TD, Buang N, et al. Acute Iron Deprivation Reprograms Human Macrophage Metabolism and Reduces Inflammation In Vivo. Cell Rep. 2019;28(2):498&#x2013;511 e495. doi: 10.1016/j.celrep.2019.06.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2019.06.039</ArticleId>
            <ArticleId IdType="pmc">PMC6635384</ArticleId>
            <ArticleId IdType="pubmed">31291584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapralov AA, Yang Q, Dar HH, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol. 2020;16(3):278&#x2013;290. doi: 10.1038/s41589-019-0462-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-019-0462-8</ArticleId>
            <ArticleId IdType="pmc">PMC7233108</ArticleId>
            <ArticleId IdType="pubmed">32080625</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34110146</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1944-8252</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS applied materials &amp; interfaces</Title>
          <ISOAbbreviation>ACS Appl Mater Interfaces</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Self-Assembling Porphyrins as a Single Therapeutic Agent for Synergistic Cancer Therapy: A One Stone Three Birds Strategy.</ArticleTitle>
        <Pagination>
          <StartPage>27856</StartPage>
          <EndPage>27867</EndPage>
          <MedlinePgn>27856-27867</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsami.1c04868</ELocationID>
        <Abstract>
          <AbstractText>Combining photodynamic therapy (PDT), chemodynamic therapy (CDT), and ferroptosis is a valuable means for an enhanced anticancer effect. However, traditional combination of PDT/CDT/ferroptosis faces several hurdles, including excess glutathione (GSH) neutralization and preparation complexity. In this work, a versatile multifunctional nanoparticle (HCNP) self-assembled from two porphyrin molecules, chlorin e6 and hemin, is developed. The as-constructed HCNPs exhibit a peroxidase-mimic catalytic activity, which can lead to the in situ generation of endogenous O2, thereby enhancing the efficacy of PDT. Furthermore, the generation of hydroxyl radicals ([]OH) in the tumor environment in reaction to the high level of H2O2 and the simultaneous disruption of intracellular GSH endow the HCNPs with the capacity of enhanced CDT, resulting in a more effective therapeutic outcome in combination with PDT. More importantly, GSH depletion further leads to the inactivation of GSH peroxide 4 and induced ferroptosis. Both in vitro and in vivo results showed that the combination of PDT/CDT/ferroptosis realizes highest antitumor efficacy significantly under laser irradiation. Therefore, by integrating the superiorities of O2 and []OH generation capacity, GSH-depletion effect, and bioimaging into a single nanosystem, the HCNPs are a promising single therapeutic agent for tumor PDT/CDT/ferroptosis combination therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Zhangyou</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yunfei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Tianye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gan</LastName>
            <ForeName>Xuelan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Hangtian</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Joint International Research Laboratory of Reproduction and Development, School of Public Health, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geng</LastName>
            <ForeName>Yanqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Joint International Research Laboratory of Reproduction and Development, School of Basic Medicine, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Xinwei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuanqiang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-8391-4080</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing 400000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Appl Mater Interfaces</MedlineTA>
        <NlmUniqueID>101504991</NlmUniqueID>
        <ISSNLinking>1944-8244</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3352-57-6</RegistryNumber>
          <NameOfSubstance UI="D017665">Hydroxyl Radical</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S2CCF3T1Z</RegistryNumber>
          <NameOfSubstance UI="C062985">phytochlorin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>743LRP9S7N</RegistryNumber>
          <NameOfSubstance UI="D006427">Hemin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="N">Chlorophyllides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006427" MajorTopicYN="N">Hemin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017665" MajorTopicYN="N">Hydroxyl Radical</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="N">Porphyrins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">chemodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">combination therapy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">porphyrin</Keyword>
        <Keyword MajorTopicYN="N">self-assembled</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34110146</ArticleId>
        <ArticleId IdType="doi">10.1021/acsami.1c04868</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34027953</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-4744</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>50</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Chemical Society reviews</Title>
          <ISOAbbreviation>Chem Soc Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Engineering nanomedicine for glutathione depletion-augmented cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>6013</StartPage>
          <EndPage>6041</EndPage>
          <MedlinePgn>6013-6041</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d0cs00718h</ELocationID>
        <Abstract>
          <AbstractText>Glutathione (GSH), the main redox buffer, has long been recognized as a pivotal modulator of tumor initiation, progression and metastasis. It is also implicated in the resistance of platinum-based chemotherapy and radiation therapy. Therefore, depleting intracellular GSH was considered a potent solution to combating cancer. However, reducing GSH within cancer cells alone always failed to yield desirable therapeutic effects. In this regard, the convergence of GSH-scavenging agents with therapeutic drugs has thus been pursued in clinical practice. Unfortunately, the therapeutic outcomes are still unsatisfactory due to untargeted drug delivery. Advanced nanomedicine of synergistic GSH depletion and cancer treatment has attracted tremendous interest because they promise to deliver superior therapeutic benefits while alleviating life-threatening side effects. In the past five years, the authors and others have demonstrated that numerous nanomedicines, by simultaneously delivering GSH-depleting agents and therapeutic components, boost not only traditional chemotherapy and radiotherapy but also multifarious emerging treatment modalities, including photodynamic therapy, sonodynamic therapy, chemodynamic therapy, ferroptosis, and immunotherapy, to name a few, and achieved decent treatment outcomes in a large number of rodent tumor models. In this review, we summarize the most recent progress in engineering nanomedicine for GSH depletion-enhanced cancer therapies. Biosynthesis of GSH and various types of GSH-consuming strategies will be briefly introduced. The challenges and perspectives of leveraging nanomedicine for GSH consumption-augmented cancer therapies will be discussed at the end.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Yuxuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China. zifuli@hust.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China. zifuli@hust.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zifu</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0001-6387-4854</Identifier>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China. zifuli@hust.edu.cn and Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China and Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medical, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China and Wuhan Institute of Biotechnology, High Tech Road 666, East Lake high tech Zone, Wuhan, 430040, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xiangliang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China. zifuli@hust.edu.cn and Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China and Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medical, Huazhong University of Science and Technology, Wuhan, 430074, P. R. China and GBA Research Innovation Institute for Nanotechnology, Guangdong, 510530, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Chem Soc Rev</MedlineTA>
        <NlmUniqueID>0335405</NlmUniqueID>
        <ISSNLinking>0306-0012</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016877">Oxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050997" MajorTopicYN="Y">Nanomedicine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016877" MajorTopicYN="N">Oxidants</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>10</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34027953</ArticleId>
        <ArticleId IdType="doi">10.1039/d0cs00718h</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33915157</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2968</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>190</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical pharmacology</Title>
          <ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Recent progress on targeting ferroptosis for cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>114584</StartPage>
          <MedlinePgn>114584</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2021.114584</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-2952(21)00190-8</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a new mode of cell death different from cell necrosis, autophagy, apoptosis, and pyroptosis, which depends on the accumulation of reactive oxygen species (ROS) caused by iron-mediated lipid peroxidation, exhibits cellular, molecular, and gene-level characteristics distinct from other cell deaths. Since ferroptosis discovery, it has become a new target for antitumor therapy actively explored by researchers. In this review, we provide an overview of the known mechanisms that regulate the sensitivity of cancer cells to ferroptosis and the research progress of ferroptosis-related drugs (western medicine, traditional Chinese medicine, and nanomedicine), as well as the relationship between ferroptosis and cancer treatment, tumor drug resistance, and antitumor immunotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Guangxiang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Han</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>The First Clinical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaoling</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental Animal Center, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Riming</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, Guangzhou 510642, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Lianxiang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, Guangdong 524023, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, Guangdong 524023, China; Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, Guangdong 524023, China. Electronic address: luolianxiang321@gdmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem Pharmacol</MedlineTA>
        <NlmUniqueID>0101032</NlmUniqueID>
        <ISSNLinking>0006-2952</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">Drug resistance</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis inducers</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis regulation</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33915157</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bcp.2021.114584</ArticleId>
        <ArticleId IdType="pii">S0006-2952(21)00190-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33881539</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1756-591X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Metallomics : integrated biometal science</Title>
          <ISOAbbreviation>Metallomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chemistry and biology of ferritin.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">mfab021</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/mtomcs/mfab021</ELocationID>
        <Abstract>
          <AbstractText>Iron is an essential element required by cells and has been described as a key player in ferroptosis. Ferritin operates as a fundamental iron storage protein in cells forming multimeric assemblies with crystalline iron cores. We discuss the latest findings on ferritin structure and activity and its link to cell metabolism and ferroptosis. The chemistry of iron, including its oxidation states, is important for its biological functions, its reactivity, and the biology of ferritin. Ferritin can be localized in different cellular compartments and secreted by cells with a variety of functions depending on its spatial context. Here, we discuss how cellular ferritin localization is tightly linked to its function in a tissue-specific manner, and how impairment of iron homeostasis is implicated in diseases, including cancer and coronavirus disease 2019. Ferritin is a potential biomarker and we discuss latest research where it has been employed for imaging purposes and drug delivery.</AbstractText>
          <CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Plays</LastName>
            <ForeName>Marina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Chemical Biology of Cancer Laboratory, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre national de la recherche scientifique UMR 3666, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut national de la sant et de la recherche mdicale U1143, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>PSL Universit Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mller</LastName>
            <ForeName>Sebastian</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-3423-5364</Identifier>
            <AffiliationInfo>
              <Affiliation>Chemical Biology of Cancer Laboratory, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre national de la recherche scientifique UMR 3666, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut national de la sant et de la recherche mdicale U1143, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>PSL Universit Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodriguez</LastName>
            <ForeName>Raphal</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-7668-446X</Identifier>
            <AffiliationInfo>
              <Affiliation>Chemical Biology of Cancer Laboratory, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre national de la recherche scientifique UMR 3666, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut national de la sant et de la recherche mdicale U1143, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>PSL Universit Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Metallomics</MedlineTA>
        <NlmUniqueID>101478346</NlmUniqueID>
        <ISSNLinking>1756-5901</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.16.3.1</RegistryNumber>
          <NameOfSubstance UI="D002570">Ceruloplasmin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001709" MajorTopicYN="N">Biotechnology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002570" MajorTopicYN="N">Ceruloplasmin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036103" MajorTopicYN="N">Nanotechnology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">chemical biology</Keyword>
        <Keyword MajorTopicYN="N">disease</Keyword>
        <Keyword MajorTopicYN="N">ferritin</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33881539</ArticleId>
        <ArticleId IdType="pmc">PMC8083198</ArticleId>
        <ArticleId IdType="doi">10.1093/mtomcs/mfab021</ArticleId>
        <ArticleId IdType="pii">6244244</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33878610</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>557</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dioscin induces ferroptosis and synergistic cytotoxicity with chemotherapeutics in melanoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>213</StartPage>
          <EndPage>220</EndPage>
          <MedlinePgn>213-220</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2021.04.024</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(21)00627-6</ELocationID>
        <Abstract>
          <AbstractText>In this study, we evaluated the anti-tumor effects of dioscin, a steroidal saponin, on melanoma cells. Dioscin significantly inhibited cell viability and induced cell death of melanoma cells in a time- and dose- dependent manner. Furthermore, dioscin increased the concentration of intracellular ferrous irons, MDA and ROS. This effect could be inhibited by L-g-glutamyl-p-nitroanilide (GPNA), compound 968 and ferroptosis inhibitor ferrostatin-1 (Fer-1). Furthermore, dioscin induced ferroptosis by affecting the expression of transferrin and ferroportin which are regulators of intracellular levels of iron. Finally, dioscin in combination with various chemotherapeutic agents showed synergistic effects against melanoma cells. Our data suggested that dioscin exerted anti-tumor effects in melanoma cells by inducing ferroptosis. Dioscin alone or with other agents might be applied as a promising strategy to treat melanoma.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Yijie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The Affiliated People's Hospital of Ningbo University, 315100, Ningbo, Zhejiang, China. Electronic address: xieyijienb@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Guangxiong</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The Affiliated People's Hospital of Ningbo University, 315100, Ningbo, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053119">Benzophenanthridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003514">Cyclohexylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014168">Transferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000598981">compound 968</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573944">ferrostatin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C409881">metal transporting protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3B95U4OLWV</RegistryNumber>
          <NameOfSubstance UI="C019357">dioscin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4Y8F71G49Q</RegistryNumber>
          <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K49P2K8WLX</RegistryNumber>
          <NameOfSubstance UI="D004144">Diosgenin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053119" MajorTopicYN="N">Benzophenanthridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003514" MajorTopicYN="N">Cyclohexylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004144" MajorTopicYN="N">Diosgenin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008315" MajorTopicYN="N">Malondialdehyde</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014168" MajorTopicYN="N">Transferrin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dioscin</Keyword>
        <Keyword MajorTopicYN="N">Ferropotosis</Keyword>
        <Keyword MajorTopicYN="N">Iron</Keyword>
        <Keyword MajorTopicYN="N">MDA</Keyword>
        <Keyword MajorTopicYN="N">Melanoma</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>20</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33878610</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2021.04.024</ArticleId>
        <ArticleId IdType="pii">S0006-291X(21)00627-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33824419</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced anti-cancer activity of andrographis with oligomeric proanthocyanidins through activation of metabolic and ferroptosis pathways in colorectal cancer.</ArticleTitle>
        <Pagination>
          <StartPage>7548</StartPage>
          <MedlinePgn>7548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">7548</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-87283-y</ELocationID>
        <Abstract>
          <AbstractText>The high degree of morbidity and mortality in colorectal cancer (CRC) patients is largely due to the development of chemoresistance against conventional chemotherapeutic drugs. In view of the accumulating evidence that various dietary botanicals offer a safe, inexpensive and multi-targeted treatment option, herein, we hypothesized that a combination of Andrographis paniculata and Oligomeric Proanthocyanidins (OPCs) might interact together with regard to anti-tumorigenic activity in CRC. As a result, we demonstrated the enhanced anti-cancer activity between these two botanical extracts in terms of their ability to inhibit cancer cell growth, suppress colony formation and induce apoptosis. Furthermore, we validated these findings in subcutaneous xenograft model and in patient derived primary epithelial 3D organoids. Transcriptomic profiling identified involvement of metabolic pathways and ferroptosis-associated genes, including HMOX1, GCLC and GCLM, that may be responsible for the increased anti-tumorigenic activity by the two compounds. Collectively, our study provides novel evidence in support of the combinatorial use of andrographis and OPCs as a potential therapeutic option, perhaps as an adjunctive treatment to classical drugs, in patients with colorectal cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Shimura</LastName>
            <ForeName>Tadanobu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott &amp; White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Sharma</LastName>
            <ForeName>Priyanka</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott &amp; White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Sharma</LastName>
            <ForeName>Geeta G</ForeName>
            <Initials>GG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Banwait</LastName>
            <ForeName>Jasjit K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott &amp; White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goel</LastName>
            <ForeName>Ajay</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott &amp; White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA. ajgoel@coh.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ajgoel@coh.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Diagnostics and Experimental Therapeutics, Biotech Innovations, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1218 S. Fifth Avenue, Suite 2226, Monrovia, CA, 91016, USA. ajgoel@coh.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044945">Proanthocyanidins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>410105JHGR</RegistryNumber>
          <NameOfSubstance UI="C030419">andrographolide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D035685" MajorTopicYN="N">Andrographis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004224" MajorTopicYN="N">Diterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044945" MajorTopicYN="N">Proanthocyanidins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33824419</ArticleId>
        <ArticleId IdType="pmc">PMC8024269</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-021-87283-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-021-87283-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7&#x2013;30. doi: 10.3322/caac.21442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21442</ArticleId>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giacchetti S, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000;18:136&#x2013;147. doi: 10.1200/JCO.2000.18.1.136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2000.18.1.136</ArticleId>
            <ArticleId IdType="pubmed">10623704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol. 2014;355:10&#x2013;20. doi: 10.1016/j.jtbi.2014.02.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtbi.2014.02.025</ArticleId>
            <ArticleId IdType="pmc">PMC4058397</ArticleId>
            <ArticleId IdType="pubmed">24681298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. Annu. Rev. Pharmacol. Toxicol. 2016;56:85&#x2013;102. doi: 10.1146/annurev-pharmtox-010715-103111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-010715-103111</ArticleId>
            <ArticleId IdType="pubmed">26514196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz LA, Jr, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537&#x2013;540. doi: 10.1038/nature11219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11219</ArticleId>
            <ArticleId IdType="pmc">PMC3436069</ArticleId>
            <ArticleId IdType="pubmed">22722843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozic I, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013;2:e00747. doi: 10.7554/eLife.00747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.00747</ArticleId>
            <ArticleId IdType="pmc">PMC3691570</ArticleId>
            <ArticleId IdType="pubmed">23805382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toews ML, Bylund DB. Pharmacologic principles for combination therapy. Proc. Am. Thorac. Soc. 2005;2:282&#x2013;289. doi: 10.1513/pats.200504-037SR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1513/pats.200504-037SR</ArticleId>
            <ArticleId IdType="pubmed">16267349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Yang P, Cao S, Zhao L. The combination of curcumin and 5-fluorouracil in cancer therapy. Arch. Pharm. Res. 2018;41:1&#x2013;13. doi: 10.1007/s12272-017-0979-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12272-017-0979-x</ArticleId>
            <ArticleId IdType="pubmed">29230689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, et al. Anti-tumor effect of cisplatin in human oral squamous cell carcinoma was enhanced by andrographolide via upregulation of phospho-p53 in vitro and in vivo. Tumour Biol. 2017;39:1010428317705330. doi: 10.1177/1010428317705330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1010428317705330</ArticleId>
            <ArticleId IdType="pubmed">28513299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindranathan P, et al. A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer. Sci. Rep. 2018;8:13869. doi: 10.1038/s41598-018-32267-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-32267-8</ArticleId>
            <ArticleId IdType="pmc">PMC6138725</ArticleId>
            <ArticleId IdType="pubmed">30218018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer. 2010;62:919&#x2013;930. doi: 10.1080/01635581.2010.509835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01635581.2010.509835</ArticleId>
            <ArticleId IdType="pubmed">20924967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: How spicy is it? Mol. Nutr. Food Res. 2008;52:1010&#x2013;1030. doi: 10.1002/mnfr.200700354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mnfr.200700354</ArticleId>
            <ArticleId IdType="pubmed">18384098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": From kitchen to clinic. Biochem. Pharmacol. 2008;75:787&#x2013;809. doi: 10.1016/j.bcp.2007.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2007.08.016</ArticleId>
            <ArticleId IdType="pubmed">17900536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Link A, et al. Curcumin modulates DNA methylation in colorectal cancer cells. PLoS ONE. 2013;8:e57709. doi: 10.1371/journal.pone.0057709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0057709</ArticleId>
            <ArticleId IdType="pmc">PMC3584082</ArticleId>
            <ArticleId IdType="pubmed">23460897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindranathan P, et al. Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer. Carcinogenesis. 2018;39:767&#x2013;777. doi: 10.1093/carcin/bgy034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgy034</ArticleId>
            <ArticleId IdType="pmc">PMC5972632</ArticleId>
            <ArticleId IdType="pubmed">29684110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toden S, et al. Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prev. Res. 2015;8:431&#x2013;443. doi: 10.1158/1940-6207.CAPR-14-0354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-14-0354</ArticleId>
            <ArticleId IdType="pmc">PMC4417447</ArticleId>
            <ArticleId IdType="pubmed">25712055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toden S, et al. Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer. Sci. Rep. 2018;8:3335. doi: 10.1038/s41598-018-21478-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-21478-8</ArticleId>
            <ArticleId IdType="pmc">PMC5820273</ArticleId>
            <ArticleId IdType="pubmed">29463813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poolsup N, Suthisisang C, Prathanturarug S, Asawamekin A, Chanchareon U. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: Systematic review of randomized controlled trials. J. Clin. Pharm. Ther. 2004;29:37&#x2013;45. doi: 10.1046/j.1365-2710.2003.00534.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2710.2003.00534.x</ArticleId>
            <ArticleId IdType="pubmed">14748896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam MT, et al. Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. Cancer Lett. 2018;420:129&#x2013;145. doi: 10.1016/j.canlet.2018.01.074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.01.074</ArticleId>
            <ArticleId IdType="pubmed">29408515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindranathan P, Pasham D, Goel A. Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40:412&#x2013;421. doi: 10.1093/carcin/bgy184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgy184</ArticleId>
            <ArticleId IdType="pmc">PMC6514448</ArticleId>
            <ArticleId IdType="pubmed">30596962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reabroi S, et al. The anti-cancer activity of an andrographolide analogue functions through a GSK-3beta-independent Wnt/beta-catenin signaling pathway in colorectal cancer cells. Sci. Rep. 2018;8:7924. doi: 10.1038/s41598-018-26278-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-26278-8</ArticleId>
            <ArticleId IdType="pmc">PMC5962551</ArticleId>
            <ArticleId IdType="pubmed">29784906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin HH, Shi MD, Tseng HC, Chen JH. Andrographolide sensitizes the cytotoxicity of human colorectal carcinoma cells toward cisplatin via enhancing apoptosis pathways in vitro and in vivo. Toxicol. Sci. 2014;139:108&#x2013;120. doi: 10.1093/toxsci/kfu032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/toxsci/kfu032</ArticleId>
            <ArticleId IdType="pubmed">24563380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell. Dev. Biol. Anim. 1996;32:315&#x2013;317. doi: 10.1007/BF02722955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02722955</ArticleId>
            <ArticleId IdType="pubmed">8842743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440&#x2013;446. doi: 10.1158/0008-5472.CAN-09-1947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1947</ArticleId>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi M, et al. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. 2012;33:2441&#x2013;2449. doi: 10.1093/carcin/bgs286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgs286</ArticleId>
            <ArticleId IdType="pmc">PMC3510738</ArticleId>
            <ArticleId IdType="pubmed">22983985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almiron Bonnin DA, et al. Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene. 2018;37:1107&#x2013;1118. doi: 10.1038/onc.2017.404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.404</ArticleId>
            <ArticleId IdType="pmc">PMC5851110</ArticleId>
            <ArticleId IdType="pubmed">29155422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinform. 2010;11:367. doi: 10.1186/1471-2105-11-367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2105-11-367</ArticleId>
            <ArticleId IdType="pmc">PMC2912887</ArticleId>
            <ArticleId IdType="pubmed">20598126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. U.S.A. 2004;101:4164&#x2013;4169. doi: 10.1073/pnas.0308531101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0308531101</ArticleId>
            <ArticleId IdType="pmc">PMC384712</ArticleId>
            <ArticleId IdType="pubmed">15016911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659&#x2013;661. doi: 10.1096/fj.07-9574LSF.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.07-9574LSF</ArticleId>
            <ArticleId IdType="pubmed">17942826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Wetering M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933&#x2013;945. doi: 10.1016/j.cell.2015.03.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.03.053</ArticleId>
            <ArticleId IdType="pmc">PMC6428276</ArticleId>
            <ArticleId IdType="pubmed">25957691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 2017;14:235&#x2013;246. doi: 10.1038/nrclinonc.2016.171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.171</ArticleId>
            <ArticleId IdType="pubmed">27922044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016;79:629&#x2013;661. doi: 10.1021/acs.jnatprod.5b01055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jnatprod.5b01055</ArticleId>
            <ArticleId IdType="pubmed">26852623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodroj MH, Jardaly A, Abi-Raad S, Zouein A, Rizk S. Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway. Cancer Manage. Res. 2018;10:1079&#x2013;1088. doi: 10.2147/CMAR.S160924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S160924</ArticleId>
            <ArticleId IdType="pmc">PMC5955015</ArticleId>
            <ArticleId IdType="pubmed">29785137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei RJ, Zhang XS, He DL. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis. Asian J. Androl. 2018;20:200&#x2013;204. doi: 10.4103/aja.aja_30_17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/aja.aja_30_17</ArticleId>
            <ArticleId IdType="pmc">PMC5858108</ArticleId>
            <ArticleId IdType="pubmed">28869219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Sun B, Gao F, Lan M. Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells. Pharm. Biol. 2016;54:2629&#x2013;2635. doi: 10.1080/13880209.2016.1176056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13880209.2016.1176056</ArticleId>
            <ArticleId IdType="pubmed">27159496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao GQ, et al. Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicol. Lett. 2013;222:23&#x2013;35. doi: 10.1016/j.toxlet.2013.06.241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2013.06.241</ArticleId>
            <ArticleId IdType="pubmed">23845849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al. Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. Biochem. Pharmacol. 2016;121:8&#x2013;17. doi: 10.1016/j.bcp.2016.09.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2016.09.024</ArticleId>
            <ArticleId IdType="pubmed">27693317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Shimura T, Banwait JK, Goel A. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of beta-catenin/Wnt-signaling pathways in colorectal cancer. Carcinogenesis. 2020;41:1385&#x2013;1394. doi: 10.1093/carcin/bgaa090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgaa090</ArticleId>
            <ArticleId IdType="pmc">PMC7566354</ArticleId>
            <ArticleId IdType="pubmed">32835374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopper O, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 2019;25:838&#x2013;849. doi: 10.1038/s41591-019-0422-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0422-6</ArticleId>
            <ArticleId IdType="pubmed">31011202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang R, et al. Andrographolide suppresses proliferation of human colon cancer SW620 cells through the TLR4/NF-kappaB/MMP-9 signaling pathway. Oncol. Lett. 2017;14:4305&#x2013;4310. doi: 10.3892/ol.2017.6669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6669</ArticleId>
            <ArticleId IdType="pmc">PMC5604146</ArticleId>
            <ArticleId IdType="pubmed">28943944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan M, Meng W, Liao W, Lian S. Andrographolide antagonizes TNF-alpha-induced IL-8 via inhibition of NADPH oxidase/ROS/NF-kappaB and Src/MAPKs/AP-1 axis in human colorectal cancer HCT116 cells. J. Agric. Food Chem. 2018;66:5139&#x2013;5148. doi: 10.1021/acs.jafc.8b00810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jafc.8b00810</ArticleId>
            <ArticleId IdType="pubmed">29672044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao CY, et al. Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells. Carcinogenesis. 2013;34:1843&#x2013;1851. doi: 10.1093/carcin/bgt131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgt131</ArticleId>
            <ArticleId IdType="pubmed">23615401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu CY, et al. Andrographolide inhibits TNFalpha-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem. Pharmacol. 2014;91:40&#x2013;50. doi: 10.1016/j.bcp.2014.06.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2014.06.024</ArticleId>
            <ArticleId IdType="pubmed">24998495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon MY, Park E, Lee SJ, Chung SW. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 2015;6:24393&#x2013;24403. doi: 10.18632/oncotarget.5162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5162</ArticleId>
            <ArticleId IdType="pmc">PMC4695193</ArticleId>
            <ArticleId IdType="pubmed">26405158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohashi T, Idogawa M, Sasaki Y, Suzuki H, Tokino T. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol. Cancer Res. 2013;11:1554&#x2013;1563. doi: 10.1158/1541-7786.MCR-13-0330-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-13-0330-T</ArticleId>
            <ArticleId IdType="pubmed">24140838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taskoparan B, et al. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Cell. Oncol. 2017;40:563&#x2013;578. doi: 10.1007/s13402-017-0351-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13402-017-0351-7</ArticleId>
            <ArticleId IdType="pubmed">28929377</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33741422</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>507</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition.</ArticleTitle>
        <Pagination>
          <StartPage>40</StartPage>
          <EndPage>54</EndPage>
          <MedlinePgn>40-54</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2021.03.013</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(21)00118-X</ELocationID>
        <Abstract>
          <AbstractText>Cancer cells evolve to survive as 'persister cells' resistant to various chemotherapeutic agents. Persister cancer cells retain mesenchymal traits that are vulnerable to ferroptosis by iron-dependent accumulation of lethal lipid peroxidation. Regulation of the KDM5A-MPC1 axis might shift cancer cells to have mesenchymal traits via epithelial-mesenchymal transition process. Therefore, we examined the therapeutic potentiality of KDM5A-MPC1 axis regulation in promoting ferroptosis in erlotinib-tolerant persister head and neck cancer cells (erPCC). ErPCC acquired mesenchymal traits and disabled antioxidant program that were more vulnerable to ferroptosis inducers of RSL3, ML210, sulfasalazine, and erastin. GPX4 and xCT suppression caused increased sensitivity to ferroptosis in vivo models of GPX4 genetic silencing. KDM5A expression increased and MPC1 expression decreased in erPCC. KDM5A inhibition increased MPC1 expression and decreased sensitivity to ferroptosis inducers in erPCC. MPC1 suppression increased vulnerability to ferroptosis in vitro and in vivo by retaining mesenchymal traits and glutaminolysis. Low expression of MPC1 was associated with low overall survival from the TCGA data. Our data suggest that regulation of the KDM5A-MPC1 axis contributes to promoting cancer ferroptosis susceptibility.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>You</LastName>
            <ForeName>Ji Hyeon</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology-Head Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jaewang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology-Head Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roh</LastName>
            <ForeName>Jong-Lyel</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology-Head Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea. Electronic address: rohjl@cha.ac.kr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573718">MPC1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027501">Monocarboxylic Acid Transporters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DA87705X9K</RegistryNumber>
          <NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.11.-</RegistryNumber>
          <NameOfSubstance UI="C070050">KDM5A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.11.27</RegistryNumber>
          <NameOfSubstance UI="D056485">Retinoblastoma-Binding Protein 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069347" MajorTopicYN="N">Erlotinib Hydrochloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027501" MajorTopicYN="N">Monocarboxylic Acid Transporters</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056485" MajorTopicYN="N">Retinoblastoma-Binding Protein 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Epithelial-mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="N">Erlotinib tolerance</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glutaminolysis</Keyword>
        <Keyword MajorTopicYN="N">MPC1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>59</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33741422</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2021.03.013</ArticleId>
        <ArticleId IdType="pii">S0304-3835(21)00118-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33675785</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0712</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>898</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmacology</Title>
          <ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>173999</StartPage>
          <MedlinePgn>173999</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2021.173999</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-2999(21)00152-7</ELocationID>
        <Abstract>
          <AbstractText>Necroptosis, ferroptosis and cyclophilin D (Cyp D)-dependent necrosis contribute to myocardial ischemia/reperfusion (I/R) injury, and ponatinib, deferoxamine and cyclosporine are reported to inhibit necroptosis, ferroptosis and Cyp D-dependent necrosis, respectively. This study aims to explore whether the any two combination between ponatinib, deferoxamine and cyclosporine exerts a better cardioprotective effect on I/R injury than single medicine does. The H9c2 cells were subjected to 10 h of hypoxia (H) plus 4 h of reoxygenation (R) to establish H/R injury model. The effects of any two combination between ponatinib, deferoxamine and cyclosporine on H/R injury were examined. On this basis, a I/R injury model in rat hearts was established to focus on the effect of ponatinib, deferoxamine and their combination on myocardial I/R injury and the underlying mechanisms. In H/R-treated H9c2 cells, all three medicines can attenuate H/R injury (decrease in LDH release and necrosis percent). However, only the combination of ponatinib with deferoxamine exerted synergistic effect on reducing H/R injury, showing simultaneous suppression of necroptosis and ferroptosis. Expectedly, administration of ponatinib or deferoxamine either before or after ischemia could suppress necroptosis or ferroptosis in the I/R-treated rat hearts as they did in vitro, concomitant with a decrease in myocardial infarct size and creatine kinase release, and the combination therapy is more efficient than single medication. Based on these observations, we conclude that the combination of ponatinib with deferoxamine reduces myocardial I/R injury via simultaneous inhibition of necroptosis and ferroptosis.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tu</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yuan-Jing</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Li-Jing</ForeName>
            <Initials>LJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China; Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Xiao-Ming</ForeName>
            <Initials>XM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China; Hunan Provincial Key Laboratory of Cardiovascular Research, School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiao-Jie</ForeName>
            <Initials>XJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ali Sheikh</LastName>
            <ForeName>Md Sayed</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Internal Medicine Department, Cardiology, College of Medicine, Jouf University, Skaka, Aljouf, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jie-Jie</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics, Xiangya Hospital Central South University, Changsha, China; Hunan Engineering Research Center of Early Life Development and Disease Prevention, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Xiu-Ju</ForeName>
            <Initials>XJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Chuang</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China. Electronic address: aeolus.yc@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China; Hunan Provincial Key Laboratory of Cardiovascular Research, School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China. Electronic address: junpeng@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharmacol</MedlineTA>
        <NlmUniqueID>1254354</NlmUniqueID>
        <ISSNLinking>0014-2999</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4340891KFS</RegistryNumber>
          <NameOfSubstance UI="C545373">ponatinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J06Y7MXW4D</RegistryNumber>
          <NameOfSubstance UI="D003676">Deferoxamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003676" MajorTopicYN="N">Deferoxamine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cyclosporine</Keyword>
        <Keyword MajorTopicYN="N">Cyp D-dependent necrosis</Keyword>
        <Keyword MajorTopicYN="N">Deferoxamine</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Myocardial ischemia/reperfusion</Keyword>
        <Keyword MajorTopicYN="N">Necroptosis</Keyword>
        <Keyword MajorTopicYN="N">Ponatinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33675785</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejphar.2021.173999</ArticleId>
        <ArticleId IdType="pii">S0014-2999(21)00152-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33649848</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2431</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncology reports</Title>
          <ISOAbbreviation>Oncol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castrationresistant prostate cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">25</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/or.2021.7976</ELocationID>
        <Abstract>
          <AbstractText>To date, there is no effective therapy available for the treatment of castrationresistant prostate cancer (CRPC), and patients generally succumb to the disease within 2 to 4 years. In the progression of CRPC, androgen receptor (AR) and its splice variants play critical roles. Hence, it is necessary to develop a drug to inhibit the expression and activity of the fulllength and splice variants of AR for the treatment of CRPC. Erastin, as the first discovered drug to induce ferroptosis, has been studied in various types of cancer. However, there are few studies focusing on the relationship between erastin and AR. In the present study, western blotting, and sulforhodamine B cell viability, glutathione, lipid peroxidation and reactive oxygen species assays were performed to verify the ferroptosis of CRPC cells; reverse transcriptionquantitative polymerase chain reaction, dualluciferase reporter, and lentiviral packaging and lentivirusinfected cell assays were employed to evaluate how erastin affects AR. A mouse xenograft assay was used to determine the underlying mechanism in vivo. Erastin, as a classical inducer of ferroptosis, can suppress the transcriptional activities of both the fulllength and splice variants in AR models in vitro and in vivo. In addition, when erastin was used for CRPC treatment combined with docetaxel, the growth inhibitory efficacy of docetaxel was found to be enhanced. Thus, these findings indicated that ferroptosis inducer erastin has potential in the treatment of CRPC via targeting AR.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yang</LastName>
            <ForeName>Yanrong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Recovery, Nursing School, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Taiyuan</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Hongyan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Analysis and Testing Center, Jilin Academy of Environmental Sciences, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Junyu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Shan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Recovery, Nursing School, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Recovery, Nursing School, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wanxia</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Recovery, Nursing School, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Lijing</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Recovery, Nursing School, Jilin University, Changchun, Jilin 130021, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Oncol Rep</MedlineTA>
        <NlmUniqueID>9422756</NlmUniqueID>
        <ISSNLinking>1021-335X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>15H5577CQD</RegistryNumber>
          <NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">castration&#x2011;resistant prostate cancer</Keyword>
        <Keyword MajorTopicYN="N">erastin</Keyword>
        <Keyword MajorTopicYN="N">androgen receptor</Keyword>
        <Keyword MajorTopicYN="N">splice variants</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33649848</ArticleId>
        <ArticleId IdType="doi">10.3892/or.2021.7976</ArticleId>
        <ArticleId IdType="pii">25</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33640304</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2405-8025</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Trends in cancer</Title>
          <ISOAbbreviation>Trends Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment.</ArticleTitle>
        <Pagination>
          <StartPage>484</StartPage>
          <EndPage>487</EndPage>
          <MedlinePgn>484-487</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trecan.2021.01.013</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2405-8033(21)00042-X</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) is widely used in cancer treatment; however, several challenges compromise its efficiency. We propose a synergistic action between PDT and ferroptotic cell death. PDT acts as a source of reactive oxygen species for the Fenton reaction, which may reinforce ferroptosis induction and increase PDT efficacy in anticancer therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mishchenko</LastName>
            <ForeName>Tatiana A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balalaeva</LastName>
            <ForeName>Irina V</ForeName>
            <Initials>IV</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vedunova</LastName>
            <ForeName>Maria V</ForeName>
            <Initials>MV</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krysko</LastName>
            <ForeName>Dmitri V</ForeName>
            <Initials>DV</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation; Cell Death Investigation and Therapy (CDIT) Laboratory, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent, Ghent, Belgium. Electronic address: dmitri.krysko@ugent.be.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Trends Cancer</MedlineTA>
        <NlmUniqueID>101665956</NlmUniqueID>
        <ISSNLinking>2405-8025</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000090783">Nanoparticle Drug Delivery System</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587550">RSL3 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S2CCF3T1Z</RegistryNumber>
          <NameOfSubstance UI="C062985">phytochlorin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="N">Chlorophyllides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090783" MajorTopicYN="Y">Nanoparticle Drug Delivery System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">immunogenic cell death</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">photosensitizes</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Interests No interests are declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>20</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33640304</ArticleId>
        <ArticleId IdType="doi">10.1016/j.trecan.2021.01.013</ArticleId>
        <ArticleId IdType="pii">S2405-8033(21)00042-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33634378</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-1182</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>58</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular neurobiology</Title>
          <ISOAbbreviation>Mol Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Thioredoxin-1 Rescues MPP[+]/MPTP-Induced Ferroptosis by Increasing Glutathione Peroxidase 4.</ArticleTitle>
        <Pagination>
          <StartPage>3187</StartPage>
          <EndPage>3197</EndPage>
          <MedlinePgn>3187-3197</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-021-02320-1</ELocationID>
        <Abstract>
          <AbstractText>Parkinson's disease (PD), a common neurodegenerative disease, is typically associated with the loss of dopaminergic neuron in the substantia nigra pars compacta (SNpc). Ferroptosis is a newly identified cell death, which associated with iron accumulation, glutathione (GSH) depletion, lipid peroxidation formation, reactive oxygen species (ROS) accumulation, and glutathione peroxidase 4 (GPX4) reduction. It has been reported that ferroptosis is linked with PD.Thioredoxin-1 (Trx-1) is a redox regulating protein and plays various roles in regulating the activity of transcription factors and inhibiting apoptosis. However, whether Trx-1 plays the role in regulating ferroptosis involved in PD is still unknown. Our present study showed that 1-methyl-4-phenylpyridinium (MPP[+]) decreased cell viability, GPX4, and Trx-1, which were reversed by Ferrostatin-1 (Fer-1) in PC 12 cells and SH-SY5Y cells. Moreover, the decreased GPX4 and GSH, and increased ROS were inhibited by Fer-1 and Trx-1 overexpression. We further repeated that behavior deficits resulted from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were improved in Trx-1 overexpression transgenic mice. Trx-1 reversed the decreases of GPX4 and tyrosine hydroxylase (TH) induced by MPTP in the substantia nigra pars compacta (SNpc). Our results suggest that Trx-1 inhibits ferroptosis in PD through regulating GPX4 and GSH.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Liping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neurobiology, Medical School, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neurobiology, Medical School, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Ruhua</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neurobiology, Medical School, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Rou</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neurobiology, Medical School, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xianwen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neurobiology, Medical School, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-1281-3159</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neurobiology, Medical School, Kunming University of Science and Technology, No.727 Jingming South Road, Kunming, 650500, China. jiebai662001@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>Nos. 81660222</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>U1202227</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Neurobiol</MedlineTA>
        <NlmUniqueID>8900963</NlmUniqueID>
        <ISSNLinking>0893-7648</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C491203">TXN protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>52500-60-4</RegistryNumber>
          <NameOfSubstance UI="D013879">Thioredoxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C000611332">glutathione peroxidase 4, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R865A5OY8J</RegistryNumber>
          <NameOfSubstance UI="D015655">1-Methyl-4-phenylpyridinium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015655" MajorTopicYN="N">1-Methyl-4-phenylpyridinium</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020267" MajorTopicYN="N">MPTP Poisoning</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008845" MajorTopicYN="N">Microinjections</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013879" MajorTopicYN="N">Thioredoxins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glutathione peroxidase 4</Keyword>
        <Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword>
        <Keyword MajorTopicYN="N">Thioredoxin-1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33634378</ArticleId>
        <ArticleId IdType="doi">10.1007/s12035-021-02320-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s12035-021-02320-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jiang X, Jin T, Zhang H, Miao J, Zhao X, Su Y, Zhang Y (2019) Current progress of mitochondrial quality control pathways underlying the pathogenesis of Parkinson&#x2019;s disease. Oxidative Med Cell Longev 2019:4578462&#x2013;4578411. https://doi.org/10.1155/2019/4578462</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/4578462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuno Y, Suzuki K, Sone N (1990) Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in mouse brain in vitro and in vivo. Adv Neurol 53:197&#x2013;200</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2122644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson&#x2019;s disease. J Bioenerg Biomembr 36(4):375&#x2013;379. https://doi.org/10.1023/B:JOBB.0000041771.66775.d5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/B:JOBB.0000041771.66775.d5</ArticleId>
            <ArticleId IdType="pubmed">15377875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rostamian Delavar M, Baghi M, Safaeinejad Z, Kiani-Esfahani A, Ghaedi K, Nasr-Esfahani MH (2018) Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson&#x2019;s disease. Gene 662:54&#x2013;65. https://doi.org/10.1016/j.gene.2018.04.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2018.04.010</ArticleId>
            <ArticleId IdType="pubmed">29631008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C (2019) Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med 133:221&#x2013;233. https://doi.org/10.1016/j.freeradbiomed.2018.09.033</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.09.033</ArticleId>
            <ArticleId IdType="pubmed">30266679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelova PR, Choi ML, Berezhnov AV, Horrocks MH, Hughes CD, De S, Rodrigues M, Yapom R et al (2020) Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell Death Differ 27:2781&#x2013;2796. https://doi.org/10.1038/s41418-020-0542-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-020-0542-z</ArticleId>
            <ArticleId IdType="pubmed">32341450</ArticleId>
            <ArticleId IdType="pmc">7492459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deas E, Cremades N, Angelova PR, Ludtmann MH, Yao Z, Chen S, Horrocks MH, Banushi B et al (2016) Alpha-Synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson&#x2019;s disease. Antioxid Redox Signal 24(7):376&#x2013;391. https://doi.org/10.1089/ars.2015.6343</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2015.6343</ArticleId>
            <ArticleId IdType="pubmed">26564470</ArticleId>
            <ArticleId IdType="pmc">4999647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jelinek A, Heyder L, Daude M, Plessner M, Krippner S, Grosse R, Diederich WE, Culmsee C (2018) Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis. Free Radic Biol Med 117:45&#x2013;57. https://doi.org/10.1016/j.freeradbiomed.2018.01.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.01.019</ArticleId>
            <ArticleId IdType="pubmed">29378335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yumnamcha T, Devi TS, Singh LP (2019) Auranofin mediates mitochondrial dysregulation and inflammatory cell death in human retinal pigment epithelial cells: implications of retinal neurodegenerative diseases. Front Neurosci 13:1065. https://doi.org/10.3389/fnins.2019.01065</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2019.01065</ArticleId>
            <ArticleId IdType="pubmed">31649499</ArticleId>
            <ArticleId IdType="pmc">6795687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cozza G, Rossetto M, Bosello-Travain V, Maiorino M, Roveri A, Toppo S, Zaccarin M, Zennaro L et al (2017) Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: the polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. Free Radic Biol Med 112:1&#x2013;11. https://doi.org/10.1016/j.freeradbiomed.2017.07.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2017.07.010</ArticleId>
            <ArticleId IdType="pubmed">28709976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauser DN, Dukes AA, Mortimer AD, Hastings TG (2013) Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radic Biol Med 65:419&#x2013;427. https://doi.org/10.1016/j.freeradbiomed.2013.06.030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.030</ArticleId>
            <ArticleId IdType="pubmed">23816523</ArticleId>
            <ArticleId IdType="pmc">4043454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93(7):2696&#x2013;2701. https://doi.org/10.1073/pnas.93.7.2696</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.7.2696</ArticleId>
            <ArticleId IdType="pubmed">8610103</ArticleId>
            <ArticleId IdType="pmc">39693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahoney-Sanchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC (2020) Ferroptosis and its potential role in the physiopathology of Parkinson&#x2019;s disease. Progress in neurobiology:101890. doi: https://doi.org/10.1016/j.pneurobio.2020.101890</Citation>
        </Reference>
        <Reference>
          <Citation>Bai J, Nakamura H, Kwon YW, Hattori I, Yamaguchi Y, Kim YC, Kondo N, Oka S et al (2003) Critical roles of thioredoxin in nerve growth factor-mediated signal transduction and neurite outgrowth in PC12 cells. J Neurosci 23(2):503&#x2013;509</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.23-02-00503.2003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai L, Zhang S, Zhou X, Li Y, Bai J (2019) Brain-derived neurotrophic factor induces thioredoxin-1 expression through TrkB/Akt/CREB pathway in SH-SY5Y cells. Biochimie 160:55&#x2013;60. https://doi.org/10.1016/j.biochi.2019.02.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2019.02.011</ArticleId>
            <ArticleId IdType="pubmed">30796965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai Y, Zhang X, Zhou X, Wu X, Li Y, Yao J, Bai J (2017) Nicotine suppresses the neurotoxicity by MPP(+)/MPTP through activating alpha7nAChR/PI3K/Trx-1 and suppressing ER stress. Neurotoxicology 59:49&#x2013;55. https://doi.org/10.1016/j.neuro.2017.01.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuro.2017.01.002</ArticleId>
            <ArticleId IdType="pubmed">28082123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Bai L, Zhang S, Zhou X, Li Y, Bai J (2018) Trx-1 ameliorates learning and memory deficits in MPTP-induced Parkinson&#x2019;s disease model in mice. Free Radic Biol Med 124:380&#x2013;387. https://doi.org/10.1016/j.freeradbiomed.2018.06.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.06.029</ArticleId>
            <ArticleId IdType="pubmed">29960099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo FC, Zhou J, Lv T, Qi L, Wang SD, Nakamura H, Yodoi J, Bai J (2012) Induction of endoplasmic reticulum stress and the modulation of thioredoxin-1 in formaldehyde-induced neurotoxicity. Neurotoxicology 33(3):290&#x2013;298. https://doi.org/10.1016/j.neuro.2012.02.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuro.2012.02.004</ArticleId>
            <ArticleId IdType="pubmed">22342837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng XS, Jia JJ, Kwon Y, Wang SD, Bai J (2014) The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease. Free Radic Biol Med 67:10&#x2013;18. https://doi.org/10.1016/j.freeradbiomed.2013.10.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.10.013</ArticleId>
            <ArticleId IdType="pubmed">24140863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talepoor Ardakani M, Rostamian Delavar M, Baghi M, Nasr-Esfahani MH, Kiani-Esfahani A, Ghaedi K (2019) Upregulation of miR-200a and miR-204 in MPP(+) -treated differentiated PC12 cells as a model of Parkinson&#x2019;s disease. Mol Genet Genomic Med 7(3):e548. https://doi.org/10.1002/mgg3.548</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mgg3.548</ArticleId>
            <ArticleId IdType="pubmed">30712312</ArticleId>
            <ArticleId IdType="pmc">6418372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR (2016) Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ 23(2):270&#x2013;278. https://doi.org/10.1038/cdd.2015.93</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.93</ArticleId>
            <ArticleId IdType="pubmed">26184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaobornyj T, Mazo T, Perez V, Gomez A, Contin M, Tripodi V, D&#x2019;Annunzio V, Gelpi RJ (2019) Thioredoxin-1 is required for the cardioprotecive effect of sildenafil against ischaemia/reperfusion injury and mitochondrial dysfunction in mice. Free Radic Res 53(9-10):993&#x2013;1004. https://doi.org/10.1080/10715762.2019.1661404</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10715762.2019.1661404</ArticleId>
            <ArticleId IdType="pubmed">31455116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagatsu T, Nagatsu I (2016) Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson&#x2019;s disease (PD): historical overview and future prospects. J Neural Transm 123(11):1255&#x2013;1278. https://doi.org/10.1007/s00702-016-1596-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-016-1596-4</ArticleId>
            <ArticleId IdType="pubmed">27491309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassarino DS, Parks JK, Parker WD Jr, Bennett JP Jr (1999) The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453(1):49&#x2013;62. https://doi.org/10.1016/s0925-4439(98)00083-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0925-4439(98)00083-0</ArticleId>
            <ArticleId IdType="pubmed">9989245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shishido T, Nagano Y, Araki M, Kurashige T, Obayashi H, Nakamura T, Takahashi T, Matsumoto M et al (2019) Synphilin-1 has neuroprotective effects on MPP(+)-induced Parkinson&#x2019;s disease model cells by inhibiting ROS production and apoptosis. Neurosci Lett 690:145&#x2013;150. https://doi.org/10.1016/j.neulet.2018.10.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2018.10.020</ArticleId>
            <ArticleId IdType="pubmed">30316984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar H, Lim HW, More SV, Kim BW, Koppula S, Kim IS, Choi DK (2012) The role of free radicals in the aging brain and Parkinson&#x2019;s disease: convergence and parallelism. Int J Mol Sci 13(8):10478&#x2013;10504. https://doi.org/10.3390/ijms130810478</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms130810478</ArticleId>
            <ArticleId IdType="pubmed">22949875</ArticleId>
            <ArticleId IdType="pmc">3431873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060&#x2013;1072. https://doi.org/10.1016/j.cell.2012.03.042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
            <ArticleId IdType="pmc">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, Dar HH, Liu B et al (2017) Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13(1):81&#x2013;90. https://doi.org/10.1038/nchembio.2238</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forred BJ, Daugaard DR, Titus BK, Wood RR, Floen MJ, Booze ML, Vitiello PF (2017) Detoxification of mitochondrial oxidants and apoptotic signaling are facilitated by Thioredoxin-2 and Peroxiredoxin-3 during hyperoxic injury. PLoS One 12(1):e0168777. https://doi.org/10.1371/journal.pone.0168777</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0168777</ArticleId>
            <ArticleId IdType="pubmed">28045936</ArticleId>
            <ArticleId IdType="pmc">5207683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62(6):649&#x2013;671. https://doi.org/10.1016/s0301-0082(99)00060-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0301-0082(99)00060-x</ArticleId>
            <ArticleId IdType="pubmed">10880854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branco V, Coppo L, Sola S, Lu J, Rodrigues CMP, Holmgren A, Carvalho C (2017) Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury. Redox Biol 13:278&#x2013;287. https://doi.org/10.1016/j.redox.2017.05.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2017.05.024</ArticleId>
            <ArticleId IdType="pubmed">28600984</ArticleId>
            <ArticleId IdType="pmc">5466585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schriever SC, Zimprich A, Pfuhlmann K, Baumann P, Giesert F, Klaus V, Kabra DG, Hafen U et al (2017) Alterations in neuronal control of body weight and anxiety behavior by glutathione peroxidase 4 deficiency. Neuroscience 357:241&#x2013;254. https://doi.org/10.1016/j.neuroscience.2017.05.050</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2017.05.050</ArticleId>
            <ArticleId IdType="pubmed">28627418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, Miki T, Manning-Bog AB, Berry MJ et al (2011) Glutathione peroxidase 4 is associated with neuromelanin in substantia nigra and dystrophic axons in putamen of Parkinson&#x2019;s brain. Mol Neurodegener 6(1):8. https://doi.org/10.1186/1750-1326-6-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1326-6-8</ArticleId>
            <ArticleId IdType="pubmed">21255396</ArticleId>
            <ArticleId IdType="pmc">3037910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, Shah R, Li B, Friedmann Angeli JP, Griesser M, Conrad M, Pratt DA (2017) On the Mechanism of cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the role of lipid peroxidation in FERROPTOTIC CELL DEATH. ACS central science 3(3):232&#x2013;243. https://doi.org/10.1021/acscentsci.7b00028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
            <ArticleId IdType="pmc">5364454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Booty LM, Gawel JM, Cvetko F, Caldwell ST, Hall AR, Mulvey JF, James AM, Hinchy EC et al (2019) Selective disruption of mitochondrial thiol redox state in cells and in vivo. Cell Chem Biol 26(3):449&#x2013;461 e448. https://doi.org/10.1016/j.chembiol.2018.12.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.12.002</ArticleId>
            <ArticleId IdType="pubmed">30713096</ArticleId>
            <ArticleId IdType="pmc">6436940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe T, Sekine S, Naguro I, Sekine Y, Ichijo H (2015) Apoptosis signal-regulating kinase 1 (ASK1)-p38 pathway-dependent cytoplasmic translocation of the orphan nuclear receptor NR4A2 Is required for oxidative stress-induced necrosis. J Biol Chem 290(17):10791&#x2013;10803. https://doi.org/10.1074/jbc.M114.623280</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.623280</ArticleId>
            <ArticleId IdType="pubmed">25752609</ArticleId>
            <ArticleId IdType="pmc">4409244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du Y, Zhang H, Zhang X, Lu J, Holmgren A (2013) Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system. J Biol Chem 288(45):32241&#x2013;32247. https://doi.org/10.1074/jbc.M113.495150</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.495150</ArticleId>
            <ArticleId IdType="pubmed">24062305</ArticleId>
            <ArticleId IdType="pmc">3820862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, He L, Wang T, Hua W, Qin H, Wang J, Wang L, Gu W et al (2020) Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-induced ferroptosis in dopaminergic cells. Mol Neurobiol 57:4628&#x2013;4641. https://doi.org/10.1007/s12035-020-02049-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-020-02049-3</ArticleId>
            <ArticleId IdType="pubmed">32770451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus JM, Conley S, Fath MA et al (2018) Targeting breast cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab 28(1):69&#x2013;86 e66. https://doi.org/10.1016/j.cmet.2018.06.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2018.06.006</ArticleId>
            <ArticleId IdType="pubmed">29972798</ArticleId>
            <ArticleId IdType="pmc">6037414</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33631189</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2968</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>186</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical pharmacology</Title>
          <ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis and its potential as a therapeutic target.</ArticleTitle>
        <Pagination>
          <StartPage>114486</StartPage>
          <MedlinePgn>114486</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2021.114486</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-2952(21)00082-4</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a recently defined form of programmed cell death that is different from apoptosis. It is an iron-dependent programmed cell death and the accumulation of lipid hydroperoxides to lethal levels make ferroptosis distinct. Ferroptosis can be effectively regulated by a number of cellular variables including iron content, amino acid uptake, polyunsaturated fatty acid incorporation, glutathione biosynthesis, and NADPH levels. A number of severe and common degenerative diseases in humans such as Parkinson's disease and Huntington's disease, as well as several acute injury scenarios, such as stroke, intracerebral hemorrhage, traumatic brain injury, and ischemia-reperfusion injury are likely to be linked to ferroptosis. Ferroptosis may play a critical role in tumor-suppression and has been proposed as a potential target for cancer therapy. However, regulating ferroptosis in vivo remains difficult due to a lack of compounds that can effectively activate or repress ferroptosis. Here we review the cellular mechanisms underlying ferroptosis and the pathophysiological circumstances where its regulation could be beneficial.</AbstractText>
          <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Hanshu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Science PhD Program, University of Connecticut Health, Farmington, CT 06030, United States. Electronic address: hyuan@uchc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pratte</LastName>
            <ForeName>Justin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, Storrs, CT 06269, United States; New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY 11568, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giardina</LastName>
            <ForeName>Charles</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cell Biology, Storrs, CT 06269, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem Pharmacol</MedlineTA>
        <NlmUniqueID>0101032</NlmUniqueID>
        <ISSNLinking>0006-2952</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33631189</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bcp.2021.114486</ArticleId>
        <ArticleId IdType="pii">S0006-2952(21)00082-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33624647</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2040-3372</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nanoscale</Title>
          <ISOAbbreviation>Nanoscale</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Iron-based nanoparticles for MR imaging-guided ferroptosis in combination with photodynamic therapy to enhance cancer treatment.</ArticleTitle>
        <Pagination>
          <StartPage>4855</StartPage>
          <EndPage>4870</EndPage>
          <MedlinePgn>4855-4870</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d0nr08757b</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis therapy, which applies ferroptotic inducers to produce lethal lipid peroxidation and induce the death of tumor cells, is regarded as a promising therapeutic strategy for cancer treatment. However, there is still a challenge regarding how to increase reactive oxygen species (ROS) accumulation in the tumor microenvironment (TME) to enhance antitumor efficacy. Herein, we designed a nanosystem coated with the FDA approved poly(lactic-co-glycolic acid) (PLGA) containing ferrous ferric oxide (Fe3O4) and chlorin E6 (Ce6) for synergistic ferroptosis-photodynamic anticancer therapy. The Fe3O4-PLGA-Ce6 nanosystem can dissociate in the acidic TME to release ferrous/ferric ions and Ce6. Then, the Fenton reaction between the released ferrous/ferric ions and intracellular excess hydrogen peroxide can occur to produce hydroxyl radicals (OH) and induce tumor cell ferroptosis. The released Ce6 can increase the generation and accumulation of ROS under laser irradiation to offer photodynamic therapy, which can boost ferroptosis in 4T1 cells. Moreover, magnetic monodisperse Fe3O4 loading provides excellent T2-weighted magnetic resonance imaging (MRI) properties. The Fe3O4-PLGA-Ce6 nanosystem possesses MRI ability and highly efficient tumor suppression with high biocompatibility in vivo due to the synergism of photodynamic and ferroptosis antitumor therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qifang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. songyangwenrong@hotmail.com zxk@swu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Xianbin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Materials and Energy &amp; Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing, 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. songyangwenrong@hotmail.com zxk@swu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Wenjie</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. songyangwenrong@hotmail.com zxk@swu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhigang</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0003-1805-5061</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Materials and Energy &amp; Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing, 400715, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Erqun</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-4026-090X</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. songyangwenrong@hotmail.com zxk@swu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Xiaokang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. songyangwenrong@hotmail.com zxk@swu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-7716-9216</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. songyangwenrong@hotmail.com zxk@swu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nanoscale</MedlineTA>
        <NlmUniqueID>101525249</NlmUniqueID>
        <ISSNLinking>2040-3364</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="Y">Porphyrins</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>8</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33624647</ArticleId>
        <ArticleId IdType="doi">10.1039/d0nr08757b</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33615565</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-2280</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Environmental and molecular mutagenesis</Title>
          <ISOAbbreviation>Environ Mol Mutagen</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Differences in cell death in methionine versus cysteine depletion.</ArticleTitle>
        <Pagination>
          <StartPage>216</StartPage>
          <EndPage>226</EndPage>
          <MedlinePgn>216-226</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/em.22428</ELocationID>
        <Abstract>
          <AbstractText>Restriction of the sulfur amino acids methionine and cysteine has recently been proposed as potential adjuvant therapy in cancer. While cysteine depletion has been associated with ferroptotic cell death, methionine depletion has not. We hypothesized that comparing the response of melanoma cell lines to depletion of the amino acids methionine and cysteine would give us insight into the critical role in cancer of these two closely related amino acids. We analyzed the response to three conditions: methionine depletion, methionine replacement with homocysteine, and cysteine depletion. In cancer cells, the transcription factor ATF4 was induced by all three tested conditions. The replacement of methionine with homocysteine produced a strong ferroptotic gene signature. We also detected an activation of the NRF2 antioxidant pathway by both methionine and cysteine depletion. Total glutathione levels were decreased by 42% in melanoma cells grown without methionine, and by 95% in cells grown without cysteine. Lipid peroxidation was increased in cells grown without cysteine, but not in cells grown without methionine. Despite the large degree of overlap in gene expression between methionine and cysteine depletion, methionine depletion and replacement of methionine with homocysteine was associated with apoptosis while cysteine depletion was associated with ferroptosis. Glutamine depletion produced comparable gene expression patterns and was associated with a 28% decrease in glutathione. Apoptosis was detected in these cells. In this experiment, a strong ATF4-driven ferroptotic gene signature was insufficient to induce ferroptosis without a concomitant profound decrease in glutathione levels.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wallis</LastName>
            <ForeName>Katherine F</ForeName>
            <Initials>KF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morehead</LastName>
            <ForeName>Lauren C</ForeName>
            <Initials>LC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bird</LastName>
            <ForeName>Jordan T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinformatics Core, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Byrum</LastName>
            <ForeName>Stephanie D</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bioinformatics Core, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miousse</LastName>
            <ForeName>Isabelle R</ForeName>
            <Initials>IR</Initials>
            <Identifier Source="ORCID">0000-0001-6543-3219</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>KL2 TR003108</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR003107</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Environ Mol Mutagen</MedlineTA>
        <NlmUniqueID>8800109</NlmUniqueID>
        <ISSNLinking>0893-6692</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497109">ATF4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0LVT1QZ0BA</RegistryNumber>
          <NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>145891-90-3</RegistryNumber>
          <NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AE28F7PNPL</RegistryNumber>
          <NameOfSubstance UI="D008715">Methionine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K848JZ4886</RegistryNumber>
          <NameOfSubstance UI="D003545">Cysteine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051701" MajorTopicYN="N">Activating Transcription Factor 4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008715" MajorTopicYN="N">Methionine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cell death</Keyword>
        <Keyword MajorTopicYN="N">cysteine</Keyword>
        <Keyword MajorTopicYN="N">glutathione</Keyword>
        <Keyword MajorTopicYN="N">methionine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33615565</ArticleId>
        <ArticleId IdType="mid">NIHMS1692317</ArticleId>
        <ArticleId IdType="pmc">PMC8130902</ArticleId>
        <ArticleId IdType="doi">10.1002/em.22428</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ables GP, Perrone CE, Orentreich D and Orentreich N (2012) Methionine-restricted C57BL/6J mice are resistant to diet-induced obesity and insulin resistance but have low bone density. PLoS One, 7, e51357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3518083</ArticleId>
            <ArticleId IdType="pubmed">23236485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee H-J, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, et al. (2020) Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science, 368, 85&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>B&#xe1;rcena C, Quir&#xf3;s PM, Durand S, Mayoral P, Rodr&#xed;guez F, Caravia XM, Mari&#xf1;o G, Garabaya C, Fern&#xe1;ndez-Garc&#xed;a MT, Kroemer G, Freije JMP and L&#xf3;pez-Ot&#xed;n C (2018) Methionine restriction extends lifespan in Progeroid mice and alters lipid and bile acid metabolism. Cell Reports, 24, 2392&#x2013;2403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6130051</ArticleId>
            <ArticleId IdType="pubmed">30157432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combs JA and DeNicola GM (2019) The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel), 11. https://www.mdpi.com/about/announcements/784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6562400</ArticleId>
            <ArticleId IdType="pubmed">31100816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS and Stockwell BR (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife, 3, e02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halpern BC, Clark BR, Hardy DN, Halpern RM and Smith RA (1974) The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proceedings of the National Academy of Sciences of the United States of America, 71, 1133&#x2013;1136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC388177</ArticleId>
            <ArticleId IdType="pubmed">4524624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokkinakis DM, Brickner AG, Kirkwood JM, Liu X, Goldwasser JE, Kastrama A, Sander C, Bocangel D and Chada S (2006) Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Molecular Cancer Research, 4, 575&#x2013;589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16908595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Law CW, Chen Y, Shi W and Smyth GK (2014) Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biology, 15, R29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4053721</ArticleId>
            <ArticleId IdType="pubmed">24485249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lees EK, Kr&#xf3;l E, Grant L, Shearer K, Wyse C, Moncur E, Bykowska AS, Mody N, Gettys TW and Delibegovic M (2014) Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell, 13, 817&#x2013;827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4331744</ArticleId>
            <ArticleId IdType="pubmed">24935677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Y, Smyth GK and Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30, 923&#x2013;930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24227677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewy AD, Niles KM, Anastasio N, Watkins D, Lavoie J, Lerner-Ellis JP, Pastinen T, Trasler JM and Rosenblatt DS (2009) Epigenetic modification of the gene for the vitamin B(12) chaperone MMACHC can result in increased tumorigenicity and methionine dependence. Molecular Genetics and Metabolism, 96, 261&#x2013;267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19200761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu S, Hoestje SM, Choo EM and Epner DE (2002) Methionine restriction induces apoptosis of prostate cancer cells via the c-Jun N-terminal kinase-mediated signaling pathway. Cancer Letter, 179, 51&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11880182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo T, Yang Y, Xu Y, Gao Q, Wu G, Jiang Y, Sun J, Shi Y and Le G (2019) Dietary methionine restriction improves glucose metabolism in the skeletal muscle of obese mice. Food Function, 10, 2676&#x2013;2690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31025993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malloy VL, Krajcik RA, Bailey SJ, Hristopoulos G, Plummer JD and Orentreich N (2006) Methionine restriction decreases visceral fat mass and preserves insulin action in aging male Fischer 344 rats independent of energy restriction. Aging Cell, 5, 305&#x2013;314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16800846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy DJ, Chen Y and Smyth GK (2012) Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Research, 40, 4288&#x2013;4297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3378882</ArticleId>
            <ArticleId IdType="pubmed">22287627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orentreich N and Zimmerman J (1993) Low methionine ingestion by rats extends life span. Age (days), 1050, 1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8429371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajanala SH, Ringquist R and Cryns VL (2019) Methionine restriction activates the integrated stress response in triple-negative breast cancer cells by a GCN2- and PERK-independent mechanism. American Journal of Cancer Research, 9, 1766&#x2013;1775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726988</ArticleId>
            <ArticleId IdType="pubmed">31497357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richie JP, Leutzinger Y, Parthasarathy S, Malloy V, Orentreich N and Zimmerman JA (1994) Methionine restriction increases blood glutathione and longevity in F344 rats. The FASEB Journal, 8, 1302&#x2013;1307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8001743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research, 43, e47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402510</ArticleId>
            <ArticleId IdType="pubmed">25605792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson MD, McCarthy DJ and Smyth GK (2010) edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26, 139&#x2013;140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796818</ArticleId>
            <ArticleId IdType="pubmed">19910308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strekalova E, Malin D, Good DM and Cryns VL (2015) Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL Receptor-2 expression. Clinical Cancer Research, 21, 2780&#x2013;2791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4470820</ArticleId>
            <ArticleId IdType="pubmed">25724522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Zheng Y, Wang C and Liu Y (2018) Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. Cell Death &amp; Disease, 9, 1&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6037763</ArticleId>
            <ArticleId IdType="pubmed">29988039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Ren B, Zhang Q, Chu C, Zhao Z, Wu J, Zhao W, Liu Z and Liu X (2020) Methionine restriction alleviates high-fat diet-induced obesity: involvement of diurnal metabolism of lipids and bile acids. Biochimica et Biophysica Acta (BBA)&#x2014;Molecular Basis of Disease, 1866, 165908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32745530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Chen XA, Hu J, Jiang J, Li Y, Chan-Salis KY, Gu Y, Chen G, Thomas C, Pugh BF and Wang Y (2015) ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3&#x2013;56 in triple negative breast cancer cells. Molecular Cancer Therapy, 14, 877&#x2013;888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4394025</ArticleId>
            <ArticleId IdType="pubmed">25612620</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33566577</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1526-4602</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomacromolecules</Title>
          <ISOAbbreviation>Biomacromolecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PDT-Enhanced Ferroptosis by a Polymer Nanoparticle with pH-Activated Singlet Oxygen Generation and Superb Biocompatibility for Cancer Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1167</StartPage>
          <EndPage>1176</EndPage>
          <MedlinePgn>1167-1176</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.biomac.0c01679</ELocationID>
        <Abstract>
          <AbstractText>In this study, we reported a nanocomplex (PAF) of PEGylated polygalacturonic acid, 5,10,15,20-tetrakis (4-aminophenyl) porphyrin (TAPP), and Fe[3+] for photodynamic therapy (PDT)-enhanced ferroptosis in cancer treatment. PAF exhibited a size of 135 nm and a TAPP and Fe[3+] loading content of 6.99 and 0.77%, respectively. The singlet oxygen ([1]O2) generation capacity of TAPP can be activated and significantly enhanced at acidic pH (4.5-5.0). Besides, the enhanced near-infrared absorption of TAPP at acidic pH enabled a further increase in [1]O2 generation capability by a near-infrared laser (760 nm). The polysaccharide-based polymer carrier offers excellent biocompatibility, and PAF displayed a proliferative effect in both normal (L929) and cancer (B16) cells. However, upon light irradiation, PAF exhibited high toxicity to B16 melanoma cells by intracellular reactive oxygen species elevation, glutathione depletion, and lipid peroxidation. PAF displayed a much better anticancer effect than the nanocomplex containing Fe[3+] or TAPP alone, indicating the PDT-enhanced ferroptosis in PAF. This study suggested that PDT-enhanced ferroptosis could be a facile and robust strategy of nanotherapeutics with high potency, tumor selectivity, and excellent biocompatibility.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemical Engineering, Sichuan University, Chengdu 610065, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Junhua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Biomaterials, School of Biomedical Engineering, Sichuan University, Chengdu 610064, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pu</LastName>
            <ForeName>Yuji</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-4465-0262</Identifier>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Biomaterials, School of Biomedical Engineering, Sichuan University, Chengdu 610064, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Sai</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemical Engineering, Sichuan University, Chengdu 610065, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Wenxia</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-3373-9827</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou 325027, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-0939-9869</Identifier>
            <AffiliationInfo>
              <Affiliation>National Engineering Research Center for Biomaterials, School of Biomedical Engineering, Sichuan University, Chengdu 610064, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biomacromolecules</MedlineTA>
        <NlmUniqueID>100892849</NlmUniqueID>
        <ISSNLinking>1525-7797</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>17778-80-2</RegistryNumber>
          <NameOfSubstance UI="D026082">Singlet Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026082" MajorTopicYN="N">Singlet Oxygen</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>17</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33566577</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.biomac.0c01679</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33554661</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1029-2330</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of drug targeting</Title>
          <ISOAbbreviation>J Drug Target</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondria autophagy: a potential target for cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>576</StartPage>
          <EndPage>591</EndPage>
          <MedlinePgn>576-591</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/1061186X.2020.1867992</ELocationID>
        <Abstract>
          <AbstractText>Mitophagy is a selective form of macroautophagy in which dysfunctional and damaged mitochondria can be efficiently degraded, removed and recycled through autophagy. Selective removal of damaged or fragmented mitochondria is critical to the functional integrity of the entire mitochondrial network and cells. In past decades, numerous studies have shown that mitophagy is involved in various diseases; however, since the dual role of mitophagy in tumour development, mitophagy role in tumour is controversial, and further elucidation is needed. That is, although mitophagy has been demonstrated to contribute to carcinogenesis, cell migration, ferroptosis inhibition, cancer stemness maintenance, tumour immune escape, drug resistance, etc. during cancer progression, many research also shows that to promote cancer cell death, mitophagy can be induced physiologically or pharmacologically to maintain normal cellular metabolism and prevent cell stress responses and genome damage by diminishing mitochondrial damage, thus suppressing tumour development accompanying these changes. Signalling pathway-specific molecular mechanisms are currently of great biological significance in the identification of potential therapeutic targets. Here, we review recent progress of molecular pathways mediating mitophagy including both canonical pathways (Parkin/PINK1- and FUNDC1-mediated mitophagy) and noncanonical pathways (FKBP8-, Nrf2-, and DRP1-mediated mitophagy); and the regulation of these pathways, and abovementioned pro-cancer and pro-death roles of mitophagy. Finally, we summarise the role of mitophagy in cancer therapy. Mitophagy can potentially be acted as the target for cancer therapy by promotion or inhibition.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Yu-Han</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Tian-Shu</ForeName>
            <Initials>TS</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiao-Wei</ForeName>
            <Initials>XW</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Meng-Yan</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Wen-Xia</ForeName>
            <Initials>WX</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Hui-Min</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Cong-Hui</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Mei-Lian</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiao-Fang</ForeName>
            <Initials>XF</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Wu-Li</ForeName>
            <Initials>WL</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shao</LastName>
            <ForeName>Rong-Guang</ForeName>
            <Initials>RG</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Drug Target</MedlineTA>
        <NlmUniqueID>9312476</NlmUniqueID>
        <ISSNLinking>1026-7158</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">LC3</Keyword>
        <Keyword MajorTopicYN="N">Mitophagy</Keyword>
        <Keyword MajorTopicYN="N">PINK1</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">parkin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33554661</ArticleId>
        <ArticleId IdType="doi">10.1080/1061186X.2020.1867992</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33483372</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-7445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>81</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1583</StartPage>
          <EndPage>1594</EndPage>
          <MedlinePgn>1583-1594</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-20-3477</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a type of programmed cell death induced by the accumulation of lipid peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated that cancer cells are vulnerable to ferroptosis inducers (FIN). However, the therapeutic potential of FINs in prostate cancer in preclinical settings has not been explored. In this study, we demonstrate that mediators of ferroptosis, solute carrier family 7 member 11, SLC3A2, and glutathione peroxidase, are expressed in treatment-resistant prostate cancer. We further demonstrate that treatment-resistant prostate cancer cells are sensitive to two FINs, erastin and RSL3. Treatment with erastin and RSL3 led to a significant decrease in prostate cancer cell growth and migration in vitro and significantly delayed the tumor growth of treatment-resistant prostate cancer in vivo, with no measurable side effects. Combination of erastin or RSL3 with standard-of-care second-generation antiandrogens for advanced prostate cancer halted prostate cancer cell growth and migration in vitro and tumor growth in vivo. These results demonstrate the potential of erastin or RSL3 independently and in combination with standard-of-care second-generation antiandrogens as novel therapeutic strategies for advanced prostate cancer. SIGNIFICANCE: These findings reveal that induction of ferroptosis is a new therapeutic strategy for advanced prostate cancer as a monotherapy and in combination with second-generation antiandrogens.</AbstractText>
          <CopyrightInformation>&#xa9;2021 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ghoochani</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-5352-0072</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>En-Chi</ForeName>
            <Initials>EC</Initials>
            <Identifier Source="ORCID">0000-0002-5671-6169</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aslan</LastName>
            <ForeName>Merve</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rice</LastName>
            <ForeName>Meghan A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0003-4578-0461</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Holly M</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, University of Washington, Seattle, Washington.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brooks</LastName>
            <ForeName>James D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Stanford University, Stanford, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corey</LastName>
            <ForeName>Eva</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-9244-3807</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Urology, University of Washington, Seattle, Washington.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paulmurugan</LastName>
            <ForeName>Ramasamy</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-7155-4738</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California. stanya@stanford.edu paulmur8@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stoyanova</LastName>
            <ForeName>Tanya</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-0119-9747</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California. stanya@stanford.edu paulmur8@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50 CA097186</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA240822</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>S10 OD023518</GrantID>
            <Acronym>OD</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 CA196387</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA244281</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA163227</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R03 CA230819</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000736">Androstenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027282">Fusion Regulatory Protein 1, Heavy Chain</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587550">RSL3 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C545989">SLC3A2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2010-15-3</RegistryNumber>
          <NameOfSubstance UI="D010669">Phenylthiohydantoin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>93T0T9GKNU</RegistryNumber>
          <NameOfSubstance UI="C540278">enzalutamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G819A456D0</RegistryNumber>
          <NameOfSubstance UI="C089740">abiraterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000736" MajorTopicYN="N">Androstenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027282" MajorTopicYN="N">Fusion Regulatory Protein 1, Heavy Chain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010669" MajorTopicYN="N">Phenylthiohydantoin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflicts of interest: The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33483372</ArticleId>
        <ArticleId IdType="mid">NIHMS1667182</ArticleId>
        <ArticleId IdType="pmc">PMC7969452</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-3477</ArticleId>
        <ArticleId IdType="pii">0008-5472.CAN-20-3477</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A, Cancer statistics, 2020. CA: A Cancer Journal for Clinicians 2020; 70: 7&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denis LJ, Griffiths K, Endocrine treatment in prostate cancer. Seminars in Surgical Oncology 2000; 18: 52&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10617897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P et al., A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU International 2005; 96: 985&#x2013;989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16225513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al., Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine 2019; 380: 1235&#x2013;1246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30763142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187&#x2013;1197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22894553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al., Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424&#x2013;433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4418931</ArticleId>
            <ArticleId IdType="pubmed">24881730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al., Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995&#x2013;2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3471149</ArticleId>
            <ArticleId IdType="pubmed">21612468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ et al., Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res 2017; 23: 3544&#x2013;3551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5543693</ArticleId>
            <ArticleId IdType="pubmed">28213364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18182665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147&#x2013;1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al., DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015; 373: 1697&#x2013;1708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5228595</ArticleId>
            <ArticleId IdType="pubmed">26510020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411&#x2013;422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20818862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ et al., Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol 2020; 38: 395&#x2013;405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7186583</ArticleId>
            <ArticleId IdType="pubmed">31774688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachostergios PJ, Puca L, Beltran H, Emerging Variants of Castration-Resistant Prostate Cancer. Curr Oncol Rep 2017; 19: 32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5479409</ArticleId>
            <ArticleId IdType="pubmed">28361223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA, Small cell carcinoma of the prostate. Nat Rev Urol 2014; 11: 213&#x2013;219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4339095</ArticleId>
            <ArticleId IdType="pubmed">24535589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY et al., Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487&#x2013;495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3290518</ArticleId>
            <ArticleId IdType="pubmed">22389870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV et al., Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol 2018; 36: 2492&#x2013;2503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6366813</ArticleId>
            <ArticleId IdType="pubmed">29985747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R et al., Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 2017; 32: 474&#x2013;489 e476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5750052</ArticleId>
            <ArticleId IdType="pubmed">29017058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B et al., Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest 2019; 129: 4492&#x2013;4505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6763249</ArticleId>
            <ArticleId IdType="pubmed">31361600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ et al., Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017; 171: 273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Dixon SJ, Mechanisms of ferroptosis. Cell Mol Life Sci 2016; 73: 2195&#x2013;2209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L, Ko PJ, Dixon SJ, Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ 2016; 23: 1099&#x2013;1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5399169</ArticleId>
            <ArticleId IdType="pubmed">26967968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR, The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10: 9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR, Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A 2016; 113: E4966&#x2013;4975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS et al., Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156: 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seibt TM, Proneth B, Conrad M, Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med 2019; 133: 144&#x2013;152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30219704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Sato H, The oxidative stress-inducible cystine/glutamate antiporter, system &#xd7; (c) (&#x2212;) : cystine supplier and beyond. Amino Acids 2012; 42: 231&#x2013;246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21409388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, Stockwell BR, Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol 2018; 16: e2006203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5991413</ArticleId>
            <ArticleId IdType="pubmed">29795546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi KN, Bjartell A, Dearnaley D, Saad F, Schroder FH, Sternberg C et al., Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009; 56: 594&#x2013;605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19560857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bebber CM, Muller F, Prieto Clemente L, Weber J, von Karstedt S, Ferroptosis in Cancer Cell Biology. Cancers (Basel) 2020; 12:</Citation>
        </Reference>
        <Reference>
          <Citation>Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W et al., Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med 2019; 23: 4900&#x2013;4912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6653007</ArticleId>
            <ArticleId IdType="pubmed">31232522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A et al., Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 2017; 551: 247&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B et al., Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 2017; 547: 453&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, Stockwell BR, Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3: 285&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L et al., Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett 2012; 22: 1822&#x2013;1826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3528973</ArticleId>
            <ArticleId IdType="pubmed">22297109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR, Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15: 234&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ et al., RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007; 447: 864&#x2013;868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M et al., Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014; 3: e02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh JL, Kim EH, Jang H, Shin D, Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol 2017; 11: 254&#x2013;262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5198738</ArticleId>
            <ArticleId IdType="pubmed">28012440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C et al., Ferroptosis: A Novel Anti-tumor Action for Cisplatin. Cancer Res Treat 2018; 50: 445&#x2013;460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912137</ArticleId>
            <ArticleId IdType="pubmed">28494534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM et al., Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife 2020; 9:</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7386908</ArticleId>
            <ArticleId IdType="pubmed">32686647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tousignant KD, Rockstroh A, Poad BLJ, Talebi A, Young RSE, Taherian Fard A et al., Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab 2020; 8: 11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7304214</ArticleId>
            <ArticleId IdType="pubmed">32577235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP et al., Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Mol Cancer Ther 2020; 19: 1708&#x2013;1718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32430485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai S, Cao S, Jin L, Kobelski M, Schouest B, Wang X et al., A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene 2019; 38: 4977&#x2013;4989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6586509</ArticleId>
            <ArticleId IdType="pubmed">30820039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X et al., AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther 2019; 18: 1875&#x2013;1886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6995728</ArticleId>
            <ArticleId IdType="pubmed">31308078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP et al., Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun 2018; 9: 4700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6240084</ArticleId>
            <ArticleId IdType="pubmed">30446660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP et al., Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 3198&#x2013;3210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4058390</ArticleId>
            <ArticleId IdType="pubmed">24740322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S et al., Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A 2020; 117: 2032&#x2013;2042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6994991</ArticleId>
            <ArticleId IdType="pubmed">31932422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice MA, Hsu EC, Aslan M, Ghoochani A, Su A, Stoyanova T, Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies. Mol Cancer Ther 2019; 18: 1230&#x2013;1242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7280023</ArticleId>
            <ArticleId IdType="pubmed">31028097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh BM, Lee SJ, Park GL, Hwang YS, Lim J, Park ES et al., Erastin Inhibits Septic Shock and Inflammatory Gene Expression via Suppression of the NF-kappaB Pathway. J Clin Med 2019; 8:</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6947339</ArticleId>
            <ArticleId IdType="pubmed">31847346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS et al., LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Prostate 2017; 77: 654&#x2013;671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5354949</ArticleId>
            <ArticleId IdType="pubmed">28156002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Maziere JC, Chauffert B et al., Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 2013; 133: 1732&#x2013;1742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23505071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gout PW, Buckley AR, Simms CR, Bruchovsky N, Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001; 15: 1633&#x2013;1640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11587223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo JH, Shimoni Y, Yang WS, Subramaniam P, Iyer A, Nicoletti P et al., Elucidating Compound Mechanism of Action by Network Perturbation Analysis. Cell 2015; 162: 441&#x2013;451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4506491</ArticleId>
            <ArticleId IdType="pubmed">26186195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787&#x2013;790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2981508</ArticleId>
            <ArticleId IdType="pubmed">19359544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg LO, Ziegler P et al., The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor &#x3b2;1 expression in prostate cancer cells. J Cell Biochem 2019; 120: 16711&#x2013;16722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31297844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X et al., HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene 2015; 34: 5617&#x2013;5625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4640181</ArticleId>
            <ArticleId IdType="pubmed">25728673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu S, Zhang Q, Sun X, Zeh HJ 3rd, Lotze MT, Kang R et al., HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Res 2017; 77: 2064&#x2013;2077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5392369</ArticleId>
            <ArticleId IdType="pubmed">28130223</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33318476</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Distinct photo-oxidation-induced cell death pathways lead to selective killing of human breast cancer cells.</ArticleTitle>
        <Pagination>
          <StartPage>1070</StartPage>
          <MedlinePgn>1070</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1070</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-03275-2</ELocationID>
        <Abstract>
          <AbstractText>Lack of effective treatments for aggressive breast cancer is still a major global health problem. We have previously reported that photodynamic therapy using methylene blue as photosensitizer (MB-PDT) massively kills metastatic human breast cancer, marginally affecting healthy cells. In this study, we aimed to unveil the molecular mechanisms behind MB-PDT effectiveness and specificity towards tumor cells. Through lipidomics and biochemical approaches, we demonstrated that MB-PDT efficiency and specificity rely on polyunsaturated fatty acid-enriched membranes and on the better capacity to deal with photo-oxidative damage displayed by non-tumorigenic cells. We found out that, in tumorigenic cells, lysosome membrane permeabilization is accompanied by ferroptosis and/or necroptosis. Our results also pointed at a cross-talk between lysosome-dependent cell death (LDCD) and necroptosis induction after photo-oxidation, and contributed to broaden the understanding of MB-PDT-induced mechanisms and specificity in breast cancer cells. Therefore, we demonstrated that efficient approaches could be designed on the basis of lipid composition and metabolic features for hard-to-treat cancers. The results further reinforce MB-PDT as a therapeutic strategy for highly aggressive human breast cancer cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dos Santos</LastName>
            <ForeName>Ancly F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inague</LastName>
            <ForeName>Alex</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-7410-9226</Identifier>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arini</LastName>
            <ForeName>Gabriel S</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terra</LastName>
            <ForeName>Letcia F</ForeName>
            <Initials>LF</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wailemann</LastName>
            <ForeName>Rosangela A M</ForeName>
            <Initials>RAM</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pimentel</LastName>
            <ForeName>Andr C</ForeName>
            <Initials>AC</Initials>
            <Identifier Source="ORCID">0000-0001-7254-3803</Identifier>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshinaga</LastName>
            <ForeName>Marcos Y</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Ricardo R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Faculdade de Cincias Farmacuticas de Ribeiro Preto, Universidade de So Paulo (USP), Ribeiro Preto, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Severino</LastName>
            <ForeName>Divinomar</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-9483-6287</Identifier>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Almeida</LastName>
            <ForeName>Daria Raquel Q</ForeName>
            <Initials>DRQ</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomes</LastName>
            <ForeName>Vincius M</ForeName>
            <Initials>VM</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bruni-Cardoso</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terra</LastName>
            <ForeName>Walter R</ForeName>
            <Initials>WR</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyamoto</LastName>
            <ForeName>Sayuri</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baptista</LastName>
            <ForeName>Maurcio S</ForeName>
            <Initials>MS</Initials>
            <Identifier Source="ORCID">0000-0001-7079-7666</Identifier>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil. baptista@iq.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Labriola</LastName>
            <ForeName>Leticia</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-3899-6088</Identifier>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqumica, Instituto de Qumica, Universidade de So Paulo (USP), So Paulo, 05508-000, Brazil. labriola@iq.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>T42P99266K</RegistryNumber>
          <NameOfSubstance UI="D008751">Methylene Blue</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008027" MajorTopicYN="Y">Light</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008751" MajorTopicYN="N">Methylene Blue</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>56</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33318476</ArticleId>
        <ArticleId IdType="pmc">PMC7736888</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-020-03275-2</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-020-03275-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front. Oncol. 2018;8:227. doi: 10.3389/fonc.2018.00227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2018.00227</ArticleId>
            <ArticleId IdType="pmc">PMC6010518</ArticleId>
            <ArticleId IdType="pubmed">29963498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harbeck N, et al. Breast cancer. Nat. Rev. Dis. Primers. 2019;5:66. doi: 10.1038/s41572-019-0111-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-019-0111-2</ArticleId>
            <ArticleId IdType="pubmed">31548545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Z, et al. Reactive oxygen species-related nanoparticle toxicity in the biomedical field. Nanoscale Res. Lett. 2020;15:115. doi: 10.1186/s11671-020-03344-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11671-020-03344-7</ArticleId>
            <ArticleId IdType="pmc">PMC7239959</ArticleId>
            <ArticleId IdType="pubmed">32436107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montaseri H, Kruger CA, Abrahamse H. Recent advances in porphyrin-based inorganic nanoparticles for cancer treatment. Int. J. Mol. Sci. 2020;21:3358. doi: 10.3390/ijms21093358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21093358</ArticleId>
            <ArticleId IdType="pmc">PMC7247422</ArticleId>
            <ArticleId IdType="pubmed">32397477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferroni C, Del Rio A, Martini C, Manoni E, Varchi G. Light-induced therapies for prostate cancer treatment. Front. Chem. 2019;7:719. doi: 10.3389/fchem.2019.00719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fchem.2019.00719</ArticleId>
            <ArticleId IdType="pmc">PMC6828976</ArticleId>
            <ArticleId IdType="pubmed">31737599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Bruijn HS, et al. Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics. 2020;10:2436&#x2013;2452. doi: 10.7150/thno.37949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.37949</ArticleId>
            <ArticleId IdType="pmc">PMC7019176</ArticleId>
            <ArticleId IdType="pubmed">32089747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos AF, De Almeida DRQ, Terra LF, Baptista MS, Labriola L. Photodynamic therapy in cancer treatment - an update review. J. Cancer Metastasis Treat. 2019;5:25.</Citation>
        </Reference>
        <Reference>
          <Citation>Maawy AA, et al. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models. J. Surg. Res. 2014;197:5&#x2013;11. doi: 10.1016/j.jss.2015.02.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jss.2015.02.037</ArticleId>
            <ArticleId IdType="pmc">PMC4457622</ArticleId>
            <ArticleId IdType="pubmed">25799527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maawy AA, et al. Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of pancreatic cancer. PLoS ONE. 2015;10:e0121989. doi: 10.1371/journal.pone.0121989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0121989</ArticleId>
            <ArticleId IdType="pmc">PMC4370703</ArticleId>
            <ArticleId IdType="pubmed">25799218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostinis P, et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011;61:250&#x2013;281. doi: 10.3322/caac.20114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.20114</ArticleId>
            <ArticleId IdType="pmc">PMC3209659</ArticleId>
            <ArticleId IdType="pubmed">21617154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sies H, Berndt C, Jones DP. Oxidative stress. Annu. Rev. Biochem. 2017;86:715&#x2013;748. doi: 10.1146/annurev-biochem-061516-045037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-061516-045037</ArticleId>
            <ArticleId IdType="pubmed">28441057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bacellar IOL, et al. Membrane damage efficiency of phenothiazinium photosensitizers. Photochem. Photobiol. 2014;90:801&#x2013;813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24571440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bacellar IOL, et al. Photosensitized membrane permeabilization requires contact-dependent reactions between photosensitizer and lipids. J. Am. Chem. Soc. 2018;140:9606&#x2013;9615. doi: 10.1021/jacs.8b05014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.8b05014</ArticleId>
            <ArticleId IdType="pubmed">29989809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos AF, et al. Fluence rate determines PDT efficiency in breast cancer cells displaying different GSH levels. Photochem. Photobiol. 2020;96:658&#x2013;667. doi: 10.1111/php.13182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.13182</ArticleId>
            <ArticleId IdType="pubmed">31742700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angell-Petersen E, et al. Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J. Neurosurg. 2006;104:109&#x2013;117. doi: 10.3171/jns.2006.104.1.109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/jns.2006.104.1.109</ArticleId>
            <ArticleId IdType="pubmed">16509154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 2006;38:489&#x2013;493. doi: 10.1002/lsm.20327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lsm.20327</ArticleId>
            <ArticleId IdType="pubmed">16615136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grossman CE, et al. Fluence rate differences in photodynamic therapy efficacy and activation of epidermal growth factor receptor after treatment of the tumor-involved murine thoracic cavity. Int. J. Mol. Sci. 2016;17:1&#x2013;14. doi: 10.3390/ijms17010101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17010101</ArticleId>
            <ArticleId IdType="pmc">PMC4730343</ArticleId>
            <ArticleId IdType="pubmed">26784170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR, Heger M. Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev. 2015;34:643&#x2013;690. doi: 10.1007/s10555-015-9588-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-015-9588-7</ArticleId>
            <ArticleId IdType="pmc">PMC4661210</ArticleId>
            <ArticleId IdType="pubmed">26516076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos AF, et al. Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells. BMC Cancer. 2017;17:194. doi: 10.1186/s12885-017-3179-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3179-7</ArticleId>
            <ArticleId IdType="pmc">PMC5353937</ArticleId>
            <ArticleId IdType="pubmed">28298203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira CS, Turchiello R, Kowaltowski AJ, Indig GL, Baptista MS. Major determinants of photoinduced cell death: Subcellular localization versus photosensitization efficiency. Free Radic. Biol. Med. 2011;51:824&#x2013;833. doi: 10.1016/j.freeradbiomed.2011.05.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.05.023</ArticleId>
            <ArticleId IdType="pubmed">21664269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl Acad. Sci. USA. 2016;113:E4966&#x2013;E4975. doi: 10.1073/pnas.1603244113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1603244113</ArticleId>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 2017;13:81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J&#xe4;nicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 1998;273:9357&#x2013;9360. doi: 10.1074/jbc.273.16.9357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.16.9357</ArticleId>
            <ArticleId IdType="pubmed">9545256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eiriksson FF, et al. Lipidomic study of cell lines reveals differences between breast cancer subtypes. PLoS ONE. 2020;15:1&#x2013;22. doi: 10.1371/journal.pone.0231289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0231289</ArticleId>
            <ArticleId IdType="pmc">PMC7156077</ArticleId>
            <ArticleId IdType="pubmed">32287294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida-Aoki N, et al. Lipidomic analysis of cells and extracellular vesicles from high- and low-metastatic triple-negative breast cancer. Metabolites. 2020;10:67. doi: 10.3390/metabo10020067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/metabo10020067</ArticleId>
            <ArticleId IdType="pmc">PMC7073695</ArticleId>
            <ArticleId IdType="pubmed">32069969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L, Ko PJ, Dixon SJ. Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ. 2016;23:1099&#x2013;1109. doi: 10.1038/cdd.2016.25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2016.25</ArticleId>
            <ArticleId IdType="pmc">PMC5399169</ArticleId>
            <ArticleId IdType="pubmed">26967968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008;9:112&#x2013;124. doi: 10.1038/nrm2330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2330</ArticleId>
            <ArticleId IdType="pmc">PMC2642958</ArticleId>
            <ArticleId IdType="pubmed">18216768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parisi LR, Morrow LM, Visser MB, Atilla-Gokcumen GE. Turning the spotlight on lipids in non-apoptotic cell death. ACS Chem. Biol. 2018;13:506&#x2013;515. doi: 10.1021/acschembio.7b01082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.7b01082</ArticleId>
            <ArticleId IdType="pubmed">29376324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nat. Rev. Mol. Cell Biol. 2018;19:281&#x2013;296. doi: 10.1038/nrm.2017.138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2017.138</ArticleId>
            <ArticleId IdType="pubmed">29410529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsubone TM, Junqueira HC, Baptista MS, Itri R. Contrasting roles of oxidized lipids in modulating membrane microdomains. Biochim. Biophys. Acta Biomembr. 2019;1861:660&#x2013;669. doi: 10.1016/j.bbamem.2018.12.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2018.12.017</ArticleId>
            <ArticleId IdType="pubmed">30605637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem. Rev. 2011;111:5944&#x2013;5972. doi: 10.1021/cr200084z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cr200084z</ArticleId>
            <ArticleId IdType="pubmed">21861450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calder PC. Functional roles of fatty acids and their effects on human health. J. Parenter. Enter. Nutr. 2015;39:18S&#x2013;32S. doi: 10.1177/0148607115595980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0148607115595980</ArticleId>
            <ArticleId IdType="pubmed">26177664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem. Biol. 2019;26:420&#x2013;432. doi: 10.1016/j.chembiol.2018.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.11.016</ArticleId>
            <ArticleId IdType="pmc">PMC6430697</ArticleId>
            <ArticleId IdType="pubmed">30686757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brigelius-floh&#xe9; R, Maiorino M. Glutathione peroxidases. Biochim. Biophys. Acta. 2013;1830:3289&#x2013;3303. doi: 10.1016/j.bbagen.2012.11.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2012.11.020</ArticleId>
            <ArticleId IdType="pubmed">23201771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun. 2019;10:1617. doi: 10.1038/s41467-019-09277-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09277-9</ArticleId>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693&#x2013;698. doi: 10.1038/s41586-019-1707-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1707-0</ArticleId>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;692. doi: 10.1038/s41586-019-1705-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1705-2</ArticleId>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelicano H, et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 2014;16:434. doi: 10.1186/s13058-014-0434-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-014-0434-6</ArticleId>
            <ArticleId IdType="pmc">PMC4303115</ArticleId>
            <ArticleId IdType="pubmed">25209360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berghe TV, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Ver. Mol. Cell Biol. 2014;15:135&#x2013;147. doi: 10.1038/nrm3737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3737</ArticleId>
            <ArticleId IdType="pubmed">24452471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagakannan P, Tabeshmehr P, Eftekharpour E. Oxidative damage of lysosomes in regulated cell death systems: pathophysiology and pharmacologic interventions. Free Radic. Biol. Med. 2020;157:94&#x2013;127. doi: 10.1016/j.freeradbiomed.2020.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.04.001</ArticleId>
            <ArticleId IdType="pubmed">32259579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486&#x2013;541. doi: 10.1038/s41418-017-0012-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0012-4</ArticleId>
            <ArticleId IdType="pmc">PMC5864239</ArticleId>
            <ArticleId IdType="pubmed">29362479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber RA, et al. Maintaining iron homeostasis is the key role of lysosomal acidity for cell proliferation. Mol. Cell. 2020;77:645&#x2013;655. doi: 10.1016/j.molcel.2020.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2020.01.003</ArticleId>
            <ArticleId IdType="pmc">PMC7176020</ArticleId>
            <ArticleId IdType="pubmed">31983508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci. 2016;41:274&#x2013;286. doi: 10.1016/j.tibs.2015.11.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2015.11.012</ArticleId>
            <ArticleId IdType="pmc">PMC4783254</ArticleId>
            <ArticleId IdType="pubmed">26725301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui S, et al. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis. 2019;10:331. doi: 10.1038/s41419-019-1564-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1564-7</ArticleId>
            <ArticleId IdType="pmc">PMC6465411</ArticleId>
            <ArticleId IdType="pubmed">30988278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dondelinger Y, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7:971&#x2013;981. doi: 10.1016/j.celrep.2014.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.04.026</ArticleId>
            <ArticleId IdType="pubmed">24813885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quarato G, et al. Sequential engagement of distinct MLKL phosphatidylinositol-binding sites executes necroptosis. Mol. Cell. 2016;61:589&#x2013;601. doi: 10.1016/j.molcel.2016.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2016.01.011</ArticleId>
            <ArticleId IdType="pmc">PMC4769881</ArticleId>
            <ArticleId IdType="pubmed">26853145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dovey CM, et al. MLKL requires the inositol phosphate code to execute necroptosis. Mol. Cell. 2018;70:936&#x2013;948. doi: 10.1016/j.molcel.2018.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2018.05.010</ArticleId>
            <ArticleId IdType="pmc">PMC5994928</ArticleId>
            <ArticleId IdType="pubmed">29883610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yashin DV, Romanova EA, Ivanova OK, Sashchenko LP. The Tag7-Hsp70 cytotoxic complex induces tumor cell necroptosis via permeabilisation of lysosomes and mitochondria. Biochimie. 2016;123:32&#x2013;36. doi: 10.1016/j.biochi.2016.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2016.01.007</ArticleId>
            <ArticleId IdType="pubmed">26796882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, et al. Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis. Cell Death Dis. 2018;9:476. doi: 10.1038/s41419-018-0469-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0469-1</ArticleId>
            <ArticleId IdType="pmc">PMC5913300</ArticleId>
            <ArticleId IdType="pubmed">29686269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology. 2016;5:1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4938314</ArticleId>
            <ArticleId IdType="pubmed">27471616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terra LF, et al. Heat shock protein B1 is a key mediator of prolactin-induced beta-cell cytoprotection against oxidative stress. Free Radic. Biol. Med. 2019;134:394&#x2013;405. doi: 10.1016/j.freeradbiomed.2019.01.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2019.01.023</ArticleId>
            <ArticleId IdType="pubmed">30699366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959;37:911&#x2013;917. doi: 10.1139/o59-099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/o59-099</ArticleId>
            <ArticleId IdType="pubmed">13671378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik ZI. Fluorescence analysis of the labile iron pool of mammalian cells. Anal. Biochem. 1997;248:31&#x2013;40. doi: 10.1006/abio.1997.2126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/abio.1997.2126</ArticleId>
            <ArticleId IdType="pubmed">9177722</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33197601</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-1186</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>164</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmacological research</Title>
          <ISOAbbreviation>Pharmacol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.</ArticleTitle>
        <Pagination>
          <StartPage>105305</StartPage>
          <MedlinePgn>105305</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phrs.2020.105305</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1043-6618(20)31613-3</ELocationID>
        <Abstract>
          <AbstractText>On account of incurable castration-resistant prostate cancer (CRPC) inevitably developing after treating with androgen deprivation therapy, it is an urgent need to find new therapeutic strategies. Flubendazole is a well-known anti-malarial drug that is recently reported to be a potential anti-tumor agent in various types of human cancer cells. However, whether flubendazole could inhibit the castration-resistant prostate cancer has not been well charified. Thus, the aim of the present study was to characterize the precise mechanism of action of flubendazole on the CRPC. In this study, we investigated the potential effect of flubendazole on cell proliferation, cell cycle and cell death in CRPC cells (PC3 and DU145). We found that flubendazole inhibited cell proliferation, caused cell cycle arrest in G2/M phase and promoted cell death in vitro, and suppressed growth of CRPC tumor in xenograft models. In addition, we reported that flubendazole induced the expression of P53, which partly accounted for the G2/M phase arrest and led to inhibition of the transcription of SLC7A11, and then downregulated the GPX4, which is a major ferroptosis-related gene. Furthermore, flubendazole exhibited synergistic effect with 5-fluorouracil (5-Fu) in chemotherapy of CRPC. This study provides biological evidence that flubendazole is a novel P53 inducer which exerts anti-proliferation and pro-apoptosis effects in CRPC through hindering the cell cycle and activating the ferroptosis, and indicates that a novel utilization of flubendazole in neoadjuvant chemotherapy of CRPC.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xumin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China; Department of Pathogen Biology and Experimental Teaching Center of Preventive Medicine, Guangdong Provincial Key Laboratory of Tropical Disease, School of Public Health, Southern Medical University, Guangzhou 510515, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Libin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Wenbin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Taowei</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Junqi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Kaihui</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shu</LastName>
            <ForeName>Fangpeng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Xiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital, Southwest Medical University, Luzhou 646000, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Peking University Shenzhen Hospital, Shenzhen 518036, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cen</LastName>
            <ForeName>Shengren</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chuanyin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China. Electronic address: li-chuanyin@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Xiangming</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China. Electronic address: mxm@smu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Pharmacol Res</MedlineTA>
        <NlmUniqueID>8907422</NlmUniqueID>
        <ISSNLinking>1043-6618</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>81G6I5V05I</RegistryNumber>
          <NameOfSubstance UI="D008463">Mebendazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R8M46911LR</RegistryNumber>
          <NameOfSubstance UI="C018945">flubendazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3P01618RT</RegistryNumber>
          <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008463" MajorTopicYN="N">Mebendazole</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">5-fluorouracil (PubChem CID: 3385)</Keyword>
        <Keyword MajorTopicYN="N">Anti-tumor</Keyword>
        <Keyword MajorTopicYN="N">Castration-resistant prostate cancer (CRPC)</Keyword>
        <Keyword MajorTopicYN="N">Dimethyl sulfoxide (PubChem CID: 679)</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Ferrostatin-1 (PubChem CID: 4068248)</Keyword>
        <Keyword MajorTopicYN="N">Flubendazole</Keyword>
        <Keyword MajorTopicYN="N">Flubendazole (PubChem CID: 35802)</Keyword>
        <Keyword MajorTopicYN="N">P53</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33197601</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phrs.2020.105305</ArticleId>
        <ArticleId IdType="pii">S1043-6618(20)31613-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33176157</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2451-9448</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell chemical biology</Title>
          <ISOAbbreviation>Cell Chem Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Using the Oxytosis/Ferroptosis Pathway to Understand and Treat Age-Associated Neurodegenerative Diseases.</ArticleTitle>
        <Pagination>
          <StartPage>1456</StartPage>
          <EndPage>1471</EndPage>
          <MedlinePgn>1456-1471</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chembiol.2020.10.010</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2451-9456(20)30426-8</ELocationID>
        <Abstract>
          <AbstractText>Oxytosis was first described over 30 years ago in nerve cells as a non-excitotoxic pathway for glutamate-induced cell death. The key steps of oxytosis, including glutathione depletion, lipoxygenase activation, reactive oxygen species accumulation, and calcium influx, were identified using a combination of chemical and genetic tools. A pathway with the same characteristics as oxytosis was identified in transformed fibroblasts in 2012 and named ferroptosis. Importantly, the pathophysiological changes seen in oxytosis and ferroptosis are also observed in multiple neurodegenerative diseases as well as in the aging brain. This led to the hypothesis that this pathway could be used as a screening tool to identify novel drug candidates for the treatment of multiple age-associated neurological disorders, including Alzheimer's disease (AD). Using this approach, we have identified several AD drug candidates, one of which is now in clinical trials, as well as new target pathways for AD.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maher</LastName>
            <ForeName>Pamela</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA. Electronic address: pmaher@salk.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Currais</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schubert</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AG046153</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R41 AI104034</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1 AG054714</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Chem Biol</MedlineTA>
        <NlmUniqueID>101676030</NlmUniqueID>
        <ISSNLinking>2451-9448</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">calcium</Keyword>
        <Keyword MajorTopicYN="N">glutamate toxicity</Keyword>
        <Keyword MajorTopicYN="N">glutathione</Keyword>
        <Keyword MajorTopicYN="N">glutathione peroxidase 4</Keyword>
        <Keyword MajorTopicYN="N">lipoxygenases</Keyword>
        <Keyword MajorTopicYN="N">mitochondria</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Interests D.S. was an unpaid advisor for Abrexa Pharmaceuticals, a company working on the development of J147 for AD therapy. The Salk Institute holds the patents for CMS121 (US9744164) and J147 (US8779002).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33176157</ArticleId>
        <ArticleId IdType="mid">NIHMS1640102</ArticleId>
        <ArticleId IdType="pmc">PMC7749085</ArticleId>
        <ArticleId IdType="doi">10.1016/j.chembiol.2020.10.010</ArticleId>
        <ArticleId IdType="pii">S2451-9456(20)30426-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adam-Vizi V, and Tretter L (2013). The role of mitochondrial dehydrogenases in the generation of oxidative stress. Neurochem Int 62, 757&#x2013;763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23357482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams JD, Klaidman LK, Odunze IN, Shen HC, and Miller CA (1991). Alzheimer&#x2019;s and Parkinson&#x2019;s disease. Brain levels of glutathione, glutathione disulfide and vitamin E. Mol Chem Neuropathol 14, 213&#x2013;226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1958264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agathocleous M, and Harris WA (2013). Metabolism in physiological cell proliferation and differentiation. Trends Cell Biol 23, 484&#x2013;492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23756093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, and Methner A (2010). Mechanisms of oxidative glutamate toxicity: The glutamate/cystine antiporter system x(c)- as a neuroprotective drug target. CNS Neurol Disord Drug Targets 9, 373&#x2013;382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20053169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez J, Alvarez-Illera P, Garcia-Casas P, Fonteriz RI, and Montero M (2020). The role of calcium signaling in aging and neurodegeneration: Insights from Caenorhabditis elegans models. Cells 9, 204.</Citation>
        </Reference>
        <Reference>
          <Citation>Ansari MA, and Scheff SW (2010). Oxidative stress in the progression of Alzheimer&#x2019;s disease in the frontal cortex. J Neuropathol Exp Neurol 69, 155&#x2013;167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826839</ArticleId>
            <ArticleId IdType="pubmed">20084018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong MM, Freedman CJ, Jung JE, Zheng YL, Kalyanaraman C, Jacodson MP, Simeonov A, Maloney DJ, van Leyen K, Jadhav A, et al. (2016). A potent and selective inhibitor targeting human and murine 12/15 LOX. Bioorg Med Chem 24, 1183&#x2013;1190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4778748</ArticleId>
            <ArticleId IdType="pubmed">26899595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ates G, Goldberg J, Currais A, and Maher P (2020). CMS121, a fatty acid synthase inhibitor, protects against excess lipi peroxidation and inflammation and alleviates cognitive loss in a transgenic model of Alzheimer&#x2019;s disease. Redox Biol in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7394765</ArticleId>
            <ArticleId IdType="pubmed">32863221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atlante A, de Bari L, Bobba A, and Amadoro G (2017). A disease with a sweet tooth: exploring the Warburg effect in Alzheimer&#x2019;s disease. Biogerontol 18, 301&#x2013;319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28314935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayala A, Munoz MF, and Arguelles S (2014). Lipid peroxidation: Production, metabolism and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014, 360438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4066722</ArticleId>
            <ArticleId IdType="pubmed">24999379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, and Hammond CL (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390, 191&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756154</ArticleId>
            <ArticleId IdType="pubmed">19166318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belanger M, Allaman I, and Magistretti PJ (2011). Brain energy metabolism:focus on astrocyte-neuron metabolic copperation. Cell Metab 14, 724&#x2013;738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22152301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, and Villar AM (2008). Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer&#x2019;s disease from mild cognitive impairment. Free Rad Res 42, 162&#x2013;170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18297609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong BCK, Maimone TJ, Zoncu R, et al. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL, and Petersen KF (2010). Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 30, 211&#x2013;221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2949111</ArticleId>
            <ArticleId IdType="pubmed">19794401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boveris A, and Navarro A (2008). Brain mitochondrial dysfunction in aging IUBMB Life 60, 308&#x2013;314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18421773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradley-Whitman MA, and Lovell MA (2015). Biomarkers of lipid peroxidation in Alzheimer&#x2019;s disease (AD): an update. Arch Toxicol 89, 1035&#x2013;1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4466146</ArticleId>
            <ArticleId IdType="pubmed">25895140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breitzig M, Bhimineni C, Lockey N, and Kolliputi N (2016). 4-Hydroxy-2-nonenal: a critical target in oxidative stress? Amer J Physiol Cell Physiol 311, C537&#x2013;C543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5129750</ArticleId>
            <ArticleId IdType="pubmed">27385721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brune B, and Ullrich V (1991). 12-Hydroperoxyeicosatetraenoic acid inhibits main platelet functions by activation of soluble guanylate cyclase. Mol Pharmacol 39, 671&#x2013;678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1674588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burkewitz K, Zhang Y, and Mair WB (2014). AMPK at the nexus of energetics and aging. Cell Metab 20, 10&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4287273</ArticleId>
            <ArticleId IdType="pubmed">24726383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabon L, Galan-Maol P, Bouharrour A, Delavallee L, Brunelle-Navas M-N, Lorenzo HK, Gross A, and Susin SA (2012). BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation. Cell Death Differ 19, 245&#x2013;256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3263500</ArticleId>
            <ArticleId IdType="pubmed">21738214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case AJ, Li S, Basu U, Tian J, and Zimmerman MC (2013). Mitochondrial-localized NADPH oxidase 4 is a soure of superoxide in angiotensin II-stimulated neurons. Amer J Physiol Heart Circ Physiol 305, H19&#x2013;H28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3727106</ArticleId>
            <ArticleId IdType="pubmed">23624625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan DC (2006). Mitochondria: dynamic organelles in disease, aging and development. Cell 125, 1241&#x2013;1252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16814712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandran R, Kumar M, Kesavan L, Jacob RS, Gunasekaran S, Lakshmi S, Sadasivan C, and Omkumar RV (2019). Cellular calcium signaling in the aging brain. J Chem Neuroanat 95, 95&#x2013;114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29129748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen M, He H, Zhan S, Krajewski S, Reed JC, and Gottlieb RA (2001). Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem 276, 30724&#x2013;30728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11404357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, Chiruta C, Akaishi T, Abe K, Maher P, et al. (2011). A novel neurotrophic drug for cognitive enhancement and Alzheimer&#x2019;s disease. PLoS ONE 6, e27865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237323</ArticleId>
            <ArticleId IdType="pubmed">22194796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinta SJ, Rajagopalan S, Butterfield DA, and Anderson JK (2006). In vitro and in vivo neuroprotection by g-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson&#x2019;s disease. Neurosci Lett 402, 137&#x2013;141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16644116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiruta C, Schubert D, Dargusch R, and Maher P (2012). Chemical modification of the multi-target neuroprotective compound fisetin. J Med Chem 55, 378&#x2013;389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3291199</ArticleId>
            <ArticleId IdType="pubmed">22192055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi DW (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623&#x2013;634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2908446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole-Ezea P, Swan D, Shanley D, and Hesketh J (2012). Glutathione peroxidase 4 has a major role in protecting mitochondria from oxidative damage and maintaining phosphorylation complexes in gut epithelial cells. Free Rad Biol Med 53, 488&#x2013;497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22634395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Kagan VE, Bayir H, Pagnussat GC, Head B, Traber MG, and Stockwell BR (2018). Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev 32, 602&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6004068</ArticleId>
            <ArticleId IdType="pubmed">29802123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costantini LC, Barr LJ, Vogel JL, and Henderson ST (2008). Hypometabolism as a therapeutic target in Alzheimer&#x2019;s disease. BMC Neurosci 9, S16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2604900</ArticleId>
            <ArticleId IdType="pubmed">19090989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crisponi G, Nurchi VM, Crespo-Alonso M, Sanna G, Zoroddu MA, Alberti G, and Biesuz R (2015). A speciation stuy on the perturbing effects of iron chelators on the homeostasis of essential metal ions. PLoS ONE 10, e0133050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4508027</ArticleId>
            <ArticleId IdType="pubmed">26192307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N, et al. (2011). Brain fuel matabolism, aging and Alzheimer&#x2019;s disease. Nutrition 27, 3&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3478067</ArticleId>
            <ArticleId IdType="pubmed">21035308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currais A (2015). Ageing and inflammation-A central role for mitochondria in brain health and disease. Ageing Res Rev 21, 30&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25684584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currais A, Farrokhi C, Dargusch R, Armando A, Quehenberger O, Schubert D, and Maher P (2018). Fisetin reduces the impact of aging on behavior and physiology in the rapidly aging SAMP8 mouse. J Gerentol A Biol Sci Med Sci 73, 299&#x2013;307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5861950</ArticleId>
            <ArticleId IdType="pubmed">28575152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, Daugherty D, Armando A, Quehenberger O, Maher P, et al. (2015). A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging 7, 937&#x2013;955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4694064</ArticleId>
            <ArticleId IdType="pubmed">26564964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currais A, Huang L, Goldberg J, Petrascheck M, Ates G, Pinto-Duarte A, Shokhirev M, Schubert D, and Maher P (2019). Elevating acetyl-CoA levels reduces aspects of brain aging. eLife 8, e47866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6882557</ArticleId>
            <ArticleId IdType="pubmed">31742554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currais A, and Maher P (2013). Functional consequences of age-dependent changes in glutathione status in the brain. Antioxid Redox Signal 19, 813&#x2013;822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23249101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currais A, Prior M, Dargusch R, Armando A, Ehren J, Schubert D, Quehenberger O, and Maher P (2014). Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer&#x2019;s disease transgenic mice. Aging Cell 13, 379&#x2013;390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3954948</ArticleId>
            <ArticleId IdType="pubmed">24341874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis JB, and Maher P (1994). Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell lines. Brain Res 652, 169&#x2013;173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7953717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. (2012). Ferroptosis: An iron-dependent form of non-apoptotic cell death. Cell 149, 1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolga AM, POppermann S, Richter M, Honrath B, Neitemeier S, Jelinek A, Ganjam G, and Culmsee C (2018). Molecular mechanisms underlying oxytosis In Apoptosis and Beyond: The Many Ways Cells Die, Radosevich J, ed. (Hoboken, NJ: Wiley;).</Citation>
        </Reference>
        <Reference>
          <Citation>Doll S, Freitas FP, Shah R, Aldrovandi M, Costa da Silva M, Ingold I, Grocin AG, da Silva TNX, Panzilius E, Scheel CH, et al. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693&#x2013;698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13, 91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, and Stockwell BR (2003). Identification of genotyps-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Droge W, Kinscherf R, Hildebrandt W, and Schmitt T (2006). The deficit in low molecular weight thiols as a target for antiageing therapy. Curr Drug Targets 7, 1505&#x2013;1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17100590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehren JL, and Maher P (2013). Concurrent regulation of the transcription factors Nrf2 and ATF4 mediates the enhancement of glutathione levels by the flavonoid fisetin. Biochem Pharmacol 85, 1816&#x2013;1826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23618921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elphick LM, Hawat M, Toms NJ, Meinander A, Mikhailov A, Eriksson JE, and Kass GEN (2008). Opposing roles for caspase and calpain proteases in L-glutamate-induced oxidative neurotoxicity. Toxicol Appl Pharmacol 232, 258&#x2013;267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18687350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emir UE, Raatz S, McPherson S, Hodges JS, Torkelson C, Tawfik P, White T, and Terpstra M (2011). Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brain. NMR Biomed 24, 888&#x2013;894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3118919</ArticleId>
            <ArticleId IdType="pubmed">21834011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, and Stockwell BR (2018). Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol 16, e2006203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5991413</ArticleId>
            <ArticleId IdType="pubmed">29795546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng W, Rosca M, fan Y, Hu Y, Feng P, Lee H-G, Monnier VM, and Fan X (2017). Gclc deficiency in mouse CNS causes mitochondrial damage and neurodegeneration. Hum Mol Gen 26, 1376&#x2013;1390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6075078</ArticleId>
            <ArticleId IdType="pubmed">28158580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez-Fernandez S, Bobo-Jimenez V, Requejo-Aguilar R, SGonzalez-Fernandez S, Resch M, Carabias-Carrasco M, Ros J, Almeida A, and Bolanos JP (2018). Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function. Redox Biol 38, 5415&#x2013;5428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6092450</ArticleId>
            <ArticleId IdType="pubmed">30107295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folmes CD, Dzeja PP, Nelson TJ, and Terzic A (2012). Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 11, 596&#x2013;606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3593051</ArticleId>
            <ArticleId IdType="pubmed">23122287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Yang F, Che J, Han Y, Chen N, Bak DW, Lai S, Xie X, Weerapana E, and Wang CX (2018). Selenium-encoded isotopic signature target profiling. ACS Cent Sci 4, 960&#x2013;970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6107865</ArticleId>
            <ArticleId IdType="pubmed">30159393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Yi JJ, Zhu JW, Minikes AM, Monian P, Thompson CB, and Jiang X (2019). Role of mitochondria in ferroptosis. Mol Cell 73, 1&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, and Stockwell BR (2017). Lipid peroxidation in cell death. Biochem Biophys Res Commun 482, 419&#x2013;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5319403</ArticleId>
            <ArticleId IdType="pubmed">28212725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gelderblom M, Leypoldt F, Lewerenz J, Birkenmayer G, Orozco D, Ludewig P, Thundyil J, Arumugam TV, Gerloff C, Tolosa E, et al. (2012). The flavonoid fisetin attenuates postischemic immune cell infiltration, activation and infarct size after transient cerebral middle artery occlusion in mice. J Cereb Blood Flow Metab 32, 835&#x2013;843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3345911</ArticleId>
            <ArticleId IdType="pubmed">22234339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giustarini D, Dalle-Donne I, Lorenzini S, Milzani A, and Rossi R (2006). Age-related influence on thiol, disulfide and protein-mixed disulfide levels in human plasma. J Gerentol A Biol Sci Med Sci 61, 1030&#x2013;1038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17077195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg J, Currais A, Ates G, Huang L, Shokhirev M, Maher P, and Schubert D (2020). Targeting of intracellular Ca+2 stores as a therapeutic strategy against age-related neurotoxicities. Aging Mech Dis in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7445274</ArticleId>
            <ArticleId IdType="pubmed">32884834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg J, Currais A, Prior M, Fischer WH, Chiruta C, Ratliff E, Daughtery D, Dargusch R, Finley D, Esparza-Molto PB, et al. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell 17, 12715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5847861</ArticleId>
            <ArticleId IdType="pubmed">29316249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gout PW, Buckley AR, Simms CR, and Bruchovsky N (2001). Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the Xc- cystine transporter: a new action for an old drug. Leukemia 15, 1633&#x2013;1640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11587223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu M, D. OA, Toffa SE, Cooper JM, Dexter DT, Jenner P, Marsden CD, and Schapira AH (1998). Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 158, 24&#x2013;29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9667773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha JS, Lim HM, and Park SS (2010). Extracellular hydrogen peroxide contributes to oxidative glutamate toxicity. Brain Res 1359, 291&#x2013;297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20816674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagmann W, Kagawa D, Renaud C, and Honn KV (1993). Activation and protein distribution of 12-lipoxygenase in HEL cells: induction of membrane-association by phorbol ester TPA, modulation of activity by glutathione and 13-HPODE and Ca+2-dependent translocation to membranes. Prostaglandins 46, 471&#x2013;477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8295977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris JJ, Jolivet R, and Attwell D (2012). Synaptic energy use and supply. Neuron 75, 762&#x2013;777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22958818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He WB, Abe K, and Akaishi T (2018). Oral administration of fisetin promotes the induction of hippocampal lonr-term potentiation in vivo. J Pharmacol Sci 136, 42&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29317180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henke N, Albrecht P, Bouchachia I, Ryazantseva M, Knoll K, Lewerenz J, Kaznacheyeva E, Maher P, and Methner A (2013). The plasma membrane channel ORA1 mediates detrimental calcium influx caused by endogenous oxidative stress. Cell Death Dis 4, e470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3564003</ArticleId>
            <ArticleId IdType="pubmed">23348584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirata Y, Yamada C, Ito Y, Yamamoto S, Nagase H, Oh-hashi K, Kiuchi K, Suzuki H, Sawada M, and Furuta K (2018). Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22 cells. Neuropharmacol 135, 242&#x2013;252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29551691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai H, and Nakagawa Y (2003). Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Rad Biol Med 34, 145&#x2013;169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12521597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishige K, Chen Q, Sagara Y, and Schubert D (2001a). The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. J Neurosci 21, 6069&#x2013;6076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6763185</ArticleId>
            <ArticleId IdType="pubmed">11487630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishige K, Schubert D, and Sagara Y (2001b). Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 30, 433&#x2013;446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11182299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayaraj RL, Elangovan N, Dhanalakshmi C, Manivasagam T, and Essa MM (2014). CNB-001, a novel pyrozole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson&#x2019;s disease mice. Chem Biol Interact 220, 149&#x2013;157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24995576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jelinek A, Heyder L, Daude M, Plessner M, Krippner S, Grosse R, Diederich WE, and Culmsee C (2018). Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis. Free Rad Biol Med 117, 45&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29378335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi YB, Giannopoulos PF, and Practico D (2015). The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer&#x2019;s disease. Trends Pharmacol Sci 36, 181&#x2013;186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4355395</ArticleId>
            <ArticleId IdType="pubmed">25708815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi YB, and Practico D (2015). The 5-lipoxygenase pathay: oxidative and inflammatory contributions to the Alzheimer&#x2019;s disease phenotype. Front Cell Neurosci 8, 436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4294160</ArticleId>
            <ArticleId IdType="pubmed">25642165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, P. AJ, Doll S, St. Croix CM, Dar HH, Liu B, Tyurin VA, Ritov VB, et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13, 81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y, Tiziani S, Park G, Kaul M, and Paternostro G (2014). Cellular protection using Flt3 and PI3Kalpha inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. Nature Commun 5, 3672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4128233</ArticleId>
            <ArticleId IdType="pubmed">24739485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapralov AA, Yang Q, Dar HH, Tyurina YY, Anthonymuthu TS, Kim R, St. Croix CM, Mikulska-Ruminiska K, Liu B, Shrivastava I, et al. (2020). Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nature Cell Biol 16, 278&#x2013;290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7233108</ArticleId>
            <ArticleId IdType="pubmed">32080625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, Vihalemm T, Kairane C, and Zilmer M (2001). The cerebrocortical areas in normal brain aging and in Alzheimer&#x2019;s disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 26, 353&#x2013;361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11495345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerr JFR, Wyllie AH, and Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 239&#x2013;257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2008650</ArticleId>
            <ArticleId IdType="pubmed">4561027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi MS, Han D, and Packer L (2000). Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Rad Res 32, 115&#x2013;124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10653482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Sato M, Kasakoshi T, Tusutsui T, Sugimoto M, Osaki M, Okada F, Igarashi K, Hiratake J, Homma T, et al. (2015). Cystathionine is a novel substrate of cystine/glutamate transporter: implciations for immune function. J Biol Chem 290, 8778&#x2013;8788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4423669</ArticleId>
            <ArticleId IdType="pubmed">25713140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota C, Torii S, Hou N, Saito N, Yoshimoto Y, Imai H, and Takeuchi T (2010). Constitutive reactive oxygen species generation from autophagosomes/lysosomes in neuronal oxidative toxicity. J Biol Chem 285, 667&#x2013;674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2804214</ArticleId>
            <ArticleId IdType="pubmed">19850931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhn H, Banthiya S, and van Leyen K (2015). Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta 1851, 308&#x2013;330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4370320</ArticleId>
            <ArticleId IdType="pubmed">25316652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landshamer S, Hoehn M, Barth N, Duvezin-Caubet S, Schwake G, Tobaben S, Kazhdan I, Becattini B, Zahler S, Vollmar A, et al. (2008). Bid-induced release of AIF from mitochondria causes immediate neuronal cell death. Cell Death Differ 15, 1553&#x2013;1563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2862690</ArticleId>
            <ArticleId IdType="pubmed">18535584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lane N, and Martin W (2010). The energetics of genome complexity. Nature 467, 929&#x2013;934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20962839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lapchak PA, Boitano PD, Bombien R, Cook DJ, Doyan S, Lara JM, and Schubert D (2019). CNB-001, a pleiotropic drug is efficacious in embolized agyrencephalic New Zealand white rabbits and ischemic gyrencephalic cynomolgus monkeys. Exp Neurol 313, 98&#x2013;108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30521790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lapchak PA, Schubert DR, and Maher PA (2011). Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem 116, 122&#x2013;131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3004475</ArticleId>
            <ArticleId IdType="pubmed">21054387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HJ, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, Tyagi S, Ma L, Westbrook TF, Steinberg GR, et al. (2020). Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol 22, 225&#x2013;234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7008777</ArticleId>
            <ArticleId IdType="pubmed">32029897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei P, Bai T, and Sun Y (2019). Mechanisms of ferroptosis and relations with regulated cell death: A review. Front Physiol 10, 139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6399426</ArticleId>
            <ArticleId IdType="pubmed">30863316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J, Ates G, Methner A, Conrad M, and Maher P (2018). Oxytosis/ferroptosis-(Re-)emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases on the central nervous system. Front Neurosci 12, 214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5920049</ArticleId>
            <ArticleId IdType="pubmed">29731704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA, Halatsch ME, Karpel-Massler G, Meakin PJ, Hayes JD, et al. (2014). Phosphoinositide 3-kinases upregulate system xc- via eukaryotic transcription factor 2&#x3b1; and activating transcription factor 4-A pathway active in glioblastoma and epilepsy. Antioxid Redox Signal 20, 2907&#x2013;2922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4038988</ArticleId>
            <ArticleId IdType="pubmed">24219064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas P, Massie A, Smolders I, Methner A, Pergande M, et al. (2013). The cystine/glutamate antiporter system x(c)- in health and disease: From molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 18, 522&#x2013;555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3545354</ArticleId>
            <ArticleId IdType="pubmed">22667998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J, Letz J, and Methner A (2003). Activation of stimulatory heteromeric G proteins increases glutathione and protects neuronal cells against oxidative stress. J Neurochem 87, 522&#x2013;531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14511129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J, and Maher P (2009). Basal levels of eIF2&#x3b1; phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. J Biol Chem 284, 1106&#x2013;1115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613630</ArticleId>
            <ArticleId IdType="pubmed">19017641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Maher P, and Schubert D (1997a). Requirement for cGMP in nerve cell death caused by glutathione depletion. J Cell Biol 139, 1317&#x2013;1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2140210</ArticleId>
            <ArticleId IdType="pubmed">9382876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Maher P, and Schubert D (1997b). A role of 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19, 453&#x2013;463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9292733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin MT, and Beal MF (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787&#x2013;795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17051205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Li L, and Suo WZ (2009). HT22 hippocampal neuronal cell line possesses functional cholinergic properties. Life Sci 84, 267&#x2013;271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19135458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Dargusch R, Maher P, and Schubert D (2008). A broadly neuroprotective derivative of curcumin. J Neurochem 105, 1336&#x2013;1345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18208543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, and Schubert DR (2009). The specificity of neuroprotection by antioxidants. J Biomed Res 16, 98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2779189</ArticleId>
            <ArticleId IdType="pubmed">19891782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Wang W, Li Y, Xiao Y, Cheng JL, and Jia J (2015). The 5-lipoxygenase inhibitor zileuton confers neuroprotection against glutamate oxidative damage by inhibiting ferroptosis. Biol Pharm Bull 38, 1234&#x2013;1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26235588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P (2005). The effects of stress and aging on glutathione metabolism. Ageing Res Rev 4, 288&#x2013;314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15936251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P (2015). How fisetin reduces the impact of age and disease on CNS function. Front Biosci 7, 58&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5527824</ArticleId>
            <ArticleId IdType="pubmed">25961687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P (2017). Potentiation of glutathione loss and nerve cell death by the transition metals iron and copper: implications for age-related neurodegenerative diseases. Free Rad Biol Med 115, 92&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29170091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P, Akaishi T, and Abe K (2006). Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci USA 103, 16568&#x2013;16573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1637622</ArticleId>
            <ArticleId IdType="pubmed">17050681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P, Dargusch R, Bodai L, Gerard P, Purcell JM, and Marsh JL (2011). ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington&#x2019;s disease. Hum Mol Gen 20, 261&#x2013;270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3005900</ArticleId>
            <ArticleId IdType="pubmed">20952447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P, and Davis JB (1996). The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 16, 6394&#x2013;6401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6578906</ArticleId>
            <ArticleId IdType="pubmed">8815918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P, Salgado KF, Zivin JA, and Lapchak PA (2007). A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173, 117&#x2013;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2111291</ArticleId>
            <ArticleId IdType="pubmed">17765210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P, and Schubert D (2000). Signaling by reactive oxygen species in the nervous system. Cell Mol Life Sci 27, 1287&#x2013;1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11028919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher P, van Leyen K, Dey PN, Honrath B, Dolga A, and Methner A (2018). The role of Ca+2 in cell death caused by oxidative glutamate toxicity and ferroptosis. Cell Calcium 70, 47&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5682235</ArticleId>
            <ArticleId IdType="pubmed">28545724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makar TK, Cooper AJ, Tofel-Grehl B, Thaler HT, and Blass JP (1995). Carnitine, carnitine acetyltransferase, and glutathione in Alzheimer brain. Neurochem Res 20, 705&#x2013;711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7566367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal PK, Saharan S, Tripathi M, and Murari G (2015). Brain glutathione levels-a novel biomarker for mild cognitive impairment and Alzheimer&#x2019;s disease. Biol Psychiatry 78, 702&#x2013;710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26003861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal PK, Shukla D, Tripathi M, and Ersland L (2019). Cognitive improvement with glutathione supplement in Alzheimer&#x2019;s disease: a way forward. J Alzheimer&#x2019;s Dis 68, 531&#x2013;535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30776003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsicano G, Moosmann B, Hermann H, Lutz B, and Behl C (2002). Neuroprotective properties of cannibinoids agaisnt oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80, 448&#x2013;456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11905991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin HL, and Teisman P (2009). Glutathione-a review on its role and significance in Parkinson&#x2019;s disease. FASEB J 23, 3263&#x2013;3272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19542204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mischley LK, Standish LJ, Weiss NS, Padowski JM, Kavanagh TJ, White CC, and Rosenfeld ME (2016). Glutathione as a biomarker in Parkinson&#x2019;s disease: Associations with aging and disease severity. Oxid Med Cell Longev 2016, 9409363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4944065</ArticleId>
            <ArticleId IdType="pubmed">27446510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto M, Murphy TH, Schnaar RL, and Coyle JT (1989). Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exper Ther 250, 1132&#x2013;1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2778712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morimoto BH, and Koshland DE (1990). Induction and expression of long and short term neurosecretory potentiation in a neural cell line. Neuron 5, 875&#x2013;880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1980069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TH, and Baraban JM (1990). Glutamate toxicity in immature cortical neurons precedes development of glutamate receptor currents. Brain Res 57, 146&#x2013;150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1982523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TH, Malouf AT, Sastre A, Schnaar RL, and Coyle JT (1988). Calcium-dependent glutamate cytotoxicity in a neuronal cell line. Brain Res 444, 325&#x2013;332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2896063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TH, Miyamoto M, Sastre A, Schnaar RL, and Coyle JT (1989). Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2, 1547&#x2013;1558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2576375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TH, Schnaar RL, and Coyle JT (1990). Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4, 1624&#x2013;1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2180770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musiek ES, Breeding RS, Milne GL, Zanoni G, Morrow JD, and McLaughlin B (2006). Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J Neurochem 97, 1301&#x2013;1313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2881557</ArticleId>
            <ArticleId IdType="pubmed">16638022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagase H, Katagiri Y, Oh-hashi K, Geller HM, and Hirata Y (2020). Reduced sulfation enhanced oxytosis and ferroptosis in mouse hippocampal HT22 cells. Biomolecules 10, 92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7022473</ArticleId>
            <ArticleId IdType="pubmed">31935947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narumoto O, Matsuo Y, Sakaguchi M, Shoji S, Yamashita N, Schubert D, Abe K, Horiguchi K, Nagase T, and Yamashita N (2012). Suppressive effects of a pyrozole of curcumin on airway inflammation and remodeling. Exp Mol Pathol 93, 18&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22542791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navarro A, and Boveris A (2010). Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson&#x2019;s disease. Front Aging Neurosci 2012, 2.</Citation>
        </Reference>
        <Reference>
          <Citation>Neitemeier S, Jelinek A, Laino V, Hoffmann L, Eisenbach I, Eying R, Ganjam G, Dolga AM, Oppermann S, and Culmsee C (2017). BID links ferroptosis to mitochondrial cell death pathways. Redox Biol 12, 558&#x2013;570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5382034</ArticleId>
            <ArticleId IdType="pubmed">28384611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norberg E, Karlsson M, Korenkovska O, Szydlowski S, Silberberg G, Uhlen P, Orrenius S, and Zhivotovsky B (2010). Critical role for hyperpolarization-activated cyclic nucleotide-gated channel 2 in AIF-mediated apoptosis. EMBO J 29, 3869&#x2013;3878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2989107</ArticleId>
            <ArticleId IdType="pubmed">21037554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onukwufor JO, Berry BJ, and Wojtovich AP (2019). Phsyiologic implications of reactive oxygen species production by mitochondrial complex I reverse electorn transport. Antioxid 8, 285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6719910</ArticleId>
            <ArticleId IdType="pubmed">31390791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onyango IG, Dennis J, and Khan SM (2016). Mitochondrial dysfunction in Alzheimer&#x2019;s disease and the rationale for bioenergetics based therapies. Aging Dis 7, 201&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4809610</ArticleId>
            <ArticleId IdType="pubmed">27114851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallas M (2012). Senescence-accelerated mice P8: A tool to study brain aging and Alzheimer&#x2019;s disease in a mouse model. ISRN Cell Biol 2012, 917167.</Citation>
        </Reference>
        <Reference>
          <Citation>Pallast S, Arai K, Wang X, Lo EH, and van Leyen K (2009). 12/15-Lipoxygenase targets neuronal mitochondria under stress. J Neurochem 111, 882&#x2013;889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2773137</ArticleId>
            <ArticleId IdType="pubmed">19737346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce RK, Owen A, Daniel S, Jenner P, and Marsden CD (1997). Alterations in the disttribution of glutathione in the substantia nigra in Parkinson&#x2019;s disease. J Neural Transm 104, 661&#x2013;677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9444566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry TL, Yong VW, Bergeron C, GHansem S, and Jones K (1987). Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer&#x2019;s disease. Ann Neurol 21, 331&#x2013;336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3579218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prior M, Chiruta C, Currais A, Goldberg J, Ramsey J, Dargusch R, Maher PA, and Schubert D (2014). Back to the future with phenotypic screening ACS Chem Neurosci 5, 503&#x2013;513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4102969</ArticleId>
            <ArticleId IdType="pubmed">24902068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prior M, Dargusch R, Ehren J, Chiruta C, and Schubert D (2013). The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer&#x2019;s disease mice. Alzheimer&#x2019;s Res Ther 5, 25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3706879</ArticleId>
            <ArticleId IdType="pubmed">23673233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prokai L, Oon S-M, Prokai-tatrai K, Abboud KA, and Simpkins JW (2001). Synthesis and biological evaluation of 17beta-alkoxyestra-1,3,5(10)-trienes as potential neuroprotectants against oxidative stress. J Med Chem 44, 110&#x2013;114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11141094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rae CD, and Williams SR (2017). Glutathione in the human brain: review of its roles and measurement by magnetic resonance spectroscopy. Anal Biochem 529, 127&#x2013;143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28034792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rai G, Joshi N, Jung JE, Liu Y, Schultz L, Yasgar A, Perry S, Diaz G, Zhang Q, Kenyon V, et al. (2014). Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J Med Chem 57, 4035&#x2013;4048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4033661</ArticleId>
            <ArticleId IdType="pubmed">24684213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratan RR (2020). The chemical biology of ferroptosis in the central nervous system. Cell Chem Biol 27, 1&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7245561</ArticleId>
            <ArticleId IdType="pubmed">32243811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed TT (2011). Lipid peroxidation and neurodegenerative disease. Free Rad Biol Med 51, 1302&#x2013;1319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21782935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sagara Y, Dargusch R, Chambers D, Davis J, Schubert D, and Maher P (1998). Cellular mechanisms of resistance to chronic oxidative stress. Free Radic Biol Med 24, 1375&#x2013;1389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9641255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, et al. (2005). Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 280, 37423&#x2013;37429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16144837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schafer FQ, and Buettner GR (2001). Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Rad Biol Med 30, 1191&#x2013;1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11368918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schramm S, Huang B, Gunesch S, Lang F, Roa J, Hogger P, Sabate R, Maher P, and Decker M (2018). Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects. Eur J Med Chem 146, 93&#x2013;107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29407994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schriau MG, Dun NJ, and Bau HH (2009). Cell electrophysiology with carbon nanopipettes. ACS Nano 3, 563&#x2013;568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19309170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, Currais A, Goldberg J, Finley K, Petrascheck M, and Maher P (2018). Geroneuroprotectors: Effective geroprotectors for the brain. Trends Pharmacol Sci 39, 1004&#x2013;1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6558984</ArticleId>
            <ArticleId IdType="pubmed">30446211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, Kimura H, and Maher P (1992). Growth factors and vitamin E modify neuronal glutamate toxicity. ProcNatlAcadSciUSA 89, 8264&#x2013;8267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC49898</ArticleId>
            <ArticleId IdType="pubmed">1387712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulz JB, Lindenau J, Seyfried J, and Dichgans J (2000). Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267, 4904&#x2013;4911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10931172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, and Rosati G (1996). Reduced intravenous glutathione in the treatment of early Parkinson&#x2019;s disease. Prog Neuro-Psychopharmacol Biol Psychiat 20, 1159&#x2013;1170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8938817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C, Plesnila N, Kremmer E, Radmark O, Wurst W, et al. (2008). Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metabolism 8, 237&#x2013;248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18762024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekhar RV, Patel SG, Guthikonda AP, Reid M, Balasubramanyam A, Taffet GE, and Jahoor F (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Amer J Clin Nutr 94, 847&#x2013;853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3155927</ArticleId>
            <ArticleId IdType="pubmed">21795440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Shchepinov MS, and Pratt DA (2018). Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci 4, 387&#x2013;396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh NK, and Rao GN (2018). Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies. Prog Lipid Res 73, 28&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6338518</ArticleId>
            <ArticleId IdType="pubmed">30472260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorbi S, Bird ED, and Blass JP (1983). Decreased pyrivate dehydrogenase complex activity in Huntington&#x2019;s and Alzheimer&#x2019;s brain. Ann Neurol 13, 72&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6219611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, et al. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 274&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Jiang X, and Gu W (2020). Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol 30, 478&#x2013;490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7230071</ArticleId>
            <ArticleId IdType="pubmed">32413317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoyanovsky DA, Tyurina YY, Shrivastava I, Bahar I, Tyurin VA, Protchenko O, Jadhav S, Bolevich SB, Kozlov AV, Vladimirov YA, et al. (2019). Iron catalysis of lipid peroxidation in ferroptosis: Regulated enzymatic or random free radical reaction? Free Rad Biol Med 133, 153&#x2013;161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6555767</ArticleId>
            <ArticleId IdType="pubmed">30217775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sultana R, Perluigi DA, and Butterfield DA (2013). Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer&#x2019;s disease brain. Free Rad Biol Med 62, 157&#x2013;169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3573239</ArticleId>
            <ArticleId IdType="pubmed">23044265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swerdlow RH, and Khan SM (2004). A mitochondrial cascade hypothesis for sporadic Alzheimer&#x2019;s disease. Med Hypotheses 63, 8&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15193340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan S, Sagara Y, Liu Y, Maher P, and Schubert D (1998a). The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141, 1423&#x2013;1432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2132785</ArticleId>
            <ArticleId IdType="pubmed">9628898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan S, Schubert D, and Maher P (2001a). Oxytosis: a novel form of programmed cell death. Curr Top Med Chem 1, 497&#x2013;506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11895126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan S, Somia N, Maher P, and Schubert P (2001b). Regulation of antioxidant metabolism by translation initiation factor 2a. J Cell Biol 152, 997&#x2013;1006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2198799</ArticleId>
            <ArticleId IdType="pubmed">11238455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan S, Wood M, and Maher P (1998b). Oxidative stress in nerve cells induces a form of cell death with characteristics of both apoptosis and necrosis. J Neurochem 71, 95&#x2013;105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9648855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kang R, Vanden Berghe T, Vandenbeele P, and Kroemer G (2019). The molecular machinery of regulated cell death. Cell Res 29, 347&#x2013;364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6796845</ArticleId>
            <ArticleId IdType="pubmed">30948788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirosh O, Sen CK, Roy S, and Packer L (2000). Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neurosci 97, 531&#x2013;541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10828535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong BCK, Wu AJ, Li M, and Cheung KH (2018). Calcium signaling in Alzheimer&#x2019;s disease and therapies. Biochim Biophys Acta 1865.</Citation>
        </Reference>
        <Reference>
          <Citation>Uchida K (2017). HNE as an inducer of COX2. Free Rad Biol Med 111, 169&#x2013;172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28192229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valera E, Dargusch R, Maher PA, and Schubert D (2013). Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer&#x2019;s disease. J Neurosci 33, 10512&#x2013;10525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3685841</ArticleId>
            <ArticleId IdType="pubmed">23785163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Leyen K, Duvoisin RM, Engelhardt H, and Wiedmann M (1998). A function for lipoxygenase in programmed organelle degradation. Nature 395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9759730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Leyen K, Kim HY, Lee S-R, Jin G, Arai K, and Lo EH (2006). Baicalein and 12/15 lipoxygenase in the ischemic brain. Stroke 37, 3014&#x2013;3018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17053180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voet D, and Voet JG (1990). Biochemistry (New York: John Wiley and Sons;).</Citation>
        </Reference>
        <Reference>
          <Citation>Wallace DC (2005). A mitochondrial paradigm of metabolic and degenerative diseases, aging and cancer: q dawn for evolutionary medicine. Annu Rev Genomics Hum Genet 39, 359&#x2013;407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2821041</ArticleId>
            <ArticleId IdType="pubmed">16285865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zimmerman HR, and Ma TP (2019). Therapeutic potential of AMP-activated protein kinase in Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis 68, 33&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6446925</ArticleId>
            <ArticleId IdType="pubmed">30776001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel SE, Tyurina YY, Zhao J, St. Croix CM, Dar HH, Mao G, Tyurin VA, Anthonymuthu TS, Kapralov AA, Amoscato AA, et al. (2017). PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171, 628&#x2013;641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5683852</ArticleId>
            <ArticleId IdType="pubmed">29053969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu A, Ying Z, Schubert D, and Gomez-Pinilla F (2011). Brain and spinal cord interaction: A dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma. Neurorehabil Neural Repair 25, 332&#x2013;342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258099</ArticleId>
            <ArticleId IdType="pubmed">21343524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadav UCS, and Ramana KV (2013). Regulation of NF-kB-induced inflammatory signaling by lipid peroxidation-derived aldehydes. Oxid Med Cell Longev 2013, 690545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3654319</ArticleId>
            <ArticleId IdType="pubmed">23710287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, et al. (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864&#x2013;868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, et al. (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques and reduces amyloid in vivo. J Biol Chem 280, 5892&#x2013;5901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15590663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, and Stockwell BR (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem &amp; Biol 15, 234&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yigitkanli K, Pekcec A, Karatas H, Pallast S, Mandeville E, Joshi N, Smirnova N, Gazaryan I, Ratan RR, Witztum JL, et al. (2013). Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann Neurol 73, 129&#x2013;135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3563836</ArticleId>
            <ArticleId IdType="pubmed">23192915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F, Boveris A, and Cadenas E (2014). Mitochondrial energy metabolism and redox signlaing in brain aging and neurodegeneration. Antioxid Redox Signal 20, 353&#x2013;371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3887431</ArticleId>
            <ArticleId IdType="pubmed">22793257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F, Sancheti H, Liu Z, and Cadenas E (2016). Mitochondrial function in ageing: coordination with signalling and transcriptional pathways. J Physiol 594, 2025&#x2013;2042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4933098</ArticleId>
            <ArticleId IdType="pubmed">26293414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeevalk GD, Razmpour R, and Bernard LP (2008). Glutathione and Parkinson&#x2019;s Disease: Is this the elephant in the room? Biomed Pharmacother 62, 236&#x2013;249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18400456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghalchi SM, Meskini RE, et al. (2007). Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67, 2964&#x2013;2971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17409402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimniak P (2011). Relationship of electrophilic stress to aging. Free Rad Biol Med 51, 1087&#x2013;1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3156362</ArticleId>
            <ArticleId IdType="pubmed">21708248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, H. L, Graham ET, Delk AA, Eaton JK, Wang W, Sandoval-Gomez G, Clish CB, Doench JG, and Schreiber SL (2020). Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat Chem Biol 16, 302&#x2013;309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7353921</ArticleId>
            <ArticleId IdType="pubmed">32080622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zundorf G, and Reiser G (2011). Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid Redox Signal 14, 1275&#x2013;1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122891</ArticleId>
            <ArticleId IdType="pubmed">20615073</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33121683</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>533</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction.</ArticleTitle>
        <Pagination>
          <StartPage>1512</StartPage>
          <EndPage>1518</EndPage>
          <MedlinePgn>1512-1518</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2020.09.140</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(20)31892-1</ELocationID>
        <Abstract>
          <AbstractText>Anti-tuberculosis drug-induced liver injury (ATB-DILI) is a common adverse reaction of anti-tuberculosis drug treatment. Studies have shown that isoniazid (INH) and rifampicin (RFP) are mainly metabolized in the liver and a large amount of intracellular glutathione is used up during the metabolism of these drugs, resulting in lipid peroxidation and hepatocyte death. Ferroptosis is a novel form of programmed cell death caused by iron-ion-dependent lipid peroxidation. In this study, we explored lipid peroxidation and ferroptosis during ATB-DILI. Morphology of ferroptosis was discovered in ATB-DILI mouse livers by transmission electron microscopy. Flow cytometry was used to assess the molecular markers of lipid peroxidation and ferroptosis including reactive oxygen species, lipid peroxidation, and cellular iron content. Glutathione peroxidase 4 (GPX4) was depleted, while acyl-CoA synthetase long chain family member 4 (ACSL4) was overexpressed in the ATB-DILI tissues. And glutathione supplementation significantly reduced the level of lipid peroxidation and the risk of liver damage. Retrospective study of tuberculosis patients who underwent INH and RFP treatment also revealed an association between the intake of glutathione and a negative ATB-DILI rate. In addition, iron supplementation enhanced the degree of lipid peroxidation and liver injury induced by INH and RFP in vivo and clinical retrospective study. Taken together, these results indicate that lipid peroxidation and evidence suggestive of ferroptosis occurs during ATB-DILI, and glutathione replenishment prevents this process while iron supplementation augmenting this effect.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Yunzhi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, 215007, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Peijun</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tuberculosis, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, 215007, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, 215007, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Quan</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, 215007, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, 215007, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Sai</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215008, China. Electronic address: marseillems@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jianping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tuberculosis, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, 215007, China. Electronic address: 906168980@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>V83O1VOZ8L</RegistryNumber>
          <NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VJT6J7R4TR</RegistryNumber>
          <NameOfSubstance UI="D012293">Rifampin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007538" MajorTopicYN="N">Isoniazid</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-tuberculosis drug-induced liver injury (ATB-DILI)</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glutathione</Keyword>
        <Keyword MajorTopicYN="N">Tuberculosis</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33121683</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2020.09.140</ArticleId>
        <ArticleId IdType="pii">S0006-291X(20)31892-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33113504</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>153370</StartPage>
          <MedlinePgn>153370</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2020.153370</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(20)30201-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cisplatin (DDP) is the first-in-class drug for advanced and non-targetable non-small-cell lung cancer (NSCLC). A recent study indicated that DDP could slightly induce non-apoptotic cell death ferroptosis, and the cytotoxicity was promoted by ferroptosis inducer. The agents enhancing the ferroptosis may therefore increase the anticancer effect of DDP. Several lines of evidence supporting the use of phytochemicals in NSCLC therapy. Ginkgetin, a bioflavonoid derived from Ginkgo biloba leaves, showed anticancer effects on NSCLC by triggering autophagy. Ferroptosis can be triggered by autophagy, which regulates redox homeostasis. Thus, we aimed to elucidate the possible role of ferroptosis involved in the synergistic effect of ginkgetin and DDP in cancer therapy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The promotion of DDP-induced anticancer effects by ginkgetin was examined via a cytotoxicity assay and western blot. Ferroptosis triggered by ginkgetin in DDP-treated NSCLC was observed via a lipid peroxidation assay, a labile iron pool assay, western blot, and qPCR. With ferroptosis blocking, the contribution of ferroptosis to ginkgetin&#xa0;+&#xa0;DDP-induced cytotoxicity, the Nrf2/HO-1 axis, and apoptosis were determined via a luciferase assay, immunostaining, chromatin immunoprecipitation (CHIP), and flow cytometry. The role of ferroptosis in ginkgetin&#xa0;+&#xa0;DDP-treated NSCLC cells was illustrated by the application of ferroptosis inhibitors, which was further demonstrated in a xenograft nude mouse model.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Ginkgetin synergized with DDP to increase cytotoxicity in NSCLC cells, which was concomitant with increased labile iron pool and lipid peroxidation. Both these processes were key characteristics of ferroptosis. The induction of ferroptosis mediated by ginkgetin was further confirmed by the decreased expression of SLC7A11 and GPX4, and a decreased GSH/GSSG ratio. Simultaneously, ginkgetin disrupted redox hemostasis in DDP-treated cells, as demonstrated by the enhanced ROS formation and inactivation of the Nrf2/HO-1 axis. Ginkgetin also enhanced DDP-induced mitochondrial membrane potential (MMP) loss and apoptosis in cultured NSCLC cells. Furthermore, blocking ferroptosis reversed the ginkgetin-induced inactivation of Nrf2/HO-1 as well as the elevation of ROS formation, MMP loss, and apoptosis in DDP-treated NSCLC cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study is the first to report that ginkgetin derived from Ginkgo biloba leaves promotes DDP-induced anticancer effects, which can be due to the induction of ferroptosis.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020. Published by Elsevier GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lou</LastName>
            <ForeName>Jian-Shu</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 31121, China. Electronic address: jlouab@connect.ust.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Li-Ping</ForeName>
            <Initials>LP</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 31121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zhi-Hui</ForeName>
            <Initials>ZH</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 31121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xia-Yin</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 31121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Jing-Ting</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Life Science, Center for Chinese Medicine, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tai</LastName>
            <ForeName>William Chi-Shing</ForeName>
            <Initials>WC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Biology &amp; Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsim</LastName>
            <ForeName>Karl W K</ForeName>
            <Initials>KWK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Life Science, Center for Chinese Medicine, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yi-Tao</ForeName>
            <Initials>YT</Initials>
            <AffiliationInfo>
              <Affiliation>College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China. Electronic address: cytworld@zcmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 31121, China. Electronic address: xbs@hznu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044946">Biflavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>481-46-9</RegistryNumber>
          <NameOfSubstance UI="C077458">ginkgetin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="C496541">HMOX1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044946" MajorTopicYN="N">Biflavonoids</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020441" MajorTopicYN="N">Ginkgo biloba</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018515" MajorTopicYN="N">Plant Leaves</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cisplatin</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Ginkgetin</Keyword>
        <Keyword MajorTopicYN="N">Non-small-cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">Redox homeostasis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>28</Day>
          <Hour>20</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33113504</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2020.153370</ArticleId>
        <ArticleId IdType="pii">S0944-7113(20)30201-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33019767</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Novel Programmed Cell Death as Therapeutic Targets in Age-Related Macular Degeneration?</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">7279</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21197279</ELocationID>
        <Abstract>
          <AbstractText>Age-related macular degeneration (AMD) is a leading cause of severe visual loss among the elderly. AMD patients are tormented by progressive central blurring/loss of vision and have limited therapeutic options to date. Drusen accumulation causing retinal pigment epithelial (RPE) cell damage is the hallmark of AMD pathogenesis, in which oxidative stress and inflammation are the well-known molecular mechanisms. However, the underlying mechanisms of how RPE responds when exposed to drusen are still poorly understood. Programmed cell death (PCD) plays an important role in cellular responses to stress and the regulation of homeostasis and diseases. Apart from the classical apoptosis, recent studies also discovered novel PCD pathways such as pyroptosis, necroptosis, and ferroptosis, which may contribute to RPE cell death in AMD. This evidence may yield new treatment targets for AMD. In this review, we summarized and analyzed recent advances on the association between novel PCD and AMD, proposing PCD's role as a therapeutic new target for future AMD treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-8600-4325</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>So</LastName>
            <ForeName>Kwok-Fai</ForeName>
            <Initials>KF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lam</LastName>
            <ForeName>Wai Ching</ForeName>
            <Initials>WC</Initials>
            <Identifier Source="ORCID">0000-0003-2057-9374</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lo</LastName>
            <ForeName>Amy Cheuk Yin</ForeName>
            <Initials>ACY</Initials>
            <Identifier Source="ORCID">0000-0003-4239-6851</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>06171516</GrantID>
            <Agency>Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region</Agency>
          </Grant>
          <Grant>
            <GrantID>17112919</GrantID>
            <Agency>General Research Fund, Research Grants Council, The Government of the Hong Kong Special Administrative Region</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0X9PA28K43</RegistryNumber>
          <NameOfSubstance UI="D000077362">Verteporfin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
          <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ZL1R02VT79</RegistryNumber>
          <NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015593" MajorTopicYN="N">Retinal Drusen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077362" MajorTopicYN="N">Verteporfin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cell damage</Keyword>
        <Keyword MajorTopicYN="N">homeostasis</Keyword>
        <Keyword MajorTopicYN="N">ocular stress</Keyword>
        <Keyword MajorTopicYN="N">retina</Keyword>
        <Keyword MajorTopicYN="N">vision</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>1</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33019767</ArticleId>
        <ArticleId IdType="pmc">PMC7582463</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms21197279</ArticleId>
        <ArticleId IdType="pii">ijms21197279</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adams M.K.M., Simpson J.A., Aung K.Z., Makeyeva G.A., Giles G.G., English D.R., Hopper J., Guymer R.H., Baird P.N., Robman L.D. Abdominal Obesity and Age-related Macular Degeneration. Am. J. Epidemiol. 2011;173:1246&#x2013;1255. doi: 10.1093/aje/kwr005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/aje/kwr005</ArticleId>
            <ArticleId IdType="pubmed">21422060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flaxman S.R., Bourne R.R.A., Resnikoff S., Ackland P., Braithwaite T., Cicinelli M.V., Das A., Jonas J.B., Keeffe J., Kempen J.H., et al. Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis. Lancet Glob. Health. 2017;5:e1221&#x2013;e1234. doi: 10.1016/S2214-109X(17)30393-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2214-109X(17)30393-5</ArticleId>
            <ArticleId IdType="pubmed">29032195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joachim N., Mitchell P., Burlutsky G., Kifley A., Wang J.J. The Incidence and Progression of Age-Related Macular Degeneration over 15 Years The Blue Mountains Eye Study. Ophthalmology. 2015;122:2482&#x2013;2489. doi: 10.1016/j.ophtha.2015.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2015.08.002</ArticleId>
            <ArticleId IdType="pubmed">26383995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fritsche L.G., Fariss R.N., Stambolian D., Abecasis G.R., Curcio C.A., Swaroop A. Age-Related Macular Degeneration: Genetics and Biology Coming Together. Annu. Rev. Genom. Hum. Genet. 2014;15:151&#x2013;171. doi: 10.1146/annurev-genom-090413-025610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-genom-090413-025610</ArticleId>
            <ArticleId IdType="pmc">PMC4217162</ArticleId>
            <ArticleId IdType="pubmed">24773320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S., Lan X., Wu J., Yue S., Zhang H., Wu Q., Zhang G., Liu L. Protocol of global incidence and progression of age-related macular degeneration: A systematic review. Medicine. 2019;98:e14645. doi: 10.1097/MD.0000000000014645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000014645</ArticleId>
            <ArticleId IdType="pmc">PMC6417534</ArticleId>
            <ArticleId IdType="pubmed">30855452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rohrer B., Frazer-Abel A., Leonard A., Ratnapriya R., Ward T., Pietraszkiewicz A., O&#x2019;Quinn E., Adams K., Swaroop A., Wolf B.J. Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent. Mol. Vis. 2019;25:79&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377374</ArticleId>
            <ArticleId IdType="pubmed">30820144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peeters A., Magliano D.J., Stevens J., Duncan B.B., Klein R., Wong T.Y. Changes in Abdominal Obesity and Age-Related Macular Degeneration The Atherosclerosis Risk in Communities Study. Arch. Ophthalmol-Chic. 2008;126:1554&#x2013;1560. doi: 10.1001/archopht.126.11.1554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.126.11.1554</ArticleId>
            <ArticleId IdType="pmc">PMC5774859</ArticleId>
            <ArticleId IdType="pubmed">19001224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haymes S.A., Lee J. Effects of task lighting on visual function in age-related macular degeneration. Ophthalmic Physiol. Opt. 2006;26:169&#x2013;179. doi: 10.1111/j.1475-1313.2006.00367.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1475-1313.2006.00367.x</ArticleId>
            <ArticleId IdType="pubmed">16460317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cougnard-Gregoire A., Delyfer M.N., Korobelnik J.F., Rougier M.B., Malet F., Le Goff M., Dartigues J.F., Colin J., Barberger-Gateau P., Delcourt C. Long-Term Blood Pressure and Age-Related Macular Degeneration: The ALIENOR Study. Investig. Ophth. Vis. Sci. 2013;54:1905&#x2013;1912. doi: 10.1167/iovs.12-10192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.12-10192</ArticleId>
            <ArticleId IdType="pubmed">23404120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Age-Related Macular Degeneration. [(accessed on 14 September 2020)];American Academy of Ophthalmology. Available online: https://www.aao.org/bcscsnippetdetail.aspx?id=9711f063-ed7b-452b-8708-c4dad0d893e8.</Citation>
        </Reference>
        <Reference>
          <Citation>Lim L.S., Mitchell P., Seddon J.M., Holz F.G., Wong T.Y. Age-related macular degeneration. Lancet. 2012;379:1728&#x2013;1738. doi: 10.1016/S0140-6736(12)60282-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)60282-7</ArticleId>
            <ArticleId IdType="pubmed">22559899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhutto I., Lutty G. Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch&#x2019;s membrane/choriocapillaris complex. Mol. Asp. Med. 2012;33:295&#x2013;317. doi: 10.1016/j.mam.2012.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2012.04.005</ArticleId>
            <ArticleId IdType="pmc">PMC3392421</ArticleId>
            <ArticleId IdType="pubmed">22542780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarks J.P., Sarks S.H., Killingsworth M.C. Evolution of Soft Drusen in Age-Related Macular Degeneration. Eye. 1994;8:269&#x2013;283. doi: 10.1038/eye.1994.57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.1994.57</ArticleId>
            <ArticleId IdType="pubmed">7525362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luibl V., Isas J.M., Kayed R., Glabe C.G., Langen R., Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J. Clin. Investig. 2006;116:378&#x2013;385. doi: 10.1172/JCI25843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI25843</ArticleId>
            <ArticleId IdType="pmc">PMC1359048</ArticleId>
            <ArticleId IdType="pubmed">16453022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rashid A., Bhatia S.K., Mazzitello K.I., Chrenek M.A., Zhang Q., Boatright J.H., Grossniklaus H.E., Jiang Y., Nickerson J.M. RPE Cell and Sheet Properties in Normal and Diseased Eyes. Adv. Exp. Med. Biol. 2016;854:757&#x2013;763. doi: 10.1007/978-3-319-17121-0_101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-17121-0_101</ArticleId>
            <ArticleId IdType="pmc">PMC5554956</ArticleId>
            <ArticleId IdType="pubmed">26427486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Priore L.V., Ku Y.H., Tezel T.H. Age-related changes in human RPE cell density and apoptosis proportion in situ. Investig. Ophth. Vis. Sci. 2002;43:3312&#x2013;3318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12356840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokkinopoulos I., Shahabi G., Colman A., Jeffery G. Mature Peripheral RPE Cells Have an Intrinsic Capacity to Proliferate; A Potential Regulatory Mechanism for Age-Related Cell Loss. PLoS ONE. 2011;6 doi: 10.1371/journal.pone.0018921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0018921</ArticleId>
            <ArticleId IdType="pmc">PMC3081302</ArticleId>
            <ArticleId IdType="pubmed">21526120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarthy U., McKay G.J., de Jong P.T.V.M., Rahu M., Seland J., Soubrane G., Tomazzoli L., Topouzis F., Vingerling J.R., Vioque J., et al. ARMS2 Increases the Risk of Early and Late Age-related Macular Degeneration in the European Eye Study. Ophthalmology. 2013;120:342&#x2013;348. doi: 10.1016/j.ophtha.2012.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2012.08.004</ArticleId>
            <ArticleId IdType="pubmed">23098369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Decanini A., Nordgaard C.L., Feng X., Ferrington D.A., Olsen T.W. Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am. J. Ophthalmol. 2007;143:607&#x2013;615. doi: 10.1016/j.ajo.2006.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2006.12.006</ArticleId>
            <ArticleId IdType="pmc">PMC2365890</ArticleId>
            <ArticleId IdType="pubmed">17280640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullins R.F., Skeie J.M., Malone E.A., Kuehn M.H. Macular and peripheral distribution of ICAM-1 in the human choriocapillaris and retina. Mol. Vis. 2006;12:224&#x2013;235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16604055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munch I.C., Ek J., Kessel L., Sander B., Almind G.J., Brondum-Nielsen K., Linneberg A., Larsen M. Small, hard macular drusen and peripheral drusen: Associations with AMD genotypes in the Inter99 Eye Study. Investig. Ophthalmol. Vis. Sci. 2010;51:2317&#x2013;2321. doi: 10.1167/iovs.09-4482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.09-4482</ArticleId>
            <ArticleId IdType="pubmed">20007824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nahavandipour A., Krogh Nielsen M., Sorensen T.L., Subhi Y. Systemic levels of interleukin-6 in patients with age-related macular degeneration: A systematic review and meta-analysis. Acta Ophthalmol. 2020 doi: 10.1111/aos.14402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/aos.14402</ArticleId>
            <ArticleId IdType="pubmed">32180348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masse A., Buhannic L. Understanding age-related macular degeneration. Actual Pharm. 2017;56:18&#x2013;21. doi: 10.1016/j.actpha.2017.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actpha.2017.02.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonilha V.L., Bell B.A., Hu J., Milliner C., Pauer G.J., Hagstrom S.A., Radu R.A., Hollyfield J.G. Geographic Atrophy: Confocal Scanning Laser Ophthalmoscopy, Histology, and Inflammation in the Region of Expanding Lesions. Investig. Ophthalmol. Vis. Sci. 2020;61:15. doi: 10.1167/iovs.61.8.15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.61.8.15</ArticleId>
            <ArticleId IdType="pmc">PMC7425718</ArticleId>
            <ArticleId IdType="pubmed">32658960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakri S.J., Thorne J.E., Ho A.C., Ehlers J.P., Schoenberger S.D., Yeh S., Kim S.J. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology. Ophthalmology. 2019;126:55&#x2013;63. doi: 10.1016/j.ophtha.2018.07.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2018.07.028</ArticleId>
            <ArticleId IdType="pubmed">30077616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell P., Foran S. Age-Related Eye Disease Study severity scale and simplified severity scale for age-related macular degeneration. Arch. Ophthalmol. 2005;123:1598&#x2013;1599. doi: 10.1001/archopht.123.11.1598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.123.11.1598</ArticleId>
            <ArticleId IdType="pubmed">16286625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yehoshua Z., Wang F.H., Rosenfeld P.J., Penha F.M., Feuer W.J., Gregori G. Natural History of Drusen Morphology in Age-Related Macular Degeneration Using Spectral Domain Optical Coherence Tomography. Ophthalmology. 2011;118:2434&#x2013;2441. doi: 10.1016/j.ophtha.2011.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2011.05.008</ArticleId>
            <ArticleId IdType="pmc">PMC3189426</ArticleId>
            <ArticleId IdType="pubmed">21724264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celkova L., Doyle S.L., Campbell M. NLRP3 Inflammasome and Pathobiology in AMD. J. Clin. Med. 2015;4:172&#x2013;192. doi: 10.3390/jcm4010172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm4010172</ArticleId>
            <ArticleId IdType="pmc">PMC4470247</ArticleId>
            <ArticleId IdType="pubmed">26237026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunaief J.L., Dentchev T., Ying G.S., Milam A.H. The role of apoptosis in age-related macular degeneration. Arch. Ophthalmol. 2002;120:1435&#x2013;1442. doi: 10.1001/archopht.120.11.1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.120.11.1435</ArticleId>
            <ArticleId IdType="pubmed">12427055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng L., Liao X., Zhang Y., Wang F. Protective Effects on Age-related Macular Degeneration by Activated Autophagy Induced by Amyloid-beta in Retinal Pigment Epithelial Cells. Discov. Med. 2019;27:153&#x2013;160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31095924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.H., Park J.W. Morin hydrate attenuates CSE-induced lipid accumulation, ER stress, and oxidative stress in RPE cells: Implications for age-related macular degeneration. Free Radic. Res. 2019;53:865&#x2013;874. doi: 10.1080/10715762.2019.1637862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10715762.2019.1637862</ArticleId>
            <ArticleId IdType="pubmed">31257945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieguez H.H., Romeo H.E., Alaimo A., Gonzalez Fleitas M.F., Aranda M.L., Rosenstein R.E., Dorfman D. Oxidative stress damage circumscribed to the central temporal retinal pigment epithelium in early experimental non-exudative age-related macular degeneration. Free Radic. Biol. Med. 2019;131:72&#x2013;80. doi: 10.1016/j.freeradbiomed.2018.11.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.11.035</ArticleId>
            <ArticleId IdType="pubmed">30502459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta S., Cano M., Ebrahimi K., Wang L., Handa J.T. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog. Retin. Eye Res. 2017;60:201&#x2013;218. doi: 10.1016/j.preteyeres.2017.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.preteyeres.2017.03.002</ArticleId>
            <ArticleId IdType="pmc">PMC5600827</ArticleId>
            <ArticleId IdType="pubmed">28336424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen M., Xu H. Parainflammation, chronic inflammation, and age-related macular degeneration. J. Leukoc. Biol. 2015;98:713&#x2013;725. doi: 10.1189/jlb.3RI0615-239R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.3RI0615-239R</ArticleId>
            <ArticleId IdType="pmc">PMC4733662</ArticleId>
            <ArticleId IdType="pubmed">26292978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jager M.J. Macrophages and macular degeneration. J. Ophthalmic. Vis. Res. 2014;9:1&#x2013;2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4074466</ArticleId>
            <ArticleId IdType="pubmed">24982724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kauppinen A., Paterno J.J., Blasiak J., Salminen A., Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell. Mol. Life Sci. 2016;73:1765&#x2013;1786. doi: 10.1007/s00018-016-2147-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2147-8</ArticleId>
            <ArticleId IdType="pmc">PMC4819943</ArticleId>
            <ArticleId IdType="pubmed">26852158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kliffen M., Sharma H.S., Mooy C.M., Kerkvliet S., de Jong P.T. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 1997;81:154&#x2013;162. doi: 10.1136/bjo.81.2.154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjo.81.2.154</ArticleId>
            <ArticleId IdType="pmc">PMC1722110</ArticleId>
            <ArticleId IdType="pubmed">9059252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda N., Tsujinaka H., Hirai H., Yamashita M., Ueda T., Ogata N. Effects of concentration of amyloid beta (Abeta) on viability of cultured retinal pigment epithelial cells. BMC Ophthalmol. 2019;19:70. doi: 10.1186/s12886-019-1076-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12886-019-1076-3</ArticleId>
            <ArticleId IdType="pmc">PMC6408759</ArticleId>
            <ArticleId IdType="pubmed">30849957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu R.T., Gao J., Cao S., Sandhu N., Cui J.Z., Chou C.L., Fang E., Matsubara J.A. Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: Implications for inflammasome activation in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013;54:2225&#x2013;2237. doi: 10.1167/iovs.12-10849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.12-10849</ArticleId>
            <ArticleId IdType="pmc">PMC3947398</ArticleId>
            <ArticleId IdType="pubmed">23462752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spilsbury K., Garrett K.L., Shen W.Y., Constable I.J., Rakoczy P.E. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am. J. Pathol. 2000;157:135&#x2013;144. doi: 10.1016/S0002-9440(10)64525-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64525-7</ArticleId>
            <ArticleId IdType="pmc">PMC1850220</ArticleId>
            <ArticleId IdType="pubmed">10880384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyosseva S.V. Targeting MAPK Signaling in Age-Related Macular Degeneration. Ophthalmol. Eye Dis. 2016;8:23&#x2013;30. doi: 10.4137/OED.S32200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/OED.S32200</ArticleId>
            <ArticleId IdType="pmc">PMC4920203</ArticleId>
            <ArticleId IdType="pubmed">27385915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byeon S.H., Lee S.C., Choi S.H., Lee H.K., Lee J.H., Chu Y.K., Kwon O.W. Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Retinal Pigment Epithelial Cells under Oxidative Stress via the VEGF-R2/PI3K/Akt. Investig. Ophth. Vis. Sci. 2010;51:1190&#x2013;1197. doi: 10.1167/iovs.09-4144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.09-4144</ArticleId>
            <ArticleId IdType="pubmed">19834034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im E., Motiejunaite R., Aranda J., Park E.Y., Federico L., Kim T.I., Clair T., Stracke M.L., Smyth S., Kazlauskas A. Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression. Mol. Cell. Biol. 2010;30:2401&#x2013;2410. doi: 10.1128/MCB.01275-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01275-09</ArticleId>
            <ArticleId IdType="pmc">PMC2863716</ArticleId>
            <ArticleId IdType="pubmed">20231358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazama F., Kadonosono K., Itoh N., Ohno S. Role of matrix metalloproteinase-7 in angiogenesis associated with age-related macular degeneration. J. Electron. Microsc. 2002;51:127&#x2013;131. doi: 10.1093/jmicro/51.2.127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jmicro/51.2.127</ArticleId>
            <ArticleId IdType="pubmed">12005165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert V., Wielockx B., Munaut C., Galopin C., Jost M., Itoh T., Werb Z., Baker A., Libert C., Krell H.W., et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003;17:2290&#x2013;2292. doi: 10.1096/fj.03-0113fje.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.03-0113fje</ArticleId>
            <ArticleId IdType="pubmed">14563686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uno K., Bhutto I.A., McLeod D.S., Merges C., Lutty G.A. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br. J. Ophthalmol. 2006;90:48&#x2013;54. doi: 10.1136/bjo.2005.074005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjo.2005.074005</ArticleId>
            <ArticleId IdType="pmc">PMC1856899</ArticleId>
            <ArticleId IdType="pubmed">16361667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawler P.R., Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med. 2012;2:a006627. doi: 10.1101/cshperspect.a006627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a006627</ArticleId>
            <ArticleId IdType="pmc">PMC3331684</ArticleId>
            <ArticleId IdType="pubmed">22553494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabral T., Mello L.G.M., Lima L.H., Polido J., Regatieri C.V., Belfort R., Jr., Mahajan V.B. Retinal and choroidal angiogenesis: A review of new targets. Int. J. Retina Vitreous. 2017;3:31. doi: 10.1186/s40942-017-0084-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40942-017-0084-9</ArticleId>
            <ArticleId IdType="pmc">PMC5563895</ArticleId>
            <ArticleId IdType="pubmed">28835854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudson N., Cahill M., Campbell M. Inner blood-retina barrier involvement in dry age-related macular degeneration (AMD) pathology. Neural. Regen. Res. 2020;15:1656&#x2013;1657. doi: 10.4103/1673-5374.276332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1673-5374.276332</ArticleId>
            <ArticleId IdType="pmc">PMC7437601</ArticleId>
            <ArticleId IdType="pubmed">32209767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forest D.L., Johnson L.V., Clegg D.O. Cellular models and therapies for age-related macular degeneration. Dis. Model. Mech. 2015;8:421&#x2013;427. doi: 10.1242/dmm.017236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.017236</ArticleId>
            <ArticleId IdType="pmc">PMC4415892</ArticleId>
            <ArticleId IdType="pubmed">26035859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K., Yao Y., Zhu X., Zhang K., Zhou F., Zhu L. Amyloid beta induces NLRP3 inflammasome activation in retinal pigment epithelial cells via NADPH oxidase- and mitochondria-dependent ROS production. J. Biochem. Mol. Toxicol. 2017;31 doi: 10.1002/jbt.21887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbt.21887</ArticleId>
            <ArticleId IdType="pubmed">28004443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K., Zhu X., Zhang K., Yao Y., Zhuang M., Tan C., Zhou F., Zhu L. Puerarin inhibits amyloid beta-induced NLRP3 inflammasome activation in retinal pigment epithelial cells via suppressing ROS-dependent oxidative and endoplasmic reticulum stresses. Exp. Cell Res. 2017;357:335&#x2013;340. doi: 10.1016/j.yexcr.2017.05.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2017.05.030</ArticleId>
            <ArticleId IdType="pubmed">28583762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M., So K.F., Lo A.C.Y., Lam W.C. The Effect of Lycium barbarum Polysaccharides on Pyroptosis-Associated Amyloid beta1-40 Oligomers-Induced Adult Retinal Pigment Epithelium 19 Cell Damage. Int. J. Mol. Sci. 2020;21:4658. doi: 10.3390/ijms21134658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21134658</ArticleId>
            <ArticleId IdType="pmc">PMC7369740</ArticleId>
            <ArticleId IdType="pubmed">32629957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X.Y., Ng T.K., Brelen M.E., Wu D., Wang J.X., Chan K.P., Yung J.S.Y., Cao D., Wang Y., Zhang S., et al. Continuous exposure to non-lethal doses of sodium iodate induces retinal pigment epithelial cell dysfunction. Sci. Rep. 2016;6:37279. doi: 10.1038/srep37279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep37279</ArticleId>
            <ArticleId IdType="pmc">PMC5110957</ArticleId>
            <ArticleId IdType="pubmed">27849035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y.C., Horng L.Y., Sung H.C., Wu R.T. Sodium Iodate Disrupted the Mitochondrial-Lysosomal Axis in Cultured Retinal Pigment Epithelial Cells. J. Ocul. Pharmacol. Ther. 2018;34:500&#x2013;511. doi: 10.1089/jop.2017.0073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jop.2017.0073</ArticleId>
            <ArticleId IdType="pubmed">30020815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang N., Kwon M.Y., Woo J.M., Chung S.W. Oxidative Stress-Induced Pentraxin 3 Expression Human Retinal Pigment Epithelial Cells is Involved in the Pathogenesis of Age-Related Macular Degeneration. Int. J. Mol. Sci. 2019;20:6028. doi: 10.3390/ijms20236028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20236028</ArticleId>
            <ArticleId IdType="pmc">PMC6928709</ArticleId>
            <ArticleId IdType="pubmed">31795454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Totsuka K., Ueta T., Uchida T., Roggia M.F., Nakagawa S., Vavvas D.G., Honjo M., Aihara M. Oxidative stress induces ferroptotic cell death in retinal pigment epithelial cells. Exp. Eye Res. 2019;181:316&#x2013;324. doi: 10.1016/j.exer.2018.08.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2018.08.019</ArticleId>
            <ArticleId IdType="pmc">PMC7418497</ArticleId>
            <ArticleId IdType="pubmed">30171859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao Y., Liu J., Wang Z., Yu L.L., Wang J. Piceatannol Protects Human Retinal Pigment Epithelial Cells against Hydrogen Peroxide Induced Oxidative Stress and Apoptosis through Modulating PI3K/Akt Signaling Pathway. Nutrients. 2019;11:1515. doi: 10.3390/nu11071515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu11071515</ArticleId>
            <ArticleId IdType="pmc">PMC6683019</ArticleId>
            <ArticleId IdType="pubmed">31277394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X., Wu X., Zhao B., Wang Y. Scutellarin protects human retinal pigment epithelial cells against hydrogen peroxide (H2O2)-induced oxidative damage. Cell Biosci. 2019;9:12. doi: 10.1186/s13578-019-0276-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13578-019-0276-0</ArticleId>
            <ArticleId IdType="pmc">PMC6341765</ArticleId>
            <ArticleId IdType="pubmed">30680088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S., Gaur U., Chong C.M., Lin S., Fang J., Zeng Z., Wang H., Zheng W. Berberine Protects Human Retinal Pigment Epithelial Cells from Hydrogen Peroxide-Induced Oxidative Damage through Activation of AMPK. Int. J. Mol. Sci. 2018;19:1736. doi: 10.3390/ijms19061736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19061736</ArticleId>
            <ArticleId IdType="pmc">PMC6032421</ArticleId>
            <ArticleId IdType="pubmed">29895743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001;119:1417&#x2013;1436. doi: 10.1001/archopht.119.10.1417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.119.10.1417</ArticleId>
            <ArticleId IdType="pmc">PMC1462955</ArticleId>
            <ArticleId IdType="pubmed">11594942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCusker M.M., Durrani K., Payette M.J., Suchecki J. An eye on nutrition: The role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. Clin. Dermatol. 2016;34:276&#x2013;285. doi: 10.1016/j.clindermatol.2015.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clindermatol.2015.11.009</ArticleId>
            <ArticleId IdType="pubmed">26903189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chew E.Y., Clemons T.E., Agron E., Sperduto R.D., Sangiovanni J.P., Kurinij N., Davis M.D., Age-Related Eye Disease Study Research Group Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120:1604&#x2013;1611. doi: 10.1016/j.ophtha.2013.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2013.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC3728272</ArticleId>
            <ArticleId IdType="pubmed">23582353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chew E.Y., Clemons T.E., Agron E., Sperduto R.D., Sangiovanni J.P., Davis M.D., Ferris F.L., Age-Related Eye Disease Study Research Group Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014;132:272&#x2013;277. doi: 10.1001/jamaophthalmol.2013.6636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2013.6636</ArticleId>
            <ArticleId IdType="pubmed">24385141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Age-Related Eye Disease Study 2 Research Group. Chew E.Y., Clemons T.E., Sangiovanni J.P., Danis R.P., Ferris F.L., 3rd, Elman M.J., Antoszyk A.N., Ruby A.J., Orth D., et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132:142&#x2013;149. doi: 10.1001/jamaophthalmol.2013.7376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2013.7376</ArticleId>
            <ArticleId IdType="pmc">PMC4636082</ArticleId>
            <ArticleId IdType="pubmed">24310343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans J.R., Lawrenson J.G. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Db Syst. Rev. 2012 doi: 10.1002/14651858.CD000253.pub3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD000253.pub3</ArticleId>
            <ArticleId IdType="pubmed">22696317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merry G.F., Munk M.R., Dotson R.S., Walker M.G., Devenyi R.G. Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Acta Ophthalmol. 2017;95:E270&#x2013;E277. doi: 10.1111/aos.13354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/aos.13354</ArticleId>
            <ArticleId IdType="pmc">PMC5484346</ArticleId>
            <ArticleId IdType="pubmed">27989012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz S.N., Devenyi R.G., Munk M.R., Croissant C.L., Tedford S.E., Ruckert R., Walker M.G., Patino B.E., Chen L., Nido M., et al. A Double-Masked, Randomized, Sham-Controlled, Single-Center Study with Photobiomodulation for the Treatment of Dry Age-Related Macular Degeneration. Retina. 2019 doi: 10.1097/IAE.0000000000002632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IAE.0000000000002632</ArticleId>
            <ArticleId IdType="pmc">PMC7392581</ArticleId>
            <ArticleId IdType="pubmed">31404033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turbert D. Anti-VEGF Treatments. [(accessed on 14 September 2020)];American Academy of Ophthalmology. Available online: https://www.aao.org/eye-health/drugs/anti-vegf-treatments.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin D.F., Maguire M.G., Fine S.L., Ying G.S., Jaffe G.J., Grunwald J.E., Toth C., Redford M., Ferris F.L., Macular C.A. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2012;119 doi: 10.1016/j.ophtha.2012.03.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2012.03.053</ArticleId>
            <ArticleId IdType="pmc">PMC3389193</ArticleId>
            <ArticleId IdType="pubmed">22555112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaffe G.J., Ying G.S., Toth C.A., Daniel E., Grunwald J.E., Martin D.F., Maguire M.G., Comparison of Age-related Macular Degeneration Treatments Trials Research Group Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2019;126:252&#x2013;260. doi: 10.1016/j.ophtha.2018.08.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2018.08.035</ArticleId>
            <ArticleId IdType="pmc">PMC6462189</ArticleId>
            <ArticleId IdType="pubmed">30189282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Maguire M.G., Martin D.F., Ying G.S., Jaffe G.J., Daniel E., Grunwald J.E., Toth C.A., Ferris F.L., 3rd, Fine S.L. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123:1751&#x2013;1761. doi: 10.1016/j.ophtha.2016.03.045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2016.03.045</ArticleId>
            <ArticleId IdType="pmc">PMC4958614</ArticleId>
            <ArticleId IdType="pubmed">27156698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniel E., Ying G.S., Kim B.J., Toth C.A., Ferris F., 3rd, Martin D.F., Grunwald J.E., Jaffe G.J., Dunaief J.L., Pan W., et al. Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2019;126:743&#x2013;751. doi: 10.1016/j.ophtha.2018.11.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2018.11.020</ArticleId>
            <ArticleId IdType="pmc">PMC6475610</ArticleId>
            <ArticleId IdType="pubmed">30476517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vazquez-Alfageme C., Nicholson L., Hamilton R.D., Patel P.J. Incidence and Long-Term Visual Acuity Outcomes of Retinal Pigment Epithelium Tears after Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. Retina-J. Ret. Vit. Dis. 2019;39:664&#x2013;669. doi: 10.1097/IAE.0000000000002029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IAE.0000000000002029</ArticleId>
            <ArticleId IdType="pubmed">29324593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder M., Westborg I., Lovestam Adrian M. Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR) Acta Ophthalmol. 2019 doi: 10.1111/aos.14239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/aos.14239</ArticleId>
            <ArticleId IdType="pmc">PMC7216980</ArticleId>
            <ArticleId IdType="pubmed">31517440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedrosa A.C., Reis-Silva A., Pinheiro-Costa J., Beato J., Freitas-da-Costa P., Falcao M.S., Falcao-Reis F., Carneiro A. Treatment of neovascular age-related macular degeneration with anti-VEGF agents: Retrospective analysis of 5-year outcomes. Clin. Ophthalmol. 2016;10:541&#x2013;546. doi: 10.2147/OPTH.S90913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OPTH.S90913</ArticleId>
            <ArticleId IdType="pmc">PMC4820212</ArticleId>
            <ArticleId IdType="pubmed">27099460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grunwald J.E., Pistilli M., Daniel E., Ying G.S., Pan W., Jaffe G.J., Toth C.A., Hagstrom S.A., Maguire M.G., Martin D.F., et al. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2017;124:97&#x2013;104. doi: 10.1016/j.ophtha.2016.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2016.09.012</ArticleId>
            <ArticleId IdType="pmc">PMC5234734</ArticleId>
            <ArticleId IdType="pubmed">28079023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaiser P.K. Verteporfin photodynamic therapy and anti-angiogenic drugs: Potential for combination therapy in exudative age-related macular degeneration. Curr. Med. Res. Opin. 2007;23:477&#x2013;487. doi: 10.1185/030079907X167624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/030079907X167624</ArticleId>
            <ArticleId IdType="pubmed">17355729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van den Bergh H. Photodynamic therapy of age-related macular degeneration: History and principles. Semin. Ophthalmol. 2001;16:181&#x2013;200. doi: 10.1076/soph.16.4.181.10299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1076/soph.16.4.181.10299</ArticleId>
            <ArticleId IdType="pubmed">15513440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parmeggiani F., Gallenga C.E., Costagliola C., Semeraro F., Romano M.R., Dell&#x2019;Omo R., Russo A., De Nadai K., Gemmati D., D&#x2019;Angelo S., et al. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration. Sci. Rep. 2019;9:2614. doi: 10.1038/s41598-019-38919-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-38919-7</ArticleId>
            <ArticleId IdType="pmc">PMC6385217</ArticleId>
            <ArticleId IdType="pubmed">30796269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer A.O., MacLaren R.E. Translating induced pluripotent stem cells from bench to bedside: Application to retinal diseases. Curr. Gene Ther. 2013;13:139&#x2013;151. doi: 10.2174/1566523211313020008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1566523211313020008</ArticleId>
            <ArticleId IdType="pmc">PMC3826973</ArticleId>
            <ArticleId IdType="pubmed">23320477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Cruz L., Fynes K., Georgiadis O., Kerby J., Luo Y.H., Ahmado A., Vernon A., Daniels J.T., Nommiste B., Hasan S.M., et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat. Biotechnol. 2018;36 doi: 10.1038/nbt.4114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.4114</ArticleId>
            <ArticleId IdType="pubmed">29553577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashani A.H., Lebkowski J.S., Rahhal F.M., Avery R.L., Salehi-Had H., Dang W., Lin C.M., Mitra D., Zhu D.H., Thomas B.B., et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci. Transl. Med. 2018;10 doi: 10.1126/scitranslmed.aao4097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aao4097</ArticleId>
            <ArticleId IdType="pubmed">29618560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz S.D., Hubschman J.P., Heilwell G., Franco-Cardenas V., Pan C.K., Ostrick R.M., Mickunas E., Gay R., Klimanskaya I., Lanza R. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet. 2012;379:713&#x2013;720. doi: 10.1016/S0140-6736(12)60028-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)60028-2</ArticleId>
            <ArticleId IdType="pubmed">22281388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz S.D., Regillo C.D., Lam B.L., Eliott D., Rosenfeld P.J., Gregori N.Z., Hubschman J.P., Davis J.L., Heilwell G., Spirn M., et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt&#x2019;s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509&#x2013;516. doi: 10.1016/S0140-6736(14)61376-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)61376-3</ArticleId>
            <ArticleId IdType="pubmed">25458728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandai M., Watanabe A., Kurimoto Y., Hirami Y., Morinaga C., Daimon T., Fujihara M., Akimaru H., Sakai N., Shibata Y., et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N. Engl. J. Med. 2017;376:1038&#x2013;1046. doi: 10.1056/NEJMoa1608368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1608368</ArticleId>
            <ArticleId IdType="pubmed">28296613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garber K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat. Biotechnol. 2015;33:890&#x2013;891. doi: 10.1038/nbt0915-890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt0915-890</ArticleId>
            <ArticleId IdType="pubmed">26348942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanus J., Anderson C., Sarraf D., Ma J., Wang S. Retinal pigment epithelial cell necroptosis in response to sodium iodate. Cell Death Discov. 2016;2:16054. doi: 10.1038/cddiscovery.2016.54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddiscovery.2016.54</ArticleId>
            <ArticleId IdType="pmc">PMC4979458</ArticleId>
            <ArticleId IdType="pubmed">27551542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colijn J.M., Buitendijk G.H.S., Prokofyeva E., Alves D., Cachulo M.L., Khawaja A.P., Cougnard-Gregoire A., Merle B.M.J., Korb C., Erke M.G., et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017;124:1753&#x2013;1763. doi: 10.1016/j.ophtha.2017.05.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2017.05.035</ArticleId>
            <ArticleId IdType="pmc">PMC5755466</ArticleId>
            <ArticleId IdType="pubmed">28712657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cookson B.T., Brennan M.A. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9:113&#x2013;114. doi: 10.1016/S0966-842X(00)01936-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0966-842X(00)01936-3</ArticleId>
            <ArticleId IdType="pubmed">11303500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Zhang Z., Ruan J., Pan Y., Magupalli V.G., Wu H., Lieberman J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153&#x2013;158. doi: 10.1038/nature18629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature18629</ArticleId>
            <ArticleId IdType="pmc">PMC5539988</ArticleId>
            <ArticleId IdType="pubmed">27383986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J.J., Gao W.Q., Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem. Sci. 2017;42:245&#x2013;254. doi: 10.1016/j.tibs.2016.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2016.10.004</ArticleId>
            <ArticleId IdType="pubmed">27932073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandes-Alnemri T., Wu J., Yu J.W., Datta P., Miller B., Jankowski W., Rosenberg S., Zhang J., Alnemri E. The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14:1590&#x2013;1604. doi: 10.1038/sj.cdd.4402194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4402194</ArticleId>
            <ArticleId IdType="pmc">PMC3345951</ArticleId>
            <ArticleId IdType="pubmed">17599095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S., Yuan Y.H., Chen N.H., Wang H.B. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson&#x2019;s disease. Int. Immunopharmacol. 2019;67:458&#x2013;464. doi: 10.1016/j.intimp.2018.12.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.12.019</ArticleId>
            <ArticleId IdType="pubmed">30594776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergsbaken T., Fink S.L., Cookson B.T. Pyroptosis: Host cell death and inflammation. Nat. Rev. Microbiol. 2009;7:99&#x2013;109. doi: 10.1038/nrmicro2070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro2070</ArticleId>
            <ArticleId IdType="pmc">PMC2910423</ArticleId>
            <ArticleId IdType="pubmed">19148178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fink S.L., Cookson B.T. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell. Microbiol. 2006;8:1812&#x2013;1825. doi: 10.1111/j.1462-5822.2006.00751.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1462-5822.2006.00751.x</ArticleId>
            <ArticleId IdType="pubmed">16824040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Man S.M., Karki R., Kanneganti T.D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol. Rev. 2017;277:61&#x2013;75. doi: 10.1111/imr.12534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12534</ArticleId>
            <ArticleId IdType="pmc">PMC5416822</ArticleId>
            <ArticleId IdType="pubmed">28462526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005;1:112&#x2013;119. doi: 10.1038/nchembio711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio711</ArticleId>
            <ArticleId IdType="pubmed">16408008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinlich R., Oberst A., Beere H.M., Green D.R. Necroptosis in development, inflammation and disease. Nat. Rev. Mol. Cell Biol. 2017;18:127&#x2013;136. doi: 10.1038/nrm.2016.149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2016.149</ArticleId>
            <ArticleId IdType="pubmed">27999438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: Controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008;9:231&#x2013;241. doi: 10.1038/nrm2312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2312</ArticleId>
            <ArticleId IdType="pubmed">18073771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 2000;1:489&#x2013;495. doi: 10.1038/82732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/82732</ArticleId>
            <ArticleId IdType="pubmed">11101870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112&#x2013;1123. doi: 10.1016/j.cell.2009.05.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.05.037</ArticleId>
            <ArticleId IdType="pmc">PMC2727676</ArticleId>
            <ArticleId IdType="pubmed">19524513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., Dong M.Q., Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332&#x2013;336. doi: 10.1126/science.1172308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1172308</ArticleId>
            <ArticleId IdType="pubmed">19498109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vercammen D., Beyaert R., Denecker G., Goossens V., Van Loo G., Declercq W., Grooten J., Fiers W., Vandenabeele P. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 1998;187:1477&#x2013;1485. doi: 10.1084/jem.187.9.1477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.187.9.1477</ArticleId>
            <ArticleId IdType="pmc">PMC2212268</ArticleId>
            <ArticleId IdType="pubmed">9565639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhuriya Y.K., Sharma D. Necroptosis: A regulated inflammatory mode of cell death. J. Neuroinflammation. 2018;15:199. doi: 10.1186/s12974-018-1235-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-018-1235-0</ArticleId>
            <ArticleId IdType="pmc">PMC6035417</ArticleId>
            <ArticleId IdType="pubmed">29980212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell B.R., Friedmann Angeli J.P., Bayir H., Bush A.I., Conrad M., Dixon S.J., Fulda S., Gascon S., Hatzios S.K., Kagan V.E., et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadian K., Stockwell B.R. SnapShot: Ferroptosis. Cell. 2020;181:1188. doi: 10.1016/j.cell.2020.04.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.04.039</ArticleId>
            <ArticleId IdType="pubmed">32470402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tseng W.A., Thein T., Kinnunen K., Lashkari K., Gregory M.S., D&#x2019;Amore P.A., Ksander B.R. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: Implications for age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013;54:110&#x2013;120. doi: 10.1167/iovs.12-10655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.12-10655</ArticleId>
            <ArticleId IdType="pmc">PMC3544415</ArticleId>
            <ArticleId IdType="pubmed">23221073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wooff Y., Fernando N., Wong J.H.C., Dietrich C., Aggio-Bruce R., Chu-Tan J.A., Robertson A.A.B., Doyle S.L., Man S.M., Natoli R. Caspase-1-dependent inflammasomes mediate photoreceptor cell death in photo-oxidative damage-induced retinal degeneration. Sci. Rep. 2020;10:2263. doi: 10.1038/s41598-020-58849-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-58849-z</ArticleId>
            <ArticleId IdType="pmc">PMC7010818</ArticleId>
            <ArticleId IdType="pubmed">32041990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J., Cui J.Z., To E., Cao S., Matsubara J.A. Evidence for the activation of pyroptotic and apoptotic pathways in RPE cells associated with NLRP3 inflammasome in the rodent eye. J. Neuroinflammation. 2018;15:15. doi: 10.1186/s12974-018-1062-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-018-1062-3</ArticleId>
            <ArticleId IdType="pmc">PMC5766992</ArticleId>
            <ArticleId IdType="pubmed">29329580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanus J., Anderson C., Wang S. RPE necroptosis in response to oxidative stress and in AMD. Ageing Res. Rev. 2015;24:286&#x2013;298. doi: 10.1016/j.arr.2015.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2015.09.002</ArticleId>
            <ArticleId IdType="pmc">PMC4661094</ArticleId>
            <ArticleId IdType="pubmed">26369358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y., Zheng Y., Wang C., Liu Y. Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. Cell Death Dis. 2018;9:753. doi: 10.1038/s41419-018-0794-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0794-4</ArticleId>
            <ArticleId IdType="pmc">PMC6037763</ArticleId>
            <ArticleId IdType="pubmed">29988039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rozing M.P., Durhuus J.A., Krogh Nielsen M., Subhi Y., Kirkwood T.B., Westendorp R.G., Sorensen T.L. Age-related macular degeneration: A two-level model hypothesis. Prog. Retin. Eye Res. 2020;76:100825. doi: 10.1016/j.preteyeres.2019.100825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.preteyeres.2019.100825</ArticleId>
            <ArticleId IdType="pubmed">31899290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner R.E., Aronson J.K. Remdesivir in covid-19. BMJ. 2020;369:m1610. doi: 10.1136/bmj.m1610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m1610</ArticleId>
            <ArticleId IdType="pubmed">32321732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liguori I., Russo G., Curcio F., Bulli G., Aran L., Della-Morte D., Gargiulo G., Testa G., Cacciatore F., Bonaduce D., et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging. 2018;13:757&#x2013;772. doi: 10.2147/CIA.S158513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CIA.S158513</ArticleId>
            <ArticleId IdType="pmc">PMC5927356</ArticleId>
            <ArticleId IdType="pubmed">29731617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung H.Y., Kim D.H., Lee E.K., Chung K.W., Chung S., Lee B., Seo A.Y., Chung J.H., Jung Y.S., Im E., et al. Redefining Chronic Inflammation in Aging and Age-Related Diseases: Proposal of the Senoinflammation Concept. Aging Dis. 2019;10:367&#x2013;382. doi: 10.14336/AD.2018.0324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14336/AD.2018.0324</ArticleId>
            <ArticleId IdType="pmc">PMC6457053</ArticleId>
            <ArticleId IdType="pubmed">31011483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tower J. Programmed cell death in aging. Ageing Res. Rev. 2015;23:90&#x2013;100. doi: 10.1016/j.arr.2015.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2015.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC4480161</ArticleId>
            <ArticleId IdType="pubmed">25862945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., He W.T., Hu L.C., Li J.X., Fang Y., Wang X., Xu X.Z., Wang Z., Huang K., Han J.H. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016;26:1007&#x2013;1020. doi: 10.1038/cr.2016.100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2016.100</ArticleId>
            <ArticleId IdType="pmc">PMC5034106</ArticleId>
            <ArticleId IdType="pubmed">27573174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Cao F., Yin H.L., Huang Z.J., Lin Z.T., Mao N., Sun B., Wang G. Ferroptosis: Past, present and future. Cell Death Dis. 2020;11:88. doi: 10.1038/s41419-020-2298-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2298-2</ArticleId>
            <ArticleId IdType="pmc">PMC6997353</ArticleId>
            <ArticleId IdType="pubmed">32015325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun H.J., Jin X.M., Xu J., Xiao Q. Baicalin Alleviates Age-Related Macular Degeneration via miR-223/NLRP3-Regulated Pyroptosis. Pharmacology. 2020;105:28&#x2013;38. doi: 10.1159/000502614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000502614</ArticleId>
            <ArticleId IdType="pubmed">31578016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang P., Yu M., Min W., Han S., Shi M., Zhang Z., Bo P. Beneficial effect of baicalin on insulin sensitivity in adipocytes of diet-induced obese mice. Diabetes Res. Clin. Pract. 2018;139:262&#x2013;271. doi: 10.1016/j.diabres.2018.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2018.03.007</ArticleId>
            <ArticleId IdType="pubmed">29526684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang P., Liu W., Chen J., Hu Y., Wang Y., Sun J., Feng J. TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3. Cell Biol. Int. 2020 doi: 10.1002/cbin.11429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbin.11429</ArticleId>
            <ArticleId IdType="pubmed">32716108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao L., Yu S., Ji W., Li H., Gao Y. The Contribution of Necroptosis in Neurodegenerative Diseases. Neurochem. Res. 2017;42:2117&#x2013;2126. doi: 10.1007/s11064-017-2249-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-017-2249-1</ArticleId>
            <ArticleId IdType="pubmed">28382594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito Y., Ofengeim D., Najafov A., Das S., Saberi S., Li Y., Hitomi J., Zhu H., Chen H., Mayo L., et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;608. doi: 10.1126/science.aaf6803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId>
            <ArticleId IdType="pmc">PMC5444917</ArticleId>
            <ArticleId IdType="pubmed">27493188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Li D., Sun H.Y., Wang W.W., Wu H., Kong W., Kong W.J. Relieving ferroptosis may partially reverse neurodegeneration of the auditory cortex. FEBS J. 2020 doi: 10.1111/febs.15266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.15266</ArticleId>
            <ArticleId IdType="pubmed">32112499</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33000412</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1674-8018</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Protein &amp; cell</Title>
          <ISOAbbreviation>Protein Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>599</StartPage>
          <EndPage>620</EndPage>
          <MedlinePgn>599-620</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13238-020-00789-5</ELocationID>
        <Abstract>
          <AbstractText>The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11[high]) also have to endure the significant cost associated with SLC7A11-mediated metabolic reprogramming, leading to glucose- and glutamine-dependency in SLC7A11[high] cancer cells, which presents potential metabolic vulnerabilities for therapeutic targeting in SLC7A11[high] cancer. In this review, we summarize diverse regulatory mechanisms of SLC7A11 in cancer, discuss ferroptosis-dependent and -independent functions of SLC7A11 in promoting tumor development, explore the mechanistic basis of SLC7A11-induced nutrient dependency in cancer cells, and conceptualize therapeutic strategies to target SLC7A11 in cancer treatment. This review will provide the foundation for further understanding SLC7A11 in ferroptosis, nutrient dependency, and tumor biology and for developing novel effective cancer therapies.</AbstractText>
          <CopyrightInformation>&#xa9; 2020. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Koppula</LastName>
            <ForeName>Pranavi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhuang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gan</LastName>
            <ForeName>Boyi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bgan@mdanderson.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA. bgan@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA181196</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA190370</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA244144</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Protein Cell</MedlineTA>
        <NlmUniqueID>101532368</NlmUniqueID>
        <ISSNLinking>1674-800X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006657">Histones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0RH81L854J</RegistryNumber>
          <NameOfSubstance UI="D005973">Glutamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3XC8GUZ6CB</RegistryNumber>
          <NameOfSubstance UI="D012460">Sulfasalazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>48TCX9A1VT</RegistryNumber>
          <NameOfSubstance UI="D003553">Cystine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003553" MajorTopicYN="N">Cystine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012460" MajorTopicYN="N">Sulfasalazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">SLC7A11</Keyword>
        <Keyword MajorTopicYN="N">cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">cysteine</Keyword>
        <Keyword MajorTopicYN="N">cystine</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">nutrient dependency</Keyword>
        <Keyword MajorTopicYN="N">xCT</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33000412</ArticleId>
        <ArticleId IdType="pmc">PMC8310547</ArticleId>
        <ArticleId IdType="doi">10.1007/s13238-020-00789-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s13238-020-00789-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Anandhan A, Dodson M, Schmidlin CJ, Liu P, Zhang DD. Breakdown of an ironclad defense system: the critical role of NRF2 in mediating ferroptosis. Cell Chem Biol. 2020;27:436&#x2013;447. doi: 10.1016/j.chembiol.2020.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2020.03.011</ArticleId>
            <ArticleId IdType="pmc">PMC7597851</ArticleId>
            <ArticleId IdType="pubmed">32275864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artegiani B, van Voorthuijsen L, Lindeboom RGH, Seinstra D, Heo I, Tapia P, Lopez-Iglesias C, Postrach D, Dayton T, Oka R, et al. Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids. Cell Stem Cell. 2019;24(927&#x2013;943):e926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badeaux AI, Shi Y. Emerging roles for chromatin as a signal integration and storage platform. Nat Rev Mol Cell Biol. 2013;14:211&#x2013;224. doi: 10.1038/nrm3545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3545</ArticleId>
            <ArticleId IdType="pmc">PMC4082330</ArticleId>
            <ArticleId IdType="pubmed">23524488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85&#x2013;89. doi: 10.1126/science.aaw9872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaw9872</ArticleId>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bannai S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chem. 1986;261:2256&#x2013;2263. doi: 10.1016/S0021-9258(17)35926-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(17)35926-4</ArticleId>
            <ArticleId IdType="pubmed">2868011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bannai S, Ishii T. A novel function of glutamine in cell culture: utilization of glutamine for the uptake of cystine in human fibroblasts. J Cell Physiol. 1988;137:360&#x2013;366. doi: 10.1002/jcp.1041370221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.1041370221</ArticleId>
            <ArticleId IdType="pubmed">2903864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bannai S, Tsukeda H, Okumura H. Effect of antioxidants on cultured human diploid fibroblasts exposed to cystine-free medium. Biochem Biophys Res Commun. 1977;74:1582&#x2013;1588. doi: 10.1016/0006-291X(77)90623-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-291X(77)90623-4</ArticleId>
            <ArticleId IdType="pubmed">843380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351&#x2013;359. doi: 10.1038/ncb3124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3124</ArticleId>
            <ArticleId IdType="pmc">PMC4939711</ArticleId>
            <ArticleId IdType="pubmed">25774832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research, N Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519&#x2013;525. doi: 10.1038/nature11404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11404</ArticleId>
            <ArticleId IdType="pmc">PMC3466113</ArticleId>
            <ArticleId IdType="pubmed">22960745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research, N Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543&#x2013;550. doi: 10.1038/nature13385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13385</ArticleId>
            <ArticleId IdType="pmc">PMC4231481</ArticleId>
            <ArticleId IdType="pubmed">25079552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217&#x2013;223. doi: 10.1038/s41586-019-1694-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1694-1</ArticleId>
            <ArticleId IdType="pubmed">31666701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Poddar A, Magtanong L, Lumb JH, Mileur TR, Reid MA, Dovey CM, Wang J, Locasale JW, Stone E, et al. A genome-wide haploid genetic screen identifies regulators of glutathione abundance and ferroptosis sensitivity. Cell Rep. 2019;26(1544&#x2013;1556):e1548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6424331</ArticleId>
            <ArticleId IdType="pubmed">30726737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153&#x2013;159. doi: 10.1038/nrc3459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3459</ArticleId>
            <ArticleId IdType="pmc">PMC3792854</ArticleId>
            <ArticleId IdType="pubmed">23550303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Fan Z, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. Oncogene. 2017;36:5593&#x2013;5608. doi: 10.1038/onc.2017.146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.146</ArticleId>
            <ArticleId IdType="pmc">PMC5633655</ArticleId>
            <ArticleId IdType="pubmed">28553953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chintala S, Li W, Lamoreux ML, Ito S, Wakamatsu K, Sviderskaya EV, Bennett DC, Park YM, Gahl WA, Huizing M, et al. Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. Proc Natl Acad Sci USA. 2005;102:10964&#x2013;10969. doi: 10.1073/pnas.0502856102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0502856102</ArticleId>
            <ArticleId IdType="pmc">PMC1178012</ArticleId>
            <ArticleId IdType="pubmed">16037214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chio IIC, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med. 2017;23:411&#x2013;429. doi: 10.1016/j.molmed.2017.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2017.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC5462452</ArticleId>
            <ArticleId IdType="pubmed">28427863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, Song S, Tavana O, Gu W. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21:579&#x2013;591. doi: 10.1038/s41556-019-0305-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0305-6</ArticleId>
            <ArticleId IdType="pmc">PMC6624840</ArticleId>
            <ArticleId IdType="pubmed">30962574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cobler L, Zhang H, Suri P, Park C, Timmerman LA. xCT inhibition sensitizes tumors to gamma-radiation via glutathione reduction. Oncotarget. 2018;9:32280&#x2013;32297. doi: 10.18632/oncotarget.25794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.25794</ArticleId>
            <ArticleId IdType="pmc">PMC6122354</ArticleId>
            <ArticleId IdType="pubmed">30190786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel) 2019;11:678. doi: 10.3390/cancers11050678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11050678</ArticleId>
            <ArticleId IdType="pmc">PMC6562400</ArticleId>
            <ArticleId IdType="pubmed">31100816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids. 2012;42:231&#x2013;246. doi: 10.1007/s00726-011-0867-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00726-011-0867-5</ArticleId>
            <ArticleId IdType="pubmed">21409388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828&#x2013;851. doi: 10.1038/nrd4389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4389</ArticleId>
            <ArticleId IdType="pmc">PMC4355017</ArticleId>
            <ArticleId IdType="pubmed">25323927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daher B, Parks SK, Durivault J, Cormerais Y, Baidarjad H, Tambutte E, Pouyssegur J, Vucetic M. Genetic ablation of the cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and tumor formation via nutrient and oxidative stresses. Cancer Res. 2019;79:3877&#x2013;3890. doi: 10.1158/0008-5472.CAN-18-3855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3855</ArticleId>
            <ArticleId IdType="pubmed">31175120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai L, Cao Y, Chen Y, Parsons C, Qin Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol. 2014;7:30. doi: 10.1186/1756-8722-7-30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-8722-7-30</ArticleId>
            <ArticleId IdType="pmc">PMC4234972</ArticleId>
            <ArticleId IdType="pubmed">24708874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, Vermoesen K, Bannai S, Sato H, Michotte Y, et al. Loss of system x(c)- does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci. 2011;31:5792&#x2013;5803. doi: 10.1523/JNEUROSCI.5465-10.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5465-10.2011</ArticleId>
            <ArticleId IdType="pmc">PMC6622811</ArticleId>
            <ArticleId IdType="pubmed">21490221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523. doi: 10.7554/eLife.02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.02523</ArticleId>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dornier E, Rabas N, Mitchell L, Novo D, Dhayade S, Marco S, Mackay G, Sumpton D, Pallares M, Nixon C, et al. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat Commun. 2017;8:2255. doi: 10.1038/s41467-017-02101-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02101-2</ArticleId>
            <ArticleId IdType="pmc">PMC5740148</ArticleId>
            <ArticleId IdType="pubmed">29269878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, Catto JW. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20:1990&#x2013;2000. doi: 10.1158/1078-0432.CCR-13-2805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-2805</ArticleId>
            <ArticleId IdType="pmc">PMC3974662</ArticleId>
            <ArticleId IdType="pubmed">24516043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eagle H. Nutrition needs of mammalian cells in tissue culture. Science. 1955;122:501&#x2013;514. doi: 10.1126/science.122.3168.501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.122.3168.501</ArticleId>
            <ArticleId IdType="pubmed">13255879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eagle H. The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture. J Exp Med. 1955;102:37&#x2013;48. doi: 10.1084/jem.102.1.37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.102.1.37</ArticleId>
            <ArticleId IdType="pmc">PMC2136494</ArticleId>
            <ArticleId IdType="pubmed">14392239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, Stockwell BR. Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol. 2018;16:e2006203. doi: 10.1371/journal.pbio.2006203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.2006203</ArticleId>
            <ArticleId IdType="pmc">PMC5991413</ArticleId>
            <ArticleId IdType="pubmed">29795546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, et al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Res. 2019;79:3251&#x2013;3267. doi: 10.1158/0008-5472.CAN-18-3527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3527</ArticleId>
            <ArticleId IdType="pmc">PMC6606351</ArticleId>
            <ArticleId IdType="pubmed">31040157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan B. DUBbing ferroptosis in cancer cells. Cancer Res. 2019;79:1749&#x2013;1750. doi: 10.1158/0008-5472.CAN-19-0487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-19-0487</ArticleId>
            <ArticleId IdType="pmc">PMC7193871</ArticleId>
            <ArticleId IdType="pubmed">30987975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan W, Dai X, Dai X, Xie J, Yin S, Zhu J, Wang C, Liu Y, Guo J, Wang M, et al. LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020;22:246&#x2013;256. doi: 10.1038/s41556-020-0463-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-020-0463-6</ArticleId>
            <ArticleId IdType="pmc">PMC7076906</ArticleId>
            <ArticleId IdType="pubmed">32015438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goji T, Takahara K, Negishi M, Katoh H. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation. J Biol Chem. 2017;292:19721&#x2013;19732. doi: 10.1074/jbc.M117.814392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.814392</ArticleId>
            <ArticleId IdType="pmc">PMC5712613</ArticleId>
            <ArticleId IdType="pubmed">29038291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1:19&#x2013;30. doi: 10.1016/S1535-6108(02)00024-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(02)00024-7</ArticleId>
            <ArticleId IdType="pubmed">12086884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT. Mol Cell. 2017;67(128&#x2013;138):e127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5521991</ArticleId>
            <ArticleId IdType="pubmed">28648777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646&#x2013;674. doi: 10.1016/j.cell.2011.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, Kao CF, Pillus L, Shilatifard A, Osley MA, Berger SL. Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev. 2003;17:2648&#x2013;2663. doi: 10.1101/gad.1144003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1144003</ArticleId>
            <ArticleId IdType="pmc">PMC280615</ArticleId>
            <ArticleId IdType="pubmed">14563679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678&#x2013;3684. doi: 10.1172/JCI69600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI69600</ArticleId>
            <ArticleId IdType="pmc">PMC3754270</ArticleId>
            <ArticleId IdType="pubmed">23999442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest. 2020;130:1752&#x2013;1766. doi: 10.1172/JCI124049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI124049</ArticleId>
            <ArticleId IdType="pmc">PMC7108883</ArticleId>
            <ArticleId IdType="pubmed">31874110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005;65:7446&#x2013;7454. doi: 10.1158/0008-5472.CAN-04-4267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-4267</ArticleId>
            <ArticleId IdType="pubmed">16103098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277&#x2013;288. doi: 10.1038/nrc776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc776</ArticleId>
            <ArticleId IdType="pubmed">12001989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishii T, Bannai S. The synergistic action of the copper chelator bathocuproine sulphonate and cysteine in enhancing growth of L1210 cells in vitro. J Cell Physiol. 1985;125:151&#x2013;155. doi: 10.1002/jcp.1041250119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.1041250119</ArticleId>
            <ArticleId IdType="pubmed">4044667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19:387&#x2013;400. doi: 10.1016/j.ccr.2011.01.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.01.038</ArticleId>
            <ArticleId IdType="pubmed">21397861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245&#x2013;254. doi: 10.1038/ng1089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1089</ArticleId>
            <ArticleId IdType="pubmed">12610534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 2016;30:918&#x2013;930. doi: 10.1101/gad.275891.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.275891.115</ArticleId>
            <ArticleId IdType="pmc">PMC4840298</ArticleId>
            <ArticleId IdType="pubmed">27034505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene. 2018;37:5007&#x2013;5019. doi: 10.1038/s41388-018-0307-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0307-z</ArticleId>
            <ArticleId IdType="pmc">PMC6127081</ArticleId>
            <ArticleId IdType="pubmed">29789716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joly JH, Delfarah A, Phung PS, Parrish S, Graham NA. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295:1350&#x2013;1365. doi: 10.1016/S0021-9258(17)49891-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(17)49891-7</ArticleId>
            <ArticleId IdType="pmc">PMC6996897</ArticleId>
            <ArticleId IdType="pubmed">31914417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Jr, Vogelstein B, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228&#x2013;231. doi: 10.1126/science.1196333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1196333</ArticleId>
            <ArticleId IdType="pmc">PMC3076894</ArticleId>
            <ArticleId IdType="pubmed">20826764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci Adv. 2015;1:e1500447. doi: 10.1126/sciadv.1500447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.1500447</ArticleId>
            <ArticleId IdType="pmc">PMC4640607</ArticleId>
            <ArticleId IdType="pubmed">26601204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandasamy P, Gyimesi G, Kanai Y, Hediger MA. Amino acid transporters revisited: new views in health and disease. Trends Biochem Sci. 2018;43:752&#x2013;789. doi: 10.1016/j.tibs.2018.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2018.05.003</ArticleId>
            <ArticleId IdType="pubmed">30177408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilberg MS, Shan J, Su N. ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab. 2009;20:436&#x2013;443. doi: 10.1016/j.tem.2009.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tem.2009.05.008</ArticleId>
            <ArticleId IdType="pmc">PMC3587693</ArticleId>
            <ArticleId IdType="pubmed">19800252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21:63&#x2013;71. doi: 10.1038/s41556-018-0205-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0205-1</ArticleId>
            <ArticleId IdType="pubmed">30602761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhang Y, Shi J, Li W, Gan B. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017;292:14240&#x2013;14249. doi: 10.1074/jbc.M117.798405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.798405</ArticleId>
            <ArticleId IdType="pmc">PMC5572906</ArticleId>
            <ArticleId IdType="pubmed">28630042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond) 2018;38:12. doi: 10.1186/s40880-018-0288-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40880-018-0288-x</ArticleId>
            <ArticleId IdType="pmc">PMC5993148</ArticleId>
            <ArticleId IdType="pubmed">29764521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P, Zhou J, Zhang Q, Dow A, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673. doi: 10.1158/2159-8290.CD-19-0338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0338</ArticleId>
            <ArticleId IdType="pmc">PMC6891128</ArticleId>
            <ArticleId IdType="pubmed">31554642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30:146&#x2013;162. doi: 10.1038/s41422-019-0263-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-019-0263-3</ArticleId>
            <ArticleId IdType="pmc">PMC7015061</ArticleId>
            <ArticleId IdType="pubmed">31949285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269&#x2013;1283. doi: 10.1016/j.cell.2012.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.04.026</ArticleId>
            <ArticleId IdType="pmc">PMC3688046</ArticleId>
            <ArticleId IdType="pubmed">22682249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lien EC, Ghisolfi L, Geck RC, Asara JM, Toker A. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT. Sci Signal. 2017;10:eaao6604. doi: 10.1126/scisignal.aao6604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aao6604</ArticleId>
            <ArticleId IdType="pmc">PMC5808948</ArticleId>
            <ArticleId IdType="pubmed">29259101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci USA. 2019;116:9433&#x2013;9442. doi: 10.1073/pnas.1821323116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1821323116</ArticleId>
            <ArticleId IdType="pmc">PMC6511045</ArticleId>
            <ArticleId IdType="pubmed">31000598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, Cao DX, He M, Chen GQ, He JR, Zhao Q. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 2011;585:1363&#x2013;1367. doi: 10.1016/j.febslet.2011.04.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2011.04.018</ArticleId>
            <ArticleId IdType="pubmed">21510944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, et al. Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun. 2017;8:14844. doi: 10.1038/ncomms14844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14844</ArticleId>
            <ArticleId IdType="pmc">PMC5379068</ArticleId>
            <ArticleId IdType="pubmed">28348409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Jiang L, Tavana O, Gu W. The Deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79:1913&#x2013;1924. doi: 10.1158/0008-5472.CAN-18-3037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3037</ArticleId>
            <ArticleId IdType="pmc">PMC6467774</ArticleId>
            <ArticleId IdType="pubmed">30709928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Olszewski K, Zhang Y, Lim EW, Shi J, Zhang X, Zhang J, Lee H, Koppula P, Lei G, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020;22:476&#x2013;486. doi: 10.1038/s41556-020-0496-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-020-0496-x</ArticleId>
            <ArticleId IdType="pmc">PMC7194135</ArticleId>
            <ArticleId IdType="pubmed">32231310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464&#x2013;472. doi: 10.1038/sj.bjc.6604485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604485</ArticleId>
            <ArticleId IdType="pmc">PMC2527809</ArticleId>
            <ArticleId IdType="pubmed">18648370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long Y, Tao H, Karachi A, Grippin AJ, Jin L, Chang YE, Zhang W, Dyson KA, Hou AY, Na M, et al. Dysregulation of glutamate transport enhances treg function that promotes VEGF blockade resistance in glioblastoma. Cancer Res. 2020;80:499&#x2013;509. doi: 10.1158/0008-5472.CAN-19-1577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-19-1577</ArticleId>
            <ArticleId IdType="pubmed">31723000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal PK, Seiler A, Perisic T, Kolle P, Banjac Canak A, Forster H, Weiss N, Kremmer E, Lieberman MW, Bannai S, et al. System x(c)- and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J Biol Chem. 2010;285:22244&#x2013;22253. doi: 10.1074/jbc.M110.121327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.121327</ArticleId>
            <ArticleId IdType="pmc">PMC2903358</ArticleId>
            <ArticleId IdType="pubmed">20463017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381&#x2013;405. doi: 10.1016/j.cell.2017.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC5546324</ArticleId>
            <ArticleId IdType="pubmed">28431241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao TL, Shih Ie M. The roles of ARID1A in gynecologic cancer. J Gynecol Oncol. 2013;24:376&#x2013;381. doi: 10.3802/jgo.2013.24.4.376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3802/jgo.2013.24.4.376</ArticleId>
            <ArticleId IdType="pmc">PMC3805919</ArticleId>
            <ArticleId IdType="pubmed">24167674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin L, Gardner LB. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11. Oncogene. 2015;34:4211&#x2013;4218. doi: 10.1038/onc.2014.352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2014.352</ArticleId>
            <ArticleId IdType="pmc">PMC4433865</ArticleId>
            <ArticleId IdType="pubmed">25399695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muir A, Danai LV, Gui DY, Waingarten CY, Lewis CA, Vander Heiden MG. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. Elife. 2017;6:e27713. doi: 10.7554/eLife.27713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.27713</ArticleId>
            <ArticleId IdType="pmc">PMC5589418</ArticleId>
            <ArticleId IdType="pubmed">28826492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2&#x2013;8. doi: 10.1038/ncb2641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2641</ArticleId>
            <ArticleId IdType="pubmed">23263379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagane M, Kanai E, Shibata Y, Shimizu T, Yoshioka C, Maruo T, Yamashita T. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma. PLoS ONE. 2018;13:e0195151. doi: 10.1371/journal.pone.0195151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0195151</ArticleId>
            <ArticleId IdType="pmc">PMC5896924</ArticleId>
            <ArticleId IdType="pubmed">29649284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura E, Sato M, Yang H, Miyagawa F, Harasaki M, Tomita K, Matsuoka S, Noma A, Iwai K, Minato N. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem. 1999;274:3009&#x2013;3016. doi: 10.1074/jbc.274.5.3009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.5.3009</ArticleId>
            <ArticleId IdType="pubmed">9915839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35(177&#x2013;190):e178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30686770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T, Bannai S. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer. 2003;88:951&#x2013;956. doi: 10.1038/sj.bjc.6600786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6600786</ArticleId>
            <ArticleId IdType="pmc">PMC2377069</ArticleId>
            <ArticleId IdType="pubmed">12644836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pader I, Sengupta R, Cebula M, Xu J, Lundberg JO, Holmgren A, Johansson K, Arner ES. Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase. Proc Natl Acad Sci USA. 2014;111:6964&#x2013;6969. doi: 10.1073/pnas.1317320111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1317320111</ArticleId>
            <ArticleId IdType="pmc">PMC4024855</ArticleId>
            <ArticleId IdType="pubmed">24778250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374&#x2013;1395. doi: 10.15252/embr.201642195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201642195</ArticleId>
            <ArticleId IdType="pmc">PMC5048378</ArticleId>
            <ArticleId IdType="pubmed">27629041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27&#x2013;47. doi: 10.1016/j.cmet.2015.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2015.12.006</ArticleId>
            <ArticleId IdType="pmc">PMC4715268</ArticleId>
            <ArticleId IdType="pubmed">26771115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457&#x2013;2467. doi: 10.1158/0008-5472.CAN-11-2612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2612</ArticleId>
            <ArticleId IdType="pmc">PMC3354961</ArticleId>
            <ArticleId IdType="pubmed">22589270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao HX, Hao CJ, Li Y, He X, Chen RS, Cui J, Xu ZH, Li W. JNK activation mediates the apoptosis of xCT-deficient cells. Biochem Biophys Res Commun. 2008;370:584&#x2013;588. doi: 10.1016/j.bbrc.2008.03.134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2008.03.134</ArticleId>
            <ArticleId IdType="pubmed">18395005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21&#x2013;43. doi: 10.1016/j.ccell.2018.03.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.03.022</ArticleId>
            <ArticleId IdType="pmc">PMC6039250</ArticleId>
            <ArticleId IdType="pubmed">29731393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sanchez-Rivera FJ, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23:1362&#x2013;1368. doi: 10.1038/nm.4407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4407</ArticleId>
            <ArticleId IdType="pmc">PMC5677540</ArticleId>
            <ArticleId IdType="pubmed">28967920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274:11455&#x2013;11458. doi: 10.1074/jbc.274.17.11455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.17.11455</ArticleId>
            <ArticleId IdType="pubmed">10206947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Nomura S, Maebara K, Sato K, Tamba M, Bannai S. Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochem Biophys Res Commun. 2004;325:109&#x2013;116. doi: 10.1016/j.bbrc.2004.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2004.10.009</ArticleId>
            <ArticleId IdType="pubmed">15522208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem. 2005;280:37423&#x2013;37429. doi: 10.1074/jbc.M506439200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M506439200</ArticleId>
            <ArticleId IdType="pubmed">16144837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, Zavitsanou AM, et al. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife. 2017;6:e28083. doi: 10.7554/eLife.28083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.28083</ArticleId>
            <ArticleId IdType="pmc">PMC5624783</ArticleId>
            <ArticleId IdType="pubmed">28967864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW, Muller J. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465:243&#x2013;247. doi: 10.1038/nature08966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08966</ArticleId>
            <ArticleId IdType="pmc">PMC3182123</ArticleId>
            <ArticleId IdType="pubmed">20436459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54:728&#x2013;736. doi: 10.1016/j.molcel.2014.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2014.05.016</ArticleId>
            <ArticleId IdType="pmc">PMC4236231</ArticleId>
            <ArticleId IdType="pubmed">24905006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin CS, Mishra P, Watrous JD, Carelli V, D&#x2019;Aurelio M, Jain M, Chan DC. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074. doi: 10.1038/ncomms15074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15074</ArticleId>
            <ArticleId IdType="pmc">PMC5413954</ArticleId>
            <ArticleId IdType="pubmed">28429737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin SS, Jeong BS, Wall BA, Li J, Shan NL, Wen Y, Goydos JS, Chen S. Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo. Oncogenesis. 2018;7:86. doi: 10.1038/s41389-018-0098-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41389-018-0098-7</ArticleId>
            <ArticleId IdType="pmc">PMC6234219</ArticleId>
            <ArticleId IdType="pubmed">30425240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart MD, Li J, Wong J. Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol. 2005;25:2525&#x2013;2538. doi: 10.1128/MCB.25.7.2525-2538.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.25.7.2525-2538.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1061631</ArticleId>
            <ArticleId IdType="pubmed">15767660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr. 2004;24:539&#x2013;577. doi: 10.1146/annurev.nutr.24.012003.132418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.nutr.24.012003.132418</ArticleId>
            <ArticleId IdType="pubmed">15189131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stipanuk MH, Dominy JE, Jr, Lee JI, Coloso RM. Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism. J Nutr. 2006;136:1652S&#x2013;1659S. doi: 10.1093/jn/136.6.1652S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jn/136.6.1652S</ArticleId>
            <ArticleId IdType="pubmed">16702335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Jiang X. The chemistry and biology of ferroptosis. Cell Chem Biol. 2020;27:365&#x2013;375. doi: 10.1016/j.chembiol.2020.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2020.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC7204503</ArticleId>
            <ArticleId IdType="pubmed">32294465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui S, Zhang J, Xu S, Wang Q, Wang P, Pang D. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis. 2019;10:331. doi: 10.1038/s41419-019-1564-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1564-7</ArticleId>
            <ArticleId IdType="pmc">PMC6465411</ArticleId>
            <ArticleId IdType="pubmed">30988278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van &#x2018;t Veer LJ, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450&#x2013;465. doi: 10.1016/j.ccr.2013.08.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.08.020</ArticleId>
            <ArticleId IdType="pmc">PMC3931310</ArticleId>
            <ArticleId IdType="pubmed">24094812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579&#x2013;591. doi: 10.1038/nrd2803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd2803</ArticleId>
            <ArticleId IdType="pubmed">19478820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-) Cancer Res. 2016;76:2954&#x2013;2963. doi: 10.1158/0008-5472.CAN-15-2121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-15-2121</ArticleId>
            <ArticleId IdType="pmc">PMC4873328</ArticleId>
            <ArticleId IdType="pubmed">26980765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029&#x2013;1033. doi: 10.1126/science.1160809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1160809</ArticleId>
            <ArticleId IdType="pmc">PMC2849637</ArticleId>
            <ArticleId IdType="pubmed">19460998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413&#x2013;431. doi: 10.1016/j.cell.2009.04.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.04.037</ArticleId>
            <ArticleId IdType="pubmed">19410540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y. Role of histone H2A ubiquitination in Polycomb silencing. Nature. 2004;431:873&#x2013;878. doi: 10.1038/nature02985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature02985</ArticleId>
            <ArticleId IdType="pubmed">15386022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SJ, Li D, Ou Y, Jiang L, Chen Y, Zhao Y, Gu W. Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 2016;17:366&#x2013;373. doi: 10.1016/j.celrep.2016.09.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.09.022</ArticleId>
            <ArticleId IdType="pmc">PMC5227654</ArticleId>
            <ArticleId IdType="pubmed">27705786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018;173(1413&#x2013;1425):e1414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29754815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Yang L, Zhang X, Cui W, Liu Y, Sun QR, He Q, Zhao S, Zhang GA, Wang Y, et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 2019;20:e47563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6607012</ArticleId>
            <ArticleId IdType="pubmed">31267712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF, Zhang J, Wang H, Chen X, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc() Cell Death Differ. 2020;27:662&#x2013;675. doi: 10.1038/s41418-019-0380-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0380-z</ArticleId>
            <ArticleId IdType="pmc">PMC7206049</ArticleId>
            <ArticleId IdType="pubmed">31273299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhao Y, Wang H, Zhang C, Wang M, Yang Y, Xu X, Hu Z. Histone demethylase KDM3B protects against ferroptosis by upregulating SLC7A11. FEBS Open Biol. 2020;10:637&#x2013;643. doi: 10.1002/2211-5463.12823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/2211-5463.12823</ArticleId>
            <ArticleId IdType="pmc">PMC7137800</ArticleId>
            <ArticleId IdType="pubmed">32107878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Sun X, Song B, Qiu X, Zhao J. MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion. Cancer Med. 2017;6:1686&#x2013;1697. doi: 10.1002/cam4.1110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1110</ArticleId>
            <ArticleId IdType="pmc">PMC5504333</ArticleId>
            <ArticleId IdType="pubmed">28627030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie L, Song X, Yu J, Guo W, Wei L, Liu Y, Wang X. Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer. J Cancer Res Clin Oncol. 2011;137:1739&#x2013;1747. doi: 10.1007/s00432-011-1050-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-011-1050-9</ArticleId>
            <ArticleId IdType="pubmed">21909646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012;3:883. doi: 10.1038/ncomms1892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms1892</ArticleId>
            <ArticleId IdType="pubmed">22673910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi I, Yoshimura SH, Katoh H. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11) J Biol Chem. 2020;295:6936&#x2013;6945. doi: 10.1074/jbc.RA119.012213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA119.012213</ArticleId>
            <ArticleId IdType="pmc">PMC7242691</ArticleId>
            <ArticleId IdType="pubmed">32265299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Yee D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC. Cancer Res. 2014;74:2295&#x2013;2305. doi: 10.1158/0008-5472.CAN-13-1803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1803</ArticleId>
            <ArticleId IdType="pmc">PMC4006361</ArticleId>
            <ArticleId IdType="pubmed">24686172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yant LJ, Ran Q, Rao L, Van Remmen H, Shibatani T, Belter JG, Motta L, Richardson A, Prolla TA. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med. 2003;34:496&#x2013;502. doi: 10.1016/S0891-5849(02)01360-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0891-5849(02)01360-6</ArticleId>
            <ArticleId IdType="pubmed">12566075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye P, Mimura J, Okada T, Sato H, Liu T, Maruyama A, Ohyama C, Itoh K. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol. 2014;34:3421&#x2013;3434. doi: 10.1128/MCB.00221-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00221-14</ArticleId>
            <ArticleId IdType="pmc">PMC4135628</ArticleId>
            <ArticleId IdType="pubmed">25002527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye LF, Chaudhary KR, Zandkarimi F, Harken AD, Kinslow CJ, Upadhyayula PS, Dovas A, Higgins DM, Tan H, Zhang Y, et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem Biol. 2020;15:469&#x2013;484. doi: 10.1021/acschembio.9b00939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.9b00939</ArticleId>
            <ArticleId IdType="pmc">PMC7180072</ArticleId>
            <ArticleId IdType="pubmed">31899616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73:1855&#x2013;1866. doi: 10.1158/0008-5472.CAN-12-3609-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3609-T</ArticleId>
            <ArticleId IdType="pubmed">23319806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14:276&#x2013;286. doi: 10.1038/ncb2432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2432</ArticleId>
            <ArticleId IdType="pmc">PMC3290742</ArticleId>
            <ArticleId IdType="pubmed">22344033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Huang Y, Ling J, Zhuo W, Yu Z, Luo Y, Zhu Y. Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma. Fut Oncol. 2018;14:927&#x2013;936. doi: 10.2217/fon-2017-0540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon-2017-0540</ArticleId>
            <ArticleId IdType="pubmed">29528250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181&#x2013;1192. doi: 10.1038/s41556-018-0178-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0178-0</ArticleId>
            <ArticleId IdType="pmc">PMC6170713</ArticleId>
            <ArticleId IdType="pubmed">30202049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Koppula P, Gan B. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle. 2019;18:773&#x2013;783. doi: 10.1080/15384101.2019.1597506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384101.2019.1597506</ArticleId>
            <ArticleId IdType="pmc">PMC6527290</ArticleId>
            <ArticleId IdType="pubmed">30907299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, Uchida K, O&#x2019;Connor OA, Stockwell BR. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019;226:623. doi: 10.1016/j.chembiol.2019.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2019.01.008</ArticleId>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhuang L, Gan B. BAP1 suppresses tumor development by inducing ferroptosis upon SLC7A11 repression. Mol Cell Oncol. 2019;6:1536845. doi: 10.1080/23723556.2018.1536845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/23723556.2018.1536845</ArticleId>
            <ArticleId IdType="pmc">PMC6370386</ArticleId>
            <ArticleId IdType="pubmed">30788415</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32958404</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-499X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Trends in molecular medicine</Title>
          <ISOAbbreviation>Trends Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting Ferroptosis: New Hope for As-Yet-Incurable Diseases.</ArticleTitle>
        <Pagination>
          <StartPage>113</StartPage>
          <EndPage>122</EndPage>
          <MedlinePgn>113-122</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molmed.2020.08.010</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1471-4914(20)30215-X</ELocationID>
        <Abstract>
          <AbstractText>Attaining control over life and death decisions facilitates the identification of new therapeutic strategies for diseases affected by early cell loss or resistance to cell death. In this context, ferroptosis, a prevailing form of non-apoptotic cell death marked by the iron-dependent oxidative destruction of lipid bilayers and metabolic aberrations, has attracted overwhelming interest among basic researchers and clinicians due to its relevance for a number of degenerative diseases, such as neurodegeneration, ischemia/reperfusion injury (IRI), and organ failure, as well as therapy-resistant tumors. As the ferroptotic death pathway offers various druggable nodes, it is anticipated that the preclinical and clinical development of ferroptosis modulators will unleash unprecedented opportunities for the treatment of as-yet-incurable diseases.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Conrad</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Metabolism and Cell Death, Helmholtz Zentrum Mnchen, Ingolstdter Landstr. 1, 85764 Neuherberg, Germany; National Research Medical University, Laboratory of Experimental Oncology, Ostrovityanova 1, Moscow 117997, Russia. Electronic address: marcus.conrad@helmholtz-muenchen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lorenz</LastName>
            <ForeName>Svenja M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Metabolism and Cell Death, Helmholtz Zentrum Mnchen, Ingolstdter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Proneth</LastName>
            <ForeName>Bettina</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Metabolism and Cell Death, Helmholtz Zentrum Mnchen, Ingolstdter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Trends Mol Med</MedlineTA>
        <NlmUniqueID>100966035</NlmUniqueID>
        <ISSNLinking>1471-4914</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068456" MajorTopicYN="N">Clinical Studies as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">ischemia/reperfusion injury</Keyword>
        <Keyword MajorTopicYN="N">lipid peroxidation</Keyword>
        <Keyword MajorTopicYN="N">necroinflammation</Keyword>
        <Keyword MajorTopicYN="N">neurodegeneration</Keyword>
        <Keyword MajorTopicYN="N">regulated necrosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32958404</ArticleId>
        <ArticleId IdType="doi">10.1016/j.molmed.2020.08.010</ArticleId>
        <ArticleId IdType="pii">S1471-4914(20)30215-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32957040</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>79</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multiple modes of cell death in neuroendocrine tumors induced by artesunate.</ArticleTitle>
        <Pagination>
          <StartPage>153332</StartPage>
          <MedlinePgn>153332</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2020.153332</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(20)30164-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The paucity of effective treatment in neuroendocrine tumors (NETs) encouraged us to investigate the therapeutic value of artesunate (ART) promised by its inhibitory effect against various tumors and broad safety profile.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the impact of ART on three NET cell lines, BON-1, QGP-1 and NCI-H727 on cellular and molecular levels.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Our results showed that ART induced endoplasmic reticulum (ER) stress through phosphorylation of eIF2&#x3b1;, which further gave rise to autophagy in all three NET cell lines. Specifically, apoptosis and ferroptosis were also observed in BON-1 cells, which made BON-1 cell line more vulnerable upon ART treatment. The different sensitivities presented on the three cell lines also associated with a differential regulation of p21 on the long run. Co-treatment with p21 inhibitor UC2288 showed an additive effect on QGP-1 and NCI-H727 cell lines indicating p21 upregulation in these two cell lines might confer resistance towards ART treatment.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It is possible to include ART in the treatment of NETs in the future.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier GmbH. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Ge</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dawood</LastName>
            <ForeName>Mona</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bckers</LastName>
            <ForeName>Madeleine</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klauck</LastName>
            <ForeName>Sabine M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cancer Genome Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), National Center for Tumor Diseases (NCT), Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fottner</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolic Diseases, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>Matthias M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolic Diseases, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Efferth</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany. Electronic address: efferth@uni-mainz.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C582887">UC2288</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>25X51I8RD4</RegistryNumber>
          <NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>60W3249T9M</RegistryNumber>
          <NameOfSubstance UI="D000077332">Artesunate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077332" MajorTopicYN="N">Artesunate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059865" MajorTopicYN="N">Endoplasmic Reticulum Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018358" MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009536" MajorTopicYN="N">Niacinamide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Artesunate</Keyword>
        <Keyword MajorTopicYN="N">Cell death</Keyword>
        <Keyword MajorTopicYN="N">Cellular response</Keyword>
        <Keyword MajorTopicYN="N">Neuroendocrine</Keyword>
        <Keyword MajorTopicYN="N">Resistance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>20</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32957040</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2020.153332</ArticleId>
        <ArticleId IdType="pii">S0944-7113(20)30164-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32928919</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-7445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Iron and Cancer: 2020 Vision.</ArticleTitle>
        <Pagination>
          <StartPage>5435</StartPage>
          <EndPage>5448</EndPage>
          <MedlinePgn>5435-5448</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-20-2017</ELocationID>
        <Abstract>
          <AbstractText>New and provocative insights into the relationships between iron and cancer have been uncovered in recent years. These include delineation of connections that link cellular iron to DNA repair, genomic integrity, and oncogenic signaling as well as the discovery of ferroptosis, a novel iron-dependent form of cell death. In parallel, new molecules and pathways that regulate iron influx, intracellular iron trafficking, and egress in normal cells, and their perturbations in cancer have been discovered. In addition, insights into the unique properties of iron handling in tumor-initiating cells (cancer stem cells), novel contributions of the tumor microenvironment to the uptake and regulation of iron in cancer cells, and new therapeutic modalities that leverage the iron dependence of cancer have emerged.</AbstractText>
          <CopyrightInformation>&#xa9;2020 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Torti</LastName>
            <ForeName>Suzy V</ForeName>
            <Initials>SV</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, Connecticut. storti@uchc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Torti</LastName>
            <ForeName>Frank M</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA188025</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA233636</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of interest: The authors declare no potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32928919</ArticleId>
        <ArticleId IdType="mid">NIHMS1629439</ArticleId>
        <ArticleId IdType="pmc">PMC8118237</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-2017</ArticleId>
        <ArticleId IdType="pii">0008-5472.CAN-20-2017</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torti SV, Torti FM. Ironing out cancer. Cancer Res 2011;71:1511&#x2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079335</ArticleId>
            <ArticleId IdType="pubmed">21363917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013;13:342&#x2013;55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4036554</ArticleId>
            <ArticleId IdType="pubmed">23594855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu Rev Nutr 2018;38:97&#x2013;125</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8118195</ArticleId>
            <ArticleId IdType="pubmed">30130469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, Dean AE, Horikoshi N, Heer C, Spitz DR, Gius D. Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. J Clin Invest 2018;128:3682&#x2013;91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6118595</ArticleId>
            <ArticleId IdType="pubmed">30168803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117:285&#x2013;97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15109490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980;2:390&#x2013;2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6105517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galbraith GM, Galbraith RM, Faulk WP. Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol 1980;49:215&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6153155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A, et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 2010;6:602&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2907470</ArticleId>
            <ArticleId IdType="pubmed">20581821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asimakopoulou A, Weiskirchen S, Weiskirchen R. Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy. Front Physiol 2016;7:430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5037186</ArticleId>
            <ArticleId IdType="pubmed">27729871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008;108:389&#x2013;97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17554627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger T, Cheung CC, Elia AJ, Mak TW. Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci U S A 2010;107:2995&#x2013;3000</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840296</ArticleId>
            <ArticleId IdType="pubmed">20133630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tung MC, Hsieh SC, Yang SF, Cheng CW, Tsai RT, Wang SC, et al. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. Prostate 2013;73:1281&#x2013;90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23775308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding G, Wang J, Feng C, Jiang H, Xu J, Ding Q. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity. Oncotarget 2016;7:64309&#x2013;17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5325444</ArticleId>
            <ArticleId IdType="pubmed">27602760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005;123:1293&#x2013;305</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16377569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehwald C, Schnetz M, Urbschat A, Mertens C, Meier JK, Bauer R, et al. The iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in clear-cell renal cell carcinoma. Br J Cancer 2020;122:421&#x2013;33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7000824</ArticleId>
            <ArticleId IdType="pubmed">31772326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi Y, Remsik J, Kiseliovas V, Derderian C, Sener U, Alghader M, et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science 2020;369:276&#x2013;82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7816199</ArticleId>
            <ArticleId IdType="pubmed">32675368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung M, Oren B, Mora J, Mertens C, Dziumbla S, Popp R, et al. Lipocalin 2 from macrophages stimulated by tumor cell-derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis. Sci Signal 2016;9:ra64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27353364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oren B, Urosevic J, Mertens C, Mora J, Guiu M, Gomis RR, et al. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis. J Pathol 2016;239:274&#x2013;85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27038000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garrick MD, Dolan KG, Horbinski C, Ghio AJ, Higgins D, Porubcin M, et al. DMT1: a mammalian transporter for multiple metals. Biometals 2003;16:41&#x2013;54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12572663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brookes MJ, Hughes S, Turner FE, Reynolds G, Sharma N, Ismail T, et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 2006;55:1449&#x2013;60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1856421</ArticleId>
            <ArticleId IdType="pubmed">16641131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue X, Ramakrishnan SK, Weisz K, Triner D, Xie L, Attili D, et al. Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis. Cell Metab 2016;24:447&#x2013;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5023486</ArticleId>
            <ArticleId IdType="pubmed">27546461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senbanjo LT, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol 2017;5:18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5339222</ArticleId>
            <ArticleId IdType="pubmed">28326306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xfc;ller S, Sindikubwabo F, Ca&#xf1;eque T, Lafon A, Versini A, Lombard B, et al. CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nature Chemistry 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32747755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xfc;ller S, Sindikubwabo F, Ca&#xf1;eque T, Lafon A, Versini A, Lombard B, et al. CD44 regulates epigenetic plasticity by mediating iron endocytosis. bioRxiv 2019:693424</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32747755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourseau-Guilmain E, Griveau A, Benoit JP, Garcion E. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One 2011;6:e25515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3180456</ArticleId>
            <ArticleId IdType="pubmed">21966538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross AJ, Leitzmann MF, Gail MH, Hollenbeck AR, Schatzkin A, Sinha R. A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med 2007;4:e325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2121107</ArticleId>
            <ArticleId IdType="pubmed">18076279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loboda A, Jozkowicz A, Dulak J. HO-1/CO system in tumor growth, angiogenesis and metabolism - Targeting HO-1 as an anti-tumor therapy. Vascul Pharmacol 2015;74:11&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26392237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiorito V, Chiabrando D, Petrillo S, Bertino F, Tolosano E. The Multifaceted Role of Heme in Cancer. Front Oncol 2019;9:1540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6974621</ArticleId>
            <ArticleId IdType="pubmed">32010627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med 2019;133:101&#x2013;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30316781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao N, Zhang AS, Wortham AM, Jue S, Knutson MD, Enns CA. The Tumor Suppressor, P53, Decreases the Metal Transporter, ZIP14. Nutrients 2017;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5748785</ArticleId>
            <ArticleId IdType="pubmed">29292794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev 2009;23:95&#x2013;104</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2717717</ArticleId>
            <ArticleId IdType="pubmed">18835072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orino K, Lehman L, Tsuji Y, Ayaki H, Torti SV, Torti FM. Ferritin and the response to oxidative stress. Biochem J 2001;357:241&#x2013;7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1221947</ArticleId>
            <ArticleId IdType="pubmed">11415455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, Torti FM. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol 2000;20:5818&#x2013;27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86059</ArticleId>
            <ArticleId IdType="pubmed">10913165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, Torti FM. FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol 1995;15:5152&#x2013;64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC230762</ArticleId>
            <ArticleId IdType="pubmed">7651432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuji Y, Kwak E, Saika T, Torti SV, Torti FM. Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J Biol Chem 1993;268:7270&#x2013;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8463262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci U S A 1991;88:4946&#x2013;50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC51784</ArticleId>
            <ArticleId IdType="pubmed">2052577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 2014;509:105&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4180099</ArticleId>
            <ArticleId IdType="pubmed">24695223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 2014;16:1069&#x2013;79</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25327288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias JD, Pontano Vaites L, Nissim S, Biancur DE, Kim AJ, Wang X, et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife 2015;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4592949</ArticleId>
            <ArticleId IdType="pubmed">26436293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santana-Codina N, Mancias JD. The Role of NCOA4-Mediated Ferritinophagy in Health and Disease. Pharmaceuticals (Basel) 2018;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6316710</ArticleId>
            <ArticleId IdType="pubmed">30360520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016;12:1425&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, et al. RET rearrangements are actionable alterations in breast cancer. Nat Commun 2018;9:4821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6240119</ArticleId>
            <ArticleId IdType="pubmed">30446652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levinson S, Cagan RL. Drosophila Cancer Models Identify Functional Differences between Ret Fusions. Cell Rep 2016;16:3052&#x2013;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5858711</ArticleId>
            <ArticleId IdType="pubmed">27626672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn YS, Tamir S, Song L, Michaeli D, Matouk I, Conlan AR, et al. NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. Proc Natl Acad Sci U S A 2013;110:14676&#x2013;81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3767537</ArticleId>
            <ArticleId IdType="pubmed">23959881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Zhang Y, Cheng X, Yuan H, Zhu S, Liu J, et al. PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Dev Cell 2018;46:441&#x2013;55 e8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7654182</ArticleId>
            <ArticleId IdType="pubmed">30100261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang R, Xie Y, Zeh HJ, Klionsky DJ, Tang D. Mitochondrial quality control mediated by PINK1 and PRKN: links to iron metabolism and tumor immunity. Autophagy 2019;15:172&#x2013;3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6287677</ArticleId>
            <ArticleId IdType="pubmed">30252570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsarou A, Pantopoulos K. Basics and principles of cellular and systemic iron homeostasis. Mol Aspects Med 2020:100866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32564977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maffettone C, Chen G, Drozdov I, Ouzounis C, Pantopoulos K. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS One 2010;5:e10163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2854138</ArticleId>
            <ArticleId IdType="pubmed">20405006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, et al. IRP2 regulates breast tumor growth. Cancer Res 2014;74:497&#x2013;507</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989290</ArticleId>
            <ArticleId IdType="pubmed">24285726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Z, Manz DH, Torti SV, Torti FM. Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth. Oncotarget 2017;8:82231&#x2013;43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5669885</ArticleId>
            <ArticleId IdType="pubmed">29137259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Kong X, Zhang Y, Sun W, Xu E, Chen X. Mdm2 is a target and mediator of IRP2 in cell growth control. FASEB J 2020;34:2301&#x2013;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7018553</ArticleId>
            <ArticleId IdType="pubmed">31907996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Feng X, Zhang J, Chen X. Iron Regulatory Protein 2 Exerts its Oncogenic Activities by Suppressing TAp63 Expression. Mol Cancer Res 2020;18:1039&#x2013;49</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7749625</ArticleId>
            <ArticleId IdType="pubmed">32276991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, Eguchi H, et al. Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis. J Exp Med 2019;216:950&#x2013;65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6446870</ArticleId>
            <ArticleId IdType="pubmed">30877170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazawa M, Bogdan AR, Tsuji Y. Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2. Cell Chem Biol 2019;26:85&#x2013;97 e4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6338505</ArticleId>
            <ArticleId IdType="pubmed">30449675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinnix ZK, Miller LD, Wang W, D&#x2019;Agostino R Jr., Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010;2:43ra56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734848</ArticleId>
            <ArticleId IdType="pubmed">20686179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res 2015;75:2254&#x2013;63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4454355</ArticleId>
            <ArticleId IdType="pubmed">25858146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene 2017;36:4089&#x2013;99</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5540148</ArticleId>
            <ArticleId IdType="pubmed">28319068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D&#x2019;Agostino R Jr., et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011;71:6728&#x2013;37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3206152</ArticleId>
            <ArticleId IdType="pubmed">21875943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babu KR, Muckenthaler MU. miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl) 2016;94:347&#x2013;59</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4803811</ArticleId>
            <ArticleId IdType="pubmed">26560875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong Y, Hu L, Lu K, Wang Y, Xie Y, Gao L, et al. Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17&#x2013;5p axis in multiple myeloma. Cell Death Dis 2019;10:624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6698482</ArticleId>
            <ArticleId IdType="pubmed">31423010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu B, Zhi Q, Xie Q, Wu X, Gao Y, Chen X, et al. Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma. J Trace Elem Med Biol 2019;56:52&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31442954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, et al. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol 2019;14:616&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6554053</ArticleId>
            <ArticleId IdType="pubmed">30911166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YF, Zhang J, Su Y, Shen YY, Jiang DX, Hou YY, et al. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun 2017;8:274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5561105</ArticleId>
            <ArticleId IdType="pubmed">28819251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010;116:1574&#x2013;84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20472835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truman-Rosentsvit M, Berenbaum D, Spektor L, Cohen LA, Belizowsky-Moshe S, Lifshitz L, et al. Ferritin is secreted via 2 distinct nonclassical vesicular pathways. Blood 2018;131:342&#x2013;52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5774206</ArticleId>
            <ArticleId IdType="pubmed">29074498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown CW, Amante JJ, Chhoy P, Elaimy AL, Liu H, Zhu LJ, et al. Prominin2 Drives Ferroptosis Resistance by Stimulating Iron Export. Dev Cell 2019;51:575&#x2013;86 e4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31735663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher J, Devraj K, Ingram J, Slagle-Webb B, Madhankumar AB, Liu X, et al. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol 2007;293:C641&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17459943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, et al. Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One 2011;6:e23800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3158792</ArticleId>
            <ArticleId IdType="pubmed">21886823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Fang CJ, Ryan JC, Niemi EC, Lebron JA, Bjorkman PJ, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A 2010;107:3505&#x2013;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840523</ArticleId>
            <ArticleId IdType="pubmed">20133674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todorich B, Zhang X, Slagle-Webb B, Seaman WE, Connor JR. Tim-2 is the receptor for H-ferritin on oligodendrocytes. J Neurochem 2008;107:1495&#x2013;505</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19014383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen TT, Li L, Chung DH, Allen CD, Torti SV, Torti FM, et al. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med 2005;202:955&#x2013;65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213179</ArticleId>
            <ArticleId IdType="pubmed">16203866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moussa RS, Kovacevic Z, Bae DH, Lane DJR, Richardson DR. Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21(CIP1/WAF1), by the chelator, Dp44mT. Biochim Biophys Acta Gen Subj 2018;1862:761&#x2013;74</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29032246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Z, Manz DH, Torti SV, Torti FM. Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer. Antioxid Redox Signal 2019;30:1043&#x2013;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6354616</ArticleId>
            <ArticleId IdType="pubmed">29061069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuss JO, Tsai CL, Ishida JP, Tainer JA. Emerging critical roles of Fe-S clusters in DNA replication and repair. Biochim Biophys Acta 2015;1853:1253&#x2013;71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4576882</ArticleId>
            <ArticleId IdType="pubmed">25655665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abeysinghe RD, Greene BT, Haynes R, Willingham MC, Turner J, Planalp RP, et al. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2001;22:1607&#x2013;14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11576999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004;104:1450&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15150082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, et al. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 2012;4:93&#x2013;108</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3306556</ArticleId>
            <ArticleId IdType="pubmed">22246988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li P, Zheng X, Shou K, Niu Y, Jian C, Zhao Y, et al. The iron chelator Dp44mT suppresses osteosarcoma&#x2019;s proliferation, invasion and migration: in vitro and in vivo. Am J Transl Res 2016;8:5370&#x2013;85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5209489</ArticleId>
            <ArticleId IdType="pubmed">28078009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding F, Zhang L, Chen H, Song H, Chen S, Xiao H. Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis. Nanoscale Horiz 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32364553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, et al. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020;20:681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7374870</ArticleId>
            <ArticleId IdType="pubmed">32698792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo W, Zhang S, Chen Y, Zhang D, Yuan L, Cong H, et al. An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim Biophys Sin (Shanghai) 2015;47:703&#x2013;15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26201356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004;104:2967&#x2013;75</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15251988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev 2001;59:140&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11396694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brookes MJ, Boult J, Roberts K, Cooper BT, Hotchin NA, Matthews G, et al. A role for iron in Wnt signalling. Oncogene 2008;27:966&#x2013;75</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17700530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 2011;71:7628&#x2013;39</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22009536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, et al. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 2012;31:213&#x2013;25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3257471</ArticleId>
            <ArticleId IdType="pubmed">21666721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang Y, Guo W, Ling J, Xu D, Liao Y, Zhao H, et al. Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway. Cell Death Dis 2019;10:297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6443808</ArticleId>
            <ArticleId IdType="pubmed">30931929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Zhang J, Song F, Tian M, Shi B, Jiang H, et al. EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett 2016;381:331&#x2013;40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27523281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park KC, Paluncic J, Kovacevic Z, Richardson DR. Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radic Biol Med 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31132412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menezes SV, Sahni S, Kovacevic Z, Richardson DR. Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. J Biol Chem 2017;292:12772&#x2013;82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5546018</ArticleId>
            <ArticleId IdType="pubmed">28615452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaomongkolgit R, Cheepsunthorn P, Pavasant P, Sanchavanakit N. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol 2008;44:587&#x2013;94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17936676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011;12:9&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401912</ArticleId>
            <ArticleId IdType="pubmed">22169972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997;272:5375&#x2013;81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9038135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275:21048&#x2013;54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10777486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274:24142&#x2013;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10446187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson SA, Nizzi CP, Chang YI, Deck KM, Schmidt PJ, Galy B, et al. The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab 2013;17:282&#x2013;90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3612289</ArticleId>
            <ArticleId IdType="pubmed">23395174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta 2010;1800:760&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2893236</ArticleId>
            <ArticleId IdType="pubmed">20304033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009;49:887&#x2013;900</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2701483</ArticleId>
            <ArticleId IdType="pubmed">19241483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertoli S, Paubelle E, Berard E, Saland E, Thomas X, Tavitian S, et al. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. Eur J Haematol 2019;102:131&#x2013;42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30325535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu KJ, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 1999;283:676&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9924025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 2006;26:2373&#x2013;86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1430295</ArticleId>
            <ArticleId IdType="pubmed">16508012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep 2014;7:180&#x2013;93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4219651</ArticleId>
            <ArticleId IdType="pubmed">24685134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen J, Sheng X, Chang Z, Wu Q, Xie D, Wang F, et al. The heme-p53 interaction: Linking iron metabolism to p53 signaling and tumorigenesis. Mol Cell Oncol 2016;3:e965642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4845248</ArticleId>
            <ArticleId IdType="pubmed">27308524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dongiovanni P, Fracanzani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, et al. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 2010;176:1006&#x2013;17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2808103</ArticleId>
            <ArticleId IdType="pubmed">20019189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 2008;283:33911&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2590700</ArticleId>
            <ArticleId IdType="pubmed">18819919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funauchi Y, Tanikawa C, Yi Lo PH, Mori J, Daigo Y, Takano A, et al. Regulation of iron homeostasis by the p53-ISCU pathway. Sci Rep 2015;5:16497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4642350</ArticleId>
            <ArticleId IdType="pubmed">26560363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson Jt, Pietsch EC, Torti SV, Torti FM. Ferritin regulation by oxidants and chemopreventive xenobiotics. Adv Enzyme Regul 2003;43:135&#x2013;51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12791388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pietsch EC, Chan JY, Torti FM, Torti SV. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 2003;278:2361&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12435735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerins MJ, Ooi A. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep 2018;8:12846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6110754</ArticleId>
            <ArticleId IdType="pubmed">30150714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakhlon O, Gruenbaum Y, Cabantchik ZI. Repression of ferritin expression modulates cell responsiveness to H-ras-induced growth. Biochem Soc Trans 2002;30:777&#x2013;80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12196194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakhlon O, Gruenbaum Y, Cabantchik ZI. Ferritin expression modulates cell cycle dynamics and cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. Biochem J 2002;363:431&#x2013;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1222495</ArticleId>
            <ArticleId IdType="pubmed">11964143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauckman KA, Haller E, Flores I, Nanjundan M. Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis 2013;4:e592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3668627</ArticleId>
            <ArticleId IdType="pubmed">23598404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rockfield S, Kee Y, Nanjundan M. Chronic iron exposure and c-Myc/H-ras-mediated transformation in fallopian tube cells alter the expression of EVI1, amplified at 3q26.2 in ovarian cancer. Oncogenesis 2019;8:46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6704182</ArticleId>
            <ArticleId IdType="pubmed">31434871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 2017;14:611&#x2013;29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5720366</ArticleId>
            <ArticleId IdType="pubmed">28397828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, et al. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell 2015;28:441&#x2013;55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4646058</ArticleId>
            <ArticleId IdType="pubmed">26461092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanojia D, Zhou W, Zhang J, Jie C, Lo PK, Wang Q, et al. Proteomic profiling of cancer stem cells derived from primary tumors of HER2/Neu transgenic mice. Proteomics 2012;12:3407&#x2013;15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22997041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobello N, Biamonte F, Pisanu ME, Faniello MC, Jakopin Z, Chiarella E, et al. Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. Oncotarget 2016;7:62019&#x2013;33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5308708</ArticleId>
            <ArticleId IdType="pubmed">27566559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aversa I, Zolea F, Ierano C, Bulotta S, Trotta AM, Faniello MC, et al. Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. J Exp Clin Cancer Res 2017;36:104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5543736</ArticleId>
            <ArticleId IdType="pubmed">28774348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, et al. Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Sci Rep 2017;7:17667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5732280</ArticleId>
            <ArticleId IdType="pubmed">29247214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. Am J Physiol Cell Physiol 2016;310:C728&#x2013;39</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26911281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domenici G, Aurrekoetxea-Rodriguez I, Simoes BM, Rabano M, Lee SY, Millan JS, et al. A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene 2019;38:3151&#x2013;69</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6756022</ArticleId>
            <ArticleId IdType="pubmed">30622340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ninomiya T, Ohara T, Noma K, Katsura Y, Katsube R, Kashima H, et al. Iron depletion is a novel therapeutic strategy to target cancer stem cells. Oncotarget 2017;8:98405&#x2013;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5716739</ArticleId>
            <ArticleId IdType="pubmed">29228699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recalcati S, Gammella E, Cairo G. Dysregulation of iron metabolism in cancer stem cells. Free Radic Biol Med 2019;133:216&#x2013;20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30040994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsura Y, Ohara T, Noma K, Ninomiya T, Kashima H, Kato T, et al. A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness. Cancers (Basel) 2019;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6406536</ArticleId>
            <ArticleId IdType="pubmed">30717462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rychtarcikova Z, Lettlova S, Tomkova V, Korenkova V, Langerova L, Simonova E, et al. Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget 2017;8:6376&#x2013;98</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5351639</ArticleId>
            <ArticleId IdType="pubmed">28031527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplagne C, Domagala M, Le Naour A, Quemerais C, Hamel D, Fournie JJ, et al. Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. Int J Mol Sci 2019;20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6801830</ArticleId>
            <ArticleId IdType="pubmed">31547627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills CD, Lenz LL, Harris RA. A Breakthrough: Macrophage-Directed Cancer Immunotherapy. Cancer Res 2016;76:513&#x2013;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4738030</ArticleId>
            <ArticleId IdType="pubmed">26772756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recalcati S, Gammella E, Cairo G. Ironing out Macrophage Immunometabolism. Pharmaceuticals (Basel) 2019;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6631308</ArticleId>
            <ArticleId IdType="pubmed">31248155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, De Pizzol M, et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol 2010;40:824&#x2013;35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques O, Porto G, Rema A, Faria F, Cruz Paula A, Gomez-Lazaro M, et al. Local iron homeostasis in the breast ductal carcinoma microenvironment. BMC Cancer 2016;16:187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4779214</ArticleId>
            <ArticleId IdType="pubmed">26944411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leftin A, Ben-Chetrit N, Joyce JA, Koutcher JA. Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy. Sci Rep 2019;9:857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6351660</ArticleId>
            <ArticleId IdType="pubmed">30696910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan X, He K, Li J, Cheng M, Song H, Liu J, et al. Tumor associated macrophages deliver iron to tumor cells via Lcn2. Int J Physiol Pathophysiol Pharmacol 2018;10:105&#x2013;14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5943609</ArticleId>
            <ArticleId IdType="pubmed">29755643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffman LG, Parsonage D, D&#x2019;Agostino R Jr., Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A 2009;106:570&#x2013;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2626744</ArticleId>
            <ArticleId IdType="pubmed">19126685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffman LG, Brown JC, Johnson DA, Parthasarathy N, D&#x2019;Agostino RB Jr., Lively MO, et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol 2008;294:L505&#x2013;15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18192590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agoro R, Taleb M, Quesniaux VFJ, Mura C. Cell iron status influences macrophage polarization. PLoS One 2018;13:e0196921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5957380</ArticleId>
            <ArticleId IdType="pubmed">29771935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Que KT, Zhang Z, Yi ZJ, Zhao PX, You Y, et al. Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. Cancer Med 2018;7:4012&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6089144</ArticleId>
            <ArticleId IdType="pubmed">29989329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM, et al. Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. Front Immunol 2017;8:1479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5682327</ArticleId>
            <ArticleId IdType="pubmed">29167669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 2019;569:270&#x2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchette-Farra N, Kita D, Konstorum A, Tesfay L, Lemler D, Hegde P, et al. Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. Oncogene 2018;37:4013&#x2013;32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6054540</ArticleId>
            <ArticleId IdType="pubmed">29695834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392&#x2013;401</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16572188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo HF, Tsai CL, Terajima M, Tan X, Banerjee P, Miller MD, et al. Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe(2+)-binding. Nat Commun 2018;9:512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5802723</ArticleId>
            <ArticleId IdType="pubmed">29410444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R. C. Iron Metabolism: from Molecular Mechanisms to Clinical Consequences. John Wiley and Sons; 2009. p 17&#x2013;58.</Citation>
        </Reference>
        <Reference>
          <Citation>Koppenol WH, Hider RH. Iron and redox cycling. Do&#x2019;s and don&#x165;s. Free Radic Biol Med 2019;133:3&#x2013;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30236787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060&#x2013;72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med 2019;133:130&#x2013;43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The Hallmarks of Ferroptosis. Annual Review of Cancer Biology 2019;3:35&#x2013;54</Citation>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008;15:234&#x2013;45</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris G, Walker AJ, Berk M, Maes M, Puri BK. Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. Mol Neurobiol 2018;55:5767&#x2013;86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5994217</ArticleId>
            <ArticleId IdType="pubmed">29052145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017;171:273&#x2013;85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewerenz J, Ates G, Methner A, Conrad M, Maher P. Oxytosis/Ferroptosis-(Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System. Front Neurosci 2018;12:214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5920049</ArticleId>
            <ArticleId IdType="pubmed">29731704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156:317&#x2013;31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell Chem Biol 2019;26:420&#x2013;32 e9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6430697</ArticleId>
            <ArticleId IdType="pubmed">30686757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, et al. Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death. Cancer Res 2019;79:5355&#x2013;66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6801059</ArticleId>
            <ArticleId IdType="pubmed">31270077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis 2020;11:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6997353</ArticleId>
            <ArticleId IdType="pubmed">32015325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 2019;572:402&#x2013;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, Kang R, Tang D. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem Biophys Res Commun 2016;478:838&#x2013;44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27510639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim EH, Shin D, Lee J, Jung AR, Roh JL. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Cancer Lett 2018;432:180&#x2013;90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29928961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie G, Chen G, Sheftel AD, Pantopoulos K, Ponka P. In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood 2006;108:2428&#x2013;34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16757684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YQ, Chang SY, Wu Q, Gou YJ, Jia L, Cui YM, et al. The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. Front Aging Neurosci 2016;8:308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5167726</ArticleId>
            <ArticleId IdType="pubmed">28066232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayir H, Anthonymuthu TS, Tyurina YY, Patel SJ, Amoscato AA, Lamade AM, et al. Achieving Life through Death: Redox Biology of Lipid Peroxidation in Ferroptosis. Cell Chem Biol 2020;27:387&#x2013;408</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7218794</ArticleId>
            <ArticleId IdType="pubmed">32275865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 2017;13:81&#x2013;90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forcina GC, Dixon SJ. GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis. Proteomics 2019;19:e1800311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30888116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoyanovsky DA, Tyurina YY, Shrivastava I, Bahar I, Tyurin VA, Protchenko O, et al. Iron catalysis of lipid peroxidation in ferroptosis: Regulated enzymatic or random free radical reaction? Free Radic Biol Med 2019;133:153&#x2013;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6555767</ArticleId>
            <ArticleId IdType="pubmed">30217775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al. PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell 2017;171:628&#x2013;41 e26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5683852</ArticleId>
            <ArticleId IdType="pubmed">29053969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyington JC, Gaffney BJ, Amzel LM. The three-dimensional structure of an arachidonic acid 15-lipoxygenase. Science 1993;260:1482&#x2013;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8502991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JM, Lee H, Kang S, Park WJ. Fatty Acid Desaturases, Polyunsaturated Fatty Acid Regulation, and Biotechnological Advances. Nutrients 2016;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4728637</ArticleId>
            <ArticleId IdType="pubmed">26742061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014;16:1180&#x2013;91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 1997;248:31&#x2013;40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9177722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hider RC, Kong XL. Glutathione: a key component of the cytoplasmic labile iron pool. Biometals 2011;24:1179&#x2013;87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21769609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel SJ, Frey AG, Palenchar DJ, Achar S, Bullough KZ, Vashisht A, et al. A PCBP1-BolA2 chaperone complex delivers iron for cytosolic [2Fe-2S] cluster assembly. Nat Chem Biol 2019;15:872&#x2013;81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6702080</ArticleId>
            <ArticleId IdType="pubmed">31406370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philpott CC, Jadhav S. The ins and outs of iron: Escorting iron through the mammalian cytosol. Free Radic Biol Med 2019;133:112&#x2013;7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30321701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philpott CC, Ryu MS, Frey A, Patel S. Cytosolic iron chaperones: Proteins delivering iron cofactors in the cytosol of mammalian cells. J Biol Chem 2017;292:12764&#x2013;71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5546017</ArticleId>
            <ArticleId IdType="pubmed">28615454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng N, Shi BJ, Li SL, Zhong ZY, Li YC, Xua WL, et al. Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci 2018;22:3826&#x2013;36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29949159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mai TT, Hamai A, Hienzsch A, Caneque T, Muller S, Wicinski J, et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem 2017;9:1025&#x2013;33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890907</ArticleId>
            <ArticleId IdType="pubmed">28937680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, Schorpp K, Jin J, Yozwiak CE, Hoffstrom BG, Decker AM, et al. Transferrin Receptor Is a Specific Ferroptosis Marker. Cell Rep 2020;30:3411&#x2013;23 e7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7172030</ArticleId>
            <ArticleId IdType="pubmed">32160546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiland A, Wang Y, Wu W, Lan X, Han X, Li Q, et al. Ferroptosis and Its Role in Diverse Brain Diseases. Mol Neurobiol 2019;56:4880&#x2013;93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506411</ArticleId>
            <ArticleId IdType="pubmed">30406908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 2019;575:688&#x2013;92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-Dependent Ferroptosis: Machinery and Regulation. Cell Chem Biol 2020;27:420&#x2013;35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7166192</ArticleId>
            <ArticleId IdType="pubmed">32160513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai E, Han L, Liu J, Xie Y, Kroemer G, Klionsky DJ, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy 2020:1&#x2013;15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7595620</ArticleId>
            <ArticleId IdType="pubmed">31920150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer 2017;17:528&#x2013;42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5975367</ArticleId>
            <ArticleId IdType="pubmed">28751651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merlot AM, Kalinowski DS, Kovacevic Z, Jansson PJ, Sahni S, Huang ML, et al. Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents. Curr Med Chem 2019;26:302&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28685681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov 2017;16:400&#x2013;23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5455971</ArticleId>
            <ArticleId IdType="pubmed">28154410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987;69:757&#x2013;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3493042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011;365:576&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21830988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, et al. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 2009;84:170&#x2013;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19140186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chitambar CR. Gallium Complexes as Anticancer Drugs. Met Ions Life Sci 2018;18</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29394029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chitambar CR. The therapeutic potential of iron-targeting gallium compounds in human disease: From basic research to clinical application. Pharmacol Res 2017;115:56&#x2013;64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27856328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf JS, Li G, Varadhachary A, Petrak K, Schneyer M, Li D, et al. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res 2007;13:1601&#x2013;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1810394</ArticleId>
            <ArticleId IdType="pubmed">17332307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moastafa TM, El-Sissy Ael D, El-Saeed GK, Koura MS. Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy. Int Sch Res Notices 2014;2014:184278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4897438</ArticleId>
            <ArticleId IdType="pubmed">27350986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603&#x2013;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2990475</ArticleId>
            <ArticleId IdType="pubmed">20840865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti SV, Torti FM. Winning the war with iron. Nat Nanotechnol 2019;14:499&#x2013;500</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8118198</ArticleId>
            <ArticleId IdType="pubmed">30911165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, et al. O2(-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 2017;32:268</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28810149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen BG, Bodeker KL, Smith MC, Monga V, Sandhu S, Hohl R, et al. First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. Clin Cancer Res 2019;25:6590&#x2013;7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6858950</ArticleId>
            <ArticleId IdType="pubmed">31427282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turcu AL, Versini A, Khene N, Gaillet C, Caneque T, Muller S, et al. DMT1 Inhibitors Kill Cancer Stem Cells by Blocking Lysosomal Iron Translocation. Chemistry 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32083771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820:291&#x2013;317</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3500658</ArticleId>
            <ArticleId IdType="pubmed">21851850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniels-Wells TR, Penichet ML. Transferrin receptor 1: a target for antibody-mediated cancer therapy. Immunotherapy 2016;8:991&#x2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27373880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SS, Harford JB, Moghe M, Rait A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 2018;46:1424&#x2013;40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5815062</ArticleId>
            <ArticleId IdType="pubmed">29202181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim LY, Koh PY, Somani S, Al Robaian M, Karim R, Yean YL, et al. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomedicine 2015;11:1445&#x2013;54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509555</ArticleId>
            <ArticleId IdType="pubmed">25933695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chifman J, Arat S, Deng Z, Lemler E, Pino JC, Harris LA, et al. Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective. PLoS Comput Biol 2017;13:e1005352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5293201</ArticleId>
            <ArticleId IdType="pubmed">28166223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konstorum A, Lynch ML, Torti SV, Torti FM, Laubenbacher RC. A Systems Biology Approach to Understanding the Pathophysiology of High-Grade Serous Ovarian Cancer: Focus on Iron and Fatty Acid Metabolism. OMICS 2018;22:502&#x2013;13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6059353</ArticleId>
            <ArticleId IdType="pubmed">30004845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konstorum A, Tesfay L, Paul BT, Torti FM, Laubenbacher RC, Torti SV. Systems biology of ferroptosis: A modeling approach. J Theor Biol 2020;493:110222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7254156</ArticleId>
            <ArticleId IdType="pubmed">32114023</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32884256</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1178-2013</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>International journal of nanomedicine</Title>
          <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zinc Oxide Nanoparticles Induce Ferroptotic Neuronal Cell Death in vitro and in vivo.</ArticleTitle>
        <Pagination>
          <StartPage>5299</StartPage>
          <EndPage>5315</EndPage>
          <MedlinePgn>5299-5315</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S250367</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Zinc oxide nanoparticles (ZnONPs) are one of the most important nanomaterials that are widely used in the food, cosmetic and medical industries. Humans are often exposed to ZnONPs via inhalation, and they may reach the brain where neurotoxic effects could occur via systemic distribution. However, the mechanisms underlying how ZnONPs produce neurotoxic effects in the brain remain unclear. In this study, we aimed to investigate the novel mechanism involved in ZnONPs-induced neurotoxicity.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We demonstrated for the first time that pulmonary exposure to ZnONPs by intratracheal instillation could trigger ferroptosis, a new form of cell death, in the neuronal cells of mouse cerebral cortex. A similar phenomenon was also observed in cultured neuron-like PC-12 cell line. By using a specific inhibitor of ferroptosis ferrostatin-1 (Fer-1), our results showed that inhibition of ferroptosis by Fer-1 could significantly alleviate the ZnONPs-induced neuronal cell death both in vivo and in vitro. Mechanistic investigation revealed that ZnONPs selectively activated the JNK pathway and thus resulted in the ferroptotic phenotypes, JNK inhibitor SP600125 could reverse lipid peroxidation upregulation and ferroptotic cell death induced by ZnONPs in PC-12 cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Taken together, this study not only demonstrates that pulmonary exposure of ZnONPs can induce JNK-involved ferroptotic cell death in mouse cortex and PC-12 cells, but also provides a clue that inhibition of ferroptosis by specific agents or drugs may serve as a feasible approach for reducing the untreatable neurotoxicity induced by ZnONPs.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 Qin et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Qin</LastName>
            <ForeName>Xia</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tang</LastName>
            <ForeName>Qianghu</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xuejun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Experimental Teaching for Public Health, Experimental Teaching and Management Center, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-5843-8705</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0003-0225-9393</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xuemei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yandan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-1651-591X</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dongsheng Lung-Brain Disease Joint Lab, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chengzhi</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-1087-4911</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dongsheng Lung-Brain Disease Joint Lab, Chongqing Medical University, Chongqing 400016, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Int J Nanomedicine</MedlineTA>
        <NlmUniqueID>101263847</NlmUniqueID>
        <ISSNLinking>1176-9114</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003514">Cyclohexylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573944">ferrostatin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1TW30Y2766</RegistryNumber>
          <NameOfSubstance UI="C432165">pyrazolanthrone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SOI2LOH54Z</RegistryNumber>
          <NameOfSubstance UI="D015034">Zinc Oxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000873" MajorTopicYN="N">Anthracenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003514" MajorTopicYN="N">Cyclohexylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015034" MajorTopicYN="N">Zinc Oxide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cerebral cortex</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">neuron</Keyword>
        <Keyword MajorTopicYN="N">zinc oxide nanoparticles</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32884256</ArticleId>
        <ArticleId IdType="pmc">PMC7436556</ArticleId>
        <ArticleId IdType="doi">10.2147/IJN.S250367</ArticleId>
        <ArticleId IdType="pii">250367</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072. doi:10.1016/j.cell.2012.03.042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The hallmarks of ferroptosis. Annual Rev Cancer Biol. 2019;3(1):35&#x2013;54. doi:10.1146/annurev-cancerbio-030518-055844</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-cancerbio-030518-055844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165&#x2013;176. doi:10.1016/j.tcb.2015.10.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Q, Bai L, Zou Z, et al. Ferroptosis is newly characterized form of neuronal cell death in response to arsenite exposure. Neurotoxicology. 2018;67:27&#x2013;36. doi:10.1016/j.neuro.2018.04.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuro.2018.04.012</ArticleId>
            <ArticleId IdType="pubmed">29678591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SE, Zhang L, Ma K, et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol. 2016;11(11):977. doi:10.1038/nnano.2016.164</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nnano.2016.164</ArticleId>
            <ArticleId IdType="pmc">PMC5108575</ArticleId>
            <ArticleId IdType="pubmed">27668796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Liu T, Li Y, et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 2018;12(11):11355&#x2013;11365. doi:10.1021/acsnano.8b06201</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06201</ArticleId>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava V, Gusain D, Sharma YC. Synthesis, characterization and application of zinc oxide nanoparticles (n-ZnO). Ceramics Int. 2013;39(8):9803&#x2013;9808. doi:10.1016/j.ceramint.2013.04.110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceramint.2013.04.110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Tang Q, Zhang J, et al. Autophagy-dependent release of zinc ions is critical for acute lung injury triggered by zinc oxide nanoparticles. Nanotoxicology. 2018;1&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30317896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao Y, Gong Y, Liao W, et al. A review of cardiovascular toxicity of TiO 2, ZnO and Ag nanoparticles (NPs). Bio Metals. 2018;31(4):457&#x2013;476. doi:10.1007/s10534-018-0113-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10534-018-0113-7</ArticleId>
            <ArticleId IdType="pubmed">29748744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S. Zinc oxide nanoparticles impacts: cytotoxicity, genotoxicity, developmental toxicity, and neurotoxicity. Toxicol Mech Methods. 2019;29(4):300&#x2013;311. doi:10.1080/15376516.2018.1553221</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15376516.2018.1553221</ArticleId>
            <ArticleId IdType="pubmed">30489211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arakha M, Roy J, Nayak PS, Mallick B, Jha S. Zinc oxide nanoparticle energy band gap reduction triggers the oxidative stress resulting into autophagy-mediated apoptotic cell death. Free Radic Biol Med. 2017;110:42&#x2013;53. doi:10.1016/j.freeradbiomed.2017.05.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2017.05.015</ArticleId>
            <ArticleId IdType="pubmed">28528796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang K-L, Lee Y-H, Chen H-I, Liao H-S, Chiang B-L, Cheng T-J. Zinc oxide nanoparticles induce eosinophilic airway inflammation in mice. J Hazard Mater. 2015;297:304&#x2013;312. doi:10.1016/j.jhazmat.2015.05.023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhazmat.2015.05.023</ArticleId>
            <ArticleId IdType="pubmed">26010476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D-Y, Kim J-H, Lee J-C, et al. Zinc oxide nanoparticles exhibit both cyclooxygenase-and lipoxygenase-mediated apoptosis in human bone marrow-derived mesenchymal stem cells. Toxicol Res. 2019;35(1):83&#x2013;91. doi:10.5487/TR.2019.35.1.083</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5487/TR.2019.35.1.083</ArticleId>
            <ArticleId IdType="pmc">PMC6354944</ArticleId>
            <ArticleId IdType="pubmed">30766660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilhelmi V, Fischer U, Weighardt H, et al. Zinc oxide nanoparticles induce necrosis and apoptosis in macrophages in a p47phox-and Nrf2-independent manner. PLoS One. 2013;8(6):e65704. doi:10.1371/journal.pone.0065704</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0065704</ArticleId>
            <ArticleId IdType="pmc">PMC3670863</ArticleId>
            <ArticleId IdType="pubmed">23755271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Qin X, Wang B, et al. Zinc oxide nanoparticles harness autophagy to induce cell death in lung epithelial cells. Cell Death Dis. 2017;8(7):e2954e2954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5550878</ArticleId>
            <ArticleId IdType="pubmed">28749469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Zhang J, Chen C, et al. The size of zinc oxide nanoparticles controls its toxicity through impairing autophagic flux in A549 lung epithelial cells. Toxicol Letters. 2018;285:51&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29289694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson MR, Foucaud L, Barlow PG, et al. Nanoparticle interactions with zinc and iron: implications for toxicology and inflammation. Toxicol Appl Pharmacol. 2007;225(1):80&#x2013;89. doi:10.1016/j.taap.2007.07.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2007.07.012</ArticleId>
            <ArticleId IdType="pubmed">17900645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali D, Alarifi S, Kumar S, Ahamed M, Siddiqui MA. Oxidative stress and genotoxic effect of zinc oxide nanoparticles in freshwater snail Lymnaea luteola L. Aquatic Toxicol. 2012;124:83&#x2013;90. doi:10.1016/j.aquatox.2012.07.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.aquatox.2012.07.012</ArticleId>
            <ArticleId IdType="pubmed">22917558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi S-J, Choy J-H. Biokinetics of zinc oxide nanoparticles: toxicokinetics, biological fates, and protein interaction. Int J Nanomedicine. 2014;9(Suppl 2):261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4279768</ArticleId>
            <ArticleId IdType="pubmed">25565844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao -Y-Y, Cheng T-J, Yang D-M, Wang C-T, Chiung Y-M, Liu P-S. Demonstration of an olfactory bulb&#x2013;brain translocation pathway for ZnO nanoparticles in rodent cells in vitro and in vivo. J Mol Neurosci. 2012;48(2):464&#x2013;471. doi:10.1007/s12031-012-9756-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-012-9756-y</ArticleId>
            <ArticleId IdType="pubmed">22528453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han D, Tian Y, Zhang T, Ren G, Yang Z. Nano-zinc oxide damages spatial cognition capability via over-enhanced long-term potentiation in hippocampus of Wistar rats. Int J Nanomedicine. 2011;6:1453. doi:10.2147/IJN.S25646</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S25646</ArticleId>
            <ArticleId IdType="pmc">PMC3141872</ArticleId>
            <ArticleId IdType="pubmed">21796247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valdiglesias V, Costa C, Kili&#xe7; G, et al. Neuronal cytotoxicity and genotoxicity induced by zinc oxide nanoparticles. Environ Int. 2013;55:92&#x2013;100. doi:10.1016/j.envint.2013.02.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.envint.2013.02.013</ArticleId>
            <ArticleId IdType="pubmed">23535050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng X, Luan Q, Chen W, et al. Nanosized zinc oxide particles induce neural stem cell apoptosis. Nanotechnology. 2009;20(11):115101. doi:10.1088/0957-4484/20/11/115101</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1088/0957-4484/20/11/115101</ArticleId>
            <ArticleId IdType="pubmed">19420431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeng HA, Swanson J. Toxicity of metal oxide nanoparticles in mammalian cells. J Environ Sci Health Part A. 2006;41(12):2699&#x2013;2711. doi:10.1080/10934520600966177</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10934520600966177</ArticleId>
            <ArticleId IdType="pubmed">17114101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Deng X, Zhang F, Chen D, Ding W. ZnO nanoparticle-induced oxidative stress triggers apoptosis by activating JNK signaling pathway in cultured primary astrocytes. Nanoscale Res Lett. 2014;9(1):117. doi:10.1186/1556-276X-9-117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1556-276X-9-117</ArticleId>
            <ArticleId IdType="pmc">PMC3995614</ArticleId>
            <ArticleId IdType="pubmed">24624962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gosens I, Kermanizadeh A, Jacobsen NR, et al. Comparative hazard identification by a single dose lung exposure of zinc oxide and silver nanomaterials in mice. Plos One. 2015;10:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4429007</ArticleId>
            <ArticleId IdType="pubmed">25966284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Park K. In vitro cytotoxicity of zinc oxide nanoparticles in cultured statens seruminstitut rabbit cornea cells. Toxicol Res. 2019;35(3):287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6629441</ArticleId>
            <ArticleId IdType="pubmed">31341558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobsen NR, Stoeger T, Van Den Br&#xfb;le S, et al. Acute and subacute pulmonary toxicity and mortality in mice after intratracheal instillation of ZnO nanoparticles in three laboratories. Food Chem Toxicol. 2015;85:84&#x2013;95. doi:10.1016/j.fct.2015.08.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2015.08.008</ArticleId>
            <ArticleId IdType="pubmed">26260750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C-H, Chuang K-J, Chen J-K, et al. Characterization of pulmonary protein profiles in response to zinc oxide nanoparticles in mice: A 24-hour and 28-day follow-up study. Int J Nanomed. 2015;10:4705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4524458</ArticleId>
            <ArticleId IdType="pubmed">26251593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai L, Tang Q, Zou Z, et al. m6A demethylase FTO regulates dopaminergic neurotransmission deficits caused by arsenite. Toxicol Sci. 2018;165(2):431&#x2013;446. doi:10.1093/toxsci/kfy172</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/toxsci/kfy172</ArticleId>
            <ArticleId IdType="pubmed">29982692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Qin X, Wang B, et al. Zinc oxide nanoparticles harness autophagy to induce cell death in lung epithelial cells. Cell Death Dis. 2017;8(7):e2954. doi:10.1038/cddis.2017.337</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2017.337</ArticleId>
            <ArticleId IdType="pmc">PMC5550878</ArticleId>
            <ArticleId IdType="pubmed">28749469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>&#xdc;nal-&#xc7;evik I, K&#x131;l&#x131;n&#xe7; M, G&#xfc;rsoy-&#xd6;zdemir Y, Gurer G, Dalkara T. Loss of NeuN immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note. Brain Res. 2004;1015(12):169&#x2013;174. doi:10.1016/j.brainres.2004.04.032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2004.04.032</ArticleId>
            <ArticleId IdType="pubmed">15223381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kee N, Sivalingam S, Boonstra R, Wojtowicz J. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods. 2002;115(1):97&#x2013;105. doi:10.1016/S0165-0270(02)00007-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-0270(02)00007-9</ArticleId>
            <ArticleId IdType="pubmed">11897369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baltaci AK, Yuce K, Mogulkoc R. Zinc metabolism and metallothioneins. Biol Trace Elem Res. 2018;183(1):22&#x2013;31. doi:10.1007/s12011-017-1119-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12011-017-1119-7</ArticleId>
            <ArticleId IdType="pubmed">28812260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayawardena DP, Heinemann IU, Stillman MJ. Zinc binds non-cooperatively to human liver metallothionein 2a at physiological pH. Biochem Biophys Res Commun. 2017;493(1):650&#x2013;653. doi:10.1016/j.bbrc.2017.08.137</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.08.137</ArticleId>
            <ArticleId IdType="pubmed">28865957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Han X, Lan X, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. JCI Insight. 2017;2:7. doi:10.1172/jci.insight.90777</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.90777</ArticleId>
            <ArticleId IdType="pmc">PMC5374066</ArticleId>
            <ArticleId IdType="pubmed">28405617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares-Silva M, Diniz FF, Gomes GN, Bahia D. The mitogen-activated protein kinase (MAPK) pathway: role in immune evasion by trypanosomatids. Front Microbiol. 2016;7:183. doi:10.3389/fmicb.2016.00183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2016.00183</ArticleId>
            <ArticleId IdType="pmc">PMC4764696</ArticleId>
            <ArticleId IdType="pubmed">26941717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mons&#xe9; C, Hagemeyer O, Raulf M, et al. Concentration-dependent systemic response after inhalation of nano-sized zinc oxide particles in human volunteers. Particle Fibre Toxicol. 2018;15(1):8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808398</ArticleId>
            <ArticleId IdType="pubmed">29429408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossner JP, Vrbova K, Strapacova S, et al. Inhalation of ZnO nanoparticles: splice junction expression and alternative splicing in mice. Toxicol Sci. 2019;168(1):190&#x2013;200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6390655</ArticleId>
            <ArticleId IdType="pubmed">30500950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adamcakova-Dodd A, Stebounova LV, Kim JS, et al. Toxicity assessment of zinc oxide nanoparticles using sub-acute and sub-chronic murine inhalation models. Particle Fibre Toxicol. 2014;11(1):15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3994238</ArticleId>
            <ArticleId IdType="pubmed">24684892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia T, Kovochich M, Liong M, et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS nano 2. 2008;2(10):2121&#x2013;2134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3959800</ArticleId>
            <ArticleId IdType="pubmed">19206459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolosi A, Cardoit L, Pasquereau P, et al. Acute exposure to zinc oxide nanoparticles critically disrupts operation of the respiratory neural network in neonatal rat. Neurotoxicology. 2018;67:150&#x2013;160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29860053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poh TY, NAtBM A, Mac Aog&#xe1;in M, et al. Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives. Particle Fibre Toxicol. 2018;15(1):46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6245551</ArticleId>
            <ArticleId IdType="pubmed">30458822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simko M, Mattsson M-O. Interactions between nanosized materials and the brain. Current Med Chem. 2014;21(37):4200&#x2013;4214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4435026</ArticleId>
            <ArticleId IdType="pubmed">25039776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao -Y-Y, Cheng T-J, Yang D-M, Wang C-T, Chiung Y-M, Liu P-S. Demonstration of an olfactory bulb&#x2013;brain translocation pathway for ZnO nanoparticles in rodent cells in vitro and in vivo. J Mol Neurosci. 2012;48(2):464&#x2013;471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22528453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shim KH, Hulme J, Maeng EH, Kim M-K, An S. Analysis of zinc oxide nanoparticles binding proteins in rat blood and brain homogenate. Int J Nanomed. 2014;9(Suppl 2):217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4279772</ArticleId>
            <ArticleId IdType="pubmed">25565839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, Shah R, Li B, et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Central Sci. 2017;3(3):232&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Feng X, Wei L, Chen L, Song B, Shao L. The toxicology of ion-shedding zinc oxide nanoparticles. Critical Rev Toxicol. 2016;46(4):348&#x2013;384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26963861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao -Y-Y, Chen Y-C, Cheng T-J, Chiung Y-M, Liu P-SJT-S. Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. Toxicol Sci. 2012;125(2):462&#x2013;472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22112499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babu Maddinedi S, Mandal BK, Patil SH, et al. Diastase induced green synthesis of bilayered reduced graphene oxide and its decoration with gold nanoparticles. J Photochem Photobio B Biol. 2017;166:252&#x2013;258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28011435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddinedi SB, Mandal BK, Anna K. Pharmacology. Environment friendly approach for size controllable synthesis of biocompatible silver nanoparticles using diastase. Environ Toxicol Pharmacol. 2017;49:131&#x2013;136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27992806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen P, Grajeda R, Melgar P, et al. Effect of zinc on efficacy of iron supplementation in improving iron and zinc status in women. J Nut Metab. 2012;2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3376765</ArticleId>
            <ArticleId IdType="pubmed">22720141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donangelo CM, Woodhouse LR, King SM, Viteri FE, King J. Supplemental zinc lowers measures of iron status in young women with low iron reserves. J Nut. 2002;132(7):1860&#x2013;1864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12097660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olivares M, Pizarro F, Gait&#xe1;n D, Ruz M. Acute inhibition of iron absorption by zinc. Nut Res. 2007;27(5):279&#x2013;282.</Citation>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369&#x2013;379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Angeli JPF, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cargnello M, Roux PPJMMBR. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3063353</ArticleId>
            <ArticleId IdType="pubmed">21372320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Xie Y, Cao L, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2(4):e1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32835374</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-2180</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Carcinogenesis</Title>
          <ISOAbbreviation>Carcinogenesis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of -catenin/Wnt-signaling pathways in colorectal cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1385</StartPage>
          <EndPage>1394</EndPage>
          <MedlinePgn>1385-1394</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/carcin/bgaa090</ELocationID>
        <Abstract>
          <AbstractText>Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality in the USA. As much as 50-60% of CRC patients develop resistance to 5-fluorouracil (5FU)-based chemotherapeutic regimens, attributing the increased overall morbidity and mortality. In view of the growing evidence that active principles in various naturally occurring botanicals can facilitate chemosensitization in cancer cells, herein, we undertook a comprehensive effort in interrogating the activity of one such botanical-andrographis-by analyzing its activity in CRC cell lines [both sensitive and 5FU resistant (5FUR)], a xenograft animal model and patient-derived tumor organoids. We observed that combined treatment with andrographis was synergistic and resulted in a significant and dose-dependent increase in the efficacy of 5FU in HCT116 and SW480 5FUR cells (P &lt; 0.05), reduced clonogenic formation (P &lt; 0.01) and increased rates of caspase-9-mediated apoptosis (P &lt; 0.05). The genomewide expression analysis in cell lines led us to uncover that activation of ferroptosis and suppression of -catenin/Wnt-signaling pathways were the key mediators for the anti-cancer and chemosensitizing effects of andrographis. Subsequently, we validated our findings in a xenograft animal model, as well as two independent CRC patient-derived organoids-which confirmed that combined treatment with andrographis was significantly more effective than 5FU and andrographis alone and that these effects were in part orchestrated through dysregulated expression of key genes (including HMOX1, GCLC, GCLM and TCF7L2) within the ferroptosis and Wnt-signaling pathways. Collectively, our data highlight that andrographis might offer a safe and inexpensive adjunctive therapeutic option in the management of CRC patients.</AbstractText>
          <CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Priyanka</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott and White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Diagnostics and Experimental Therapeutics and Biotech Innovations, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimura</LastName>
            <ForeName>Tadanobu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott and White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Banwait</LastName>
            <ForeName>Jasjit K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott and White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goel</LastName>
            <ForeName>Ajay</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Gastrointestinal Research, Baylor Scott and White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Diagnostics and Experimental Therapeutics and Biotech Innovations, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Carcinogenesis</MedlineTA>
        <NlmUniqueID>8008055</NlmUniqueID>
        <ISSNLinking>0143-3334</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3P01618RT</RegistryNumber>
          <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D035685" MajorTopicYN="N">Andrographis</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32835374</ArticleId>
        <ArticleId IdType="pmc">PMC7566354</ArticleId>
        <ArticleId IdType="doi">10.1093/carcin/bgaa090</ArticleId>
        <ArticleId IdType="pii">5896563</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL &#xa0;et al. (2020) Cancer statistics, 2020. CA Cancer J. Clin., 70, 7&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobrero AF &#xa0;et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol., 26, 2311&#x2013;2319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18390971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorlick R &#xa0;et al. (2002) Fluoropyrimidine resistance in colon cancer. Expert Rev. Anticancer Ther., 2, 409&#x2013;416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12647984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giacchetti S &#xa0;et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 18, 136&#x2013;147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10623704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz LA Jr &#xa0;et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 486, 537&#x2013;540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3436069</ArticleId>
            <ArticleId IdType="pubmed">22722843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komarova NL &#xa0;et al. (2013) Cancer: calculated treatment. Nature, 499, 291&#x2013;292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3831845</ArticleId>
            <ArticleId IdType="pubmed">23868257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozic I &#xa0;et al. (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. Elife, 2, e00747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3691570</ArticleId>
            <ArticleId IdType="pubmed">23805382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#x2019;Andre S &#xa0;et al. (2005) 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin. Colorectal Cancer, 4, 325&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15663836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wigmore PM &#xa0;et al. (2010) Effects of 5-FU. Adv. Exp. Med. Biol., 678, 157&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20738018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker DD &#xa0;et al. (2007) The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep., 24, 1225&#x2013;1244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18033577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu RH. (2004) Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr., 134 (12 suppl), 3479S&#x2013;3485S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15570057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sala de Oyanguren FJ &#xa0;et al. (2020) Highlighting curcumin-induced crosstalk between autophagy and apoptosis as supported by its specific subcellular localization. Cells, 9, 361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7072416</ArticleId>
            <ArticleId IdType="pubmed">32033136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M &#xa0;et al. (2018) Andrographolide sulfonate reduces mortality in Enterovirus 71 infected mice by modulating immunity. Int. Immunopharmacol., 55, 142&#x2013;150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29253820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan WSD &#xa0;et al. (2017) Is there a future for andrographolide to be an anti-inflammatory drug? Deciphering its major mechanisms of action. Biochem. Pharmacol., 139, 71&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28377280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan SP &#xa0;et al. (2011) Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue of andrographolide, in allergic airway inflammation. J. Nat. Prod., 74, 1484&#x2013;1490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21598983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan GR &#xa0;et al. (2013) Protective effects of andrographolide analogue AL-1 on ROS-induced RIN-m&#x3b2; cell death by inducing ROS generation. PLoS One, 8, e63656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672203</ArticleId>
            <ArticleId IdType="pubmed">23750203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Y &#xa0;et al. (2018) Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J. Exp. Clin. Cancer Res., 37, 248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6186120</ArticleId>
            <ArticleId IdType="pubmed">30314513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu CC &#xa0;et al. (2018) Andrographolide enhances the anti-metastatic effect of radiation in Ras-transformed cells via suppression of ERK-mediated MMP-2 activity. PLoS One, 13, e0205666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6201887</ArticleId>
            <ArticleId IdType="pubmed">30359388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin HH &#xa0;et al. (2014) Andrographolide sensitizes the cytotoxicity of human colorectal carcinoma cells toward cisplatin via enhancing apoptosis pathways in vitro and in vivo. Toxicol. Sci., 139, 108&#x2013;120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24563380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su M &#xa0;et al. (2017) Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway. Drug Des. Devel. Ther., 11, 3333&#x2013;3341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5703152</ArticleId>
            <ArticleId IdType="pubmed">29200829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L &#xa0;et al. (2009) Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells. Cancer Lett., 276, 180&#x2013;188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19097688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao GQ &#xa0;et al. (2013) Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicol. Lett., 222, 23&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23845849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chowdhury KD &#xa0;et al. (2019) Cathepsin B mediated scramblase activation triggers cytotoxicity and cell cycle arrest by andrographolide to overcome cellular resistance in cisplatin resistant human hepatocellular carcinoma HepG2 cells. Environ. Toxicol. Pharmacol., 68, 120&#x2013;132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30889542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W &#xa0;et al. (2016) Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. Biochem. Pharmacol., 121, 8&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27693317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaiser J. (2017) When less is more. Science, 355, 1144&#x2013;1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28302821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burrell RA &#xa0;et al. (2014) Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol., 8, 1095&#x2013;1111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528620</ArticleId>
            <ArticleId IdType="pubmed">25087573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindranathan P &#xa0;et al. (2018) Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer. Carcinogenesis, 39, 767&#x2013;777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5972632</ArticleId>
            <ArticleId IdType="pubmed">29684110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindranathan P &#xa0;et al. (2019) Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. Carcinogenesis, 40, 412&#x2013;421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6514448</ArticleId>
            <ArticleId IdType="pubmed">30596962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reagan-Shaw S &#xa0;et al. (2008) Dose translation from animal to human studies revisited. FASEB J., 22, 659&#x2013;661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17942826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toden S &#xa0;et al. (2018) Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer. Sci. Rep., 8, 3335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5820273</ArticleId>
            <ArticleId IdType="pubmed">29463813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kendziorra E &#xa0;et al. (2011) Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis, 32, 1824&#x2013;1831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3254167</ArticleId>
            <ArticleId IdType="pubmed">21983179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>P&#xe1;ez D &#xa0;et al. (2014) Association of common gene variants in the WNT/&#x3b2;-catenin pathway with colon cancer recurrence. Pharmacogenomics J., 14, 142&#x2013;150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23817222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douillard JY &#xa0;et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041&#x2013;1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10744089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel A &#xa0;et al. (2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer, 62, 919&#x2013;930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20924967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel A &#xa0;et al. (2008) Multi-targeted therapy by curcumin: how spicy is it? Mol. Nutr. Food Res., 52, 1010&#x2013;1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18384098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toden S &#xa0;et al. (2015) Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prev. Res. (Phila.), 8, 431&#x2013;443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4417447</ArticleId>
            <ArticleId IdType="pubmed">25712055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toden S &#xa0;et al. (2015) Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis, 36, 355&#x2013;367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400529</ArticleId>
            <ArticleId IdType="pubmed">25653233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan I, et al. (2019) Antiproliferative and apoptotic property of andrographolide against human colon cancer DLD1 cell line. Endocr Metab. Immune Disord. Drug Targets, 20, 930&#x2013;942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31774047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le DT &#xa0;et al. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med., 372, 2509&#x2013;2520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481136</ArticleId>
            <ArticleId IdType="pubmed">26028255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelderman S &#xa0;et al. (2015) Mismatch repair-deficient cancers are targets for anti-PD-1 therapy. Cancer Cell, 28, 11&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26175412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahin IH &#xa0;et al. (2019) Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br. J. Cancer, 121, 809&#x2013;818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6889302</ArticleId>
            <ArticleId IdType="pubmed">31607751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai Z &#xa0;et al. (2015) Inhibition of MDA-MB-231 breast cancer cell migration and invasion activity by andrographolide via suppression of nuclear factor-&#x3ba;B-dependent matrix metalloproteinase-9 expression. Mol. Med. Rep., 11, 1139&#x2013;1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6413764</ArticleId>
            <ArticleId IdType="pubmed">25374279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reabroi S &#xa0;et al. (2018) The anti-cancer activity of an andrographolide analogue functions through a GSK-3&#x3b2;-independent Wnt/&#x3b2;-catenin signaling pathway in colorectal cancer cells. Sci. Rep., 8, 7924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5962551</ArticleId>
            <ArticleId IdType="pubmed">29784906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S &#xa0;et al. (2012) Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Curr. Mol. Med., 12, 952&#x2013;966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22804248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheeja K &#xa0;et al. (2007) Activation of cytotoxic T lymphocyte responses and attenuation of tumor growth in vivo by Andrographis paniculata extract and andrographolide. Immunopharmacol. Immunotoxicol., 29, 81&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17464769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh JL &#xa0;et al. (2016) Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett., 381, 96&#x2013;103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27477897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X &#xa0;et al. (2020) Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J. Cell. Physiol., 235, 3425&#x2013;3437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31556117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B &#xa0;et al. (2019) Targeting ferroptosis to iron out cancer. Cancer Cell, 35, 830&#x2013;849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon MY &#xa0;et al. (2015) Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget, 6, 24393&#x2013;24403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4695193</ArticleId>
            <ArticleId IdType="pubmed">26405158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao CY &#xa0;et al. (2013) Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells. Carcinogenesis, 34, 1843&#x2013;1851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23615401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B &#xa0;et al. (2013) CHP1002, a novel andrographolide derivative, inhibits pro-inflammatory inducible nitric oxide synthase and cyclooxygenase-2 expressions in RAW264.7 macrophages via up-regulation of heme oxygenase-1 expression. Int. Immunopharmacol., 15, 289&#x2013;295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23261362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu CY &#xa0;et al. (2014) Andrographolide inhibits TNF&#x3b1;-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem. Pharmacol., 91, 40&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24998495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L &#xa0;et al. (2018) Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp. Mol. Med., 50, 101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6093888</ArticleId>
            <ArticleId IdType="pubmed">30111797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghadimi BM &#xa0;et al. (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol., 23, 1826&#x2013;1838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4721601</ArticleId>
            <ArticleId IdType="pubmed">15774776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J &#xa0;et al. (2012) Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells. PLoS One, 7, e45617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3454396</ArticleId>
            <ArticleId IdType="pubmed">23029137</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32816618</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1551-4005</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell cycle (Georgetown, Tex.)</Title>
          <ISOAbbreviation>Cell Cycle</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis: a new unexpected chance to treat metastatic melanoma?</ArticleTitle>
        <Pagination>
          <StartPage>2411</StartPage>
          <EndPage>2425</EndPage>
          <MedlinePgn>2411-2425</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384101.2020.1806426</ELocationID>
        <Abstract>
          <AbstractText>Human skin melanoma is one of the most aggressive and difficult to treat human malignancies, with an increasing incidence over the years. While the resection of the early diagnosed primary tumor remains the best clinical approach, advanced/metastatic melanoma still remains with a poor prognosis. Indeed, although enormous progress in the therapeutic treatment of human tumors has been made in recent years, patients affected by metastatic melanoma are still poorly affected by these clinical advances. Therefore, new valuable therapeutic approaches are urgently needed, to design and define effective treatments to consistently increase the overall survival rate of patients affected by this malignancy. In this review we summarize the main signaling pathways studied to kill human skin melanoma, and introduce the ferroptotic cell death as a new pathway to be explored to eradicate this tumor.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gagliardi</LastName>
            <ForeName>Mara</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-3222-790X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saverio</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-1770-2661</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monzani</LastName>
            <ForeName>Romina</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-9750-8342</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrari</LastName>
            <ForeName>Eleonora</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0001-9254-853X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piacentini</LastName>
            <ForeName>Mauro</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-2919-1296</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biology, University of Rome Tor Vergata , Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Cytology of the Russian Academy of Sciences , Saint Petersburg, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corazzari</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-6246-5968</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale , Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Cycle</MedlineTA>
        <NlmUniqueID>101137841</NlmUniqueID>
        <ISSNLinking>1551-4005</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AKR</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">NRF2</Keyword>
        <Keyword MajorTopicYN="N">lipid-ROS</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32816618</ArticleId>
        <ArticleId IdType="pmc">PMC7553499</ArticleId>
        <ArticleId IdType="doi">10.1080/15384101.2020.1806426</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tsao H, Atkins MB, Sober Arthur J.. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Proceed Mayo Clin Proceed. Elsevier Ltd. 2007;82:364&#x2013;380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17352373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>All cancers; 2018. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/16-Melanoma-of-skin-fact-sheet.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Table S. Tobacco use 44 sources of statistics 68 American cancer society recommendations for the early detection of cancer in average-risk asymptomatic people 71. Atlanta: American Cancer Society; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Rigel DS. Rigel epidemiology of melanoma. Semin Cutan Med Surg. 2010. December;29(4):204&#x2013;209. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21277533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasithiotakis KG, Petrakis IE, Garbe C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res. 2010;20:163&#x2013;170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20375923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho E, BA R, GA. C. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev. 2005;14:1241&#x2013;1244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraemer KH, Greene MH. Dysplastic nevus syndrome. Familial and sporadic precursors of cutaneous melanoma. Dermatol Clin. 1985;3:225&#x2013;237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3830486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corazzari M, PE. L. Harnessing autophagy for melanoma benefit. Cell Biol Res Ther. 2013;2:1.</Citation>
        </Reference>
        <Reference>
          <Citation>DE B, JA R, JA S, et al. J., P. A role for sunlight in skin cancer: uVinduced p53 mutations in squamous cell carcinoma. PNAS. 1991;88:10124&#x2013;10128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC52880</ArticleId>
            <ArticleId IdType="pubmed">1946433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436&#x2013;440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8153634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potrony M, Badenas C, Aguilera P, et al. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015;3:210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4583600</ArticleId>
            <ArticleId IdType="pubmed">26488006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagliabue E, Gandini S, Bellocco R, et al. MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. Cancer Manag Res. 2018;10:1143&#x2013;1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5958947</ArticleId>
            <ArticleId IdType="pubmed">29795986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2012;367:1694&#x2013;1703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549295</ArticleId>
            <ArticleId IdType="pubmed">23020132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray-Schopfer V, Wellbrock C, Marais R. R., M. Melanoma biology and new targeted therapy. Nature. 2007;445:851&#x2013;857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17314971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ER C-D, JJ O, OM. S. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385&#x2013;394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21388974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhomen N, Marais R, Signaling BRAF. Targeted Therapies in Melanoma. Hematol Oncol Clin North Am. 2009;23:529&#x2013;545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19464601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AH A-T, Li G. G., L. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci. 2012;69:1475&#x2013;1491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22076652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giglio P, Fimia GM, Lovat PE, et al. Fateful music from a talented orchestra with a wicked conductor: connection between oncogenic BRAF, ER stress, and autophagy in human melanoma. Mol Cell Oncol. 2015;2:e995016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4905314</ArticleId>
            <ArticleId IdType="pubmed">27308477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12:401&#x2013;410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3664381</ArticleId>
            <ArticleId IdType="pubmed">22534666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hersey P, Zhang XD. Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res. 2008;21:358&#x2013;367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18476909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corazzari M, Lovat PE, Armstrong JL, et al. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer. 2007;96:1062&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2360126</ArticleId>
            <ArticleId IdType="pubmed">17353921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corazzari M, Fimia GM, Lovat P, et al. Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. Semin Cancer Biol. 2013;23:337&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23856558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JL A, Corazzari M, Martin S, et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res. 2011;17:2216&#x2013;2226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21270111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DT R, SM A, Miller CN, et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol. 2006;4:e374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1634883</ArticleId>
            <ArticleId IdType="pubmed">17090218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corazzari M, Gagliardi M, Fimia GM, et al. Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol. 2017;7:78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5405076</ArticleId>
            <ArticleId IdType="pubmed">28491820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corazzari M, Rapino F, Ciccosanti F, et al. Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ. 2015;22:946&#x2013;958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4423179</ArticleId>
            <ArticleId IdType="pubmed">25361077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovat PE, Corazzari M, Armstrong JL, et al. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res. 2008;68:5363&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917766</ArticleId>
            <ArticleId IdType="pubmed">18593938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niezgoda A, Niezgoda P, Czajkowski R. R., C. Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy. Biomed Res Int. 2015;2015:851387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4478296</ArticleId>
            <ArticleId IdType="pubmed">26171394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>TR W, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505&#x2013;509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3724525</ArticleId>
            <ArticleId IdType="pubmed">22763448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877&#x2013;1888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25265492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23890059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Lu W, Zheng X, et al. Emerging immune checkpoints for cancer therapy. Acta Oncol. 2015;54:1706&#x2013;1713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26361073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncol. 2008;13:16&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19001147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252&#x2013;264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889&#x2013;1894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5089162</ArticleId>
            <ArticleId IdType="pubmed">25667295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O&#x2019;Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363:711&#x2013;723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, SE S, DR S, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793&#x2013;800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12091876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853&#x2013;1862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28822576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366:2517&#x2013;2519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22658126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, JM A, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107&#x2013;120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252826</ArticleId>
            <ArticleId IdType="pubmed">21760595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DR G, Ferguson T, Zitvogel L. G., K. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9:353&#x2013;363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818721</ArticleId>
            <ArticleId IdType="pubmed">19365408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AM D, Martin S, AD G. P., A. Immature, semi&#x2010;mature, and fully mature dendritic cells: toward a DC&#x2010;cancer cells interface that augments anticancer immunity.. Front Immunol. 2013;4:438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3858649</ArticleId>
            <ArticleId IdType="pubmed">24376443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AD G, Galluzzi L, Apetoh L, et al. Molecular and translational Classifications of DaMPs in immunogenic cell death. Front Immunol. 2015;6:588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4653610</ArticleId>
            <ArticleId IdType="pubmed">26635802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bezu L, LC G-S, Ewitte HBK, et al. G., K. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4408862</ArticleId>
            <ArticleId IdType="pubmed">25964783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fucikova J, Kralikova P, Fialova A, et al. R., S. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011;71:4821&#x2013;4833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21602432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482&#x2013;491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19881547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71:768&#x2013;778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21156650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109:4839&#x2013;4845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1885516</ArticleId>
            <ArticleId IdType="pubmed">17299090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giglio P, Gagliardi M, Tumino N, et al. PKR and GCN2 stress kinases promote an ER stress-independent eIF2&#x3b1; phosphorylation responsible for calreticulin exposure in melanoma cells. Oncoimmunology. 2018. DOI:10.1080/2162402X.2018.1466765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1466765</ArticleId>
            <ArticleId IdType="pmc">PMC6136861</ArticleId>
            <ArticleId IdType="pubmed">30221067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giglio P, Gagliardi M, Bernardini R, et al. Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma. Genes Immun 2019;20:509&#x2013;513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30282994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, SL L, WC H, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WS Y, BR S. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2744427</ArticleId>
            <ArticleId IdType="pubmed">18846107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Aaronson SA, et al.. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486&#x2013;541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5864239</ArticleId>
            <ArticleId IdType="pubmed">29362479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an Iron-Dependent Form of Nonapoptotic Cell Death. Cell. 2012;149:1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Shchepinov MS, Pratt DA. Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent Sci. 2018;4:387&#x2013;396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DM W. J., and K. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012;1823:1426&#x2013;1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718258</ArticleId>
            <ArticleId IdType="pubmed">22440327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Qudri N, et al. Glutaminolysis and Transferrin Regulate Ferroptosis. Mol Cell. 2015;59:298&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JD M, Wang X, Steven PG, et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy.. Nature. 2014;509:105&#x2013;109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4180099</ArticleId>
            <ArticleId IdType="pubmed">24695223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JD M, VL. P, Nissim S, et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife. 2015;4:e10308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4592949</ArticleId>
            <ArticleId IdType="pubmed">26436293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Zhu S, Chen P, et al. AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc&#x2013; activity. Curr Biol. 2018;28:2388&#x2013;2399.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6081251</ArticleId>
            <ArticleId IdType="pubmed">30057310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WS Y, KJ K, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113:E4966&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JZ H, CD. F. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev. 2011;111:5866&#x2013;5898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21936577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan S, XF Y, Liu HL, et al. Longchain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update. World J Gastroenterol. 2015;21:3492&#x2013;3498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4375570</ArticleId>
            <ArticleId IdType="pubmed">25834313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birben E, UM S, Sackesen C, et al., O., K . Oxidative Stress and Antioxidant Defense. World Allergy Organ J. 2012;5:9&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3488923</ArticleId>
            <ArticleId IdType="pubmed">23268465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagliardi M, Cotella D, Santoro C, et al. M., C. Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis. 2019;10:902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883066</ArticleId>
            <ArticleId IdType="pubmed">31780644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SJ D, GE W, LS M, et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol. 2015;10:1604&#x2013;1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509420</ArticleId>
            <ArticleId IdType="pubmed">25965523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, et al. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478:1338&#x2013;1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burton GW, KU I. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res. 1986;19:194&#x2013;201.</Citation>
        </Reference>
        <Reference>
          <Citation>Lucarini M, Pedrielli P, Pedulli GF, et al. Bond Dissociation Energies of O&#x2212;H Bonds in Substituted Phenols from Equilibration Studies. J Org Chem. 1996;61:9259&#x2013;9263.</Citation>
        </Reference>
        <Reference>
          <Citation>Feng H, Stockwell BR. Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLOS Biol. 2018;16:e2006203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5991413</ArticleId>
            <ArticleId IdType="pubmed">29795546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693&#x2013;698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>QZ T, Lei P, Jackman KA, et al. Tau-mediated iron export prevents ferroptotic damage after ischemic stroke.. Mol Psychiatry. 2017;22:1520&#x2013;1530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28886009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez MA, Magtanong L, Dixon SJ, et al. Dietary Lipids Induce Ferroptosis in Caenorhabditis elegans and Human Cancer Cells. Dev Cell. 2020;S1534-5807(20)30498-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Sato H, Tamba M, Ishii T. S., B.Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274:11455&#x2013;11458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10206947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MC J, DD. Z. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179&#x2013;2191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3814639</ArticleId>
            <ArticleId IdType="pubmed">24142871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Had-Aissouni L. Toward a new role for plasma membrane sodium-dependent glutamate transporters of astrocytes: maintenance of antioxidant defenses beyond extracellular glutamate clearance. Amin Acids. 2012;42:181&#x2013;197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21399919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okuno S, Sato H, Kuriyama-Matsumura K, et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer. 2003;88:951&#x2013;956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2377069</ArticleId>
            <ArticleId IdType="pubmed">12644836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SC B, SL C, BR H, et al. H., S. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17:1269&#x2013;1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3192231</ArticleId>
            <ArticleId IdType="pubmed">21909104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coriat R, Nicco C, Ch&#xe9;reau C, et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012;11:2284&#x2013;2293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22902857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, Zhang X, Wei C, et al. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis. Eur J Pharm Sci. 2020;152:105450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32621966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayano M, WS Y, CK C, et al. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016;23:270&#x2013;278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4716307</ArticleId>
            <ArticleId IdType="pubmed">26184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LJ Y, Ran Q, Rao L, et al. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med. 2003;34:496&#x2013;502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12566075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brigelius-Floh&#xe9; R. M., M. Glutathione Peroxidases. Biochim Biophys Acta. 2013;1830:3289&#x2013;3303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23201771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X, Zhang R, Liu S, et al. RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer. Front Pharmacol. 2018;9:1371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6262051</ArticleId>
            <ArticleId IdType="pubmed">30524291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell. 2014;156:317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinowaki Y, Kurata M, Ishibashi S, et al. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab Invest. 2018;98:609&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29463878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K, Hayano M, NC P, et al. Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity. Cell Chem Biol. 2016;23:225&#x2013;235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4792701</ArticleId>
            <ArticleId IdType="pubmed">26853626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krajka-Ku&#x17a;niak V, Paluszczak J. W., B.-D. The Nrf2-ARE signaling pathway: an update on its regulation and possible role in cancer prevention and treatment. Pharmacol Rep. 2017;69:393&#x2013;402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28267640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291&#x2013;13295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2679427</ArticleId>
            <ArticleId IdType="pubmed">19182219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Q. Role of Nrf2 in Oxidative Stress and Toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401&#x2013;426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4680839</ArticleId>
            <ArticleId IdType="pubmed">23294312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MB S, KT L. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12:564&#x2013;571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3836441</ArticleId>
            <ArticleId IdType="pubmed">22810811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Liu C, Li Z, et al. Regulation of GSK3&#x3b2;/Nrf2 signaling pathway modulated erastin-induced ferroptosis in breast cancer. Mol Cell Biochem. 2020;10.1007/s11010-020-03821-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32642794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B, Chen XB, Ying MD, et al. The Role of Ferroptosis in Cancer Development and Treatment Response. Front Pharmacol. 2018;8:992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5770584</ArticleId>
            <ArticleId IdType="pubmed">29375387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollak N, D&#xf6;lle C, Ziegler M. M., Z. The power to reduce: pyridine nucleotides&#x2013;small molecules with a multitude of functions. Biochem J. 2007;402:205&#x2013;218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1798440</ArticleId>
            <ArticleId IdType="pubmed">17295611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>TM P, JE D. Human Aldo-Keto Reductases: function, Gene Regulation, and Single Nucleotide Polymorphisms. Arch Biochem Biophys. 2007;464:241&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2025677</ArticleId>
            <ArticleId IdType="pubmed">17537398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barski OA, Bhatnagar A, Bhatnagar A. T.S.M. The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification. Drug Metab Rev. 2008;40:553&#x2013;624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663408</ArticleId>
            <ArticleId IdType="pubmed">18949601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>TM D, DW B, FL A, et al. PTHrP stimulates prostate cancer cell growth and upregulates aldo&#x2013;keto reductase 1C3. Cancer Lett. 2011;306:52&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21444150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>HK L, Steckelbroeck S, Fung KM, et al. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3&#x3b1;-hydroxysteroid dehydrogenase/type 5 17&#x3b2;-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids. 2004;69:795&#x2013;801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15582534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AK J, Gunnarsson C, Cohen M, et al. O., S. 17&#x3b2;-Hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor positive breast cancer. Canc Res. 2006;66:11471&#x2013;11477. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17145895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasano H, Suzuki T, Miki Y. T., M. Intracrinology of estrogens and androgens in breast carcinoma. J Steroid Biochem Mol Biol. 2008;108:181&#x2013;185. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17933521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsoi J, Robert L, Paraiso K, et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018;33(890&#x2013;904.e5). DOI:10.1016/j.ccell.2018.03.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.03.017</ArticleId>
            <ArticleId IdType="pmc">PMC5953834</ArticleId>
            <ArticleId IdType="pubmed">29657129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DW D, Gout PW, Kurita T, et al. W., P. . Sulfasalazine-Induced Cystine Starvation: potential Use for Prostate CancerTherapy. Prostate. 2007;67:162&#x2013;171. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17075799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VS N, GM P, Gout PW, et al. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy. 2007;53:210&#x2013;217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17356269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo M, Ling V, YZ W, et al. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464&#x2013;472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2527809</ArticleId>
            <ArticleId IdType="pubmed">18648370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Dai Z, Barbacioru C. W., S. Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance. Cancer Res. 2005;65:7446&#x2013;7454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16103098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JP FA, DV K, Conrad M. M., C. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19:405&#x2013;414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31101865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32814169</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-1186</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>161</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmacological research</Title>
          <ISOAbbreviation>Pharmacol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>105157</StartPage>
          <MedlinePgn>105157</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phrs.2020.105157</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1043-6618(20)31465-1</ELocationID>
        <Abstract>
          <AbstractText>Increasing evidence shows that Traditional Chinese Medicine (TCM) has an obvious appeal for cancer treatment, but there is still a lack of scientific investigation of its underlying molecular mechanisms. Bitter melon or bitter gourd (Momordica charantia) is an edible fruit that is commonly consumed, and it is used to cure different diseases in various ancient folk medical practices. We report that a bioactive protein, MAP30, isolated from bitter melon seeds exhibited potent anticancer and anti-chemoresistant effects on ovarian cancer cells. Functional studies revealed that MAP30 inhibited cancer cell migration, cell invasion, and cell proliferation in various ovarian cancer cells but not normal immortalized ovarian epithelial cells. When administered with cisplatin, MAP30 produced a synergistic effect on cisplatin-induced cell cytotoxicity in ovarian cancer cells. When low doses of cisplatin and MAP30 were co-injected intraperitoneally, a remarkable reduction of tumor dissemination and tumor growth was observed in an ovarian cancer ascites mouse model. Notably, blood tests confirmed that MAP30 did not cause any adverse effects on liver and kidney functions in the treated mice. MAP30 activated AMP-activated protein kinase (AMPK) signaling via CaMKK and induced cell cycle arrest in the S-phase. MAP30 modulated cell metabolism of ovarian cancer cells via suppression of GLUT-1/-3-mediated glucose uptake, adipogenesis, and lipid droplet formation in tumor development and progression. MAP30 also induced an increase in intracellular Ca[2+] ion concentration, which triggered ROS-mediated cancer cell death via apoptosis and ferroptosis. Collectively, these findings suggest that natural MAP30 is a non-toxic supplement that may enhance chemotherapeutic outcomes and benefit ovarian cancer patients with peritoneal metastases.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>David W</ForeName>
            <Initials>DW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: dwchan@hku.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yung</LastName>
            <ForeName>Mingo Mh</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Yau-Sang</ForeName>
            <Initials>YS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xuan</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Huijuan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Dakang</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhan</LastName>
            <ForeName>Jin-Biao</ForeName>
            <Initials>JB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Zhejiang University School of Medicine, 866 Yuhangtang Road, Zijingang Campus, Hangzhou, Zhejiang, 310058, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Karen Kl</ForeName>
            <Initials>KK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ng</LastName>
            <ForeName>Tzi-Bun</ForeName>
            <Initials>TB</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ngan</LastName>
            <ForeName>Hextan Ys</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: hysngan@hku.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Pharmacol Res</MedlineTA>
        <NlmUniqueID>8907422</NlmUniqueID>
        <ISSNLinking>1043-6618</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C066347">MAP30 protein, Momordica charantia</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054790">Ribosome Inactivating Proteins, Type 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050155" MajorTopicYN="N">Lipogenesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029777" MajorTopicYN="Y">Momordica charantia</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054790" MajorTopicYN="N">Ribosome Inactivating Proteins, Type 2</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">A23187 (PubChem CID: 40486)</Keyword>
        <Keyword MajorTopicYN="N">AICAR (PubChem CID: 46780289)</Keyword>
        <Keyword MajorTopicYN="N">BODIPY (PubChem: CID: 25058173)</Keyword>
        <Keyword MajorTopicYN="N">Cisplatin (PubChem CID: 441203)</Keyword>
        <Keyword MajorTopicYN="N">Erastin (PubChem CID: 11214940)</Keyword>
        <Keyword MajorTopicYN="N">Ferrostatin 1 (PubChem CID: 4068248)</Keyword>
        <Keyword MajorTopicYN="N">MAP30</Keyword>
        <Keyword MajorTopicYN="N">NaCl (PubChem CID: 5234)</Keyword>
        <Keyword MajorTopicYN="N">PVDF (PubChem CID: 3082294)</Keyword>
        <Keyword MajorTopicYN="N">Phenylmethylsulfonyl fluoride (PMSF) (PubChem CID: 4784)</Keyword>
        <Keyword MajorTopicYN="N">Propidium iodide (PI) (PubChem CID: 104981)</Keyword>
        <Keyword MajorTopicYN="N">STO-609 (PubChem CID: 3467590)</Keyword>
        <Keyword MajorTopicYN="N">Tris-HCl (PubChem CID: 93573)</Keyword>
        <Keyword MajorTopicYN="N">bitter melon</Keyword>
        <Keyword MajorTopicYN="N">chemoresistance</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
        <Keyword MajorTopicYN="N">ovarian cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32814169</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phrs.2020.105157</ArticleId>
        <ArticleId IdType="pii">S1043-6618(20)31465-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32699265</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1745-7254</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta pharmacologica Sinica</Title>
          <ISOAbbreviation>Acta Pharmacol Sin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>301</StartPage>
          <EndPage>310</EndPage>
          <MedlinePgn>301-310</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41401-020-0478-3</ELocationID>
        <Abstract>
          <AbstractText>Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it can only extend limited survival. It is imperative to find a combination strategy to increase sorafenib efficacy. Artesunate is such a preferred candidate, because artesunate is clinically well-tolerated and more importantly both drugs can induce ferroptosis through different mechanisms. In this study we investigated the combined effect of sorafenib and artesunate in inducing ferroptosis of HCC and elucidated the involved molecular mechanisms. We showed that artesunate greatly enhanced the anticancer effects of low dose of sorafenib against Huh7, SNU-449, and SNU-182 HCC cell lines in vitro and against Huh7 cell xenograft model in Balb/c nude mice. The combination index method confirmed that the combined effect of sorafenib and artesunate was synergistic. Compared with the treatment with artesunate or sorafenib alone, combined treatment induced significantly exacerbated lipid peroxidation and ferroptosis, which was blocked by N-acetyl cysteine and ferroptosis inhibitors liproxstatin-1 and deferoxamine mesylate, but not by inhibitors of other types of cell death (z-VAD, necrostatin-1 and belnacasan). In Huh7 cells, we demonstrated that the combined treatment induced oxidative stress and lysosome-mediated ferritinophagy, two essential aspects of ferroptosis. Sorafenib at low dose mainly caused oxidative stress through mitochondrial impairments and SLC7A11-invovled glutathione depletion. Artesunate-induced lysosome activation synergized with sorafenib-mediated pro-oxidative effects by promoting sequential reactions including lysosomal cathepsin B/L activation, ferritin degradation, lipid peroxidation, and consequent ferroptosis. Taken together, artesunate could be repurposed to sensitize sorafenib in HCC treatment. The combined treatment can be easily translated into clinical applications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Zhong-Jie</ForeName>
            <Initials>ZJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Dai</LastName>
            <ForeName>Hui-Qi</ForeName>
            <Initials>HQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Huang</LastName>
            <ForeName>Xiao-Wei</ForeName>
            <Initials>XW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Ji</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Jing-Huan</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, Guangxi Medical University, Nanning, 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zi-Xuan</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xiao-Mei</ForeName>
            <Initials>XM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yu-Jia</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Pan-Hong</ForeName>
            <Initials>PH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ji-Gang</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China. jgwang@icmm.ac.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. jgwang@icmm.ac.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shenzhen People's Hospital, Shenzhen, 518020, China. jgwang@icmm.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China. gardenia_zhou@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Guo-Dong</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China. golden_lu@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Guangxi Medical University, Nanning, 530021, China. golden_lu@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, Guangxi Medical University, Nanning, 530021, China. golden_lu@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of High-incidence-Tumor Prevention &amp; Treatment (Guangxi Medical University), Ministry of Education of China, Nanning, 530021, China. golden_lu@hotmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore. golden_lu@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Acta Pharmacol Sin</MedlineTA>
        <NlmUniqueID>100956087</NlmUniqueID>
        <ISSNLinking>1671-4083</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>60W3249T9M</RegistryNumber>
          <NameOfSubstance UI="D000077332">Artesunate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077332" MajorTopicYN="N">Artesunate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Artesunate</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">HCC</Keyword>
        <Keyword MajorTopicYN="N">Lysosome</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Sorafenib</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32699265</ArticleId>
        <ArticleId IdType="pmc">PMC8026986</ArticleId>
        <ArticleId IdType="doi">10.1038/s41401-020-0478-3</ArticleId>
        <ArticleId IdType="pii">10.1038/s41401-020-0478-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2012;10:34&#x2013;42. doi: 10.1038/nrgastro.2012.199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2012.199</ArticleId>
            <ArticleId IdType="pubmed">23147664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182&#x2013;236. doi: 10.1016/j.jhep.2018.03.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2018.03.019</ArticleId>
            <ArticleId IdType="pubmed">29628281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378&#x2013;90. doi: 10.1056/NEJMoa0708857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0708857</ArticleId>
            <ArticleId IdType="pubmed">18650514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25&#x2013;34. doi: 10.1016/S1470-2045(08)70285-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(08)70285-7</ArticleId>
            <ArticleId IdType="pubmed">19095497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599&#x2013;616. doi: 10.1038/s41571-018-0073-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-018-0073-4</ArticleId>
            <ArticleId IdType="pubmed">30061739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270&#x2013;9. doi: 10.1634/theoncologist.2011-0105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2011-0105</ArticleId>
            <ArticleId IdType="pmc">PMC3228178</ArticleId>
            <ArticleId IdType="pubmed">21885876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72:342&#x2013;52. doi: 10.1016/j.jhep.2019.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2019.09.010</ArticleId>
            <ArticleId IdType="pubmed">31954496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725&#x2013;33. doi: 10.1016/j.jhep.2009.03.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2009.03.028</ArticleId>
            <ArticleId IdType="pmc">PMC2970800</ArticleId>
            <ArticleId IdType="pubmed">19665249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung DH, Tak E, Hwang S, Song GW, Ahn CS, Kim KH, et al. Antitumor effect of sorafenib and mTOR inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence. Liver Transpl. 2018;24:932&#x2013;45. doi: 10.1002/lt.25191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lt.25191</ArticleId>
            <ArticleId IdType="pubmed">29710388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CH, Elkholy KH, Wani NA, Li D, Hu P, Barajas JM, et al. Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma. Mol Cancer Ther. 2020;19:384&#x2013;96. doi: 10.1158/1535-7163.MCT-19-0135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-19-0135</ArticleId>
            <ArticleId IdType="pmc">PMC7007841</ArticleId>
            <ArticleId IdType="pubmed">31582534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, et al. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res. 2009;15:5820&#x2013;8. doi: 10.1158/1078-0432.CCR-08-3294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-3294</ArticleId>
            <ArticleId IdType="pubmed">19737956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52:88&#x2013;95. doi: 10.1016/j.jhep.2009.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2009.10.011</ArticleId>
            <ArticleId IdType="pubmed">19913321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased &#x3b1;-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282&#x2013;96. doi: 10.1016/S1470-2045(18)30937-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30937-9</ArticleId>
            <ArticleId IdType="pubmed">30665869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer. 2010;127:2949&#x2013;58. doi: 10.1002/ijc.25498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25498</ArticleId>
            <ArticleId IdType="pmc">PMC2955185</ArticleId>
            <ArticleId IdType="pubmed">21351273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, et al. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget. 2015;6:28296&#x2013;311. doi: 10.18632/oncotarget.5064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5064</ArticleId>
            <ArticleId IdType="pmc">PMC4695061</ArticleId>
            <ArticleId IdType="pubmed">26299806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Chiang IT, Hsu FT. Protein kinase B inactivation is associated with magnolol-enhanced therapeutic efficacy of sorafenib in hepatocellular carcinoma in vitro and in vivo. Cancers. 2019;12:87. doi: 10.3390/cancers12010087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12010087</ArticleId>
            <ArticleId IdType="pmc">PMC7017147</ArticleId>
            <ArticleId IdType="pubmed">31905887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu WD, Chen PS, Omar HA, Arafa ES, Pan HW, Jeng J, et al. Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Sci Rep. 2018;8:12914. doi: 10.1038/s41598-018-31209-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-31209-8</ArticleId>
            <ArticleId IdType="pmc">PMC6110745</ArticleId>
            <ArticleId IdType="pubmed">30150684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of non-apoptotic cell death. Cell. 2012;149:1060&#x2013;72. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Angeli FJP, Bayir H, Bush AI, Conrad M, et al. Ferroptosis: aregulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;85. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife. 2014;3:e02523. doi: 10.7554/eLife.02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.02523</ArticleId>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2015;2:517&#x2013;32. doi: 10.18632/oncoscience.160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncoscience.160</ArticleId>
            <ArticleId IdType="pmc">PMC4468338</ArticleId>
            <ArticleId IdType="pubmed">26097885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Yan P, Zou C, Wong YK, Shu Y, Lee YM, et al. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev. 2019;39:2172&#x2013;93. doi: 10.1002/med.21580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/med.21580</ArticleId>
            <ArticleId IdType="pubmed">30972803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Xu C, Wong YK, Li Y, Liao F, Jiang T, et al. Artemisinin, the magic drug discovered from traditional chinese medicine. Engineering. 2018;5:32&#x2013;9. doi: 10.1016/j.eng.2018.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eng.2018.11.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in plasmodium falciparum. Nat Commun. 2015;6:10111. doi: 10.1038/ncomms10111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10111</ArticleId>
            <ArticleId IdType="pmc">PMC4703832</ArticleId>
            <ArticleId IdType="pubmed">26694030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang ND, Tan SH, Ng S, Shi Y, Zhou J, Tan KSW, et al. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem. 2014;289:33425&#x2013;41. doi: 10.1074/jbc.M114.564567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.564567</ArticleId>
            <ArticleId IdType="pmc">PMC4246098</ArticleId>
            <ArticleId IdType="pubmed">25305013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440&#x2013;6. doi: 10.1158/0008-5472.CAN-09-1947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1947</ArticleId>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou J, Tan SH, Nicolas V, Chantal B, Yang ND, Zhang J, et al. Activation of lysosomal function in the course of autophagy via MTORC1 suppression and autophagosome-lysosome fusion. Cell Res. 2013;23:508&#x2013;23. doi: 10.1038/cr.2013.11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2013.11</ArticleId>
            <ArticleId IdType="pmc">PMC3616426</ArticleId>
            <ArticleId IdType="pubmed">23337583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671&#x2013;5. doi: 10.1038/nmeth.2089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId>
            <ArticleId IdType="pmc">PMC5554542</ArticleId>
            <ArticleId IdType="pubmed">22930834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu GD, Ang YH, Zhou J, Tamilarasi J, Yan B, Lim YC, et al. CCAAT/enhancer binding protein &#x3b1; predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. Hepatology. 2015;61:965&#x2013;78. doi: 10.1002/hep.27593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27593</ArticleId>
            <ArticleId IdType="pmc">PMC4365685</ArticleId>
            <ArticleId IdType="pubmed">25363290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254&#x2013;62. doi: 10.1016/j.redox.2016.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2016.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC5198738</ArticleId>
            <ArticleId IdType="pubmed">28012440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenshields AL, Shepherd TG, Hoskin DW. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog. 2017;56:75&#x2013;93. doi: 10.1002/mc.22474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22474</ArticleId>
            <ArticleId IdType="pubmed">26878598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, Singh NP, et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett. 2009;274:290&#x2013;8. doi: 10.1016/j.canlet.2008.09.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2008.09.023</ArticleId>
            <ArticleId IdType="pubmed">19006645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong DE, Song HJ, Lim S, Lee SJ, Lim JE, Nam DH, et al. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget. 2015;6:33046&#x2013;64. doi: 10.18632/oncotarget.5422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5422</ArticleId>
            <ArticleId IdType="pmc">PMC4741748</ArticleId>
            <ArticleId IdType="pubmed">26426994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, et al. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 2014;26:861&#x2013;70. doi: 10.1097/MEG.0000000000000066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MEG.0000000000000066</ArticleId>
            <ArticleId IdType="pubmed">24987823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Liu S, Xing YR, Zhao RP, Xie J, Hu D, et al. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;519:41&#x2013;5. doi: 10.1016/j.bbrc.2019.08.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.08.115</ArticleId>
            <ArticleId IdType="pubmed">31481232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91&#x2013;8. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J, Lu PZ, Zhu GZ, Hooi SC, Wu Y, Huang XW, et al. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin. 2020. 10.1038/s41401-020-0439-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7921679</ArticleId>
            <ArticleId IdType="pubmed">32541921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houessinon A, Fran&#xe7;ois C, Sauzay C, Louandre C, Mongelard G, Godin C, et al. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Mol Cancer. 2016;15:38. doi: 10.1186/s12943-016-0526-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-016-0526-2</ArticleId>
            <ArticleId IdType="pmc">PMC4894370</ArticleId>
            <ArticleId IdType="pubmed">27184800</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32686685</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>3637</StartPage>
          <MedlinePgn>3637</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">3637</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-17380-5</ELocationID>
        <Abstract>
          <AbstractText>We report a strategy to boost Fenton reaction triggered by an exogenous circularly polarized magnetic field (MF) to enhance ferroptosis-like cell-death mediated immune response, as well as endow a responsive MRI capability by using a hybrid core-shell vesicles (HCSVs). HCSVs are prepared by loading ascorbic acid (AA) in the core and poly(lactic-co-glycolic acid) shell incorporating iron oxide nanocubes (IONCs). MF triggers the release of AA, resulting in the increase of ferrous ions through the redox reaction between AA and IONCs. A significant tumor suppression is achieved by Fenton reaction-mediated ferroptosis-like cell-death. The oxidative stress induced by the Fenton reaction leads to the exposure of calreticulin on tumor cells, which leads to dendritic cells maturation and the infiltration of cytotoxic T lymphocytes in tumor. Furthermore, the depletion of ferric ions during treatment enables monitoring of the Fe reaction in MRI-R2* signal change. This strategy provides a perspective on ferroptosis-based immunotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Bongseo</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-8754-9199</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Weiguo</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0001-8125-3824</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60607, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Dong-Hyun</ForeName>
            <Initials>DH</Initials>
            <Identifier Source="ORCID">0000-0001-6815-3319</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60607, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, 60611, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Evanston, IL, 60208, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA218659</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EB026207</GrantID>
            <Acronym>EB</Acronym>
            <Agency>NIBIB NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037282">Calreticulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058185">Magnetite Nanoparticles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1K09F3G675</RegistryNumber>
          <NameOfSubstance UI="C000499">ferric oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PQ6CK8PD0R</RegistryNumber>
          <NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037282" MajorTopicYN="N">Calreticulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060526" MajorTopicYN="Y">Magnetic Fields</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058185" MajorTopicYN="Y">Magnetite Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32686685</ArticleId>
        <ArticleId IdType="pmc">PMC7371635</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-020-17380-5</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-020-17380-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hu QY, Sun WJ, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 2016;98:19&#x2013;34. doi: 10.1016/j.addr.2015.10.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2015.10.022</ArticleId>
            <ArticleId IdType="pmc">PMC4998845</ArticleId>
            <ArticleId IdType="pubmed">26546751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F, et al. Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade. Adv. Mater. 2019;31:e1805888. doi: 10.1002/adma.201805888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201805888</ArticleId>
            <ArticleId IdType="pubmed">30762908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng B, et al. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment. Adv. Mater. 2018;30:e1803001. doi: 10.1002/adma.201803001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201803001</ArticleId>
            <ArticleId IdType="pubmed">30063262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv. Mater. 2019;31:e1802228. doi: 10.1002/adma.201802228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201802228</ArticleId>
            <ArticleId IdType="pubmed">30663118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv. Cancer Res. 2002;85:145&#x2013;174. doi: 10.1016/S0065-230X(02)85005-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-230X(02)85005-9</ArticleId>
            <ArticleId IdType="pubmed">12374285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer. 2014;14:199&#x2013;208. doi: 10.1038/nrc3672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3672</ArticleId>
            <ArticleId IdType="pubmed">24561446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen ZY, et al. Emerging strategies of cancer therapy based on ferroptosis. Adv. Mater. 2018;30:e1704007. doi: 10.1002/adma.201704007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201704007</ArticleId>
            <ArticleId IdType="pmc">PMC6377162</ArticleId>
            <ArticleId IdType="pubmed">29356212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SF, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano. 2018;12:12380&#x2013;12392. doi: 10.1021/acsnano.8b06399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06399</ArticleId>
            <ArticleId IdType="pubmed">30495919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;868. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol. Sci. 2017;38:489&#x2013;498. doi: 10.1016/j.tips.2017.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2017.02.005</ArticleId>
            <ArticleId IdType="pubmed">28363764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3&#x2013;11. doi: 10.1038/cdd.2008.150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2008.150</ArticleId>
            <ArticleId IdType="pmc">PMC2744427</ArticleId>
            <ArticleId IdType="pubmed">18846107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107&#x2013;120. doi: 10.1038/cdd.2011.96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2011.96</ArticleId>
            <ArticleId IdType="pmc">PMC3252826</ArticleId>
            <ArticleId IdType="pubmed">21760595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue W, et al. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nat. Commun. 2019;10:2025. doi: 10.1038/s41467-019-09760-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09760-3</ArticleId>
            <ArticleId IdType="pmc">PMC6497709</ArticleId>
            <ArticleId IdType="pubmed">31048681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YJ, et al. Oxidative stress-induced calreticulin expression and translocation: new insights into the destruction of melanocytes. J. Investig. Dermatol. 2014;134:183&#x2013;191. doi: 10.1038/jid.2013.268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2013.268</ArticleId>
            <ArticleId IdType="pubmed">23771121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 2018;12:11355&#x2013;11365. doi: 10.1021/acsnano.8b06201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06201</ArticleId>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, et al. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction. Angew. Chem. Int. Ed. 2016;55:2101&#x2013;2106. doi: 10.1002/anie.201510031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201510031</ArticleId>
            <ArticleId IdType="pubmed">26836344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao W, et al. Nanolongan with multiple on-demand conversions for ferroptosis&#x2013;apoptosis combined anticancer therapy. ACS Nano. 2019;13:260&#x2013;273. doi: 10.1021/acsnano.8b05602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b05602</ArticleId>
            <ArticleId IdType="pubmed">30616348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng DW, et al. Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy. Nano Lett. 2017;17:284&#x2013;291. doi: 10.1021/acs.nanolett.6b04060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.6b04060</ArticleId>
            <ArticleId IdType="pubmed">28027643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duesterberg CK, Mylon SE, Waite TD. pH effects on iron-catalyzed oxidation using Fenton&#x2019;s reagent. Environ. Sci. Technol. 2008;42:8522&#x2013;8527. doi: 10.1021/es801720d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/es801720d</ArticleId>
            <ArticleId IdType="pubmed">19068842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta. 2012;1826:443&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3608474</ArticleId>
            <ArticleId IdType="pubmed">22728050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta H, Paul P, Kumar N, Baxi S, Das DP. One pot synthesis of water-dispersible dehydroascorbic acid coated Fe3O4 nanoparticles under atmospheric air: blood cell compatibility and enhanced magnetic resonance imaging. J. Colloid Interface Sci. 2014;430:221&#x2013;228. doi: 10.1016/j.jcis.2014.05.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcis.2014.05.043</ArticleId>
            <ArticleId IdType="pubmed">24956575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drummen GP, van Liebergen LC, Op den Kamp JA, Post JA. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic. Biol. Med. 2002;33:473&#x2013;490. doi: 10.1016/S0891-5849(02)00848-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0891-5849(02)00848-1</ArticleId>
            <ArticleId IdType="pubmed">12160930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhang YL, Zhuang L, Gan BY. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38:12. doi: 10.1186/s40880-018-0288-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40880-018-0288-x</ArticleId>
            <ArticleId IdType="pmc">PMC5993148</ArticleId>
            <ArticleId IdType="pubmed">29764521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, Guo G, Zhou X, Chen H. Potential mechanism of ferroptosis in pancreatic cancer. Oncol. Lett. 2020;19:579&#x2013;587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6923864</ArticleId>
            <ArticleId IdType="pubmed">31897173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietrich O, et al. MR imaging differentiation of Fe(2+) and Fe(3+) based on relaxation and magnetic susceptibility properties. Neuroradiology. 2017;59:403&#x2013;409. doi: 10.1007/s00234-017-1813-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00234-017-1813-3</ArticleId>
            <ArticleId IdType="pubmed">28324122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon W, et al. Elimination pathways of nanoparticles. ACS Nano. 2019;13:5785&#x2013;5798. doi: 10.1021/acsnano.9b01383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.9b01383</ArticleId>
            <ArticleId IdType="pubmed">30990673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syed AM, Sindhwani S, Chan WCW. Making vessels more permeable. Nat. Biomed. Eng. 2017;1:629&#x2013;631. doi: 10.1038/s41551-017-0123-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41551-017-0123-8</ArticleId>
            <ArticleId IdType="pubmed">31015603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH. Image-guided cancer nanomedicine. J. Imaging. 2018;4:18. doi: 10.3390/jimaging4010018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jimaging4010018</ArticleId>
            <ArticleId IdType="pmc">PMC6197060</ArticleId>
            <ArticleId IdType="pubmed">30364459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto MM, Kim DH, Larson AC, Mouli SK. Interventional nanotheranostics: advancing nanotechnology applications with IR. J. Vasc. Interv. Radio. 2019;30:1824&#x2013;1829 e1821. doi: 10.1016/j.jvir.2019.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvir.2019.07.026</ArticleId>
            <ArticleId IdType="pubmed">31655765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park W, et al. Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells. ACS Appl. Mater. Interfaces. 2017;9:13819&#x2013;13824. doi: 10.1021/acsami.7b02258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.7b02258</ArticleId>
            <ArticleId IdType="pmc">PMC5719880</ArticleId>
            <ArticleId IdType="pubmed">28406012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang P, et al. Engineering dendritic-cell-based vaccines and PD-1 blockade in self-assembled peptide nanofibrous hydrogel to amplify antitumor T-cell immunity. Nano Lett. 2018;18:4377&#x2013;4385. doi: 10.1021/acs.nanolett.8b01406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.8b01406</ArticleId>
            <ArticleId IdType="pubmed">29932335</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32685019</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1838-7640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>17</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Theranostics</Title>
          <ISOAbbreviation>Theranostics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>7775</StartPage>
          <EndPage>7786</EndPage>
          <MedlinePgn>7775-7786</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.46903</ELocationID>
        <Abstract>
          <AbstractText>Rationale: Loss of iron-sulfur cluster function predisposes cancer cells to ferroptosis by upregulating iron-starvation response, but the role of glutaredoxin 5 (GLRX5) silencing in ferroptosis remains unknown. We examined the role of GLRX5 functional loss in promoting ferroptosis in cisplatin-resistant head and neck cancer (HNC) cells. Methods: The effects of sulfasalazine treatment and GLRX5 gene silencing were tested on HNC cell lines and mouse tumor xenograft models. These effects were analyzed concerning cell viability and death, lipid reactive oxygen species (ROS) and mitochondrial iron production, labile iron pool, mRNA/protein expression, and malondialdehyde assays. Results: Cyst(e)ine deprivation, erastin, or sulfasalazine induced ferroptosis in HNC cells, which was relatively less sensitive in cisplatin-resistant HNC cells. Sulfasalazine or cyst(e)ine deprivation-induced ferroptosis resulted from increased lipid peroxidation and intracellular free iron, which were significantly promoted by short-interfering RNA or short hairpin RNA (shRNA) targeting GLRX5 (P&lt;0.05). GLRX5 silencing activated iron-starvation response and boosted up intracellular free iron through the iron-responsive element-binding activity of increased iron regulatory protein (increased transferrin receptor and decreased ferritin). These effects were rescued by resistant GLRX5 cDNA but not by catalytically inactive mutant GLRX5 K101Q. The same results were noted in an in vivo mouse model transplanted with vector or shGLRX5-transduced HNC cells and treated with sulfasalazine. Conclusion: Our data suggest that inhibition of GLRX5 predisposes therapy-resistant HNC cells to ferroptosis.</AbstractText>
          <CopyrightInformation>&#xa9; The author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jaewang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>You</LastName>
            <ForeName>Ji Hyeon</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shin</LastName>
            <ForeName>Daiha</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Western Seoul Center, Korea Basic Science Institute, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roh</LastName>
            <ForeName>Jong-Lyel</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Theranostics</MedlineTA>
        <NlmUniqueID>101552395</NlmUniqueID>
        <ISSNLinking>1838-7640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C516011">GLRX5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054477">Glutaredoxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3XC8GUZ6CB</RegistryNumber>
          <NameOfSubstance UI="D012460">Sulfasalazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054477" MajorTopicYN="N">Glutaredoxins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012460" MajorTopicYN="N">Sulfasalazine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">cancer cells</Keyword>
        <Keyword MajorTopicYN="N">free iron</Keyword>
        <Keyword MajorTopicYN="N">gene silencing</Keyword>
        <Keyword MajorTopicYN="N">glutaredoxin 5</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32685019</ArticleId>
        <ArticleId IdType="pmc">PMC7359084</ArticleId>
        <ArticleId IdType="doi">10.7150/thno.46903</ArticleId>
        <ArticleId IdType="pii">thnov10p7775</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu Rev Nutr. 2018;38:97&#x2013;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30130469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Hout M, Dos Santos L, Hamai A, Mehrpour M. A promising new approach to cancer therapy: Targeting iron metabolism in cancer stem cells. Semin Cancer Biol. 2018;53:125&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30071257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ. et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, Kang R, Tang D. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem Biophys Res Commun. 2016;478:838&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27510639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim EH, Shin D, Lee J, Jung AR, Roh JL. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Cancer Lett. 2018;432:180&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29928961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez SW, Sviderskiy VO, Terzi EM, Papagiannakopoulos T, Moreira AL, Adams S. et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature. 2017;551:639&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808442</ArticleId>
            <ArticleId IdType="pubmed">29168506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciofi-Baffoni S, Nasta V, Banci L. Protein networks in the maturation of human iron-sulfur proteins. Metallomics. 2018;10:49&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29219157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye H, Jeong SY, Ghosh MC, Kovtunovych G, Silvestri L, Ortillo D. et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest. 2010;120:1749&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2860907</ArticleId>
            <ArticleId IdType="pubmed">20364084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Wang Y, Anderson GJ, Camaschella C, Chang Y, Nie G. Functional Analysis of GLRX5 Mutants Reveals Distinct Functionalities of GLRX5 Protein. J Cell Biochem. 2016;117:207&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26100117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SY, Chu KC, Lee HR, Lee KS, Carey TE. Establishment and characterization of nine new head and neck cancer cell lines. Acta Oto-laryngol. 1997;117:775&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9349880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh JL, Park JY, Kim EH, Jang HJ, Kwon M. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Cancer Lett. 2016;371:20&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26607904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura M, Nakatani K, Uzawa K, Ono K, Uesugi H, Ogawara K. et al. Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol Rep. 2005;14:1281&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16211297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer cell. 2011;19:387&#x2013;400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21397861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X. et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camaschella C, Campanella A, De Falco L, Boschetto L, Merlini R, Silvestri L. et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood. 2007;110:1353&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17485548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lane DJ, Merlot AM, Huang ML, Bae DH, Jansson PJ, Sahni S. et al. Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. Biochim Biophys Acta. 2015;1853:1130&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25661197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends Biochem Sci. 2016;41:274&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4783254</ArticleId>
            <ArticleId IdType="pubmed">26725301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson CP, Shen M, Eisenstein RS, Leibold EA. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta. 2012;1823:1468&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3675657</ArticleId>
            <ArticleId IdType="pubmed">22610083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metabol. 2008;8:237&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18762024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Rad Biol Med. 2019;133:130&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochem. 2012;51:5705&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3572738</ArticleId>
            <ArticleId IdType="pubmed">22703180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederbick A, Stehling O, Rosser R, Niggemeyer B, Nakai Y, Elsasser HP. et al. Role of human mitochondrial Nfs1 in cytosolic iron-sulfur protein biogenesis and iron regulation. Mol Cell Biol. 2006;26:5675&#x2013;87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1592756</ArticleId>
            <ArticleId IdType="pubmed">16847322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572:402&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D. et al. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Cell Rep. 2019;28:2501&#x2013;8.e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31484063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joo YH, Cho JK, Koo BS, Kwon M, Kwon SK, Kwon SY. et al. Guidelines for the surgical management of oral cancer: Korean Society of Thyroid-Head and Neck Surgery. Clin Exp Otorhinolaryngol. 2019;12:107&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6453784</ArticleId>
            <ArticleId IdType="pubmed">30703871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haddad RI, Shin DM. Recent advances in head and neck cancer. New Engl J Med. 2008;359:1143&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18784104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008;58:32&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18096865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denaro N, Merlano MC. Immunotherapy in head and neck squamous cell cancer. Clin Exp Otorhinolaryngol. 2018;11:217&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6222190</ArticleId>
            <ArticleId IdType="pubmed">29973040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695&#x2013;709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7720415</ArticleId>
            <ArticleId IdType="pubmed">18486742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A. et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2017;7:72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5422557</ArticleId>
            <ArticleId IdType="pubmed">28536670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim BH, Park SJ, Jeong WJ, Ahn SH. Comparison of treatment outcomes for T3 glottic squamous cell carcinoma: A meta-analysis. Clin Exp Otorhinolaryngol. 2018;11:1&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5831661</ArticleId>
            <ArticleId IdType="pubmed">29486540</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32308771</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1838-7640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Theranostics</Title>
          <ISOAbbreviation>Theranostics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combinative treatment of -elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.</ArticleTitle>
        <Pagination>
          <StartPage>5107</StartPage>
          <EndPage>5119</EndPage>
          <MedlinePgn>5107-5119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.44705</ELocationID>
        <Abstract>
          <AbstractText>Background and Purpose: RAS mutations limit the effectiveness of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in combination with chemotherapy for metastatic colorectal cancer (mCRC) patients. Therefore, new cell death forms have focused on identifying indirect targets to inhibit Ras-induced oncogenesis. Recently, emerging evidence has shown the potential of triggering ferroptosis for cancer therapy, particularly for eradicating aggressive malignancies that are resistant to traditional therapies. Methods: KRAS mutant CRC cell HCT116 and Lovo were treated with cetuximab and -elemene, a bioactive compound isolated from Chinese herb Curcumae Rhizoma. Ferroptosis and epithelial-mesenchymal transformation (EMT) were detected in vitro and in vivo. Orthotopic CRC animal model were established and the tumor growth was monitored by IVIS bioluminescence imaging. Tumor tissues were collected to determine ferroptosis effect and the expression of EMT markers after the treatment. Results: CCK-8 assay showed that synergetic effect was obtained when 125 g/ml -elemene was combined with 25 g/ml cetuximab in KRAS mutant CRC cells. AV/PI staining suggested a non-apoptotic mode of cell death after the treatment with -elemene and cetuximab. In vitro, -elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant CRC cells. Meanwhile, combinative treatment of -elemene and cetuximab inhibited cell migration and decreased the expression of mesenchymal markers (Vimentin, N-cadherin, Slug, Snail and MMP-9), but promoted the expression of epithelial marker E-cadherin. Moreover, ferroptosis inhibitors but not other cell death suppressors abrogated the effect of -elemene in combination with cetuximab on KRAS mutant CRC cells. In vivo, co-treatment with -elemene and cetuximab inhibited KRAS mutant tumor growth and lymph nodes metastases. Conclusions: Our data for the first time suggest that the natural product -elemene is a new ferroptosis inducer and combinative treatment of -elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations.</AbstractText>
          <CopyrightInformation>&#xa9; The author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xuejie</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ruonan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Shuiping</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Mingming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiaying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Da</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Colorectal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Bi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wengang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Liuxi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Xingxing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wenzheng</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yitian</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guohua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Lingpan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiaohui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yongqiang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Zuyi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhuo</LastName>
            <ForeName>Lvjia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sui</LastName>
            <ForeName>Xinbing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Theranostics</MedlineTA>
        <NlmUniqueID>101552395</NlmUniqueID>
        <ISSNLinking>1838-7640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C445979">beta-elemene</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PQX0D8J21J</RegistryNumber>
          <NameOfSubstance UI="D000068818">Cetuximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068818" MajorTopicYN="N">Cetuximab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012717" MajorTopicYN="N">Sesquiterpenes</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">KRAS mutation</Keyword>
        <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">epithelial-mesenchymal transformation</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">&#x3b2;-elemene</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32308771</ArticleId>
        <ArticleId IdType="pmc">PMC7163451</ArticleId>
        <ArticleId IdType="doi">10.7150/thno.44705</ArticleId>
        <ArticleId IdType="pii">thnov10p5107</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CC W, JH W, PC L, CA L, CY H, HC L. et al. Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. Crit Rev Oncol Hematol. 2020;145:102823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31783291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IG S, C C, G F, J N, M C, V M. et al. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019;10:3722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6700103</ArticleId>
            <ArticleId IdType="pubmed">31427573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA. et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol. 2018;14:507&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Li F, Lu GH, Nie W, Zhang L, Lv Y. et al. Engineering magnetosomes for ferroptosis/immunomodulation synergism in cancer. ACS Nano. 2019;13:5662&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31046234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W. et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10:1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu T, Shi L, Yu C, Dong Y, Qiu F, Shen L. et al. Ferroptosis promotes photodynamic therapy: supramolecular photosensitizer-inducer nanodrug for enhanced cancer treatment. Theranostics. 2019;9:3293&#x2013;307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6567978</ArticleId>
            <ArticleId IdType="pubmed">31244955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Lin Y, Hsu C, Chao Y, Hou Y, Chiu T. et al. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Theranostics. 2019;9:7168&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6831292</ArticleId>
            <ArticleId IdType="pubmed">31695760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashoreludlow B. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F. et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics. 2019;9:6209&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6735518</ArticleId>
            <ArticleId IdType="pubmed">31534546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai B, Zhang N, Han X, Li Q, Zhang M, Chen X. et al. Molecular targets of &#x3b2;-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review. Biomed Pharmacother. 2019;114:108812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30965237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan Y, Wang W, Huang S, Ni W, Wei Z, Cao Y. et al. Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation. J Cell Mol Med. 2019;23:6846&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6787513</ArticleId>
            <ArticleId IdType="pubmed">31343107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrat F, de Groot H, Rauen U. Determination of the chelatable iron pool of single intact cells by laser scanning microscopy. Arch Biochem Biophys. 2000;376:74&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10729192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X, Wang Z, Zhang F, Zhu G, Song J, Teng G. et al. Mapping sentinel lymph node metastasis by dual-probe optical imaging. Theranostics. 2017;7:153&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5196893</ArticleId>
            <ArticleId IdType="pubmed">28042324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Tian X, Cao X. Transferrin-functionalised microemulsion co-delivery of beta-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity. Drug Deliv Transl Res. 2019;9:667&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30798476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Liu Z, Sui X, Wu Q, Wang J, Xu C. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines. Phytomedicine. 2019;59:152787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31005810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi MZ, Attar R, Romero MA, Sabitaliyevich UY, Nurmurzayevich SB, Ozturk O. et al. Regulation of signaling pathways by beta-elemene in cancer progression and metastasis. J Cell Biochem. 2019;120:12091&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30912190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai B, Zeng Y, Zeng Z, Zhang N, Li C, Zeng Y. et al. Drug delivery systems for elemene, its main active ingredient beta-elemene, and its derivatives in cancer therapy. Int J Nanomedicine. 2018;13:6279&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6186893</ArticleId>
            <ArticleId IdType="pubmed">30349250</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32231343</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4469</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature chemical biology</Title>
          <ISOAbbreviation>Nat Chem Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles.</ArticleTitle>
        <Pagination>
          <StartPage>497</StartPage>
          <EndPage>506</EndPage>
          <MedlinePgn>497-506</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41589-020-0501-5</ELocationID>
        <Abstract>
          <AbstractText>We recently described glutathione peroxidase 4 (GPX4) as a promising target for killing therapy-resistant cancer cells via ferroptosis. The onset of therapy resistance by multiple types of treatment results in a stable cell state marked by high levels of polyunsaturated lipids and an acquired dependency on GPX4. Unfortunately, all existing inhibitors of GPX4 act covalently via a reactive alkyl chloride moiety that confers poor selectivity and pharmacokinetic properties. Here, we report our discovery that masked nitrile-oxide electrophiles, which have not been explored previously as covalent cellular probes, undergo remarkable chemical transformations in cells and provide an effective strategy for selective targeting of GPX4. The new GPX4-inhibiting compounds we describe exhibit unexpected proteome-wide selectivity and, in some instances, vastly improved physiochemical and pharmacokinetic properties compared to existing chloroacetamide-based GPX4 inhibitors. These features make them superior tool compounds for biological interrogation of ferroptosis and constitute starting points for development of improved inhibitors of GPX4.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Eaton</LastName>
            <ForeName>John K</ForeName>
            <Initials>JK</Initials>
            <Identifier Source="ORCID">0000-0003-4633-5546</Identifier>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Furst</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruberto</LastName>
            <ForeName>Richard A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moosmayer</LastName>
            <ForeName>Dieter</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hilpmann</LastName>
            <ForeName>Andr</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ryan</LastName>
            <ForeName>Matthew J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zimmermann</LastName>
            <ForeName>Katja</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Luke L</ForeName>
            <Initials>LL</Initials>
            <Identifier Source="ORCID">0000-0003-4204-1938</Identifier>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niehues</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Badock</LastName>
            <ForeName>Volker</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kramm</LastName>
            <ForeName>Anneke</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Sixun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hillig</LastName>
            <ForeName>Roman C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clemons</LastName>
            <ForeName>Paul A</ForeName>
            <Initials>PA</Initials>
            <Identifier Source="ORCID">0000-0002-1800-5112</Identifier>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gradl</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montagnon</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lazarski</LastName>
            <ForeName>Kiel E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christian</LastName>
            <ForeName>Sven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bajrami</LastName>
            <ForeName>Besnik</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neuhaus</LastName>
            <ForeName>Roland</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eheim</LastName>
            <ForeName>Ashley L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>Bayer AG, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Viswanathan</LastName>
            <ForeName>Vasanthi S</ForeName>
            <Initials>VS</Initials>
            <Identifier Source="ORCID">0000-0001-9878-3629</Identifier>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA. Vasanthi.Sridhar@post.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreiber</LastName>
            <ForeName>Stuart L</ForeName>
            <Initials>SL</Initials>
            <Identifier Source="ORCID">0000-0003-1922-7558</Identifier>
            <AffiliationInfo>
              <Affiliation>Broad Institute, Cambridge, MA, USA. stuart_schreiber@harvard.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA. stuart_schreiber@harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 GM038627</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 GM127045</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nat Chem Biol</MedlineTA>
        <NlmUniqueID>101231976</NlmUniqueID>
        <ISSNLinking>1552-4450</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015335">Molecular Probes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0CH9049VIS</RegistryNumber>
          <NameOfSubstance UI="D017279">Selenocysteine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Chem Biol. 2020 May;16(5):482-483</RefSource>
          <PMID Version="1">32231342</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015335" MajorTopicYN="N">Molecular Probes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010087" MajorTopicYN="N">Oxides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017279" MajorTopicYN="N">Selenocysteine</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>COMPETING INTERESTS STATEMENT. S.L.S. declares no conflicts associated with this research. A complete accounting of his outside professional activities, including a disclosure statement and links to the governing conflict of interest policies, are available at https://chemistry.harvard.edu/people/stuart-l-schreiber. P.A.C. is an advisor to Pfizer, Inc. D.M., A.H., K.Z., M.N., V.B., R.C.H., S.G., S.Ch., R.N., and A.L.E. are employed by Bayer AG.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32231343</ArticleId>
        <ArticleId IdType="mid">NIHMS1590000</ArticleId>
        <ArticleId IdType="pmc">PMC7251976</ArticleId>
        <ArticleId IdType="doi">10.1038/s41589-020-0501-5</ArticleId>
        <ArticleId IdType="pii">10.1038/s41589-020-0501-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Viswanathan VS et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453&#x2013;457 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247&#x2013;250 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsoi J et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell 33, 890&#x2013;904 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5953834</ArticleId>
            <ArticleId IdType="pubmed">29657129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas JP, Geiger PG, Maiorino M, Ursini F &amp; Girotti AW Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim. Biophys. Acta - Lipids Lipid Metab 1045, 252&#x2013;260 (1990).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2386798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xfc;hn H &amp; Borchert A Regulation of enzymatic lipid peroxidation: the interplay of peroxidizing and peroxide reducing enzymes. Free Radic. Biol. Med 33, 154&#x2013;172 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12106812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheerer P et al. Structural Basis for Catalytic Activity and Enzyme Polymerization of Phospholipid. Biochemistry 46, 9041&#x2013;9049 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17630701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borchert A et al. Crystal structure and functional characterization of selenocysteine-containing glutathione peroxidase 4 suggests an alternative mechanism of peroxide reduction. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1863, 1095&#x2013;1107 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29883798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci 113, E4966&#x2013;E4975 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol 12, 497&#x2013;503 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS &amp; Stockwell BR Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells. Chem. Biol 15, 234&#x2013;245 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakamoto K et al. Discovery of GPX4 inhibitory peptides from random peptide T7 phage display and subsequent structural analysis. Biochem. Biophys. Res. Commun 482, 195&#x2013;201 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27836545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C, Chen R, Pandey A, Kalita B &amp; Duraiswamy AJ US 2019/0263802 A1. 1&#x2013;292 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>We&#xef;wer M et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorganic Med. Chem. Lett 22, 1822&#x2013;1826 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3528973</ArticleId>
            <ArticleId IdType="pubmed">22297109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seashore-Ludlow B et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210&#x2013;1223 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4631646</ArticleId>
            <ArticleId IdType="pubmed">26482930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rees MG et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol 12, 109&#x2013;116 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4718762</ArticleId>
            <ArticleId IdType="pubmed">26656090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu A et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151&#x2013;1161 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3954635</ArticleId>
            <ArticleId IdType="pubmed">23993102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol 14, 507&#x2013;515 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060&#x2013;1072 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc 136, 4551&#x2013;4556 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O et al. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci 3, 232&#x2013;243 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina DM et al. Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay. Science 341, 84&#x2013;87 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23828940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J et al. Selenium-Encoded Isotopic Signature Targeted Profiling. ACS Cent. Sci 4, 960&#x2013;970 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6107865</ArticleId>
            <ArticleId IdType="pubmed">30159393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol 16, 1180&#x2013;1191 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trefzer C et al. Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-beta-D-ribose 2&#x2019;-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc 132, 13663&#x2013;13665 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20828197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patterson S &amp; Wyllie S Nitro drugs for the treatment of trypanosomatid diseases: Past, present, and future prospects. Trends Parasitol. 30, 289&#x2013;298 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4045206</ArticleId>
            <ArticleId IdType="pubmed">24776300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J et al. Elucidation of a novel bioactivation pathway of a 3,4-unsubstituted isoxazole in human liver microsomes: Formation of a glutathione adduct of a cyanoacrolein derivative after isoxazole ring opening. Drug Metab. Dispos 39, 302&#x2013;311 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21045198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duranti E, Balsamini C, Spadoni G &amp; Staccioli L Reaction of Secondary Acetylenic Bromides with Sodium Nitrite: Synthesis of 3,5-Alkyl(aryl)-4-nitroisoxazoles. J. Org. Chem 2870&#x2013;2872 (1988).</Citation>
        </Reference>
        <Reference>
          <Citation>Ray S, Kreitler DF, Gulick AM &amp; Murkin AS The Nitro Group as a Masked Electrophile in Covalent Enzyme Inhibition. ACS Chem. Biol 13, 1470&#x2013;1473 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6300134</ArticleId>
            <ArticleId IdType="pubmed">29782144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curini M et al. Alumina promoted cyclization of &#x3b1;-nitro-oximes: A new entry to the synthesis of 1,2,5-oxadiazoles N-oxides (furoxans). Tetrahedron Lett. 41, 8817&#x2013;8820 (2000).</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao JQ et al. Synthesis of furoxan derivatives: DABCO-mediated cascade sulfonylation/cyclization reaction of &#x3b1;-nitro-ketoximes. Tetrahedron 71, 1560&#x2013;1565 (2015).</Citation>
        </Reference>
        <Reference>
          <Citation>Burakevich JV, Butler RS &amp; Volpp GP Phenylfurazan Oxide. Chemistry. J. Org. Chem 37, 593&#x2013;596 (1972).</Citation>
        </Reference>
        <Reference>
          <Citation>Kalinina MI &amp; Mosiev IK Properties of Furoxans Monosubstituted with Adamantanes. Chem. Heterocycl. Compd 24, 217&#x2013;220 (1988).</Citation>
        </Reference>
        <Reference>
          <Citation>Eaton JK, Ruberto RA, Kramm A, Viswanathan VS &amp; Schreiber SL Diacylfuroxans Are Masked Nitrile Oxides That Inhibit GPX4 Covalently. J. Am. Chem. Soc 141, 20407&#x2013;20415 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31841309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelton BR, Howe R &amp; Liu KC A Particularly Convenient Preparation of Benzohydroximinoyl Chlorides (Nitrile Oxide Precursors). J. Org. Chem 45, 3916&#x2013;3918 (1980).</Citation>
        </Reference>
        <Reference>
          <Citation>Egan C, Clery M, Hegarty AF &amp; Welch AJ Mechanism of Reaction of Isomeric Nitrolic Acids to Nitrile Oxides in Aqueous Solution. J. Chem. Soc. Perkin Trans 2 249&#x2013;256 (1991).</Citation>
        </Reference>
        <Reference>
          <Citation>Matt C, Gissot A, Wagner A &amp; Mioskowski C Nitrolic acids: Efficient precursors of nitrile oxides under neutral conditions. Tetrahedron Lett. 41, 1191&#x2013;1194 (2000).</Citation>
        </Reference>
        <Reference>
          <Citation>Matt C, Wagner A &amp; Mioskowski C Novel Transformation of Primary Nitroalkanes and Primary Alkyl Bromides to the Corresponding Carboxylic Acids. J. Org. Chem 62, 234&#x2013;235 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11671390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyers RM et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet 49, 1779&#x2013;1784 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5709193</ArticleId>
            <ArticleId IdType="pubmed">29083409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O et al. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci 3, 232&#x2013;243 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Shchepinov MS &amp; Pratt DA Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent. Sci 4, 387&#x2013;396 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weerapana E et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790&#x2013;797 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3058684</ArticleId>
            <ArticleId IdType="pubmed">21085121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Backus KM et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534, 570&#x2013;574 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4919207</ArticleId>
            <ArticleId IdType="pubmed">27309814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-Peled L et al. Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell 171, 696&#x2013;709 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728659</ArticleId>
            <ArticleId IdType="pubmed">28965760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allimuthu D &amp; Adams DJ 2-Chloropropionamide As a Low-Reactivity Electrophile for Irreversible Small-Molecule Probe Identification. ACS Chem. Biol 12, 2124&#x2013;2131 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28613814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shindo N et al. Selective and reversible modification of kinase cysteines with chlorofluoroacetamides. Nat. Chem. Biol 15, 250&#x2013;258 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30643284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaro BW, Whitby LR, Lum KM &amp; Cravatt BF Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors. J. Am. Chem. Soc 138, 15841&#x2013;15844 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5273863</ArticleId>
            <ArticleId IdType="pubmed">27960302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mart&#xed;n-Gago P et al. Covalent Protein Labeling at Glutamic Acids. Cell Chem. Biol 24, 589&#x2013;597.e5 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28434875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geu-Flores F et al. Glucosinolate engineering identifies a &#x3b3;-glutamyl peptidase. Nat. Chem. Biol 5, 575&#x2013;577 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19483696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mutlib AE et al. P450-Mediated Metabolism of 1-[3-(Aminomethyl)phenyl]- N -[3-fluoro-2&#x2019;-(methylsulfonyl)- [1,1&#x2019;-biphenyl]-4-yl]-3-(trifluoromethyl)-1 H -pyrazole- 5-carboxamide (DPC 423) and Its Analogues to Aldoximes. Characterization of Glutathione Conjugates of Postula. Chem. Res. Toxicol 15, 63&#x2013;75 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11800598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roveri A, Maiorino M &amp; Ursini F Myoglobin Which Possesses a Very Slow Rate of Autoreduction; (3) Its Formation Is Relatively Easy, Requiring Only Metmyoglobin and. Methods Enzymol. 233, 202&#x2013;212 (1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8015457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato S et al. Preparation of 13 or 9-hydroperoxy-9Z,11E (9E,11E) or 10E,12Z (10E,12E)-octadecadienoic phosphatidylcholine hydroperoxide. J. Oleo Sci 63, 431&#x2013;437 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24717544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kriska T &amp; Girotti AW A thin layer chromatographic method for determining the enzymatic activity of peroxidases catalyzing the two-electron reduction of lipid hydroperoxides. J. Chromatogr. B Anal. Technol. Biomed. Life Sci 827, 58&#x2013;64 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15899595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novoselov SV et al. A highly efficient form of the selenocysteine insertion sequence element in protozoan parasites and its use in mammalian cells. Proc. Natl. Acad. Sci 104, 7857&#x2013;62 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1876537</ArticleId>
            <ArticleId IdType="pubmed">17470795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durocher Y, Perret S &amp; Kamen A High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, 9e&#x2013;9 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC99848</ArticleId>
            <ArticleId IdType="pubmed">11788735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen D et al. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5. J. Med. Chem 62, 928&#x2013;940 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30563338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werner S et al. Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile. J. Med. Chem 8, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31746599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cee VJ et al. Systematic Study of the Glutathione (GSH) Reactivity of N -Arylacrylamides: 1. Effects of Aryl Substitution. J. Med. Chem 58, 9171&#x2013;9178 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26580091</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32160546</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2211-1247</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell reports</Title>
          <ISOAbbreviation>Cell Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transferrin Receptor Is a Specific Ferroptosis Marker.</ArticleTitle>
        <Pagination>
          <StartPage>3411</StartPage>
          <EndPage>3423.e7</EndPage>
          <MedlinePgn>3411-3423.e7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.02.049</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)30210-2</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a type of regulated cell death driven by the iron-dependent accumulation of oxidized polyunsaturated fatty acid-containing phospholipids. There is no reliable way to selectively stain ferroptotic cells in tissue sections to characterize the extent of ferroptosis in animal models or patient samples. We address this gap by immunizing mice with membranes from lymphoma cells treated with the ferroptosis inducer piperazine erastin and screening 4,750 of the resulting monoclonal antibodies generated for their ability to selectively detect cells undergoing ferroptosis. We find that one antibody, 3F3 ferroptotic membrane antibody (3F3-FMA), is effective as a selective ferroptosis-staining reagent. The antigen of 3F3-FMA is identified as the human transferrin receptor 1 protein (TfR1). We validate this finding with several additional anti-TfR1 antibodies and compare them to other potential ferroptosis-detecting reagents. We find that anti-TfR1 and anti-malondialdehyde adduct antibodies are effective at staining ferroptotic tumor cells in multiple cell culture and tissue contexts.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Huizhong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schorpp</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>HelmholtzZentrum Mnchen, German Research Center for Environmental Health (GmbH), Assay Development and Screening Platform, Institute for Molecular Toxicology and Pharmacology, Ingolstdter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Jenny</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yozwiak</LastName>
            <ForeName>Carrie E</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoffstrom</LastName>
            <ForeName>Benjamin G</ForeName>
            <Initials>BG</Initials>
            <AffiliationInfo>
              <Affiliation>Antibody Technology Resource, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA 98109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Decker</LastName>
            <ForeName>Aubrianna M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rajbhandari</LastName>
            <ForeName>Presha</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stokes</LastName>
            <ForeName>Michael E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bender</LastName>
            <ForeName>Hannah G</ForeName>
            <Initials>HG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Csuka</LastName>
            <ForeName>Joleen M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Upadhyayula</LastName>
            <ForeName>Pavan S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Canoll</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 1130 St. Nicholas Ave., Room 1001, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uchida</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soni</LastName>
            <ForeName>Rajesh K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hadian</LastName>
            <ForeName>Kamyar</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>HelmholtzZentrum Mnchen, German Research Center for Environmental Health (GmbH), Assay Development and Screening Platform, Institute for Molecular Toxicology and Pharmacology, Ingolstdter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stockwell</LastName>
            <ForeName>Brent R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA; Department of Chemistry, Columbia University, Northwest Corner Building, 12th Floor, MC 4846, 550 West 120(th) Street, New York, NY 10027, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: bstockwell@columbia.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R35 CA209896</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA087497</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>TL1 TR001875</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R61 NS109407</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA013696</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Rep</MedlineTA>
        <NlmUniqueID>101573691</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000941">Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1RTM4PAL0V</RegistryNumber>
          <NameOfSubstance UI="D000077489">Piperazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077489" MajorTopicYN="N">Piperazine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">biomarker</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">cell death</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis marker</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis-specific antibody</Keyword>
        <Keyword MajorTopicYN="N">iron</Keyword>
        <Keyword MajorTopicYN="N">tissue staining</Keyword>
        <Keyword MajorTopicYN="N">transferrin receptor</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Interests B.R.S. is a consultant to and has equity in Inzen Therapeutics. B.R.S. also is an inventor on patents and patent applications related to ferroptosis. C.E.Y. is currently an employee of Vertex Pharmaceuticals.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32160546</ArticleId>
        <ArticleId IdType="mid">NIHMS1574786</ArticleId>
        <ArticleId IdType="pmc">PMC7172030</ArticleId>
        <ArticleId IdType="doi">10.1016/j.celrep.2020.02.049</ArticleId>
        <ArticleId IdType="pii">S2211-1247(20)30210-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aisen P (2004). Transferrin receptor 1. Int. J. Biochem. Cell Biol 36, 2137&#x2013;2143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15313461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alkan SS (2004). Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat. Rev. Immunol 4, 153&#x2013;156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15040588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, et al. (2006). CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1794559</ArticleId>
            <ArticleId IdType="pubmed">17076895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox J, and Mann M (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol 26, 1367&#x2013;1372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19029910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, and Mann M (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res 10, 1794&#x2013;1805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21254760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniels TR, Bernabeu E, Rodr&#xed;guez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, and Penichet ML (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 291&#x2013;317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3500658</ArticleId>
            <ArticleId IdType="pubmed">21851850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, and Stockwell BR (2019). The Hallmarks of Ferroptosis. Annu. Rev. Cancer Biol 3, 35&#x2013;54.</Citation>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, and Stockwell BR (2014). Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, Superti-Furga G, and Stockwell BR (2015). Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem. Biol 10, 1604&#x2013;1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509420</ArticleId>
            <ArticleId IdType="pubmed">25965523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol 13, 91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, and Stockwell BR (2003). Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drummen GP, van Liebergen LC, Op den Kamp JA, and Post JA (2002). C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic. Biol. Med 33, 473&#x2013;490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12160930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng H, and Stockwell BR (2018). Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol. 16, e2006203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5991413</ArticleId>
            <ArticleId IdType="pubmed">29795546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Quadri N, Ramasamy R, and Jiang X (2015). Glutaminolysis and Transferrin Regulate Ferroptosis. Mol. Cell 59, 298&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, Heindel DW, Zuckerman DS, Bos PH, Reznik E, et al. (2018). FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol 14, 507&#x2013;515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison PM, and Arosio P (1996). The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161&#x2013;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8695634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, and Kalyanaraman B (2002). Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J. Biol. Chem 277, 17179&#x2013;17187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11856741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larraufie MH, Yang WS, Jiang E, Thomas AG, Slusher BS, and Stockwell BR (2015). Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorg. Med. Chem. Lett 25, 4787&#x2013;4792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4653046</ArticleId>
            <ArticleId IdType="pubmed">26231156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques O, Porto G, R&#xea;ma A, Faria F, Cruz Paula A, Gomez-Lazaro M, Silva P, Martins da Silva B, and Lopes C (2016). Local iron homeostasis in the breast ductal carcinoma microenvironment. BMC Cancer 16, 187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4779214</ArticleId>
            <ArticleId IdType="pubmed">26944411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xfc;ller T, Dewitz C, Schmitz J, Schr&#xf6;der AS, Br&#xe4;sen JH, Stockwell BR, Murphy JM, Kunzendorf U, and Krautwald S (2017). Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cell. Mol. Life Sci 74, 3631&#x2013;3645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5589788</ArticleId>
            <ArticleId IdType="pubmed">28551825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schorpp K, and Hadian K (2014). Small molecule screening at Helmholtz Zentrum M&#xfc;nchen - from biology to molecules. Comb. Chem. High Throughput Screen 17, 266&#x2013;271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24409952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ, and Stockwell BR (2016). Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol 12, 497&#x2013;503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4920070</ArticleId>
            <ArticleId IdType="pubmed">27159577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A, and Stockwell BR (2014). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc 136, 4551&#x2013;4556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonabend AM, Yun J, Lei L, Leung R, Soderquist C, Crisman C, Gill BJ, Carminucci A, Sisti J, Castelli M, et al. (2013). Murine cell line model of proneural glioma for evaluation of anti-tumor therapies. J. Neurooncol 112, 375&#x2013;382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3694577</ArticleId>
            <ArticleId IdType="pubmed">23504257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gasc&#xf3;n S, Hatzios SK, Kagan VE, et al. (2017). Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171, 273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tampo Y, Kotamraju S, Chitambar CR, Kalivendi SV, Keszler A, Joseph J, and Kalyanaraman B (2003). Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: role of transferrin receptor-dependent iron uptake in apoptosis. Circ. Res 92, 56&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12522121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, et al. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vizca&#xed;no JA, C&#xf4;t&#xe9; RG, Csordas A, Dianes JA, Fabregat A, Foster JM, Griss J, Alpi E, Birim M, Contell J, et al. (2013). The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 41 (D1), D1063&#x2013;D1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3531176</ArticleId>
            <ArticleId IdType="pubmed">23203882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiland A, Wang Y, Wu W, Lan X, Han X, Li Q, and Wang J (2019). Ferroptosis and Its Role in Diverse Brain Diseases. Mol. Neurobiol 56, 4880&#x2013;4893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506411</ArticleId>
            <ArticleId IdType="pubmed">30406908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada S, Kumazawa S, Ishii T, Nakayama T, Itakura K, Shibata N, Kobayashi M, Sakai K, Osawa T, and Uchida K (2001). Immunochemical detection of a lipofuscin-like fluorophore derived from malondialdehyde and lysine. J. Lipid Res 42, 1187&#x2013;1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11483619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamanaka K, Saito Y, Sakiyama J, Ohuchi Y, Oseto F, and Noguchi N (2012). A novel fluorescent probe with high sensitivity and selective detection of lipid hydroperoxides in cells. RSC Adv. 2, 7894&#x2013;7900.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang WS, and Stockwell BR (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol 15, 234&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, Kang R, and Tang D (2016). Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun 478, 1338&#x2013;1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, Uchida K, O&#x2019;Connor OA, and Stockwell BR (2019). Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem. Biol 26, 623&#x2013;633.e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32155051</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1936-086X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS nano</Title>
          <ISOAbbreviation>ACS Nano</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced Ferroptosis by Oxygen-Boosted Phototherapy Based on a 2-in-1 Nanoplatform of Ferrous Hemoglobin for Tumor Synergistic Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>3414</StartPage>
          <EndPage>3425</EndPage>
          <MedlinePgn>3414-3425</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsnano.9b09426</ELocationID>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) combined with oxygenating strategies is widely employed in cancer treatment; however, oxygen-boosted PDT has failed to achieve an ideal effect due to the complexity, heterogeneity, and irreversible hypoxic environment generated by tumor tissues. With the emergence of Fe-dependent ferroptosis boasting reactive oxygen species (ROS) cytotoxicity as well, such a chemodynamic approach to cancer therapy has drawn extensive attention. In this study, hemoglobin (Hb) is connected with the photosensitizer chlorin e6 (Ce6) to construct a 2-in-1 nanoplatform (SRF@Hb-Ce6) with Sorafenib (SRF, ferroptosis promotor) loaded, combining oxygen-boosted PDT and potent ferroptosis. Benefiting from the intrinsic presence of Fe capable of binding oxygen, hemoglobin concurrently furnishes oxygen for oxygen-dependent PDT and Fe for Fe-dependent ferroptosis. Furthermore, amphiphilic MMP2-responsive peptide is incorporated into the skeleton of the nanoplatform to ensure drug-release specificity for safety improvement. Correlative measurements demonstrate the potentiation of PDT and ferroptosis with SRF@Hb-Ce6. More importantly, PDT strengthens ferroptosis by recruiting immune cells to secrete IFN-, which can sensitize the tumor to ferroptosis in our findings. The therapeutic effect of synergistic treatment with SRF@Hb-Ce6 in vitro and in vivo was proven significant, revealing the promising prospects of combined PDT and ferroptosis therapy with the 2-in-1 nanoplatform.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Yuying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Qinling</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Huixin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Xinkai</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Zhiyu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, School of Automation, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rolle</LastName>
            <ForeName>Janiqua Kyiesha</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Yueqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Siwen</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-1242-7365</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Nano</MedlineTA>
        <NlmUniqueID>101313589</NlmUniqueID>
        <ISSNLinking>1936-0851</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">hemoglobin</Keyword>
        <Keyword MajorTopicYN="N">nanoplatform</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">synergistic therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32155051</ArticleId>
        <ArticleId IdType="doi">10.1021/acsnano.9b09426</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32077821</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1873-5592</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current drug targets</Title>
          <ISOAbbreviation>Curr Drug Targets</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Edaravone May Prevent Ferroptosis in ALS.</ArticleTitle>
        <Pagination>
          <StartPage>776</StartPage>
          <EndPage>780</EndPage>
          <MedlinePgn>776-780</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/1389450121666200220123305</ELocationID>
        <Abstract>
          <AbstractText>Radicava (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.</AbstractText>
          <CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Spasi</LastName>
            <ForeName>Sneana</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nikoli-Koki</LastName>
            <ForeName>Aleksandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute for Biological Research "Sinisa Stankovic", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mileti</LastName>
            <ForeName>Sran</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oreanin-Dui</LastName>
            <ForeName>Zorana</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute for Biological Research "Sinisa Stankovic", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spasi</LastName>
            <ForeName>Mihajlo B</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute for Biological Research "Sinisa Stankovic", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blagojevi</LastName>
            <ForeName>Duko</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute for Biological Research "Sinisa Stankovic", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stevi</LastName>
            <ForeName>Zorica</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Clinic of Neurology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Drug Targets</MedlineTA>
        <NlmUniqueID>100960531</NlmUniqueID>
        <ISSNLinking>1389-4501</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S798V6YJRP</RegistryNumber>
          <NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Edaravone</Keyword>
        <Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">neurodegeneration</Keyword>
        <Keyword MajorTopicYN="N">neurons</Keyword>
        <Keyword MajorTopicYN="N">therapy.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32077821</ArticleId>
        <ArticleId IdType="doi">10.2174/1389450121666200220123305</ArticleId>
        <ArticleId IdType="pii">CDT-EPUB-104689</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31907052</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-3155</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of nanobiotechnology</Title>
          <ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Biological response and cytotoxicity induced by lipid nanocapsules.</ArticleTitle>
        <Pagination>
          <StartPage>5</StartPage>
          <MedlinePgn>5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">5</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-019-0567-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lipid nanocapsules (LNCs) are promising vehicles for drug delivery. However, since not much was known about cellular toxicity of these nanoparticles in themselves, we have here investigated the mechanisms involved in LNC-induced intoxication of the three breast cancer cell lines MCF-7, MDA-MD-231 and MDA-MB-468. The LNCs used were made of Labrafac Lipophile WL1349, Lipoid[] S75 and Solutol[] HS15.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">High resolution SIM microscopy showed that the DiD-labeled LNCs ended up in lysosomes close to the membrane. Empty LNCs, i.e. without encapsulated drug, induced not only increased lysosomal pH, but also acidification of the cytosol and a rapid inhibition of protein synthesis. The cytotoxicity of the LNCs were measured for up to 72&#xa0;h of incubation using the MTT assay and ATP measurements in all three cell lines, and revealed that MDA-MB-468 was the most sensitive cell line and MCF-7 the least sensitive cell line to these LNCs. The LNCs induced generation of reactive free oxygen species and lipid peroxidation. Experiments with knock-down of kinases in the near-haploid cell line HAP1 indicated that the kinase HRI is essential for the observed phosphorylation of eIF2&#x3b1;. Nrf2 and ATF4 seem to play a protective role against the LNCs in MDA-MB-231 cells, as knock-down of these factors sensitizes the cells to the LNCs. This is in contrast to MCF-7 cells where the knock-down of these factors had a minor effect on the toxicity of the LNCs. Inhibitors of ferroptosis provided a large protection against LNC toxicity in MDA-MB-231 cells, but not in MCF-7 cells.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High doses of LNCs showed a different degree of toxicity on the three cell lines studied, i.e. MCF-7, MDA-MD-231 and MDA-MB-468 and affected signaling factors and the cell fate differently in these cell lines.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Szwed</LastName>
            <ForeName>Marzena</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-2102-3741</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Torgersen</LastName>
            <ForeName>Maria Lyngaas</ForeName>
            <Initials>ML</Initials>
            <Identifier Source="ORCID">0000-0003-2616-7194</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumari</LastName>
            <ForeName>Remya Valsala</ForeName>
            <Initials>RV</Initials>
            <Identifier Source="ORCID">0000-0001-8064-4268</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Indian Institute of Technology, Hyderabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yadava</LastName>
            <ForeName>Sunil Kumar</ForeName>
            <Initials>SK</Initials>
            <Identifier Source="ORCID">0000-0002-5749-1758</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Indian Institute of Technology, Hyderabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pust</LastName>
            <ForeName>Sascha</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-0178-2206</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iversen</LastName>
            <ForeName>Tore Geir</ForeName>
            <Initials>TG</Initials>
            <Identifier Source="ORCID">0000-0003-1148-6117</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skotland</LastName>
            <ForeName>Tore</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-6524-612X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giri</LastName>
            <ForeName>Jyotsnendu</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-2313-4912</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Indian Institute of Technology, Hyderabad, India. j.giri@iith.ac.in.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sandvig</LastName>
            <ForeName>Kirsten</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-4174-9072</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway. ksandvig@radium.uio.no.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biosciences, University of Oslo, Oslo, Norway. ksandvig@radium.uio.no.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>228200</GrantID>
            <Agency>The Research Council of Norway</Agency>
          </Grant>
          <Grant>
            <GrantID>DST/IMRCD/INNO-INDIGO/NANOBREASTCO/2015</GrantID>
            <Agency>India Nanomission</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Nanobiotechnology</MedlineTA>
        <NlmUniqueID>101152208</NlmUniqueID>
        <ISSNLinking>1477-3155</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497109">ATF4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053769">Nanocapsules</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>145891-90-3</RegistryNumber>
          <NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051701" MajorTopicYN="N">Activating Transcription Factor 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053769" MajorTopicYN="N">Nanocapsules</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer cells</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Lipid nanocapsules</Keyword>
        <Keyword MajorTopicYN="N">Stress responses</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31907052</ArticleId>
        <ArticleId IdType="pmc">PMC6943936</ArticleId>
        <ArticleId IdType="doi">10.1186/s12951-019-0567-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s12951-019-0567-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387&#x2013;6392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2946403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target. 1996;3:391&#x2013;398. doi: 10.3109/10611869608996830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10611869608996830</ArticleId>
            <ArticleId IdType="pubmed">8866658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barenholz Y. Doxil(R)&#x2013;the first FDA-approved nano-drug: lessons learned. J Controll Release. 2012;160:117&#x2013;134. doi: 10.1016/j.jconrel.2012.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2012.03.020</ArticleId>
            <ArticleId IdType="pubmed">22484195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fusser M, Overbye A, Pandya AD, Morch Y, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Maelandsmo GM. Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. J Controll Release. 2019;293:183&#x2013;192. doi: 10.1016/j.jconrel.2018.11.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2018.11.029</ArticleId>
            <ArticleId IdType="pubmed">30529259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redka DS, Gutschow M, Grinstein S, Canton J. Differential ability of proinflammatory and anti-inflammatory macrophages to perform macropinocytosis. Mol Biol Cell. 2018;29:53&#x2013;65. doi: 10.1091/mbc.E17-06-0419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.E17-06-0419</ArticleId>
            <ArticleId IdType="pmc">PMC5746066</ArticleId>
            <ArticleId IdType="pubmed">29093026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madsen DH, Jurgensen HJ, Siersbaek MS, Kuczek DE, Grey Cloud L, Liu S, Behrendt N, Grontved L, Weigert R, Bugge TH. Tumor-associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake. Cell Reports. 2017;21:3662&#x2013;3671. doi: 10.1016/j.celrep.2017.12.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.12.011</ArticleId>
            <ArticleId IdType="pmc">PMC5753792</ArticleId>
            <ArticleId IdType="pubmed">29281816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Disc. 2014;13:813&#x2013;827. doi: 10.1038/nrd4333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4333</ArticleId>
            <ArticleId IdType="pmc">PMC4489143</ArticleId>
            <ArticleId IdType="pubmed">25287120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20&#x2013;37. doi: 10.1038/nrc.2016.108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2016.108</ArticleId>
            <ArticleId IdType="pmc">PMC5575742</ArticleId>
            <ArticleId IdType="pubmed">27834398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skotland T, Iversen TG, Sandvig K. Development of nanoparticles for clinical use. Nanomedicine (London, England) 2014;9:1295&#x2013;1299. doi: 10.2217/nnm.14.81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nnm.14.81</ArticleId>
            <ArticleId IdType="pubmed">25204821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523&#x2013;580. doi: 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/CritRevTherDrugCarrierSyst.v26.i6.10</ArticleId>
            <ArticleId IdType="pmc">PMC2885142</ArticleId>
            <ArticleId IdType="pubmed">20402623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379:201&#x2013;209. doi: 10.1016/j.ijpharm.2009.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2009.04.026</ArticleId>
            <ArticleId IdType="pubmed">19409468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami T. Phospholipid nanodisc engineering for drug delivery systems. Biotechnol J. 2012;7:762&#x2013;767. doi: 10.1002/biot.201100508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biot.201100508</ArticleId>
            <ArticleId IdType="pubmed">22581727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitorre M, Gonde H, Haury C, Messous M, Poilane J, Boudaud D, Kanber E, Rossemond Ndombina GA, Benoit JP, Bastiat G. Recent advances in nanocarrier-loaded gels: which drug delivery technologies against which diseases? J Control Release. 2017;266:140&#x2013;155. doi: 10.1016/j.jconrel.2017.09.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2017.09.031</ArticleId>
            <ArticleId IdType="pubmed">28951319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beloqui A, Solinis MA, Rodriguez-Gascon A, Almeida AJ, Preat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12:143&#x2013;161. doi: 10.1016/j.nano.2015.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nano.2015.09.004</ArticleId>
            <ArticleId IdType="pubmed">26410277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bastiat G, Pritz CO, Roider C, Fouchet F, Lignieres E, Jesacher A, Glueckert R, Ritsch-Marte M, Schrott-Fischer A, Saulnier P, Benoit JP. A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging. J Controll Release. 2013;170:334&#x2013;342. doi: 10.1016/j.jconrel.2013.06.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2013.06.014</ArticleId>
            <ArticleId IdType="pubmed">23792117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paillard A, Hindre F, Vignes-Colombeix C, Benoit JP, Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials. 2010;31:7542&#x2013;7554. doi: 10.1016/j.biomaterials.2010.06.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2010.06.024</ArticleId>
            <ArticleId IdType="pubmed">20630585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Roux G, Moche H, Nieto A, Benoit JP, Nesslany F, Lagarce F. Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicol In Vitro. 2017;41:189&#x2013;199. doi: 10.1016/j.tiv.2017.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tiv.2017.03.007</ArticleId>
            <ArticleId IdType="pubmed">28323104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. BCR. 2011;13:215. doi: 10.1186/bcr2889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr2889</ArticleId>
            <ArticleId IdType="pmc">PMC3236329</ArticleId>
            <ArticleId IdType="pubmed">21884641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szwed M, Sonstevold T, Overbye A, Engedal N, Grallert B, Morch Y, Sulheim E, Iversen TG, Skotland T, Sandvig K, Torgersen ML. Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death. Nanotoxicology. 2019;8:1&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30760074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19:875&#x2013;880. doi: 10.1023/A:1016121319668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1016121319668</ArticleId>
            <ArticleId IdType="pubmed">12134960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aulas A, Fay MM, Lyons SM, Achorn CA, Kedersha N, Anderson P, Ivanov P. Stress&#x2013;specific differences in assembly and composition of stress granules and related foci. J Cell Sci. 2017;130:927&#x2013;937. doi: 10.1242/jcs.199240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.199240</ArticleId>
            <ArticleId IdType="pmc">PMC5358336</ArticleId>
            <ArticleId IdType="pubmed">28096475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ailte I, Lingelem AB, Kvalvaag AS, Kavaliauskiene S, Brech A, Koster G, Dommersnes PG, Bergan J, Skotland T, Sandvig K. Exogenous lysophospholipids with large head groups perturb clathrin-mediated endocytosis. Traffic (Copenhagen, Denmark) 2017;18:176&#x2013;191. doi: 10.1111/tra.12468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/tra.12468</ArticleId>
            <ArticleId IdType="pubmed">28067430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciechanover A, Schwartz AL, Dautry-Varsat A, Lodish HF. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol Chem. 1983;258:9681&#x2013;9689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6309781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wauthoz N, Bastiat G, Moysan E, Cieslak A, Kondo K, Zandecki M, Moal V, Rousselet MC, Hureaux J, Benoit JP. Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice. Nanomed Nanotechnol Biol Med. 2015;11:1237&#x2013;1245. doi: 10.1016/j.nano.2015.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nano.2015.02.010</ArticleId>
            <ArticleId IdType="pubmed">25791812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber LA, Teis D. Lysosomal signaling in control of degradation pathways. Curr Opin Cell Biol. 2016;39:8&#x2013;14. doi: 10.1016/j.ceb.2016.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2016.01.006</ArticleId>
            <ArticleId IdType="pubmed">26827287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cahn F, Lubin M. Inhibition of elongation steps of protein synthesis at reduced potassium concentrations in reticulocytes and reticulocyte lysate. J Biol Chem. 1978;253:7798&#x2013;7803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">701288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13:89&#x2013;102. doi: 10.1038/nrm3270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3270</ArticleId>
            <ArticleId IdType="pubmed">22251901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374&#x2013;1395. doi: 10.15252/embr.201642195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201642195</ArticleId>
            <ArticleId IdType="pmc">PMC5048378</ArticleId>
            <ArticleId IdType="pubmed">27629041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao Y, Long J, Liu L, He T, Jiang L, Zhao C, Li Z. A review of endoplasmic reticulum (ER) stress and nanoparticle (NP) exposure. Life Sci. 2017;186:33&#x2013;42. doi: 10.1016/j.lfs.2017.08.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2017.08.003</ArticleId>
            <ArticleId IdType="pubmed">28782531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L, Han AP, Chen JJ. Translation initiation control by heme-regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under cytoplasmic stresses. Mol Cell Biol. 2001;21:7971&#x2013;7980. doi: 10.1128/MCB.21.23.7971-7980.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.21.23.7971-7980.2001</ArticleId>
            <ArticleId IdType="pmc">PMC99965</ArticleId>
            <ArticleId IdType="pubmed">11689689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodossiou TA, Olsen CE, Jonsson M, Kubin A, Hothersall JS, Berg K. The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy. Redox Biol. 2017;12:191&#x2013;197. doi: 10.1016/j.redox.2017.02.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2017.02.018</ArticleId>
            <ArticleId IdType="pmc">PMC5333531</ArticleId>
            <ArticleId IdType="pubmed">28254657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165&#x2013;176. doi: 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, Shah R, Li B, FriedmannAngeli JP, Griesser M, Conrad M, Pratt DA. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent Sci. 2017;3:232&#x2013;243. doi: 10.1021/acscentsci.7b00028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasai S, Yamazaki H, Tanji K, Engler MJ, Matsumiya T, Itoh K. Role of the ISR-ATF4 pathway and its cross talk with Nrf2 in mitochondrial quality control. J Clin Biochem Nutr. 2019;64:1&#x2013;12. doi: 10.3164/jcbn.18-37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3164/jcbn.18-37</ArticleId>
            <ArticleId IdType="pmc">PMC6348405</ArticleId>
            <ArticleId IdType="pubmed">30705506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiCiccio JE, Steinberg BE. Lysosomal pH and analysis of the counter ion pathways that support acidification. J Gen Physiol. 2011;137:385&#x2013;390. doi: 10.1085/jgp.201110596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1085/jgp.201110596</ArticleId>
            <ArticleId IdType="pmc">PMC3068279</ArticleId>
            <ArticleId IdType="pubmed">21402887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marwaha R, Sharma M, DQ-Red BSA Trafficking assay in cultured cells to assess cargo delivery to lysosomes. Bio Protoc. 2017;5:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5657473</ArticleId>
            <ArticleId IdType="pubmed">29082291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011;12:517&#x2013;533. doi: 10.1038/nrm3151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3151</ArticleId>
            <ArticleId IdType="pubmed">21779028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Bi Y, Wang T, Li P, Yan X, Hou S, Bammert CE, Ju J, Gibson KM, Pavan WJ, Bi L. Lysosomal targeting with stable and sensitive fluorescent probes (Superior LysoProbes): applications for lysosome labeling and tracking during apoptosis. Sci Rep. 2015;5:9004. doi: 10.1038/srep09004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep09004</ArticleId>
            <ArticleId IdType="pmc">PMC4355733</ArticleId>
            <ArticleId IdType="pubmed">25758662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulheim E, Iversen TG, To Nakstad V, Klinkenberg G, Sletta H, Schmid R, Hatletveit AR, Wagbo AM, Sundan A, Skotland T, Sandvig K, Morch Y. Cytotoxicity of poly(alkyl cyanoacrylate) nanoparticles. Int J Mol Sci. 2017;18:2454. doi: 10.3390/ijms18112454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18112454</ArticleId>
            <ArticleId IdType="pmc">PMC5713421</ArticleId>
            <ArticleId IdType="pubmed">29156588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandvig K, Olsnes S, Petersen OW, van Deurs B. Acidification of the cytosol inhibits endocytosis from coated pits. J Cell Biol. 1987;105:679&#x2013;689. doi: 10.1083/jcb.105.2.679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.105.2.679</ArticleId>
            <ArticleId IdType="pmc">PMC2114767</ArticleId>
            <ArticleId IdType="pubmed">2887575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maupas C, Moulari B, Beduneau A, Lamprecht A, Pellequer Y. Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells. Int J Pharm. 2011;411:136&#x2013;141. doi: 10.1016/j.ijpharm.2011.03.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2011.03.056</ArticleId>
            <ArticleId IdType="pubmed">21463666</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31769461</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2050-7518</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of materials chemistry. B</Title>
          <ISOAbbreviation>J Mater Chem B</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hypoxia-augmented and photothermally-enhanced ferroptotic therapy with high specificity and efficiency.</ArticleTitle>
        <Pagination>
          <StartPage>78</StartPage>
          <EndPage>87</EndPage>
          <MedlinePgn>78-87</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/c9tb02268f</ELocationID>
        <Abstract>
          <AbstractText>The rigorous reaction conditions (sufficient H2O2 and a low pH value) of an efficient Fenton reaction limit its further biomedical translation. Therefore, it is urgent to improve the efficacy of the Fenton reaction at the tumor site for efficient ferroptotic therapy. Herein, a hypoxia-responsive-Azo-BSA functionalized biomimetic nanoreactor (Fe(iii)-GA/GOx@ZIF-Azo), encapsulating ultrasmall ferric-gallic acid coordination polymer nanoparticles (Fe(iii)-GA) and glucose oxidase (GOx) into a zeolitic imidazolate framework (ZIF), was constructed for tumor ablation through an intensive Fenton reaction accelerated by not only sustained Fe[2+] and H2O2 supply but also low pH and photothermal stimulation. Moreover, Azo achieved charge reversal in a hypoxia microenvironment caused by the sustained oxygen consumption by GOx, which resulted in selective and enhanced tumor accumulation based on the hypoxia-activated positive feedback cellular uptake. This rationally designed biomimetic nanoreactor might lay a foundation for the clinical translation of ferroptotic therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>An</LastName>
            <ForeName>Peijing</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, P. R. China. chmsunbw@seu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Dihai</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, P. R. China. chmsunbw@seu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Zhiguo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, P. R. China. chmsunbw@seu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Fengying</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, P. R. China. chmsunbw@seu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-5815-1480</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, P. R. China. chmsunbw@seu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Baiwang</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0001-6789-0798</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, P. R. China. chmsunbw@seu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Mater Chem B</MedlineTA>
        <NlmUniqueID>101598493</NlmUniqueID>
        <ISSNLinking>2050-750X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001391">Azo Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000073396">Metal-Organic Frameworks</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1318-02-1</RegistryNumber>
          <NameOfSubstance UI="D017641">Zeolites</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>632XD903SP</RegistryNumber>
          <NameOfSubstance UI="D005707">Gallic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7GBN705NH1</RegistryNumber>
          <NameOfSubstance UI="C029899">imidazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.3.4</RegistryNumber>
          <NameOfSubstance UI="D005949">Glucose Oxidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001391" MajorTopicYN="N">Azo Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005707" MajorTopicYN="N">Gallic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005949" MajorTopicYN="N">Glucose Oxidase</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073396" MajorTopicYN="Y">Metal-Organic Frameworks</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="Y">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072258" MajorTopicYN="N">Tumor Hypoxia</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017641" MajorTopicYN="N">Zeolites</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31769461</ArticleId>
        <ArticleId IdType="doi">10.1039/c9tb02268f</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31678528</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3476</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>572</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Dec</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of pharmaceutics</Title>
          <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>118782</StartPage>
          <MedlinePgn>118782</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2019.118782</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-5173(19)30827-0</ELocationID>
        <Abstract>
          <AbstractText>Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths. Unfortunately, there is still no completely effective treatment. Ferroptosis could affect the development of HCC by regulating the level of glutathione (GSH), intracellular lipid peroxidation, and other related substances. This paper introduced a new one-pot reaction for the synthesis of manganese doped mesoporous silica nanoparticles (manganese-silica nanoparticles, MMSNs) which could induce ferroptosis of the tumor cells through the consumption of intracellular GSH caused by the degradation of MMSNs. The more amount of MnCl2 added during the preparation, the larger doping amount of manganese presented in MMSNs. When the molar ratio of TEOS to MnCl2 was 5:1, the prepared MMSNs had a small size (102.6  3.06 nm), uniform structure (pore sizes of 3.67 nm) and large pore volume. Manganese-oxidation bonds of MMSNs could break in high GSH concentration, which in turn consume GSH in the environment rapidly. Sorafenib (SO), an inhibitor of Xc[-] transport system was loaded in the MMSNs (MMSNs@SO) with a drug loading rate of 2.68  0.32%. MMSNs@SO achieved on-demand drug release in the tumor microenvironment due to the degradation of MMSNs. Subsequently, a significant tumor cell (HepG2) suppression effect of MMSNs@SO was achieved through the consumption of GSH and synthesis inhibition of intracellular GSH. The depletion of GSH led to the inactivity of glutathione peroxidase 4 and increase of intracellular lipid peroxide, which could induce the ferroptosis of HCC cells. In summary, such dual GSH-exhausting nanodrugs have a great potential to induce ferroptosis of HCC cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Hongxia</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Danfei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chaoqun</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Caihong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Xiaodong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Qianqian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fei</LastName>
            <ForeName>Weidong</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address: feiweidong@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Pharm</MedlineTA>
        <NlmUniqueID>7804127</NlmUniqueID>
        <ISSNLinking>0378-5173</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002712">Chlorides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017895">Manganese Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7631-86-9</RegistryNumber>
          <NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>QQE170PANO</RegistryNumber>
          <NameOfSubstance UI="C025340">manganese chloride</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002712" MajorTopicYN="N">Chlorides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="Y">Drug Carriers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017895" MajorTopicYN="N">Manganese Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="Y">Metal Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012822" MajorTopicYN="N">Silicon Dioxide</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Biodegradable</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Glutathione</Keyword>
        <Keyword MajorTopicYN="N">Manganese-silica nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">Sorafenib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31678528</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijpharm.2019.118782</ArticleId>
        <ArticleId IdType="pii">S0378-5173(19)30827-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31613630</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1543-8392</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Dec</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular pharmaceutics</Title>
          <ISOAbbreviation>Mol Pharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ultrastable and Biofunctionalizable Conjugated Polymer Nanoparticles with Encapsulated Iron for Ferroptosis Assisted Chemodynamic Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>4852</StartPage>
          <EndPage>4866</EndPage>
          <MedlinePgn>4852-4866</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.9b00737</ELocationID>
        <Abstract>
          <AbstractText>We report the development of novel tumor-targeted conjugated polymer nanoparticles (CPNPs) carrying iron for chemodynamic therapy (CDT). Tumor cell killing proceeds through ferroptosis, a reactive oxygen species (ROS) mechanism that is not dependent on external activation by, for example, light, as is the case in photodynamic therapy (PDT). The ferroptosis mechanism is also not heavily reliant on oxygen availability and is, therefore, promising for the treatment of hypoxic tumors. In this work, we apply this development to the case study of melanoma, a difficult to treat cancer in advanced stages due to resistance to chemotherapy. The iron-carrying CPNPs reported here are targeted to endothelin-B receptors (EDNRB) through endothelin-3 surface moieties (EDN3-CPNPs). Our results show excellent targeting to tumor cells that overexpress EDNRB, specifically for melanoma and bladder tumor cells. In these cases, efficient cell killing, over 80% at higher doses, was found. Conversely, tumor cells not targeted by the EDN3-CPNPs show little effects of CDT, with tumor cell death under 20% in most cases. The outcomes of our work demonstrate that EDN3-CPNPs enable ferroptosis-assisted CDT and present a new therapeutic avenue for tumor treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jasim</LastName>
            <ForeName>Khalaf A</ForeName>
            <Initials>KA</Initials>
            <Identifier Source="ORCID">0000-0002-3111-9712</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of Central Florida, Orlando, Florida 32816, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NanoScience Technology Center, University of Central Florida, Orlando, Florida 32826, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, College of Science, Tikrit University, Tikrit 34001, Iraq.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gesquiere</LastName>
            <ForeName>Andre J</ForeName>
            <Initials>AJ</Initials>
            <Identifier Source="ORCID">0000-0003-3244-6771</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of Central Florida, Orlando, Florida 32816, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NanoScience Technology Center, University of Central Florida, Orlando, Florida 32826, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering, University of Central Florida, Orlando, Florida 32816, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The College of Optics and Photonics (CREOL), University of Central Florida, Orlando, Florida 32816, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Pharm</MedlineTA>
        <NlmUniqueID>101197791</NlmUniqueID>
        <ISSNLinking>1543-8384</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044023">Receptor, Endothelin B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067493" MajorTopicYN="N">Dynamic Light Scattering</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017348" MajorTopicYN="N">Microscopy, Electron, Scanning Transmission</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044023" MajorTopicYN="N">Receptor, Endothelin B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CDT</Keyword>
        <Keyword MajorTopicYN="N">EDN3</Keyword>
        <Keyword MajorTopicYN="N">EDNRA</Keyword>
        <Keyword MajorTopicYN="N">EDNRB</Keyword>
        <Keyword MajorTopicYN="N">Fenton reaction</Keyword>
        <Keyword MajorTopicYN="N">PCPDTBT</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">cell viability</Keyword>
        <Keyword MajorTopicYN="N">chemodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">conjugated polymer nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">endothelin-3</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron</Keyword>
        <Keyword MajorTopicYN="N">metastatic melanoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31613630</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00737</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31594301</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-6992</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nano letters</Title>
          <ISOAbbreviation>Nano Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Triggered All-Active Metal Organic Framework: Ferroptosis Machinery Contributes to the Apoptotic Photodynamic Antitumor Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>7866</StartPage>
          <EndPage>7876</EndPage>
          <MedlinePgn>7866-7876</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.nanolett.9b02904</ELocationID>
        <Abstract>
          <AbstractText>Nanoscale photodynamic therapy (PDT) is an appealing antitumor modality for which apoptosis is the major mechanism of toxicity induction. It was postulated that the highly reactive singlet oxygen in PDT could deplete glutathione (GSH) and activate ferroptosis, the extent to which could be further manipulated by a redox-responsive nanocarrier. To validate this, a disulfide-bearing imidazole ligand coordinated with zinc to form an all-active metal organic framework (MOF) nanocarrier where a photosensitizer (chlorin e6/Ce6) was encapsulated. Regardless of light irradiation, the Ce6-loaded nanocarrier caused the depletion of intracellular GSH via the disulfide-thiol exchange reaction in a murine mammary carcinoma cell line (4T1). The GSH depletion further caused the inactivation of glutathione peroxide 4 (GPX4) and the enhancement of cytotoxicity that was alleviated by ferroptosis inhibitors. The superior in vivo antitumor efficacy of the all-active nanocarrier was corroborated in a 4T1 tumor-bearing mice model regarding tumor growth suppression and animal survival rate. The coadministration of an iron chelator weakened the antitumor potency of the nanocarrier due to ferroptosis inhibition, which was supported by the fact of tumor growth upsurge and the recovered GPX4 activity. The current work highlights the contribution of ferroptotic machinery to antitumor PDT via an activatable, adaptable, all-active MOF nanocarrier.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Xuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital , Tianjin 300120 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Mengying</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Peipei</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Aiping</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yanjun</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-5739-1960</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Science &amp; Technology, Tianjin Key Laboratory for Modern Drug Delivery &amp; High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Tianjin University , Tianjin 300072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nano Lett</MedlineTA>
        <NlmUniqueID>101088070</NlmUniqueID>
        <ISSNLinking>1530-6984</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002735">Chlorophyllides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000073396">Metal-Organic Frameworks</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S2CCF3T1Z</RegistryNumber>
          <NameOfSubstance UI="C062985">phytochlorin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002735" MajorTopicYN="N">Chlorophyllides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015674" MajorTopicYN="N">Mammary Neoplasms, Animal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073396" MajorTopicYN="N">Metal-Organic Frameworks</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="N">Porphyrins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">drug delivery</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">metal organic framework</Keyword>
        <Keyword MajorTopicYN="N">redox-responsive</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31594301</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.nanolett.9b02904</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31409375</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1465-542X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Aug</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research : BCR</Title>
          <ISOAbbreviation>Breast Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2[+ve] breast cancer metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>94</StartPage>
          <MedlinePgn>94</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">94</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-019-1177-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients progress to incurable brain metastases due to acquired resistance and/or limited permeability of inhibitors across the blood-brain barrier. Neratinib, a potent irreversible pan-tyrosine kinase inhibitor, prolongs disease-free survival in the extended adjuvant setting, and several trials evaluating its efficacy alone or combination with other inhibitors in early and advanced HER2-positive breast cancer patients are ongoing. However, its efficacy as a first-line therapy against HER2-positive breast cancer brain metastasis has not been fully explored, in part due to the lack of relevant pre-clinical models that faithfully recapitulate this disease. Here, we describe the development and characterisation of a novel syngeneic model of spontaneous HER2-positive breast cancer brain metastasis (TBCP-1) and its use to evaluate the efficacy and mechanism of action of neratinib.</AbstractText>
          <AbstractText Label="METHODS">TBCP-1 cells were derived from a spontaneous BALB/C mouse mammary tumour and characterised for hormone receptors and HER2 expression by flow cytometry, immunoblotting and immunohistochemistry. Neratinib was evaluated in vitro and in vivo in the metastatic and neoadjuvant setting. Its mechanism of action was examined by transcriptomic profiling, function inhibition assays and immunoblotting.</AbstractText>
          <AbstractText Label="RESULTS">TBCP-1 cells naturally express high levels of HER2 but lack expression of hormone receptors. TBCP-1 tumours maintain a HER2-positive phenotype in vivo and give rise to a high incidence of spontaneous and experimental metastases in the brain and other organs. Cell proliferation/viability in vitro is inhibited by neratinib and by other HER2 inhibitors, but not by anti-oestrogens, indicating phenotypic and functional similarities to human HER2-positive breast cancer. Mechanistically, neratinib promotes a non-apoptotic form of cell death termed ferroptosis. Importantly, metastasis assays demonstrate that neratinib potently inhibits tumour growth and metastasis, including to the brain, and prolongs survival, particularly when used as a neoadjuvant therapy.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The TBCP-1 model recapitulates the spontaneous spread of HER2-positive breast cancer to the brain seen in patients and provides a unique tool to identify novel therapeutics and biomarkers. Neratinib-induced ferroptosis provides new opportunities for therapeutic intervention. Further evaluation of neratinib neoadjuvant therapy is warranted.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nagpal</LastName>
            <ForeName>Aadya</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Redvers</LastName>
            <ForeName>Richard P</ForeName>
            <Initials>RP</Initials>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Metastasis Research Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ling</LastName>
            <ForeName>Xiawei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Metastasis Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ayton</LastName>
            <ForeName>Scott</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Florey Institute of Neuroscience and Mental Health, Parkville, VIC, 3052, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fuentes</LastName>
            <ForeName>Miriam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tavancheh</LastName>
            <ForeName>Elnaz</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diala</LastName>
            <ForeName>Irmina</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Puma Biotechnology, Inc., 10880 Wilshire Blvd, Los Angeles, CA, 90024, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lalani</LastName>
            <ForeName>Alshad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Puma Biotechnology, Inc., 10880 Wilshire Blvd, Los Angeles, CA, 90024, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loi</LastName>
            <ForeName>Sherene</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Breast Cancer Genomics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>David</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Peter MacCallum Cancer Centre, Moorabbin Campus, East Bentleigh, VIC, 3165, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>Robin L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Metastasis Research Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3000, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, 3000, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Yvonne</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Royal College of Surgeons, Dublin, D02 YN77, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Merino</LastName>
            <ForeName>Delphine</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tumour Progression and Heterogeneity Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Division, The Walter and ELIZA Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Denoyer</LastName>
            <ForeName>Delphine</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pouliot</LastName>
            <ForeName>Normand</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-7654-3445</Identifier>
            <AffiliationInfo>
              <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia. Normand.Pouliot@onjcri.org.au.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia. Normand.Pouliot@onjcri.org.au.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, 3000, Australia. Normand.Pouliot@onjcri.org.au.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>08</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Breast Cancer Res</MedlineTA>
        <NlmUniqueID>100927353</NlmUniqueID>
        <ISSNLinking>1465-5411</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JJH94R3PWB</RegistryNumber>
          <NameOfSubstance UI="C487932">neratinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064596" MajorTopicYN="N">Isografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Brain metastasis</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">HER2-positive breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Neratinib</Keyword>
        <Keyword MajorTopicYN="N">Syngeneic mouse model</Keyword>
        <Keyword MajorTopicYN="N">TBCP-1</Keyword>
        <Keyword MajorTopicYN="N">Tyrosine kinase inhibitors</Keyword>
      </KeywordList>
      <CoiStatement>ID and AL are employed by Puma Biotechnology, Inc. All other authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31409375</ArticleId>
        <ArticleId IdType="pmc">PMC6693253</ArticleId>
        <ArticleId IdType="doi">10.1186/s13058-019-1177-1</ArticleId>
        <ArticleId IdType="pii">10.1186/s13058-019-1177-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394&#x2013;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oehrlich NE, Spineli LM, Papendorf F, Park-Simon TW. Clinical outcome of brain metastases differs significantly among breast cancer subtypes. Oncol Lett. 2017;14(1):194&#x2013;200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5494902</ArticleId>
            <ArticleId IdType="pubmed">28693153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips C, Jeffree R, Khasraw M. Management of breast cancer brain metastases: a practical review. Breast. 2017;31:90&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27829201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719&#x2013;726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11821453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673&#x2013;1684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16236738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005;16(11):1772&#x2013;1777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16150805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894&#x2013;900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2661774</ArticleId>
            <ArticleId IdType="pubmed">19240719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 2014;12:132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4243818</ArticleId>
            <ArticleId IdType="pubmed">25285786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drugs. 2007;18(1):23&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17159499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O&#x2019;Byrne KJ, O&#x2019;Donovan N, Crown J. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cell Immunol. 2017;319:35&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28735814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018;67:71&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29772459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263&#x2013;275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3092522</ArticleId>
            <ArticleId IdType="pubmed">21342044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang N, Lin JJ, Wang J, Zhang BN, Li A, Chen ZY, Guo S, Li BB, Duan YZ, Yan RY, et al. Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs. Exp Ther Med. 2018;16(3):2183&#x2013;2192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6122384</ArticleId>
            <ArticleId IdType="pubmed">30186457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 2015;7:147&#x2013;162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4467661</ArticleId>
            <ArticleId IdType="pubmed">26089701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958&#x2013;3965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15173008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O&#x2019;Brien NA, Roxanis I, Li JL, Bridge E, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4(10):1592&#x2013;1605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3858548</ArticleId>
            <ArticleId IdType="pubmed">24009064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cocco Emiliano, Javier Carmona F., Razavi Pedram, Won Helen H., Cai Yanyan, Rossi Valentina, Chan Carmen, Cownie James, Soong Joanne, Toska Eneda, Shifman Sophie G., Sarotto Ivana, Savas Peter, Wick Michael J., Papadopoulos Kyriakos P., Moriarty Alyssa, Cutler Richard E., Avogadri-Connors Francesca, Lalani Alshad S., Bryce Richard P., Chandarlapaty Sarat, Hyman David M., Solit David B., Boni Valentina, Loi Sherene, Baselga Jos&#xe9;, Berger Michael F., Montemurro Filippo, Scaltriti Maurizio. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) Science Signaling. 2018;11(551):eaat9773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6498841</ArticleId>
            <ArticleId IdType="pubmed">30301790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan A. Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol. 2016;8(5):339&#x2013;350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4981294</ArticleId>
            <ArticleId IdType="pubmed">27583026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao Z, Li SX, Shen K, Zhao Y, Zeng H, Ma X. Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 prospective clinical trials. Clin Drug Investig. 2019;39(1):27&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30370488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegedus C, Truta-Feles K, Antalffy G, Brozik A, Kasza I, Nemet K, Orban TI, Ozvegy-Laczka C, Varadi A, Sarkadi B. PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter. Biochem Biophys Res Commun. 2012;420(4):869&#x2013;874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22449574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X, Liang YJ, Singh S, Talele TT, Sun Y, Ambudkar SV, et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol. 2012;82(1):47&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3382829</ArticleId>
            <ArticleId IdType="pubmed">22491935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freedman RA, Gelman RS, Melisko ME, Anders CK, Moy B, Blackwell KL. TBCRC 022: phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM) J Clin Oncol. 2017;35(15_sUPPL):1005.</Citation>
        </Reference>
        <Reference>
          <Citation>Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2016;34(9):945&#x2013;952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5070554</ArticleId>
            <ArticleId IdType="pubmed">26834058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016;2(12):1557&#x2013;1564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27078022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688&#x2013;1700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29146401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daphu I, Sundstrom T, Horn S, Huszthy PC, Niclou SP, Sakariassen PO, Immervoll H, Miletic H, Bjerkvig R, Thorsen F. In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis. 2013;30(5):695&#x2013;710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23322381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo HW. EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) 2016;8:245&#x2013;263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4809353</ArticleId>
            <ArticleId IdType="pubmed">26709660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479&#x2013;497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22653217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. Strategies to overcome bypass mechanisms mediating clinical resistance to EGFR tyrosine kinase inhibition in lung cancer. Mol Cancer Ther. 2017;16(2):265&#x2013;272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28159915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez VG, O&#x2019;Neill S, Salimu J, Breslin S, Clayton A, Crown J, O&#x2019;Driscoll L. Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncoimmunology. 2017;6(12):e1362530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5706614</ArticleId>
            <ArticleId IdType="pubmed">29209569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slaney CY, Rautela J, Parker BS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 2013;73(19):5852&#x2013;5857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24062312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A. 1992;89(22):10578&#x2013;10582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC50384</ArticleId>
            <ArticleId IdType="pubmed">1359541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng L, Zhou B, Meng X, Zhu W, Zuo A, Wang X, Jiang R, Yu S. A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer. Int J Oncol. 2014;45(6):2241&#x2013;2249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4215580</ArticleId>
            <ArticleId IdType="pubmed">25230850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim Soo-Hyun, Redvers Richard P., Chi Lap Hing, Ling Xiawei, Lucke Andrew J., Reid Robert C., Fairlie David P., Martin Ana Carolina Baptista Moreno, Anderson Robin L., Denoyer Delphine, Pouliot Normand. Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis. Disease Models &amp; Mechanisms. 2018;11(7):DMM034850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6078399</ArticleId>
            <ArticleId IdType="pubmed">29784888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusuma N, Denoyer D, Eble JA, Redvers RP, Parker BS, Pelzer R, Anderson RL, Pouliot N. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int J Cancer. 2012;130(3):555&#x2013;566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21387294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denoyer D, Potdevin T, Roselt P, Neels OC, Kirby L, Greguric I, Katsifis A, Dorow DS, Hicks RJ. Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med. 2011;52(1):115&#x2013;122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21149487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denoyer D, Kusuma N, Burrows A, Ling X, Jupp L, Anderson RL, Pouliot N. Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells. Growth Factors. 2014;32(2):63&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24601751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12(4):357&#x2013;360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4655817</ArticleId>
            <ArticleId IdType="pubmed">25751142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28(16):2184&#x2013;2185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22743226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923&#x2013;930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24227677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139&#x2013;140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796818</ArticleId>
            <ArticleId IdType="pubmed">19910308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin A, Fuzer AM, Becceneri AB, da Silva JA, Tomasin R, Denoyer D, Kim SH, McIntyre KA, Pearson HB, Yeo B, et al. [10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo. Oncotarget. 2017;8(42):72260&#x2013;72271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5641128</ArticleId>
            <ArticleId IdType="pubmed">29069785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, et al. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech. 2015;8(3):237&#x2013;251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4348562</ArticleId>
            <ArticleId IdType="pubmed">25633981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harms JF, Welch DR. MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis. 2003;20(4):327&#x2013;334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12856720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Neill F, Madden SF, Clynes M, Crown J, Doolan P, Aherne ST, O&#x2019;Connor R. A gene expression profile indicative of early stage HER2 targeted therapy response. Mol Cancer. 2013;12:69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3725168</ArticleId>
            <ArticleId IdType="pubmed">23816254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73(11&#x2013;12):2195&#x2013;2209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B, Chen XB, Ying MD, He QJ, Cao J, Yang B. The role of ferroptosis in cancer development and treatment response. Front Pharmacol. 2017;8:992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5770584</ArticleId>
            <ArticleId IdType="pubmed">29375387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369&#x2013;379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Guo P, Xie X, Wang Y, Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21(4):648&#x2013;657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5345622</ArticleId>
            <ArticleId IdType="pubmed">27860262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, Chauffert B, Galmiche A. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34(11):6417&#x2013;6422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25368241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3(3):285&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, Shah R, Li B, Friedmann Angeli JP, Griesser M, Conrad M, Pratt DA. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent Sci. 2017;3(3):232&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, Kang R, Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338&#x2013;1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YQ, Chang SY, Wu Q, Gou YJ, Jia L, Cui YM, Yu P, Shi ZH, Wu WS, Gao G, et al. The protective role of mitochondrial ferritin on erastin-induced ferroptosis. Front Aging Neurosci. 2016;8:308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5167726</ArticleId>
            <ArticleId IdType="pubmed">28066232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng N, Shi BJ, Li SL, Zhong ZY, Li YC, Xua WL, Zhou H, Cai JH. Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci. 2018;22(12):3826&#x2013;3836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29949159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinnix ZK, Miller LD, Wang W, D&#x2019;Agostino R, Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2(43):43ra56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734848</ArticleId>
            <ArticleId IdType="pubmed">20686179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varga Z, Tubbs RR, Moch H. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification. PLoS One. 2014;9(8):e105961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4143343</ArticleId>
            <ArticleId IdType="pubmed">25153153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, et al. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res. 2016;18(1):68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4924300</ArticleId>
            <ArticleId IdType="pubmed">27349894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley NE, Forde C, McArt DG, Boyle DP, Mullan PB, James JA, Maxwell P, McQuaid S, Salto-Tellez M. Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment. Sci Rep. 2016;6:23383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4800308</ArticleId>
            <ArticleId IdType="pubmed">26996207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoppoli G, Garuti A, Cirmena G, di Cantogno LV, Botta C, Gallo M, Ferraioli D, Carminati E, Baccini P, Curto M, et al. Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases. J Transl Med. 2017;15(1):91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5412048</ArticleId>
            <ArticleId IdType="pubmed">28460632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segovia-Mendoza M, Gonzalez-Gonzalez ME, Barrera D, Diaz L, Garcia-Becerra R. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res. 2015;5(9):2531&#x2013;2561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4633889</ArticleId>
            <ArticleId IdType="pubmed">26609467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matkar S, An C, Hua X. Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop. Am J Cancer Res. 2017;7(7):1476&#x2013;1485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5523029</ArticleId>
            <ArticleId IdType="pubmed">28744398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342&#x2013;350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22888144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moulder SL, Borges V, Chia SKL, Baetz T, Barrett E, Garrus J, Guthrie K, Kass C, Laird E, Lyssikatos J, et al. ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation [Abstract #A143]. In: Proceedings of the AACR-NCI-EORTC International conference: Molecular Targets and Cancer Therapeutics 2011 Nov 12-16; San Francisco, CA, Philadelphia (PA): AACR. Mol Cancer Therapeutics. 2011;10(11 Supplement):Abstract nr A143.</Citation>
        </Reference>
        <Reference>
          <Citation>Pheneger T, Bouhana K, Anderson D, Garrus J, Ahrendt K, Allen S, von Carlowitz I, Greschuk J, Gross S, Hoffman K, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. [Abstract #1795]. In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR. Cancer Res. 2009;69(9 Supplement):1795.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4973350</ArticleId>
            <ArticleId IdType="pubmed">27441659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain? Clin Cancer Res. 2018;24(8):1795&#x2013;1804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899637</ArticleId>
            <ArticleId IdType="pubmed">29437794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegedus C, Truta-Feles K, Antalffy G, Varady G, Nemet K, Ozvegy-Laczka C, Keri G, Orfi L, Szakacs G, Settleman J, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012;84(3):260&#x2013;267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22548830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JW, Liu MC, Yee D, Yau C, van&#x2019;t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5259558</ArticleId>
            <ArticleId IdType="pubmed">27406346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seyhan AA, Varadarajan U, Choe S, Liu W, Ryan TE. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Mol BioSyst. 2012;8(5):1553&#x2013;1570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22446932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breslin S, Lowry MC, O&#x2019;Driscoll L. Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Cancer. 2017;116(5):620&#x2013;625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5344284</ArticleId>
            <ArticleId IdType="pubmed">28152547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget. 2017;8(52):90262&#x2013;90277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685747</ArticleId>
            <ArticleId IdType="pubmed">29163826</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31244955</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1838-7640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2019</Year>
            </PubDate>
          </JournalIssue>
          <Title>Theranostics</Title>
          <ISOAbbreviation>Theranostics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis Promotes Photodynamic Therapy: Supramolecular Photosensitizer-Inducer Nanodrug for Enhanced Cancer Treatment.</ArticleTitle>
        <Pagination>
          <StartPage>3293</StartPage>
          <EndPage>3307</EndPage>
          <MedlinePgn>3293-3307</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.32867</ELocationID>
        <Abstract>
          <AbstractText>The noninvasive nature of photodynamic therapy (PDT) enables the preservation of organ function in cancer patients. However, PDT is impeded by hypoxia in the tumor microenvironment (TME) caused by high intracellular oxygen (O2) consumption and distorted tumor blood vessels. Therefore, increasing oxygen generation in the TME would be a promising methodology for enhancing PDT. Herein, we proposed a concept of ferroptosis-promoted PDT based on the biochemical characteristics of cellular ferroptosis, which improved the PDT efficacy significantly by producing reactive oxygen species (ROS) and supplying O2 sustainably through the Fenton reaction. In contrast to traditional strategies that increase O2 based on decomposition of limited concentration of hydrogen peroxide (H2O2), our methodology could maintain the concentration of H2O2 and O2 through the Fenton reaction. Methods: For its association with sensitivity to ferroptosis, solute carrier family 7 member 11 (SLC7A11) expression was characterized by bioinformatics analysis and immunohistochemistry of oral tongue squamous cell carcinoma (OTSCC) specimens. Afterwards, the photosensitizer chlorin e6 (Ce6) and the ferroptosis inducer erastin were self-assembled into a novel supramolecular Ce6-erastin nanodrug through hydrogen bonding and - stacking. Then, the obtained Ce6-erastin was extensively characterized and its anti-tumor efficacy towards OTSCC was evaluated both in vitro and in vivo. Results: SLC7A11 expression is found to be upregulated in OTSCC, which is a potential target for ferroptosis-mediated OTSCC treatment. Ce6-erastin nanoparticles exhibited low cytotoxicity to normal tissues. More significantly, The over-accumulated intracellular ROS, increased O2 concentration and inhibited SLC7A11 expression lead to enhanced toxicity to CAL-27 cells and satisfactory antitumor effects to xenograft tumour mouse model upon irradiation. Conclusion: Our ferroptosis promoted PDT approach markedly enhances anticancer actions by relieving hypoxia and promoting ROS production, thereby our work provides a new approach for overcoming hypoxia-associated resistance of PDT in cancer treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial-Head Neck Oncology, Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Oral Diseases, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Stomatology &amp; Shanghai Research Institute of Stomatology, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Leilei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Chunyang</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dong</LastName>
            <ForeName>Yabing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial-Head Neck Oncology, Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Oral Diseases, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Stomatology &amp; Shanghai Research Institute of Stomatology, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai 201418, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Lingyue</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial-Head Neck Oncology, Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Oral Diseases, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Stomatology &amp; Shanghai Research Institute of Stomatology, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Qiuhui</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Guoyu</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial-Head Neck Oncology, Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Oral Diseases, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Stomatology &amp; Shanghai Research Institute of Stomatology, Shanghai 200011, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Xinyuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Theranostics</MedlineTA>
        <NlmUniqueID>101552395</NlmUniqueID>
        <ISSNLinking>1838-7640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011166" MajorTopicYN="N">Porphyrins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014062" MajorTopicYN="N">Tongue Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Fenton reaction</Keyword>
        <Keyword MajorTopicYN="N">carrier free</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">nanodrug</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31244955</ArticleId>
        <ArticleId IdType="pmc">PMC6567978</ArticleId>
        <ArticleId IdType="doi">10.7150/thno.32867</ArticleId>
        <ArticleId IdType="pii">thnov09p3293</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 1987;47:3110&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3581062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piette J, Volanti C, Vantieghem A, Matroule JY, Habraken Y, Agostinis P. Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers. Biochem Pharmacol. 2003;66:1651&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14555246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang J, He H, Chen D, Yin L. Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT) Biomater Sci. 2017;5:1500&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28681887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan W, Huang P, Chen X. Overcoming the Achilles' heel of photodynamic therapy. Chem Soc Rev. 2016;45:6488&#x2013;519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27722560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li RQ, Zhang C, Xie BR, Yu WY, Qiu WX, Cheng H. et al. A two-photon excited O2-evolving nanocomposite for efficient photodynamic therapy against hypoxic tumor. Biomaterials. 2019;194:84&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30583151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu WL, Liu T, Zou MZ, Yu WY, Li CX, He ZY. et al. Aggressive Man-Made Red Blood Cells for Hypoxia-Resistant Photodynamic Therapy. Adv Mater. 2018;30:e1802006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30015997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu LH, Zhang YH, Qiu WX, Zhang L, Gao F, Li B. et al. Dual-Stage Light Amplified Photodynamic Therapy against Hypoxic Tumor Based on an O2 Self-Sufficient Nanoplatform. Small. 2017;13:1701621&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28783253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Ni Q, Jacobson O, Cheng S, Liao A, Wang Z. et al. Polymeric Nanoparticles with a Glutathione-Sensitive Heterodimeric Multifunctional Prodrug for In Vivo Drug Monitoring and Synergistic Cancer Therapy. Angew Chem Int Ed Engl. 2018;57:7066&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29624828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen L, Huang Y, Chen D, Qiu F, Ma C, Jin X. et al. pH-Responsive Aerobic Nanoparticles for Effective Photodynamic Therapy. Theranostics. 2017;7:4537&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5695147</ArticleId>
            <ArticleId IdType="pubmed">29158843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li SY, Cheng H, Xie BR, Qiu WX, Zeng JY, Li CX. et al. Cancer Cell Membrane Camouflaged Cascade Bioreactor for Cancer Targeted Starvation and Photodynamic Therapy. ACS Nano. 2017;11:7006&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28665106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X. et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016;26:165&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends Biochem Sci. 2016;41:274&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4783254</ArticleId>
            <ArticleId IdType="pubmed">26725301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi W, Cao L, Zhang H, Zhou X, An B, Lin Z. et al. Surface Modification of Two-Dimensional Metal-Organic Layers Creates Biomimetic Catalytic Microenvironments for Selective Oxidation. Angew Chem Int Ed Engl. 2017;56:9704&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28543992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Liu T, Li Y, Lau J, Yang Z, Fan W. et al. Fenton-Reaction-Acceleratable Magnetic Nanoparticles for Ferroptosis Therapy of Orthotopic Brain Tumors. ACS Nano. 2018;12:11355&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng DW, Lei Q, Zhu JY, Fan JX, Li CX, Li C. et al. Switching Apoptosis to Ferroptosis: Metal-Organic Network for High-Efficiency Anticancer Therapy. Nano Lett. 2017;17:284&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28027643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Song J, Yung BC, Zhou Z, Wu A, Chen X. Emerging Strategies of Cancer Therapy Based on Ferroptosis. Adv Mater. 2018;30:1704007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377162</ArticleId>
            <ArticleId IdType="pubmed">29356212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Liu W, Zhang M, Yu W, Gao F, Li C. et al. Ferrous-Supply-Regeneration Nanoengineering for Cancer-Cell-Specific Ferroptosis in Combination with Imaging-Guided Photodynamic Therapy. ACS Nano. 2018;12:12181&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30458111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundquist E, Kauppila JH, Veijola J, Mroueh R, Lehenkari P, Laitinen S. et al. Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups. Br J Cancer. 2017;116:640&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5344290</ArticleId>
            <ArticleId IdType="pubmed">28095396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75:1782&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25855379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiozaki A, Iitaka D, Ichikawa D, Nakashima S, Fujiwara H, Okamoto K. et al. xCT, component of cysteine/glutamate transporter, as an independent prognostic factor in human esophageal squamous cell carcinoma. J Gastroenterol. 2014;49:853&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23771433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhang Y, Shi J, Li W, Gan B. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017;292:14240&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5572906</ArticleId>
            <ArticleId IdType="pubmed">28630042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT. et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2:e1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A. et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3931310</ArticleId>
            <ArticleId IdType="pubmed">24094812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE. et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20:1990&#x2013;2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3974662</ArticleId>
            <ArticleId IdType="pubmed">24516043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E. et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73:1855&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23319806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabeyama A, Kurita A, Asano K, Miyake Y, Yasuda T, Miura I. et al. xCT deficiency accelerates chemically induced tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:6436&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2852021</ArticleId>
            <ArticleId IdType="pubmed">20308543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005;65:7446&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16103098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye H, Yu T, Temam S, Ziober BL, Wang J, Schwartz JL. et al. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics. 2008;9:69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2262071</ArticleId>
            <ArticleId IdType="pubmed">18254958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3065247</ArticleId>
            <ArticleId IdType="pubmed">20838415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta. 2007;1776:86&#x2013;107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17693025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J. et al. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Rep. 2017;20:1692&#x2013;704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28813679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10699287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuylen S, Blaukopf C, Politi AZ, Muller-Reichert T, Neumann B, Poser I. et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature. 2016;535:308&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4947524</ArticleId>
            <ArticleId IdType="pubmed">27362226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Zhang M, Liu W, Zeng X, Song X, Yang X. et al. Metal Ion/Tannic Acid Assembly as a Versatile Photothermal Platform in Engineering Multimodal Nanotheranostics for Advanced Applications. ACS Nano. 2018;12:3917&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29578680</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31105042</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-3686</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer cell</Title>
          <ISOAbbreviation>Cancer Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting Ferroptosis to Iron Out Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>830</StartPage>
          <EndPage>849</EndPage>
          <MedlinePgn>830-849</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccell.2019.04.002</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1535-6108(19)30197-7</ELocationID>
        <Abstract>
          <AbstractText>One of the key challenges in cancer research is how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the main reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hassannia</LastName>
            <ForeName>Behrouz</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>VIB Center for Inflammation Research (IRC), Ghent, Belgium; Department of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vandenabeele</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>VIB Center for Inflammation Research (IRC), Ghent, Belgium; Department of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, Belgium; Methusalem Program, Ghent University, Ghent, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vanden Berghe</LastName>
            <ForeName>Tom</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>VIB Center for Inflammation Research (IRC), Ghent, Belgium; Department of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, Belgium; Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, 2000 Antwerp, Belgium; Ferroptosis And Inflammation Research (FAIR), VIB-Ghent University and University of Antwerp, Belgium. Electronic address: tom.vandenberghe@uantwerp.be.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Cell</MedlineTA>
        <NlmUniqueID>101130617</NlmUniqueID>
        <ISSNLinking>1535-6108</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">GPX4</Keyword>
        <Keyword MajorTopicYN="N">HMOX1</Keyword>
        <Keyword MajorTopicYN="N">Iron</Keyword>
        <Keyword MajorTopicYN="N">anti-cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">lipid peroxidation</Keyword>
        <Keyword MajorTopicYN="N">nanomedicine</Keyword>
        <Keyword MajorTopicYN="N">p53</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31105042</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ccell.2019.04.002</ArticleId>
        <ArticleId IdType="pii">S1535-6108(19)30197-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30799221</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2451-9448</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell chemical biology</Title>
          <ISOAbbreviation>Cell Chem Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model.</ArticleTitle>
        <Pagination>
          <StartPage>623</StartPage>
          <EndPage>633.e9</EndPage>
          <MedlinePgn>623-633.e9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chembiol.2019.01.008</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2451-9456(19)30030-3</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a form of regulated cell death that can be induced by inhibition of the cystine-glutamate antiporter, system xc[-]. Among the existing system xc[-] inhibitors, imidazole ketone erastin (IKE) is a potent, metabolically stable inhibitor of system xc[-] and inducer of ferroptosis potentially suitable for in vivo applications. We investigated the pharmacokinetic and pharmacodynamic features of IKE in a diffuse large B cell lymphoma (DLBCL) xenograft model and demonstrated that IKE exerted an antitumor effect by inhibiting system xc[-], leading to glutathione depletion, lipid peroxidation, and the induction of ferroptosis biomarkers both in vitro and in vivo. Using untargeted lipidomics and qPCR, we identified distinct features of lipid metabolism in IKE-induced ferroptosis. In addition, biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanoparticles were employed to aid in IKE delivery and exhibited reduced toxicity compared with free IKE in a DLBCL xenograft model.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Columbia University, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Columbia University, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daniels</LastName>
            <ForeName>Jacob D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zandkarimi</LastName>
            <ForeName>Fereshteh</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, New York, NY 10027, USA; Quantitative Proteomics and Metabolomics Center, Columbia University, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Hengrui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Columbia University, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Lewis M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Columbia University, New York, NY 10027, USA; Quantitative Proteomics and Metabolomics Center, Columbia University, New York, NY 10027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uchida</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Connor</LastName>
            <ForeName>Owen A</ForeName>
            <Initials>OA</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10019, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stockwell</LastName>
            <ForeName>Brent R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Columbia University, New York, NY 10027, USA; Department of Biological Sciences, Columbia University, New York, NY 10027, USA. Electronic address: bstockwell@columbia.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA087497</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA209896</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>02</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Chem Biol</MedlineTA>
        <NlmUniqueID>101676030</NlmUniqueID>
        <ISSNLinking>2451-9448</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000705694">imidazole ketone erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C520330">polyethylene glycol-poly(lactic-co-glycolic acid)-polyethylene glycol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>34346-01-5</RegistryNumber>
          <NameOfSubstance UI="D011098">Polyglactin 910</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
          <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cell Chem Biol. 2019 May 16;26(5):621-622</RefSource>
          <PMID Version="1">31100261</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008223" MajorTopicYN="N">Lymphoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011098" MajorTopicYN="N">Polyglactin 910</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DLBCL</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">cell death</Keyword>
        <Keyword MajorTopicYN="N">cysteine</Keyword>
        <Keyword MajorTopicYN="N">cystine</Keyword>
        <Keyword MajorTopicYN="N">erastin</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">glutathione</Keyword>
        <Keyword MajorTopicYN="N">lipidomics</Keyword>
        <Keyword MajorTopicYN="N">lymphoma</Keyword>
        <Keyword MajorTopicYN="N">nanoparticle</Keyword>
        <Keyword MajorTopicYN="N">peroxidation</Keyword>
        <Keyword MajorTopicYN="N">system x(c)(&#x2013;)</Keyword>
      </KeywordList>
      <CoiStatement>DECLARATION OF INTERESTS. BRS holds equity in and consults with Inzen Therapeutics. BRS is an inventor on a patent related to this work. BRS and YZ are inventors on a patent application related to this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30799221</ArticleId>
        <ArticleId IdType="mid">NIHMS1519063</ArticleId>
        <ArticleId IdType="pmc">PMC6525071</ArticleId>
        <ArticleId IdType="doi">10.1016/j.chembiol.2019.01.008</ArticleId>
        <ArticleId IdType="pii">S2451-9456(19)30030-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>BLANCO E, SHEN H &amp; FERRARI M 2015. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature biotechnology, 33, 941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978509</ArticleId>
            <ArticleId IdType="pubmed">26348965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CHAKRABORTI S 2003. Phospholipase A2 isoforms: a perspective. Cellular signalling, 15, 637&#x2013;665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12742226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CHAPUY B, STEWART C, DUNFORD AJ, KIM J, KAMBUROV A, REDD RA, LAWRENCE MS, ROEMER MGM, LI AJ, ZIEPERT M, STAIGER AM, WALA JA, DUCAR MD, LESHCHINER I, RHEINBAY E, TAYLOR-WEINER A, COUGHLIN CA, HESS JM, PEDAMALLU CS, LIVITZ D, ROSEBROCK D, ROSENBERG M, TRACY AA, HORN H, VAN HUMMELEN P, FELDMAN AL, LINK BK, NOVAK AJ, CERHAN JR, HABERMANN TM, SIEBERT R, ROSENWALD A, THORNER AR, MEYERSON ML, GOLUB TR, BEROUKHIM R, WULF GG, OTT G, RODIG SJ, MONTI S, NEUBERG DS, LOEFFLER M, PFREUNDSCHUH M, TRUMPER L, GETZ G &amp; SHIPP MA 2018. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med, 24, 679&#x2013;690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6613387</ArticleId>
            <ArticleId IdType="pubmed">29713087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CHEN L, LI X, LIU L, YU B, XUE Y &amp; LIU Y 2015. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-&#x3b3;-lyase function. Oncology reports, 33, 1465&#x2013;1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25585997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DIXON SJ, LEMBERG KM, LAMPRECHT MR, SKOUTA R, ZAITSEV EM, GLEASON CE, PATEL DN, BAUER AJ, CANTLEY AM &amp; YANG WS 2012. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149, 1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DIXON SJ, PATEL DN, WELSCH M, SKOUTA R, LEE ED, HAYANO M, THOMAS AG, GLEASON CE, TATONETTI NP &amp; SLUSHER BS 2014. Pharmacological inhibition of cystine&#x2013;glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife, 3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DOLL S, PRONETH B, TYURINA YY, PANZILIUS E, KOBAYASHI S, INGOLD I, IRMLER M, BECKERS J, AICHLER M, WALCH A, PROKISCH H, TRUMBACH D, MAO G, QU F, BAYIR H, FULLEKRUG J, SCHEEL CH, WURST W, SCHICK JA, KAGAN VE, ANGELI JP &amp; CONRAD M 2017. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol, 13, 91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GASCHLER MM &amp; STOCKWELL BR 2017. Lipid peroxidation in cell death. Biochem Biophys Res Commun, 482, 419&#x2013;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5319403</ArticleId>
            <ArticleId IdType="pubmed">28212725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GDOWSKI A, JOHNSON K, SHAH S, GRYCZYNSKI I, VISHWANATHA J &amp; RANJAN A 2018. Optimization and scale up of microfluidic nanolipomer production method for preclinical and potential clinical trials. Journal of Nanobiotechnology, 16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808420</ArticleId>
            <ArticleId IdType="pubmed">29433518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GORACCI L, TORTORELLA S, TIBERI P, PELLEGRINO RM, DI VEROLI A, VALERI A &amp; CRUCIANI G 2017. Lipostar, a comprehensive platform-neutral cheminformatics tool for lipidomics. Analytical chemistry, 89, 6257&#x2013;6264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28471643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GOUT P, BUCKLEY A, SIMMS C &amp; BRUCHOVSKY N 2001. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x c&#x2212; cystine transporter: a new action for an old drug. Leukemia, 15, 1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11587223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GUAN J, LO M, DOCKERY P, MAHON S, KARP CM, BUCKLEY AR, LAM S, GOUT PW &amp; WANG Y-Z 2009. The x c&#x2212; cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer chemotherapy and pharmacology, 64, 463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19104813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>KAGAN VE, MAO G, QU F, ANGELI JPF, DOLL S, ST CROIX C, DAR HH, LIU B, TYURIN VA &amp; RITOV VB 2017. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature chemical biology, 13, 81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>KIM SE, ZHANG L, MA K, RIEGMAN M, CHEN F, INGOLD I, CONRAD M, TURKER MZ, GAO M, JIANG X, MONETTE S, PAULIAH M, GONEN M, ZANZONICO P, QUINN T, WIESNER U, BRADBURY MS &amp; OVERHOLTZER M 2016. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol, 11, 977&#x2013;985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5108575</ArticleId>
            <ArticleId IdType="pubmed">27668796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LARRAUFIE M-H, YANG WS, JIANG E, THOMAS AG, SLUSHER BS &amp; STOCKWELL BR 2015. Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorganic &amp; medicinal chemistry letters, 25, 4787&#x2013;4792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4653046</ArticleId>
            <ArticleId IdType="pubmed">26231156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LISTENBERGER LL, HAN XL, LEWIS SE, CASES S, FARESE RV, ORY DS &amp; SCHAFFER JE 2003. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 100, 3077&#x2013;3082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC152249</ArticleId>
            <ArticleId IdType="pubmed">12629214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LIU DS, DUONG CP, HAUPT S, MONTGOMERY KG, HOUSE CM, AZAR WJ, PEARSON HB, FISHER OM, READ M, GUERRA GR, HAUPT Y, CULLINANE C, WIMAN KG, ABRAHMSEN L, PHILLIPS WA &amp; CLEMONS NJ 2017. Inhibiting the system xC(&#x2212;)/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun, 8, 14844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5379068</ArticleId>
            <ArticleId IdType="pubmed">28348409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LO M, LING V, LOW C, WANG Y &amp; GOUT P 2010. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Current oncology, 17, 9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880911</ArticleId>
            <ArticleId IdType="pubmed">20567622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LU B, CHEN XB, YING MD, HE QJ, CAO J &amp; YANG B 2018. The role of ferroptosis in cancer development and treatment response. Frontiers in pharmacology, 8, 992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5770584</ArticleId>
            <ArticleId IdType="pubmed">29375387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MAGTANONG L, KO PJ &amp; DIXON SJ 2016. Emerging roles for lipids in non-apoptotic cell death. Cell Death and Differentiation, 23, 1099&#x2013;1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5399169</ArticleId>
            <ArticleId IdType="pubmed">26967968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MCCULLAGH EA &amp; FEATHERSTONE DE 2014. Behavioral characterization of system xc-mutant mice. Behav Brain Res, 265, 1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24548853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NARANG VS, PAULETTI GM, GOUT PW, BUCKLEY DJ &amp; BUCKLEY AR 2007. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy, 53, 210&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17356269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SATO H, SHIIYA A, KIMATA M, MAEBARA K, TAMBA M, SAKAKURA Y, MAKINO N, SUGIYAMA F, YAGAMI K, MORIGUCHI T, TAKAHASHI S &amp; BANNAI S 2005. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem, 280, 37423&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16144837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SATO M, KUSUMI R, HAMASHIMA S, KOBAYASHI S, SASAKI S, KOMIYAMA Y, IZUMIKAWA T, CONRAD M, BANNAI S &amp; SATO H 2018. The ferroptosis inducer erastin irreversibly inhibits system xc&#x2212; and synergizes with cisplatin to increase cisplatin&#x2019;s cytotoxicity in cancer cells. Scientific reports, 8, 968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5772355</ArticleId>
            <ArticleId IdType="pubmed">29343855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SENGUPTA A, LICHTI UF, CARLSON BA, CATAISSON C, RYSCAVAGE AO, MIKULEC C, CONRAD M, FISCHER SM, HATFIELD DL &amp; YUSPA SH 2013. Targeted disruption of glutathione peroxidase 4 in mouse skin epithelial cells impairs postnatal hair follicle morphogenesis that is partially rescued through inhibition of COX-2. Journal of Investigative Dermatology, 133, 1731&#x2013;1741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3652900</ArticleId>
            <ArticleId IdType="pubmed">23364477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SHINDOU H &amp; SHIMIZU T 2009. Acyl-CoA: lysophospholipid acyltransferases. Journal of biological chemistry, 284, 1&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18718904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SKOUTA R, DIXON SJ, WANG J, DUNN DE, ORMAN M, SHIMADA K, ROSENBERG PA, LO DC, WEINBERG JM &amp; LINKERMANN A 2014. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. Journal of the American Chemical Society, 136, 4551&#x2013;4556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>STOCKWELL BR, ANGELI JPF, BAYIR H, BUSH AI, CONRAD M, DIXON SJ, FULDA S, GASC&#xd3;N S, HATZIOS SK &amp; KAGAN VE 2017. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 171, 273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SUN T, ZHANG YS, PANG B, HYUN DC, YANG M &amp; XIA Y 2014. Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie International Edition, 53, 12320&#x2013;12364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25294565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>UCHIDA K 2017. HNE as an inducer of COX-2. Free Radical Biology and Medicine, 111, 169&#x2013;172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28192229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VALENCIA PM, PRIDGEN EM, RHEE M, LANGER R, FAROKHZAD OC &amp; KARNIK R 2013. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano, 7, 10671&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3963607</ArticleId>
            <ArticleId IdType="pubmed">24215426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YAMADA S, KUMAZAWA S, ISHII T, NAKAYAMA T, ITAKURA K, SHIBATA N, KOBAYASHI M, SAKAI K, OSAWA T &amp; UCHIDA K 2001. Immunochemical detection of a lipofuscin-like fluorophore derived from malondialdehyde and lysine. Journal of Lipid Research, 42, 1187&#x2013;1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11483619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YAMAGUCHI H, HSU JL, CHEN C-T, WANG Y-N, HSU M-C, CHANG S-S, DU Y, KO H-W, HERBST R &amp; HUNG M-C 2013. Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non&#x2013;Small Cell Lung Cancer Cells. Clinical cancer research.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3703145</ArticleId>
            <ArticleId IdType="pubmed">23344263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YANG WS, KIM KJ, GASCHLER MM, PATEL M, SHCHEPINOV MS &amp; STOCKWELL BR 2016. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proceedings of the National Academy of Sciences, 113, E4966&#x2013;E4975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YANG WS, SRIRAMARATNAM R, WELSCH ME, SHIMADA K, SKOUTA R, VISWANATHAN VS, CHEAH JH, CLEMONS PA, SHAMJI AF &amp; CLISH CB 2014. Regulation of ferroptotic cancer cell death by GPX4. Cell, 156, 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YU HT, GUO PY, XIE XZ, WANG Y &amp; CHEN G 2017. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. Journal of Cellular and Molecular Medicine, 21, 648&#x2013;657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5345622</ArticleId>
            <ArticleId IdType="pubmed">27860262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YU Y, XIE Y, CAO L, YANG L, YANG M, LOTZE MT, ZEH HJ, KANG R &amp; TANG D 2015. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular &amp; cellular oncology, 2, e1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YUE Z, YOU Z, YANG Q, LV P, YUE H, WANG B, NI D, SU Z, WEI W &amp; MA G 2013. Molecular structure matters: PEG-b-PLA nanoparticles with hydrophilicity and deformability demonstrate their advantages for high-performance delivery of anti-cancer drugs. Journal of Materials Chemistry B, 1, 3239&#x2013;3247.</Citation>
        </Reference>
        <Reference>
          <Citation>ZILKA O, SHAH R, LI B, FRIEDMANN ANGELI JP, GRIESSER M, CONRAD M &amp; PRATT DA 2017. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent Sci, 3, 232&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30677556</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-5905</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>197</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomaterials</Title>
          <ISOAbbreviation>Biomaterials</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multifunctional nanoplatform for photoacoustic imaging-guided combined therapy enhanced by CO induced ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>268</StartPage>
          <EndPage>283</EndPage>
          <MedlinePgn>268-283</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biomaterials.2019.01.026</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0142-9612(19)30044-4</ELocationID>
        <Abstract>
          <AbstractText>A multifunctional CO/thermo/chemotherapy nanoplatform is here reported, which is composed of mesoporous carbon nanoparticles (MCN) as near infrared (NIR)-responsive drug carrier, doxorubicin (DOX) as chemotherapeutic drug and triiron dodecacarbonyl (FeCO) as thermosensitive CO prodrug. The nanoplatform could absorb near-infrared (NIR) light and convert it into ample heat to trigger CO release and could also release DOX in the acidic tumor microenvironment. More importantly, the generated CO molecules successfully increase cancer cell sensitivity to chemotherapeutics by the ferroptosis pathway. Subsequently, under the guidance of photoacoustic imaging, the FeCO-DOX@MCN nanoplatform demonstrates high treatment efficacies in vitro and in vivo by combination of chemotherapy, photothermal therapy and gas therapy. This multifunctional platform with excellent antitumor efficacy has great potential in precision cancer therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Xianxian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Zhaokui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Ranran</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Ruihong</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qianjun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, Guangdong, China. Electronic address: nanoflower@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Wuli</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Molecular Engineering of Polymers &amp; Department of Macromolecular Science, Fudan University, Shanghai, 200433, China. Electronic address: wlyang@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>01</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biomaterials</MedlineTA>
        <NlmUniqueID>8100316</NlmUniqueID>
        <ISSNLinking>0142-9612</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058085">Iron Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>17685-52-8</RegistryNumber>
          <NameOfSubstance UI="C515099">dodecacarbonyl iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7U1EE4V452</RegistryNumber>
          <NameOfSubstance UI="D002248">Carbon Monoxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002248" MajorTopicYN="N">Carbon Monoxide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006979" MajorTopicYN="N">Hyperthermia, Induced</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058085" MajorTopicYN="N">Iron Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061088" MajorTopicYN="N">Photoacoustic Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Carbon monoxide</Keyword>
        <Keyword MajorTopicYN="N">Controlled release</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Mesoporous materials</Keyword>
        <Keyword MajorTopicYN="N">Photothermal therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30677556</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biomaterials.2019.01.026</ArticleId>
        <ArticleId IdType="pii">S0142-9612(19)30044-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30635474</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-0103</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>369</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of pharmacology and experimental therapeutics</Title>
          <ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis as a Novel Therapeutic Target for Friedreich's Ataxia.</ArticleTitle>
        <Pagination>
          <StartPage>47</StartPage>
          <EndPage>54</EndPage>
          <MedlinePgn>47-54</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.118.252759</ELocationID>
        <Abstract>
          <AbstractText>Friedreich ataxia (FRDA) is a progressive neuro- and cardio-degenerative disorder characterized by ataxia, sensory loss, and hypertrophic cardiomyopathy. In most cases, the disorder is caused by GAA repeat expansions in the first introns of both alleles of the FXN gene, resulting in decreased expression of the encoded protein, frataxin. Frataxin localizes to the mitochondrial matrix and is required for iron-sulfur-cluster biosynthesis. Decreased expression of frataxin is associated with mitochondrial dysfunction, mitochondrial iron accumulation, and increased oxidative stress. Ferropotosis is a recently identified pathway of regulated, iron-dependent cell death, which is biochemically distinct from apoptosis. We evaluated whether there is evidence for ferroptotic pathway activation in cellular models of FRDA. We found that primary patient-derived fibroblasts, murine fibroblasts with FRDA-associated mutations, and murine fibroblasts in which a repeat expansion had been introduced (knockin/knockout) were more sensitive than normal control cells to erastin, a known ferroptosis inducer. We also found that the ferroptosis inhibitors ethyl 3-(benzylamino)-4-(cyclohexylamino)benzoate (SRS11-92) and ethyl 3-amino-4-(cyclohexylamino)benzoate, used at 500 nM, were efficacious in protecting human and mouse cellular models of FRDA treated with ferric ammonium citrate (FAC) and an inhibitor of glutathione synthesis [L-buthionine (S,R)-sulfoximine (BSO)], whereas caspase-3 inhibitors failed to show significant biologic activity. Cells treated with FAC and BSO consistently showed decreased glutathione-dependent peroxidase activity and increased lipid peroxidation, both hallmarks of ferroptosis. Finally, the ferroptosis inhibitor SRS11-92 decreased the cell death associated with frataxin knockdown in healthy human fibroblasts. Taken together, these data suggest that ferroptosis inhibitors may have therapeutic potential in FRDA.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cotticelli</LastName>
            <ForeName>M Grazia</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Shujuan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Taehee</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terrab</LastName>
            <ForeName>Leila</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wipf</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huryn</LastName>
            <ForeName>Donna M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>Robert B</ForeName>
            <Initials>RB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Philadelphia, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); The Penn Medicine/CHOP Center of Excellence for Friedreich's Ataxia Research, Philadelphia, Pennsylvania (M.G.C., S.X., D.L., T.L., R.B.W.); Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (L.T., P.W.); Department of Chemistry (D.M.H.), and Perelman School of Medicine (R.B.W.), University of Pennsylvania, Philadelphia, Pennsylvania wilsonr@pennmedicine.upenn.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>01</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
        <NlmUniqueID>0376362</NlmUniqueID>
        <ISSNLinking>0022-3565</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033862">Iron-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C098527">frataxin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005621" MajorTopicYN="N">Friedreich Ataxia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033862" MajorTopicYN="N">Iron-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30635474</ArticleId>
        <ArticleId IdType="doi">10.1124/jpet.118.252759</ArticleId>
        <ArticleId IdType="pii">jpet.118.252759</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30616348</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1936-086X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jan</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS nano</Title>
          <ISOAbbreviation>ACS Nano</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanolongan with Multiple On-Demand Conversions for Ferroptosis-Apoptosis Combined Anticancer Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>260</StartPage>
          <EndPage>273</EndPage>
          <MedlinePgn>260-273</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsnano.8b05602</ELocationID>
        <Abstract>
          <AbstractText>As a type of programmed cell death, ferroptosis is distinct from apoptosis. The combination of the two thus provides a promising modality with which to significantly improve anticancer treatment efficacy. To fully utilize this combination, we herein designed a nanolongan delivery system, which possessed a typical structure of one core (up-conversion nanoparticles, UCNP) in one gel particle (Fe[3+] cross-linked oxidized starch) with multiple on-demand conversions. The charge conversion of the nanolongan surface in a slightly acidic microenvironment enhanced circulation time for utilizing the enhanced permeability and retention effect, enabled efficient uptake by tumor cells, and induced subsequently lysosomal escape. As the core component, the UCNP with light conversion from near-infrared light to ultraviolet light circumvented the impediment of limited penetration depth and enabled the reduction of Fe[3+] to Fe[2+]. Accordingly, gel networks of nanolongan could be deconstructed due to this valence conversion, leading to the rapid release of Fe[2+] and doxorubicin (Dox). In this case, the Fenton reaction between Fe[2+] and intracellular H2O2 generated potent reactive oxygen species for ferroptosis, while the co-released Dox penetrated into nucleus and induced apoptosis in a synergistic way. As a result, superior anticancer therapeutic effects were achieved with little systemic toxicity, indicating that our nanolongan could serve as a safe and high-performance platform for ferroptosis-apoptosis combined anticancer therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bao</LastName>
            <ForeName>Weier</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Advanced Innovation Center for Food Nutrition and Human Health, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering , China Agricultural University , 100083 Beijing , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Life Science and Technology , Beijing University of Chemical Technology , 100029 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xianwu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Advanced Innovation Center for Food Nutrition and Human Health, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering , China Agricultural University , 100083 Beijing , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Life Science and Technology , Beijing University of Chemical Technology , 100029 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Yanlin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Gui-Hong</ForeName>
            <Initials>GH</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Advanced Innovation Center for Food Nutrition and Human Health, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering , China Agricultural University , 100083 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Advanced Innovation Center for Food Nutrition and Human Health, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering , China Agricultural University , 100083 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-6244-3187</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-6285-3522</Identifier>
            <AffiliationInfo>
              <Affiliation>Beijing Advanced Innovation Center for Food Nutrition and Human Health, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering , China Agricultural University , 100083 Beijing , China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>01</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Nano</MedlineTA>
        <NlmUniqueID>101313589</NlmUniqueID>
        <ISSNLinking>1936-0851</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008299">Maleic Anhydrides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6PP3N541QA</RegistryNumber>
          <NameOfSubstance UI="C007474">2,3-dimethylmaleic anhydride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-25-8</RegistryNumber>
          <NameOfSubstance UI="D013213">Starch</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007259" MajorTopicYN="N">Infrared Rays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008299" MajorTopicYN="N">Maleic Anhydrides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013213" MajorTopicYN="N">Starch</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014466" MajorTopicYN="N">Ultraviolet Rays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NIR-responsive</Keyword>
        <Keyword MajorTopicYN="N">anticancer</Keyword>
        <Keyword MajorTopicYN="N">combined therapy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">multiple on-demand responsive</Keyword>
        <Keyword MajorTopicYN="N">nanolongan</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30616348</ArticleId>
        <ArticleId IdType="doi">10.1021/acsnano.8b05602</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
